<SEC-DOCUMENT>0000882095-21-000029.txt : 20211103
<SEC-HEADER>0000882095-21-000029.hdr.sgml : 20211103
<ACCEPTANCE-DATETIME>20211103163001
ACCESSION NUMBER:		0000882095-21-000029
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211103
DATE AS OF CHANGE:		20211103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES INC
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19731
		FILM NUMBER:		211375872

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>gild-20210930.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:f99a0a1f-0889-484d-b0ab-b227dc47b3c9,g:c9f039a1-0400-492d-bc3a-193c416450f4,d:2c1b4d102d99434b956b3b8616d0836a--><html xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:gild="http://www.gilead.com/20210930" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>gild-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80L2ZyYWc6ZTkzZjUzZjY5NzNjNGJmN2JmNDlkZWJlNjQzYTZmZTQvdGFibGU6ZDlkZjE5ZWFkMTZlNDVhMzgwODRiNWQ1ZWQ1ZTE4MTQvdGFibGVyYW5nZTpkOWRmMTllYWQxNmU0NWEzODA4NGI1ZDVlZDVlMTgxNF80LTEtMS0xLTA_c06cf68a-0df1-4b81-ad97-72d84e081397">0000882095</ix:nonNumeric><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80L2ZyYWc6ZTkzZjUzZjY5NzNjNGJmN2JmNDlkZWJlNjQzYTZmZTQvdGFibGU6ZDlkZjE5ZWFkMTZlNDVhMzgwODRiNWQ1ZWQ1ZTE4MTQvdGFibGVyYW5nZTpkOWRmMTllYWQxNmU0NWEzODA4NGI1ZDVlZDVlMTgxNF81LTEtMS0xLTA_9519a0f5-a985-487d-a40f-06b88d936db2">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80L2ZyYWc6ZTkzZjUzZjY5NzNjNGJmN2JmNDlkZWJlNjQzYTZmZTQvdGFibGU6ZDlkZjE5ZWFkMTZlNDVhMzgwODRiNWQ1ZWQ1ZTE4MTQvdGFibGVyYW5nZTpkOWRmMTllYWQxNmU0NWEzODA4NGI1ZDVlZDVlMTgxNF85LTEtMS0xLTA_107b9f75-ad6d-4494-9dda-0c07bddc5caa">2021</ix:nonNumeric><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80L2ZyYWc6ZTkzZjUzZjY5NzNjNGJmN2JmNDlkZWJlNjQzYTZmZTQvdGFibGU6ZDlkZjE5ZWFkMTZlNDVhMzgwODRiNWQ1ZWQ1ZTE4MTQvdGFibGVyYW5nZTpkOWRmMTllYWQxNmU0NWEzODA4NGI1ZDVlZDVlMTgxNF8xMC0xLTEtMS0w_31c3ecc7-6f25-4d88-9402-5f9635997df3">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80L2ZyYWc6ZTkzZjUzZjY5NzNjNGJmN2JmNDlkZWJlNjQzYTZmZTQvdGFibGU6ZDlkZjE5ZWFkMTZlNDVhMzgwODRiNWQ1ZWQ1ZTE4MTQvdGFibGVyYW5nZTpkOWRmMTllYWQxNmU0NWEzODA4NGI1ZDVlZDVlMTgxNF8xMy0xLTEtMS0w_75130ee1-5412-4a23-8f08-cc0b7dcc7393">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="gild-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i3eac3303cc9649e2a0b0fd67ca07ce16_I20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0300f6dad76745ceafff278866806c16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ifcc4638e68b041b3aed502ac0da98085_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i113f7696af45458ba1c6270ba2e89d75_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7a2ec8073884bc5881bfa3d3afda11c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4666b276ec7d40ea86d10c4ded816760_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if593c50c51de4ecab2682f502e43fe0b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80719b1e7cda4bf6adddc01b671e7d5f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a47277681854c0eaa992a6c02b6acb3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i528488c905dd4c8da2e5a1389a8b0a59_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7cadd9af8cb4d648ad69a6bf5f40afb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic320c878f7da497289eedfe7777dbd63_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47c2e7921e224837ab97ee0fe6c8f222_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51b36b57f62a4b6f9933e96a8a774a03_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ce088514657437793db4cb212d85fa9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93cee50aef154d89907a30e4b6fe3dad_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38550fb4b8e545b6933ed2239c97d37d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9a23e1ecf384ef8854c99561d634f7b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4232b9569ef4dc784f4c812cd10758a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47d05e5d8c89426f941e19ac183a993e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3c507e951f04b82bce9764e6f829c9b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcc67220f43e4bb097d163125b104986_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a7f62ba5efc4ba2a75848977dcd0f28_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic607fe5efeb4462ba677a36d66cea69e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07b01e048e144df19a994cf3c542a026_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3db1326cef2b4443b8901640d2a96bc8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67dfd12ea224410a8e53fd74958a0afb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4708079b07443c7a62480f7e6915098_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68c8176bb4194abc96d3c13de341cd01_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if83cc5f617644ec28eca6ba9626e3244_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40898fd2e2e842e88088320ba442b8f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4751784eb024137a55a00f62297811b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa59bbe2a2154f068815ed93165ba107_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdca6d608af14f87aeafba62f5b528f1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71ab8e199657427eb6e86e9e2a9be3a8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33c2cfa2e7ec445881cec30e9eed5e76_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if91124405d414b9dba81e4453951813a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79f810b4c15c48908cf2409474335f75_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id36e5ff34aee4ca1a00a4a484c912ba8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic03e12a879694340bc9fdc68aa15f297_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44d0ae25eecf499fb680c4e796d4bbaf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i740e8f78f6c348b0b796258c902c6df7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf9c8e7ee0794bd18997a355702704fd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68393aa2cad140b0813dae42d797b81c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4276333617e7401db14493cc3da842ae_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9f4a9c842e640eb850df6488920516c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2310959eb5074abf916d6715b8aa87fc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib82a8b96d9074a4fb728c152000179b2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ca43e6b419249ee89f9dcf2bf9735ed_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eb53663397049a380603edf12d76c3a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb7e694d30cd45e3a1e9103b0b1e82e1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i377473f7a7634d6cba9a5bb6603d6547_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05bfa65a7fdd430ea5429b49909dff6d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19f0cbf8e15f44e3a8bf106f16ddf237_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863402769fcf4a3abffd39d64a185584_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i188cf2bc805343608e1a7c9417d2404d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2552479e6ff476e92abd17114269cd7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f3b569ef25240f1a155a0024e7b8e90_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c214ead3cf04a2e9fc7bc2b14bdaf84_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4e29df1f11f450ca7eb2e638244a8d1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaae18a74fca47d1b00b45a50b94910d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a3a3fc257534802a47360ab1e00d78c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65979baffae041ae8ddc09c614f2ebb8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3bd1b11f59e45f4ad008ef2737fcd81_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57db840e2919481eb28184ec2cbb0a50_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i612f84efa15449cc9787e2a73fa82064_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>gild:segment</xbrli:measure></xbrli:unit><xbrli:context id="ia55ca9423cea4d12b888483189b2ac1f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8aa096b135f48158580b40a60e33019_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36a8c27aca7b4c4eb248168068a32aa5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9c91fbfc86b4896a3a819c4d77bdb7d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6111ed4b4e34cc0938dc6143421bf29_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i846bb97183f648a1a345c7417b016402_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idde4cb31f8274161ba1a860f8c484f38_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c0f1a209914347a5e69fa51270ee29_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i768c3bc1ec8c43ddad2162082a96cd6c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9a118513ef49819b2577666b0ec096_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i733e5fef29374d46b413dee54bb19109_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b02afac5b7406d9c151b1f25da49ab_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba9d39a80c434949bcf4d4dbaa9759d7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63ca5be4690f44a7bf33e1db73a1d060_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0257f3a298140fc84dee8d53d699670_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f7a64d9f59c4811a20101fd386ee115_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i417036899f4b4ba6a942d6c89d2cf9b8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4e1d6d95b2c4d2a920c8653b06216b5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83e6d6c2611b4c2e8c4aecf466648862_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bfa430609e94754b5309dcbd1f54afa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i524768e71ccf4918b463a9f11d0b12ad_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bbd970a4b1c41ac826211b086ec75c6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i585135633c624761b4c1a83f8fb3835f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcda312d5cda40abbb9ac037d9a20f64_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6c13cff5ea440d6856dd460e75e1cce_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i972c68c99d2b48aa9f0ab252eaded219_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bcac0500428449ba45e660bcf11a22e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b5f64fafefb476897c670520ef3e684_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb444609f3c343faae5bc31dc0f2969a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11b21909ece24606afb19d200d6cbf45_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie64f24cc49d2461993b4706f48070582_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia581ec4341004cacbe1676f4824925d5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0beeedfff0ab464dacc2dfe91fea027f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifda373a4474d4fddbe280b1ceeb9773b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa5ff99375b246b19d9a454b2bfcd5c4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6072428678a4c13b3bc2cefe46e2367_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5830a8e44aad42d6b4e5c07745f1a654_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2499d0efe544c88b850f4e06d6d0fe2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3df12d48d77f444687886781f8f13ce0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9021fb6917c34472a60654a134736f11_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i340ad048883f42aa821f43d0819810b8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i593cc1643d3b4cffbe6c45b7b951be8b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if96b216119514bd5b34e404efd229b24_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fd1cab9c1fd4ca68901a86b57b2fb99_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3484ed15b64c4fc291da3be7d9248674_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f663d9f8f284b539edc2448996d7698_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i121ea362bc6448bc8bed2159e95e89b0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a9823f6159647fb992be0b7838c2a93_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb9dfdb77c104c9ca832bcf98a8246d3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75b44da404f64237881a6460aa4636ca_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ab0ac7cc574410790fabeb761d1d174_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38e2ac5333234a66b3903412e42f3e68_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75c03337a48d4a949b4288448d18a1cb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idca8d358805f479b89d1fb6e6719e857_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52e40c6015764bd69ee9cbf82d281820_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a28cac4b61d41f5b9356a0b6aac960f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd6bc5b0bed743c29791702bead202bb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id310e22cdbef4eb1baca5c55f8b8fa02_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65d60a8d39b34372a1be78e500f813c3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6a580919a214b2d895ab413f26c8880_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a7ae2ad394446693596affca1e12ab_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i754a2616edfb4f3fb575bf9a85114f6a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48939703477c47fe9550c4f92c6ba557_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie40a71d15ea447a2ae8f68926fced7a6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e606e91fa3e46acac32b0de0f54dbd0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c941e621c4b4cb1a5e4e5d4ba5a859a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icee57962d9df495e8b9f2cbabe1f503e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb5b96718e3d479492237b8214637bd9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0ca8a58c2d94581bcfdc60a41cf40ec_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i864044e4908b498e881e97143cb3166e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51ab94a8ddba44f79cfe371276e8f9bf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia93c6c5c009b4c31b3fa92708b8d815b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b348befa53e4159bedea795454be27c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab1615ced09e40b1aa3cc44738550dd1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if20f435a41c348cbbdc43f245ac16861_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73bf790cd1a346988b368c7d3cde8b8f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8612d631840e48e895d251930e52c4b9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76968fb55cbc4ae28307471f0cccfdd7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10ab46addd4942a0b01ed1d3a2011f31_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47709a114cd148c0838a562496cab936_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c463d05c4ab40cdb9e847fd0f510bea_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i171565ffc87743c1aba490024359250a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied3ad8d00ec64e84b7f987b2ba29eabb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b9c2f39bff448a95abbd58f45d0fd8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib86391bc6dae4373b89bd8ab38605880_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ad4a6158ebe4dff890142a1696e812f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dffca717ae24d34a470d8d9a38dc095_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61275390a7e640b2897c50f960fc2caa_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia61446b694c74e7d9f5a65b521566c20_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib982a6b7a5ef409bb13733f8c74abbbc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e3676630be045daad191ec0e8486184_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a702cd0f2e242db85b30aa6ce77bd11_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99d0c47edbf149b4b42fcf95a60ac88b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82bf2e8a84c54403aff0f3a4e0827765_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529a378d1a634502932448df5c7dfc96_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5c2caa8a7da4d24a4facd4e5589dff4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28240f36b37149c0aebeb17174beff82_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a5536e23c6241a49f1464d8fe7455fc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1a32343f5754479b35423074bb85146_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7520be9c8c2b44299328cc6ffba5984a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i505f00cc79eb434fab41a8fc651c07bb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia266f177505e46e1bf32006d610309d5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i871de7451e1745a0a07ed808518e7b3d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99b5ce6646c74d90aff700749d2e8cfb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceedaa27c5974485aef9d4d3a5782af9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i554974bf2ebf487c9a569c72bf26081f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cbc708d4b1a44a7a2159db8585b1eee_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ac3e5d698614f858c14ebe4eb398eb7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b6ded5571864ffd9ce7c0d50dc74892_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b63f63cabe44e2585bbadd57fa354b1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac3caa38232a4a51a8ab79f61e2251ff_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieffd3dd156194386848193bc49944ee6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83a6dddb7daa4a5ca29ac5484a6fd6e7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f0238d623444989439cf7baaffa508_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45562ada92804faaba94694bf0efa14a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i826c955d2db24a8fac6267b635be2cde_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia73efd497975415fa3b80207050da730_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc2ba5e907414bfd8ea65cf2a73b82dd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic82244d6f2a444548484e7aec01540b2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19aa5a3f35bf4604808d9f2e3a8da3d0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb7d7312714a49a0a36fa523e3b8b0a4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0baa0f95e2af4393a1730300142cc581_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88742fc2c2b34f5ea2b9520a011826a8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf9b1de4fa0b4462bd3dc919628df7de_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1115a331568c4809844ce0028077a85a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8837076c1a0d4dfc86bd66bf5152de38_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i444db132af094e4bbf54b5614246e999_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a81a8e5d9974ac7bde5d42f5a4fc336_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa8b523c2e824076a748ebd245595664_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id70ba4cf64c94219a9e327880de4ffb7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f05f61614c147efa464532642700a6e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93f53d3fb034456b9a305a7ed3d3e66e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a017e3308ef4cbb9b933e55ec090998_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea639de29d0e4d668506abf5fe3550ad_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife19093e97a54f5c9eb24677048ec618_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5266ed380c4d492c9019fc51f76cefd0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eb9b983d1b54d55beb90a63dddb2c59_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf984fd7000f4775a945b8b0f7942e2a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29ec2e59c50f41ca958a6fac1402679d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f4e484bfe8744e48ad91049bec90979_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3732c23942243a9a941c7c4e278892a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i877e24c5d0694819b01d486f5d882659_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf1741a698e64669b6b86f03281e3c65_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a1dce33288a4302aaad5691f38a09dc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80097a5080c0445eb9773bcbbb99bc1c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19103f7ddbeb423abb4a6bb401db7fff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica155088076646c3a5bd1588f0bceb4b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia812590aed6d4ab39be1d578c15c1486_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e007c33751b4a5c978064214accac0e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33137ec5b6634022892adaf4e137ea2b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02900307815d45ee8652b90be7d1be4c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieba46f08b484419da5dcf2ea9265939b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f89bf00ca354d5bb864b9f0cd155397_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e029ac4bf384381be5a78e8fb2e5178_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd034ba2efa44a2db164c8aea8825436_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04bfbceaa25142cc84ac6378009c15a3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i992039dc5c0441c5b5f6174dce19c781_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae99aee62f846139d54de729834ff14_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i678692608fbd4c1fa178eabaae64217c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b6c99a3b9fb41af94b2683664d43cb7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieec0b95176c043cfbbc5a9f6fa983587_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0507455b49474b93a38ead6ff2615419_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ee4d5996924966837c8c99c967f51a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic78827f1965b425dba08fd9f4c2e4d58_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39b4ec9525e44e808926dba562992f53_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5113443b36744e9e982775ec8eddc113_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i736b122cf29c43ee95e28299d9a585f1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c967382fd7e4043b63ff0da2d1242a2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie85528a66b46438d9ef9265272241283_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb5dc4dc454649c4a9f9a11210acdf30_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c45e550d01b429cb2b091b9902532c0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35a4693d3cc04b62b20fbe12a1d5a54c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9751f0cadc8491e945ca44b0b80b126_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4395e1c88544cc4b60097ece5543cd3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia30e8d354ab04f3a97abc398675713dd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id953d64ac7fc4fccbf566a8d9a4e880e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6ecbe4c2b2d407793fd3b236408f12a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b07ea93a6f54fd0a91bf6672ff04b65_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73b68324728248e48095f5acec992615_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8f3b797b0784b5e98a1ebecc9731bc1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c6152e617b143c19295e79115efbfde_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55ce6c803e5044689d6f072466cdb84a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbb1331a5dd2469fae50b0f82ccdc186_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32399ea9bc584449a570a053a33d5913_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b87fa8d5dc94c15bba720f6e25ca2c4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id317edd4885848da96375a5d6890f972_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5d1c49fd62e488a9d8f1b1bf40b098e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c6dddbd6632497799ce67bce0d386c2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2a5f3cc54f848f1a10d35d090a03387_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fb67792ca1a4e87a11d779d955afe4c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71818c2f40544a51bd97f8265ec8d26e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8d2d00f525545e0bfeaff95a0d0fbae_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffba5b40986f41988004b66efa3262e3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie950ff8a161b4f3cb591feb0c61f2b65_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i014ae1acc1a0400cb0833dd1ec4d8c95_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i248f6f4d0b1743b8ac49ee8a4893a138_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb48adf7671d4b5095439fa1db112f98_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dea3ee0ff204b6a859461e1d1f6d8ef_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98dbae32b00044609d015af32ec98ca2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb6c3fd5a3c7472f93e4bcc1e14205f1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93a4e05cc8d84ef193edc737f58313f3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c4a3efb665a4e32b3fab9bc46d0e840_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07b88223ff894ebeb782ba78c923b80f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ef52ca9d6a84708adf4f8bd716acb1b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia60d842da95f4557a472db9a4f20944c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i312af34f38c3480f92c1180516ce4b2f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69497b92cda24b32bb318450db656d59_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c83f4a3e9804930b2a2b194201c1c9a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b526ba862f347ec9e038db912732159_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8674bb821a143ffbf0e7c0a4bbc23f5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f44e89624524a3f85af2769737da0e9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i106ed528aea94b3e84e167881f011048_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06672ac481ba4a9bb5bd08dacfe71e88_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0753fdb7e8f479fa676298a44c409a3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84e6d6f192a24ac8b2f45a194dfc508a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86eebf78b2f54e5789f05f6de57a33ff_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90831c4bec134c3d9479dc73821bd890_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f950f4a2a1943729bd08af5465b17bc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00d836d842884745a9b0c054d60b3106_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94d80d18f64348a6952ff66466587e5e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i420349f096da42faa5a1507cb5af2bac_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c028e5643ea425b858bce273dbb43ff_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f15774b1a2c46f9849e41b07da947da_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfa297463bca43108958d1bc0d817e62_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i801113c804f84bf68a7ce7874e0fdfff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22120ea38a6f43808c0a51b6b42c907a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd65b051c3c43a09723cf00754a0d11_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ee5d0fa9bc243609b1326fffc9420dc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64edf3f2b52641b0b8963f1e7ecaf35e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd113a548354e83adbc4e684d0b7c6b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad59f43c9584895b43102b96b356bf6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e7dca62ce034df2965648995f1e45c3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide81ff472a904e96bd7c11cfb160bb5a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c657737c9a44da0bd9a0a0ed937b77a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i761660c0e36b44119d0a377956dca1fa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42344c7afe36415a9346e765e883f109_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i780ad9f4faff41188b82d5ee6efad1c7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i771dc583a85d484996619f6a24a1e310_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12d2e276cf194b249b5381b7c0d564e7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a788a5a397c4d3c9c4273e20cb2eaaa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf04a6872a2045d9aba3f8ee749ef8cd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89aba37ab3bb4d6f995db3f1ef7313fb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib47fccef93064956b207fbf3f4b0c07b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c6ae907411a40a09a29dc2bf329268a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibea8c08b19a845a7bc3ab84d8743dac6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbbee8f040784dbbbba5f6f7708c8260_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06591e9d784f4725a4a3f560f9165fdf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic63411681ae343ee931a1ef0fa134389_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7017bfe2cca74515a9c77805ce3e685c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if87c9a9443ac49bbbc5f60c80bdb0cf5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34a4aea2fb6941c9b82af8675d2a96d6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic38c735785bf4de499f546ffb3cbbafb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if590ab24b0d24195a1751c7e37eda7d6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86322bce038342589d4f3d411cce6b67_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i122291e0c90149469fe7f534977d4bd1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7be015c2d53f492face1090466f96194_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41905ceca0e14646bdbb966a276724c5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96b919aa74e64ed8953496faef33cead_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id55d71c6943b41688ba0c99c12c4b0a0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib74e3480706c4ceea2eeaa33e8a29a04_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia50f0d178a34403ba582f4fd7b081032_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1125817792a24e229eac03cff110ec3d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b4c349c2ec345e9b842096c5ccaf53e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i175a2429ab0a4e3b8b1e75f43911073d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bb3ecdf995d4d6d812e8c4cbd7c50e7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1b6b1928d21482d9b69713fe3e4a90b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia342fd853fbe4fafbfdb82fc8f51be9c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23e096ae4d344ee6812e02f2cc006dcb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8bdd6612962405a995125b9413576f2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i028a2e4438b44cd584805fb7db0521f3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8cf4df7cb3b4e0b86839f9b4fc78b33_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfac141d6cd44e59b0b264ad26f95be5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4522ce1c0acc43ec92a475e4619c9ded_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5f3f15ae4734085be8c32af347a19ab_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id78d2215b759479ba1d4220802e6d2d0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ec8a9a644aa4b0ebccca4dab9dca43c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8af2ad96fab4466bb054d82d939ab1e0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id37247af540b49ffb68edae4f0e29c75_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fb751dac07449418c170631d9d26c50_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5761b86071f3408392639773ba999d6c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf1124b457b6443b9adc6d3bca56384b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21c3ea05d2d6469bb4402a1e7bc7b6ea_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf14c77718b943c99cce1bd3bf1a1bb8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i985f8bd1a9864259bc024e136e98165e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib17bea95dcb84138abe482f8fe033d2e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i721ea7e79a674506888fa965f545242b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id19b27572f12412498a2fbdc8b6f03d3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i294f1f3217554943bc9e24fd2f2d7b62_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71ecaf56026f4bd5be46fe08dedcfbad_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74defff37d6741aea5e3b56c22443253_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27247f779d88460f9b4a30781c8e204e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i621eef6cf69b42cb94aae8c92e1e958f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e09c9fb52974397863d698886f2e887_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida707d8753fe48d2aeba73c027150355_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie768d1c6a00b48d5bda81338c8079975_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9708db6e96ec46d5880ab00e9b04a81e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id562523bafee46199bfba4a84d9ab6f7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c6bd8c13db64a3ab7f8eb8574846b45_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8899f03cb424167ad78b89040f1a538_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21d311bd075f4f02b44de6feb4ab37f9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7979efe4ac394083a361addf3d2a49be_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a303146ddae40fdbd9eede2a54e5625_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i036eac2d8114497bb332d3456f541e87_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17d484b178dd4b64b7766ad74bfc4575_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9283b98610164ee6bf6bb05476c6b514_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf92e99dbb2140f493dd3d8fb8410ba5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d74d0421c60403c8a6f350e1d3b261f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d962d727ea437a9d9bf778a9145642_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab1b92b6f4ea4a199a439cefdcf33eb4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaad6f61dc4d43cb950a28292948294a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dadedf4a3a0408cb0d1d97265933589_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d7e5fc9e484420c99dbd9d31335006d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94648f1cf2334fd39189ddd5a2526fea_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87770df84d314b2d9aad501ce6c1d18e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03ba162945dc41be8591b11496c129d2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42e31f17d8bd4d23b055d34e97fc4ca7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bc60dcceb644702ad795c8522e3f1fc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieff814faff8a4823a581ff8c22875f06_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i898ffefc3e8041be98cde4df6be2c6c8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41d525086d2940c8bc5faa039d023674_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie975ec0d59844df5ba2bc20d9d8ed6d0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iade9dfaea73c44d59d5ed5c0b2478333_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie07906aa3788456f883989affdbca674_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a36ba79c6f545ebae95e83233deca01_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73a607992c5c4d25ad9c3ac39d2b5086_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87e96b04266246398a423cbb059ca43a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0314692dcb914529b1c58577b2b23a0d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68a023cfdfda4020ad80e31bfc9b887a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8af6b5ba80b548de8cc9f594408ecc5e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6362737d64e24ccf8210a3c52840afb6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b03fbb1ad6b40f19a144436859a94f2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bdb0af715f34b249428381e9aecddf7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i086ee71ea26941e88d86269d05ffe0da_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ad8c8ce385e48069566ed761014713d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6462e169d53f4b4fa0ce56f4c177fbec_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb8274f710244001811907e50cd4649f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia087c8100b6442799b592343e8d561ee_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2963d1dc4f004cde8fd58fc8adeb9698_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cb3a52c0f00489082cde7485cbe447c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cb8226c97a04cce9da6c55eaa7cbf5c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66452d493a694b09b553e49d6ab26de1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie00c38ed5e114e7c9b2c757c827e0138_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41eae22e9d694cdfbbc45e5052d09e8f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i896a5a5651944bfe84bb61cec75fe4ed_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96c7b41d05fe44dc98629f17bcb23c36_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14cb743958c641659fbba039af3651c2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i130fc4df5c3a4447ad6bafc4c36d9a70_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i743f436a82f046efabc844f2f53f0827_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5636e6fa99514854be00d8ce0f92da0f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i089d7a7d04eb4354a426b6f111e8c9a1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97fd886a21164803a5ecfb1a6ca689a2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9f9350bc75c442d91a688c62b89b6e1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5763ac2ae7874bc3949baeefcb466bb9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic843439826b2471ba7693acebb1e44f4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i952a37c342574b4fb556d2cb998f1dbf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3bbe012fe22423491ec35738ee162d6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie50a6de3cd234635ab5eef79157b0e1e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c55fd7299a240adbf6d39bdf17aa7cc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96ab85ae6a2d499f8162d50d3fe1dde3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief5bc9a6130945279a3ed73051e33bdd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc475161995042e1b32b3447cfd8372a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa3ddd3a8d67413d8ccc8f4f45930641_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabb8e6fba8504ecf8c222643ff4b5f9b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0a5589d4d564f57bd7d3624c5dadb39_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0891181a1f1841c3ac6a145676585a41_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b86819db2a34c97be76a722a5625303_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e952d3e460445a9baeec1dcc88eb745_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3a2d6364e6440d2be0d03705fab3cff_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb620cd6eaf04c1c8f121fab54f876c5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if09794c214e347d6bea03f6a5b211ada_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a9462d61d0f479b9fd7e5b189d86696_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7fa3912b241402d8cd650313d3c7018_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf0e9011b3d24494816bcc206c0c68f6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30b2167174a94caf9d1f6bb56760edcd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20212de8e88345cd81a0017d04adec4d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc4680796da146cb8f0e19e816cc8a1a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20583fb976024f8f8e57d6812ece8f46_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06b5d4b507e1433ca2793f5756b1393c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia59084cd434e42fbafd89bb8ba03f4cd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1678eb4959ea4499b972f90192b36d19_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c6ce327bc5a423fa9c0482e0ab2581c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if50b052e699145cb95a035c96c0cbee3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54a055cd7cae4d1c9803fa1d5c85d26c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i323ac2db963e406abe6b6c72a52169c4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i306cc17766184506a102f49dd753f257_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f7ccddf15fb48a6ad13341a6b918c1f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id66d30a90b1d4991894bd9de74896ac3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie93d3106744048369cdab984d1705db3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb480f4f198e4b9bbf94fe25b67eb48c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i350d04c2a6974b8d81fb176e56b5a2e5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72f473445dae45a5ba0d6b6eb575f11d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac82bc33803743e89507ebfd8155528b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e01dfafe5e548d9960d2188b833a39f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie071dc0e5b3949d9839bd24e374990ea_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i912fe4ab93f14a9f8e6b580172900315_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c166e53abf24fc9af7b888824f5bb49_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id99eff088b5d453b929c3d11f5802852_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i663bd657772843f4ab8018e6a76865dd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c90a17fa3db439e94799030d2aa841e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib095572329c649af806dff6bf6648e2e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52882de359e54c22ae4f7a72a8137b42_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eb10e809c404f009423263342e5e7ec_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59f4724ec2d14aad8052c7338d1e1a70_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i539e9d57820a4905bcab08d23c1fcdb6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i414c554b9ef34e0b9825b306a35bc339_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41352f9abff2460ea53c3161faa76af2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15f5acec533141a6afaedf118bb678bd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i974c2dbea9c44cadbbed8b52fc7f0508_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba449c38763d4a5bb15ee5d3583e8506_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ea474d996994c7cbaa07eff099c4759_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3414950d11449a089e780e1462c6861_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ce7e4d4685422fbdf942d3bd865108_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib600ed3308d64a8b946e889611b8cf20_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib31f6766705e412abe5b95c86b77a3bf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i375d592d929047a993e6735cac3e7524_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25802e2404924e7bb626581d9cdcd76e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i485672b302d740d299e2875e2d04bb74_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida399d53d569435ca887d4b734cbe214_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9518115801fa4a4e943fb879f5bf25ba_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51826c7e75b64381862b2f02fb933540_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife3535d931384c729359473d5f8a4507_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d1b980a3c9844768bbe2d46b8be2e7d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aeebdc4428e44828acedd57caa0faca_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib41e7dc04b7148b4bfbba74683bb45cd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b6f5dee9cac47efba1d637a42bd0f68_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id530903404aa44608666ca2ea201cad0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53bbf05572d84302be77973d5913a305_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4505c57940594da1a6edc651f9236d9e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i704f5a35c74142ebb14940a3a4fc0d89_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b5618b046614ad186793fefd8dcf5bd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6081efd3f9744514a207bf9f739d1607_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide124041bcd946b29f470c0a14b6de2d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaadc71dd3a2547cea41b38c3c9ce7424_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52a87250c5f446d8ab703b837cedde5b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4b70689a9f142a9bd885d142547defc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17f4e1512b3f4a6a988b52b2020f402c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93ca470d7fdc4eb5bdee6dda889e6593_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91affe4ed5b44ccc8baafb617adf2e9e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a57a9c4342a4d129d4b551d06423da8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f55f5d973df4988979569a529db6926_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e801c7e1af45b1ad4f62e390c18253_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i887c3ef61a3a45dbb40ba7652320c71b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i431029e24f704dde9b7df67fe1ba94ee_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i067f537de5404b9dba9eae8cc5fe8ba2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i040023fa9ea949e99260ae268fb58313_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d85864fc37443df93104eb46275dfb2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie785b0f49c10443fb9de1408de71f21e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb0b8d70240b45f9af68a14c1bc14401_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc055133d0cf433781d778bd29bcf851_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b7dd3e6b3fb460b8f290204f2ad10aa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4342f00fa51e4687acb11f09198af17a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60da582576d74709b9d1fabc050be19e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaba56c135c2949f5a73bf185229f9d9c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id250fc6f2b094e5a9eaae0b8f02e6283_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e8e47a466d34118bfe22a1393d5b447_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b0094bc7ae7468e8f94517cdc8d4c16_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c9cf81f27044e40ae5a06b91f4fed65_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i832adea04eeb4821973a36b8d8054b28_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5defc88095b45f88cbef65982c863b2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74e9b2ae35f94059a42f289e242fd5d6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5d4f53a05ed4cf9a3c013c511bb6d57_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib495e1983c7d43ad954d6982a1acc6df_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia65f96edddf14125a0ceff48dd6ce529_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ac5d731345b49a89e720e60b2bd6179_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1472bae377ce48de85232d1f7e78a6f1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9da54dcd88e46a7a00d599ef8199f51_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa2fa3fc25c348288b3ec143881904ce_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae77bc715f014b6abd4b797b309ecbd3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b06166a143f46ac8b776fcfa056152c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b1c82a1c7814ef0bae95b14cd89caa3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i833340a21ed94b68a7b86f7be0fdf2ab_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i513c462b957b48c38384730437388578_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a22bab8816347da9de17b819770d4a1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i156443fab6604e7abefd184b681ac88f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0453ae248b4871a513cc0481e0ba95_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88b9b3ecee864a188d3318a7b3b10134_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79b02c41c5dd4f85b666bb73366db6a9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i664b0e413d3e45a1b02ea0aca6fa69a3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61127c264a134cadac4433659a4b2a07_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73ed798ddb0d4b829c8f9df19472898e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ccbeb9d2904b8494fcca05b0e0aabe_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb505b42a7d41d197183c8cbc88fa17_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7c7645be0b7483282e2fa48a952ce6a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aaff90d56d04403ab9bcbaf508a1fb9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d2ca052afdd41308acfee42874d16bc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c6f15ef048940a2ba4ba7ff83b36db4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e56043c08ff44629cc394d2f686ed56_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98bd71b2478e4a04916636f59012d953_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13822eeebaf946b9a83f2a817987763e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc2e5f8264194107aa51706375b167fd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i794e4f01cf834ef6b6cb3fac8633384e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide78b4b7f0d04153ad16104b60a2684f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69842657a0724c8bb9baf66aa7591fe5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b7e271684784d7dae794919a0acb56b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61a064a1cde64b1196d2dce7960e85f5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34484c2dc9304341be78db8166e621e3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ca680e493e94c14a2d7345742f31836_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i092466e16cdb43f4bb4f2f9191a72a85_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e494a218a634591bd5ed5db40a1c47f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f12c7af337245d5afb3786a6258a024_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bb2f8457d7b431ea9f1c47d5413415c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc4cacc943a04c45aa40ab1aca412a24_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a6bf17320054464a3bc267f3849d5c1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40c1afde566a44a2b60890f7234a9889_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f0226418aa141e08a04b3292d3d6a3b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69b2aa2945ce4106a4fcf5c0bdca8f28_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2a8467fbacf40c38e699b24ac162d3a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f9291215372429da56d3bf18442238f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ie89b30127587468d9e71733bf07d5081_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedd6b57e5ee3433abe93e62847e14d87_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6546a28c4524eaab7537c0d6bf777fc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21718856cc7648018662a2e392cd71a4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74a16f60814741f98bcabd2ce43bcb36_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac98ca2d21064f81a59741305eb998b4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0f301d0c0aa40ab958148e4f5814aa1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1f131cf4a5b4202aa0a668ee3ad2bc5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if33c4729f0e84f61be8298fc81de60ff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i348e70f83b254e66adb00f1a55a6328e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4979a9738ed14d44a7fc44641a6b295b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44900a3d2ba94688bb7a0dfade50db90_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f07727060b14c0d872f5f929cc9fdf2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30f8590a90374b4fbc764b63834fe5ed_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e302cf42eb74c9a84eab7578f54195e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92825af11f15411da7e658f2ec15da12_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic35f4c541e614d33a6437788299fdc0c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45e0d18c597e4ca2ae01fdfbd7881c3a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfaa631e8e95431a9bdfa133e0488d8a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id69559bfdfb948d1a4ffa643418f21c9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3548698f1b14ba68822ef5950d4915a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c690fe00ac54cd0a140a27f890f5c48_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i824f7d8e5c4243208069c78b91bbb9a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27bd677e9c7f4ab69c1c65c4a2154029_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8e5aea4693e4a208fbfbf2e410e5c40_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c621536eda94c6f8d03472cdac1cc35_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic59f42fcfdbc43379e5b44f081585c47_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i780e0de404214dc29d45580e7b2531b8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41956a7c7b7a4ab299edca9f380ca798_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79c41df237804e668c0da56a46ee0085_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c07df65da1d41098cd48baa32f21d8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide714ebff4fb46809c7b477daae2d962_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifce16fa84c314d2d8b2732c6bf0d57e1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf10f2216a934d5b9d20de4fa33c7e6f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86ec4abb19ae49f0b238c47892dd4df4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1839e6fac09a4a4d9210d56808c687d5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54f21829201d45aa939df14dd7b96c21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa7361567a884284b89e7bf5a20638a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i549d3edb71ed44988ab49d3637f8cf90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36270f186c97490e84c4d0dd8788d411_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd9e6e86e84a497aa1ba2c847b3e7767_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22c6271275734808a0ff96495b000a60_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2217b0ea8f50482aa528fde408cb76e3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfea4630e695464ea306f7481b6e32ec_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fbed77deabb4de589efde4d54035191_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i961ed43970894b70b047d465504721d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d59baf4935e4b848a146a795052db24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84eee8925bd946b48b71e527c679a789_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic665639028ad4946b03ef3d0a7ca3192_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3960deda1f4d454eb5bece595f0566f3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i897098b154ce4014a6261d31477a3023_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0adcb1eef7cb452f847c13e9842de931_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b8ac7aca374e42ba0903e04a423882_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idab563e4309c42b6991e40459e65c9bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i484390e670d3449786a771db7ab9ade5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i526c131b580f42bc9d870f04c6d8d5b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i926b7e069399438cb0fa7f1d96f3e3e0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68a0012537fe46c5969295f09f2f6dd4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ee3cd97581a4d2abdb377c19e3ebfc0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide347640da714f3395ba489a540c603a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i276c9ea2224d4affa06277ba327a2d61_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72a95ff7958c4fb7ac5a1798d4dce9cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3136714317f0456c977067551e4bd81f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8a7c2c25d974d61a8013b71288affd0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44d10b847f5e406db45e5ac1953efe55_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14621646e10c4fd1b6c4a65065d514ab_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3b775bacbe44316aae442a85d447f1c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide0afddf10ce4f31895aad1d16c1d85c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c1629420b3f4c80b65c3eb9d05ee4ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96153a6dea77431eb98e9c8200e6181a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f662a891d89402584dcecd95385ff8e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4532563975f4635bce45eb0d2ae51f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78c02433e66541af99b97939d39e23a0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e8d9e0325a1434c858eb9522b968441_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic21fe9fe9de1442b89efde9577f52f46_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b838d5587cb496093b251362509ac97_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1f0e139c0cd44a6b90716186d108008_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fe330b4018048f1898231a7f4ff4ecb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b84e22ee5ab4a49ba427501bba85dd7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b4898fa0a764d7aafa5e9a1d6d72ef3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf1508526e8c4ee1b4e7b2a680bad4c4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9769a32b3db420e9bd1bec55f864b91_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i316acb6201d34cd8b84ad4bc0a229326_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29435eace9144606b96eee2d02e381a8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbabaed951aa4295ae68d516beb80338_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a4501dcb7b04327b30565529b2d48aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i799dd8cb5a934a67aad9f2247cd1f8b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb74d6dc685f4234af1aa0e61f985bf7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia380e72b9e514a0dbc10fa47a96a37b9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0202af8459b4f3789926f58b9cf9752_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42edfdab86c9426e93701ffdc0c7fe94_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c80ed86b032450995903fbe43ad034e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54901c86be024d34813c278457433dd1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c04316279d5406ebb97ec435e024e2d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1502ee19eaa24b0992c9886bfc77cb5b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib15e0bfd36234157af17a4ce20b77d43_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if364edca58da421d9d61dae9fcad7914_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40461f1ac8b940ce8fec799328c0881a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe2d6409bd5447b881a310ce4725db2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87d5b42f92744945842d42ff308f0e20_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6428c6244bd40588e98b0566fc843e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b69704c2d87477fa4c4e048aef6c84a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28c7735eb6934c9290f2ee14fb060da0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba8e7f03185947608f3762d7182fac94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icccb697c433d4ec09b49c19f13ab8a83_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i373b78381e234c3ca41660182ac003fe_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e9cc0b50d7c4ab6bc2905f65769e3b1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8a9ceaf8e034398898fc7c7ed8656c9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ee81b72feb64a13bb9b256646717944_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ccfe72a95f54aa78e87fe00e6420d4a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e7f4d6bbc524f168c63679b9a7e91fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91039368c3bd4bfb910457fd3dd4c000_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i989d63bf16b04e01a3d9b072d85d1ba9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31da5834b4314564824f60b82ecae0f1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35eec1666a264bd3b71436f39b919d85_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3e238999bb54c4099da8e86105699dc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cd694a407d04faab683d1cd31f7d8a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c237a39755447a48b076df315f9ace7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48f04e6cd6d84fc3bb90b473f068279d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5faee6f594734e2eadc6353454b6d927_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72ccac9d876f460bb41bf5ff8f83566d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i176ff44bb5764e3b809a6d1ac92b4178_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6ef3db73cbc4509905d24a522ce5757_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0da35341d6714931bc1689adaba0f122_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4da087316a0f42869c52cd83bef39303_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1511de451544838b5b9f248bbe33b1a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94f9fa2675c74baf9fc13fcaa1d41e1f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id37cb24882ef449585ce764d602b950d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1be5d0f90b94ff6beab639c85963cc9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff3127bd77e544569634499a4cf507c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6cc9ca3679429daa7ddad7be3b18f8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i823c5759f91342788099a4a119a8361f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ccaa167281f4a20b66d52b3c71f1dae_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dcf510e014b414ea7b2dc9b96ebd136_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78a2c5f5c07343a095efd1f37fda91fd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4df9dcc40c9941ea8c7e26f4f58967e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dfebbffea394aacba0aba288b9dc053_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gild:EquitySecuritiesDonationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gild:GileadFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b50cb54d91f4e6c99676d255fa29fad_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6a9dc16a8a0426d985e8a948bb5bfb1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4da7a64c618429d8996f9b339ac38a8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c6903daf0954d94b44190d9b3e1b5ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76c056d0bef64de1a20dc89b76c1fa78_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5d7dd3905d64e28ac9327a66e603863_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd2639a9859c40faa55868710c142818_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48f52dc3cab841a3809ef785e4e66ca3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03b29e17a2c248719dab9a52b28f2838_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9848c60df524b6d8597f27a5c2348a7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1b6844083d54dd6b01c081a66abc0ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf1a2f42beca4dbfb5c2042c0e6ec2c9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b301a386454cff8a23c0f9d5802e0b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9edacacd9fed40b19c21f8c9a2d1066a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdd06b56ab884773b9a6d59b91979118_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4d28e4219744460aa5d638f0e4748d7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb6a3f0759ad4433953398e7ad344fd5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fcdeab4094c40bc957aa0ac494ab157_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aa08afccd2c4c3c920afbf679603457_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie91dfb2ea1ff4696bbe46980e5074985_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36fc4c8f965c42f091bfa62e48d5188c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77ef7763dceb461d8ba101eedb3ec351_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a621708b219448a9f522102302751fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>gild:position</xbrli:measure></xbrli:unit><xbrli:context id="i358d5e6dcfe74eb2bd53d281984be1b6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd2b0d3a5d754eba9ec5ab61ab8a496c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba883e2763fc4f24aa849f2ba1b18762_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i441b41e448e24773b07474571334d688_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic68b8c1df06a4e9ebf5ecc3162d4e91b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41080ff3b0f84bb6ac2d71f26d888ae3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9de9bbb3a16148ef822890fed3ae38df_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f577e7ed1d9420a854f73986479f887_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a621ab557e54d8aae26f9664ee66d03_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0316527653e540b79aaa8ffd4daeb2e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcc66a969998454596abd65746688f8d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33df3af625fb41ae885fec733687b6cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2c72fc1463e44eb96aabd7dae05dad7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2c8de705884a04944f9028afb662e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07a3a9b39d3f40068ad241a4bf584ecf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d9378e46bcd49c1aeccf6c8f61de218_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3efa4fc2e80425d911786fe90f0577e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i318a011bf49b49c3a79192b82583bb57_D20210304-20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-04</xbrli:startDate><xbrli:endDate>2021-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5181ad1c63c4deeb36365ffdce5e584_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59fefc5ad8ec413db93d451131df6e85_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i352358e211a34a23b9dc88776f5a0076_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d953182d7f349f7880aa6b8782ddbea_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46f837bb32354303808450010f541cf2_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d0182ee77884d308f972ee3ac8635f4_D20210304-20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-04</xbrli:startDate><xbrli:endDate>2021-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91c7b3ebdf1649509a1e026f30a65baa_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0680e69caed6418b9c239d0f897aa373_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a84de62d1ec4a0db403459b92a7debd_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if38c0f756f6945658b15ba7c6e9bb284_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15facb5b1aa5415199d533abd8de3199_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie94f540fb43d41c2a993dcfcce7e6d9e_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7a6d7dbc5194ce3a5c2c451b949a083_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90be553f64364971a7f334cad33d512f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e6bdf7f4837439c93c50b528a400b0e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59fc30c6ac6b49d88f04a9291366fc62_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id248063645c14c6ca92fb1d761be74e4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice9f0c8cd2fc4c7ebfd9c7829f4948e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica281eb0ea274e8fbe28117ec9397184_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i423d39bed9384081904c47d75b0d641a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a0f810172a14dfaa8af6a1edfc4646b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25358862393f4ca4b14b4364da42d681_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie35fe5b3532249fbaa1d215c6cea8f90_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a065190f73644d7a438667b54161f4e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26cf0458992d429ba5ed5fb92c5a2436_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a12c46bb79a4f2797fb774367f4f73d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1922554024b64cb8898c1f3fd434e8da_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i969a0f7a4e6f4d7bb52b87c7b652a57b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i097e3a84fba5476487ee41ea9a26f8b0_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58f39982e7154710a0e9bffb98d87c09_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i186934b8fe964624a8c713e57b5bc48a_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f1396f1bd31451bb640de4f9f3638b4_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5af10497a26b467daee57d68cbd93a36_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic84bc582b1d04652bd6754bb4901989d_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i856f386d4aa44a00a2c20f4010d3fbc5_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i199d5ca3470540be922bc9d2707767c8_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida214684d6f748fa94820133c41fb9cb_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">gild:MerckMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4b2d0d8fb10491f844ccbf3c9d99659_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OralFormulationProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a7ea0a008d44d19aeaba7ea8a234a79_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:InjectableFormulationProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fbddaa5defd43eda896eb3f45f893de_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94b469d6b3cb4b1cae15cc21665e0bbb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcb33e823a4c4f73a7d1f634b45cee94_D20200527-20200527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-27</xbrli:startDate><xbrli:endDate>2020-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3878c6df63be4399a67430941e5732c7_D20200527-20200527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:CommonStockPurchaseAgreementAndInvestorRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-27</xbrli:startDate><xbrli:endDate>2020-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e4ffaa955f9435b9bf6dff41e50e726_D20200529-20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-29</xbrli:startDate><xbrli:endDate>2020-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18ae4cc7725f4c96842b14bc9e4daf0e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48dadb586c444781b30fb3c1b0888939_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i819ce30a96d84a66915bb6c431c7a737_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeaa95ca088c4fe285e88b406cff5320_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcaa35425c334e66adfe9c0143a54cc5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36771d101b1945cd9d9de5fa0410171b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2084f6bcb60540018e9a4b1e4715c369_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i075533c7d37d491793ebc09f561f12c8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1beee1ec406146d38e3211fa2933708d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43c2519105dc4bfdb185e7ebc59a5a2a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b6417210f0c45cab95af5ede847f506_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic250ebc316ec45b1bbe84636770ce814_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a816c3a555a4fa08e58b54a04015ffb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A440SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2fd7afacc2446fdb2b73b021c7ec4c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A440SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c2641db1ef947ebb5c2e598d80af8b7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A195SeniorUnsecuredNotesDueMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i047f7d6efaab4949ba75985dec2bd448_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A195SeniorUnsecuredNotesDueMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b207ad1f4604e47bf243a142f719c3d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A325SeniorUnsecuredNotesDueSeptember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide3713760e2f406f87de6a771c56330c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A325SeniorUnsecuredNotesDueSeptember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i378aa93017824e3e9bd151f32b47c054_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ebf78ad2ccb4d43a991df3fd307bba9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafda4276088e42e3a214977fd3664e77_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2c0f1bb661849bbafaaac95aa413df7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i718060d949f64ee2b8c966d8822e9de3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd18b3372b0d4339ba7e932b3bcfb631_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a673086504e43c08aba24aa7d8a2fb6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie39bf03ca3dd4c7eaf82c5f3247707e0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96e9697694914c628eb31495e561618f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if73fdd4a8341456487fd2dedf6c2e9d7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81c97bf760b64de9bbdde1c94a7b8ae2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4ac5b7017d1476fb5bcd16b536f43e8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb213534bbcd45118c1bb26b41e1e907_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia58159b24bd345179d097a8c8fa338da_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a046019e56c4f54b51b48b7aa1d9d88_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3836e4ff9f5545ad88927b7ccfe6ce9a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4cd61c4d420435f8f8a47a822a2fb94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia75a4a1f883644e593643caeeb64e8c8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i831cf307aaac48e3a4f36b76c1ae6821_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia606b7a94a2a4a27be3bac90bae27db7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i033466f65d06435daaf05ce68cdea42a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26def8fc057343cea1511af0a42bbd82_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i793861fc864b4d84a4d7675fd3879f56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i334415af3e3b4544a67d9d7fca63abc9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab18c39cd70d4664b5614e5d608d97f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3a50f56b0a243339131abb7a4e8302f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aab6acda6824604a29d697a10699b89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56cf1e78acd541bf8bda7634c9734818_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d8992e066ac492e96f9427867db1b37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id18ba93f1f954ea7825f560783159641_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47bdb44a5bf54303b2b1c5d712c9b5f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69e5c28f892a4699b116990ce04af8d5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida4a76b2bb9c486ab32b0ed960911667_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c9e673628f24f989a48a76bc085f8ad_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib475552eda99433d86c1a416ace1cc9a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i063be5049ee1464b8b050a5513490bf2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3282c94d1c174c6ea5efa7ab36b47b19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1bfce21e9994d52bbeedde558474519_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i729835fd97c847689dae526ba4c3f80f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09bfaa553aa8422b9801e9811d4f84ff_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31b25ed89c604903b3ab2cb0f953dae9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacd82538440946f2b5a64f02e99bd78e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ecfcc11f2b44bee8fc31ff744993188_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20624e63c9d342039f2acd0aa0e221dc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5e1397cca1b4612bda3fec5029c7caa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A440SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a838956d382494aa01dce9ce9a74af3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f517572134b4e7bb737cffba5c07c94_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50cd74cb77d0435b838bbc259636ca23_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i755d8293c829458682df87bc82180dd0_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf9f1c5fb1234d22a178a74091f99dd1_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6198bb2c3e1b4f7a86b03b31b9a31291_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife22d5290cb340d48c49cda6ebce356c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia55d69200ead47739810b75c12b1c289_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294c3dd1a0044d64b2a2c206819a4787_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08188eab1c8f48659c9fb097dbfa6ad9_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e74f009f33c41a1b3024e5689146bb1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>gild:agreement</xbrli:measure></xbrli:unit><xbrli:context id="i40650c0325e24e0db701d2ab8acfe659_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:PreExposureProphylaxisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>gild:patent</xbrli:measure></xbrli:unit><xbrli:context id="ie57e22e42a844c1c934bc94bfc2e2e72_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="opposingparty"><xbrli:measure>gild:opposingParty</xbrli:measure></xbrli:unit><xbrli:context id="ic6c268206d494d42a3e01744ecb78d28_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2024ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i842ab5644f88423ea3fb5a3f08f81d21_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2026ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5c2c8d7ed2c407cb3c28ad661f37190_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2032ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="party"><xbrli:measure>gild:party</xbrli:measure></xbrli:unit><xbrli:context id="ib144fc19e2424cdea1de575c395ea438_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2027ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32e0f49607724a678979d40a5566567c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2027ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>gild:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i50d725ee8e5d42e8b1d6a84547e3f2dc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>gild:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="if347b8e9f0f441978924331eb15b50e0_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:QuiTamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86e5d209900446c0b30dc2880295f243_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2016StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id644c4f270bd409c8d4eb7dbc0893a59_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2020StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a5998ee4b384480a72487be18641c7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c3d265770c244a0a765e499a4ee7cb9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c0ff94d0a674ceabb8a179fc4e48905_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45325645469947adb3cc8720858aa852_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b5cc9befb344284aed69e9c8209aba9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if101dcd8b89a438ab7ac5691e108990a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8bee7f2d6524b07b87afe756d78590e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4990ffc169374b34bdd3f918810fc418_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79d0985dca0949ec872d8eb72624d97f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i414821821100441394f7829f268ffe4e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cf07b371d2f4766b8d9469daa886de3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e4e4f7365f94609beeaed0a72a5533b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i967254dd024046df825693124da51c02_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id89abf1e3aba470fbcbb850fec50b11b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i216f4d250c4d49e19ca6cf3b0d5a5818_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54fe2a88a4c14a76a2d768cacc3e0995_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20b67d0bcd224fc9a3adb44b3d27fd5b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cf587a459224feaac6e5a4412d46585_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ce0a2da343c4d92b5c1b28c7b50805f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2c1b4d102d99434b956b3b8616d0836a_1"></div><div style="min-height:33.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM184OA_d7f163ba-83c5-4a9c-86fc-a55a9c0b261d">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGFibGU6NDMzMzkwMWQ5MWU1NGQzMWEyYjBkZTlhMTZmMjAwNDkvdGFibGVyYW5nZTo0MzMzOTAxZDkxZTU0ZDMxYTJiMGRlOWExNmYyMDA0OV8wLTAtMS0xLTA_b7d104ea-54c6-40cc-8973-b49dd177fd6f">&#9746;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18xMDY_a4d6cfbe-306d-4685-8032-96839821c4fe">September 30, 2021</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGFibGU6YjQyMDU5NmFkNjgzNDczMWJhMDQ3N2NlZTBkYjM1YWQvdGFibGVyYW5nZTpiNDIwNTk2YWQ2ODM0NzMxYmEwNDc3Y2VlMGRiMzVhZF8wLTAtMS0xLTA_165c8b72-3a3b-4f99-b1bb-168425085bfc">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">     For the transition period from ________ to ________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18xOTM_f866df4c-22e0-42c3-9c1e-64330e563ce8">0-19731</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yMDE_40197ec0-d025-4c76-a2e6-4a09e0e52868">GILEAD SCIENCES, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGFibGU6NzZkMGFmOGZiY2QzNGM0OWEyZTkyZTNhMmZmNjAwY2YvdGFibGVyYW5nZTo3NmQwYWY4ZmJjZDM0YzQ5YTJlOTJlM2EyZmY2MDBjZl8wLTAtMS0xLTA_8db0d471-6d73-41a2-b47d-d4ba7f45d481">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGFibGU6NzZkMGFmOGZiY2QzNGM0OWEyZTkyZTNhMmZmNjAwY2YvdGFibGVyYW5nZTo3NmQwYWY4ZmJjZDM0YzQ5YTJlOTJlM2EyZmY2MDBjZl8wLTEtMS0xLTA_2b423a58-8525-404e-a3f2-8bd6ae7a54e3">94-3047598</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yNjU_b544f0ea-2db1-4a3b-acf3-852427b54621">333 Lakeside Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yNjk_84339777-84d1-4f40-bc53-571820aa5f86">Foster City</ix:nonNumeric>, <ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yNzM_609966ac-4509-41fd-97a6-ad1ebe3efffa">California</ix:nonNumeric> <ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yNzY_74b96839-a04d-43dc-aaa7-2bd2b81843c0">94404</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18zMzI_38f42e47-ad30-4ea7-a294-9bfa3465c102">650</ix:nonNumeric>-<ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18zMzU_f15260cd-4373-4787-95ff-5b829872f1ed">574-3000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGFibGU6ZTg3Nzg3OTU4Yjc4NDUzMWJmOGU2MjhjMzY2MjExZWMvdGFibGVyYW5nZTplODc3ODc5NThiNzg0NTMxYmY4ZTYyOGMzNjYyMTFlY18xLTAtMS0xLTA_28a5d219-616c-4387-a68f-c704be315487">Common Stock, par value, $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGFibGU6ZTg3Nzg3OTU4Yjc4NDUzMWJmOGU2MjhjMzY2MjExZWMvdGFibGVyYW5nZTplODc3ODc5NThiNzg0NTMxYmY4ZTYyOGMzNjYyMTFlY18xLTItMS0xLTA_13e33f68-446a-4325-9c1a-cacbf51593af">GILD</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGFibGU6ZTg3Nzg3OTU4Yjc4NDUzMWJmOGU2MjhjMzY2MjExZWMvdGFibGVyYW5nZTplODc3ODc5NThiNzg0NTMxYmY4ZTYyOGMzNjYyMTFlY18xLTQtMS0xLTA_9bec9a5c-e7a8-4968-b2fb-dbee330e522e">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM184MDM_db43193d-70f4-4164-ac39-b562c5cd53b7">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant&#160;has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18xMTIy_1d07015e-d6ed-4fba-900b-008f446f0d74">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yMDgz_46b14de5-2afe-406f-9860-d1d449a2b264">Large accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated&#160;filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yMDg0_8ac63091-d201-4957-a351-fcbb992cb255">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yMDg1_22ed2acb-a724-428d-881a-41d3d5067ac7">&#9744;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yMDg2_99b9ccfa-b8fb-4e44-b109-94ba49c9801b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of shares outstanding of the issuer&#8217;s common stock, par value $0.001 per share, as of October&#160;29, 2021: <ix:nonFraction unitRef="shares" contextRef="i3eac3303cc9649e2a0b0fd67ca07ce16_I20211029" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yMDgw_3baa4bba-e01a-4ba2-add6-719f3249c84c">1,254,383,522</ix:nonFraction></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_10">PART&#160;I.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_10">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_13">Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_13">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_16">Condensed Consolidated Balance Sheets at September 30, 2021 and December 31, 2020 (unaudited)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_16">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_19">Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2021 and 2020 (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_19">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_22">Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2021 and 2020 (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_22">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_25">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three and Nine Months Ended September 30, 2021 and 2020 (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_25">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_28">Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2021 and 2020 (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_28">7</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_31">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_31">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_76">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_76">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_76">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_100">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_100">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_100">45</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_103">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_103">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_103">45</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_106">PART&#160;II.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_106">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_106">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_109">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_109">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_109">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_112">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_112">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_112">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_115">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_115">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_115">59</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_118">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_118">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_118">59</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_121">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_121">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_121">59</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_124">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_124">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_124">59</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_127">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_127">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_127">59</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_133">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2c1b4d102d99434b956b3b8616d0836a_133">63</a></span></div></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own or have rights to various trademarks, copyrights and trade names used in our business, including the following: GILEAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, GILEAD SCIENCES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, AMBISOME</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, ATRIPLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, BIKTARVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, CAYSTON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, COMPLERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, DESCOVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, DESCOVY FOR PREP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, EMTRIVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, EPCLUSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, EVIPLERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, GENVOYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, HARVONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, HEPCLUDEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(BULEVIRTIDE), HEPSERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, JYSELECA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, LETAIRIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, ODEFSEY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, RANEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, SOVALDI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, STRIBILD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, TECARTUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, TRODELVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, TRUVADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, TRUVADA FOR PREP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, TYBOST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, VEKLURY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, VEMLIDY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, VIREAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, VOSEVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, YESCARTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and ZYDELIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. This report also includes other trademarks, service marks and trade names of other companies.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I.&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_13"></div><div style="margin-top:16.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_16"></div><div style="margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMy0yLTEtMS0w_acf7e619-54ae-4f7c-8489-179b17eb8644">4,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMy00LTEtMS0w_c7be5e97-21d7-4377-bf7b-5ca97eedfa4f">5,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNC0yLTEtMS0w_cbaacc94-3133-4362-a620-2c45e90a129d">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNC00LTEtMS0w_7d656edb-5a43-44e7-8a41-18a860fc8ba8">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNS0yLTEtMS0w_c1c9221a-b1b2-45cb-bce8-568a444b0420">4,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNS00LTEtMS0w_b6b9d9b5-938e-4997-b9a7-f8cd3e08997e">4,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNi0yLTEtMS0w_bc51ffc9-f735-4f79-8b58-86e21905abcf">1,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNi00LTEtMS0w_cbeb2af3-d33e-419a-bcd2-ac8b0035de6d">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNy0yLTEtMS0w_a51fa232-f35e-457b-9af8-0de7063eda35">2,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNy00LTEtMS0w_95df602b-17ac-4ddd-a841-ba453cf2f699">2,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfOC0yLTEtMS0w_d9fc7487-1627-4edc-a198-6e2a4b664a62">13,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfOC00LTEtMS0w_5746a1e3-9295-4147-90cf-ac8cf3d914c9">15,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfOS0yLTEtMS0w_4299a45f-f7ab-478b-bcce-737d6fbff379">5,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfOS00LTEtMS0w_4b6acb07-c9e3-432f-a1b9-0eea98c3c11e">4,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTAtMi0xLTEtMA_21a3ddd1-90c6-41b6-a8b9-75b159f6d49f">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTAtNC0xLTEtMA_b6e867b8-62a8-40bc-be2f-4cceb62be1d4">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTEtMi0xLTEtMA_deeeddf7-c331-4f1d-a45e-8b2a4444ef92">33,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTEtNC0xLTEtMA_67f8d0a3-30c1-4bef-a5d5-a8a4aaab1ae1">33,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTItMi0xLTEtMA_6610c622-ea66-4d60-96c0-c97db83beccc">8,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTItNC0xLTEtMA_d4eec289-38af-43d7-bb31-1421728c8101">8,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTMtMi0xLTEtMA_3391c752-df97-4219-ae06-ef8a5c46c11a">4,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTMtNC0xLTEtMA_fedd686a-9211-4273-8f2a-29af2cf26dba">5,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTQtMi0xLTEtMA_21de837a-c693-40a6-af10-a817a59a4258">67,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTQtNC0xLTEtMA_bef9c0da-d66f-4566-ba6b-d555c8f20705">68,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTctMi0xLTEtMA_7955f049-888d-426d-91bd-28eda0fc746b">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTctNC0xLTEtMA_b11c4c0f-0429-41e7-aff0-819e2fa93c5c">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued government and other rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="gild:AccruedGovernmentAndOtherRebates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTgtMi0xLTEtMA_6fcc587e-fd61-4cbd-808a-b4e3b780a92b">3,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="gild:AccruedGovernmentAndOtherRebates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTgtNC0xLTEtMA_4e6183fd-0a48-4cb0-9dbf-b88ae1fd9660">3,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTktMi0xLTEtMA_726efd7e-2404-426d-8548-270c2dbd490d">3,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTktNC0xLTEtMA_b3c64286-c825-4bf2-ac9a-3948bcc953f4">4,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjAtMi0xLTEtMA_eef6f5c3-18aa-4b39-aa25-89a23118c439">2,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjAtNC0xLTEtMA_43085672-022f-42ed-9f82-cc9ef0645730">2,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjEtMi0xLTEtMA_155c053f-5c0b-4be9-9568-226acfab3acb">10,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjEtNC0xLTEtMA_164a79ea-a3a7-4009-87e9-12a273f00f46">11,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjItMi0xLTEtMA_3981c46d-7599-477b-b65c-4591211412a8">25,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjItNC0xLTEtMA_22739a13-0968-47a1-bf24-903511706e64">28,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjMtMi0xLTEtMA_b56e6918-2774-45a2-9dd3-a47acdd23c5f">4,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjMtNC0xLTEtMA_a3179c13-e77a-408c-83f0-f72ac42b80d4">5,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjQtMi0xLTEtMA_8d96c6d9-9a46-48e3-bed7-960713131f7d">4,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjQtNC0xLTEtMA_b825c2e3-4217-4168-aaca-6c2fbd2b43d3">3,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjUtMi0xLTEtMA_cadd006d-6a53-478e-a640-f09bcf7e579f">962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjUtNC0xLTEtMA_65001a10-1a23-4b71-84b3-10d89f4dc3cf">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjYtMi0xLTEtMA_c160dfa1-8b92-48c6-98a8-7fed549d9ccc"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjYtNC0xLTEtMA_d5155486-a7de-43a7-a297-f0b38c2718a2"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjVlMTViODMwNjFhNDQ4YmI4ZTQzMmY3YTcyZDNiYTQ5XzMx_713ce8ca-558a-4f2c-b9bd-ac02050402af"><ix:nonFraction unitRef="usdPerShare" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjVlMTViODMwNjFhNDQ4YmI4ZTQzMmY3YTcyZDNiYTQ5XzMx_da316f45-1c30-4428-9125-4c25fe36a7fa">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjVlMTViODMwNjFhNDQ4YmI4ZTQzMmY3YTcyZDNiYTQ5XzQ1_9c1bd033-c7f8-49a3-848b-4e2e73c16afd"><ix:nonFraction unitRef="shares" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjVlMTViODMwNjFhNDQ4YmI4ZTQzMmY3YTcyZDNiYTQ5XzQ1_fe3e7b5a-4a65-4b01-83fc-d10623ef5f91">5</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjVlMTViODMwNjFhNDQ4YmI4ZTQzMmY3YTcyZDNiYTQ5XzY3_08762b48-24ab-402c-8fc9-c2716add2c9f"><ix:nonFraction unitRef="shares" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjVlMTViODMwNjFhNDQ4YmI4ZTQzMmY3YTcyZDNiYTQ5XzY3_32ce2d2c-273c-4e3c-8d90-00030d597e23">no</ix:nonFraction></ix:nonFraction>ne outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtMi0xLTEtMA_83f3152b-1f73-4cb1-bab8-596bc3ec7a6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtNC0xLTEtMA_6cc1d84a-8d17-4e09-ae96-112c2ddf9816">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzI4_1418abb8-f304-4727-be2e-b6081bf6d1cb"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzI4_1e5a973a-e563-4531-95d1-b86880ea99f8">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzQy_3a153e5b-0682-4838-933a-631ddd624486"><ix:nonFraction unitRef="shares" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzQy_caafc6f1-3c4b-466b-8900-b37117bf59c8">5,600</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzY0_067fe071-15ec-457e-834a-660c9c25e035"><ix:nonFraction unitRef="shares" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzY0_aed738fd-5cb7-4873-8778-8ce89b9617d3">1,255</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzE2NDkyNjc0NDE3ODk_04cc31d9-8fd1-4065-b2a9-4a03b6944629"><ix:nonFraction unitRef="shares" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzE2NDkyNjc0NDE3ODk_5b74f9f2-0c9c-4775-aadf-7b81feb40d08">1,254</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMi0xLTEtMA_1648b7ac-e9e0-411d-8ccf-73b0fe7568c8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktNC0xLTEtMA_ea6e86bf-09c7-4a22-b037-2129648ec134">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzAtMi0xLTEtMA_f08075c0-1e51-488e-ac79-1682996c90dc">4,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzAtNC0xLTEtMA_e29541cd-8a4b-448b-9537-a6f756b7db35">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzEtMi0xLTEtMA_0e5272a5-d526-4d75-b167-6ce3624663cb">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzEtNC0xLTEtMA_5194a20b-e362-4c65-8ada-a00cc216fe6f">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzItMi0xLTEtMA_b142aba4-95f4-42b0-9fa7-d15635971351">16,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzItNC0xLTEtMA_0b0dde27-f085-4702-b64b-864b56d3e906">14,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gilead stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzMtMi0xLTEtMA_30da2aba-157f-426c-869e-4744ce2d2b0e">21,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzMtNC0xLTEtMA_ffc22a8a-7704-4afa-a028-abc32f19db7d">18,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzQtMi0xLTEtMA_d4c7cf5a-5b2a-4c87-8318-bea77b69d62c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzQtNC0xLTEtMA_b6d79273-ba5a-4faf-bf93-054a6698116a">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzUtMi0xLTEtMA_6beca6ba-a5e9-4859-9db3-916a9df0877b">21,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzUtNC0xLTEtMA_76faec9e-7105-49f9-9950-33f20127adea">18,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzYtMi0xLTEtMA_dad3058c-3c06-48c2-adc6-7e2d55e7fc82">67,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzYtNC0xLTEtMA_52f4fa92-f983-48b1-8be3-40a02bce3e3c">68,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> GILEAD SCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc4638e68b041b3aed502ac0da98085_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNC0yLTEtMS0w_778d90d7-743f-447d-b10c-78910fce8647">7,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f7696af45458ba1c6270ba2e89d75_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNC00LTEtMS0w_cde0eaea-80aa-4077-93e4-eb46150ed084">6,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7a2ec8073884bc5881bfa3d3afda11c_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNC02LTEtMS0w_c1e30d6a-10e3-4f05-bc02-9b05d35efeb7">19,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4666b276ec7d40ea86d10c4ded816760_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNC04LTEtMS0w_bf0ebbef-f3a1-411d-b54d-8a1de1b7fd21">17,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if593c50c51de4ecab2682f502e43fe0b_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNS0yLTEtMS0w_5aba8e30-8408-4e44-b1bc-c175f291be7b">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80719b1e7cda4bf6adddc01b671e7d5f_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNS00LTEtMS0w_2938e66c-2272-4def-85a2-cde3a9a32186">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a47277681854c0eaa992a6c02b6acb3_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNS02LTEtMS0w_b839332b-4105-4c6f-8af4-d151518e5546">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528488c905dd4c8da2e5a1389a8b0a59_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNS04LTEtMS0w_3a1cce88-5bf4-4b66-917b-78f8f9351108">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNi0yLTEtMS0w_6a693999-0855-4092-8465-bde662d6a2f7">7,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNi00LTEtMS0w_4321661c-2f8b-458e-88b2-b9a4071a4b6b">6,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNi02LTEtMS0w_c59fc90c-1b94-46d3-8c74-68745f2f26e1">20,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNi04LTEtMS0w_1b6e1eb0-be89-40c3-a037-31e3ae1f871c">17,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOC0yLTEtMS0w_f3a223b9-9f2f-4438-aa4a-518552568b88">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOC00LTEtMS0w_d2efbe11-714e-4b81-88e6-4a19baa33766">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOC02LTEtMS0w_e2ef5ce3-64b1-4f42-8b30-95e11bc9e9c0">3,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOC04LTEtMS0w_5337637b-5080-4f20-930d-c6433d384782">3,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOS0yLTEtMS0w_b505774c-811e-43d0-a993-4c4f0abeb340">1,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOS00LTEtMS0w_b214193e-c853-490b-bf45-6cef4377ff08">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOS02LTEtMS0w_c19b5327-4264-4367-ba23-a1b1f15ab490">3,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOS04LTEtMS0w_91f18296-9268-445f-b18c-0cbb3a62360e">3,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTAtMi0xLTEtMA_efdd920e-8b9f-4c6e-b4d4-2fdf9928656a">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTAtNC0xLTEtMA_f026f8a5-3494-4b08-8982-27a0a585170b">1,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTAtNi0xLTEtMA_c12dd00e-79ef-4ca7-9e7e-f40df9b0cda6">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTAtOC0xLTEtMA_f3195434-76fb-492f-ac7b-4f40115d8af0">5,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTEtMi0xLTEtMA_0458e2e3-815e-44bd-a2b5-3725f73f5512">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTEtNC0xLTEtMA_b6fe8f2d-0332-499a-a370-9bbcf10726c7">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTEtNi0xLTEtMA_46371e09-6942-4b32-9690-5124cb7b9ed2">3,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTEtOC0xLTEtMA_8144184b-6265-4795-bc38-58308e627a15">3,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTItMi0xLTEtMA_e3ef2ce8-6710-40e3-8192-924c201fb5a8">3,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTItNC0xLTEtMA_05ac4b4e-4d42-4d23-a012-546fa5f6d4e2">4,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTItNi0xLTEtMA_4ac7ed3b-ef78-4e37-91fb-bc4748431b49">11,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTItOC0xLTEtMA_ac55e62a-f4c7-4242-8ce7-93745d219ebe">15,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTMtMi0xLTEtMA_5a20458c-c129-47e5-8add-f9c67741f160">3,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTMtNC0xLTEtMA_415e5e15-a329-4384-8de8-03c5f13ca740">2,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTMtNi0xLTEtMA_02fc6761-68ca-4b51-a5d3-452cf1cf56ae">8,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTMtOC0xLTEtMA_a44b0e8f-9a61-418c-a80b-23ef0b25f11f">1,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTQtMi0xLTEtMA_2b2c34ec-6caf-4f95-989c-a3fce9f71df1">250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTQtNC0xLTEtMA_507c9f55-3465-44a6-b32a-2ca04979c48f">236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTQtNi0xLTEtMA_6355c2c2-4829-45eb-bda5-898bf2a9fa18">763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTQtOC0xLTEtMA_a51b51b0-5733-4b52-b5ad-6f9c5f03a580">717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTUtMi0xLTEtMA_807f2eda-dd9d-4dee-9c43-95fc42005985">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTUtNC0xLTEtMA_e166eb9d-bb33-42e6-a3e8-324087b5028e">940</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTUtNi0xLTEtMA_eed1fafe-f996-490d-8b40-bc08789bb3cc">696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTUtOC0xLTEtMA_819a2f7c-ca4e-4b52-85ad-dd6b52084ab2">848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTYtMi0xLTEtMA_c0f1cedd-4c62-4504-894e-7eefdca5190a">3,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTYtNC0xLTEtMA_a56b9641-1ce3-494e-a175-8cf605cf57a0">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTYtNi0xLTEtMA_1c722f21-6020-46f6-b702-e020c6c8c9c0">7,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTYtOC0xLTEtMA_da3022a1-b718-4531-8fa2-a345a27b5be3">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTctMi0xLTEtMA_a739ce53-4f96-4153-8951-72935364c9eb">852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTctNC0xLTEtMA_b5d7c797-e715-40a7-935f-481f179b605f">472</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTctNi0xLTEtMA_09d911e5-2d90-4d5f-a4af-4f421ca32902">1,694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTctOC0xLTEtMA_15ad47df-33bb-49cb-8941-eed6fec54dd9">1,310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTgtMi0xLTEtMA_1a6df507-318e-4441-8ce0-285aa5d2058f">2,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTgtNC0xLTEtMA_79756a0c-9642-41e5-a52c-d2588200a970">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTgtNi0xLTEtMA_dc22c516-1109-45f0-a992-735d404769b7">5,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTgtOC0xLTEtMA_180d5d34-a378-4fb3-849d-a8f3a01284e4">1,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTktMi0xLTEtMA_c3551425-fc69-41db-ac63-d5cad1a45215">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTktNC0xLTEtMA_6a06d42e-cf15-49fa-b8d6-8ecb95fbe179">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTktNi0xLTEtMA_b5487b12-00e7-4727-a099-6250968c3101">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTktOC0xLTEtMA_4b8ab49c-7d8f-44f9-84e5-b9a37c4e74e1">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjAtMi0xLTEtMA_2ae7cead-ef05-4ba5-88dc-033def53f9fa">2,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjAtNC0xLTEtMA_619513d8-4af8-4e7a-accd-ae0fb4fe598f">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjAtNi0xLTEtMA_7b614bec-7c63-40dd-b5a9-5560a2691c8a">5,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjAtOC0xLTEtMA_3d575997-8a51-45f0-b1de-9b8a973661dd">1,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjEtMi0xLTEtMA_57cb18e4-86cd-42b9-b9c6-e8ae752c1e01">2.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjEtNC0xLTEtMA_4a639e4d-44dd-45e5-8d17-24cb56f74acb">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjEtNi0xLTEtMA_510e00ca-66e9-40a6-8ccf-6fdecc9c22ea">4.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjEtOC0xLTEtMA_1e58b78f-9d8b-44d1-b26f-eda768b91943">1.14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjItMi0xLTEtMA_44418776-8607-4130-bdf9-7e7e3203f6c1">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjItNC0xLTEtMA_76a94e61-8fd2-4cc5-8634-ede928b1fd95">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjItNi0xLTEtMA_7b56f8da-b6d7-44f9-90f4-d0f1ff58dfe9">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjItOC0xLTEtMA_221edcfc-0899-4c56-9ab1-96ed8f3dcc9a">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjMtMi0xLTEtMA_277950c8-cf9a-45af-ace0-d655273d9efa">2.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjMtNC0xLTEtMA_ed69da37-78d1-4c11-94b5-68260ef74e68">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjMtNi0xLTEtMA_2429d6fa-2dec-4550-a254-6fd6573da824">4.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjMtOC0xLTEtMA_50288d8f-aed1-4ad1-9a6f-f3d78414a826">1.14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjQtMi0xLTEtMA_e6e2e7bf-eff0-4479-b189-94cb7314ba21">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjQtNC0xLTEtMA_95089e6c-0866-41fe-8fc7-e795462e9866">1,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjQtNi0xLTEtMA_98fa3a04-308f-40b3-8d88-1b8742e4c78b">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjQtOC0xLTEtMA_5ad4b668-41f1-4829-b27a-5e559ce2308f">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> GILEAD SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMy0yLTEtMS0w_1a6df507-318e-4441-8ce0-285aa5d2058f">2,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMy00LTEtMS0w_79756a0c-9642-41e5-a52c-d2588200a970">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMy02LTEtMS0w_2d563853-221d-4f57-812d-5eb7d1a67c6b">5,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMy04LTEtMS0w_e3bd1109-9eeb-4230-ab23-5d135688bc02">1,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation gain (loss), net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNS0yLTEtMS0w_904b7040-dd56-4c8e-9bad-9d248fc137f2">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNS00LTEtMS0w_66ca8aa3-8131-45d4-996e-2693205b6151">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNS02LTEtMS0w_ece42b32-9b68-4237-8f77-04947d1a6575">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNS04LTEtMS0w_6832c359-9f7a-45c5-8492-e2032e431db3">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss), net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNy0yLTEtMS0w_37784c25-4c76-48f3-a5df-a0cec22d1617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNy00LTEtMS0w_1af78750-9daa-44fb-8119-98e2fc018b51">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNy02LTEtMS0w_c9e1b346-02c0-4e64-827c-09399ff6c530">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNy04LTEtMS0w_60cb4782-6ed6-451c-ba0b-5458f8ae3f49">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOC0yLTEtMS0w_cfc23036-173b-4536-9eea-fe5d88b4d877">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOC00LTEtMS0w_2620e223-64c5-43e5-ad52-eb2db155ec72">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOC02LTEtMS0w_780cd31d-de3a-4be0-98f9-b9b1aa499c86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOC04LTEtMS0w_b825c797-74e8-4112-86aa-cf739481ae8e">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOS0yLTEtMS0w_e0eb4422-6489-42a8-b8f0-67dd8117b88e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOS00LTEtMS0w_855be1b2-10e7-4bd1-b198-457110e55025">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOS02LTEtMS0w_8354f63e-b30b-4703-ae9d-a4a5093d370f">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOS04LTEtMS0w_48a0d992-69bd-4670-a29d-16cf9fb6f4cd">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss), net of tax </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTEtMi0xLTEtMA_712efb03-259c-421e-aa22-60a5f335f790">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTEtNC0xLTEtMA_79656257-186a-4bad-ab05-9a0863d53b82">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTEtNi0xLTEtMA_54c0d36c-2525-4205-a247-cbac5e460a92">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTEtOC0xLTEtMA_0a4069bc-1dc0-45b4-9bfc-fb083704972a">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTItMi0xLTEtMA_74313866-3f9b-4f6f-a8e0-67c65fc4c119">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTItNC0xLTEtMA_11057d5e-2d63-4b97-b900-4d7544a641ba">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTItNi0xLTEtMA_a5063f8e-9009-4816-99dd-8b97d5c1dd5a">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTItOC0xLTEtMA_702b4372-29df-4709-8ed2-136e50147d3a">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTMtMi0xLTEtMA_0868b7b4-a6eb-4e7d-b94c-266acc0b6c5f">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTMtNC0xLTEtMA_276fec76-b687-434a-9479-940a506cf080">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTMtNi0xLTEtMA_0d20213f-1700-436c-b7db-bf9977546ba0">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTMtOC0xLTEtMA_9b240957-1e95-4a43-91d5-2ccd199cec56">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTQtMi0xLTEtMA_3b7d34d2-c338-4bde-8888-99caf0959780">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTQtNC0xLTEtMA_8308ec40-72f1-424d-afa4-013ea5abcbf9">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTQtNi0xLTEtMA_f9463994-14da-4204-84a7-0ea7c1fc75fb">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTQtOC0xLTEtMA_e81ada15-973e-4653-878b-ed5e13824b7a">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTUtMi0xLTEtMA_52b9d48e-00f6-4144-a0f6-000606e2f2f2">2,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTUtNC0xLTEtMA_9a2afd7e-5d5e-4041-95a9-96f5a20183ce">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTUtNi0xLTEtMA_e4772ad1-9b82-4cba-a7d3-ba809b9d72aa">5,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTUtOC0xLTEtMA_c424abf0-09d0-4d21-8e95-e82ede957a3a">1,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTYtMi0xLTEtMA_25abed72-ce97-44d6-875d-c1be02dcbd9b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTYtNC0xLTEtMA_f93c84d9-59a4-4a8b-931f-d131f2f3213c">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTYtNi0xLTEtMA_17582e2a-6d25-4b67-8465-84afce4128f3">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTYtOC0xLTEtMA_d8981612-948f-4064-b449-519a630e627b">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTctMi0xLTEtMA_3db29321-269d-4dbb-a790-c63adaf36215">2,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTctNC0xLTEtMA_a4acbe03-332b-49b4-b3b7-2d1d87442b90">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTctNi0xLTEtMA_9c1792cf-3f9d-4cab-a6a3-8c63bbcdcbd3">5,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTctOC0xLTEtMA_658c6d84-4e22-4dff-9cc6-fed349fbb886">1,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gilead Stockholders&#8217; Equity&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; <br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive <br/>Income</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7cadd9af8cb4d648ad69a6bf5f40afb_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNC0yLTEtMS0w_683bb819-890e-4c49-b11b-6189ddd80dc9">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cadd9af8cb4d648ad69a6bf5f40afb_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNC00LTEtMS0w_af798078-99c5-41f8-8e4a-680fe1dec87b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic320c878f7da497289eedfe7777dbd63_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNC02LTEtMS0w_a548c4ae-7eec-4bc4-83fe-9ff1f808a929">4,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c2e7921e224837ab97ee0fe6c8f222_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNC04LTEtMS0w_06da1080-df22-4050-9283-aff0fface1d5">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b36b57f62a4b6f9933e96a8a774a03_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNC0xMC0xLTEtMA_ac71638e-6731-4467-a5fd-e84422515c5f">15,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce088514657437793db4cb212d85fa9_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNC0xMi0xLTEtMA_ad19653b-f7c0-4d6d-952a-10afb14048b9">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93cee50aef154d89907a30e4b6fe3dad_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNC0xNC0xLTEtMA_83a060da-ad24-4151-9010-b780e3e89146">19,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38550fb4b8e545b6933ed2239c97d37d_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNS0xMC0xLTEtMA_7dfbfa6f-fe14-4d55-8c12-bfb4f12587e1">2,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9a23e1ecf384ef8854c99561d634f7b_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNS0xMi0xLTEtMA_4d06163d-dc8a-45a6-bc58-87d3e63de72a">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNS0xNC0xLTEtMA_2be80482-2536-4828-a8b6-f5364dba7cbb">2,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4232b9569ef4dc784f4c812cd10758a_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNi04LTEtMS0w_bb3e6bc7-8eaf-46eb-ad5c-5ce92d38c2b2">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNi0xNC0xLTEtMA_d97ef09c-e05f-4852-a616-76f57dfc8813">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47d05e5d8c89426f941e19ac183a993e_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNy0yLTEtMS00NTg0NQ_7ceb1f68-5ef5-425a-9f35-75c204b16fe0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3c507e951f04b82bce9764e6f829c9b_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNy02LTEtMS00NTg0NQ_4df0655e-5569-4b2c-a15a-a8b7c95f0c83">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNy0xNC0xLTEtNDU4NDU_ee4ef760-5d72-4ad8-b6f5-04ebe5b1d5a2">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47d05e5d8c89426f941e19ac183a993e_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNy0yLTEtMS0w_3aebb3d1-2422-4c7b-8f08-13b22cfe892b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3c507e951f04b82bce9764e6f829c9b_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNy02LTEtMS0w_fda52b73-4e84-4378-928a-ddffc27b14fe">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNy0xNC0xLTEtMA_c514c8c4-2847-4fb4-afaa-12374a663afb">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3c507e951f04b82bce9764e6f829c9b_D20210701-20210930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfOC02LTEtMS0w_114fb092-821a-48bf-85dc-69880a96d5fd">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfOC0xNC0xLTEtMA_b67e6a26-23b3-46ac-96d2-298b7f59200d">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i47d05e5d8c89426f941e19ac183a993e_D20210701-20210930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfOS0yLTEtMS0w_a80f375e-0f30-46b5-90e1-c66d001b1a97">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3c507e951f04b82bce9764e6f829c9b_D20210701-20210930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfOS02LTEtMS0w_15fc2e1d-93d8-4bfd-a771-73e1481c0392">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38550fb4b8e545b6933ed2239c97d37d_D20210701-20210930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfOS0xMC0xLTEtMA_6fb8fab2-52d4-49ce-86e7-d58ea1971f08">176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfOS0xNC0xLTEtMA_5e1e8a92-0ef9-402b-9498-c64f693a0e3c">183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOmE4ZWE4ZTU0ZTBlZjQ1OWM4YmM4NmI3OWNkNDI1MjRmXzI0_6ca31a94-53a5-40aa-93b9-8d72889899f1">0.71</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38550fb4b8e545b6933ed2239c97d37d_D20210701-20210930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTAtMTAtMS0xLTA_5f5422aa-2bc9-464a-9a61-61d5f6629eff">905</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTAtMTQtMS0xLTA_88c6727d-6dd9-47a6-adda-cfa910b7210a">905</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcc67220f43e4bb097d163125b104986_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTEtMi0xLTEtMA_0ec45b3d-cc8e-4cce-9ddf-5395641d62ea">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc67220f43e4bb097d163125b104986_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTEtNC0xLTEtMA_274a74a3-e49b-4cd2-bf9b-f8e6294cc7ba">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a7f62ba5efc4ba2a75848977dcd0f28_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTEtNi0xLTEtMA_09ecd1c6-cd10-40c7-bd41-cee28819adfa">4,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic607fe5efeb4462ba677a36d66cea69e_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTEtOC0xLTEtMA_d2ef5de0-79b3-44e7-9a9d-aefc8085a4f8">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b01e048e144df19a994cf3c542a026_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTEtMTAtMS0xLTA_e02fcdd2-4973-4e2d-aff2-b1d89b86f8d3">16,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3db1326cef2b4443b8901640d2a96bc8_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTEtMTItMS0xLTA_9e6dec0e-1f32-4722-b7fd-9055452a7df8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTEtMTQtMS0xLTA_b4d0028f-a82f-4828-ab57-1f0f8d0835f3">21,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gilead Stockholders&#8217; Equity&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; <br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive <br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67dfd12ea224410a8e53fd74958a0afb_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNC0yLTEtMS0w_ce37a7b3-f349-4ed4-9643-588bb467d586">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67dfd12ea224410a8e53fd74958a0afb_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNC00LTEtMS0w_371a101b-aa6a-4ce8-932c-f9a16de81a93">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4708079b07443c7a62480f7e6915098_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNC02LTEtMS0w_c05e6620-e800-4246-9884-b5244ae2d2f8">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c8176bb4194abc96d3c13de341cd01_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNC04LTEtMS0w_ddcb312a-a2c7-49fa-9849-b0aed6915424">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if83cc5f617644ec28eca6ba9626e3244_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNC0xMC0xLTEtMA_81ce1bb0-b29a-436f-870c-7fd7bc57df8e">14,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40898fd2e2e842e88088320ba442b8f2_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNC0xMi0xLTEtMA_79919359-2fca-43c7-a00f-c16aa40b3e51">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNC0xNC0xLTEtMA_65f6fa3f-e6ce-4c7b-a577-3e8b36dbfa77">18,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4751784eb024137a55a00f62297811b_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNS0xMC0xLTEtMA_ab07cb4e-b673-4432-b6cd-d6f8a771cb76">5,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa59bbe2a2154f068815ed93165ba107_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNS0xMi0xLTEtMA_7a70f5cc-99f5-465c-bd41-7cad3df2ae59">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNS0xNC0xLTEtMA_5e23150e-0036-479c-87a9-d72022310666">5,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdca6d608af14f87aeafba62f5b528f1_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNi04LTEtMS0w_cb51d21b-5076-4613-b037-100ac7be4ae5">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNi0xNC0xLTEtMA_366cdc24-6131-42d1-bdaa-fe69ee149eeb">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71ab8e199657427eb6e86e9e2a9be3a8_D20210101-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNy0yLTEtMS0w_56fd44b0-e85d-40ff-85f7-c00ec21fb2cc">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c2cfa2e7ec445881cec30e9eed5e76_D20210101-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNy02LTEtMS0w_b0a93e41-b870-4e28-b534-fa0e1a0e3839">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNy0xNC0xLTEtMA_0c96106d-6448-4265-af90-dbbcc8d20664">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71ab8e199657427eb6e86e9e2a9be3a8_D20210101-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfOC0yLTEtMS0w_d1fdf602-3510-4eac-be4a-5596c85b243d">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c2cfa2e7ec445881cec30e9eed5e76_D20210101-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfOC02LTEtMS0w_d2fdf099-43e8-49ff-aeb5-eaf6514b9631">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfOC0xNC0xLTEtMA_846bdb8e-abcc-4c5d-bb51-ddaa9140d017">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c2cfa2e7ec445881cec30e9eed5e76_D20210101-20210930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfOS02LTEtMS0w_3505f9ac-5dba-4ba6-91ae-31a312544198">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfOS0xNC0xLTEtMA_d5a586df-25a0-4660-90bc-a5ae2bc77798">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i71ab8e199657427eb6e86e9e2a9be3a8_D20210101-20210930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTAtMi0xLTEtMA_41b2e2de-42c4-4f05-a652-24f6bf69eecb">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33c2cfa2e7ec445881cec30e9eed5e76_D20210101-20210930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTAtNi0xLTEtMA_3ea6ef19-d157-467d-987c-0a4ce2c2d285">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4751784eb024137a55a00f62297811b_D20210101-20210930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTAtMTAtMS0xLTA_192eb70e-fd2e-47f8-befa-81cff91a3454">607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTAtMTQtMS0xLTA_4d1cd8bd-8a93-4649-a15b-a6acc1c76586">631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOmE0MjkyODY3YjJkNzQ1MDc5NDIxZWM1YmYyODM2ODFiXzI0_0c9a20bb-7760-4096-9d48-bbad84f4b47d">2.13</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4751784eb024137a55a00f62297811b_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTEtMTAtMS0xLTA_2b51b99a-bfc4-484e-9ed0-fda792117298">2,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTEtMTQtMS0xLTA_26ec88be-1afa-4ea1-a240-f5258a449b10">2,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcc67220f43e4bb097d163125b104986_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTItMi0xLTEtMA_0a4eb44e-fd12-4f4a-8d75-59bc6eddffb8">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc67220f43e4bb097d163125b104986_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTItNC0xLTEtMA_38fc40e9-20d3-41f5-b6ef-87f1aa4392c7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a7f62ba5efc4ba2a75848977dcd0f28_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTItNi0xLTEtMA_c0829cb4-0490-4b4d-b80f-b3ac63ee80b2">4,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic607fe5efeb4462ba677a36d66cea69e_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTItOC0xLTEtMA_585288ee-59d6-43db-bc8b-167fe4531688">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b01e048e144df19a994cf3c542a026_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTItMTAtMS0xLTA_cab40b8e-a9ba-4fd0-a395-b806ccec3b37">16,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3db1326cef2b4443b8901640d2a96bc8_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTItMTItMS0xLTA_ee817bde-5042-4aa7-9f44-6fc6d9fd4690">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTItMTQtMS0xLTA_6cc68c0f-d7f1-402a-a32b-9e3210fc1a42">21,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gilead Stockholders&#8217; Equity&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; <br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income (Loss)</span></div></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if91124405d414b9dba81e4453951813a_I20200630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNC0yLTEtMS0w_9b13403a-2c07-4659-8355-6436bc6f8c76">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if91124405d414b9dba81e4453951813a_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNC00LTEtMS0w_0c89ad3c-9eef-43b5-a047-c3c0d6ca75c2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f810b4c15c48908cf2409474335f75_I20200630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNC02LTEtMS0w_05b69d38-c5df-4e0c-8209-dd99a60e582e">3,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id36e5ff34aee4ca1a00a4a484c912ba8_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNC04LTEtMS0w_f5159f61-3491-44b2-8c87-3f5f4b398c4b">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic03e12a879694340bc9fdc68aa15f297_I20200630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNC0xMC0xLTEtMA_516a1c1d-e650-45f7-9984-accad3827e7b">14,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44d0ae25eecf499fb680c4e796d4bbaf_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNC0xMi0xLTEtMA_b900946d-0e10-4a2b-89d9-82bb9215d7f6">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i740e8f78f6c348b0b796258c902c6df7_I20200630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNC0xNC0xLTEtMA_7e860cb8-dabc-4a3c-af86-3bc16bc8769f">18,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf9c8e7ee0794bd18997a355702704fd_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNS0xMi0xLTEtMA_ea66586f-d8ae-456b-bda1-5e9bd7445900">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNS0xNC0xLTEtMA_c1bd6370-9a82-455e-b0cc-e19190a46def">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68393aa2cad140b0813dae42d797b81c_D20200701-20200930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNi0xMC0xLTEtMA_5c192d24-2155-4d9e-89c7-ae055528a36d">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf9c8e7ee0794bd18997a355702704fd_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNi0xMi0xLTEtMA_8b9d67b2-498e-48ce-99ac-91a198cc1307">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNi0xNC0xLTEtMA_1b450576-432e-4555-9ee4-e47c49cf1d3a">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4276333617e7401db14493cc3da842ae_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNy02LTEtMS0w_4897f390-236f-4e19-a727-c17680b7959f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9f4a9c842e640eb850df6488920516c_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNy04LTEtMS0w_2f78214c-7f94-4683-8b00-42906b642a80">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68393aa2cad140b0813dae42d797b81c_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNy0xMC0xLTEtMA_8f7bb01d-2544-4925-84ec-09cdd25275a8">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNy0xNC0xLTEtMA_29e58cb7-68d5-421b-83bc-923564f43a5c">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2310959eb5074abf916d6715b8aa87fc_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOC0yLTEtMS0xMTU_fc88ab1a-a50b-40b2-8867-7849d2e19477">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4276333617e7401db14493cc3da842ae_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOC02LTEtMS0xMTU_54bad866-769a-4bb3-8614-7334ac87b634">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOC0xNC0xLTEtMTE1_0d0a9019-0517-42d5-8b4d-eee4ba6469bd">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2310959eb5074abf916d6715b8aa87fc_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOC0yLTEtMS0w_cef16e71-7e61-4142-ba58-e59400e5f413">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4276333617e7401db14493cc3da842ae_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOC02LTEtMS0w_b91239ad-b273-4fb4-865f-2bb8be00ff8e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOC0xNC0xLTEtMA_05b96706-35dd-40de-b081-78437b29f92b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4276333617e7401db14493cc3da842ae_D20200701-20200930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOS02LTEtMS0w_150f0253-2411-4c0c-a19f-a209b2de4205">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOS0xNC0xLTEtMA_99df4da5-156f-4b27-b5f7-59967bea3b25">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2310959eb5074abf916d6715b8aa87fc_D20200701-20200930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTAtMi0xLTEtMA_7e2c05ac-0d9a-40c1-a601-5c8a69a4a569">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4276333617e7401db14493cc3da842ae_D20200701-20200930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTAtNi0xLTEtMA_2398e6ec-ad68-46f5-8e7d-669f3ba3b14a">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68393aa2cad140b0813dae42d797b81c_D20200701-20200930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTAtMTAtMS0xLTA_a4411456-3521-4eb3-a913-b46b8ba09eea">229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTAtMTQtMS0xLTA_fac97fcd-b5df-4b9a-b5ef-61e7a07b75a8">238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRkYzA5ZTBmYWIyYTRmNGVhZDQ5YmZkYWY3ODY1ZTgxXzI0_511765df-8709-4887-8a47-18d64789b64e">0.68</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68393aa2cad140b0813dae42d797b81c_D20200701-20200930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTEtMTAtMS0xLTA_97d18302-9959-4f47-bebf-c745fd594e4b">866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTEtMTQtMS0xLTA_6551fee9-d458-488d-abc9-77efebfa30cf">866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib82a8b96d9074a4fb728c152000179b2_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTItMi0xLTEtMA_ae5aed8e-ff4c-4e02-aa4c-033baac542e5">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib82a8b96d9074a4fb728c152000179b2_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTItNC0xLTEtMA_d9c4bdb1-29fd-4395-9485-bf85a198fa72">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ca43e6b419249ee89f9dcf2bf9735ed_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTItNi0xLTEtMA_71addef3-6499-40b9-a9dc-705cd1eaf6a9">3,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb53663397049a380603edf12d76c3a_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTItOC0xLTEtMA_fbc4857a-fa60-4350-9f72-6494967ee0b1">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7e694d30cd45e3a1e9103b0b1e82e1_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTItMTAtMS0xLTA_aa0fec1d-41d7-45c0-8e30-ad367bbf464d">13,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377473f7a7634d6cba9a5bb6603d6547_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTItMTItMS0xLTA_78406e96-cd17-4f19-93b8-70fa3d27e275">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05bfa65a7fdd430ea5429b49909dff6d_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTItMTQtMS0xLTA_c93b769f-d309-4f30-85d8-d82d4ab4f966">17,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gilead Stockholders&#8217; Equity&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; <br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income (Loss)</span></div></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19f0cbf8e15f44e3a8bf106f16ddf237_I20191231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNC0yLTEtMS0w_76de0af4-f49d-403c-8ae1-fe81fff336ed">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f0cbf8e15f44e3a8bf106f16ddf237_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNC00LTEtMS0w_4f64090a-a435-4b6d-96bb-4e62f894825a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863402769fcf4a3abffd39d64a185584_I20191231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNC02LTEtMS0w_f4b20847-9ffb-4291-a840-45fcc6e2bcaf">3,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i188cf2bc805343608e1a7c9417d2404d_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNC04LTEtMS0w_2b17f1fc-40fd-4906-b5d9-cd6879148255">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2552479e6ff476e92abd17114269cd7_I20191231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNC0xMC0xLTEtMA_62f37c18-b30a-4a51-81a7-718a20ca9c2e">19,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f3b569ef25240f1a155a0024e7b8e90_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNC0xMi0xLTEtMA_c47c1bb6-c5c2-4cab-8ef3-66bd0aaa5ce1">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c214ead3cf04a2e9fc7bc2b14bdaf84_I20191231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNC0xNC0xLTEtMA_006e6d11-b4ae-49f8-9b4b-14780ac1f071">22,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative effect from the adoption of new accounting standard</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4e29df1f11f450ca7eb2e638244a8d1_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNS0xMC0xLTEtMA_9239f280-bb69-4dae-8a0d-7d3d875ff65e">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaae18a74fca47d1b00b45a50b94910d_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNS0xNC0xLTEtMA_0a69a55c-136c-4561-8fba-c0563b0c966c">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a3a3fc257534802a47360ab1e00d78c_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNi0xMi0xLTEtMA_f3ba9ae9-c24f-4ba0-9a0e-136dc6412e6c">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNi0xNC0xLTEtMA_76aa338e-a4b5-4cc1-93fb-e7d1670a587a">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65979baffae041ae8ddc09c614f2ebb8_D20200101-20200930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNy0xMC0xLTEtMA_9aa1fc29-7101-43c4-b3b1-a753e3f1f47b">1,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a3a3fc257534802a47360ab1e00d78c_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNy0xMi0xLTEtMA_c8886453-49b2-4e36-a76f-724a8a3252fc">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNy0xNC0xLTEtMA_a7bf51e1-171f-4fec-9d39-2644f142ef51">1,455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3bd1b11f59e45f4ad008ef2737fcd81_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfOC02LTEtMS0w_cb80eadc-cd75-46dd-8062-833df3ac9607">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57db840e2919481eb28184ec2cbb0a50_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfOC04LTEtMS0w_066072b5-ce80-4db2-86a8-ef952d1f4af2">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65979baffae041ae8ddc09c614f2ebb8_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfOC0xMC0xLTEtMA_091cddbe-1e98-41e6-9a24-c27d1204a48d">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfOC0xNC0xLTEtMA_82fc8232-933d-455d-9591-69ba27bc2ded">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i612f84efa15449cc9787e2a73fa82064_D20200101-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfOS0yLTEtMS0w_2dc3f4c0-a63e-4ca9-b5ca-2100596b3ffd">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3bd1b11f59e45f4ad008ef2737fcd81_D20200101-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfOS02LTEtMS0w_9ca1564b-f8f8-4f81-b435-122e891a02c3">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfOS0xNC0xLTEtMA_109e0389-6c30-497e-b909-68dead4719c2">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i612f84efa15449cc9787e2a73fa82064_D20200101-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTAtMi0xLTEtMA_f0d861bb-2a89-41d4-9285-a01f25818644">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3bd1b11f59e45f4ad008ef2737fcd81_D20200101-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTAtNi0xLTEtMA_6a481c55-e3b4-49b2-8412-1ce85d708310">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTAtMTQtMS0xLTA_fadfcefb-ef50-495e-b90d-0da09c341864">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3bd1b11f59e45f4ad008ef2737fcd81_D20200101-20200930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTEtNi0xLTEtMA_c1f9fb55-f503-4c80-a1e8-a3c1e0f0e682">482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTEtMTQtMS0xLTA_a003d93a-b5b3-419b-96f3-cb4291d95b4c">482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i612f84efa15449cc9787e2a73fa82064_D20200101-20200930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTItMi0xLTEtMA_9816afd2-0ac4-4f37-a6e4-dc27dab74103">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3bd1b11f59e45f4ad008ef2737fcd81_D20200101-20200930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTItNi0xLTEtMA_2e44a1d7-63b5-4729-8bef-7c71345abf62">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65979baffae041ae8ddc09c614f2ebb8_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTItMTAtMS0xLTA_93a6782b-818d-4fe0-8a84-6e4026daf82b">1,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTItMTQtMS0xLTA_eb577080-74f5-4502-8398-82fd8dfc801f">1,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTMtMC0xLTEtMC90ZXh0cmVnaW9uOjE2NGU0NWMwYWQ4NDRlMDRiZmZlOTg2MzdiNzA2ZDY5XzI0_1c5c46ac-f5b4-4cbf-a10d-9b4eef540b07">2.04</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65979baffae041ae8ddc09c614f2ebb8_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTMtMTAtMS0xLTA_6c29e802-1901-4515-b04c-bf3a889a3226">2,599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTMtMTQtMS0xLTA_86b8fce8-777d-4dcf-a9e9-7a6be7e75269">2,599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib82a8b96d9074a4fb728c152000179b2_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTQtMi0xLTEtMA_0221b73a-38eb-4f05-9ea7-cacf4ae74511">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib82a8b96d9074a4fb728c152000179b2_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTQtNC0xLTEtMA_92c3f547-d40d-497a-967e-1678c7d51c68">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ca43e6b419249ee89f9dcf2bf9735ed_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTQtNi0xLTEtMA_e29023ca-8e4b-4fbe-aa84-6b9410dfdf1c">3,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb53663397049a380603edf12d76c3a_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTQtOC0xLTEtMA_1eb5ba5c-8099-4d55-80dc-7a3a5eda2ca0">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7e694d30cd45e3a1e9103b0b1e82e1_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTQtMTAtMS0xLTA_a6e00014-e01c-4107-9b03-c20fb383873d">13,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377473f7a7634d6cba9a5bb6603d6547_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTQtMTItMS0xLTA_6b76e31e-20bf-4fd2-b634-c8ea0e2e3015">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05bfa65a7fdd430ea5429b49909dff6d_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTQtMTQtMS0xLTA_76a71e20-22f7-4cbc-b4bd-e17e4a4c4fbe">17,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNC0yLTEtMS0w_dc22c516-1109-45f0-a992-735d404769b7">5,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNC00LTEtMS0w_180d5d34-a378-4fb3-849d-a8f3a01284e4">1,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNi0yLTEtMS0w_d3beae80-9ee7-408f-96f1-2e6c81cba931">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNi00LTEtMS0w_7449b166-b821-42b9-a336-a57113ddea5b">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNy0yLTEtMS0w_8fce7abc-866b-4c2d-bca1-694a28dbd261">1,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNy00LTEtMS0w_94fc6cc0-70f5-4181-bce8-b4bf92d59cfe">844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfOC0yLTEtMS0w_10c6758e-3825-4a44-813a-d7aefd3283ab">476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfOC00LTEtMS0w_665a5717-5848-4261-bd7e-d82dfa235443">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfOS0yLTEtMS0w_c87636cf-ebef-487e-8a72-d5d35be56474">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfOS00LTEtMS0w_eaa26349-b429-4c62-a42f-6836e9bccb84">5,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTAtMi0xLTEtMA_23d18f72-b140-4ee9-9477-71671dfb27c4">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTAtNC0xLTEtMA_e607f813-dfb5-442e-92a3-c0a35c04fc1a">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss from equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTEtMi0xLTEtMA_71295755-bc38-4462-b247-6273ea26b319">667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTEtNC0xLTEtMA_39636e45-a631-4724-8801-567f1dc18243">1,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTItMi0xLTEtMA_6ed22c58-1743-4a21-96fb-d90455d154d2">601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTItNC0xLTEtMA_15ec5a15-772a-40b8-b318-28e9d0be30ca">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTQtMi0xLTEtMA_861be1b1-987c-44e9-8e23-003dfd380ef8">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTQtNC0xLTEtMA_48a489d6-2ddd-4454-ba59-e757e9178654">334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTUtMi0xLTEtMA_9e7772b6-087e-49ae-b622-4b7ee170a7f7">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTUtNC0xLTEtMA_feebc8f9-6824-4167-8e34-129a2148d4f9">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTYtMi0xLTEtMA_a007d44e-a1ba-48b8-928d-21dfd6713c69">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTYtNC0xLTEtMA_8e239059-3c12-450f-8b6f-011bcd850cee">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTctMi0xLTEtMA_c7f67589-b61d-434e-8f6b-8df927a87369">242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTctNC0xLTEtMA_f14e5a77-126a-4b25-a810-2eb69f4ebd6f">134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTgtMi0xLTEtMA_87bd9cb0-24bb-4d12-92a5-65d0752b20ba">463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTgtNC0xLTEtMA_75cb65cc-e763-43ae-aba3-38dbe4f08a18">428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTktMi0xLTEtMA_d8b67d89-30ed-4722-a1b3-870084a1c095">851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTktNC0xLTEtMA_e31fdf0e-723e-4a7f-a0ef-6df942c07794">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjAtMi0xLTEtMA_ca97cf50-9a23-4ac4-99d2-194f1f5282d0">8,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjAtNC0xLTEtMA_07c7eaf5-c924-482f-9fad-fc44a1e20783">6,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchases of marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjItMi0xLTEtMA_c1da62ad-156e-436f-b57b-1006f105227f">2,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjItNC0xLTEtMA_2e6c66a5-a130-457e-9b7c-bbedd2e48394">19,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from sales of marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjMtMi0xLTEtMA_1731e512-ab5b-43cf-96cd-0b29572628d7">506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjMtNC0xLTEtMA_af5306c1-2f18-4c73-9091-d53d52acfcfa">12,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjQtMi0xLTEtMA_5f59a3be-7003-49af-a35d-f2d084b8403c">1,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjQtNC0xLTEtMA_103e0567-4536-4a79-ad26-f864ebbb5c53">8,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquisitions, including in-process research and development, net of cash acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjUtMi0xLTEtMA_d73a737e-b238-49eb-8bb7-1dfed73fb7b1">1,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjUtNC0xLTEtMA_79f3454e-f0c1-43ce-a97c-a60c9f54a186">5,804</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjYtMi0xLTEtMA_2708411a-ea21-40bc-8c88-b8b2aebb3162">332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjYtNC0xLTEtMA_e69d4da9-97bd-4031-b5ec-cc7a74442cee">388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjctMi0xLTEtMA_6c5b30f2-3734-4da0-8cd7-2f00dcafe032">423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjctNC0xLTEtMA_260307ef-aaa2-4783-ac3d-9e6852db3696">469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjgtMi0xLTEtMA_ed826e4d-b3d4-4f14-affb-50ab27af6ee7">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjgtNC0xLTEtMA_083f749a-2edd-4007-9645-acb5cee8fc3e">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjktMi0xLTEtMA_af02a7cf-a99c-4c70-b493-0a19cf52ab7a">2,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjktNC0xLTEtMA_57373ede-8f09-4a4b-96c4-55d61d6532e3">5,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from debt financing, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzEtMi0xLTEtMTI3_88e24bb2-8d60-46c7-a57a-94509f933b3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzEtNC0xLTEtMTI3_aada7063-0721-4c64-9c72-3e353540f2a7">7,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from issuances of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzEtMi0xLTEtMA_d482648d-f91e-42b1-8bf1-278ba038ea3a">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzEtNC0xLTEtMA_8320871e-7d72-4c2a-8959-9c8f2f8c8c3f">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzItMi0xLTEtMA_403e72a7-b92c-4317-93f4-a3ad78f5b58b">497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzItNC0xLTEtMA_6ff34848-9ec5-4c6c-b652-521842a4e13c">1,583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Repayments of debt and other obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzMtMi0xLTEtMA_57a98dca-f952-4853-86f5-af23494f4cf6">3,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzMtNC0xLTEtMA_7c8e65a9-964f-4009-b044-495d89dd5769">2,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments of dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzQtMi0xLTEtMA_f45d4dc0-0323-486d-9359-bddc11bd6331">2,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzQtNC0xLTEtMA_7172a580-e262-47c2-823a-94e222a8ea16">2,591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzUtMi0xLTEtMA_a2d6bcfc-1683-47b5-9130-0f2db46d4c64">134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzUtNC0xLTEtMA_73e056e8-5f9b-4500-843c-522ecc02fea9">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzYtMi0xLTEtMA_febdf105-6ec5-4fda-aff9-25764462bd2e">6,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzYtNC0xLTEtMA_d9808276-619d-4bd5-8fc7-91b058d491fb">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzctMi0xLTEtMA_c99fcf02-b1a3-4112-be8a-a15c1a12a341">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzctNC0xLTEtMA_f79c4a0e-1f18-4b6b-8eef-2a2bbe4fe99d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzgtMi0xLTEtMA_5163b52c-d71b-42d3-98b3-89fd119cda95">1,635</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzgtNC0xLTEtMA_7f9b8ed2-0eb1-454d-b907-d07c7aa26986">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzktMi0xLTEtMA_1a4d0c33-ecd1-4ca6-9741-3cad623b4e97">5,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c214ead3cf04a2e9fc7bc2b14bdaf84_I20191231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzktNC0xLTEtMA_a1561ee6-69b6-4d6e-86b4-aa7ad3871f5a">11,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNDAtMi0xLTEtMA_c4ae238b-938a-49c3-a46c-eef94d40dff8">4,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05bfa65a7fdd430ea5429b49909dff6d_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNDAtNC0xLTEtMA_b24b76ff-f3e8-4c24-b54e-df307d2f1ce6">12,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_34"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTc5Mw_f9710ffe-f76b-482a-a4c8-c1d799c9a868" continuedAt="i2daea195ced342bbb09369fe37c07a6b" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i2daea195ced342bbb09369fe37c07a6b" continuedAt="i8d7d0511b4e34cacac3af39f23926cc1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTc4OA_46ab677d-cce7-4c50-ac63-d782cee6b839" continuedAt="i1fed3aa4df5f4d83893be9fe5233bf41" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and a variable interest entity (&#8220;VIE&#8221;) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We did not have any material VIEs as of September&#160;30, 2021.</span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1fed3aa4df5f4d83893be9fe5233bf41">The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission.</ix:continuation> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTgxNw_440cac44-690a-42fb-8302-b75f287f3771" escape="true">We have <ix:nonFraction unitRef="segment" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfMTgyOQ_690c6c66-eeb8-45cb-882b-f2e6688c5f09">one</ix:nonFraction> operating segment, which focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of the company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business.</ix:nonNumeric> See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies, Estimates and Judgments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTc5Nw_9f853e44-6fca-4e20-8502-9c31bb98c33d" escape="true">The preparation of these Condensed Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the coronavirus disease 2019 (&#8220;COVID-19&#8221;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTgyMQ_372467da-f00c-4425-92c9-af8a5d6effa9" continuedAt="i4e1d690573e2453da7d0aab227363c8f" escape="true">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8d7d0511b4e34cacac3af39f23926cc1"><ix:continuation id="i4e1d690573e2453da7d0aab227363c8f">We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States and Europe. There were <ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTA3OQ_210f55ba-57a5-482e-90a9-9a6999fcb939"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTA3OQ_33d5173f-192c-407f-a763-ce13b0bba8d0"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTA3OQ_8e10fac9-0b99-43cf-9ba7-ae607900a97b"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTA3OQ_923417c5-d79b-4c48-a305-751b470155b1">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> material write-offs charged against the allowance for the three and nine months ended September 30, 2021 and 2020.</ix:continuation></ix:continuation> </span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_37"></div><div style="margin-top:13.5pt;padding-left:22.5pt;text-indent:-22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMjUzMw_871e907f-3db7-4527-aff1-1ee489a67f11" continuedAt="i8967e29a8cfc4ba583e13ed7963588ea" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i8967e29a8cfc4ba583e13ed7963588ea" continuedAt="i6489e1f41c1a4257bd43c2f07e37ff18"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenues</span></div><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMjU0NQ_fb3a9a04-df7c-4339-919a-16fdddfb766d" continuedAt="i254b016aa6814c45a1cd9ab6cde1494e" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.660%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Sales:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia55ca9423cea4d12b888483189b2ac1f_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC0yLTEtMS0w_6d15e035-016f-43e7-b9a0-f60e674417f1">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8aa096b135f48158580b40a60e33019_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC00LTEtMS0w_beff4668-53bc-4743-a12b-1eee416b31bf">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36a8c27aca7b4c4eb248168068a32aa5_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC02LTEtMS0w_757b1154-bae8-4602-817d-6ad0da5e4978">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c91fbfc86b4896a3a819c4d77bdb7d_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC04LTEtMS0w_485aff05-719f-40c8-9535-a89fd17eade5">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6111ed4b4e34cc0938dc6143421bf29_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC0xMC0xLTEtMA_1c50c3de-09e3-48c4-910d-ef844817346e">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846bb97183f648a1a345c7417b016402_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC0xMi0xLTEtMA_37abecf6-72ee-4a2b-ab65-1be05e5f1897">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde4cb31f8274161ba1a860f8c484f38_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC0xNC0xLTEtMA_46cef4b3-e45c-4ffe-ae30-896c18200497">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c0f1a209914347a5e69fa51270ee29_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC0xNi0xLTEtMA_ea02e353-c410-4354-85fa-31d265bfdbf2">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768c3bc1ec8c43ddad2162082a96cd6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS0yLTEtMS0w_a22ba602-8a76-44e4-b68f-476d4783f76f">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9a118513ef49819b2577666b0ec096_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS00LTEtMS0w_6881a87c-2b67-4065-87c4-75699779d466">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733e5fef29374d46b413dee54bb19109_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS02LTEtMS0w_02004383-d01c-4367-aa96-50672a937012">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90b02afac5b7406d9c151b1f25da49ab_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS04LTEtMS0w_3502b122-3a4f-4d50-8a7d-dba7d382f933">2,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9d39a80c434949bcf4d4dbaa9759d7_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS0xMC0xLTEtMA_1a7ba771-3827-4215-83f4-d12949c8c87a">1,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ca5be4690f44a7bf33e1db73a1d060_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS0xMi0xLTEtMA_f7d184ff-91f3-40b7-8873-6b2862687599">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0257f3a298140fc84dee8d53d699670_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS0xNC0xLTEtMA_dc40237a-a1da-42cf-932a-8f6c2c9c8a74">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f7a64d9f59c4811a20101fd386ee115_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS0xNi0xLTEtMA_53ac2798-41e5-4e88-80fd-e981c7946bbf">1,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i417036899f4b4ba6a942d6c89d2cf9b8_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi0yLTEtMS0w_4021fce1-7239-44ba-aa8b-a58834e7c145">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e1d6d95b2c4d2a920c8653b06216b5_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi00LTEtMS0w_b225343e-5fe9-446d-a805-2214d41aa318">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83e6d6c2611b4c2e8c4aecf466648862_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi02LTEtMS0w_7e1ce8ef-ca59-44c5-9212-5818e7c009df">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bfa430609e94754b5309dcbd1f54afa_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi04LTEtMS0w_e4bd0bbf-5040-48a1-9245-f2104fcc1f93">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524768e71ccf4918b463a9f11d0b12ad_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi0xMC0xLTEtMA_f8f4c68e-b936-43dc-a03f-5626981a7beb">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bbd970a4b1c41ac826211b086ec75c6_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi0xMi0xLTEtMA_b98c9ab2-2173-452f-8226-5bf3eb79bef1">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585135633c624761b4c1a83f8fb3835f_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi0xNC0xLTEtMA_6e9156a0-8d30-4070-a7c7-b2cc5b333c32">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcda312d5cda40abbb9ac037d9a20f64_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi0xNi0xLTEtMA_ff364812-35cc-4fad-8c82-71da3f801960">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c13cff5ea440d6856dd460e75e1cce_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy0yLTEtMS0w_6b6cc507-99ae-4aaa-9f6c-5db6f3553e95">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972c68c99d2b48aa9f0ab252eaded219_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy00LTEtMS0w_2eb0e089-b683-4ee0-a690-7ec173d06be2">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bcac0500428449ba45e660bcf11a22e_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy02LTEtMS0w_355df11e-6f5a-4325-8fdf-b4bed2f5581d">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5f64fafefb476897c670520ef3e684_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy04LTEtMS0w_9b1de614-5516-45eb-be2e-3f1fb0c5acd7">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb444609f3c343faae5bc31dc0f2969a_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy0xMC0xLTEtMA_be97978a-5663-41aa-941e-b7c9e9ca1b72">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11b21909ece24606afb19d200d6cbf45_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy0xMi0xLTEtMA_fb474e29-f623-4f09-b27b-cf8d3ef5417b">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie64f24cc49d2461993b4706f48070582_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy0xNC0xLTEtMA_5e11e7b4-fb78-447f-82f4-1fb03240d93d">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia581ec4341004cacbe1676f4824925d5_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy0xNi0xLTEtMA_63657381-d926-46c3-84e2-072a4977c3e2">508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0beeedfff0ab464dacc2dfe91fea027f_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC0yLTEtMS0w_d08d3070-afa1-4dd1-a4b7-3cdf6a1eb09c">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda373a4474d4fddbe280b1ceeb9773b_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC00LTEtMS0w_40cc960b-3af1-495c-8616-88ed85b2f1f2">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5ff99375b246b19d9a454b2bfcd5c4_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC02LTEtMS0w_3908ff36-89a7-4a26-ace3-b3a70eb9adc8">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6072428678a4c13b3bc2cefe46e2367_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC04LTEtMS0w_52c6db33-a43d-4246-9a60-a6443b5453ed">744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5830a8e44aad42d6b4e5c07745f1a654_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC0xMC0xLTEtMA_b0aa0a55-72d3-40e3-b739-dba053738aaa">669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2499d0efe544c88b850f4e06d6d0fe2_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC0xMi0xLTEtMA_99f818e7-99dd-4d3a-a2b9-7daa59b81add">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3df12d48d77f444687886781f8f13ce0_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC0xNC0xLTEtMA_315d084a-d229-4cc9-b5e5-e0932282da68">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9021fb6917c34472a60654a134736f11_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC0xNi0xLTEtMA_2c031ebb-9b42-44e5-ae4d-615cd9f001ea">846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i340ad048883f42aa821f43d0819810b8_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS0yLTEtMS0w_36133d40-cf1f-4afe-bf49-9c24ea8d72f0">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i593cc1643d3b4cffbe6c45b7b951be8b_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS00LTEtMS0w_83d30979-564b-4ca8-b9ad-4aaeb659a587">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96b216119514bd5b34e404efd229b24_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS02LTEtMS0w_14c73d51-24cc-4e47-8fc8-32165694fce3">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd1cab9c1fd4ca68901a86b57b2fb99_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS04LTEtMS0w_553cc1bc-3bb8-4ea1-919e-c2a4ea76206d">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3484ed15b64c4fc291da3be7d9248674_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS0xMC0xLTEtMA_db996a34-d8c1-49e1-95bd-14ff23797502">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f663d9f8f284b539edc2448996d7698_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS0xMi0xLTEtMA_f6365c23-953a-4abe-ae61-a9f16c74b251">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i121ea362bc6448bc8bed2159e95e89b0_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS0xNC0xLTEtMA_3747add7-0ed7-40fb-92ec-5eda8de26d89">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a9823f6159647fb992be0b7838c2a93_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS0xNi0xLTEtMA_92bba081-ccbf-4865-9a13-46371ce51a98">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9dfdb77c104c9ca832bcf98a8246d3_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtMi0xLTEtMA_ea26c46d-86cb-4aba-821c-90634301ac07">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b44da404f64237881a6460aa4636ca_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtNC0xLTEtMA_efc92776-53a9-4b86-8e48-522f9f7d2579">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab0ac7cc574410790fabeb761d1d174_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtNi0xLTEtMA_2066feb3-0cb6-42ab-9d55-93ca719a6b6f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e2ac5333234a66b3903412e42f3e68_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtOC0xLTEtMA_04198d76-68e9-4612-a282-b1444a193f47">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75c03337a48d4a949b4288448d18a1cb_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtMTAtMS0xLTA_a2ec1d73-6c0e-41ea-a69a-c30e11e7a4c3">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idca8d358805f479b89d1fb6e6719e857_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtMTItMS0xLTA_66abed2c-99e8-4748-a66e-4f90cb7d01ce">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52e40c6015764bd69ee9cbf82d281820_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtMTQtMS0xLTA_3ced7eec-0b84-4bac-b06f-5aa198a1fd14">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a28cac4b61d41f5b9356a0b6aac960f_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtMTYtMS0xLTA_39c34bf2-dccc-4a59-b041-fa72f1a6f8d1">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd6bc5b0bed743c29791702bead202bb_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtMi0xLTEtMA_7d3f9a91-8e11-4b60-8aae-57c12d31ae8d">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id310e22cdbef4eb1baca5c55f8b8fa02_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtNC0xLTEtMA_d8ce5f24-f3b8-4790-8238-4136cbdf5661">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d60a8d39b34372a1be78e500f813c3_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtNi0xLTEtMA_b407e242-a9df-4eea-9eec-152db09d369e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a580919a214b2d895ab413f26c8880_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtOC0xLTEtMA_7f9cda84-0daf-414e-b84c-362a20fd9233">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a7ae2ad394446693596affca1e12ab_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtMTAtMS0xLTA_a95a8c94-6b22-47f9-b5da-15d024048c1b">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754a2616edfb4f3fb575bf9a85114f6a_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtMTItMS0xLTA_1004f0b1-fb72-440c-84e7-e2c13b30c560">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48939703477c47fe9550c4f92c6ba557_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtMTQtMS0xLTA_70809368-e934-4c2b-b15b-ffd3ce5f47ec">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie40a71d15ea447a2ae8f68926fced7a6_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtMTYtMS0xLTA_4db0c86c-9595-49fd-972c-c33cc25bcf2a">509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e606e91fa3e46acac32b0de0f54dbd0_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItMi0xLTEtMA_4d9c6a0c-a725-4950-922e-db9d7e34f9cc">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c941e621c4b4cb1a5e4e5d4ba5a859a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItNC0xLTEtMA_29532596-c6b0-4c8d-af2e-597d3f671e0a">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icee57962d9df495e8b9f2cbabe1f503e_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItNi0xLTEtMA_1a068d86-1dc0-47e8-8c31-90ef1ff801b2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb5b96718e3d479492237b8214637bd9_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItOC0xLTEtMA_e9e983a4-7292-4f2c-8a46-caa9cc75f142">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ca8a58c2d94581bcfdc60a41cf40ec_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItMTAtMS0xLTA_5ce706a3-0901-46be-8d7e-56e37aa9e1b9">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864044e4908b498e881e97143cb3166e_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItMTItMS0xLTA_9fe8b681-9b9d-4127-9383-2c1d0398999f">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ab94a8ddba44f79cfe371276e8f9bf_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItMTQtMS0xLTA_b930fa54-9379-4ff3-9c39-fadbb3bec369">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia93c6c5c009b4c31b3fa92708b8d815b_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItMTYtMS0xLTA_92a7374d-cb46-475f-8735-5ddc42ef8f23">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b348befa53e4159bedea795454be27c_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtMi0xLTEtNDI0NzY_108102e5-d685-41ab-a201-8a0a8b6026a2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab1615ced09e40b1aa3cc44738550dd1_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtNC0xLTEtNDI0NzY_3860c166-4481-48ae-9318-ef9246d6f1ea">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if20f435a41c348cbbdc43f245ac16861_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtNi0xLTEtNDI0NzY_f2213a41-0f7f-4326-b82f-405c923ec4d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73bf790cd1a346988b368c7d3cde8b8f_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtOC0xLTEtNDI0NzY_bca89de3-662a-4a0c-a6b5-745e9232e0bd">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8612d631840e48e895d251930e52c4b9_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtMTAtMS0xLTQyNDc2_2b63b1e4-8392-4a13-bc73-7629d439ccd4">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76968fb55cbc4ae28307471f0cccfdd7_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtMTItMS0xLTQyNDc2_136ac9d8-1493-45fd-8c0d-ba1c1502e391">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10ab46addd4942a0b01ed1d3a2011f31_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtMTQtMS0xLTQyNDc2_1d3e6f85-ca02-4767-884d-67ddddd2d8eb">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47709a114cd148c0838a562496cab936_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtMTYtMS0xLTQyNDc2_5e23d6a3-6bb0-418a-aa89-bd75fea91c95">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c463d05c4ab40cdb9e847fd0f510bea_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtMi0xLTEtMA_6f6278e0-0032-44a6-8cb6-3e38fafcd85d">3,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i171565ffc87743c1aba490024359250a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtNC0xLTEtMA_df307c8e-3f23-447e-8a79-c103fc1cec67">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3ad8d00ec64e84b7f987b2ba29eabb_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtNi0xLTEtMA_018cfd61-f884-4992-8860-79443890c086">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b9c2f39bff448a95abbd58f45d0fd8_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtOC0xLTEtMA_80d48b62-aefc-4096-b454-779b6d00667e">4,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86391bc6dae4373b89bd8ab38605880_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtMTAtMS0xLTA_a040216c-33bb-43d5-8653-dd998c930623">3,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ad4a6158ebe4dff890142a1696e812f_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtMTItMS0xLTA_c64b650e-cd7e-4f83-999d-f56882cbbc63">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dffca717ae24d34a470d8d9a38dc095_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtMTQtMS0xLTA_f26f4701-988f-49d3-bccf-47149588d371">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61275390a7e640b2897c50f960fc2caa_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtMTYtMS0xLTA_12f68429-aa54-4df4-8ec4-99fc1893b382">4,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61446b694c74e7d9f5a65b521566c20_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtMi0xLTEtMA_ed638451-fe4a-4ebe-8756-c43445d420d2">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib982a6b7a5ef409bb13733f8c74abbbc_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtNC0xLTEtMA_77f2ea67-5d50-4fc3-ae15-d6fe88c1afd4">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e3676630be045daad191ec0e8486184_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtNi0xLTEtMA_39bd7519-91b2-4fb2-95a3-3367d0b764f3">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a702cd0f2e242db85b30aa6ce77bd11_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtOC0xLTEtMA_0fa134b8-11f5-4fc8-ba1c-e13c0089af3b">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d0c47edbf149b4b42fcf95a60ac88b_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtMTAtMS0xLTA_98e26edb-0d7d-4463-a0de-cf15a9d1e52a">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82bf2e8a84c54403aff0f3a4e0827765_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtMTItMS0xLTA_d98f5ef5-03cc-42b2-b672-2e9d30bfe735">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529a378d1a634502932448df5c7dfc96_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtMTQtMS0xLTA_f75fce04-80e4-4d89-9025-5b7a6550c0e7">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c2caa8a7da4d24a4facd4e5589dff4_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtMTYtMS0xLTA_45698578-aa22-40ef-85d0-747b4d36ae85">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28240f36b37149c0aebeb17174beff82_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctMi0xLTEtMA_1189b5c7-d3d6-442e-a082-1d75290ea488">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5536e23c6241a49f1464d8fe7455fc_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctNC0xLTEtMA_02b73f71-5147-4ad7-bf10-8e50c581fc82">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a32343f5754479b35423074bb85146_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctNi0xLTEtMA_b2f997ca-8807-4a00-b089-6ea014283fa6">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7520be9c8c2b44299328cc6ffba5984a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctOC0xLTEtMA_b83d4698-0cd7-44dd-ae43-1cdb9a6ce4a7">332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505f00cc79eb434fab41a8fc651c07bb_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctMTAtMS0xLTA_426c60b8-0b0f-49b3-966f-31b65815df08">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia266f177505e46e1bf32006d610309d5_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctMTItMS0xLTA_d6975e35-3f9c-4f39-b3fe-9116913b19cb">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871de7451e1745a0a07ed808518e7b3d_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctMTQtMS0xLTA_31270a3a-5d8d-48ad-ae76-b8f124a6cbce">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99b5ce6646c74d90aff700749d2e8cfb_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctMTYtMS0xLTA_c3f2a20d-5765-4a1a-8541-f99c4d4aa581">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceedaa27c5974485aef9d4d3a5782af9_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtMi0xLTEtMA_5f452b87-9ad9-4ed6-994b-4f6d26e79fb9">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554974bf2ebf487c9a569c72bf26081f_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtNC0xLTEtMA_65e42ce4-e0ab-49a6-8237-2fb67024a510">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cbc708d4b1a44a7a2159db8585b1eee_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtNi0xLTEtMA_f49ec81b-edc6-4c13-96d4-b31e4e6d8687">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac3e5d698614f858c14ebe4eb398eb7_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtOC0xLTEtMA_b199883d-a119-4031-9943-b19db9a15df4">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6ded5571864ffd9ce7c0d50dc74892_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtMTAtMS0xLTA_c76f29cb-2e8e-4344-b557-ec3f1c88cd8f">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b63f63cabe44e2585bbadd57fa354b1_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtMTItMS0xLTA_18faf89e-8213-4df9-981d-6180ce841a89">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac3caa38232a4a51a8ab79f61e2251ff_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtMTQtMS0xLTA_734fe6da-3d49-4fcf-8b91-f70fad805f9e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieffd3dd156194386848193bc49944ee6_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtMTYtMS0xLTA_18f75d8e-b4c6-4f41-a15c-7fbaf2cad943">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83a6dddb7daa4a5ca29ac5484a6fd6e7_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktMi0xLTEtMA_fa2c9b85-f9a7-4a69-8b5e-eccb3303db1d">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f0238d623444989439cf7baaffa508_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktNC0xLTEtMA_d4366c48-094e-455b-b30f-798de0edb127">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45562ada92804faaba94694bf0efa14a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktNi0xLTEtMA_32b6986a-3da1-4534-b551-bd525a71c51d">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i826c955d2db24a8fac6267b635be2cde_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktOC0xLTEtMA_85c71a50-4a2b-403b-99be-683691f70d88">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73efd497975415fa3b80207050da730_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktMTAtMS0xLTA_d5c1488c-62c1-4326-a058-2e3817ba4d27">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2ba5e907414bfd8ea65cf2a73b82dd_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktMTItMS0xLTA_f1048073-5733-466d-a3e4-2fadc7329163">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic82244d6f2a444548484e7aec01540b2_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktMTQtMS0xLTA_2ea53ee9-a16f-4f13-8c54-e5aa718a08b0">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19aa5a3f35bf4604808d9f2e3a8da3d0_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktMTYtMS0xLTA_0ba3185b-1c50-4c40-8326-a791b970d144">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis B virus (&#8220;HBV&#8221;) / Hepatitis Delta virus (&#8220;HDV&#8221;)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7d7312714a49a0a36fa523e3b8b0a4_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtMi0xLTEtMA_2eefd392-c46c-4f10-b0ae-648101348d28">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0baa0f95e2af4393a1730300142cc581_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtNC0xLTEtMA_55e43fab-61a1-4999-8c76-8ca6ede77a81">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88742fc2c2b34f5ea2b9520a011826a8_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtNi0xLTEtMA_c97c710c-85e2-4687-a918-2c6af9c341e1">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf9b1de4fa0b4462bd3dc919628df7de_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtOC0xLTEtMA_7858af8e-d82a-45c0-8c28-51e984251631">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1115a331568c4809844ce0028077a85a_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtMTAtMS0xLTA_3a8fbcac-24be-4f58-9e1e-a294a1643468">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8837076c1a0d4dfc86bd66bf5152de38_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtMTItMS0xLTA_60db4e0a-da84-4ff1-b873-b385a3e800fc">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i444db132af094e4bbf54b5614246e999_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtMTQtMS0xLTA_fd55813d-2d0c-4f19-bc0e-5b7d1ed7c838">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a81a8e5d9974ac7bde5d42f5a4fc336_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtMTYtMS0xLTA_72171d55-3cdc-4ba5-8fbe-20a363ade880">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa8b523c2e824076a748ebd245595664_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItMi0xLTEtMA_a8646aa7-4bc1-4ce0-b101-8724c7ee7f01">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70ba4cf64c94219a9e327880de4ffb7_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItNC0xLTEtMA_ccfb6196-eada-41a4-bbd3-598706a5aff6">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f05f61614c147efa464532642700a6e_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItNi0xLTEtMA_d397d51d-b07d-459b-bbd5-cd2b0e51e378">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f53d3fb034456b9a305a7ed3d3e66e_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItOC0xLTEtMA_e7ac6090-9bfd-442a-881e-6c4eecb7a4f9">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a017e3308ef4cbb9b933e55ec090998_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItMTAtMS0xLTA_32b30ebc-e1f8-4d67-8743-af32448ca060">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea639de29d0e4d668506abf5fe3550ad_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItMTItMS0xLTA_3ea461cd-7d21-4331-be91-a53c9d81115a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife19093e97a54f5c9eb24677048ec618_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItMTQtMS0xLTA_bc512ae7-a976-456d-8462-a665684aa16c">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5266ed380c4d492c9019fc51f76cefd0_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItMTYtMS0xLTA_8b6e99b8-5e5c-4846-9a91-3bd35252202b">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eb9b983d1b54d55beb90a63dddb2c59_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtMi0xLTEtMA_3cd510c9-aca4-4c9f-9d39-5f9cbe0a491b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf984fd7000f4775a945b8b0f7942e2a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtNC0xLTEtMA_fce2e293-aad6-45e3-bcba-3b197a71a1d9">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29ec2e59c50f41ca958a6fac1402679d_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtNi0xLTEtMA_0e73b5ee-399c-49ff-b51c-4c92bc6c54fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f4e484bfe8744e48ad91049bec90979_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtOC0xLTEtMA_8cde92ee-f6cc-4ac9-9d43-6ccf05c2a2dd">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3732c23942243a9a941c7c4e278892a_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtMTAtMS0xLTA_0794001c-98c3-46cc-9a41-5aa19d5ee209">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i877e24c5d0694819b01d486f5d882659_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtMTItMS0xLTA_e9e98a00-94db-4973-8344-fb32dbacf60d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf1741a698e64669b6b86f03281e3c65_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtMTQtMS0xLTA_6d6ec1d8-870a-4579-af19-be2fae4fa2eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1dce33288a4302aaad5691f38a09dc_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtMTYtMS0xLTA_218c1f34-ad9a-4006-a729-abad2eaf149f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80097a5080c0445eb9773bcbbb99bc1c_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtMi0xLTEtMA_88dbafd4-3c41-483a-ab4f-549bb67d7520">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19103f7ddbeb423abb4a6bb401db7fff_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtNC0xLTEtMA_7716181c-2a4d-431a-b38b-6cf754f1fbf0">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica155088076646c3a5bd1588f0bceb4b_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtNi0xLTEtMA_bd056b31-e302-4cbe-a0c7-084b05e27e18">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia812590aed6d4ab39be1d578c15c1486_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtOC0xLTEtMA_c4c3d1ba-a7b2-4bf0-b0fb-0dff985cd1d3">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e007c33751b4a5c978064214accac0e_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtMTAtMS0xLTA_043f0028-42a6-4cbc-b8a6-3fdc8fbc1646">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33137ec5b6634022892adaf4e137ea2b_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtMTItMS0xLTA_f3284b9b-04fc-4e07-813c-11cc25d08c08">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02900307815d45ee8652b90be7d1be4c_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtMTQtMS0xLTA_2852efe0-74c1-45b1-b5b4-cea429dd5106">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieba46f08b484419da5dcf2ea9265939b_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtMTYtMS0xLTA_3ce1dea6-ef2a-42ee-aa6a-e6f62d6bde36">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f89bf00ca354d5bb864b9f0cd155397_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtMi0xLTEtMA_cae72440-97c1-4360-a18e-2de95ff9889c">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e029ac4bf384381be5a78e8fb2e5178_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtNC0xLTEtMA_de0a61fd-6e22-421b-af95-9adb33cc06c5">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd034ba2efa44a2db164c8aea8825436_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtNi0xLTEtMA_f6e02a78-364f-4abc-aac5-38b8c917a462">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04bfbceaa25142cc84ac6378009c15a3_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtOC0xLTEtMA_fd050680-b280-4e73-bfcd-1fb60480cbb4">1,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992039dc5c0441c5b5f6174dce19c781_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtMTAtMS0xLTA_5d047526-b6e5-4930-9607-2a8dee62365c">785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae99aee62f846139d54de729834ff14_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtMTItMS0xLTA_50bcfd4c-64a2-475d-a83a-b9072dbd1124">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678692608fbd4c1fa178eabaae64217c_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtMTQtMS0xLTA_9086f8a0-f5f0-45ae-9799-f2ce411440fb">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6c99a3b9fb41af94b2683664d43cb7_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtMTYtMS0xLTA_e15e29e5-7990-4f59-be9f-af601efa008e">873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec0b95176c043cfbbc5a9f6fa983587_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktMi0xLTEtMA_103b0d2e-9371-48b6-aa5d-7b0cd97f96e8">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0507455b49474b93a38ead6ff2615419_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktNC0xLTEtMA_6631dd96-3349-4c3e-8e8e-9b97d4b732f8">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ee4d5996924966837c8c99c967f51a_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktNi0xLTEtMA_db93037f-029f-4a1c-a896-affa02c54153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78827f1965b425dba08fd9f4c2e4d58_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktOC0xLTEtMA_4c63dc7c-6777-4893-ac9a-4ee594e6e7a9">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39b4ec9525e44e808926dba562992f53_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktMTAtMS0xLTA_a9a713b5-7fd0-48cf-88d0-5ea7fcd9f0f6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5113443b36744e9e982775ec8eddc113_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktMTItMS0xLTA_fd7f7700-0194-4453-8e22-c520fbcfd1ce">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736b122cf29c43ee95e28299d9a585f1_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktMTQtMS0xLTA_28f7ea69-87cc-4fe8-a55e-57d9886dfb14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c967382fd7e4043b63ff0da2d1242a2_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktMTYtMS0xLTA_efaf6c84-b7e2-4d84-91bd-a0384bc8e501">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie85528a66b46438d9ef9265272241283_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtMi0xLTEtMA_bbcb0d07-ddff-4b68-aba5-d32202dabbb3">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5dc4dc454649c4a9f9a11210acdf30_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtNC0xLTEtMA_fddc56af-99b5-4e65-9f5b-665b6df2b0d2">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45e550d01b429cb2b091b9902532c0_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtNi0xLTEtMA_b189bc34-446b-4603-895b-5308138decc4">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35a4693d3cc04b62b20fbe12a1d5a54c_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtOC0xLTEtMA_c06851cd-7c20-4435-a9f9-a33e94bb9e95">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9751f0cadc8491e945ca44b0b80b126_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtMTAtMS0xLTA_b127352e-5a70-49d1-8974-cd81213c93b3">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4395e1c88544cc4b60097ece5543cd3_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtMTItMS0xLTA_8cc5b760-e26e-454b-8440-d6f0e2e8e24c">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia30e8d354ab04f3a97abc398675713dd_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtMTQtMS0xLTA_b6cb5c15-f9c3-4b0b-aa26-e2b2fb8c5d34">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id953d64ac7fc4fccbf566a8d9a4e880e_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtMTYtMS0xLTA_efe3d617-e305-40ff-8f5b-5801c0c327a9">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ecbe4c2b2d407793fd3b236408f12a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtMi0xLTEtMA_cb102291-bf2f-4799-8384-2fe7c0b6a4b7">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b07ea93a6f54fd0a91bf6672ff04b65_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtNC0xLTEtMA_9e8de06e-2f34-47bb-b833-f267a8b44756">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73b68324728248e48095f5acec992615_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtNi0xLTEtMA_18826e31-cba0-4958-8b9d-2eb2430c53b0">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8f3b797b0784b5e98a1ebecc9731bc1_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtOC0xLTEtMA_5c460de9-6c89-4e03-b9a7-6a8e9d9ca582">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6152e617b143c19295e79115efbfde_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtMTAtMS0xLTA_b3568c93-e434-4160-a3e5-516a83d31cb4">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ce6c803e5044689d6f072466cdb84a_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtMTItMS0xLTA_ebf7f012-0376-4189-bdde-fb0a1dbc10f1">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb1331a5dd2469fae50b0f82ccdc186_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtMTQtMS0xLTA_f568751c-dddc-4732-8369-364df1881595">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32399ea9bc584449a570a053a33d5913_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtMTYtMS0xLTA_38985e51-9211-4bc6-ad2b-2199ebb5c39a">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b87fa8d5dc94c15bba720f6e25ca2c4_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtMi0xLTEtMA_17ff3a44-394b-4b28-8b74-af6f0e0f132f">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id317edd4885848da96375a5d6890f972_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtNC0xLTEtMA_dcaca6da-8c2b-4957-94a8-7db1c60eab11">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d1c49fd62e488a9d8f1b1bf40b098e_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtNi0xLTEtMA_591cae46-d455-4a5b-a0f7-dfb475fbcad9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c6dddbd6632497799ce67bce0d386c2_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtOC0xLTEtMA_7fc5d80a-4a01-493f-9638-f37a17b5bd0c">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2a5f3cc54f848f1a10d35d090a03387_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtMTAtMS0xLTA_9f56cdef-da1a-4fd5-a0b2-eb7cc3b76dff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fb67792ca1a4e87a11d779d955afe4c_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtMTItMS0xLTA_29eb1b93-d362-4688-9722-ff6238b71df5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71818c2f40544a51bd97f8265ec8d26e_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtMTQtMS0xLTA_75b6ec97-e792-4f3d-a784-19d21db44ef6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8d2d00f525545e0bfeaff95a0d0fbae_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtMTYtMS0xLTA_fad5f5e2-76d0-4f38-8816-f6d0cfca2e69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffba5b40986f41988004b66efa3262e3_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtMi0xLTEtMA_5c069fdf-45ec-4ba1-9a00-10825953e7bc">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie950ff8a161b4f3cb591feb0c61f2b65_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtNC0xLTEtMA_8c8e863a-6e1e-4195-a7f3-032c2f810c04">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i014ae1acc1a0400cb0833dd1ec4d8c95_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtNi0xLTEtMA_821abfd4-5315-474b-b8ac-94ecb577a668">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248f6f4d0b1743b8ac49ee8a4893a138_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtOC0xLTEtMA_baf681ff-3caa-4d1c-9ba2-8ba24cb6ac5c">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb48adf7671d4b5095439fa1db112f98_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtMTAtMS0xLTA_b97c00bc-813a-4446-b3ea-5b9567d30824">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dea3ee0ff204b6a859461e1d1f6d8ef_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtMTItMS0xLTA_fc3578ac-2934-4b65-9bc9-4408066ddbfb">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98dbae32b00044609d015af32ec98ca2_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtMTQtMS0xLTA_60b0ed0a-dbb4-4cd6-bfd9-4c1113dd1c14">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb6c3fd5a3c7472f93e4bcc1e14205f1_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtMTYtMS0xLTA_89409dc3-19a0-4b40-ace5-626660cbb00a">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93a4e05cc8d84ef193edc737f58313f3_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtMi0xLTEtMA_8d744c8d-7214-476b-b052-d810b9d87369">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c4a3efb665a4e32b3fab9bc46d0e840_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtNC0xLTEtMA_e116809d-7e23-4859-b501-0fcaf4f5cf72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b88223ff894ebeb782ba78c923b80f_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtNi0xLTEtMA_5e3d40a0-961f-4fbe-9d40-5c6f02ce51aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ef52ca9d6a84708adf4f8bd716acb1b_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtOC0xLTEtMA_639e4824-082a-4301-a43a-efbb88d1cc24">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60d842da95f4557a472db9a4f20944c_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtMTAtMS0xLTA_a01502c9-4f4a-4c0f-a17e-eb18f80604ba">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312af34f38c3480f92c1180516ce4b2f_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtMTItMS0xLTA_4c1e1a6c-cf09-4da6-862a-1956e4257e71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69497b92cda24b32bb318450db656d59_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtMTQtMS0xLTA_3e56f783-5a92-46aa-a776-511801889f0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c83f4a3e9804930b2a2b194201c1c9a_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtMTYtMS0xLTA_1f2502ca-ba07-471a-8db3-73835d333ce3">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b526ba862f347ec9e038db912732159_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtMi0xLTEtMA_b7210307-2e7c-43b8-8ce4-61cdb70df498">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8674bb821a143ffbf0e7c0a4bbc23f5_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtNC0xLTEtMA_e697bdc6-e799-4b7b-a56e-b2f1a823cab2">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f44e89624524a3f85af2769737da0e9_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtNi0xLTEtMA_425370f9-8e91-46cd-95f0-1ce3a3e513eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106ed528aea94b3e84e167881f011048_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtOC0xLTEtMA_e8f7b489-4e41-4cd0-aeb5-dc3ea3776847">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06672ac481ba4a9bb5bd08dacfe71e88_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtMTAtMS0xLTA_e6a3418b-741b-4991-b21c-6fd46a58fffe">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0753fdb7e8f479fa676298a44c409a3_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtMTItMS0xLTA_934e4a1d-d9e2-41fc-846d-82a623f5c4e6">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84e6d6f192a24ac8b2f45a194dfc508a_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtMTQtMS0xLTA_d48e7d5e-0884-4c2d-acec-3aa27f647652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86eebf78b2f54e5789f05f6de57a33ff_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtMTYtMS0xLTA_3d0ea6f0-7b0c-4415-9946-6f8089eb7441">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90831c4bec134c3d9479dc73821bd890_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktMi0xLTEtMA_9719bebe-2359-4005-b36b-a03c258f241a">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f950f4a2a1943729bd08af5465b17bc_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktNC0xLTEtMA_cc63cf55-4590-4340-be3a-78ea6afb616a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d836d842884745a9b0c054d60b3106_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktNi0xLTEtMA_1954617b-597a-46a7-add8-b969995566dc">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d80d18f64348a6952ff66466587e5e_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktOC0xLTEtMA_523f15f7-58eb-4c21-a6fb-a03e4a24806b">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i420349f096da42faa5a1507cb5af2bac_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktMTAtMS0xLTA_2f64a6ba-fc16-4586-9185-181f8c9c14b7">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c028e5643ea425b858bce273dbb43ff_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktMTItMS0xLTA_ac764b8f-cf00-4fba-866d-2be1bd06126d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f15774b1a2c46f9849e41b07da947da_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktMTQtMS0xLTA_fadbbf1c-190d-4084-becc-4d3f6fc76299">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa297463bca43108958d1bc0d817e62_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktMTYtMS0xLTA_8d305cf1-a5fc-4ec8-86b4-e12c5715cae1">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i801113c804f84bf68a7ce7874e0fdfff_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtMi0xLTEtMA_db3d818a-fbc6-4ae2-8326-12189c329eb6">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22120ea38a6f43808c0a51b6b42c907a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtNC0xLTEtMA_11738258-bffc-4e65-a95f-881cf983304e">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd65b051c3c43a09723cf00754a0d11_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtNi0xLTEtMA_bef5eb04-0b1b-45f1-8866-2c0423cb4248">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee5d0fa9bc243609b1326fffc9420dc_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtOC0xLTEtMA_a5e563fc-7935-4488-8452-e023f1cd9a0b">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64edf3f2b52641b0b8963f1e7ecaf35e_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtMTAtMS0xLTA_c6f98c85-0a50-4392-8a0c-f8336546b6a1">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd113a548354e83adbc4e684d0b7c6b_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtMTItMS0xLTA_cf03e04b-1225-434b-9068-620eb18a496a">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad59f43c9584895b43102b96b356bf6_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtMTQtMS0xLTA_60d0433e-7970-444d-842d-300c8da605d2">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e7dca62ce034df2965648995f1e45c3_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtMTYtMS0xLTA_36decea2-54d1-4e33-a7cd-a0fd209d237d">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide81ff472a904e96bd7c11cfb160bb5a_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtMi0xLTEtMA_a50b7e3a-377b-4cbb-b16e-b92d6a8b4559">5,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c657737c9a44da0bd9a0a0ed937b77a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtNC0xLTEtMA_5d7d3f8a-ca97-4b4f-9449-2e4f41c9fe0d">997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i761660c0e36b44119d0a377956dca1fa_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtNi0xLTEtMA_d7ff2c96-7085-49ff-9242-19ab74bca295">880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc4638e68b041b3aed502ac0da98085_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtOC0xLTEtMA_a8957ffd-a3f3-49d3-be4a-afb5c6846738">7,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42344c7afe36415a9346e765e883f109_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtMTAtMS0xLTA_22984a6e-e582-43a7-b029-d570b002708f">5,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i780ad9f4faff41188b82d5ee6efad1c7_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtMTItMS0xLTA_151e2517-daa5-4782-870e-15e0b7a16f0e">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771dc583a85d484996619f6a24a1e310_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtMTQtMS0xLTA_36db3f42-368a-4baa-a44d-a5c8469afac7">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f7696af45458ba1c6270ba2e89d75_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtMTYtMS0xLTA_85b9ff25-f257-416c-a7fb-452a8bb615ff">6,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12d2e276cf194b249b5381b7c0d564e7_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItMi0xLTEtMA_c9ec77b3-7963-440f-a640-1f4ef6b0be05">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a788a5a397c4d3c9c4273e20cb2eaaa_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItNC0xLTEtMA_3dbfe82d-a10b-4be4-8068-0862b742d12b">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf04a6872a2045d9aba3f8ee749ef8cd_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItNi0xLTEtMA_b85e797f-1c87-49ce-9a61-18a23c253a19">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if593c50c51de4ecab2682f502e43fe0b_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItOC0xLTEtMA_b9b37025-93a4-4e13-bdaa-39dcf5cde7b8">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89aba37ab3bb4d6f995db3f1ef7313fb_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItMTAtMS0xLTA_c3260b5f-2b27-43e0-b3a0-ed801f07c5aa">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47fccef93064956b207fbf3f4b0c07b_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItMTItMS0xLTA_bbbcde5b-5e34-4a0e-a0df-37ac7b0d173a">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6ae907411a40a09a29dc2bf329268a_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItMTQtMS0xLTA_a4870628-8f0c-4226-aa94-f5d37d765cec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80719b1e7cda4bf6adddc01b671e7d5f_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItMTYtMS0xLTA_765848be-ef18-43dc-9c50-3b77356cf1f5">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibea8c08b19a845a7bc3ab84d8743dac6_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtMi0xLTEtMA_7725d5c9-8ce6-4bda-b2c1-fc5d0e8b0d6c">5,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbee8f040784dbbbba5f6f7708c8260_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtNC0xLTEtMA_37eaf8dd-857d-4786-b0f0-36258d17271b">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06591e9d784f4725a4a3f560f9165fdf_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtNi0xLTEtMA_e58d781d-2040-4c60-9699-f504ee96d52c">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtOC0xLTEtMA_ba8e2db6-5d76-4108-b7ea-380bc4c2cab8">7,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic63411681ae343ee931a1ef0fa134389_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtMTAtMS0xLTA_3346eed7-c48c-4f2b-82fe-91806e702513">5,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7017bfe2cca74515a9c77805ce3e685c_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtMTItMS0xLTA_6aabcc19-68cc-4e91-8d10-4360f3e77075">937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87c9a9443ac49bbbc5f60c80bdb0cf5_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtMTQtMS0xLTA_8fc676a9-f70d-439b-a7cc-087f821d221c">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtMTYtMS0xLTA_aece37be-197c-47a7-9297-7216131cead2">6,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i6489e1f41c1a4257bd43c2f07e37ff18" continuedAt="iaa92e3a4f973450cbae2f0e12eff9055"><ix:continuation id="i254b016aa6814c45a1cd9ab6cde1494e"><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.660%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Sales:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a4aea2fb6941c9b82af8675d2a96d6_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC0yLTEtMS0w_b1d8494e-036a-4aed-8383-431be8c8d840">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic38c735785bf4de499f546ffb3cbbafb_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC00LTEtMS0w_e7bb3256-9ea8-44ed-9636-8679eefec17d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if590ab24b0d24195a1751c7e37eda7d6_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC02LTEtMS0w_17fbe949-6195-4c90-be4d-741790e48b03">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86322bce038342589d4f3d411cce6b67_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC04LTEtMS0w_78e2d6bd-3675-4b76-9909-f9dafda2241d">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122291e0c90149469fe7f534977d4bd1_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC0xMC0xLTEtMA_bfe33f82-2853-4f02-b4e6-fb5c98335d01">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7be015c2d53f492face1090466f96194_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC0xMi0xLTEtMA_329d150d-baba-4306-9826-f062cc9e8f05">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41905ceca0e14646bdbb966a276724c5_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC0xNC0xLTEtMA_24d0621b-fd23-4a1c-9101-5c63874bf215">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b919aa74e64ed8953496faef33cead_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC0xNi0xLTEtMA_d20b0f5d-8298-447c-b828-52438d9e6141">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55d71c6943b41688ba0c99c12c4b0a0_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS0yLTEtMS0w_063cc84f-9837-471f-baeb-537339219e23">4,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib74e3480706c4ceea2eeaa33e8a29a04_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS00LTEtMS0w_1c48650e-5a58-46b3-a7ec-017b42a4c562">707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia50f0d178a34403ba582f4fd7b081032_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS02LTEtMS0w_b76d9461-4bca-4693-962e-e59654ea7f08">461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1125817792a24e229eac03cff110ec3d_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS04LTEtMS0w_7be0af88-e147-41c0-bbdb-db0e9fbf96f7">6,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4c349c2ec345e9b842096c5ccaf53e_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS0xMC0xLTEtMA_2e5b3811-d67b-47ff-897b-ae2573c112dc">4,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i175a2429ab0a4e3b8b1e75f43911073d_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS0xMi0xLTEtMA_18290232-947f-4e0e-be21-078130d4fccd">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb3ecdf995d4d6d812e8c4cbd7c50e7_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS0xNC0xLTEtMA_48fa7c5c-3199-45fb-80a1-b2105aacbb00">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1b6b1928d21482d9b69713fe3e4a90b_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS0xNi0xLTEtMA_83662abe-5005-4edc-acbc-9ea4db265ace">5,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia342fd853fbe4fafbfdb82fc8f51be9c_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi0yLTEtMS0w_eb7c9e02-50a2-4e73-9776-d320c82e5108">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23e096ae4d344ee6812e02f2cc006dcb_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi00LTEtMS0w_754fba5f-2df3-4c68-a460-52e81b282a02">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bdd6612962405a995125b9413576f2_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi02LTEtMS0w_4f5c1c5f-7798-47f8-ad46-01ea0ec60ccf">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a2e4438b44cd584805fb7db0521f3_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi04LTEtMS0w_516a3151-238d-44a5-85fa-100184962adf">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8cf4df7cb3b4e0b86839f9b4fc78b33_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi0xMC0xLTEtMA_57248eaf-06cf-4738-b94c-1294eb619148">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfac141d6cd44e59b0b264ad26f95be5_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi0xMi0xLTEtMA_d538ed04-22d4-4c30-a8b6-1970bf068ee1">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4522ce1c0acc43ec92a475e4619c9ded_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi0xNC0xLTEtMA_352bc435-89e6-4806-b36f-09770ab0210d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5f3f15ae4734085be8c32af347a19ab_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi0xNi0xLTEtMA_a2a05522-458d-432c-ad45-007a02a46630">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78d2215b759479ba1d4220802e6d2d0_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy0yLTEtMS0w_8f022bad-c1a8-4277-988c-200dbe87d8fe">994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ec8a9a644aa4b0ebccca4dab9dca43c_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy00LTEtMS0w_19ff6515-6e9c-452c-a8f2-883591c6790e">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af2ad96fab4466bb054d82d939ab1e0_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy02LTEtMS0w_a1ad762f-67ac-4cf8-8ffe-22231cfeb0e1">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37247af540b49ffb68edae4f0e29c75_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy04LTEtMS0w_9d9fde8e-0c7b-4997-b239-910ec289dc69">1,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb751dac07449418c170631d9d26c50_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy0xMC0xLTEtMA_10bbc903-f7df-4b15-bdb3-e8ca2ac00e70">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5761b86071f3408392639773ba999d6c_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy0xMi0xLTEtMA_b743b0f6-363f-42a2-ac9c-2799c968851c">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1124b457b6443b9adc6d3bca56384b_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy0xNC0xLTEtMA_acc94b15-3f7a-4023-b20a-d5b8ce15608c">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21c3ea05d2d6469bb4402a1e7bc7b6ea_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy0xNi0xLTEtMA_34724a72-cfbe-4695-a36c-64ac04903584">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf14c77718b943c99cce1bd3bf1a1bb8_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC0yLTEtMS0w_b0486f80-24d8-47fe-840d-5d77d4445e05">1,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i985f8bd1a9864259bc024e136e98165e_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC00LTEtMS0w_8222c2b3-1fc0-474b-96dd-dcc86f1191cd">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17bea95dcb84138abe482f8fe033d2e_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC02LTEtMS0w_e8ed8497-4ea1-449c-aba5-eec98308b423">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721ea7e79a674506888fa965f545242b_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC04LTEtMS0w_253c3dff-1ddb-47a7-8c98-bb3ee8f524f4">2,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id19b27572f12412498a2fbdc8b6f03d3_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC0xMC0xLTEtMA_37ec5607-2bce-42e7-93fb-67df9f7ccdb0">1,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294f1f3217554943bc9e24fd2f2d7b62_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC0xMi0xLTEtMA_36d5369b-9f6c-4a13-bf2a-cfd01767b5b4">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ecaf56026f4bd5be46fe08dedcfbad_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC0xNC0xLTEtMA_5cdee1aa-d6d2-4585-b3a8-a1ba31d6fc95">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74defff37d6741aea5e3b56c22443253_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC0xNi0xLTEtMA_2897ef8d-001e-4455-bba1-be6aa34f1cb4">2,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27247f779d88460f9b4a30781c8e204e_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS0yLTEtMS0w_d902682d-4794-4936-ba8f-0e7097e03e7a">773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i621eef6cf69b42cb94aae8c92e1e958f_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS00LTEtMS0w_ad70a236-2661-43e0-9161-084120729c82">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e09c9fb52974397863d698886f2e887_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS02LTEtMS0w_54481ca9-12b2-4afa-8a84-1f6461d14baa">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida707d8753fe48d2aeba73c027150355_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS04LTEtMS0w_75fb3060-26fd-4d02-ae7a-45bbeb6aabf4">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie768d1c6a00b48d5bda81338c8079975_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS0xMC0xLTEtMA_fa07416f-e8e4-4109-9a2f-0fd3f4792f05">851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9708db6e96ec46d5880ab00e9b04a81e_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS0xMi0xLTEtMA_fb6de3cf-c93e-4be3-85c6-b9ab8ec26c37">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id562523bafee46199bfba4a84d9ab6f7_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS0xNC0xLTEtMA_f21c947c-9367-435f-bbfc-621657ebcfb5">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c6bd8c13db64a3ab7f8eb8574846b45_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS0xNi0xLTEtMA_5e36df7e-dc33-45a9-954d-2005698d23de">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8899f03cb424167ad78b89040f1a538_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtMi0xLTEtMA_11276cb2-9b8a-4cd2-8b73-caef2f640297">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d311bd075f4f02b44de6feb4ab37f9_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtNC0xLTEtMA_32388288-1ec8-43ae-9aa8-e5e4e18ec8a3">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7979efe4ac394083a361addf3d2a49be_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtNi0xLTEtMA_abf772d3-d591-425b-bb39-221e2ad7032f">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a303146ddae40fdbd9eede2a54e5625_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtOC0xLTEtMA_4cdd0967-cded-44e9-a29d-7456e5a412b5">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i036eac2d8114497bb332d3456f541e87_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtMTAtMS0xLTA_fd1ec560-c90d-41df-93ef-f1579cca4e5f">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d484b178dd4b64b7766ad74bfc4575_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtMTItMS0xLTA_b132f13f-9275-4781-9db0-00e7e5e14054">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9283b98610164ee6bf6bb05476c6b514_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtMTQtMS0xLTA_4ded22ef-6bb9-4071-b395-360e6bac05dc">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf92e99dbb2140f493dd3d8fb8410ba5_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtMTYtMS0xLTA_43ad8cd9-d9fe-45b9-a4b2-b86c29178df8">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d74d0421c60403c8a6f350e1d3b261f_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtMi0xLTEtMA_a8b7c3d5-0ae6-4683-925b-9cba23e38bbf">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d962d727ea437a9d9bf778a9145642_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtNC0xLTEtMA_9c0bf2b8-0e92-43ad-9667-7f291500782b">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab1b92b6f4ea4a199a439cefdcf33eb4_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtNi0xLTEtMA_f3956cd5-fd7f-4fef-aae9-4e5095171f81">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaad6f61dc4d43cb950a28292948294a_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtOC0xLTEtMA_7e687e8f-2811-44fe-9f18-60a98733ff4f">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dadedf4a3a0408cb0d1d97265933589_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtMTAtMS0xLTA_6dc6b238-92f4-4768-84db-c635c794d940">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7e5fc9e484420c99dbd9d31335006d_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtMTItMS0xLTA_405de7d5-2d42-48ac-ad5e-02a8bf083d96">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94648f1cf2334fd39189ddd5a2526fea_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtMTQtMS0xLTA_9f6db3fd-c8b0-4852-9a21-fbd8d9ce8227">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87770df84d314b2d9aad501ce6c1d18e_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtMTYtMS0xLTA_1ef5cd1f-f6e0-42d2-a2d2-dce7ad512e29">1,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03ba162945dc41be8591b11496c129d2_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMi0xLTEtNDI0MDg_e167e422-30b6-43cb-ad2f-c4ffffd9916b">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e31f17d8bd4d23b055d34e97fc4ca7_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItNC0xLTEtNDI0MDg_d0c4b603-e54e-4e4a-a814-336270d11422">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc60dcceb644702ad795c8522e3f1fc_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItNi0xLTEtNDI0MDg_8c2035a6-9297-4593-a451-b3c527466e5c">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieff814faff8a4823a581ff8c22875f06_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItOC0xLTEtNDI0MDg_3ac9b7e4-3c40-4bb5-abbe-daafda65c89f">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898ffefc3e8041be98cde4df6be2c6c8_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTAtMS0xLTQyNDA4_99d97f3d-14fd-4057-a297-45c3f2dfe3b0">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41d525086d2940c8bc5faa039d023674_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTItMS0xLTQyNDA4_d6021cf7-bc3d-4cf0-b2e0-b672970e2d44">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie975ec0d59844df5ba2bc20d9d8ed6d0_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTQtMS0xLTQyNDA4_f1b4afa0-76a2-48a1-971a-d12d9d4a8eed">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade9dfaea73c44d59d5ed5c0b2478333_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTYtMS0xLTQyNDA4_fb3b9056-02b3-48d1-ad98-eb39143d9d3e">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie07906aa3788456f883989affdbca674_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMi0xLTEtMA_e6724924-8a41-4783-8ebe-48df0f963d0d">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a36ba79c6f545ebae95e83233deca01_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItNC0xLTEtMA_9752fdef-33b3-49ed-a751-50c281315786">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a607992c5c4d25ad9c3ac39d2b5086_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItNi0xLTEtMA_700af084-d4cd-4a66-8cb2-ed05d3eb987b">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87e96b04266246398a423cbb059ca43a_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItOC0xLTEtMA_59b650b9-401d-4bc6-b357-4ca2b9b2585e">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0314692dcb914529b1c58577b2b23a0d_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTAtMS0xLTA_451ccd45-efe9-48ad-8300-15188e2e9097">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a023cfdfda4020ad80e31bfc9b887a_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTItMS0xLTA_58e46c18-b481-42af-896c-8a899a29cfb5">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af6b5ba80b548de8cc9f594408ecc5e_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTQtMS0xLTA_3c662caf-a3dd-4f49-a561-198b871cc95a">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6362737d64e24ccf8210a3c52840afb6_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTYtMS0xLTA_e11e634a-6d4f-441e-afec-fb7bd2ccf34d">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b03fbb1ad6b40f19a144436859a94f2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtMi0xLTEtMA_5926af1b-e4a8-4d9e-9563-da7efb4fe90a">9,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bdb0af715f34b249428381e9aecddf7_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtNC0xLTEtMA_5ea68265-79dc-490d-97ec-3dd82a1f0d09">1,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086ee71ea26941e88d86269d05ffe0da_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtNi0xLTEtMA_dc6b1f50-040f-455b-be31-149282d17484">869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ad8c8ce385e48069566ed761014713d_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtOC0xLTEtMA_d2b42f31-a68f-4b09-b1ae-ff1eaa65aba8">11,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6462e169d53f4b4fa0ce56f4c177fbec_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtMTAtMS0xLTA_d49264f0-7a23-414e-bd60-e0f1efbd3d0d">10,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8274f710244001811907e50cd4649f_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtMTItMS0xLTA_47f6237f-1e7a-404c-857a-78656a553fef">1,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia087c8100b6442799b592343e8d561ee_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtMTQtMS0xLTA_0f8aeace-bdf4-4263-9c70-8a73e6ca0765">748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2963d1dc4f004cde8fd58fc8adeb9698_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtMTYtMS0xLTA_fd5faac5-ed25-4562-93e8-265301217ec2">12,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">HCV</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cb3a52c0f00489082cde7485cbe447c_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtMi0xLTEtMA_dbb9994a-e959-4b49-b5ec-542b3a907156">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cb8226c97a04cce9da6c55eaa7cbf5c_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtNC0xLTEtMA_92cacec9-b274-4ee8-b88e-e8ee81f2e5eb">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66452d493a694b09b553e49d6ab26de1_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtNi0xLTEtMA_3a030ba4-da63-4374-81f3-75fb1e0c41d7">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie00c38ed5e114e7c9b2c757c827e0138_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtOC0xLTEtMA_de1399e1-f222-448f-9835-92fad2cc9a26">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41eae22e9d694cdfbbc45e5052d09e8f_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtMTAtMS0xLTA_cfba95d0-e7fa-43a3-b3bf-e5ac93e062ef">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i896a5a5651944bfe84bb61cec75fe4ed_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtMTItMS0xLTA_ec7f01fa-ee35-42f3-b3e0-45a55192aab0">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c7b41d05fe44dc98629f17bcb23c36_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtMTQtMS0xLTA_a2b82123-7535-4cf9-a4de-d8ae845b8233">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14cb743958c641659fbba039af3651c2_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtMTYtMS0xLTA_bde6fb7a-a141-48f2-90cc-f49a52e52bd2">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i130fc4df5c3a4447ad6bafc4c36d9a70_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctMi0xLTEtMA_45c8ed25-69d5-4600-a44b-6f6db0d1b7fd">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f436a82f046efabc844f2f53f0827_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctNC0xLTEtMA_a0578fcb-a133-489e-98e4-4af8462d9e68">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5636e6fa99514854be00d8ce0f92da0f_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctNi0xLTEtMA_b980b5ef-ce1a-4a2e-9212-3e0b17efe08a">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i089d7a7d04eb4354a426b6f111e8c9a1_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctOC0xLTEtMA_c6875dce-0043-49b6-81f5-f42200c781b5">1,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97fd886a21164803a5ecfb1a6ca689a2_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctMTAtMS0xLTA_9b0402b1-c50c-4ba3-b1d0-e28268b63b03">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9f9350bc75c442d91a688c62b89b6e1_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctMTItMS0xLTA_b1483531-d531-4934-8007-c35263d39a27">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5763ac2ae7874bc3949baeefcb466bb9_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctMTQtMS0xLTA_b0648063-f525-4bc5-890e-32438bf929c8">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic843439826b2471ba7693acebb1e44f4_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctMTYtMS0xLTA_b02e751e-4c4d-4afe-920e-f3c1dcd69aea">1,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i952a37c342574b4fb556d2cb998f1dbf_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtMi0xLTEtMA_16259d67-a492-4648-b689-8af25bf0d3cd">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3bbe012fe22423491ec35738ee162d6_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtNC0xLTEtMA_786ba2fa-3478-486e-b0e1-286b628488a0">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie50a6de3cd234635ab5eef79157b0e1e_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtNi0xLTEtMA_2bd1d135-5dd2-4077-ae3b-4f08e02dfa12">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c55fd7299a240adbf6d39bdf17aa7cc_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtOC0xLTEtMA_2a0ffee7-cfbf-4a69-8526-2550c955722a">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ab85ae6a2d499f8162d50d3fe1dde3_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtMTAtMS0xLTA_a8cc9757-db93-4a59-b361-b6f3eeef2b86">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief5bc9a6130945279a3ed73051e33bdd_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtMTItMS0xLTA_7d82c037-cb57-47f2-986a-d153e321ba4d">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc475161995042e1b32b3447cfd8372a_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtMTQtMS0xLTA_24f8ebfe-e10b-481e-95cf-768a624ab904">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3ddd3a8d67413d8ccc8f4f45930641_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtMTYtMS0xLTA_c577603c-c36a-4f6d-9a99-9e2094f3b1f8">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabb8e6fba8504ecf8c222643ff4b5f9b_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktMi0xLTEtMA_d37acbb8-e6e7-414d-addc-40bc7921de34">809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a5589d4d564f57bd7d3624c5dadb39_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktNC0xLTEtMA_f137f1c8-0743-4f27-acf4-f36584e81146">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0891181a1f1841c3ac6a145676585a41_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktNi0xLTEtMA_688da1c2-d0a7-42f5-bb25-cc078b91c2f9">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b86819db2a34c97be76a722a5625303_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktOC0xLTEtMA_75021970-1b6e-4e82-a785-6eb73eb81823">1,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e952d3e460445a9baeec1dcc88eb745_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktMTAtMS0xLTA_4d4bc7ad-da2d-449c-90be-ea050c88949b">859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a2d6364e6440d2be0d03705fab3cff_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktMTItMS0xLTA_47fc174e-a692-44c1-aee9-9f3c100fd2ba">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb620cd6eaf04c1c8f121fab54f876c5_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktMTQtMS0xLTA_d8722d9d-2853-4822-857d-53f141db5eb0">466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09794c214e347d6bea03f6a5b211ada_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktMTYtMS0xLTA_51bfd983-5331-4e16-995b-6faf1141ecfb">1,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">HBV / HDV</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9462d61d0f479b9fd7e5b189d86696_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtMi0xLTEtMA_10a51438-5cb9-4e93-8b33-cb11b5ab789b">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7fa3912b241402d8cd650313d3c7018_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtNC0xLTEtMA_82dda43e-f2e2-4602-af70-e80460db14a5">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e9011b3d24494816bcc206c0c68f6_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtNi0xLTEtMA_fc7f374a-0a91-4cd5-b1fa-f6e2f7d2601e">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b2167174a94caf9d1f6bb56760edcd_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtOC0xLTEtMA_fd9c669e-fb40-46fe-a36c-dd90a048bd6d">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20212de8e88345cd81a0017d04adec4d_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtMTAtMS0xLTA_e7be0449-7bfe-4bd3-9f03-8a813835d8ab">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc4680796da146cb8f0e19e816cc8a1a_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtMTItMS0xLTA_62a2498d-d018-41d5-8513-f581bf06629d">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20583fb976024f8f8e57d6812ece8f46_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtMTQtMS0xLTA_d64c883e-cdbb-4e5d-a063-09461b3953e1">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b5d4b507e1433ca2793f5756b1393c_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtMTYtMS0xLTA_08ef5dbd-35ff-4b70-8392-9013b46618ba">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia59084cd434e42fbafd89bb8ba03f4cd_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItMi0xLTEtMA_e2b7ce82-ba88-4b61-b256-558f1dcfd64d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1678eb4959ea4499b972f90192b36d19_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItNC0xLTEtMA_5d3502c3-5283-4659-93fc-bcb6cae1d7b6">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6ce327bc5a423fa9c0482e0ab2581c_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItNi0xLTEtMA_4578f2b1-e54e-4962-a0a0-a6bc0afd89b6">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50b052e699145cb95a035c96c0cbee3_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItOC0xLTEtMA_cbef0781-0847-4d02-85cb-d8a9c32dae8f">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a055cd7cae4d1c9803fa1d5c85d26c_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItMTAtMS0xLTA_9ec82d53-0121-4f8d-9c7e-66a488bf027b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i323ac2db963e406abe6b6c72a52169c4_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItMTItMS0xLTA_5e4b36ba-4431-450d-8d16-2cfa19b85f8d">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306cc17766184506a102f49dd753f257_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItMTQtMS0xLTA_3ed6fd80-8722-4d49-b609-b2e3bef42dd4">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f7ccddf15fb48a6ad13341a6b918c1f_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItMTYtMS0xLTA_a42d696e-971f-4f1b-98de-09e6590792c4">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id66d30a90b1d4991894bd9de74896ac3_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtMi0xLTEtMA_cfacf867-b501-461f-ac43-d096cee9cd3d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie93d3106744048369cdab984d1705db3_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtNC0xLTEtMA_e13ea09d-7e87-4937-ab13-cf29aac95b80">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb480f4f198e4b9bbf94fe25b67eb48c_D20210101-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtNi0xLTEtMA_d1135fe7-4a4e-41f2-b19e-dc9bd0caaa88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350d04c2a6974b8d81fb176e56b5a2e5_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtOC0xLTEtMA_3d3c611b-7967-4f53-ae3f-a2d2d349c275">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72f473445dae45a5ba0d6b6eb575f11d_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtMTAtMS0xLTA_3c232076-0dea-4fa8-8fed-6de61f8196ba">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac82bc33803743e89507ebfd8155528b_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtMTItMS0xLTA_1f0f44f9-36bb-4e0a-b1db-73abea3ff2e7">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e01dfafe5e548d9960d2188b833a39f_D20200101-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtMTQtMS0xLTA_7f021662-a5aa-49da-878c-6a2dfd959d4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie071dc0e5b3949d9839bd24e374990ea_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtMTYtMS0xLTA_f16af153-078d-4770-a25a-44cb5d969264">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i912fe4ab93f14a9f8e6b580172900315_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtMi0xLTEtMA_2ab17d10-fa4b-4167-ad70-2c2567c2ecdb">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c166e53abf24fc9af7b888824f5bb49_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtNC0xLTEtMA_3de395ad-4e07-4b1d-9ebc-49f11bd286d4">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99eff088b5d453b929c3d11f5802852_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtNi0xLTEtMA_6321e896-6a5c-46e3-86cd-54e2e0c89ed9">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663bd657772843f4ab8018e6a76865dd_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtOC0xLTEtMA_e34ff363-c598-449f-ab12-a90f7b5256e1">704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c90a17fa3db439e94799030d2aa841e_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtMTAtMS0xLTA_11c6e659-f96a-4f61-b102-b12b0f530b23">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib095572329c649af806dff6bf6648e2e_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtMTItMS0xLTA_59f8036b-7342-4e2b-9beb-15341ecbd0d4">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52882de359e54c22ae4f7a72a8137b42_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtMTQtMS0xLTA_3fc32638-04e5-488b-8eb4-adff38ff7d4b">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb10e809c404f009423263342e5e7ec_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtMTYtMS0xLTA_8d82ecb4-d471-4d4e-8338-d2b732a4fa2c">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59f4724ec2d14aad8052c7338d1e1a70_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtMi0xLTEtMA_0e11bd76-4494-45bf-8978-8aa03f265687">2,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539e9d57820a4905bcab08d23c1fcdb6_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtNC0xLTEtMA_d8c266f1-cba7-4f66-8bfa-49981e86e5c1">761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414c554b9ef34e0b9825b306a35bc339_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtNi0xLTEtMA_9cd0968a-6e9f-457f-9e09-f68dfeeee476">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41352f9abff2460ea53c3161faa76af2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtOC0xLTEtMA_400813c0-2036-43ca-9b57-09eb9d67af89">4,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f5acec533141a6afaedf118bb678bd_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtMTAtMS0xLTA_2e83c00e-48a6-4026-aa80-96324d3f10a0">785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974c2dbea9c44cadbbed8b52fc7f0508_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtMTItMS0xLTA_1e285d13-148c-4014-969a-db369b948b84">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba449c38763d4a5bb15ee5d3583e8506_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtMTQtMS0xLTA_d07b5346-8881-45af-a80c-94326af4afd7">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ea474d996994c7cbaa07eff099c4759_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtMTYtMS0xLTA_50baf287-1e42-42fc-8018-9959c1fd8029">873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3414950d11449a089e780e1462c6861_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktMi0xLTEtMA_4bea5db0-04ed-46be-9ed7-1f94f85cb006">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ce7e4d4685422fbdf942d3bd865108_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktNC0xLTEtMA_65667959-639f-4541-ae52-5e81e0d977f3">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib600ed3308d64a8b946e889611b8cf20_D20210101-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktNi0xLTEtMA_6a51f047-5111-425f-9952-3c90eced995a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31f6766705e412abe5b95c86b77a3bf_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktOC0xLTEtMA_3956f991-0b65-4b03-b0da-14ce51a09001">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375d592d929047a993e6735cac3e7524_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktMTAtMS0xLTA_75c392e9-0ea9-48e8-878a-d98d77bc81ea">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25802e2404924e7bb626581d9cdcd76e_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktMTItMS0xLTA_7b7ed709-2d2e-4f5c-91c6-133aa2ab1b03">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485672b302d740d299e2875e2d04bb74_D20200101-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktMTQtMS0xLTA_583300da-c990-4b51-9b03-bf115a67b7e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida399d53d569435ca887d4b734cbe214_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktMTYtMS0xLTA_6992f988-e9a3-4337-82cf-3e4dfbb2577b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9518115801fa4a4e943fb879f5bf25ba_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtMi0xLTEtMA_f0b87b19-fb7f-4ce3-830d-dde653334469">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51826c7e75b64381862b2f02fb933540_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtNC0xLTEtMA_f3e5e326-df84-4d67-a94c-9d55304fcbe3">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife3535d931384c729359473d5f8a4507_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtNi0xLTEtMA_e8d8ba19-90c9-4885-b2ee-64b05d4f98ab">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d1b980a3c9844768bbe2d46b8be2e7d_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtOC0xLTEtMA_35b5fe18-9074-4bd9-9fc2-06fd6bb9ee3a">513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aeebdc4428e44828acedd57caa0faca_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtMTAtMS0xLTA_0223e6fd-d687-41d5-b4b2-e9b488875d48">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib41e7dc04b7148b4bfbba74683bb45cd_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtMTItMS0xLTA_320b8da2-d9c2-488d-8d54-dee01e73d9d6">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6f5dee9cac47efba1d637a42bd0f68_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtMTQtMS0xLTA_67b57507-4912-47a6-8969-887d937caaa7">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id530903404aa44608666ca2ea201cad0_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtMTYtMS0xLTA_480e4216-7276-4f2e-b072-5ea4f695af49">434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53bbf05572d84302be77973d5913a305_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtMi0xLTEtMA_38b429b0-c120-4c30-a0fd-b202affe86b8">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4505c57940594da1a6edc651f9236d9e_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtNC0xLTEtMA_fa42827b-be6d-48b3-8757-760fb1d3de18">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i704f5a35c74142ebb14940a3a4fc0d89_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtNi0xLTEtMA_c01f8ee9-a0da-415c-bb00-8913697299b8">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b5618b046614ad186793fefd8dcf5bd_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtOC0xLTEtMA_9880c9e0-3c8f-43b3-93ba-34edf8cb768e">632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6081efd3f9744514a207bf9f739d1607_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtMTAtMS0xLTA_0686b705-6ed1-4f8c-8fb8-6e20ebb67344">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide124041bcd946b29f470c0a14b6de2d_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtMTItMS0xLTA_fed3ca78-02f3-4c1b-932f-835147f9b40e">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaadc71dd3a2547cea41b38c3c9ce7424_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtMTQtMS0xLTA_f4a60339-201b-4588-88c8-d29b4bdfcbd8">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a87250c5f446d8ab703b837cedde5b_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtMTYtMS0xLTA_d5d0d8c2-ff05-4020-a6ca-0e3788bc73be">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b70689a9f142a9bd885d142547defc_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtMi0xLTEtMA_5c475227-b387-47e9-ae40-3737b045c11a">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f4e1512b3f4a6a988b52b2020f402c_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtNC0xLTEtMA_bd3f7543-bb6d-4d5f-94b2-76aaa471cefa">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ca470d7fdc4eb5bdee6dda889e6593_D20210101-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtNi0xLTEtMA_43b7f8e3-4961-4de7-8416-47fdf3b1d1eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91affe4ed5b44ccc8baafb617adf2e9e_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtOC0xLTEtMA_579ad3d7-597c-4233-b766-4bee91de3def">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a57a9c4342a4d129d4b551d06423da8_D20200101-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtMTAtMS0xLTA_49e478ad-d927-4c24-97d0-17a32fd80872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f55f5d973df4988979569a529db6926_D20200101-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtMTItMS0xLTA_d6b63e1e-9fee-4e60-9b10-7dcb8a8bd96b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e801c7e1af45b1ad4f62e390c18253_D20200101-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtMTQtMS0xLTA_de3d3941-5e9e-4fe1-b173-d28583c91ae2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i887c3ef61a3a45dbb40ba7652320c71b_D20200101-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtMTYtMS0xLTA_1af0d4f1-2a93-4f6e-b7f1-1eef6258639c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i431029e24f704dde9b7df67fe1ba94ee_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtMi0xLTEtMA_6ed70f5e-3047-4098-a60b-2a7139ff3a9c">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i067f537de5404b9dba9eae8cc5fe8ba2_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtNC0xLTEtMA_ad60af96-9a20-44d7-abc7-b27b5110af6e">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040023fa9ea949e99260ae268fb58313_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtNi0xLTEtMA_37f557a1-ae20-436c-b7a2-41e2b09fc09d">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d85864fc37443df93104eb46275dfb2_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtOC0xLTEtMA_266e64d1-a53a-4d2c-8fa3-11034817123b">420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie785b0f49c10443fb9de1408de71f21e_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtMTAtMS0xLTA_8059898a-43e0-4f38-9550-17a6d9980c59">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb0b8d70240b45f9af68a14c1bc14401_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtMTItMS0xLTA_25ce7a5b-d841-4767-85be-7d30716d9042">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc055133d0cf433781d778bd29bcf851_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtMTQtMS0xLTA_c67c16f8-ea24-46c0-9793-0ef01df91d32">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7dd3e6b3fb460b8f290204f2ad10aa_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtMTYtMS0xLTA_9c652b6a-4faf-4149-90f0-3a1060a8136a">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4342f00fa51e4687acb11f09198af17a_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtMi0xLTEtMA_451f1cd5-a329-4c28-9b8c-deab7786bcdc">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60da582576d74709b9d1fabc050be19e_D20210101-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtNC0xLTEtMA_383ee1ac-6391-42d9-9476-8551949741b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba56c135c2949f5a73bf185229f9d9c_D20210101-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtNi0xLTEtMA_cade3464-a880-4d6c-bff1-83274812d32d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id250fc6f2b094e5a9eaae0b8f02e6283_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtOC0xLTEtMA_e53693cb-2714-4670-aabf-c7bd003d0738">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8e47a466d34118bfe22a1393d5b447_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtMTAtMS0xLTA_305bff9b-cc33-4cec-bb54-aee3a5779a5f">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0094bc7ae7468e8f94517cdc8d4c16_D20200101-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtMTItMS0xLTA_ab875d00-c849-4db6-a9f1-b206a1d7ac01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c9cf81f27044e40ae5a06b91f4fed65_D20200101-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtMTQtMS0xLTA_dfa93dd8-6bed-4162-aed0-288fead22f59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i832adea04eeb4821973a36b8d8054b28_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtMTYtMS0xLTA_531a3ee4-f195-472d-8722-6eb164c2bd7f">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ranexa</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5defc88095b45f88cbef65982c863b2_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctMi0xLTEtMA_d834f45e-c727-4e4d-bfab-9d384c5b302f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e9b2ae35f94059a42f289e242fd5d6_D20210101-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctNC0xLTEtMA_552b4a17-0d9c-41e5-91bd-0c881da0af25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d4f53a05ed4cf9a3c013c511bb6d57_D20210101-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctNi0xLTEtMA_dff1525a-24f3-4771-b5a8-2f95e4db9d0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib495e1983c7d43ad954d6982a1acc6df_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctOC0xLTEtMA_283bbce1-ff29-46e6-acdd-44a406d18be6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia65f96edddf14125a0ceff48dd6ce529_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctMTAtMS0xLTA_779da52e-cb3a-4513-ab25-f03fc52181b8">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac5d731345b49a89e720e60b2bd6179_D20200101-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctMTItMS0xLTA_05628e37-f0fc-4635-9b3e-e8655ea4d15d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1472bae377ce48de85232d1f7e78a6f1_D20200101-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctMTQtMS0xLTA_090db458-d883-4387-b60f-b5498fb8a27e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9da54dcd88e46a7a00d599ef8199f51_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctMTYtMS0xLTA_e52f382f-deb7-4795-92c4-f7e7528796a8">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa2fa3fc25c348288b3ec143881904ce_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtMi0xLTEtMA_014a22da-f7c7-482f-bf94-bc302770bf09">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae77bc715f014b6abd4b797b309ecbd3_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtNC0xLTEtMA_6726915a-b5a8-4a1c-96a3-ac4792d7e19e">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b06166a143f46ac8b776fcfa056152c_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtNi0xLTEtMA_60ae36f3-a82b-4034-814e-2398c4c94739">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1c82a1c7814ef0bae95b14cd89caa3_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtOC0xLTEtMA_34b1ca3c-d4fd-4792-a72a-f106b51c4d9e">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833340a21ed94b68a7b86f7be0fdf2ab_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtMTAtMS0xLTA_f8ab2ddd-4002-4606-98b5-c54503856d80">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513c462b957b48c38384730437388578_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtMTItMS0xLTA_6db2ba3d-f894-4689-935c-c158fa66355a">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a22bab8816347da9de17b819770d4a1_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtMTQtMS0xLTA_70c65a4b-f21e-4148-b381-416d14371cc0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i156443fab6604e7abefd184b681ac88f_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtMTYtMS0xLTA_6f9caa1f-e901-42c3-aa00-ec2f00935819">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0453ae248b4871a513cc0481e0ba95_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktMi0xLTEtMA_886ab69a-e83e-4c88-bbb3-024be5f7f32a">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b9b3ecee864a188d3318a7b3b10134_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktNC0xLTEtMA_e7079a31-bb85-4fc4-9c3c-7ff57a6320fa">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79b02c41c5dd4f85b666bb73366db6a9_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktNi0xLTEtMA_4552568b-2714-42a9-bcbf-f717898782e3">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i664b0e413d3e45a1b02ea0aca6fa69a3_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktOC0xLTEtMA_43695efb-3e98-49ac-9712-ac9dfde418eb">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61127c264a134cadac4433659a4b2a07_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktMTAtMS0xLTA_30c97633-9f77-46c6-aa7c-d2b6c5356961">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73ed798ddb0d4b829c8f9df19472898e_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktMTItMS0xLTA_0fc80ee6-5cb3-4787-8754-584e9323c87f">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ccbeb9d2904b8494fcca05b0e0aabe_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktMTQtMS0xLTA_cfc9d4a2-e9ab-4b0f-a693-45aec32c5aac">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb505b42a7d41d197183c8cbc88fa17_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktMTYtMS0xLTA_f937ac8d-031b-491f-b8a1-a3d848fc43d7">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c7645be0b7483282e2fa48a952ce6a_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtMi0xLTEtMA_14268160-282f-4b2a-9c9b-f6182faed9c0">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aaff90d56d04403ab9bcbaf508a1fb9_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtNC0xLTEtMA_72d62533-541c-4076-8e8c-727c5b97e46e">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2ca052afdd41308acfee42874d16bc_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtNi0xLTEtMA_95b8597d-133c-454e-9323-72620360dc2a">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6f15ef048940a2ba4ba7ff83b36db4_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtOC0xLTEtMA_ed549d4d-4fa2-468b-996f-d03c74adc73f">777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e56043c08ff44629cc394d2f686ed56_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtMTAtMS0xLTA_110929c7-df83-41e0-b775-0491d6ad6300">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98bd71b2478e4a04916636f59012d953_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtMTItMS0xLTA_445869d2-6f7a-4acf-9a4e-b5e7f63a6d61">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13822eeebaf946b9a83f2a817987763e_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtMTQtMS0xLTA_33064583-c1a3-4ccd-bc7f-616e928bc6a1">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2e5f8264194107aa51706375b167fd_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtMTYtMS0xLTA_5daa4ef3-741c-46bb-83f7-36b629d966cb">772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794e4f01cf834ef6b6cb3fac8633384e_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtMi0xLTEtMA_d080f96b-56cf-4368-9da7-93eb4a2b647e">13,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide78b4b7f0d04153ad16104b60a2684f_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtNC0xLTEtMA_5a0fb394-7198-4eff-a58a-62224a071313">3,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69842657a0724c8bb9baf66aa7591fe5_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtNi0xLTEtMA_10e4ab47-0084-45d9-8b23-4fd1619e46da">2,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7a2ec8073884bc5881bfa3d3afda11c_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtOC0xLTEtMA_8ae01873-4ac3-4e20-8462-d99a9e4e4aac">19,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b7e271684784d7dae794919a0acb56b_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtMTAtMS0xLTA_02075981-41b0-4a32-a817-f3d695be3aa4">12,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61a064a1cde64b1196d2dce7960e85f5_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtMTItMS0xLTA_d1de43ab-703b-43f9-a79b-531ffafb0b0c">2,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34484c2dc9304341be78db8166e621e3_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtMTQtMS0xLTA_db2509d2-fe57-4358-9bda-49d2d2626e13">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4666b276ec7d40ea86d10c4ded816760_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtMTYtMS0xLTA_d4536e71-a539-4c68-b7a0-1b4992db341b">17,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ca680e493e94c14a2d7345742f31836_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItMi0xLTEtMA_5c29a200-8834-4e4f-922d-59c7fc794a7f">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092466e16cdb43f4bb4f2f9191a72a85_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItNC0xLTEtMA_7e917a3f-a4fa-45a0-b39b-e34b19bf6e74">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e494a218a634591bd5ed5db40a1c47f_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItNi0xLTEtMA_878f9686-8d76-4be4-ba14-1345b537c357">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a47277681854c0eaa992a6c02b6acb3_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItOC0xLTEtMA_5c8bdb3b-ea4b-4543-a37b-48485b4ba3d7">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f12c7af337245d5afb3786a6258a024_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItMTAtMS0xLTA_508b199e-cad6-492e-a57e-3798a32e15e2">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bb2f8457d7b431ea9f1c47d5413415c_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItMTItMS0xLTA_0666a55a-4a06-498b-87e0-db22e886eb2f">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc4cacc943a04c45aa40ab1aca412a24_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItMTQtMS0xLTA_ca017402-4125-41b0-b099-3792b4c455eb">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528488c905dd4c8da2e5a1389a8b0a59_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItMTYtMS0xLTA_b7b4a38f-5ad0-451b-8b1b-c1cc487a4ef0">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6bf17320054464a3bc267f3849d5c1_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtMi0xLTEtMA_f4c1c2d5-56c2-4280-b3f1-bdfa674671b2">14,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40c1afde566a44a2b60890f7234a9889_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtNC0xLTEtMA_3bc9d5c6-81e9-438a-93d1-3e6d85b18507">3,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f0226418aa141e08a04b3292d3d6a3b_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtNi0xLTEtMA_7b42a17b-91d8-48ad-b05b-3f7528b6884d">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtOC0xLTEtMA_2b253fed-cfe2-4d60-b4f5-67eae2f83ec1">20,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69b2aa2945ce4106a4fcf5c0bdca8f28_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtMTAtMS0xLTA_93109ba2-e369-4c6a-8a41-41ff955787a1">12,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a8467fbacf40c38e699b24ac162d3a_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtMTItMS0xLTA_62983fc0-c874-472d-9624-dc118af2867a">2,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f9291215372429da56d3bf18442238f_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtMTQtMS0xLTA_aaaeb5e2-4eac-46a8-96cb-4d66f10c469f">1,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtMTYtMS0xLTA_d05a4b0c-b9dd-4294-898c-2914913301f1">17,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="iaa92e3a4f973450cbae2f0e12eff9055"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues from Major Customers</span></div><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMjUzNw_47060d27-4079-4384-a9f5-2da57c2c40fb" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:</span></div><div style="margin-bottom:4pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie89b30127587468d9e71733bf07d5081_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfMy0yLTEtMS0w_a894ba42-fc28-4387-9627-a5d285c03a31">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedd6b57e5ee3433abe93e62847e14d87_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfMy00LTEtMS0w_aa99b8e5-0c5e-4546-8193-161cc3efc4e1">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if6546a28c4524eaab7537c0d6bf777fc_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfMy02LTEtMS0w_a9fd6282-1a9c-43e8-aee5-54c22f8bb1d4">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21718856cc7648018662a2e392cd71a4_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfMy04LTEtMS0w_4086f524-49b1-4c49-8b3a-cd52547e8617">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74a16f60814741f98bcabd2ce43bcb36_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNC0yLTEtMS0w_17dd1606-02b4-4934-8f7e-1c56388e48f9">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac98ca2d21064f81a59741305eb998b4_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNC00LTEtMS0w_7bf53fd2-cf66-4bef-914c-69437b39dc92">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic0f301d0c0aa40ab958148e4f5814aa1_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNC02LTEtMS0w_d658eea3-3335-435c-8624-e9c04d6858d4">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1f131cf4a5b4202aa0a668ee3ad2bc5_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNC04LTEtMS0w_97272760-1705-4e96-96d1-4e9211dd966d">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if33c4729f0e84f61be8298fc81de60ff_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNS0yLTEtMS0w_fdcea9cc-12b3-460e-921a-8e71f1d9f420">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i348e70f83b254e66adb00f1a55a6328e_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNS00LTEtMS0w_3b8238b0-10a5-427b-8ded-e10bf253f1b4">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4979a9738ed14d44a7fc44641a6b295b_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNS02LTEtMS0w_54e6657d-66d9-4036-9cea-48f0a92890c3">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i44900a3d2ba94688bb7a0dfade50db90_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNS04LTEtMS0w_91595697-5f4d-4683-a7a6-711190e6c73a">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues Recognized from Performance Obligations Satisfied in Prior Periods </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $<ix:nonFraction unitRef="usd" contextRef="i8f07727060b14c0d872f5f929cc9fdf2_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTE1Mg_204e5423-de5a-4910-816f-e5b144347355">190</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i30f8590a90374b4fbc764b63834fe5ed_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTE1OQ_6143d4a5-c8db-4408-8dfc-731607c631b4">625</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i0e302cf42eb74c9a84eab7578f54195e_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTE5Mg_bca7ca10-1d02-4b36-bea7-2f9e73d98425">206</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i92825af11f15411da7e658f2ec15da12_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTE5OQ_c4edcd2a-68e4-421a-a589-088fe5fad85d">618</ix:nonFraction> million for the three and nine months ended September 30, 2020, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates for variable consideration related to sales made in prior years resulted in a $<ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTY3Mw_a64f49d4-974f-4435-8198-4e8f267eb13d">188</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTY4MA_2c51eb51-9fb9-4fd9-b9ff-3f207bd5e2a7">661</ix:nonFraction> million increase in revenues for the three and nine months ended September 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTczNA_c94b3500-4912-44e5-9406-0785ba1ea6b3">13</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTc0MQ_a638aa86-7b5c-496f-a98b-4e8970f74b8e">94</ix:nonFraction> million increase in revenues for the three and nine months ended September 30, 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $<ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTk5Nw_f1689b62-0674-4f8b-9076-be28a93c292a">167</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMjAwNA_900d4dd3-3444-46e7-9067-55fb538c8a58">198</ix:nonFraction> million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were $<ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMjE2Mw_155592f3-b6ab-4cd7-95e1-10a79ef98b4d">85</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMjE3MA_04ec9e0e-2ae1-4e1f-b9b9-92b6fdc8c346">97</ix:nonFraction>&#160;million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. During the three and nine months ended September 30, 2021 and 2020, revenue recognized that was included in the contract liability balance as of the beginning of the respective years was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div></ix:continuation><div id="i2c1b4d102d99434b956b3b8616d0836a_40"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNzcyMw_a1b36890-633a-4f7a-ba5f-d0f3a43fb20e" continuedAt="ic8b0e6e72bdf41d0b8344198b64f1bf0" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="ic8b0e6e72bdf41d0b8344198b64f1bf0" continuedAt="i9568dee4bdd94b558a6da47dfbfa834d"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNzcyNw_25a881c6-34c5-43be-a17d-dfc878375d2c" continuedAt="ie707874fbadb4a6282945053e5b46f02" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. </span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie707874fbadb4a6282945053e5b46f02" continuedAt="i4d52158a08644fb2afd61ad75440e234">Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9568dee4bdd94b558a6da47dfbfa834d" continuedAt="ic3c3a3bc64be4b08b86179a5b18e9804"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNzc0OQ_beced561-2c7d-4538-a3dc-bdfe40258274" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35f4c541e614d33a6437788299fdc0c_I20210930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC0yLTEtMS0w_639ba40c-495e-4f78-8d56-f743d6de4bc8">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e0d18c597e4ca2ae01fdfbd7881c3a_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC00LTEtMS0w_22856123-ed22-43d4-930e-037c71ca1d06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaa631e8e95431a9bdfa133e0488d8a_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC02LTEtMS0w_3d42ac2c-b1e7-456c-9427-49e62d2ec7ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id69559bfdfb948d1a4ffa643418f21c9_I20210930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC04LTEtMS0w_4e549a56-6d07-4171-acdc-05309346ee53">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3548698f1b14ba68822ef5950d4915a_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC0xMC0xLTEtMA_12b7bcb0-c12a-4d3b-90bd-eb338fd4325a">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c690fe00ac54cd0a140a27f890f5c48_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC0xMi0xLTEtMA_ba889682-9321-4a14-bf54-fc463a0afcd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824f7d8e5c4243208069c78b91bbb9a3_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC0xNC0xLTEtMA_67822ef3-11cd-4df6-9a7d-7b0d0d8c75c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27bd677e9c7f4ab69c1c65c4a2154029_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC0xNi0xLTEtMA_21cdb6d5-be88-4554-9968-ca5635b90b82">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e5aea4693e4a208fbfbf2e410e5c40_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi0yLTEtMS0w_2d2032fc-01ed-4732-bd9d-1feea1b323cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c621536eda94c6f8d03472cdac1cc35_I20210930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi00LTEtMS0w_cf85a004-2441-423e-bde2-d252433a41f3">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic59f42fcfdbc43379e5b44f081585c47_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi02LTEtMS0w_05236374-edb9-4f2e-a055-5e6322efbf9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i780e0de404214dc29d45580e7b2531b8_I20210930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi04LTEtMS0w_51f9508f-a173-444f-b2bb-a9363589da68">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41956a7c7b7a4ab299edca9f380ca798_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi0xMC0xLTEtMA_74d5a12e-1037-4291-8a0a-10363b7a5f4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79c41df237804e668c0da56a46ee0085_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi0xMi0xLTEtMA_d8996e46-ac58-4083-8a82-91a39240321a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c07df65da1d41098cd48baa32f21d8a_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi0xNC0xLTEtMA_f6878097-4f8e-4fae-a37a-cd99d2dbb276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide714ebff4fb46809c7b477daae2d962_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi0xNi0xLTEtMA_5b5d0b1b-d641-49be-8da0-d179ead47581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce16fa84c314d2d8b2732c6bf0d57e1_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy0yLTEtMS0w_2ec54d03-3596-49cd-8a76-5b713a63e665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf10f2216a934d5b9d20de4fa33c7e6f_I20210930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy00LTEtMS0w_3223efd8-49eb-442f-a01c-1585bef10ec4">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ec4abb19ae49f0b238c47892dd4df4_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy02LTEtMS0w_4861e964-91a6-46f4-8a77-96376adfd7d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1839e6fac09a4a4d9210d56808c687d5_I20210930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy04LTEtMS0w_332eb3b1-14e8-4067-9662-5bb3fcea2ee9">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54f21829201d45aa939df14dd7b96c21_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy0xMC0xLTEtMA_011f9153-ce1c-448b-9f2e-f11f6e46801f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7361567a884284b89e7bf5a20638a8_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy0xMi0xLTEtMA_ad1d32e8-b2ee-48a3-b41b-53af99879766">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i549d3edb71ed44988ab49d3637f8cf90_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy0xNC0xLTEtMA_d3cfa027-fdce-47d2-92b6-c5b778185a0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36270f186c97490e84c4d0dd8788d411_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy0xNi0xLTEtMA_87f9f18e-a698-4270-881d-c05ef921021c">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9e6e86e84a497aa1ba2c847b3e7767_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0yLTEtMS00NjIzMw_afa05c7e-0111-44f4-bcdb-81f9c0b119fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c6271275734808a0ff96495b000a60_I20210930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC00LTEtMS00NjIzMw_dc9811e0-e5a7-473b-aca7-4d0b507632dc">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2217b0ea8f50482aa528fde408cb76e3_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC02LTEtMS00NjIzMw_29be6d76-7064-4bea-837c-9feb9a22f010">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfea4630e695464ea306f7481b6e32ec_I20210930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC04LTEtMS00NjIzMw_35533258-7092-4fe1-87ba-2d15c46818b0">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fbed77deabb4de589efde4d54035191_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xMC0xLTEtNDYyMzM_bf3e34a7-42d8-4aaf-8ed3-853e3061fbd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961ed43970894b70b047d465504721d5_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xMi0xLTEtNDYyMzM_ef91dfb1-263c-4e22-988a-65ce39640621">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d59baf4935e4b848a146a795052db24_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xNC0xLTEtNDYyMzM_94d2b3e2-59e6-4ebc-ba2d-46c91a1f1a2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84eee8925bd946b48b71e527c679a789_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xNi0xLTEtNDYyMzM_134bc098-1bb3-4aea-802a-626a7fe8a3aa">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic665639028ad4946b03ef3d0a7ca3192_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0yLTEtMS0w_c0a7e387-b507-4fe6-8a33-205e4344c803">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3960deda1f4d454eb5bece595f0566f3_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC00LTEtMS0w_5ea2509b-4944-41b5-a393-6bcbb69de1f0">1,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897098b154ce4014a6261d31477a3023_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC02LTEtMS0w_997a463a-89bf-46ea-bddd-505b43bad141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0adcb1eef7cb452f847c13e9842de931_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC04LTEtMS0w_1e6873cc-9739-40ae-8847-35a3052c65db">1,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b8ac7aca374e42ba0903e04a423882_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xMC0xLTEtMA_8a40d021-e0c6-4541-9ce2-2c0b91a62f5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idab563e4309c42b6991e40459e65c9bd_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xMi0xLTEtMA_ef5d5b75-3b6e-4aeb-939d-afb755b4fa1b">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i484390e670d3449786a771db7ab9ade5_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xNC0xLTEtMA_43b3aeb9-979a-491e-9b72-9cfe65c0f876">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526c131b580f42bc9d870f04c6d8d5b9_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xNi0xLTEtMA_697f0214-5e13-429c-b057-090c88716441">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926b7e069399438cb0fa7f1d96f3e3e0_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS0yLTEtMS0w_183218e7-acdd-448c-852e-ec6025579d00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a0012537fe46c5969295f09f2f6dd4_I20210930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS00LTEtMS0w_37aef324-a255-4037-b5b2-25ab1b7fd239">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ee3cd97581a4d2abdb377c19e3ebfc0_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS02LTEtMS0w_2656c4bc-4c84-4ca8-a069-1eb6518396dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide347640da714f3395ba489a540c603a_I20210930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS04LTEtMS0w_12e1a152-61fb-4f8a-a163-dcf8e237f53c">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i276c9ea2224d4affa06277ba327a2d61_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS0xMC0xLTEtMA_778b83dc-b8c3-407f-8f1a-0ba8870dff9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a95ff7958c4fb7ac5a1798d4dce9cf_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS0xMi0xLTEtMA_bc792f0f-8b8b-4f9e-97b5-c32dbd77e786">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3136714317f0456c977067551e4bd81f_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS0xNC0xLTEtMA_6cae3740-53db-461d-ad57-0b7048628c78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a7c2c25d974d61a8013b71288affd0_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS0xNi0xLTEtMA_38a67ef8-650d-45f3-8cab-43fc6c5166be">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44d10b847f5e406db45e5ac1953efe55_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtMi0xLTEtMA_82bb1419-f8a9-4f77-8b5e-f3bebe22087b">2,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14621646e10c4fd1b6c4a65065d514ab_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtNC0xLTEtMA_c74a4170-63ed-42e1-980b-1c09b50875ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b775bacbe44316aae442a85d447f1c_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtNi0xLTEtMA_63f557ee-b5c3-4d7e-b5ca-35d5cd54e05e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide0afddf10ce4f31895aad1d16c1d85c_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtOC0xLTEtMA_61d28987-d31b-4ff3-bab5-617e99bbfb79">2,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c1629420b3f4c80b65c3eb9d05ee4ec_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtMTAtMS0xLTA_832f5d42-a676-4407-b429-1336d33856d8">4,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96153a6dea77431eb98e9c8200e6181a_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtMTItMS0xLTA_c169eeed-33c2-467a-bd7b-82480e6c1659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f662a891d89402584dcecd95385ff8e_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtMTQtMS0xLTA_5d9d726d-be84-42c4-8f7d-5e6005cf86f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4532563975f4635bce45eb0d2ae51f2_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtMTYtMS0xLTA_8968e4fc-2d9a-43ad-9183-521676f33e05">4,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78c02433e66541af99b97939d39e23a0_I20210930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItMi0xLTEtMA_e0736e63-4e51-444f-817f-8829e0a69c95">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8d9e0325a1434c858eb9522b968441_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItNC0xLTEtMA_f5ef8f33-cefb-43e4-b56b-d6eb8ff5c154">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21fe9fe9de1442b89efde9577f52f46_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItNi0xLTEtMA_0f344dc4-2ce0-477f-b005-1817454acf73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b838d5587cb496093b251362509ac97_I20210930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItOC0xLTEtMA_e63f3da3-e02c-48bb-add7-a44252430b2d">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1f0e139c0cd44a6b90716186d108008_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItMTAtMS0xLTA_ccb03fc0-1811-4e6a-8f1e-278f29187375">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe330b4018048f1898231a7f4ff4ecb_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItMTItMS0xLTA_0ebb0e2a-38fc-4304-ad97-9611180e3a15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b84e22ee5ab4a49ba427501bba85dd7_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItMTQtMS0xLTA_be6bb57b-443f-43b0-9f18-3ad5dda3f021">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b4898fa0a764d7aafa5e9a1d6d72ef3_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItMTYtMS0xLTA_ca402c8b-1f9f-4a9e-8c51-a3cf4ed95b0d">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf1508526e8c4ee1b4e7b2a680bad4c4_I20210930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtMi0xLTEtMA_682a124e-9403-4370-a9dd-7fdfb31bc7b0">876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9769a32b3db420e9bd1bec55f864b91_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtNC0xLTEtMA_f2ad278e-4783-457e-a35c-adb61893ee2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i316acb6201d34cd8b84ad4bc0a229326_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtNi0xLTEtMA_8e81c75d-8b56-47e7-9eb0-9f07ea2ba55e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29435eace9144606b96eee2d02e381a8_I20210930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtOC0xLTEtMA_ddf3fb75-a4d5-4975-a925-13a54f5d4534">876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbabaed951aa4295ae68d516beb80338_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtMTAtMS0xLTA_b45891ca-be3b-4895-932a-255bafa95abc">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4501dcb7b04327b30565529b2d48aa_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtMTItMS0xLTA_f3869f6d-cbcf-4607-9be6-d8eb2afde899">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i799dd8cb5a934a67aad9f2247cd1f8b6_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtMTQtMS0xLTA_b9160050-b5d6-4f26-9fb4-a33bcd515070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb74d6dc685f4234af1aa0e61f985bf7_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtMTYtMS0xLTA_68dde13d-7d22-43ea-be31-71efa86889e7">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia380e72b9e514a0dbc10fa47a96a37b9_I20210930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtMi0xLTEtMA_85b318af-424b-420f-a47a-5048a2569d77">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0202af8459b4f3789926f58b9cf9752_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtNC0xLTEtMA_abb94cf4-36db-4490-91c4-804b9fbf134a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42edfdab86c9426e93701ffdc0c7fe94_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtNi0xLTEtMA_d0151553-dfbf-4f14-afdc-e11d3ab8902d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c80ed86b032450995903fbe43ad034e_I20210930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtOC0xLTEtMA_fc9b265f-cd64-4d8e-a66c-ab34aea4bd2f">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54901c86be024d34813c278457433dd1_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtMTAtMS0xLTA_da675228-2fce-425d-aaa3-e00e614aa9e4">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c04316279d5406ebb97ec435e024e2d_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtMTItMS0xLTA_16018e9b-60ff-4afc-bd43-8183ec3fcaa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1502ee19eaa24b0992c9886bfc77cb5b_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtMTQtMS0xLTA_98871279-d090-45a9-949a-e3ef83ccb4ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib15e0bfd36234157af17a4ce20b77d43_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtMTYtMS0xLTA_bc725902-e269-4073-99f9-5dbc62bd9884">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if364edca58da421d9d61dae9fcad7914_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtMi0xLTEtMA_b43a561a-81c0-4741-8bd8-d9a77c3fac26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40461f1ac8b940ce8fec799328c0881a_I20210930" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtNC0xLTEtMA_f8351ed3-6240-42e6-9872-5d4334252d51">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe2d6409bd5447b881a310ce4725db2_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtNi0xLTEtMA_64c37eb6-5473-48a4-8db0-498084fd8a81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d5b42f92744945842d42ff308f0e20_I20210930" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtOC0xLTEtMA_c02fa321-8c05-47b1-b98b-f6429a4fcace">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6428c6244bd40588e98b0566fc843e1_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtMTAtMS0xLTA_bb83065b-c019-493a-a765-cd2024b1bccf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b69704c2d87477fa4c4e048aef6c84a_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtMTItMS0xLTA_de1e13d7-484b-4ede-8f04-1ea70433d8d1">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28c7735eb6934c9290f2ee14fb060da0_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtMTQtMS0xLTA_7efc2ccf-78aa-45ac-a7e5-690f14cedbf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8e7f03185947608f3762d7182fac94_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtMTYtMS0xLTA_07546a11-6d9c-4fee-a25a-d384a8e02879">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icccb697c433d4ec09b49c19f13ab8a83_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtMi0xLTEtMA_89eff2b4-5938-4431-bb8d-5679e15ecbe1">5,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i373b78381e234c3ca41660182ac003fe_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtNC0xLTEtMA_6ad49414-5f16-473a-a733-121515fa5208">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9cc0b50d7c4ab6bc2905f65769e3b1_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtNi0xLTEtMA_0b5e9e50-07fa-4e07-970c-a8222506f5b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8a9ceaf8e034398898fc7c7ed8656c9_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtOC0xLTEtMA_d3a970c0-236a-46ad-af91-e12134b38568">7,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee81b72feb64a13bb9b256646717944_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtMTAtMS0xLTA_6a4c8aef-525d-4962-96ee-cbb324078a30">7,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ccfe72a95f54aa78e87fe00e6420d4a_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtMTItMS0xLTA_2ed9d347-ccd7-4d51-a2fe-99c433fe3cce">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e7f4d6bbc524f168c63679b9a7e91fb_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtMTQtMS0xLTA_7dd217c0-7f84-4021-bc92-f88edb335d55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91039368c3bd4bfb910457fd3dd4c000_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtMTYtMS0xLTA_216be828-2e33-4e0a-942c-d48db885af5c">9,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i989d63bf16b04e01a3d9b072d85d1ba9_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtMi0xLTEtMA_3c83b72a-2d5b-4bfa-b716-849a9969562a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31da5834b4314564824f60b82ecae0f1_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtNC0xLTEtMA_96226f68-dff5-4601-9f44-f24625bb118e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35eec1666a264bd3b71436f39b919d85_I20210930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtNi0xLTEtMA_ca55942b-6480-42f8-a6d2-5e1bee2178af">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e238999bb54c4099da8e86105699dc_I20210930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtOC0xLTEtMA_358318fd-800c-4c3c-bb64-2480a76574fd">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd694a407d04faab683d1cd31f7d8a9_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtMTAtMS0xLTA_7a9bf9ab-9875-463c-a646-97289de09a69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c237a39755447a48b076df315f9ace7_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtMTItMS0xLTA_1fe30a36-3359-4057-8da6-d5083685d6e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f04e6cd6d84fc3bb90b473f068279d_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtMTQtMS0xLTA_39e57879-2da6-4ddf-8738-8c0c82fddd10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5faee6f594734e2eadc6353454b6d927_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtMTYtMS0xLTA_e3c382f5-8b25-4d09-ab47-f13d6c2b71ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia380e72b9e514a0dbc10fa47a96a37b9_I20210930" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktMi0xLTEtMA_eee08247-2c83-4fe5-b409-029363478627">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0202af8459b4f3789926f58b9cf9752_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktNC0xLTEtMA_07262822-7573-4eea-a0d9-24f1e70d3a71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42edfdab86c9426e93701ffdc0c7fe94_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktNi0xLTEtMA_e6da06ab-b76e-4f1a-b3e0-3ffade33ac7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c80ed86b032450995903fbe43ad034e_I20210930" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktOC0xLTEtMA_91dc95e0-13fa-49c5-b086-47a9c9713101">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54901c86be024d34813c278457433dd1_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktMTAtMS0xLTA_bf2ca411-9102-4d1c-adaa-8ec096721efe">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c04316279d5406ebb97ec435e024e2d_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktMTItMS0xLTA_be24060c-fa52-494b-ac34-84261cf2e7d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1502ee19eaa24b0992c9886bfc77cb5b_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktMTQtMS0xLTA_b72e2f2b-911c-456d-9943-4614b7b97085">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib15e0bfd36234157af17a4ce20b77d43_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktMTYtMS0xLTA_d8a5e4bc-61d7-42ae-b21f-f277e78d2aaa">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if364edca58da421d9d61dae9fcad7914_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtMi0xLTEtMA_1ed9c6af-42b5-46f8-abb0-a79f8836997a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40461f1ac8b940ce8fec799328c0881a_I20210930" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtNC0xLTEtMA_659a46a5-9c0e-44a4-b57f-552da794cc11">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe2d6409bd5447b881a310ce4725db2_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtNi0xLTEtMA_5c6256e9-a50d-4cef-a2c4-5e7a5a04deb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d5b42f92744945842d42ff308f0e20_I20210930" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtOC0xLTEtMA_82963863-f705-4750-8cb0-00ca33253253">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6428c6244bd40588e98b0566fc843e1_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtMTAtMS0xLTA_820bbd66-2a83-4f85-9b27-51450c96f79b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b69704c2d87477fa4c4e048aef6c84a_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtMTItMS0xLTA_dccbcba1-cf3a-4855-a3cc-b90568e3fdb4">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28c7735eb6934c9290f2ee14fb060da0_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtMTQtMS0xLTA_e81844ca-e336-4beb-82f7-ad8880bf278e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8e7f03185947608f3762d7182fac94_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtMTYtMS0xLTA_f509ecb5-5815-441a-bf22-99b516444149">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icccb697c433d4ec09b49c19f13ab8a83_I20210930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtMi0xLTEtMA_e52ad917-2f96-43c0-8cde-e9b76319c681">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i373b78381e234c3ca41660182ac003fe_I20210930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtNC0xLTEtMA_5f33b6d9-482d-46d0-afe1-3a4343ed6e06">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9cc0b50d7c4ab6bc2905f65769e3b1_I20210930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtNi0xLTEtMA_1aafe058-0ab3-4ea9-ac16-1acf2410dad0">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8a9ceaf8e034398898fc7c7ed8656c9_I20210930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtOC0xLTEtMA_1475fca8-ea38-40ee-9668-5ec90928b66c">585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee81b72feb64a13bb9b256646717944_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtMTAtMS0xLTA_51fb3b79-b708-44b6-8b19-d0aa41e0072c">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ccfe72a95f54aa78e87fe00e6420d4a_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtMTItMS0xLTA_1a675994-f670-435a-831f-d6c68a373eea">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e7f4d6bbc524f168c63679b9a7e91fb_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtMTQtMS0xLTA_103a2cde-888e-42fe-ad11-d03ad0b36ab2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91039368c3bd4bfb910457fd3dd4c000_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtMTYtMS0xLTA_260e736e-51b2-4111-bc39-b6b79235f2f9">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:4.5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes our equity investment in Arcus Biosciences, Inc. (&#8220;Arcus&#8221;) of $<ix:nonFraction unitRef="usd" contextRef="i72ccac9d876f460bb41bf5ff8f83566d_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTA5OTUxMTY0NDk5Mw_6ba1ba31-ac10-4b88-8cfe-136e34e3906a">482</ix:nonFraction> million as of September&#160;30, 2021 recorded in Prepaid and other current assets and $<ix:nonFraction unitRef="usd" contextRef="i176ff44bb5764e3b809a6d1ac92b4178_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTA5OTUxMTY0NTAxMA_4cae37b3-bf41-4457-8844-c92b3ca567bd">212</ix:nonFraction> million as of December&#160;31, 2020 recorded in Other long-term assets on our Condensed Consolidated Balance Sheets. See Note 9. Collaborations and Other Arrangements for further information.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Securities</span></div><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNzc0Ng_fa7cce93-e6e4-419b-8224-c659ce3183f7" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis on our Condensed Consolidated Balance Sheets:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ef3db73cbc4509905d24a522ce5757_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfMS0yLTEtMS0w_d59c32f8-2dde-4959-a715-12d8040588ce">2,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0da35341d6714931bc1689adaba0f122_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfMS00LTEtMS0w_b3823e92-9299-4536-bf68-e61fc56c615f">4,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4da087316a0f42869c52cd83bef39303_I20210930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfMi0yLTEtMS0w_7681d917-23f9-4fc0-a110-688c3e16a615">871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1511de451544838b5b9f248bbe33b1a_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfMi00LTEtMS0w_29b92c67-9ef6-4061-a746-3c3123e51dd4">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f9fa2675c74baf9fc13fcaa1d41e1f_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfMy0yLTEtMS0w_20687fa3-6bb6-4a95-92f4-e532a23f155f">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37cb24882ef449585ce764d602b950d_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfMy00LTEtMS0w_515b1002-ad25-41eb-9807-cd138f849ca0">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1be5d0f90b94ff6beab639c85963cc9_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfNC0yLTEtMS0w_d207ea1f-db41-49c6-979c-9f1460e98026">4,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3127bd77e544569634499a4cf507c8_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfNC00LTEtMS0w_2400aa97-9128-448e-b45b-285ca3b93966">6,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:4.5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;See the table under the Equity Investment in Galapagos NV (&#8220;Galapagos&#8221;) for more information.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of equity securities resulted in net unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTY0OTI2NzQ0Mjg1NDE_553df822-7cfa-495b-8483-6eb9901453de">142</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTY0OTI2NzQ1MzU3Ng_8a092c20-b2d0-4d18-a52e-863ca240ec69">667</ix:nonFraction>&#160;million for the three and nine months ended September 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTA5OTUxMTYyODY5MTU_a45d4ac5-c604-4f17-9846-6080ddba6862">964</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-8" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTA5OTUxMTYzOTcwOQ_8f8e8cdd-93f2-4b50-80c5-8f867809e24b">1.0</ix:nonFraction> billion for the three and nine months ended September 30, 2020, respectively, which were included in Other income (expense), net on our Condensed Consolidated Statements of Operations.</span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale debt securities are classified as cash equivalents, short-term marketable securities and long-term marketable securities in our Condensed Consolidated Balance Sheets. See Note 4. Available-For-Sale Debt Securities for additional information. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic3c3a3bc64be4b08b86179a5b18e9804" continuedAt="i15904a1827274d0e83d96b64593ccb3b"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investment in Galapagos</span></div><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNTQ5NzU1ODE1MDgwNw_40fc1567-91c2-410c-8002-3cc97a92a63c" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity investment in Galapagos in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6cc9ca3679429daa7ddad7be3b18f8_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjlhNTI4ODZmN2FlZjQxMDI5MTUzYjM4MmEzMjA1YmNhL3RhYmxlcmFuZ2U6OWE1Mjg4NmY3YWVmNDEwMjkxNTNiMzgyYTMyMDViY2FfMS0yLTEtMS0zOTYwMQ_f2c0d649-dee7-4540-aa16-51d338a3e69d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i823c5759f91342788099a4a119a8361f_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjlhNTI4ODZmN2FlZjQxMDI5MTUzYjM4MmEzMjA1YmNhL3RhYmxlcmFuZ2U6OWE1Mjg4NmY3YWVmNDEwMjkxNTNiMzgyYTMyMDViY2FfMS00LTEtMS0zOTYwMQ_b63e573c-7be5-4078-beeb-63cf3ec9f9e4">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ccaa167281f4a20b66d52b3c71f1dae_I20210930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjlhNTI4ODZmN2FlZjQxMDI5MTUzYjM4MmEzMjA1YmNhL3RhYmxlcmFuZ2U6OWE1Mjg4NmY3YWVmNDEwMjkxNTNiMzgyYTMyMDViY2FfMi0yLTEtMS0zOTYwMQ_e1f0cdca-3020-4a3f-a582-f55bc0759336">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dcf510e014b414ea7b2dc9b96ebd136_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjlhNTI4ODZmN2FlZjQxMDI5MTUzYjM4MmEzMjA1YmNhL3RhYmxlcmFuZ2U6OWE1Mjg4NmY3YWVmNDEwMjkxNTNiMzgyYTMyMDViY2FfMi00LTEtMS0zOTYwMQ_d53e3cc5-ea4d-40c9-a3e8-d4835cfdc1d7">1,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a2c5f5c07343a095efd1f37fda91fd_I20210930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjlhNTI4ODZmN2FlZjQxMDI5MTUzYjM4MmEzMjA1YmNhL3RhYmxlcmFuZ2U6OWE1Mjg4NmY3YWVmNDEwMjkxNTNiMzgyYTMyMDViY2FfMy0yLTEtMS0zOTYwMQ_ba5e03bd-c9f0-43be-87c6-7a689f38f0c0">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df9dcc40c9941ea8c7e26f4f58967e9_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjlhNTI4ODZmN2FlZjQxMDI5MTUzYjM4MmEzMjA1YmNhL3RhYmxlcmFuZ2U6OWE1Mjg4NmY3YWVmNDEwMjkxNTNiMzgyYTMyMDViY2FfMy00LTEtMS0zOTYwMQ_c31446ab-a888-4544-b557-0b473d377b9c">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected and applied the fair value option to account for our equity investment in Galapagos whereby the investment is marked to market through earnings each reporting period based on the market price of Galapagos shares. We believe the fair value option best reflects the underlying economics of the investment. The portion of the investment subject to long-term contractual lock-up provisions is classified within Other long-term assets and the remainder is classified as Prepaid and other current assets on our Condensed Consolidated Balance Sheets. In April 2021, we amended the Galapagos subscription agreement to extend the initial lock-up provision for certain Galapagos shares from August 2021 to August 2024. As of September&#160;30, 2021, all of our equity investment in Galapagos was classified as Other long-term assets on our Condensed Consolidated Balance Sheets.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Equity Securities</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments not measured at fair value and excluded from the above tables were limited partnerships and other equity method investments of $<ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMzE5MQ_c8cf3e2f-9858-47f3-845f-0bcc2db60c12">96</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMzE5OA_737dc1c2-8332-4431-bb71-22e324104f68">58</ix:nonFraction> million at September&#160;30, 2021 and December&#160;31, 2020, respectively, and other equity investments without readily determinable fair values of $<ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMzMwMg_3bf89603-6591-478b-b76f-c59f8fccb911">211</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMzMwOQ_ba23c6e4-b815-42d5-af1d-6a059d6fed5f">204</ix:nonFraction> million at September&#160;30, 2021 and December&#160;31, 2020, respectively. These amounts were included in Other long-term assets on our Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Transaction</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, Gilead donated certain equity securities at fair value to the Gilead Foundation, a California nonprofit organization (the &#8220;Foundation&#8221;). The Foundation is a related party as certain officers of the Company also serve as directors of the Foundation. The donation expense of $<ix:nonFraction unitRef="usd" contextRef="i7dfebbffea394aacba0aba288b9dc053_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNDE3Mg_24b833ad-212e-4297-b104-9f6c3ae064d1">212</ix:nonFraction>&#160;million was recorded within Selling, general and administrative expenses on our Condensed Consolidated Statements of Operations during the nine months ended September 30, 2021.</span></div><ix:continuation id="i4d52158a08644fb2afd61ad75440e234"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair values of Level 2 financial instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates (&#8220;LIBOR&#8221;) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div></ix:continuation><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair values of our aggregate short-term and long-term debt, determined using Level 2 inputs based on their quoted market values, were approximately $<ix:nonFraction unitRef="usd" contextRef="i0b50cb54d91f4e6c99676d255fa29fad_I20210930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNjY2MQ_124ca565-0da6-4359-94ff-1958e9b9e5f7">29.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ic6a9dc16a8a0426d985e8a948bb5bfb1_I20201231" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNjY2OA_a6a01d20-252b-4f5a-947b-c01fd4e8f7cd">34.6</ix:nonFraction> billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and the carrying values were $<ix:nonFraction unitRef="usd" contextRef="ia4da7a64c618429d8996f9b339ac38a8_I20210930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTY0OTI2NzQ0Mjg0NzI_61b99972-143f-43ed-9393-3fcc1801eb0f">26.6</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i6c6903daf0954d94b44190d9b3e1b5ba_I20201231" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNjczOA_0f233633-b04f-4c62-9140-6f4287e5a5a4">30.3</ix:nonFraction> billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i15904a1827274d0e83d96b64593ccb3b"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3 Inputs </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We measured assets acquired and liabilities assumed at fair value as of the acquisition on a nonrecurring basis, in connection with our first quarter 2021 acquisition of MYR. The liability for contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i76c056d0bef64de1a20dc89b76c1fa78_I20210331" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNzAyMg_1fad4322-36fa-4917-a4f2-08469b98003f">341</ix:nonFraction> million as of the acquisition date is remeasured on a recurring basis. The estimated fair value of this contingent liability was $<ix:nonFraction unitRef="usd" contextRef="i35eec1666a264bd3b71436f39b919d85_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTY0OTI2NzQ0Mjg0ODA_3853746e-f56d-4629-8292-255fad8547d3">328</ix:nonFraction>&#160;million as of September&#160;30, 2021. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of Hepcludex. See Note 6. Acquisitions for additional information. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measured assets acquired and liabilities assumed at fair value as of the acquisition on a nonrecurring basis, in connection with our fourth quarter 2020 acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;). The liability related to future royalties assumed is recorded at amortized cost, which approximated fair value as of September&#160;30, 2021 and December&#160;31, 2020. See Note 6. Acquisitions and Note 10. Debt and Credit Facilities for additional information.</span></div></ix:continuation><div id="i2c1b4d102d99434b956b3b8616d0836a_43"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNzI1_ee89ce0e-c966-49ed-93f1-c948421a069f" continuedAt="i6fc2a6bdac804f5ba753d49dcb629fb9" escape="true">AVAILABLE-FOR-SALE DEBT SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i6fc2a6bdac804f5ba753d49dcb629fb9"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNzAw_8f0af4e6-f5bc-4d24-8112-bed4ad5033be" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d7dd3905d64e28ac9327a66e603863_I20210930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi0yLTEtMS0w_57b08cc3-2afd-42cd-93e3-b1415e50914e">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d7dd3905d64e28ac9327a66e603863_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi00LTEtMS0w_c5c7424f-6b82-4349-8dbc-40e897626a85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d7dd3905d64e28ac9327a66e603863_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi02LTEtMS0w_c571c0d4-3101-477a-a6b4-7184d41969a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d7dd3905d64e28ac9327a66e603863_I20210930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi04LTEtMS0w_ea45cc56-3d4d-47c4-aa93-743346bffc1e">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2639a9859c40faa55868710c142818_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi0xMC0xLTEtMA_3b6b3855-e52f-4ea3-8a48-c0b54cebb56e">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2639a9859c40faa55868710c142818_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi0xMi0xLTEtMA_2fe220d2-7ab4-4096-b5c2-e45f284804fc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2639a9859c40faa55868710c142818_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi0xNC0xLTEtMA_f39e2c90-9b8e-42ad-9e08-a27e9d1053d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2639a9859c40faa55868710c142818_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi0xNi0xLTEtMA_dde58ebe-80ec-4068-bf87-75f7279f40a5">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f52dc3cab841a3809ef785e4e66ca3_I20210930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0yLTEtMS00NjI0MA_22d499c7-f02a-4427-b1b5-63e48d6822ea">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f52dc3cab841a3809ef785e4e66ca3_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC00LTEtMS00NjI0MA_7b15a10b-0079-48d1-884b-6b1a027f9e5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f52dc3cab841a3809ef785e4e66ca3_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC02LTEtMS00NjI0MA_098b699b-7d80-4d4e-9f7b-afe4783325ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f52dc3cab841a3809ef785e4e66ca3_I20210930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC04LTEtMS00NjI0MA_529017e1-a2f6-41e9-8f85-c10242510338">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03b29e17a2c248719dab9a52b28f2838_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xMC0xLTEtNDYyNDA_ccd8566e-aca5-4ef8-a17b-776905450d3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03b29e17a2c248719dab9a52b28f2838_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xMi0xLTEtNDYyNDA_d6b5364d-f27b-4b6f-872a-94c088dea1f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03b29e17a2c248719dab9a52b28f2838_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xNC0xLTEtNDYyNDA_1fa7aa5f-c945-44ed-b276-d4ca7421c72c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03b29e17a2c248719dab9a52b28f2838_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xNi0xLTEtNDYyNDA_9baa8d1a-ba5f-4132-ac0e-1c1a0d3e4b82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9848c60df524b6d8597f27a5c2348a7_I20210930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0yLTEtMS0w_95d2eae0-028a-4776-8da4-286dd0cca4eb">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9848c60df524b6d8597f27a5c2348a7_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC00LTEtMS0w_db604131-7e15-4690-b645-4ca97e225579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9848c60df524b6d8597f27a5c2348a7_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC02LTEtMS0w_940e2351-f4d7-4957-b4e8-3cd4b183755d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9848c60df524b6d8597f27a5c2348a7_I20210930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC04LTEtMS0w_5e25accc-7bd5-40f4-b39f-f5bf1449d7b8">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1b6844083d54dd6b01c081a66abc0ac_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xMC0xLTEtMA_cb4d32d8-2f79-4f90-b2dc-25e50b04dbee">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1b6844083d54dd6b01c081a66abc0ac_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xMi0xLTEtMA_3d55acd4-4e69-4c46-9037-951fb28b1161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1b6844083d54dd6b01c081a66abc0ac_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xNC0xLTEtMA_b6fece2e-2375-4a2b-8449-ed67080e64be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1b6844083d54dd6b01c081a66abc0ac_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xNi0xLTEtMA_89f98591-ac06-4bd6-9c7b-a3d7f8a4b2c0">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1a2f42beca4dbfb5c2042c0e6ec2c9_I20210930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0yLTEtMS00NDcyNQ_6cea095e-4b7f-454d-85d4-74733d4727dd">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1a2f42beca4dbfb5c2042c0e6ec2c9_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS00LTEtMS00NDcyNQ_82b2b3ac-5c8b-408d-a88e-f4c3c611cc20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1a2f42beca4dbfb5c2042c0e6ec2c9_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS02LTEtMS00NDcyNQ_a61e1ef3-1a63-4447-8414-fe6fa50d5ffa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1a2f42beca4dbfb5c2042c0e6ec2c9_I20210930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS04LTEtMS00NDcyNQ_7bbe4505-2704-4386-a994-683e89dc2830">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b301a386454cff8a23c0f9d5802e0b_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xMC0xLTEtNDQ3MjU_cb8c3ed0-c7ad-4313-a1d3-fb386e2c789e">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b301a386454cff8a23c0f9d5802e0b_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xMi0xLTEtNDQ3MjU_5eab8282-2152-4d64-b93b-b7d6fc1577ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b301a386454cff8a23c0f9d5802e0b_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xNC0xLTEtNDQ3MjU_d7e069f1-bf72-4d68-8caf-4a1c73bb7700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b301a386454cff8a23c0f9d5802e0b_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xNi0xLTEtNDQ3MjU_a155837a-8ea5-49d8-b297-089201e15d33">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9edacacd9fed40b19c21f8c9a2d1066a_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0yLTEtMS0w_fa930565-da52-47ab-ba99-210ba02f9037">1,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9edacacd9fed40b19c21f8c9a2d1066a_I20210930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS00LTEtMS0w_836b41b6-66c5-46d4-b3d7-54d9a4cf40e3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9edacacd9fed40b19c21f8c9a2d1066a_I20210930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS02LTEtMS0w_e513a913-bf77-47ef-b597-def46c85629d">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9edacacd9fed40b19c21f8c9a2d1066a_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS04LTEtMS0w_a9f4b923-0e25-4d6c-84cb-a03494383010">1,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd06b56ab884773b9a6d59b91979118_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xMC0xLTEtMA_4f6cd6a7-6bf3-42aa-bed0-6a7149201701">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd06b56ab884773b9a6d59b91979118_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xMi0xLTEtMA_352ed836-c94a-4984-b30c-66957f91f5ac">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd06b56ab884773b9a6d59b91979118_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xNC0xLTEtMA_0f6fe123-bd9b-44ca-8016-80e6118fb6c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd06b56ab884773b9a6d59b91979118_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xNi0xLTEtMA_963dea10-c41e-40f2-87b9-e0cc14184585">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4d28e4219744460aa5d638f0e4748d7_I20210930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi0yLTEtMS0w_df2a3233-2b72-45e9-a4c8-6f72a33f1d4a">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4d28e4219744460aa5d638f0e4748d7_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi00LTEtMS0w_766deef4-66fa-47c8-a804-e26d84d69872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4d28e4219744460aa5d638f0e4748d7_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi02LTEtMS0w_308a8216-272f-4aab-a649-27809fd952fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4d28e4219744460aa5d638f0e4748d7_I20210930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi04LTEtMS0w_abf769d9-a176-41b6-a9be-dad1b8448386">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb6a3f0759ad4433953398e7ad344fd5_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi0xMC0xLTEtMA_7b69b41e-e2c4-496f-8691-c04c0917ec90">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb6a3f0759ad4433953398e7ad344fd5_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi0xMi0xLTEtMA_69151171-e850-40bf-945e-c3f48c0382eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb6a3f0759ad4433953398e7ad344fd5_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi0xNC0xLTEtMA_d84f8f43-ee59-4869-8cea-f9ad7b750e8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb6a3f0759ad4433953398e7ad344fd5_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi0xNi0xLTEtMA_c8ae022f-52d9-4059-93ee-33361ff6a090">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy0yLTEtMS0w_1e3a1697-ec33-49a7-b5d5-afc4a9dc36e2">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy00LTEtMS0w_37f20232-ac49-441b-8bde-c5d072033d66">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy02LTEtMS0w_73b4f9bf-32cd-442d-a3ac-31cfc6b9e056">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy04LTEtMS0w_8d5d4269-b305-40b7-b131-e81a86c4f0a8">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy0xMC0xLTEtMA_fd480d1b-1f76-44ef-b116-f4958b0d2be8">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy0xMi0xLTEtMA_e664e801-7a6b-45d4-8859-d8da9f5fb323">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy0xNC0xLTEtMA_6ad4ab0c-8a44-48bf-a263-9e8c2f760249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy0xNi0xLTEtMA_49cddd0a-03a3-41a9-8f1a-5868b76d32c0">2,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNjkx_20636eab-804a-4f23-af25-584a7bab3349" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-bottom:11pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fcdeab4094c40bc957aa0ac494ab157_I20210930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfMS0yLTEtMS0w_73d96e8c-016d-4f19-8523-51fc78c3430e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa08afccd2c4c3c920afbf679603457_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfMS00LTEtMS0w_0f4aca6a-5f97-4c19-a37b-d005469a8481">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie91dfb2ea1ff4696bbe46980e5074985_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfMi0yLTEtMS0w_09501e32-2890-4b3c-ba17-edb27e9f046a">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36fc4c8f965c42f091bfa62e48d5188c_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfMi00LTEtMS0w_cb61bb1e-01d8-46e8-a7e4-8aa808f08bd3">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ef7763dceb461d8ba101eedb3ec351_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfMy0yLTEtMS0w_e38013d1-d50a-4ecc-8f03-19ad57874f49">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a621708b219448a9f522102302751fe_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfMy00LTEtMS0w_5f6dd4a9-0379-4bf9-99e8-660af945dfc1">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfNC0yLTEtMS0w_a31da331-6623-4af1-b366-de60d505d0b9">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfNC00LTEtMS0w_68245248-f4a2-4a51-86a6-c5b947e593f3">2,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNzIx_90839b99-73cf-45f5-ae1d-f25f56809bdd" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfMi0yLTEtMS0w_52c5404e-bfd8-4ffa-8861-9dde1263a504">1,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfMi00LTEtMS0w_80b1f2bf-3a97-4f07-be88-00406ee76116">1,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfMy0yLTEtMS0w_55ffbba5-4723-44e2-a848-ec63f1eadb11">1,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfMy00LTEtMS0w_c907c04a-12ef-4b90-8959-d26ff52a7dfa">1,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfNC0yLTEtMS0w_90d69536-362e-424c-8573-bfea9b408a1b">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfNC00LTEtMS0w_4e446658-5ca4-4307-920e-9b7606c22690">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfNS0yLTEtMS0w_db791e20-a5e7-4a3d-a306-8de5742bb807">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfNS00LTEtMS0w_97a1bf8d-a2ed-4701-a2e8-0dfd1b5fcdc1">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held a total of <ix:nonFraction unitRef="position" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfMzA3_4a02f22f-34f6-4a48-bd6a-88c6e81c84a8">214</ix:nonFraction> and <ix:nonFraction unitRef="position" contextRef="i05bfa65a7fdd430ea5429b49909dff6d_I20200930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfMTA5OTUxMTYyNzg2MDU_4e17ec6c-d484-48db-bfb2-990fa70311a7">208</ix:nonFraction> positions which were in unrealized loss positions as of September&#160;30, 2021 and 2020, respectively. The unrealized losses were largely due to changes in interest rates. Aggregated gross unrealized losses on available-for-sale debt securities were not material for the three and nine months ended September 30, 2021 and 2020. <ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNTMz_027e6186-d1e3-4020-af5d-26c6595530e7"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNTMz_17db7020-4495-4388-a10c-cab1e4db1fa3"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNTMz_6962c841-cbd0-48b8-b1c9-2efd9acc1be1"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNTMz_80fd1033-2c1b-448a-8c24-59654afe5a5b">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment was recognized for the three and nine months ended September 30, 2021 and 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzMzMg_cf6798ad-9283-4f49-9aa9-c78c31328c90" continuedAt="ic619ec5c6cc4455b802a33552e36e7da" escape="true">DERIVATIVE FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="ic619ec5c6cc4455b802a33552e36e7da" continuedAt="i2002014368ae49fab4fbd9c56809df39"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we may hedge a portion of our foreign currency exposure related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward or option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for certain monetary assets and liabilities that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are not designated as hedges and, as a result, changes in their fair value are recorded in Other income (expense), net on our Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of <ix:nonNumeric contextRef="i358d5e6dcfe74eb2bd53d281984be1b6_D20210101-20210930" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMTg3Ng_5d4c6d0b-4eb8-4bcc-b94f-76c4c96824c7">18</ix:nonNumeric> months or less. Upon executing a hedging contract and quarterly thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses in Accumulated other comprehensive income (&#8220;AOCI&#8221;) are reclassified into product sales when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of September&#160;30, 2021 are expected to be reclassified to product sales within <ix:nonNumeric contextRef="i358d5e6dcfe74eb2bd53d281984be1b6_D20210101-20210930" format="ixt-sec:durmonth" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMjM0MQ_ef713134-3936-476e-a1ea-24bedba7e4e8">12</ix:nonNumeric> months.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts for the nine months ended September 30, 2021 and 2020 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had notional amounts on foreign currency exchange contracts outstanding of $<ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMjU2NQ_3336cfb5-fadd-4c3a-bd73-391ee9c330f8">3.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMjU3Mg_c6aaceb6-52d7-4b2e-8016-69b106264a38">2.4</ix:nonFraction> billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. <ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzMyNw_0e285158-7698-4148-8213-89dd699a6a6c" continuedAt="i8629c1825c174d729b4d60ded39e808a" escape="true">The following table summarizes the classification and fair values of derivative instruments on our Condensed Consolidated Balance Sheets:</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:5pt"><ix:continuation id="i8629c1825c174d729b4d60ded39e808a" continuedAt="i2ef110eb65214c3ab410efcae4a118eb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.315%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2b0d3a5d754eba9ec5ab61ab8a496c_I20210930" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfNC00LTEtMS0w_63c98b61-8f20-49d5-9bd0-69a28faaae9a">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba883e2763fc4f24aa849f2ba1b18762_I20210930" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfNC04LTEtMS0w_ac6f7e94-0788-4e50-9073-54367b7b2922">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i441b41e448e24773b07474571334d688_I20210930" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfNS00LTEtMS0w_241921f2-2dea-4fac-aa0b-d9043ac3f746">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic68b8c1df06a4e9ebf5ecc3162d4e91b_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfNS04LTEtMS0w_17f9575c-2545-4083-8b7b-3fc95c5ec3f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41080ff3b0f84bb6ac2d71f26d888ae3_I20210930" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfNi00LTEtMS0w_b341fb9a-271f-441a-b9d6-f37011d11cf3">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41080ff3b0f84bb6ac2d71f26d888ae3_I20210930" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfNi04LTEtMS0w_9caa9ae0-b942-4022-abaf-9d143503e009">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9de9bbb3a16148ef822890fed3ae38df_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfOC00LTEtMS0w_a9290c22-b58a-4b80-88c6-b2a8e8fa3c50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f577e7ed1d9420a854f73986479f887_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfOC04LTEtMS0w_549ea077-b2ad-4b19-9e20-699ac4687b1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a621ab557e54d8aae26f9664ee66d03_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfOS00LTEtMS0w_c2b54f85-c4b2-48b1-812c-67ead28b0017">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a621ab557e54d8aae26f9664ee66d03_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfOS04LTEtMS0w_dc98dc88-f6f5-462e-8c90-349dc53a2e16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfMTAtNC0xLTEtMA_3de762c1-49fe-4dd5-903e-a4aa1687b5d6">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfMTAtOC0xLTEtMA_d9704c6f-e19d-4048-a272-3f43f1878364">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2002014368ae49fab4fbd9c56809df39"><div><ix:continuation id="i2ef110eb65214c3ab410efcae4a118eb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0316527653e540b79aaa8ffd4daeb2e4_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfNC00LTEtMS0w_c1c0848c-9f8c-4b4b-a448-07705b1d2e24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcc66a969998454596abd65746688f8d_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfNC04LTEtMS0w_72a40809-2cda-488a-88cf-e1bf8b46ad1c">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33df3af625fb41ae885fec733687b6cf_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfNS00LTEtMS0w_ca56b777-43b1-434e-8740-7c86a796a131">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2c72fc1463e44eb96aabd7dae05dad7_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfNS04LTEtMS0w_042e7a34-6353-4fba-ac4d-b25eaa889d0a">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2c8de705884a04944f9028afb662e6_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfNi00LTEtMS0w_70c810b8-f828-49b4-9c5b-abc44ff51e25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a2c8de705884a04944f9028afb662e6_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfNi04LTEtMS0w_388bbd09-4404-42a5-bcc1-612b0978f1c8">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a3a9b39d3f40068ad241a4bf584ecf_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfOC00LTEtMS0w_ad908818-e252-4c3c-9be8-ad4cd5ce47de">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d9378e46bcd49c1aeccf6c8f61de218_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfOC04LTEtMS0w_271ab4fe-e109-4ab1-b991-41b7ebcf8fba">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3efa4fc2e80425d911786fe90f0577e_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfOS00LTEtMS0w_99040c3d-f43d-41b1-b400-95c577fe57a5">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3efa4fc2e80425d911786fe90f0577e_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfOS04LTEtMS0w_035c3aed-e720-4306-81e8-856c8d210ccb">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfMTAtNC0xLTEtMA_e68b9fcc-affb-42cc-99d3-71019f2fbeff">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfMTAtOC0xLTEtMA_e18ec714-891d-41b8-b1ad-392e051f03c0">121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzMxNw_246e81fb-252b-497e-86cd-fc0cdd4219aa" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: </span></div><div style="margin-bottom:11pt;margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNC0yLTEtMS0w_fcbc2900-6be9-4b3e-b100-c0c2c206c455">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNC00LTEtMS0w_eb981166-d392-4dc0-9638-164d6eea734a">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNC02LTEtMS0w_aedabde2-5e98-44f8-89f4-4fe6196bb07f">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNC04LTEtMS0w_74875bfb-6057-44fa-9376-217c23d8a4f5">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) reclassified from AOCI into product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNS0yLTEtMS0w_1f977c66-7e7c-4025-a9be-bf1310bf5d60">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNS00LTEtMS0w_7cc5e41c-1a76-4b53-ba48-3a4d5651fd17">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNS02LTEtMS0w_fac0570e-0be5-45b2-a62a-5b0c37b09114">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNS04LTEtMS0w_cd1619be-4c88-4ee7-ae96-d137b84f0f27">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNy0yLTEtMS0w_d5e07564-1d72-4596-97ae-9b0d668bb42f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNy00LTEtMS0w_ebe3b2a1-a3fe-4a55-97bd-40fdc225fecd">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNy02LTEtMS0w_e84b0d9b-2405-4da6-a233-a9003b4bac69">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNy04LTEtMS0w_9d006894-7f34-44dd-a983-1a49492d737e">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Condensed Consolidated Statements of Operations. There were <ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzA2OQ_544d91b8-9a11-44a9-ac83-2ab470b9bd96"><ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzA2OQ_6092d477-c552-48a0-b4d3-f2a35ec1af16"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzA2OQ_6c14782e-d768-42c6-a003-b17eccb14d99"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzA2OQ_8c61216a-a763-44de-8bfb-205d959a7fd4">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> discontinuances of cash flow hedges for the three and nine months ended September 30, 2021 and 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, we only held foreign currency exchange contracts. <ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzM0OQ_0902b00e-f622-4ea4-85a3-63fac00e0da3" continuedAt="i584b59c8d4d24011b3fbfde5996d5149" escape="true">The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets:</ix:nonNumeric></span></div><div style="margin-top:9.5pt;text-align:center"><ix:continuation id="i584b59c8d4d24011b3fbfde5996d5149"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:22.507%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts Not Offset <br/>on our Condensed <br/>Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts<br/>&#160;of Recognized <br/>Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts<br/>&#160;Offset on our <br/>Condensed <br/>Consolidated <br/>Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amounts of Assets/Liabilities Presented<br/>&#160;on our Condensed Consolidated<br/>Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Derivative <br/>Financial <br/>Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cash Collateral <br/>Received/<br/>Pledged</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Amount<br/>&#160;(Legal Offset)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNC0yLTEtMS0w_453529f6-c861-4b18-ad92-66fffe0d03f0">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNC00LTEtMS0w_c27b4cf6-9d5b-45ff-827a-17bd36fceb48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNC02LTEtMS0w_2fd51f94-40a4-4031-8741-e70ba3a9ecdc">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNC04LTEtMS0w_3e63e440-ae40-4196-91e2-75f644b13e64">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNC0xMC0xLTEtMA_e13ee9a4-8d62-481b-84ce-7393705442db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNC0xMi0xLTEtMA_a66d4c9f-e0ed-4abb-aad6-4d32e8065472">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNS0yLTEtMS0w_f857d3e9-395b-4dd1-83e8-744216e539ba">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNS00LTEtMS0w_88194b82-8519-4638-ab71-dcb85c0b31c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNS02LTEtMS0w_267b341e-2ebb-4979-97b5-296b319b67a0">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNS04LTEtMS0w_e561e3e4-1b44-4b72-945e-18eab1939e41">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNS0xMC0xLTEtMA_8ed8f914-a324-4ff2-a1ba-dc6d990ac31c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNS0xMi0xLTEtMA_62422d3c-8478-4ce0-8007-d2c5c33c79e9">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNy0yLTEtMS0w_7b48140a-4109-453f-87d5-fbaca1deb74a">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNy00LTEtMS0w_f45c70dd-1636-450e-86c8-436f221503bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNy02LTEtMS0w_46a0112c-f91d-4b60-b742-42fc7fe9a107">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNy04LTEtMS0w_76a2a516-4e51-470f-ac65-685a64e6a233">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNy0xMC0xLTEtMA_9c2c442a-a02d-4f99-b388-4b75f8612b8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNy0xMi0xLTEtMA_188797a2-3542-4a4a-a31d-ebc4b09f2a74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfOC0yLTEtMS0w_30ddf171-34ab-46a8-ada1-6d033a2eaaf2">121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfOC00LTEtMS0w_eed3cc21-b4b6-4555-a17e-df95d2468f7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfOC02LTEtMS0w_ff4aa29e-08f3-49f5-a974-de4f4a34a6e8">121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfOC04LTEtMS0w_fed88dfd-0369-4059-8b9e-5c739c33e138">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfOC0xMC0xLTEtMA_74bfcdff-9bd1-4a6f-b22e-0fcb52ab1330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfOC0xMi0xLTEtMA_bebd607c-0af9-4cd0-83e8-a28e0979277c">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i2c1b4d102d99434b956b3b8616d0836a_49"></div><div style="margin-top:13.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNzE0OA_9d3ac2c7-a263-4c01-8e3d-fc7f40b1f712" continuedAt="i3126c4ef1ced4df0a3bae71b317497c1" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><ix:continuation id="i3126c4ef1ced4df0a3bae71b317497c1" continuedAt="i4460694d9f224048aa9fa493e82fa5f4"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Condensed Consolidated Balance Sheets. Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. Transaction costs associated with business combinations are expensed as they are incurred. The first quarter 2021 acquisition of MYR and the fourth quarter 2020 acquisition of Immunomedics were accounted for as business combinations. </span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets. For an asset acquisition, no goodwill is recorded and contingent consideration, such as payments upon achievement of various development, regulatory and commercial milestones, generally is not recognized as of the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are expensed unless there is an alternative future use. The second quarter 2020 acquisition of Forty Seven, Inc. (&#8220;Forty Seven&#8221;) was accounted for as an asset acquisition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYR</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provided Gilead with Hepcludex, which was conditionally approved by the European Medicines Agency (&#8220;EMA&#8221;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. Upon closing, MYR became a wholly-owned subsidiary of Gilead. The financial results of MYR were included in our Condensed Consolidated Financial Statements from the date of the acquisition. Acquisition-related expenses were not material for the three and nine months ended September 30, 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate consideration for this acquisition of &#8364;<ix:nonFraction unitRef="eur" contextRef="i318a011bf49b49c3a79192b82583bb57_D20210304-20210304" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMjAwMg_f31026fc-4284-479f-9fa6-605071c82789">1.3</ix:nonFraction> billion (or $<ix:nonFraction unitRef="usd" contextRef="i318a011bf49b49c3a79192b82583bb57_D20210304-20210304" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMjAwOQ_69501c35-4654-415e-9667-84b49dd5edfc">1.6</ix:nonFraction> billion) primarily consists of &#8364;<ix:nonFraction unitRef="eur" contextRef="i318a011bf49b49c3a79192b82583bb57_D20210304-20210304" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMjAzNQ_292a9738-11fa-474c-9b88-0605af590f24">1.0</ix:nonFraction> billion (or $<ix:nonFraction unitRef="usd" contextRef="i318a011bf49b49c3a79192b82583bb57_D20210304-20210304" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMjA1Ng_9ea8e0ce-3f1a-480b-89ae-93fc08f42c75">1.2</ix:nonFraction> billion) paid upon closing and contingent consideration of up to &#8364;<ix:nonFraction unitRef="eur" contextRef="ib5181ad1c63c4deeb36365ffdce5e584_I20210304" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMjExNg_09067a39-e1ce-4500-9a0c-f3a8107730c7">300</ix:nonFraction> million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability-weighted scenarios for FDA approval, was $<ix:nonFraction unitRef="usd" contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMjM1MA_3d85ea3b-dff3-4a19-b71c-b7dac437ef64">341</ix:nonFraction> million as of the acquisition date and was initially recorded in Other long-term obligations on our Condensed Consolidated Balance Sheets. In the second quarter of 2021, the balance was reclassified to Accrued and other current liabilities on our Condensed Consolidated Balance Sheets. The estimated fair value of the contingent liability was $<ix:nonFraction unitRef="usd" contextRef="i35eec1666a264bd3b71436f39b919d85_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNDM5ODA0NjUxODM3OQ_3853746e-f56d-4629-8292-255fad8547d3">328</ix:nonFraction>&#160;million as of September&#160;30, 2021. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value estimates for the assets acquired and liabilities assumed were based upon valuations using information known and knowable as of the date of this filing. Changes to these assumptions and estimates could cause an impact to the valuation of assets acquired, including intangible assets, goodwill and the related tax impacts of the acquisition, as well as legal and other contingencies. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date.</span></div><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNzE0Ng_ebc66751-1940-45b5-8573-cd14c9503c0a" continuedAt="i227e91870bab41bc936db18fa64c984d" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjJmYWRhNmUwYzZmYjRlM2E4OWQ1ODAxYjA0NDI2ZDYzL3RhYmxlcmFuZ2U6MmZhZGE2ZTBjNmZiNGUzYTg5ZDU4MDFiMDQ0MjZkNjNfMi0yLTEtMS0w_adf8ad01-8e7c-4cab-b9c7-edfd2e2fe773">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i352358e211a34a23b9dc88776f5a0076_I20210304" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjJmYWRhNmUwYzZmYjRlM2E4OWQ1ODAxYjA0NDI2ZDYzL3RhYmxlcmFuZ2U6MmZhZGE2ZTBjNmZiNGUzYTg5ZDU4MDFiMDQ0MjZkNjNfMy0yLTEtMS0w_f1b46bbc-534f-4ebf-84ad-5ece5c0d5757">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjJmYWRhNmUwYzZmYjRlM2E4OWQ1ODAxYjA0NDI2ZDYzL3RhYmxlcmFuZ2U6MmZhZGE2ZTBjNmZiNGUzYTg5ZDU4MDFiMDQ0MjZkNjNfNC0yLTEtMS0w_a5bf74bf-dd7c-42b9-a42b-f0f9b58f498f">513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304" decimals="-6" sign="-" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjJmYWRhNmUwYzZmYjRlM2E4OWQ1ODAxYjA0NDI2ZDYzL3RhYmxlcmFuZ2U6MmZhZGE2ZTBjNmZiNGUzYTg5ZDU4MDFiMDQ0MjZkNjNfNS0yLTEtMS0w_013da903-7b78-4a44-add4-f79229365e9a">187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjJmYWRhNmUwYzZmYjRlM2E4OWQ1ODAxYjA0NDI2ZDYzL3RhYmxlcmFuZ2U6MmZhZGE2ZTBjNmZiNGUzYTg5ZDU4MDFiMDQ0MjZkNjNfNi0yLTEtMS0w_24b6810f-3519-4e2b-8e82-c49d95833f47">1,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304" decimals="-6" name="us-gaap:GoodwillGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjJmYWRhNmUwYzZmYjRlM2E4OWQ1ODAxYjA0NDI2ZDYzL3RhYmxlcmFuZ2U6MmZhZGE2ZTBjNmZiNGUzYTg5ZDU4MDFiMDQ0MjZkNjNfNy0yLTEtMS0w_a848505b-c621-4e3e-b164-91b4c6e4a194">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjJmYWRhNmUwYzZmYjRlM2E4OWQ1ODAxYjA0NDI2ZDYzL3RhYmxlcmFuZ2U6MmZhZGE2ZTBjNmZiNGUzYTg5ZDU4MDFiMDQ0MjZkNjNfOC0yLTEtMS0w_91020b8d-84c8-46cb-b8cd-b73b254fa9f0">1,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4460694d9f224048aa9fa493e82fa5f4" continuedAt="ib598f07b0a8c42b194e50c72b814924c"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finite-lived intangible asset of $<ix:nonFraction unitRef="usd" contextRef="i7d953182d7f349f7880aa6b8782ddbea_I20210304" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMzMwNA_f02ae5e3-eaa8-4a9e-a78f-f9654c1c7172">845</ix:nonFraction> million represents the estimated fair value of Hepcludex for HDV in Europe as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Hepcludex for HDV in Europe and a discount rate of <ix:nonFraction unitRef="number" contextRef="i46f837bb32354303808450010f541cf2_I20210304" decimals="2" name="gild:IntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMzYwNQ_4fa69033-7e3d-4568-9ed9-1711be5fc8e0">12</ix:nonFraction>%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of <ix:nonNumeric contextRef="i6d0182ee77884d308f972ee3ac8635f4_D20210304-20210304" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMzgwMw_863f00ce-9f70-4f71-ad2a-8936d32ed657">10</ix:nonNumeric> years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangible assets related to IPR&amp;D consist of Hepcludex for HDV in all other regions without regulatory approval, including the United States. The estimated aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="i352358e211a34a23b9dc88776f5a0076_I20210304" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNDAwMg_f1e7200b-8c72-4fe5-9256-7e85f3072227">1.2</ix:nonFraction> billion as of the acquisition date was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to this asset and a discount rate of <ix:nonFraction unitRef="number" contextRef="i91c7b3ebdf1649509a1e026f30a65baa_I20210304" decimals="2" name="gild:IntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNDIwMw_a9c19c37-dd6d-41f8-b693-cd9dd13b1871">12</ix:nonFraction>%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the more significant assumptions inherent in the development of intangible asset fair values include: estimates of projected future cash flows including revenues and operating profits; probability of success; the discount rate selected; the life of the potential commercialized products and the risks related to the viability of and potential alternative treatments in any future target markets, among other factors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived assets until the completion or abandonment of the associated R&amp;D efforts. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The inputs used for valuing these identifiable intangibles are unobservable and considered Level 3 under the fair value measurement and disclosure guidance. See Note 3. Fair Value Measurements for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability was based upon the difference between the estimated book basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of MYR.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:GoodwillGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNTQ1NQ_d60c4fbe-3bb0-4545-ab1e-a538c03603e5">226</ix:nonFraction> million was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for MYR is <ix:nonFraction unitRef="usd" contextRef="i0680e69caed6418b9c239d0f897aa373_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNTY3Mw_2451aa22-20e7-4ea7-b424-ab58d450fd9a">no</ix:nonFraction>t expected to be deductible for income tax purposes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the three and nine months ended September 30, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunomedics</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we completed the acquisition of Immunomedics, a company focused on the development of antibody-drug conjugate technology, for cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i8a84de62d1ec4a0db403459b92a7debd_D20201023-20201023" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNjA1MQ_873d7850-5c64-41ad-9512-bff375d5f3a0">20.6</ix:nonFraction> billion. Upon closing, Immunomedics became a wholly-owned subsidiary of Gilead. The acquisition was financed with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $<ix:nonFraction unitRef="usd" contextRef="if38c0f756f6945658b15ba7c6e9bb284_D20201001-20201231" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNjI2MA_d0dc1955-7a2f-4931-912c-84e8041f6e11">1.0</ix:nonFraction> billion borrowing under a new senior unsecured term loan facility and cash on hand. During the nine months ended September 30, 2021, we repaid the borrowing under the senior unsecured term loan facility. See Note 10. Debt and Credit Facilities for further information.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib598f07b0a8c42b194e50c72b814924c"><ix:continuation id="i227e91870bab41bc936db18fa64c984d"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfMS0yLTEtMS0w_8c04612e-45d5-4a3d-a31f-dbc6a35034b9">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfMi0yLTEtMS0w_1ecd1a06-a263-4a1a-a02b-1e4aff3bcf9b">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15facb5b1aa5415199d533abd8de3199_I20201023" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfNC0yLTEtMS0w_fa59b474-8686-4cac-9c53-635ede3a47f6">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie94f540fb43d41c2a993dcfcce7e6d9e_I20201023" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfNS0yLTEtMS0w_0467b6fd-db84-466c-8e79-ff08931e0ecf">15,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlicense contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a6d7dbc5194ce3a5c2c451b949a083_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfNi0yLTEtMS0w_98b79569-9b78-4617-9f0c-0c6db798c606">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfNy0yLTEtMS0w_1cbe5b90-548f-407b-8c15-0e5ab0033f43">4,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023" decimals="-6" format="ixt:num-dot-decimal" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfOC0yLTEtMS0w_dc61df67-5f10-4ad0-a26d-331087db2c5e">1,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023" decimals="-6" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfOS0yLTEtMS0w_40636703-6ae5-4721-8268-aa800c94e0a5">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfMTAtMi0xLTEtMA_ffa128bf-26b5-47ad-9840-4e5311e8498e">16,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:GoodwillGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfMTEtMi0xLTEtMA_34c4fcac-790c-49f5-95e7-2c89b4185acf">3,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfMTItMi0xLTEtMA_d3c40446-29d1-4653-8556-5c1404da960d">20,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the three and nine months ended September 30, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forty Seven</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, we completed the acquisition of Forty Seven, a clinical-stage immuno-oncology company focused on developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for total consideration of $<ix:nonFraction unitRef="usd" contextRef="i90be553f64364971a7f334cad33d512f_D20200401-20200630" decimals="-8" format="ixt:num-dot-decimal" name="gild:PaymentsToAcquireAssetsNetOfCashAcquired" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNjg2Ng_48a92268-d1c0-4eed-906a-2d1b95f04dac">4.7</ix:nonFraction> billion, net of acquired cash. Upon closing, Forty Seven became a wholly-owned subsidiary of Gilead. During the nine months ended September 30, 2020, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i5e6bdf7f4837439c93c50b528a400b0e_D20200101-20200930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNjk5MQ_e1d1f7a7-a43f-432f-bb4c-bb62a592c17a">4.5</ix:nonFraction> billion charge representing an acquired IPR&amp;D asset with no alternative future use in Acquired in-process research and development expenses, and stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i59fc30c6ac6b49d88f04a9291366fc62_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNzExNg_998b2418-8091-4b6c-93b7-3a98bf61e1e5">144</ix:nonFraction> million primarily in Research and development expenses on our Condensed Consolidated Statements of Operations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTMwOA_f38853d1-42cc-4fd8-917d-e5dee5fda17a" continuedAt="i5d7201f6696c481cb09bc5954f533a36" escape="true">GOODWILL AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="i5d7201f6696c481cb09bc5954f533a36"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTMzNw_a3a17490-9cdf-48e4-9c0b-b9dba716c63e" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.106%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjdmMzlkOTNmNGU0NjRkZWE5NzI0OTNlOWViOWZjMGY3L3RhYmxlcmFuZ2U6N2YzOWQ5M2Y0ZTQ2NGRlYTk3MjQ5M2U5ZWI5ZmMwZjdfMS0yLTEtMS0w_8c0d525f-d1de-4b87-82a8-37b3ae51fcdb">8,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from the acquisition of MYR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjdmMzlkOTNmNGU0NjRkZWE5NzI0OTNlOWViOWZjMGY3L3RhYmxlcmFuZ2U6N2YzOWQ5M2Y0ZTQ2NGRlYTk3MjQ5M2U5ZWI5ZmMwZjdfMi0yLTEtMS0w_a072e4d1-37c9-4a6c-8df1-e3fa31e67335">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjdmMzlkOTNmNGU0NjRkZWE5NzI0OTNlOWViOWZjMGY3L3RhYmxlcmFuZ2U6N2YzOWQ5M2Y0ZTQ2NGRlYTk3MjQ5M2U5ZWI5ZmMwZjdfMy0yLTEtMS00MzY2Ng_ff371298-9c85-4995-9746-9a14ce5313e6">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjdmMzlkOTNmNGU0NjRkZWE5NzI0OTNlOWViOWZjMGY3L3RhYmxlcmFuZ2U6N2YzOWQ5M2Y0ZTQ2NGRlYTk3MjQ5M2U5ZWI5ZmMwZjdfMy0yLTEtMS0w_721bf30a-ec74-4b76-834b-c2b688575503">8,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTMwMQ_77a8ce25-3e57-4319-8ec4-808a89c47fbd" continuedAt="i599e851866ab42569ce0fe45b4d2dbb8" escape="true"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTMyNg_0867a553-f68f-46aa-9076-ca485dad69f1" continuedAt="ia6b1ce233cad4884a335cc0ec2e6f14c" escape="true"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="margin-top:1.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:22.360%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id248063645c14c6ca92fb1d761be74e4_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy0yLTEtMS0w_622ef743-28b8-43f6-a0de-f583170859a1">10,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id248063645c14c6ca92fb1d761be74e4_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy00LTEtMS0w_c380de85-d518-42a8-b3b6-4572886f62f7">5,477</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id248063645c14c6ca92fb1d761be74e4_I20210930" decimals="-6" format="ixt:fixed-zero" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy02LTEtMS0w_4ae80c0a-2e4f-47f2-8528-ffafb8c5e393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id248063645c14c6ca92fb1d761be74e4_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy04LTEtMS0w_aa9bf4a8-23de-4f60-917b-a62975a11eb4">5,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9f0c8cd2fc4c7ebfd9c7829f4948e4_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy0xMC0xLTEtMA_7fcb136c-6f61-455b-91d8-bf89c34dae4b">10,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice9f0c8cd2fc4c7ebfd9c7829f4948e4_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy0xMi0xLTEtMA_99c6d91a-c57d-4f31-9eca-72a597aa44f2">4,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9f0c8cd2fc4c7ebfd9c7829f4948e4_I20201231" decimals="-6" format="ixt:fixed-zero" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy0xNC0xLTEtMA_33253e19-ef25-482a-a60e-410718b5d116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9f0c8cd2fc4c7ebfd9c7829f4948e4_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy0xNi0xLTEtMA_2b477c04-11b3-48e5-80aa-efe9009d3271">5,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica281eb0ea274e8fbe28117ec9397184_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC0yLTEtMS0w_a978eac3-13eb-4ce9-a00e-37ded6947195">7,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica281eb0ea274e8fbe28117ec9397184_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC00LTEtMS0w_6ce90776-165c-4896-82dd-7785eb4eb1e0">1,400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica281eb0ea274e8fbe28117ec9397184_I20210930" decimals="-6" format="ixt:fixed-zero" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC02LTEtMS0w_121bc20b-13a5-44c0-a7ce-abc99094c090">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica281eb0ea274e8fbe28117ec9397184_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC04LTEtMS0w_46dd2a5a-97d1-41be-b0fb-e2c02c3b4185">5,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i423d39bed9384081904c47d75b0d641a_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC0xMC0xLTEtMA_d9b92008-c6b2-4a35-9a50-8718e8067c04">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i423d39bed9384081904c47d75b0d641a_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC0xMi0xLTEtMA_b091e7d1-66d6-4ec4-8b6b-5c289f95fa0d">1,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i423d39bed9384081904c47d75b0d641a_I20201231" decimals="-6" format="ixt:fixed-zero" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC0xNC0xLTEtMA_52870a4c-80dc-465d-86e6-5308a6f5bd73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i423d39bed9384081904c47d75b0d641a_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC0xNi0xLTEtMA_de596e4d-f744-4448-af19-278c01ea57da">5,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a0f810172a14dfaa8af6a1edfc4646b_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS0yLTEtMS0w_ae4776ed-376b-4c77-973f-bbf7c11c4e2e">5,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a0f810172a14dfaa8af6a1edfc4646b_I20210930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS00LTEtMS0w_6f1c690b-a287-4519-bda3-6588cfb45b63">390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a0f810172a14dfaa8af6a1edfc4646b_I20210930" decimals="-6" format="ixt:fixed-zero" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS02LTEtMS0w_37578846-a169-4ec8-bc7f-82c346e80ec3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a0f810172a14dfaa8af6a1edfc4646b_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS04LTEtMS0w_8fee6984-01a6-4006-ac27-5925f8afcdc7">5,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25358862393f4ca4b14b4364da42d681_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS0xMC0xLTEtMA_5092764b-4ba2-4e8c-8fbc-96d6aa43a253">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25358862393f4ca4b14b4364da42d681_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS0xMi0xLTEtMA_36986866-f8cb-4a65-955b-90f426be9bf8">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25358862393f4ca4b14b4364da42d681_I20201231" decimals="-6" format="ixt:fixed-zero" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS0xNC0xLTEtMA_23f513f9-06c4-4e62-bef2-8938494cfc55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25358862393f4ca4b14b4364da42d681_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS0xNi0xLTEtMA_46ceb507-e56a-48f2-98c1-f514488aac99">4,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie35fe5b3532249fbaa1d215c6cea8f90_I20210930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi0yLTEtMS0w_c84e5061-87d8-4107-8fc0-0d631d30a470">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie35fe5b3532249fbaa1d215c6cea8f90_I20210930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi00LTEtMS0w_c903705b-10d6-4d7c-a163-56e9c2f9ccc5">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie35fe5b3532249fbaa1d215c6cea8f90_I20210930" decimals="-6" format="ixt:fixed-zero" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi02LTEtMS0w_aab64039-b1a8-49be-895c-39759b27f695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie35fe5b3532249fbaa1d215c6cea8f90_I20210930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi04LTEtMS0w_316acc1b-7b7d-4baf-8618-1a4c481684cc">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a065190f73644d7a438667b54161f4e_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi0xMC0xLTEtMA_c606766e-cf00-4ae2-8ace-637b0b9db05a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a065190f73644d7a438667b54161f4e_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi0xMi0xLTEtMA_37d68411-30ef-4ef2-b925-d76c505691ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a065190f73644d7a438667b54161f4e_I20201231" decimals="-6" format="ixt:fixed-zero" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi0xNC0xLTEtMA_451004f3-c7ae-4856-873e-dbe4ee340b6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a065190f73644d7a438667b54161f4e_I20201231" decimals="-6" format="ixt:fixed-zero" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi0xNi0xLTEtMA_4053643f-726e-45d4-82d7-900f25c77e72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26cf0458992d429ba5ed5fb92c5a2436_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy0yLTEtMS0w_95f289ac-893f-4d16-a51c-79a590d94f7e">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26cf0458992d429ba5ed5fb92c5a2436_I20210930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy00LTEtMS0w_a8f59efc-4d2b-4b2d-9c7e-8b506729cf60">619</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26cf0458992d429ba5ed5fb92c5a2436_I20210930" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy02LTEtMS0w_d8f79cca-1cf6-4517-b766-39ffa00b83e8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26cf0458992d429ba5ed5fb92c5a2436_I20210930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy04LTEtMS0w_314a7ab9-3851-4cec-bf86-05d44474d690">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a12c46bb79a4f2797fb774367f4f73d_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy0xMC0xLTEtMA_38be9613-0d7c-4f07-b0ef-d1f785f75a52">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a12c46bb79a4f2797fb774367f4f73d_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy0xMi0xLTEtMA_ed3db778-6883-4167-81d8-85c56cc1b28d">540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a12c46bb79a4f2797fb774367f4f73d_I20201231" decimals="-6" sign="-" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy0xNC0xLTEtMA_45aa79c1-6892-4d92-9840-0fdd48812a47">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a12c46bb79a4f2797fb774367f4f73d_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy0xNi0xLTEtMA_db75dee4-4695-4f94-bfc2-07b90fca4d0c">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC0yLTEtMS0w_68431871-f8b6-46f7-a6f5-47aa538d2683">25,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC00LTEtMS0w_d8b2882b-0c5c-47e8-a90c-5db33d9eb6c2">7,936</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC02LTEtMS0w_edecbfc4-c699-4285-ae15-d2063c9068e1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC04LTEtMS0w_98e06492-86ab-49f7-b4f2-1216decfb930">17,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC0xMC0xLTEtMA_bd37e552-1f21-4507-a1c0-d79451d69e1a">22,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC0xMi0xLTEtMA_bb5a72d3-987f-4e57-95da-44abe01f5b0f">6,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" sign="-" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC0xNC0xLTEtMA_6a8b10d1-054e-4636-9371-0d16988812b3">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC0xNi0xLTEtMA_1bf91b7f-c8eb-4ce2-967b-82c27b5c07a8">16,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)(2)(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1922554024b64cb8898c1f3fd434e8da_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOS0yLTEtMS0w_74bdd178-aae8-49c2-b320-a797ec2ad561">16,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1922554024b64cb8898c1f3fd434e8da_I20210930" decimals="-6" format="ixt:fixed-zero" name="gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOS02LTEtMS0w_113a9426-1a99-4500-819d-d36b2df18497">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1922554024b64cb8898c1f3fd434e8da_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOS04LTEtMS0w_9c2da3ac-3de3-4659-be96-ff8960cfbb79">16,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i969a0f7a4e6f4d7bb52b87c7b652a57b_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOS0xMC0xLTEtMA_de1d9606-d6f4-4426-a735-b38cd916ab40">16,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i969a0f7a4e6f4d7bb52b87c7b652a57b_I20201231" decimals="-6" format="ixt:fixed-zero" name="gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOS0xNC0xLTEtMA_c9fb8c42-18c2-417e-b1e3-79a3ce48ee97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i969a0f7a4e6f4d7bb52b87c7b652a57b_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOS0xNi0xLTEtMA_9b38fdaa-4809-4de1-9ced-b0c86925b6f3">16,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtMi0xLTEtMA_6200c553-5ccd-4d6c-8f00-4a9b1a0dc219">41,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtNC0xLTEtMA_e31c20f5-8932-4b8d-bfce-bdebf0cdd803">7,936</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtNi0xLTEtMA_34960785-2fbf-4744-8e81-2a89ee4234ce">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtOC0xLTEtMA_56d91385-2a51-4a9e-ad06-7dcb3c6a7181">33,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtMTAtMS0xLTA_f5d8a00b-1edd-4ca5-bac6-b74f4a6a241f">39,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtMTItMS0xLTA_5bee9620-ea19-45ea-94c1-0b3a1d7809d0">6,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" sign="-" name="gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtMTQtMS0xLTA_78502d46-0c4b-4511-88ee-45656a40996b">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtMTYtMS0xLTA_16774e51-12c7-4ef3-a480-ad484f3d72f0">33,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes $<ix:nonFraction unitRef="usd" contextRef="i097e3a84fba5476487ee41ea9a26f8b0_D20210301-20210331" decimals="-6" format="ixt:num-dot-decimal" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMjM5_e2349b07-11ed-4e62-9034-f5ec580d856d"><ix:nonFraction unitRef="usd" contextRef="i58f39982e7154710a0e9bffb98d87c09_D20210301-20210331" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMjM5_fd546713-d978-421b-bd8d-78c969c7c1b4">910</ix:nonFraction></ix:nonFraction>&#160;million reclassified from indefinite-lived assets - IPR&amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes Trodelvy for metastatic triple-negative breast cancer which was granted approval by FDA in April 2021 and Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer (&#8220;UC&#8221;) which was granted accelerated approval by FDA in April 2021. The amount related to UC of $<ix:nonFraction unitRef="usd" contextRef="i186934b8fe964624a8c713e57b5bc48a_D20210401-20210430" decimals="-8" sign="-" format="ixt:num-dot-decimal" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfNzE2_3bebf781-8c50-4b54-8629-661007c1fcf5"><ix:nonFraction unitRef="usd" contextRef="i0f1396f1bd31451bb640de4f9f3638b4_D20210401-20210430" decimals="-8" format="ixt:num-dot-decimal" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfNzE2_6ffae4e9-57f1-4190-8156-0a7daef8b677">1.0</ix:nonFraction></ix:nonFraction> billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&amp;D.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes $<ix:nonFraction unitRef="usd" contextRef="i5af10497a26b467daee57d68cbd93a36_I20210331" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfODgw_ec12cd6d-954f-4d0c-936b-ca7487b3ac12">1.2</ix:nonFraction>&#160;billion recognized from the first quarter 2021 acquisition of MYR. See Note 6. Acquisitions for additional information.</span></div></ix:nonNumeric></ix:nonNumeric><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i599e851866ab42569ce0fe45b4d2dbb8" continuedAt="ib2398166473f4fc59e9599f4f446a9a9"><ix:continuation id="ia6b1ce233cad4884a335cc0ec2e6f14c" continuedAt="i685a5480bdc24d49829b258424b12b61">(4)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="ib2398166473f4fc59e9599f4f446a9a9"><ix:continuation id="i685a5480bdc24d49829b258424b12b61"> &#160;&#160;&#160;&#160;In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $<ix:nonFraction unitRef="usd" contextRef="ic84bc582b1d04652bd6754bb4901989d_D20211001-20211231" decimals="-6" format="ixt:num-dot-decimal" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfNDM5ODA0NjUxMzMyMg_a39f5d69-a335-429e-b049-579685f3834c"><ix:nonFraction unitRef="usd" contextRef="i856f386d4aa44a00a2c20f4010d3fbc5_D20211001-20211231" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfNDM5ODA0NjUxMzMyMg_f2e1aa22-7f2b-41e8-a100-a6201ff45e79">200</ix:nonFraction></ix:nonFraction>&#160;million will be reclassified to finite-lived assets in the fourth quarter of 2021.</ix:continuation></ix:continuation> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to finite-lived intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTA1OQ_94a2d68a-b35c-4b19-8825-5b9b903deb9c">441</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTA2Ng_b9b5aba8-0b6a-4506-8efa-2e58c3cca9bd">1.3</ix:nonFraction> billion for the three and nine months ended September 30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTA4NA_23de5dc7-9551-474c-b32a-3dc388fb30a2">281</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTA5MQ_8dcafd44-809d-4f31-a260-12b198acb7c7">844</ix:nonFraction> million for the three and nine months ended September 30, 2020, respectively, and was primarily included in Cost of goods sold on our Condensed Consolidated Statements of Operations.</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTMxNw_92386bb6-b4e7-47db-9445-e721966c2cac" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of September&#160;30, 2021:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:86.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOmIzNDBjZGYzMzEwYTRhMTZiNzI1YzA3M2E2YzcxYzY1L3RhYmxlcmFuZ2U6YjM0MGNkZjMzMTBhNGExNmI3MjVjMDczYTZjNzFjNjVfMS0yLTEtMS0w_56d39ad6-83bb-4fc5-9e00-bf69d59f1010">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOmIzNDBjZGYzMzEwYTRhMTZiNzI1YzA3M2E2YzcxYzY1L3RhYmxlcmFuZ2U6YjM0MGNkZjMzMTBhNGExNmI3MjVjMDczYTZjNzFjNjVfMi0yLTEtMS0w_3fbc5fe9-746a-4b12-9783-09985ef04c08">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOmIzNDBjZGYzMzEwYTRhMTZiNzI1YzA3M2E2YzcxYzY1L3RhYmxlcmFuZ2U6YjM0MGNkZjMzMTBhNGExNmI3MjVjMDczYTZjNzFjNjVfMy0yLTEtMS0w_77cb31c4-59c2-4100-babe-dbbc94ea6348">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOmIzNDBjZGYzMzEwYTRhMTZiNzI1YzA3M2E2YzcxYzY1L3RhYmxlcmFuZ2U6YjM0MGNkZjMzMTBhNGExNmI3MjVjMDczYTZjNzFjNjVfNC0yLTEtMS0w_176025c9-8b7a-4bf9-857c-4670ff5a975e">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOmIzNDBjZGYzMzEwYTRhMTZiNzI1YzA3M2E2YzcxYzY1L3RhYmxlcmFuZ2U6YjM0MGNkZjMzMTBhNGExNmI3MjVjMDczYTZjNzFjNjVfNS0yLTEtMS0w_532cad19-bb13-4dfc-90c3-934c2c2900c3">1,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="gild:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOmIzNDBjZGYzMzEwYTRhMTZiNzI1YzA3M2E2YzcxYzY1L3RhYmxlcmFuZ2U6YjM0MGNkZjMzMTBhNGExNmI3MjVjMDczYTZjNzFjNjVfNi0yLTEtMS0w_907ba036-9e68-493d-9650-88800e8ab4a0">10,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOmIzNDBjZGYzMzEwYTRhMTZiNzI1YzA3M2E2YzcxYzY1L3RhYmxlcmFuZ2U6YjM0MGNkZjMzMTBhNGExNmI3MjVjMDczYTZjNzFjNjVfNy0yLTEtMS0w_46a76cee-a6fe-4b90-bcaf-9466061114b7">17,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RleHRyZWdpb246NDkyYWU5MmYwNTE2NDk2MmJiZjFlNWQwOTc1N2NlNDBfMTgy_85d31900-b3b2-4159-aa32-470c7d727f8d" continuedAt="i6858dbe3a03f48b8b87a800f816b8cd8" escape="true">OTHER FINANCIAL INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i6858dbe3a03f48b8b87a800f816b8cd8"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net</span></div><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RleHRyZWdpb246NDkyYWU5MmYwNTE2NDk2MmJiZjFlNWQwOTc1N2NlNDBfMTcw_670b7f14-83a1-4e9f-959c-7cb583c023ca" escape="true"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net:</span></div><div style="margin-bottom:1pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfMS0yLTEtMS0w_6ab108a9-23d2-4629-9ce8-8a1b66d4b5e4">5,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfMS00LTEtMS0w_58587882-d19f-4e61-aee5-1a4d3a35822b">5,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="gild:AccountsReceivableChargebacksCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfMi0yLTEtMS0w_f116518f-505f-4104-95ca-e3851137d675">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="gild:AccountsReceivableChargebacksCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfMi00LTEtMS0w_e834391b-2f05-448f-bbf7-984ce4a4e524">552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="gild:AccountsReceivableCashDiscountsAndOtherCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfMy0yLTEtMS0w_ee371d81-7da4-48bb-aa60-00bbc0d3c043">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="gild:AccountsReceivableCashDiscountsAndOtherCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfMy00LTEtMS0w_09a3b71d-ee6a-4890-9c27-fb223c36a06d">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfNC0yLTEtMS0w_c0fae8e0-8c06-4b0e-a525-884c28009efd">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfNC00LTEtMS0w_5328d074-a115-4dcd-8885-98dbcb730386">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfNS0yLTEtMS0w_feef9abe-7e42-4662-8789-bda82b61da6d">4,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfNS00LTEtMS0w_5c435cb5-00ef-4e95-ae02-1dcb57e60b66">4,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RleHRyZWdpb246NDkyYWU5MmYwNTE2NDk2MmJiZjFlNWQwOTc1N2NlNDBfMTc4_50d3928e-dc9e-41b4-afca-dab86041371a" escape="true"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfMS0yLTEtMS0w_f3a326ca-58aa-4281-8dce-04e281afc57f">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfMS00LTEtMS0w_bfb91f96-4705-4f0c-b02b-46e0ff857154">1,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfMi0yLTEtMS0w_ca8f8a35-329b-4bdc-92a3-ddaddbb2a3d7">727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfMi00LTEtMS0w_d4cddbca-681b-4d2e-a1d4-46997e220507">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfMy0yLTEtMS0w_66b508e5-9356-4c28-925f-f177b38dbd0e">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfMy00LTEtMS0w_41a038cb-c661-400a-a47f-f89819331305">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="gild:InventoryNetAndInventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfNC0yLTEtMS0w_31f3ff0b-7490-47d4-8d64-42e9356ece17">2,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="gild:InventoryNetAndInventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfNC00LTEtMS0w_ceb38397-c8f9-497f-a66e-1b99324b2f11">3,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfNy0yLTEtMS0w_bc51ffc9-f735-4f79-8b58-86e21905abcf">1,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfNy00LTEtMS0w_cbeb2af3-d33e-419a-bcd2-ac8b0035de6d">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfOC0yLTEtMS0w_58500feb-2114-4687-b7d5-50f1cc09ff95">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfOC00LTEtMS0w_91ebfb20-7513-4cdc-a0c6-9878907c94f4">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="gild:InventoryNetAndInventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfOS0yLTEtMS0w_62d482e8-a509-4e2c-a897-f1a801a8657d">2,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="gild:InventoryNetAndInventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfOS00LTEtMS0w_29b71856-973a-4ec9-96c5-2119006a91dc">3,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued and other current liabilities </span></div><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RleHRyZWdpb246NDkyYWU5MmYwNTE2NDk2MmJiZjFlNWQwOTc1N2NlNDBfMTc2_4950a390-d634-4c73-99b8-10d5a4518ed9" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Accrued and other current liabilities:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfMS0yLTEtMS0w_7121eb3b-c32a-47aa-b12c-d6b6eda53dfd">691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfMS00LTEtMS0w_281e8a52-c2ad-4c11-af4b-e160bbcd2448">864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfMi0yLTEtMS0w_d4d69b60-670a-4bc8-b48b-c0d59f0c7606">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfMi00LTEtMS0w_e44da9a4-210c-47b8-b791-12df86267e3a">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfMy0yLTEtMS0w_68780428-dbd7-41a8-8981-f6dd73528cd6">530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfMy00LTEtMS0w_dd8eef50-6ce9-4718-bef3-3d2598afec17">587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfNC0yLTEtMS0w_dc311bb3-48cb-4f4a-858b-1361580ea864">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfNC00LTEtMS0w_1a916dd4-05e3-4a13-a3f9-2444467a8b00">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfNS0yLTEtMS0w_507fdb3b-3f8b-4973-a168-febc2f56a800">3,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfNS00LTEtMS0w_2bc9b3c2-f675-4026-8037-92d58b4f5e75">4,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i2c1b4d102d99434b956b3b8616d0836a_58"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="gild:CollaborativeAndOtherArrangementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNzA1NA_3c16ebb6-74ad-4984-bca6-6e3fb65fa52b" continuedAt="ie4b4dff856f2436b954b04f29c3017db" escape="true">COLLABORATIONS AND OTHER ARRANGEMENTS</ix:nonNumeric></span></div><ix:continuation id="ie4b4dff856f2436b954b04f29c3017db" continuedAt="i94b33b5c411f4765b21c3f29e9f35e40"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to pursue licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements and cost-sharing arrangements. We also continue to pursue equity investments in third parties focused on the development and commercialization of products and product candidates. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merck Sharp &amp; Dohme Corp. (&#8220;Merck&#8221;) </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2021, we entered into a license and collaboration agreement with Merck, a subsidiary of Merck &amp; Co., Inc. to jointly develop and commercialize long-acting investigational treatments in HIV that combine Gilead&#8217;s investigational capsid inhibitor, lenacapavir, and Merck&#8217;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The collaboration will initially focus on long-acting oral and injectable formulations. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Gilead and Merck will share global development and commercialization costs at <ix:nonFraction unitRef="number" contextRef="i199d5ca3470540be922bc9d2707767c8_D20210313-20210313" decimals="2" name="gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMTU1Nw_8ec3e7a7-4713-4436-a2c1-0d180a734c80">60</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ida214684d6f748fa94820133c41fb9cb_D20210313-20210313" decimals="2" name="gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMTU2NA_7bee1148-f1cd-4c8a-b132-1c8741f49928">40</ix:nonFraction>%, respectively, across the oral and injectable formulation programs. For long-acting oral products, Gilead will lead commercialization in the United States, and Merck will lead commercialization in the European Union (&#8220;EU&#8221;) and rest of the world. For long-acting injectable products, Merck will lead commercialization in the United States and Gilead will lead commercialization in the EU and rest of the world. Gilead and Merck will jointly promote the combination products in the United States and certain other major markets. We will share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $<ix:nonFraction unitRef="usd" contextRef="ic4b2d0d8fb10491f844ccbf3c9d99659_D20210313-20210313" decimals="-8" format="ixt:num-dot-decimal" name="gild:CollaborationArrangementNetProductSalesThreshold" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMjI0OA_5626ef65-4f37-41a2-ac15-94577b1786df">2.0</ix:nonFraction> billion in net product sales for the oral combination in a given calendar year, our share of revenue will increase to <ix:nonFraction unitRef="number" contextRef="ic4b2d0d8fb10491f844ccbf3c9d99659_D20210313-20210313" decimals="2" name="gild:CollaborationArrangementPercentOfGlobalProductRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMjM2MQ_ac37e8ab-b5d5-4327-8bb4-306cd41e51bf">65</ix:nonFraction>% for any revenues above the threshold for such calendar year. Upon passing $<ix:nonFraction unitRef="usd" contextRef="i7a7ea0a008d44d19aeaba7ea8a234a79_D20210313-20210313" decimals="-8" format="ixt:num-dot-decimal" name="gild:CollaborationArrangementNetProductSalesThreshold" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMjQzOA_1674c010-a517-4705-beb5-0b983cbac56a">3.5</ix:nonFraction> billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to <ix:nonFraction unitRef="number" contextRef="i7a7ea0a008d44d19aeaba7ea8a234a79_D20210313-20210313" decimals="2" name="gild:CollaborationArrangementPercentOfGlobalProductRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMjU1Nw_f66cf751-4879-44a0-86fc-6f2481ffc25e">65</ix:nonFraction>% for any revenues above the threshold for such calendar year. Reimbursements of research and development costs to or from Merck are recorded within Research and development expenses on our Condensed Consolidated Statements of Operations. Expenses recognized under the agreement were not material for the three and nine months ended September 30, 2021. <ix:nonFraction unitRef="usd" contextRef="i4fbddaa5defd43eda896eb3f45f893de_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMjc5MQ_314326bf-2e2c-4123-ab7d-d8241d586f35"><ix:nonFraction unitRef="usd" contextRef="i94b469d6b3cb4b1cae15cc21665e0bbb_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMjc5MQ_4f45d141-f322-40ec-946c-8dc676733b94">No</ix:nonFraction></ix:nonFraction> revenues have been recognized under the agreement for the three and nine months ended September 30, 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also have the option to license certain of Merck&#8217;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#8217;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for such investigational oral integrase inhibitor of the other company within the first <ix:nonNumeric contextRef="i199d5ca3470540be922bc9d2707767c8_D20210313-20210313" format="ixt-sec:durwordsen" name="gild:CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNzA1Mg_03ce3192-5ddf-4f65-9109-b43fe4221574">five years</ix:nonNumeric> after execution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt-out, in which case the non-exercising company will be paid a royalty.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arcus</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On&#160;May 27, 2020, we entered into a transaction with Arcus, which included entry into an option, license and collaboration agreement (the &#8220;Collaboration Agreement&#8221;) and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended the &#8220;Stock Purchase Agreements&#8221;). Under the Stock Purchase Agreements, we have the right to purchase additional shares of Arcus from Arcus over the <ix:nonNumeric contextRef="idcb33e823a4c4f73a7d1f634b45cee94_D20200527-20200527" format="ixt-sec:durwordsen" name="gild:EquitySecuritiesFVNIPurchasePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxNw_50c0cb34-9b66-4ee4-83d7-02a63a2c68dd">five-year</ix:nonNumeric> period beginning on the closing of the Stock Purchase Agreements, up to a maximum of <ix:nonFraction unitRef="number" contextRef="i3878c6df63be4399a67430941e5732c7_D20200527-20200527" decimals="INF" name="gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDM5ODA0NjUyMTY1MQ_80297e8e-7d7a-4e8f-b24a-f846527c02db">35</ix:nonFraction>% of the outstanding voting stock. We are subject to a <ix:nonNumeric contextRef="idcb33e823a4c4f73a7d1f634b45cee94_D20200527-20200527" format="ixt-sec:durwordsen" name="gild:EquitySecuritiesFVNIRestrictionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOA_6e8ed4b8-28c4-4dcf-a456-a45845bec7b2">three-year</ix:nonNumeric> standstill, which period began on the date the parties entered into the Stock Purchase Agreements, restricting our ability to acquire voting stock of Arcus exceeding more than <ix:nonFraction unitRef="number" contextRef="i3878c6df63be4399a67430941e5732c7_D20200527-20200527" decimals="INF" name="gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDM5ODA0NjUyMTg5Mw_80297e8e-7d7a-4e8f-b24a-f846527c02db">35</ix:nonFraction>% of the then issued and outstanding voting stock of Arcus, subject to certain exceptions. Additionally, we agreed not to dispose of any equity securities of Arcus prior to the second anniversary of the closing of the Stock Purchase Agreements without the prior consent of Arcus, subject to certain exceptions. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i94b33b5c411f4765b21c3f29e9f35e40"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Collaboration Agreement and Stock Purchase Agreements which closed on July 13, 2020, and a separate secondary equity offering which closed on May 29, 2020, we acquired approximately <ix:nonFraction unitRef="shares" contextRef="i7e4ffaa955f9435b9bf6dff41e50e726_D20200529-20200529" decimals="-5" format="ixt:num-dot-decimal" name="gild:EquitySecuritiesFVNISharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDEyOA_84b4779c-8141-4139-be1b-df8cfe9ca399">8.2</ix:nonFraction>&#160;million shares of Arcus common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="i7e4ffaa955f9435b9bf6dff41e50e726_D20200529-20200529" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDE3OA_900f9c6f-62cb-4fb1-9267-94cf15c27750">261</ix:nonFraction> million. In the first quarter of 2021, we amended and restated the common stock purchase agreement and acquired approximately <ix:nonFraction unitRef="shares" contextRef="i18ae4cc7725f4c96842b14bc9e4daf0e_D20210101-20210331" decimals="-5" format="ixt:num-dot-decimal" name="gild:EquitySecuritiesFVNISharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDI5OQ_4ba40085-e890-45f2-a978-7c3f59f2aef7">5.7</ix:nonFraction>&#160;million additional shares of Arcus common stock for $<ix:nonFraction unitRef="usd" contextRef="i18ae4cc7725f4c96842b14bc9e4daf0e_D20210101-20210331" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDM0Ng_288aa44e-82d5-4e2c-b55a-b3c902547ade">220</ix:nonFraction> million. As a result, we currently own a total of <ix:nonFraction unitRef="shares" contextRef="i48dadb586c444781b30fb3c1b0888939_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="gild:EquitySecuritiesFVNIShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDM5MQ_fb8559bb-cd8c-4c3f-b095-f9bacff69edf">13.8</ix:nonFraction>&#160;million shares of Arcus, which represented approximately <ix:nonFraction unitRef="number" contextRef="i819ce30a96d84a66915bb6c431c7a737_I20210331" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDQ0Mw_577a4625-f93d-4ba2-b576-4617f149add6">19.5</ix:nonFraction>% of the issued and outstanding voting stock of Arcus immediately following the closing of the first quarter 2021 transaction. The amendment and restatement of the common stock purchase agreement in the first quarter of 2021 did not modify any of the terms above. We elected and applied the fair value option to account for our equity investment in Arcus whereby the investment is marked to market each reporting period based on the market price of Arcus shares. We believe the fair value option best reflects the underlying economics of the investment. Changes in fair value of the investment are recognized in Other income (expense), net on our Condensed Consolidated Statements of Operations. We initially recorded our equity investments in Arcus in Other long-term assets on our Condensed Consolidated Balance Sheets as the investments are subject to contractual lock-up provisions, subject to certain conditions. In the third quarter of 2021, we reclassified our equity investments in Arcus to Prepaid and other current assets on our Condensed Consolidated Balance Sheets as the contractual lock-up provisions will expire in July 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Arrangements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2021 and 2020, we entered into several collaborations, equity investments and licensing arrangements as well as other similar arrangements that we do not consider to be individually material. We recorded upfront collaboration expenses related to these arrangements within Acquired in-process research and development expenses on our Condensed Consolidated Statements of Operations. Upfront collaboration expenses and cash payments made related to our equity investments were <ix:nonFraction unitRef="usd" contextRef="iaeaa95ca088c4fe285e88b406cff5320_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="gild:CashPaymentsMadeRelatedToEquityInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_230e2a29-572b-4f33-983f-485ee1565b9f"><ix:nonFraction unitRef="usd" contextRef="ibcaa35425c334e66adfe9c0143a54cc5_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_4864fd96-6cf2-4609-a984-cb113106e18a"><ix:nonFraction unitRef="usd" contextRef="i36771d101b1945cd9d9de5fa0410171b_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_4afdc8f0-68c2-4bda-b2e4-b79146dd9150"><ix:nonFraction unitRef="usd" contextRef="i2084f6bcb60540018e9a4b1e4715c369_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="gild:CashPaymentsMadeRelatedToEquityInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_4dd2910b-9d1e-4c46-a0cd-c76486c9e9bd"><ix:nonFraction unitRef="usd" contextRef="ibcaa35425c334e66adfe9c0143a54cc5_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="gild:CashPaymentsMadeRelatedToEquityInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_5ae15d95-62a0-4380-b29f-3ddae755dff1"><ix:nonFraction unitRef="usd" contextRef="i36771d101b1945cd9d9de5fa0410171b_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="gild:CashPaymentsMadeRelatedToEquityInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_723762d9-9781-4133-87df-a8c274ad643f"><ix:nonFraction unitRef="usd" contextRef="iaeaa95ca088c4fe285e88b406cff5320_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_aed5f23f-9d19-43a6-8e88-c803a28206bc"><ix:nonFraction unitRef="usd" contextRef="i2084f6bcb60540018e9a4b1e4715c369_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_de793d99-d8a9-4285-bb54-1b0169f5f8f0">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t material for the three and nine months ended September 30, 2021 and 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the financial terms of these arrangements, we may be required to make payments upon achievement of developmental, regulatory and commercial milestones, which could be significant. Future milestone payments, if any, will be reflected in our Condensed Consolidated Statements of Operations when the corresponding events become probable. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfOTgy_4d0a2862-0163-4fab-8342-2cf4ab1c9f0e" continuedAt="ibe40cdd5ce3844389a836f773da6a1e8" escape="true">DEBT AND CREDIT FACILITIES</ix:nonNumeric></span></div><ix:continuation id="ibe40cdd5ce3844389a836f773da6a1e8" continuedAt="ib5097e8679ff4d6185334552cfb62147"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfOTg5_5d00ecbd-bc9b-42b5-bb63-c14f26a1a2c0" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i075533c7d37d491793ebc09f561f12c8_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMi02LTEtMS0w_e3918455-da77-48ba-a933-83d228cf51ca">4.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i075533c7d37d491793ebc09f561f12c8_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMi04LTEtMS0w_ad1cea55-439a-4cc0-8adb-ee7c0c48ff01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1beee1ec406146d38e3211fa2933708d_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMi0xMC0xLTEtMA_b9b1502b-a5e6-463d-819d-4a2b719c73cb">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + <ix:nonFraction unitRef="number" contextRef="i43c2519105dc4bfdb185e7ebc59a5a2a_D20210101-20210930" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMy02LTEtMS0wL3RleHRyZWdpb246YmY3YmNjZTNjNmZkNDQ3YmFmMDU2YTQyMTJiZjM2MDhfMjA_26bb615f-31f1-4036-a1e9-5ed6c7628c5a">0.15</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6417210f0c45cab95af5ede847f506_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMy04LTEtMS0w_a37e2541-280f-4168-98cc-0879d9e86925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic250ebc316ec45b1bbe84636770ce814_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMy0xMC0xLTEtMA_e1f1ea24-7717-4b16-87a8-c921f765fe46">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a816c3a555a4fa08e58b54a04015ffb_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNC02LTEtMS0w_08e4c8f2-b66f-4503-88b8-26405e0e3138">4.40</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a816c3a555a4fa08e58b54a04015ffb_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNC04LTEtMS0w_8587bdbc-482c-4bb8-8ee0-07ea1aa35632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2fd7afacc2446fdb2b73b021c7ec4c5_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNC0xMC0xLTEtMA_6e1deb4c-6d6a-41cd-86f5-d2883262328a">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4c2641db1ef947ebb5c2e598d80af8b7_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNS02LTEtMS0w_cda0f8e4-c7c3-4751-a2a9-89a361589aaa">1.95</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c2641db1ef947ebb5c2e598d80af8b7_I20210930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNS04LTEtMS0w_bae7f328-57c5-4135-a289-a413975fee3c">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047f7d6efaab4949ba75985dec2bd448_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNS0xMC0xLTEtMA_0717004b-c700-41bd-b07b-6cb708bc9f04">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b207ad1f4604e47bf243a142f719c3d_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNi02LTEtMS0w_fa45a78b-5932-46bf-b4df-648b45c75da5">3.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b207ad1f4604e47bf243a142f719c3d_I20210930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNi04LTEtMS0w_70778c1d-9c2d-42e6-b201-515d0fe648a3">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide3713760e2f406f87de6a771c56330c_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNi0xMC0xLTEtMA_ec19a8f7-fbe1-45d9-8f47-0255beaf62a3">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i378aa93017824e3e9bd151f32b47c054_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNy02LTEtMS0w_5650ad9d-fff8-4ac6-86b7-b648d05c4f67">2.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378aa93017824e3e9bd151f32b47c054_I20210930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNy04LTEtMS0w_b42d6dcb-b4dd-44db-911c-186b99f1bb8f">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ebf78ad2ccb4d43a991df3fd307bba9_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNy0xMC0xLTEtMA_c8c9f3af-f828-40b4-b758-3ce5f73dfa35">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + <ix:nonFraction unitRef="number" contextRef="iafda4276088e42e3a214977fd3664e77_D20210101-20210930" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfOC02LTEtMS0wL3RleHRyZWdpb246NTE3MjRhNDhkYTY5NDZhN2I5YjdmYWJiYjk3YjU4N2JfMjA_11c3cd05-aa5a-4c84-99f4-3ddc5bf5b4b4">0.52</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2c0f1bb661849bbafaaac95aa413df7_I20210930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfOC04LTEtMS0w_b59c7e54-9744-4340-a3d7-6c3efb710256">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i718060d949f64ee2b8c966d8822e9de3_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfOC0xMC0xLTEtMA_4195f8d2-ec90-40c0-a31b-5da10847dd9b">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd18b3372b0d4339ba7e932b3bcfb631_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfOS02LTEtMS0w_a19f5428-c8d3-4365-b5f6-1b350883b415"><ix:nonFraction unitRef="number" contextRef="icd18b3372b0d4339ba7e932b3bcfb631_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfOS02LTEtMS0w_cfde161c-af6b-4d9e-b9f7-cdf45873ab25">0.75</ix:nonFraction></ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd18b3372b0d4339ba7e932b3bcfb631_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfOS04LTEtMS0w_e134bb60-6cf6-4183-9509-b48b388790c7">1,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a673086504e43c08aba24aa7d8a2fb6_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfOS0xMC0xLTEtMA_f7c78b88-a943-4367-a590-177394acb4b5">1,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39bf03ca3dd4c7eaf82c5f3247707e0_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTAtOC0xLTEtMA_2b85d003-8d3a-43e2-9bd6-8b7415a2fe5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96e9697694914c628eb31495e561618f_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTAtMTAtMS0xLTA_732d35b4-a941-4ccb-92b4-2b843f103843">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if73fdd4a8341456487fd2dedf6c2e9d7_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTEtNi0xLTEtMA_020ecc61-0402-4246-9335-6f0838dbfbc2">3.70</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if73fdd4a8341456487fd2dedf6c2e9d7_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTEtOC0xLTEtMA_3016ef49-9b85-4e1d-b844-d05b49417c75">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81c97bf760b64de9bbdde1c94a7b8ae2_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTEtMTAtMS0xLTA_698a293f-9e8a-4651-a6c9-56174957cb28">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id4ac5b7017d1476fb5bcd16b536f43e8_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTItNi0xLTEtMA_2041fab4-7d80-4816-89e6-45253b8350ec">3.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ac5b7017d1476fb5bcd16b536f43e8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTItOC0xLTEtMA_262e2e94-e9a6-4268-93ca-c479416ff58d">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb213534bbcd45118c1bb26b41e1e907_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTItMTAtMS0xLTA_10458695-92c1-4789-88ad-361159ec75da">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia58159b24bd345179d097a8c8fa338da_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTMtNi0xLTEtMA_c2d1397c-3b06-4367-bf7c-a5daa9c74fbd">3.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia58159b24bd345179d097a8c8fa338da_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTMtOC0xLTEtMA_5dff9b8e-617a-4b98-8c7a-beade7426bb0">2,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a046019e56c4f54b51b48b7aa1d9d88_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTMtMTAtMS0xLTA_e41173d6-937e-4d62-94d6-febdafb8a861">2,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3836e4ff9f5545ad88927b7ccfe6ce9a_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTQtNi0xLTEtMA_9968fd62-8a04-4fec-81b4-a2b01526495a">2.95</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3836e4ff9f5545ad88927b7ccfe6ce9a_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTQtOC0xLTEtMA_6f811084-c9eb-45a3-805c-37fed9ce4c0a">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4cd61c4d420435f8f8a47a822a2fb94_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTQtMTAtMS0xLTA_30779990-bec5-457c-a2db-3788306638f1">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia75a4a1f883644e593643caeeb64e8c8_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTUtNi0xLTEtMA_67cf099b-7794-4393-b848-bde3d82f7bfa"><ix:nonFraction unitRef="number" contextRef="ia75a4a1f883644e593643caeeb64e8c8_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTUtNi0xLTEtMA_680adc62-f37b-45b4-8fe3-22800b24e12a">1.20</ix:nonFraction></ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75a4a1f883644e593643caeeb64e8c8_I20210930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTUtOC0xLTEtMA_0a5f424a-29bb-46e0-b370-065687292c5d">746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i831cf307aaac48e3a4f36b76c1ae6821_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTUtMTAtMS0xLTA_d5bfbdbe-f3ae-40a2-84e3-0e2a0c85123a">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia606b7a94a2a4a27be3bac90bae27db7_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTYtNi0xLTEtMA_784b6b86-615f-4745-97ba-eeb492e9ed28"><ix:nonFraction unitRef="number" contextRef="ia606b7a94a2a4a27be3bac90bae27db7_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTYtNi0xLTEtMA_aee01b7e-865a-4fcc-a6df-89db2317250a">1.65</ix:nonFraction></ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia606b7a94a2a4a27be3bac90bae27db7_I20210930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTYtOC0xLTEtMA_0056b7fc-30c3-44cd-ad6a-fe986d2d08b2">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i033466f65d06435daaf05ce68cdea42a_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTYtMTAtMS0xLTA_581289e5-2554-4b62-b782-5a3976dd9512">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26def8fc057343cea1511af0a42bbd82_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTctNi0xLTEtMA_450ef8a8-220c-438f-ab31-6c8ad15b2086">4.60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26def8fc057343cea1511af0a42bbd82_I20210930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTctOC0xLTEtMA_7ce38a0b-1c2f-4592-aa0a-14fe367b9f60">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i793861fc864b4d84a4d7675fd3879f56_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTctMTAtMS0xLTA_0a712125-574f-4083-95fe-a4ebb97e3dda">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i334415af3e3b4544a67d9d7fca63abc9_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTgtNi0xLTEtMA_2619a274-767e-4afd-a1c4-fcf5e1703f5f">4.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i334415af3e3b4544a67d9d7fca63abc9_I20210930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTgtOC0xLTEtMA_3b490209-e224-4bb6-a88a-b2c049520c3a">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab18c39cd70d4664b5614e5d608d97f5_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTgtMTAtMS0xLTA_f020a9a0-b20e-4361-a980-5b1dc96e24a7">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3a50f56b0a243339131abb7a4e8302f_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTktNi0xLTEtMA_44337804-1373-450a-ad1d-dcfc36d4191e"><ix:nonFraction unitRef="number" contextRef="ib3a50f56b0a243339131abb7a4e8302f_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTktNi0xLTEtMA_c125b541-5f91-4729-a8e0-3564caf008cb">2.60</ix:nonFraction></ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3a50f56b0a243339131abb7a4e8302f_I20210930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTktOC0xLTEtMA_456a5f01-5d93-4472-8d2e-39890a462859">987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aab6acda6824604a29d697a10699b89_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTktMTAtMS0xLTA_a50df14b-a3f9-4be6-9a53-f4e4abe81eef">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56cf1e78acd541bf8bda7634c9734818_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjAtNi0xLTEtMA_db73d87d-75a2-44f6-80ad-96223cfe2381">5.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56cf1e78acd541bf8bda7634c9734818_I20210930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjAtOC0xLTEtMA_0f957e67-0a5c-4249-8514-819cc9bc5dc0">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8992e066ac492e96f9427867db1b37_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjAtMTAtMS0xLTA_ce21cfc5-e893-4250-bc51-0afd18671861">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id18ba93f1f954ea7825f560783159641_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjEtNi0xLTEtMA_f9907386-d43a-4452-9ead-154b726abb4c">4.80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id18ba93f1f954ea7825f560783159641_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjEtOC0xLTEtMA_37c2476d-eab8-4bf2-a28d-55de88e999fa">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47bdb44a5bf54303b2b1c5d712c9b5f1_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjEtMTAtMS0xLTA_031cc743-64b2-48b3-a389-8eafbda9cbe3">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69e5c28f892a4699b116990ce04af8d5_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjItNi0xLTEtMA_c78fd149-3827-4680-9925-0baf7542ce86">4.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e5c28f892a4699b116990ce04af8d5_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjItOC0xLTEtMA_879e6d2b-6a04-4efa-bd4e-6e52b5837a3a">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida4a76b2bb9c486ab32b0ed960911667_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjItMTAtMS0xLTA_fab89540-0655-418b-bd58-8ca5b3217ae2">1,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c9e673628f24f989a48a76bc085f8ad_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjMtNi0xLTEtMA_7dc6a714-f6f5-4d9c-900c-8400614874b1">4.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9e673628f24f989a48a76bc085f8ad_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjMtOC0xLTEtMA_c46e3517-3d99-4df6-85d7-c58052f0b63b">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib475552eda99433d86c1a416ace1cc9a_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjMtMTAtMS0xLTA_88a7212e-1964-4d3b-be0f-020db5700f1a">2,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i063be5049ee1464b8b050a5513490bf2_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjQtNi0xLTEtMA_8bb62e97-e120-44db-ad48-6fa9f37988a1">4.15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i063be5049ee1464b8b050a5513490bf2_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjQtOC0xLTEtMA_5a159373-c121-49ea-a6fa-dcbed92c52cd">1,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3282c94d1c174c6ea5efa7ab36b47b19_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjQtMTAtMS0xLTA_c5e51df7-055c-4d90-b165-118a52522fe4">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1bfce21e9994d52bbeedde558474519_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjUtNi0xLTEtMA_23e2a05a-2475-40c6-8939-f7d55e284767"><ix:nonFraction unitRef="number" contextRef="if1bfce21e9994d52bbeedde558474519_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjUtNi0xLTEtMA_ad9f6a4a-5636-4882-8e2e-3dd785d41ecb">2.80</ix:nonFraction></ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1bfce21e9994d52bbeedde558474519_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjUtOC0xLTEtMA_e1f7d169-4b8f-45c2-95e7-0706cd16546d">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i729835fd97c847689dae526ba4c3f80f_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjUtMTAtMS0xLTA_459f8908-2dcd-4cf0-bb58-66552f061dc6">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes and term loan facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bfaa553aa8422b9801e9811d4f84ff_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjYtOC0xLTEtMA_a242eeeb-f53f-4335-8b48-a2d915a09107">26,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31b25ed89c604903b3ab2cb0f953dae9_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjYtMTAtMS0xLTA_0753e2e5-60b6-49d8-91cc-ecebe119d5b6">30,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacd82538440946f2b5a64f02e99bd78e_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjctOC0xLTEtMA_f633dad5-20eb-4549-9508-d4cb095e6daf">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ecfcc11f2b44bee8fc31ff744993188_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjctMTAtMS0xLTA_29ddbd4e-0439-40e2-a31f-0f9fb177378c">1,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjgtOC0xLTEtMA_00e9427c-f662-4359-9864-fc0c05e556ff">27,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjgtMTAtMS0xLTA_2f562d56-a1ed-4c68-8018-b33bb023ae2e">31,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjktOC0xLTEtMA_d12f571b-c515-4581-ada9-c7ac0cd3f9b1">2,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjktMTAtMS0xLTA_494961c8-9702-49ef-aa22-cb2333a457f6">2,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMzAtOC0xLTEtMA_2d908b1d-3126-4078-8c59-8a933f2614dc">25,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0300f6dad76745ceafff278866806c16_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMzAtMTAtMS0xLTA_b3b358f7-6e4b-4461-8875-e50bd5733c8d">28,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, we repaid $<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0NjQ5Nw_f00fd7df-6a44-469d-95f1-808f59388d87">3.75</ix:nonFraction> billion of debt. We repaid $<ix:nonFraction unitRef="usd" contextRef="i20624e63c9d342039f2acd0aa0e221dc_D20210101-20210331" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfUnsecuredDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0Njc4MA_53d8742c-0ba0-4458-80cf-fbbcc7a5922a">1.0</ix:nonFraction> billion of senior unsecured notes due April 2021 in the first quarter of 2021 and $<ix:nonFraction unitRef="usd" contextRef="ia5e1397cca1b4612bda3fec5029c7caa_D20210701-20210930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0NjUyOA_5b588ef0-e45d-43e9-bb75-fdff1d81488e">1.25</ix:nonFraction> billion of senior unsecured notes due December 2021 in the third quarter of 2021. Additionally, we repaid $<ix:nonFraction unitRef="usd" contextRef="i4a838956d382494aa01dce9ce9a74af3_D20210101-20210930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfUnsecuredDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0Njc5NQ_cd0a7b9b-0779-4a75-91a3-093f4dfa9a4e">1.0</ix:nonFraction> billion principal amount outstanding under our <ix:nonNumeric contextRef="i4a838956d382494aa01dce9ce9a74af3_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfNTQ5NzU1ODE0NTYwMA_3bceaa41-f914-425f-b4bb-46848f2886ff">three-year</ix:nonNumeric> $<ix:nonFraction unitRef="usd" contextRef="i4f517572134b4e7bb737cffba5c07c94_I20210930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0NjU4Nw_0fde0df5-4c8c-4e92-b194-148900596bcf">1.0</ix:nonFraction> billion senior unsecured term loan facility due October 2023 and $<ix:nonFraction unitRef="usd" contextRef="i50cd74cb77d0435b838bbc259636ca23_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfUnsecuredDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0NjYyMA_ef02ffd5-7d54-4485-8f85-1f9739a76b35">500</ix:nonFraction> million of our senior unsecured floating rate notes due September 2021 upon maturity. In October 2021, we exercised our option to call $<ix:nonFraction unitRef="usd" contextRef="i755d8293c829458682df87bc82180dd0_D20211001-20211031" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0NjczNg_7f196d14-c0ba-408f-b0b0-26cbaf8906fe">500</ix:nonFraction> million of our floating rate senior unsecured notes and $<ix:nonFraction unitRef="usd" contextRef="iaf9f1c5fb1234d22a178a74091f99dd1_D20211001-20211031" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0Njc1MQ_40df2e5e-651a-4966-a873-10f2cceadda6">500</ix:nonFraction> million of our <ix:nonFraction unitRef="number" contextRef="icd18b3372b0d4339ba7e932b3bcfb631_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0Njc1OQ_a19f5428-c8d3-4365-b5f6-1b350883b415"><ix:nonFraction unitRef="number" contextRef="icd18b3372b0d4339ba7e932b3bcfb631_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0Njc1OQ_cfde161c-af6b-4d9e-b9f7-cdf45873ab25">0.75</ix:nonFraction></ix:nonFraction>% senior unsecured notes, both having a final maturity of September 2023. The notes will be repaid in November 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfNTQ5NzU1ODE0NTYwNw_9e14aebe-9f40-43fa-8b57-0c84097c8978"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfNTQ5NzU1ODE0NTYwNw_cec7e564-b51b-473f-ad64-8d6fccda7d5b">No</ix:nonFraction></ix:nonFraction> new debt was issued during the three and nine months ended September 30, 2021. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of September&#160;30, 2021, we were in compliance with all covenants.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib5097e8679ff4d6185334552cfb62147"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, there were <ix:nonFraction unitRef="usd" contextRef="i6198bb2c3e1b4f7a86b03b31b9a31291_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:LineOfCredit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfODQw_744258b5-d32f-4ece-8c1e-90f7762a740e"><ix:nonFraction unitRef="usd" contextRef="ife22d5290cb340d48c49cda6ebce356c_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:LineOfCredit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfODQw_d62de857-72a3-41ca-affa-f75554b4aaad">no</ix:nonFraction></ix:nonFraction> amounts outstanding under our $<ix:nonFraction unitRef="usd" contextRef="ia55d69200ead47739810b75c12b1c289_I20210930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfODcz_c421aac7-331c-409a-af7c-0e9bc0a866bd">2.5</ix:nonFraction> billion revolving credit facility maturing in June 2025, and we were in compliance with all covenants.</span></div></ix:continuation><div id="i2c1b4d102d99434b956b3b8616d0836a_64"></div><div style="margin-top:13.5pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMjU2NTE_c5d30b7e-7926-4cf5-80aa-6341e5e8cbbb" continuedAt="ia019545c33774c38810173abb5d3c59b" escape="true">COMMITMENTS AND CONTINGENCIES </ix:nonNumeric></span></div><ix:continuation id="ia019545c33774c38810173abb5d3c59b" continuedAt="i637027654f974be4b38963557aa995b1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, it is not possible to determine the outcome of these matters or the outcome (including in excess of any accrual) is not expected to be material, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss. In the third quarter of 2021, we reversed a $<ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMjQxODkyNTU5MDAyNjU_b2afa065-56c0-4d48-a037-9ffd2975bc18">175</ix:nonFraction> million previously recorded litigation accrual following a favorable court decision.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any material accruals for the matters described below on our Condensed Consolidated Balance Sheets as of September&#160;30, 2021 and December&#160;31, 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Sofosbuvir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of the HCV. In 2013, we received approval from FDA for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with the University of Minnesota</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The University of Minnesota (the &#8220;University&#8221;) has obtained U.S. Patent No. 8,815,830 (the &#8220;&#8217;830 patent&#8221;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#8217;830 patent. We believe the &#8217;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#8220;PTAB&#8221;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concludes the inter partes review that it has initiated. In May 2021, the PTAB issued a written decision finding the asserted claims of the University&#8217;s patent invalid. In July 2021, the University appealed this decision. The litigation in the U.S. District Court will remain stayed through the appeal proceedings.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with NuCana plc. (&#8220;NuCana&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NuCana has obtained European Patent No. 2,955,190 (the &#8220;EP &#8217;190 patent&#8221;) that allegedly covers sofosbuvir. In Opposition proceedings before the European Patent Office (&#8220;EPO&#8221;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#8217;190 patent in amended form. We believe that the amended EP &#8217;190 patent claims are invalid. Subsequently, we initiated proceedings to invalidate the UK counterpart of the EP &#8217;190 patent in the High Court of England &amp; Wales. In March 2021, NuCana filed a counterclaim against us in the High Court of England &amp; Wales alleging patent infringement of the UK counterpart and seeking damages and other relief. In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#252;sseldorf alleging patent infringement of the German counterpart of the EP &#8217;190 patent and seeking damages and other relief. The hearing date for the German NuCana case has been scheduled for May 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i637027654f974be4b38963557aa995b1" continuedAt="i8d9622e8d5c049d48785ac840949e32f"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Axicabtagene Ciloleucel</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes on U.S. Patent No. 7,446,190 (the &#8220;&#8217;190 patent&#8221;). A jury trial was held on the &#8217;190 patent, and in December 2019, the jury found that the asserted claims of the &#8217;190 patent were valid, and that we willfully infringed the asserted claims of the &#8217;190 patent. The jury also awarded Juno damages in amounts of $<ix:nonFraction unitRef="usd" contextRef="i294c3dd1a0044d64b2a2c206819a4787_D20191201-20191231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfNTA4Nw_91ecd9dd-7383-4c45-bccf-246dc2393bf6">585</ix:nonFraction> million in an up-front payment and a <ix:nonFraction unitRef="number" contextRef="i294c3dd1a0044d64b2a2c206819a4787_D20191201-20191231" decimals="3" name="gild:JudgmentRoyaltyRateFromOctober2017" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfNTExOQ_14efcc23-0095-40f9-94eb-9d7dfb5ccd80">27.6</ix:nonFraction>% running royalty from October 2017 through the date of the jury&#8217;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#8217;s verdict, enhanced the past damages by <ix:nonFraction unitRef="number" contextRef="i08188eab1c8f48659c9fb097dbfa6ad9_I20200430" decimals="2" name="gild:JudgmentEnhancedDamagesOnPastSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfNTM5MQ_8bfe8800-2bb7-4839-bc80-aecc5e996f28">50</ix:nonFraction>% and maintained the royalties on future Yescarta sales at <ix:nonFraction unitRef="number" contextRef="i08188eab1c8f48659c9fb097dbfa6ad9_I20200430" decimals="3" name="gild:JudgmentRoyaltyRateOnFutureSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfNTQ1MQ_11353d2a-187a-40ce-90ba-88635dde7a7b">27.6</ix:nonFraction>%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge, and in July 2021, the appeals court heard oral arguments. In August 2021, the Court of Appeals for the Federal Circuit (the &#8220;CAFC&#8221;) reversed the jury verdict finding the asserted claims of Juno&#8217;s patent invalid. In October 2021, Juno filed a petition for rehearing with the CAFC. We believe that the likelihood of a material adverse outcome in this matter is remote.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Bictegravir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV Healthcare Company (&#8220;ViiV&#8221;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes ViiV&#8217;s U.S. Patent No. 8,129,385 (the &#8220;&#8217;385 patent&#8221;) covering ViiV&#8217;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the &#8217;385 patent. The court has set a trial date of January 2022 for this lawsuit. ViiV is seeking billions of dollars for alleged damages comprised of ViiV&#8217;s lost profits and a royalty on sales of bictegravir from launch through the trial. ViiV calculates these damages based on the cumulative U.S. revenues from Biktarvy since launch, which have totaled $<ix:nonFraction unitRef="usd" contextRef="i1e74f009f33c41a1b3024e5689146bb1_D20210101-20210930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfNzg4OQ_2e2b40f6-b1ed-422b-b018-64c92d933f9f">16.4</ix:nonFraction> billion through September&#160;30, 2021. In addition, should a court find that we are liable for infringement, we expect ViiV will seek a royalty on sales after the trial. Although we cannot predict with certainty the ultimate outcome of this litigation, an adverse judgment could result in substantial monetary damages, including ViiV&#8217;s lost profits and royalties through trial, and a going-forward royalty stream on future sales. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound have infringed ViiV&#8217;s Canadian Patent No. 2,606,282 (the &#8220;&#8217;282 patent&#8221;), which was issued to Shionogi &amp; Co. Ltd. and ViiV. The &#8217;282 patent is the compound patent covering ViiV&#8217;s dolutegravir. We believe that bictegravir does not infringe the claims of the &#8217;282 patent. In January 2020, the court held a summary trial to assess ViiV&#8217;s infringement allegations. In April 2020, the court determined that bictegravir does not infringe the claims of the &#8217;282 patent and dismissed the case. ViiV appealed this decision, and in June 2021, the Canadian Federal Court of Appeal upheld the Federal Court of Canada&#8217;s decision. ViiV has sought leave to appeal to the Canadian Supreme Court. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019, ViiV filed lawsuits in France, Germany, Ireland and the UK asserting the relevant national designations of European Patent No. 3 045 206 (&#8220;EP &#8217;206&#8221;); in Australia asserting Australian Patent No. 2006239177; in Japan asserting Japanese Patent No. 4295353; and in Korea asserting Korean Patent Nos. 1848819 (&#8220;KR &#8217;819&#8221;) and 1363875. These patents all relate to molecules that ViiV claims would act as integrase inhibitors. We believe that bictegravir does not infringe the claims of any of ViiV&#8217;s patents. In 2019, we filed an opposition in the EPO requesting revocation of EP &#8217;206. The EPO hearing took place in January 2021, and the patent claims, which do not cover bictegravir, were maintained in amended form. Both parties have appealed this decision. Additionally, in 2020, we filed a petition in the Korean Intellectual Property Office requesting invalidation of KR &#8217;819. Following a trial, a tribunal of the Korean Intellectual Property Trial and Appeal Board found KR &#8217;819 to be invalid. In March 2021, ViiV appealed this decision. In April 2021, the court in Germany held a hearing on the issue of infringement, and in September 2021, determined that Gilead does not infringe ViiV&#8217;s EP &#8217;206 patent both in its original form and as amended by the EPO. ViiV has appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In all jurisdictions, to the extent that the claims of ViiV&#8217;s patents are interpreted to cover bictegravir, we believe that those claims are invalid. We cannot predict the ultimate outcome of intellectual property claims related to bictegravir. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8d9622e8d5c049d48785ac840949e32f" continuedAt="ib537abff77b6405b8bd156b044a1fef0"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Relating to Pre-Exposure Prophylaxis</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#8220;HHS Patents&#8221;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of emtricitabine and tenofovir or TDF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#8220;PrEP&#8221;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the Court of Federal Claims, alleging violations of <ix:nonFraction unitRef="agreement" contextRef="i40650c0325e24e0db701d2ab8acfe659_I20200430" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyMaterialTransferAgreementsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTE1ODk_aae5497a-17dd-4ce4-b9b9-f94ee4480c78">four</ix:nonFraction> material transfer agreements (&#8220;MTAs&#8221;) related to the research underlying the HHS Patents and a clinical trial agreement (&#8220;CTA&#8221;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#8217;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the Court of Federal Claims has been set for June 2022, and a trial date for the lawsuit in the District Court of Delaware has been set for May 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Generic Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#8220;NCE&#8221;) exclusivity period during which other manufacturers&#8217; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#8220;ANDA&#8221;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#8217;s approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in December 2019, we received letters from Lupin Ltd., Apotex Inc., Shilpa Medicare Ltd., Sunshine Lake Pharma Co. Ltd., Laurus Labs, Natco Pharma Ltd., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. (collectively, &#8220;generic manufacturers&#8221;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of certain of our tenofovir alafenamide (&#8220;TAF&#8221;)-containing products. Between them, these generic manufacturers seek to market generic versions of Odefsey, Descovy and Vemlidy. Some generic manufacturers have challenged the validity of <ix:nonFraction unitRef="patent" contextRef="ie57e22e42a844c1c934bc94bfc2e2e72_D20191201-20191231" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTQwNzY_29f93f42-43fc-4917-a96a-b4eb71596a8d">four</ix:nonFraction> patents listed on the Orange Book and associated with TAF, while others have challenged the validity of <ix:nonFraction unitRef="patent" contextRef="ie57e22e42a844c1c934bc94bfc2e2e72_D20191201-20191231" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTQxODM_6a40ba83-73a3-4f34-a381-ac127b470397">two</ix:nonFraction> of our Orange Book-listed patents associated with TAF. We filed lawsuits against the generic manufacturers, and we intend to enforce and defend our intellectual property.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we received a letter from Lupin Ltd. indicating that it has submitted an ANDA to the FDA requesting permission to market and manufacture a generic version of Symtuza. We are evaluating the letter and intend to enforce and defend our intellectual property.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Claims</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. An appeal hearing originally scheduled for July 2021 has been canceled and a new date has not yet been set by the EPO.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. <ix:nonFraction unitRef="opposingparty" contextRef="ic6c268206d494d42a3e01744ecb78d28_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyPartiesAppealedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTUxNDY_9434634c-1adb-4606-9044-b29052bdfcff">Two</ix:nonFraction> of the original opposing parties have appealed, requesting full revocation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2026. In 2017, the EPO upheld the validity of the claims of our TAF patent. <ix:nonFraction unitRef="opposingparty" contextRef="i842ab5644f88423ea3fb5a3f08f81d21_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyPartiesAppealedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTU0Mzg_f25278fa-e493-4ccd-93f5-ac6bf4de0b89">Three</ix:nonFraction> parties have appealed this decision. The appeal hearing was held in March 2021, and the validity of all claims were upheld.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. <ix:nonFraction unitRef="opposingparty" contextRef="ie5c2c8d7ed2c407cb3c28ad661f37190_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyPartiesAppealedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTU4MDY_eed2e7c3-4313-4709-9d67-50f06f856557">Three</ix:nonFraction> parties have appealed this decision. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib537abff77b6405b8bd156b044a1fef0" continuedAt="if4e9a1bd6a4a43ea883fe1de56001165"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, <ix:nonFraction unitRef="party" contextRef="ib144fc19e2424cdea1de575c395ea438_D20160101-20161231" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyPartiesFilingOppositionNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTU4NTY_24070d07-e50b-40b1-bbe9-68e1ac840fbd">three</ix:nonFraction> parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2027. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. <ix:nonFraction unitRef="opposingparty" contextRef="i32e0f49607724a678979d40a5566567c_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyPartiesAppealedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTYwNjg_88c05758-5314-4362-b53a-f166c329d572">Two</ix:nonFraction> parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF, TAF hemifumarate and cobicistat in the European Union could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust and Consumer Protection</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We (along with Japan Tobacco, Inc. (&#8220;Japan Tobacco&#8221;), Bristol-Myers Squibb Company (&#8220;BMS&#8221;) and Johnson &amp; Johnson, Inc.) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Japan Tobacco was dismissed from the lawsuit after a favorable court ruling on the defendants&#8217; motion to dismiss. Plaintiffs allege that we (and the other remaining defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of two nationwide classes - one of direct purchasers consisting largely of wholesalers, and another of end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In September 2021, we, along with BMS and generic manufacturer Teva Pharmaceuticals USA (&#8220;Teva&#8221;), were named as defendants in similar lawsuits filed by CVS, Rite Aid, Walgreens, Safeway, Kroger, Albertsons and HEB (the &#8220;Retailers&#8221;) in the U.S. District Court for the Northern District of California. The Retailers are opting out of the proposed direct purchaser class and, based on assignments by their wholesalers, seek to bring claims substantially the same as the putative class.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we, along with generic manufacturers Cipla Ltd. and Cipla USA Inc. (together, &#8220;Cipla&#8221;), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#8220;Jacksonville Trust&#8221;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and Cipla, which settled a patent dispute relating to patents covering our Emtriva, Truvada, and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. The Plaintiff seeks damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we along with BMS and Teva were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="i50d725ee8e5d42e8b1d6a84547e3f2dc_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfNTQ5NzU1ODIyNDI4OA_9b359531-3b8b-4169-aba4-2a1dc9817e4d">one</ix:nonFraction> class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Missouri and New Jersey, involve more than <ix:nonFraction unitRef="plaintiff" contextRef="i50d725ee8e5d42e8b1d6a84547e3f2dc_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfNTQ5NzU1ODIyNDI5Nw_1a1ad6d9-c505-4b11-874d-6c6ed4b03b7a">24,000</ix:nonFraction> plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if4e9a1bd6a4a43ea883fe1de56001165"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#8217;s decision not to intervene in the suit, the relator served us with a Second Amended Complaint in January 2021. The lawsuit alleges that Gilead&#8217;s HCV patient access programs, clinical educator programs, speaker programs, and other sales and marketing programs violated the federal False Claims Act and various state false claims acts. In July 2021, the relator filed a Third Amended Complaint, removing allegations against us regarding our patient access programs, clinical educator programs and relationships with specialty pharmacies. The relator seeks all available relief under these statutes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="plaintiff" contextRef="if347b8e9f0f441978924331eb15b50e0_D20200401-20200430" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMjIzNTQ_ce15150b-5669-4e7f-8a21-61dc5688c57f">Two</ix:nonFraction> former employees filed a qui tam lawsuit against Gilead in April 2020 in California state court. These same former employees had previously filed a qui tam lawsuit in federal court in California, and the U.S. Department of Justice declined intervention and moved to dismiss relators&#8217; federal False Claims Act claims. Relators subsequently voluntarily dismissed their federal lawsuit and refiled their lawsuit in California state court. Following the California Attorney General&#8217;s Office&#8217;s decision not to intervene, relators served Gilead with their complaint in August 2020. The complaint alleges violations of the California False Claims Act (&#8220;CFCA&#8221;) and employment law claims. Relators seek all available relief under the CFCA.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice Advocates, LLC (&#8220;Health Choice&#8221;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court&#8217;s dismissal.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#8220;TMFPA&#8221;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA. In September 2021, the Texas Court of Appeals for the Sixth Court Appeals District granted our request to stay the Texas litigation. The case is stayed pending final judgment in the Eastern District of Pennsylvania lawsuit filed in March 2017, as discussed above.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019, which were consolidated in September 2019. Plaintiffs filed a consolidated complaint in November 2019 and an amended complaint in July 2021. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#8217; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the U.S. District Court for the District of New Jersey. While we believe this case is without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.</span></div></ix:continuation><div id="i2c1b4d102d99434b956b3b8616d0836a_67"></div><div style="margin-top:13.5pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTYwOA_49506f63-1ebf-42ba-a68f-5acdf9195b22" continuedAt="i86b164ed871b450cb88a8447d1d021a6" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i86b164ed871b450cb88a8447d1d021a6" continuedAt="i304cfaa9797048bbaec5ba9d09b6f1c6"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Programs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2016, our Board of Directors authorized a $<ix:nonFraction unitRef="usd" contextRef="i86e5d209900446c0b30dc2880295f243_I20160331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTA0_28917f6c-e98a-44e9-aa2b-cec71563c4a7">12.0</ix:nonFraction> billion stock repurchase program (&#8220;2016 Program&#8221;) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a new $<ix:nonFraction unitRef="usd" contextRef="id644c4f270bd409c8d4eb7dbc0893a59_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMzU3_e47b9f49-05e8-492b-a0ae-25c6646be5c2">5.0</ix:nonFraction> billion&#160;stock repurchase program (&#8220;2020 Program&#8221;), which will commence upon the completion of the&#160;2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i304cfaa9797048bbaec5ba9d09b6f1c6"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2021, we repurchased and retired <ix:nonFraction unitRef="shares" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTUzOTMxNjI3OTA1NDI_0e27f5f4-93cd-4777-917b-568104f1a825">2.1</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTUzOTMxNjI3OTA1OTg_d9d5d635-f3a9-4c97-9706-2d6fb11cc33a">7.5</ix:nonFraction> million shares of our common stock for $<ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTUzOTMxNjI3OTA1NzE_d15f9bd3-dfbd-4774-b35d-ea27a9dbb614">145</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTUzOTMxNjI3OTA2MzA_877dd657-0e7d-4760-aae3-a17f5d8b21c8">497</ix:nonFraction> million, respectively, through open market transactions under the 2016 Program. During the three and nine months ended September 30, 2020, we repurchased and retired <ix:nonFraction unitRef="shares" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTU5NDI5MTg2MDQ2MzE_31eb2a74-87fc-4109-a110-9db2fd4a8f6d">3.0</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTU5NDI5MTg2MDQ2Mzg_66381c9e-11b6-4000-b498-fc323f582ae0">22.4</ix:nonFraction> million shares of our common stock for $<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTU5NDI5MTg2MDQ2NTM_0e12dcad-4b6d-407d-a4df-0d1d5416231c">201</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTU5NDI5MTg2MDQ2NzA_953cbbbb-7f1b-481b-bfac-01f543deb7bb">1.6</ix:nonFraction> billion, respectively, through open market transactions under the 2016 Program.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the remaining authorized repurchase amount under both programs was $<ix:nonFraction unitRef="usd" contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTUzOTMxNjI3OTA2NjE_4eb1c112-a71c-4799-8761-53b3a47e717c">6.3</ix:nonFraction> billion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></div><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTYxMg_c076a63a-d7f4-483e-b42d-810467e72533" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in AOCI by component, net of tax:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5998ee4b384480a72487be18641c7e_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMS0yLTEtMS0w_3a254c4c-14ae-4144-8f9e-2cb1d332a758">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3d265770c244a0a765e499a4ee7cb9_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMS00LTEtMS0w_e2270ee6-6f34-40a5-b0ac-7c1831013ce6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c0ff94d0a674ceabb8a179fc4e48905_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMS02LTEtMS0w_dc67e61a-8a3b-4c53-b908-805e8537bc37">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68c8176bb4194abc96d3c13de341cd01_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMS04LTEtMS0w_c4b28401-0e18-4397-9f11-0a6c3067b149">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45325645469947adb3cc8720858aa852_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMi0yLTEtMS0w_6b368d4d-85b3-4c8b-a5dd-56c6c159a0cf">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b5cc9befb344284aed69e9c8209aba9_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMi00LTEtMS0w_ab2aff5d-eeac-4449-9386-621129e61bca">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if101dcd8b89a438ab7ac5691e108990a_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMi02LTEtMS0w_9e810dd4-c544-49fd-a79b-261bb8df0a63">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdca6d608af14f87aeafba62f5b528f1_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMi04LTEtMS0w_7c105c09-bc46-4b5c-a1ed-1100b2faee97">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45325645469947adb3cc8720858aa852_D20210101-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMy0yLTEtMS0w_5e9c1019-38dd-4f65-ac78-d40e461d721c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b5cc9befb344284aed69e9c8209aba9_D20210101-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMy00LTEtMS0w_2aa227af-6a7d-4645-8d9f-c62482cf7c2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if101dcd8b89a438ab7ac5691e108990a_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMy02LTEtMS0w_71c64ca7-5c3d-45c0-abbb-b3e97840f861">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdca6d608af14f87aeafba62f5b528f1_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMy04LTEtMS0w_1356fba5-6ca3-499d-8f3f-62ea87fc9128">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45325645469947adb3cc8720858aa852_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNC0yLTEtMS0w_ae1c3d29-f4e5-4287-b55d-9c6616bdf5d0">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b5cc9befb344284aed69e9c8209aba9_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNC00LTEtMS0w_54013248-3b68-462b-8d6b-a79fed6815a2">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if101dcd8b89a438ab7ac5691e108990a_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNC02LTEtMS0w_68261b09-75ab-44db-a87e-01a1bcc34a27">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdca6d608af14f87aeafba62f5b528f1_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNC04LTEtMS0w_591915a5-70bc-4156-97e6-9e115b3c7657">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8bee7f2d6524b07b87afe756d78590e_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNS0yLTEtMS0w_cbb47e00-3b3a-42f0-bce9-c40e9b48e607">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4990ffc169374b34bdd3f918810fc418_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNS00LTEtMS0w_5e14e655-d1b3-48f8-bd43-851ca9b20960">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79d0985dca0949ec872d8eb72624d97f_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNS02LTEtMS0w_9c195daa-938d-4cbf-b975-b62920c22f80">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic607fe5efeb4462ba677a36d66cea69e_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNS04LTEtMS0w_475f3cd7-77d0-4779-833b-65adc94e9391">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414821821100441394f7829f268ffe4e_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMS0yLTEtMS0w_9dc96859-43b5-4771-9e76-58f55f315eca">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf07b371d2f4766b8d9469daa886de3_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMS00LTEtMS0w_0969b318-ebf7-4cab-a5fc-0f3239fd2f23">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4e4f7365f94609beeaed0a72a5533b_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMS02LTEtMS0w_f9ce5fa9-6584-4cfa-8e6c-a14f6635de6a">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i188cf2bc805343608e1a7c9417d2404d_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMS04LTEtMS0w_6502473d-7d86-4fd4-b5f0-34f8ba13c7e6">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i967254dd024046df825693124da51c02_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMi0yLTEtMS0w_91a90771-517a-4474-be3c-495a8e401e5f">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id89abf1e3aba470fbcbb850fec50b11b_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMi00LTEtMS0w_9f07105a-0271-4912-ab57-abc253b2c59d">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i216f4d250c4d49e19ca6cf3b0d5a5818_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMi02LTEtMS0w_3c4adc70-1bd8-488f-a53f-aa765edc3033">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57db840e2919481eb28184ec2cbb0a50_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMi04LTEtMS0w_367cd7a5-e56e-486d-b552-bbc9fe29f1a0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income (loss) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i967254dd024046df825693124da51c02_D20200101-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMy0yLTEtMS0w_e0d05b08-ddcf-45d5-a240-7294d2fce624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id89abf1e3aba470fbcbb850fec50b11b_D20200101-20200930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMy00LTEtMS0w_0430790a-7129-4713-83d8-e3b08decad99">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i216f4d250c4d49e19ca6cf3b0d5a5818_D20200101-20200930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMy02LTEtMS0w_39b05ad3-0eb8-4896-b1b5-6eba753e079d">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57db840e2919481eb28184ec2cbb0a50_D20200101-20200930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMy04LTEtMS0w_35c079c6-632f-40b3-86fa-33175aa0d0ae">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i967254dd024046df825693124da51c02_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNC0yLTEtMS0w_d869a47c-ace5-44be-a58f-7c3f93bdb623">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id89abf1e3aba470fbcbb850fec50b11b_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNC00LTEtMS0w_d186201b-e550-4782-8c02-8fc399214f2d">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i216f4d250c4d49e19ca6cf3b0d5a5818_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNC02LTEtMS0w_910c645b-c77d-4df2-8d9e-6055227b6ef6">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57db840e2919481eb28184ec2cbb0a50_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNC04LTEtMS0w_f63682a2-15ff-4fa6-8a71-b89ff89684ed">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54fe2a88a4c14a76a2d768cacc3e0995_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNS0yLTEtMS0w_690c93ae-15a7-4200-a85d-5c1bf2049157">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b67d0bcd224fc9a3adb44b3d27fd5b_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNS00LTEtMS0w_7c93d1d4-cced-462a-9c08-e54f5df79860">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cf587a459224feaac6e5a4412d46585_I20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNS02LTEtMS0w_c2bc5911-9c19-4425-924e-add4350b0d93">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb53663397049a380603edf12d76c3a_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNS04LTEtMS0w_d8a42ccf-5b91-4b27-8d9a-7f20c38eeea6">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts reclassified to net income (loss) for gains and losses on cash flow hedges are recorded as part of Product sales on our Condensed Consolidated Statements of Operations. See Note 5. Derivative Financial Instruments for additional information. The amounts reclassified to net income (loss) for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net on our Condensed Consolidated Statements of Operations. Gross realized gains and losses on available-for-sale debt securities were not material for the nine months ended September 30, 2021 and 2020. The income tax impact allocated to each component of other comprehensive income (loss) was not material for the periods presented.</span></div></ix:continuation><div id="i2c1b4d102d99434b956b3b8616d0836a_70"></div><div style="margin-top:13.5pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RleHRyZWdpb246MGVhMWM5YzRlMzExNGQ2ZjliMmY1ZWNjNmJlOGE4OWFfMTAzNA_dea10c16-a393-4c9c-a5b9-564dd5efac00" continuedAt="id70c26d30ec64d04881179e0c6016f3b" escape="true">NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</ix:nonNumeric></span></div><ix:continuation id="id70c26d30ec64d04881179e0c6016f3b" continuedAt="ibbbab03dd9984b069c8df680b32c91b9"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share attributable to Gilead common stockholders is calculated based on the weighted average number of shares of our common stock outstanding during the period. Diluted net income (loss) per share attributable to Gilead common stockholders is calculated based on the weighted average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock metho</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential shares of common stock excluded from the computation of diluted net income (loss) per share attributable to Gilead common stockholders because their effect would have been antidilutive were <ix:nonFraction unitRef="shares" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RleHRyZWdpb246MGVhMWM5YzRlMzExNGQ2ZjliMmY1ZWNjNmJlOGE4OWFfODA1_5dd44657-0ef4-42a8-af54-1903b9148d83">14</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RleHRyZWdpb246MGVhMWM5YzRlMzExNGQ2ZjliMmY1ZWNjNmJlOGE4OWFfODEy_88494450-17e8-4ba1-934d-231033d66f2f">15</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively, and <ix:nonFraction unitRef="shares" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RleHRyZWdpb246MGVhMWM5YzRlMzExNGQ2ZjliMmY1ZWNjNmJlOGE4OWFfODQ1_90bd147e-489e-4abe-b2f6-a3fbe803dcc1">13</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RleHRyZWdpb246MGVhMWM5YzRlMzExNGQ2ZjliMmY1ZWNjNmJlOGE4OWFfODUy_cb0600fe-be42-4c68-b7ae-a8cd3a9313dd">38</ix:nonFraction> million for the three and nine months ended September 30, 2020, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibbbab03dd9984b069c8df680b32c91b9"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RleHRyZWdpb246MGVhMWM5YzRlMzExNGQ2ZjliMmY1ZWNjNmJlOGE4OWFfMTAzNQ_ad51bf35-61b7-42e3-8665-3ad106723c1f" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the calculation of basic and diluted net income (loss) per share attributable to Gilead common stockholders:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfMy0yLTEtMS0w_2ae7cead-ef05-4ba5-88dc-033def53f9fa">2,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfMy00LTEtMS0w_619513d8-4af8-4e7a-accd-ae0fb4fe598f">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfMy02LTEtMS0w_cfb36777-8a2f-4112-b343-fff0f7a7549f">5,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfMy04LTEtMS0w_510fc3b6-f7e7-4062-bf87-9dde725bac5e">1,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNC0yLTEtMS0w_103ec50a-b78b-4fed-ac5f-2030c87c7d6e">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNC00LTEtMS0w_fd2d1425-2084-4df7-aab7-f66b7706a933">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNC02LTEtMS0w_aee8a1b2-95fd-44aa-9800-427a3d3a6366">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNC04LTEtMS0w_c9231cae-e69f-4312-825e-3cde090aead9">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNS0yLTEtMS0w_eb53ef0c-3a86-47fa-9cb5-611922e6aa78">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNS00LTEtMS0w_5ce0e860-6f66-4004-8894-4b97bab0ac1a">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNS02LTEtMS0w_18fc4ae5-1a4a-4f00-8a5c-d48518ede98b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNS04LTEtMS0w_fbbc1564-98ab-4cf5-ad3e-2ab4bcf4cb3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNi0yLTEtMS0w_b7cf0d64-6c19-40e9-9acf-01fc846458a8">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNi00LTEtMS0w_5184d87a-f9fd-42a3-864d-e732c4e00ceb">1,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNi02LTEtMS0w_17c9bdf3-0924-4728-b891-8ecb1d1d65c6">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNi04LTEtMS0w_c4a4f6ab-bbe0-4f6a-bb7f-41e6331dba43">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOC0yLTEtMS0w_57cb18e4-86cd-42b9-b9c6-e8ae752c1e01">2.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOC00LTEtMS0w_4a639e4d-44dd-45e5-8d17-24cb56f74acb">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOC02LTEtMS0w_510e00ca-66e9-40a6-8ccf-6fdecc9c22ea">4.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOC04LTEtMS0w_1e58b78f-9d8b-44d1-b26f-eda768b91943">1.14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOS0yLTEtMS0w_277950c8-cf9a-45af-ace0-d655273d9efa">2.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOS00LTEtMS0w_ed69da37-78d1-4c11-94b5-68260ef74e68">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOS02LTEtMS0w_2429d6fa-2dec-4550-a254-6fd6573da824">4.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOS04LTEtMS0w_50288d8f-aed1-4ad1-9a6f-f3d78414a826">1.14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i2c1b4d102d99434b956b3b8616d0836a_73"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RleHRyZWdpb246NmE1MjMyZDcwNDE0NDJhNjg4NzA2N2E5NDM1OGI5ZjdfMTY0Mw_b9e67c8f-2333-40a9-ae6c-2447244edca7" continuedAt="ib5e5ac9b912f49eb8d66a6edad4b242e" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="ib5e5ac9b912f49eb8d66a6edad4b242e"><ix:nonNumeric contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RleHRyZWdpb246NmE1MjMyZDcwNDE0NDJhNjg4NzA2N2E5NDM1OGI5ZjdfMTY0NA_02572c17-fb2a-4c12-add8-0958df003f29" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our income tax expense:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfMy0yLTEtMS0w_c0f1cedd-4c62-4504-894e-7eefdca5190a">3,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfMy00LTEtMS0w_a56b9641-1ce3-494e-a175-8cf605cf57a0">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfMy02LTEtMS0w_1c722f21-6020-46f6-b702-e020c6c8c9c0">7,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfMy04LTEtMS0w_da3022a1-b718-4531-8fa2-a345a27b5be3">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNC0yLTEtMS0w_a739ce53-4f96-4153-8951-72935364c9eb">852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNC00LTEtMS0w_b5d7c797-e715-40a7-935f-481f179b605f">472</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNC02LTEtMS0w_09d911e5-2d90-4d5f-a4af-4f421ca32902">1,694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNC04LTEtMS0w_15ad47df-33bb-49cb-8941-eed6fec54dd9">1,310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNS0yLTEtMS0w_bf4a9491-15b3-42ff-818e-5eb09d5aaae9">24.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNS00LTEtMS0w_c025ce5d-e795-49e3-a0c0-2afca3f67b5d">57.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNS02LTEtMS0w_9a705fee-e122-4210-bea8-b2c3ed1b73f7">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNS04LTEtMS0w_11ee4293-7f5d-47ed-a485-335d9461845d">903.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of <ix:nonFraction unitRef="number" contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RleHRyZWdpb246NmE1MjMyZDcwNDE0NDJhNjg4NzA2N2E5NDM1OGI5ZjdfMTAy_bf4a9491-15b3-42ff-818e-5eb09d5aaae9">24.8</ix:nonFraction>% for the three months ended September 30, 2021 is higher than the U.S. federal statutory rate of 21% primarily due to remeasurement of certain deferred tax liabilities related to acquired intangible assets, partially offset by provision to return adjustments.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of <ix:nonFraction unitRef="number" contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RleHRyZWdpb246NmE1MjMyZDcwNDE0NDJhNjg4NzA2N2E5NDM1OGI5ZjdfNTMw_9a705fee-e122-4210-bea8-b2c3ed1b73f7">22.5</ix:nonFraction>% for the nine months ended September 30, 2021 is higher than the U.S. federal statutory rate of 21% primarily due to remeasurement of certain deferred tax liabilities related to acquired intangible assets and unfavorable changes in the fair value of our equity investment in Galapagos that are non-deductible for income tax purposes, partially offset by provision to return adjustments.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of <ix:nonFraction unitRef="number" contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RleHRyZWdpb246NmE1MjMyZDcwNDE0NDJhNjg4NzA2N2E5NDM1OGI5ZjdfNzcw_c025ce5d-e795-49e3-a0c0-2afca3f67b5d">57.2</ix:nonFraction>% for the three months ended September 30, 2020 differed from the U.S. federal statutory rate of 21% primarily due to certain acquired IPR&amp;D charges and unfavorable changes in the fair value of our equity investment in Galapagos that are non-deductible for income tax purposes, partially offset by a net discrete tax benefit related to a settlement with a taxing authority.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of (<ix:nonFraction unitRef="number" contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RleHRyZWdpb246NmE1MjMyZDcwNDE0NDJhNjg4NzA2N2E5NDM1OGI5ZjdfNzc3_11ee4293-7f5d-47ed-a485-335d9461845d">903.4</ix:nonFraction>)% for the nine months ended September 30, 2020 differed from the U.S. federal statutory rate of 21% primarily due to a non-deductible $<ix:nonFraction unitRef="usd" contextRef="i3ce0a2da343c4d92b5c1b28c7b50805f_D20200401-20200630" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RleHRyZWdpb246NmE1MjMyZDcwNDE0NDJhNjg4NzA2N2E5NDM1OGI5ZjdfODky_ae9960fb-b3a8-4f6f-b977-63462fc13111">4.5</ix:nonFraction>&#160;billion IPR&amp;D charge recorded in connection with our second quarter 2020 acquisition of Forty Seven, in addition to the above mentioned amounts for the three months ended September 30, 2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently under examination by the U.S. Internal Revenue Service for the tax years from 2016 to 2018 and by various state and foreign jurisdictions. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We regularly evaluate our exposures associated with our tax filing positions to determine our assessment of unrecognized tax benefits in accordance with the income tax guidance which clarifies the accounting for uncertainty in income taxes.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. The forward-looking statements are contained principally in this section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Risk Factors.&#8221; Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;project,&#8221; &#8220;hope,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;might,&#8221; and variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, any statements other than statements of historical fact are forward-looking statements, including statements regarding overall trends, operating cost and revenue trends, liquidity and capital needs, collaboration and licensing arrangements, ongoing litigation and investigation matters, statements regarding the anticipated future impact on our business of the ongoing coronavirus disease 2019 (&#8220;COVID-19&#8221;) and related public health measures and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions. We have based these forward-looking statements on our current expectations about future events. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Our actual results may differ materially from those suggested by these forward-looking statements for various reasons, including those identified below under Risk Factors. Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof unless otherwise specified. Except as required under federal securities laws and the rules and regulations of the Securities and Exchange Commission, we do not undertake and specifically decline any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise. In evaluating our business, you should carefully consider the risks described in the section entitled Risk Factors under Part II, Item 1A of this Quarterly Report in addition to the other information in this Quarterly Report on Form&#160;10-Q. Any of the risks contained herein could materially and adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read the following management&#8217;s discussion and analysis of our financial condition and results of operations in conjunction with our audited Consolidated Financial Statements and related notes thereto included as part of our <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm">Annual Report on Form 10-K</a> for the year ended December&#160;31, 2020 and our unaudited Condensed Consolidated Financial Statements for the nine months ended September 30, 2021 and other disclosures (including the disclosures under Part II, Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) included in this Quarterly Report on Form&#160;10-Q. Our Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles and are presented in U.S. dollars.</span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_79"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT OVERVIEW</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of marketed products includes AmBisome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Atripla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biktarvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cayston</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Complera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/Eviplera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Emtriva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Epclusa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Genvoya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Harvoni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(bulevirtide), Hepsera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jyseleca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Letairis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Odefsey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ranexa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Sovaldi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Stribild</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tecartus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tybost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vemlidy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Viread</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vosevi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zydelig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The approval status of Hepcludex and Jyseleca vary worldwide, and Hepcludex and Jyseleca are not approved in the United States. We also sell and distribute authorized generic versions of Epclusa and Harvoni in the United States through our separate subsidiary, Asegua Therapeutics, LLC. In addition, we sell and distribute certain products through our corporate partners under collaborative agreements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Highlights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In October 2021, we entered into a clinical trial collaboration and supply agreement with Merck &amp; Co., Inc. (&#8220;Merck&#8221;) to evaluate the efficacy of Trodelvy in combination with Merck&#8217;s anti-PD-1 therapy, Keytruda, as a first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (&#8220;TNBC&#8221;). </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In October 2021, U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (&#8220;ALL&#8221;). Tecartus is the first and only CAR T cell therapy approved for adults with ALL.</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In September 2021, Kite Pharma Inc. (&#8220;Kite&#8221;), a Gilead Company, submitted a supplemental Biologics License Application to FDA for Yescarta to expand its current indication to include the treatment of adults with relapsed or refractory large B-cell lymphoma in the second-line setting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In September 2021, Health Canada approved Trodelvy for the treatment of adult patients with unresectable TNBC who have received two or more therapies, at least one of them for metastatic disease. Canada joins Australia, Great Britain, Switzerland and the United States among the countries that have approved Trodelvy for use under Project Orbis, a global collaborative review program for high impact oncology marketing applications across participating countries.</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In August 2021, Kite and Appia Bio, Inc. entered into a collaboration and license agreement to research and develop hematopoietic stem cell derived cell therapies directed toward hematological malignancies. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Viral Diseases</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In October 2021, FDA approved a new low-dose tablet dosage form of Biktarvy for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy.</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In August 2021, our Marketing Authorization Application for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, was fully validated and is now under evaluation with the European Medicines Agency.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We announced and discussed these updates, subsequent to the issuance of our Quarterly Report on Form 10-Q for the second quarter of 2021, in further detail in press releases available on our website at www.gilead.com. Readers are also encouraged to review all other press releases available on our website mentioned above. The content on the referenced websites does not constitute a part of and is not incorporated by reference into this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quarterly Financial Highlights</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.825%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,421&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,061&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,268&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings (loss) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues increased by 13% to $7.4 billion for the three months ended September 30, 2021, compared to $6.6 billion for the same period in 2020, primarily due to increased sales of Veklury, our FDA-approved treatment for hospitalized patients with the coronavirus disease 2019 (&#8220;COVID-19&#8221;).</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to Gilead was $2.6 billion, or $2.05 diluted earnings per share, for the three months ended September 30, 2021, compared to $360 million, or $0.29 for the same period in 2020. The change was primarily due to lower acquired in-process research and development (&#8220;IPR&amp;D&#8221;) charges, revenue growth and a decrease in unrealized losses from our equity investments primarily in Galapagos NV (&#8220;Galapagos&#8221;). Our IPR&amp;D expenses for the three months ended September 30, 2020 were $1.2 billion and related to our collaborations and other investments with Arcus Biosciences, Inc. (&#8220;Arcus&#8221;), Pionyr Immunotherapeutics, Inc. (&#8220;Pionyr&#8221;), Tango Therapeutics (&#8220;Tango&#8221;) and Tizona Therapeutics, Inc. (&#8220;Tizona&#8221;). Our IPR&amp;D expenses for the three months ended September 30, 2021 were not material.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our revenues:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HCV</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HBV/HDV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,493&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,848&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,027&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,061&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,268&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">For the three months ended September 30, 2021 compared to the three months ended September 30, 2020</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Total Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total product sales increased by 13% to $7.4 billion for the three months ended September 30, 2021, compared to $6.5 billion for the same period in 2020, primarily due to increased sales of Veklury. The three months ended September 30, 2021 also reflects the continued growth of Biktarvy and the continued uptake of Trodelvy in the United States and Cell Therapy products in the United States and Europe. We obtained Trodelvy through the fourth quarter 2020 acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;). The increases were partially offset by lower HIV product sales, as expected, primarily due to the continued generic competition following the October 2020 loss of exclusivity of Truvada and Atripla in the United States.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HIV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIV product sales decreased by 8% to $4.2 billion for the three months ended September 30, 2021, compared to $4.5 billion for the same period in 2020. The decline was primarily due to the anticipated decline in sales volume of our Truvada (emtricitabine (&#8220;FTC&#8221;) and tenofovir disoproxil fumarate (&#8220;TDF&#8221;))-based products driven by the continued generic competition following the October 2020 loss of exclusivity of Truvada and Atripla in the United States. Truvada and Atripla product sales were $528 million lower for the three months ended September 30, 2021, compared to the same period in 2020. The decrease was also impacted by lower channel inventory, primarily driven by pandemic-related stocking as compared to the same period in 2020 as well as lower sales of Descovy driven by lower average net selling price and lower sales of Genvoya driven by volume. The decline was partially offset by an increase in Biktarvy product sales driven by higher demand and higher average net selling price. We expect Truvada sales to continue to decline for the remainder of 2021 and beyond as multiple generics are expected to enter the market.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to impact our HIV business. In the United States, as anticipated, we continued to see a modest recovery in the HIV treatment market volume in the third quarter of 2021; however, it may take several quarters for the U.S. treatment market to return to pre-pandemic levels.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HCV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HCV product sales decreased by 8% to $429 million for the three months ended September 30, 2021, compared to $464 million for the same period in 2020, primarily driven by fewer patient starts due to the impact of the COVID-19 pandemic and lower average net selling price.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hepatitis B Virus (&#8220;HBV&#8221;) / Hepatitis Delta Virus (&#8220;HDV&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HBV and HDV product sales increased by 17% to $247 million for the three months ended September 30, 2021, compared to $211 million for the same period in 2020, primarily due to higher Vemlidy sales volume driven by increased demand primarily in geographies outside the United States. Hepcludex sales were $12 million as launch activities continued across Europe following our first quarter 2021 acquisition of MYR GmbH (&#8220;MYR&#8221;).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Veklury</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veklury product sales were $1.9 billion for the three months ended September 30, 2021, compared to $873 million for the same period in 2020. The increase was primarily due to higher hospital demand consistent with the recent surge in COVID-19 cases. While sales of Veklury are generally affected by, among other things, COVID-19 related rates of infections, hospitalizations and vaccinations, and will continue to be subject to significant volatility and uncertainty, we expect Veklury sales to reduce significantly in the fourth quarter of 2021 as hospitalization rates decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cell Therapy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell Therapy product sales increased by 51% to $222 million for the three months ended September 30, 2021, compared to $147 million for the same period in 2020, primarily due to the continued demand of Yescarta for the treatment of relapsed or refractory large B-cell lymphoma and strong uptake in relapsed or refractory indolent follicular lymphoma in the United States and Europe. The increase was also driven by higher Tecartus sales volume for the treatment of mantle cell lymphoma in the United States and Europe.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trodelvy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trodelvy product sales were $101 million in the United States and Europe for the three months ended September 30, 2021, following the full FDA approval for second-line metastatic TNBC and accelerated approval for metastatic urothelial cancer both in April 2021. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other product sales, which include AmBisome, Cayston, Jyseleca, Letairis, Ranexa and Zydelig, decreased by 2% to $245 million for the three months ended September 30, 2021, compared to $251 million for the same period in 2020, primarily due to lower Letairis sales, as anticipated, due to continued generic competition following the loss of exclusivity in 2019, partially offset by higher AmBisome sales volume driven by higher demand in geographies outside the United States.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Sales by Geographic Area</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our total product sales, 26% and 22% were generated outside the United States for the three months ended September 30, 2021 and 2020, respectively. We generally face exposure to movements in foreign currency exchange rates, primarily in the Euro. We use foreign currency exchange contracts to hedge a portion of our foreign currency exposures. Foreign currency exchange, net of hedges, had an immaterial impact on our product sales for the three months ended September 30, 2021, based on a comparison using foreign currency exchange rates from the three months ended September 30, 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales in the United States increased by 8% to $5.5 billion for the three months ended September 30, 2021, compared to $5.1 billion for the same period in 2020, primarily due to increased sales of Veklury as well as the continued growth of Biktarvy, and the continued uptake of Trodelvy and Cell Therapy products. The increases were partially offset by the loss of exclusivity in 2020 of Truvada and Atripla, as expected, and lower sales of Letairis, as anticipated, due to the loss of exclusivity in 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales in Europe increased by 14% to $997 million for the three months ended September 30, 2021, compared to $877 million for the same period in 2020, primarily due to the continued growth of Biktarvy, increased sales of Veklury and higher Cell Therapy sales driven by continued growth of Yescarta and Tecartus. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales in other locations increased by 63% to $880 million for the three months ended September 30, 2021, compared to $540 million for the same period in 2020, primarily due to higher sales volumes of Veklury, AmBisome, Biktarvy and Vemlidy.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">For the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Total Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total product sales increased by 17% to $19.8 billion for the nine months ended September 30, 2021, compared to $17.0 billion for the same period in 2020, primarily</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to increased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales of Veklury. The nine months ended September 30, 2021 also reflects the continued growth of Biktarvy in all geographies and the continued uptake of Trodelvy and Cell Therapy and HBV/HDV products. The increases were partially offset by a decline in HIV product sales, as well as lower HCV product sales driven by fewer patient starts. The decrease in HIV product sales, as expected, was primarily due to the continued generic competition following the October 2020 loss of exclusivity of Truvada and Atripla in the United States.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HIV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIV product sales decreased by 7% to $11.8 billion for the nine months ended September 30, 2021, compared to $12.7 billion for the same period in 2020, primarily due to the anticipated decline in sales volume of our Truvada (FTC/TDF)-based products driven by the continued generic competition following the October 2020 loss of exclusivity of Truvada and Atripla in the United States. Truvada and Atripla product sales were $1.2 billion lower for the nine months ended September 30, 2021, compared to the same period in 2020. The decrease was also impacted by lower sales of Descovy driven by lower average net selling price and lower sales of Genvoya driven by volume. The decline was partially offset by an increase in Biktarvy product sales driven by higher demand.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HCV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HCV product sales decreased by 9% to $1.5 billion for the nine months ended September 30, 2021, compared to $1.6 billion for the same period in 2020, primarily due to fewer patient starts.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HBV/HDV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HBV and HDV product sales increased by 14% to $704 million for the nine months ended September 30, 2021, compared to $616 million for the same period in 2020, primarily due to higher Vemlidy sales volume. The nine months ended September 30, 2021 also reflects $25 million of Hepcludex sales following the completion of our first quarter 2021 acquisition of MYR.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Veklury</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veklury product sales were $4.2 billion for the nine months ended September 30, 2021, compared to $873 million for the same period in 2020. The increase was primarily due to higher hospital demand. Veklury became commercially available in the third quarter of 2020 resulting in partial year sales for the nine months ended September 30, 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cell Therapy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell Therapy product sales increased by 42% to $632 million for the nine months ended September 30, 2021, compared to $444 million for the same period in 2020, primarily due to higher sales volume of Yescarta and Tecartus in the United States and Europe.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trodelvy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trodelvy product sales were $262 million in the United States and Europe for the nine months ended September 30, 2021, following the completion of our fourth quarter 2020 acquisition of Immunomedics.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other product sales, which include AmBisome, Cayston, Jyseleca, Letairis, Ranexa and Zydelig, increased by 1% to $777 million for the nine months ended September 30, 2021, compared to $772 million for the same period in 2020. The increase was primarily due to higher AmBisome sales volume driven by higher demand in geographies outside the United States, partially offset by lower Letairis sales, as anticipated, due to continued generic competition following the loss of exclusivity in 2019.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Sales by Geographic Area</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our total product sales, 30% and 25% were generated outside the United States for the nine months ended September 30, 2021 and 2020, respectively. We generally face exposure to movements in foreign currency exchange rates, primarily in the Euro. We use foreign currency exchange contracts to hedge a portion of our foreign currency exposures. Foreign currency exchange, net of hedges, had a favorable impact on our product sales of $160 million for the nine months ended September 30, 2021, based on a comparison using foreign currency exchange rates from the nine months ended September 30, 2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales in the United States increased by 9% to $13.9 billion for the nine months ended September 30, 2021, compared to $12.8 billion for the same period in 2020, primarily due to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales of Veklury, the growth of Biktarvy, the continued uptake of Trodelvy, and the continued growth of Cell Therapy products. The increases were partially offset by the loss of exclusivity of Truvada and Atripla, as expected, the anticipated decline in sales volume of Letairis following the loss of exclusivity in 2019 and lower HCV sales driven by lower demand.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales in Europe increased by 35% to $3.4 billion for the nine months ended September 30, 2021, compared to $2.5 billion for the same period in 2020, primarily due to increased sales of Veklury, the continued growth of Biktarvy, higher AmBisome sales driven by higher demand, and the continued growth of Cell Therapy products. HCV sales volume decreased due to the impact of the COVID-19 pandemic, partially offset by a favorable government rebate adjustment. Foreign currency exchange, net of hedges, had a favorable impact on our Europe product sales of $101 million for the nine months ended September 30, 2021, based on a comparison using foreign currency exchange rates from the nine months ended September 30, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales in other locations increased by 50% to $2.5 billion for the nine months ended September 30, 2021, compared to $1.7 billion for the same period in 2020, primarily due to higher sales volumes of Veklury, Biktarvy, Vemlidy and AmBisome, partially offset by lower HCV sales volume.</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our product sales: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">HIV Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Descovy (FTC/TAF) Based Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biktarvy &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biktarvy &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biktarvy &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,891&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,094&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,188&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genvoya &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genvoya &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genvoya &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Odefsey &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Odefsey &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Odefsey &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue share &#8211; Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue share &#8211; Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue share &#8211; Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Descovy (FTC/TAF) Based Products &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Descovy (FTC/TAF) Based Products &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Descovy (FTC/TAF) Based Products &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,982&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,800&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,986&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,647&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Truvada (FTC/TDF) Based Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Atripla &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Atripla &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Atripla &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complera / Eviplera &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complera / Eviplera &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complera / Eviplera &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stribild &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stribild &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stribild &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Truvada (FTC/TDF) Based Products &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Truvada (FTC/TDF) Based Products &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Truvada (FTC/TDF) Based Products &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,985&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HIV &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HIV &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HIV &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,189&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,547&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,777&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,681&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">HCV Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ledipasvir / Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ledipasvir / Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ledipasvir / Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(38)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sofosbuvir / Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sofosbuvir / Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sofosbuvir / Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,229&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HCV &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HCV &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HCV &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">HBV/HDV Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vemlidy &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vemlidy &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vemlidy &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viread &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viread &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viread &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HBV/HDV &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HBV/HDV &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HBV/HDV &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Veklury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Veklury &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Veklury &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Veklury &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,923&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,208&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Cell Therapy Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tecartus &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tecartus &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yescarta &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yescarta &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yescarta &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Cell Therapy &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Cell Therapy &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Cell Therapy &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trodelvy </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trodelvy &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trodelvy&#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Other Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmBisome &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmBisome &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmBisome &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Letairis &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ranexa &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Zydelig &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Zydelig &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Zydelig &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Other &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Other &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Other &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product sales &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product sales &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product sales &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,356&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,493&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,848&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,027&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs and Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our costs and expenses:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,974&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,174&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Product gross margin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">83.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">82.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">100 bps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">-140 bps</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (&#8220;R&amp;D&#8221;) expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold and Product Gross Margin</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold for the three and nine months ended September 30, 2021 increased by $82 million and $800 million, or 7% and 25%, respectively, compared to the same periods in 2020, primarily due to higher acquisition-related expenses from amortization of finite-lived intangible assets and inventory step-up charges driven by our acquisitions of Immunomedics and MYR, as well as higher product sales and inventory reserves. The increases were partially offset by the reversal of a previously recorded $175 million litigation reserve following a favorable court decision and a decrease in royalty expenses primarily due to lower sales of products containing emtricitabine and elvitegravir.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross margin for the three months ended September 30, 2021, compared to the same period in 2020, increased primarily due to the reversal of the aforementioned previously recorded litigation reserve following a favorable court decision, lower royalty expenses and change in product mix, partially offset by higher amortization expense of finite-lived intangible assets.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross margin for the nine months ended September 30, 2021, compared to the same period in 2020, decreased primarily due to higher amortization expense of finite-lived intangible assets, partially offset by lower royalty expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of clinical studies performed by contract research organizations, materials and supplies, payments related to collaborative and other arrangements including milestone payments, licenses and fees, expense reimbursements to the collaboration partners, personnel costs including salaries, benefits and stock-based compensation expense, and overhead allocations including various support and infrastructure costs.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track total R&amp;D expenses by product candidate, therapeutic area or development phase. However, we manage our R&amp;D expenses by identifying the R&amp;D activities we anticipate will be performed during a given period and then prioritizing efforts based on scientific data, probability of technical and regulatory successful development, market potential, available human and capital resources and other considerations. We continually review our R&amp;D projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities that we believe will best support the long-term growth of our business.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a period-over-period breakout of our R&amp;D expenses by major cost type:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical studies and outside services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel, infrastructure and other expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,336&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,461&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses for the three and nine months ended September 30, 2021 decreased by 1% and 4%, respectively, compared to the same periods in 2020, primarily due to lower expenses largely driven by wind-down or completion of certain remdesivir and inflammation related clinical programs, partially offset by higher investments in Trodelvy and magrolimab clinical activities. R&amp;D expenses for the nine months ended September 30, 2020 included stock-based compensation expense related to our second quarter 2020 acquisition of Forty Seven, Inc. (&#8220;Forty Seven&#8221;). </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expenses reflect IPR&amp;D impairments as well as the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront and other payments related to various collaborations and the initial costs of rights to IPR&amp;D projects. IPR&amp;D assets capitalized are tested for impairment in the fourth quarter of each year, or earlier if impairment indicators exist. No IPR&amp;D impairment charges were recorded during the three and nine months ended September 30, 2021 and 2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expenses of $19 million and $177 million for the three and nine months ended September 30, 2021, respectively, were related to licensing, collaboration, investment and other arrangements we entered into during the periods. Acquired IPR&amp;D expenses of $1.2 billion for the three months ended September 30, 2020 included charges related to our collaborations and other investments we entered into during the quarter with Arcus, Pionyr, Tango and Tizona. Acquired IPR&amp;D expenses of $5.8 billion for the nine months ended September 30, 2020 also included a $4.5 billion charge recorded in connection with the second quarter 2020 acquisition of Forty Seven. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses relate to sales and marketing, finance, human resources, legal and other administrative activities, including information technology investments. Expenses consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses and other general and administrative costs. SG&amp;A expenses also include the branded prescription drug fee. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses for the three months ended September 30, 2021 increased by $84 million or 8%, compared to the same period in 2020, primarily due to higher promotional and marketing activities across all geographies, partially offset by lower commercial activities in inflammation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses for the nine months ended September 30, 2021, increased by $175 million or 5%, compared to the same period in 2020, primarily due to an expense of $212&#160;million related to the donation of certain equity securities at fair value to the Gilead Foundation, a California nonprofit organization (the &#8220;Foundation&#8221;), during the second quarter of 2021. SG&amp;A expenses for nine months ended September 30, 2020 included a second quarter 2020 charge of $97&#160;million related to a Department of Justice investigation, which settled in the third quarter of 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense), Net and Interest Expense</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our Other income (expense), net and Interest expense:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(940)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(696)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(848)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Other income (expense), net for the three and nine months ended September 30, 2021, compared to the same periods in 2020, primarily reflect a decrease in unrealized losses from fair value adjustments of our investments in equity securities largely driven by our investment in Galapagos, partially offset by lower interest income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three and nine months ended September 30, 2021 increased by $14 million and $46 million, or 6% and 6%, respectively, compared to the same periods in 2020, primarily due to an increase in borrowing related to the fourth quarter 2020 acquisition of Immunomedics, partially offset by favorable effects from debt maturities and repayments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our Income tax expense:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,438&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,519&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7,664&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate and provision differed for the three months ended September 30, 2021, compared to the same period in 2020, primarily due to certain acquired IPR&amp;D charges and unfavorable changes in the fair value of our equity investment in Galapagos that are non-deductible for income tax purposes, recorded in the three months ended September 30, 2020.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our effective tax rate and provision differed for the nine months ended September 30, 2021, compared to the same period in 2020, primarily due to a non-deductible $4.5 billion IPR&amp;D charge recorded in connection with our second quarter 2020 acquisition of Forty Seven, in addition to the above mentioned amounts for the three months ended September 30, 2020.</span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_85"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing capital resources, supplemented by our cash flows generated from operating activities, will be adequate to satisfy our capital needs for the foreseeable future.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash, cash equivalents and marketable debt securities and working capital:</span></div><div style="margin-bottom:6pt;margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,837&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,910&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,599&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable debt securities as of September 30, 2021 decreased by $1.1 billion, or 14%, compared to December&#160;31, 2020. During the nine months ended September 30, 2021, we generated $8.2 billion in operating cash flow, made debt repayments of $3.75 billion, utilized $1.2 billion for our first quarter 2021 acquisition of MYR, paid cash dividends of $2.7 billion, utilized $497 million on open market repurchases of our common stock and had additional investing cash outlays of approximately $1.1 billion.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital, which is current assets less current liabilities, decreased by $853 million, or 19%, compared to December&#160;31, 2020, primarily due to the utilization of cash, cash equivalents and marketable debt securities and other activities as noted above.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable decreased by $326 million, compared to December&#160;31, 2020, primarily due to collections of Veklury receivables during the nine months ended September 30, 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities decreased by $555 million compared to December&#160;31, 2020, primarily reflecting the timing of accruals and payments, as well as estimated and transition tax payments made to taxing authorities during the nine months ended September 30, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activities:</span></div><div style="margin-bottom:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:75.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by (used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,853)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,638)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,935)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities represents the cash receipts and disbursements related to all activities other than investing and financing activities. Operating cash flow is derived by adjusting our net income for non-cash items and changes in operating assets and liabilities. Cash provided by operating activities increased by $1.9 billion to $8.2 billion for the nine months ended September 30, 2021, compared to the same period in 2020. The increase was primarily due to revenue growth from sales of Veklury as well as higher collections of receivables during the nine months ended September 30, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities primarily consists of purchases, sales and maturities of our marketable debt securities, capital expenditures, acquisitions, including IPR&amp;D, net of cash acquired, purchases of equity securities and other investments. Cash used in investing activities decreased by $2.8 billion to $2.9 billion for the nine months ended September 30, 2021, compared to the same period in 2020. The change in cash used in investing activities was primarily due to $1.2 billion of payments made for our first quarter 2021 acquisition of MYR, compared to $4.7 billion of payments made for our second quarter 2020 acquisition of Forty Seven.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities for the nine months ended September 30, 2021 was $6.9 billion, compared to cash provided by financing activities of $639&#160;million for the same period in 2020. During the nine months ended September 30, 2021, we utilized cash for $3.8 billion debt repayments, $2.7 billion dividend payments and $497&#160;million common stock repurchases. During the nine months ended September 30, 2020, we obtained $7.2 billion in proceeds from the September 2020 senior unsecured notes offering, net of issuance costs, in anticipation of our fourth quarter 2020 Immunomedics acquisition, partially offset by cash utilized for $2.6 billion dividend payments, $2.5 billion debt repayments and $1.6 billion common stock repurchases. In October 2021, the Board of Directors declared a quarterly dividend of $0.71 per share of common stock, which is payable in December 2021. Future dividends will be subject to Board approval.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt and Credit Facilities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our borrowings under various financing arrangements is included in Note 10. Debt and Credit Facilities of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q. We may choose to repay certain of our long-term debt obligations prior to maturity dates based on our assessment of current and long-term liquidity and capital requirements.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, we repaid $3.75 billion of debt. We repaid $1.0 billion of senior unsecured notes due April 2021 in the first quarter of 2021 and $1.25 billion of senior unsecured notes due December 2021 in the third quarter of 2021. Additionally, we repaid $1.0 billion principal amount outstanding under our three-year $1.0 billion senior unsecured term loan facility due October 2023 and $500 million of our senior unsecured floating rate notes due September 2021 upon maturity. In October 2021, we exercised our option to call $500 million of our floating rate senior unsecured notes and $500 million of our 0.75% senior unsecured notes, both having a final maturity of September 2023. The notes will be repaid in November 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No new debt was issued during the three and nine months ended September 30, 2021. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of September&#160;30, 2021, we were in compliance with all covenants.</span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_88"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES, ESTIMATES AND JUDGMENTS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our Condensed Consolidated Financial Statements in accordance with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts in the financial statements and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing COVID-19 pandemic could have on our significant accounting estimates. Actual results may differ significantly from these estimates. A summary of our critical accounting policies and estimates is presented in Part II, Item 7 of our <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm">Annual Report on Form 10-K</a> for the year ended December&#160;31, 2020. There were no material changes to our critical accounting policies and estimates during the nine months ended September 30, 2021.</span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_91"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.</span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_94"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements issued nor adopted during the nine months ended September 30, 2021 that are of significance to us.</span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_97"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6. Acquisitions and Note 9. Collaborations and Other Arrangements of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q for additional information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our market risk during the three and nine months ended September 30, 2021 compared to the disclosures in Part II, Item 7A of our <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm">Annual Report on Form 10-K</a> for the year ended December&#160;31, 2020.</span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_103"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation as of September&#160;30, 2021 was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our &#8220;disclosure controls and procedures,&#8221; which are defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), as controls and other procedures of a company that are designed to ensure that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September&#160;30, 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, has evaluated any changes in our internal control over financial reporting that occurred during the quarter ended September&#160;30, 2021, and has concluded that there was no change during such quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on the Effectiveness of Controls</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_109"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant pending legal proceedings, please see Note 11. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q. </span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_112"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. &#160;&#160;&#160;&#160;RISK FACTORS </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In evaluating our business, you should carefully consider the following discussion of material risks, events and uncertainties that make an investment in us speculative or risky in addition to the other information in this Quarterly Report on Form 10-Q. A manifestation of any of the following risks and uncertainties could, in circumstances we may or may not be able to accurately predict, materially and adversely affect our business and operations, growth, reputation (including the commercial or scientific reputation of our products), prospects, product pipeline and sales, operating and financial results, financial condition, cash flows, liquidity and stock price. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. It is not possible to predict or identify all such factors; our operations could also be affected by factors, events or uncertainties that are not presently known to us or that we currently do not consider to present significant risks to our operations. Therefore, you should not consider the following risks to be a complete statement of all the potential risks or uncertainties that we face.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product and Commercialization Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain of our products subject us to additional or heightened risks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HIV Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a substantial portion of our revenue from sales of our products for the treatment and prevention of HIV infection. During the nine months ended September 30, 2021, sales of our HIV products accounted for approximately 59% of our total product sales. We may be unable to sustain or increase sales of our HIV products for any number of reasons, including market share gains by competitive products, including generics, or the inability to introduce new HIV medications necessary to remain competitive. In such case, we may need to scale back our operations, including our future drug development and spending on research and development (&#8220;R&amp;D&#8221;) efforts. For example, most of our HIV products contain tenofovir alafenamide (&#8220;TAF&#8221;), tenofovir disoproxil fumarate (&#8220;TDF&#8221;) and/or emtricitabine (&#8220;FTC&#8221;), which belong to the nucleoside class of antiviral therapeutics, and any changes to the treatment paradigm for HIV may cause nucleoside-based therapeutics to fall out of favor.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Veklury</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks related to our supply and distribution of Veklury, which was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in October 2020 as a treatment for hospitalized patients with COVID-19. While the utilization of Veklury has largely tracked rates of COVID-19 infections, hospitalizations and vaccinations, we are unable to accurately predict our revenues or supply needs over the short and long term due to the dynamic nature of the pandemic, including the potential for new and better therapeutics, the availability, uptake and effectiveness of vaccines, fluctuating hospital utilization rates and the emergence of new variants. If we are unable to accurately forecast demand or manufacture Veklury at levels to meet actual demand, then this may result in shortages or excess inventory that may be written off. We also remain subject to significant public attention and scrutiny over the complex decisions made regarding the clinical data, allocation, distribution and pricing of Veklury, all of which affects our corporate reputation. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cell Therapy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advancing a novel and personalized therapy such as Yescarta or Tecartus, which are Chimeric Antigen Receptor (&#8220;CAR&#8221;) T cell therapies, creates significant challenges, including:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">educating and certifying medical personnel regarding the procedures and the potential side effects, such as cytokine release syndrome and neurologic toxicities, in compliance with the Risk Evaluation and Mitigation Strategy program required by FDA;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">securing sufficient supply of other medications to manage side effects, such as tocilizumab and corticosteroids, which may not be available in sufficient quantities, may not adequately control the side effects and/or may have detrimental impacts on the efficacy of cell therapy;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and maintaining a robust and reliable process for engineering a patient&#8217;s T cells in our facilities and infusing them back into the patient; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditioning patients with chemotherapy in advance of administering our therapy, which may increase the risk of adverse side effects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of engineered T cells as a potential cancer treatment is a recent development and may not be broadly accepted by physicians, patients, hospitals, cancer treatment centers, payers and others in the medical community. We may not be able to demonstrate to the medical community and payers the potential advantages of cell therapy compared to existing and future therapeutics. For challenges related to the reimbursement of Yescarta and Tecartus, see also &#8220;Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party sites to collect patients&#8217; white blood cells, known as apheresis centers, as well as shippers, couriers, and hospitals for the logistical collection of patients&#8217; white blood cells and ultimate delivery of Yescarta or Tecartus to patients. These vendors may encounter disruptions or difficulties that could result in product loss and regulatory action. Apheresis centers may also choose not to participate in our quality certification process, or we may be unable to complete such certification in a timely manner or at all, which could delay or constrain our manufacturing and commercialization efforts.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our success depends on developing and commercializing new products or expanding the indications for existing products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to launch commercially successful new products or new indications for existing products our business will be adversely impacted. The launch of commercially successful products is necessary to grow our business, cover our substantial R&amp;D expenses, and offset revenue losses when existing products lose market share due to factors such as competition and loss of patent exclusivity. There are many difficulties and uncertainties inherent in drug development and the introduction of new products. The product development cycle is characterized by significant investments of resources, long lead times and unpredictable outcomes due to the nature of developing medicines for human use. We expend significant time and resources on our product pipeline without any assurance that we will recoup our investments or that our efforts will be commercially successful. A high rate of failure is inherent in the discovery and development of new products, and failure can occur at any point in the process, including late in the process after substantial investment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to accurately predict demand for our products, including the uptake of new products, as demand depends on a number of factors. For example, product demand may be adversely affected if physicians do not see the benefit of our products. Additionally, the non-retail sector in the United States, which includes government institutions, including state AIDS Drug Assistance Programs, the U.S. Department of Veterans Affairs, correctional facilities and large health maintenance organizations, tends to be less consistent in terms of buying patterns and often causes quarter-over-quarter fluctuations that do not necessarily mirror patient demand for our products. Federal and state budget pressures, as well as the annual grant cycles for federal and state funds, may cause purchasing patterns to not reflect patient demand for our products. We expect to continue to experience fluctuations in the purchasing patterns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe. We believe these measures have caused some government agencies and other purchasers to reduce inventory of our products in the distribution channels. We may continue to see this trend in the future. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell and distribute most of our products in the United States exclusively through the wholesale channel. For the nine months ended September 30, 2021, approximately 92% of our product sales in the United States were to three wholesalers, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Corporation. The U.S. wholesalers with whom we have entered into inventory management agreements make estimates to determine end user demand and may not be completely effective in matching their inventory levels to actual end user demand. As a result, changes in inventory levels held by those wholesalers can cause our operating results to fluctuate unexpectedly if our sales to these wholesalers do not match end user demand. In addition, inventory is held at retail pharmacies and other non-wholesaler locations with whom we have no inventory management agreements and no control over buying patterns. Adverse changes in economic conditions, increased competition or other factors may cause retail pharmacies to reduce their inventories of our products, which would reduce their orders from wholesalers and, consequently, the wholesalers&#8217; orders from us, even if end user demand has not changed. In addition, we have observed that strong wholesaler and sub-wholesaler purchases of our products in the fourth quarter typically results in inventory draw-down by wholesalers and sub-wholesalers in the subsequent first quarter. As inventory in the distribution channel fluctuates from quarter to quarter, we may continue to see fluctuations in our earnings and a mismatch between prescription demand for our products and our revenues. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face significant competition from global pharmaceutical and biotechnology companies, specialized pharmaceutical firms and generic drug manufacturers.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New branded or generic products entering major markets affects our ability to maintain pricing and market share. Our products compete with other available products based primarily on efficacy, safety, tolerability, acceptance by doctors, ease of patient compliance, ease of use, price, insurance and other reimbursement coverage, distribution and marketing. A number of companies are pursuing the development of technologies which are competitive with our existing products or research programs. These competing companies include large pharmaceutical and biotechnology companies and specialized pharmaceutical firms acting either independently or together with other such companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection or may establish collaborative arrangements for competitive products or programs. We may be adversely impacted if any of these competitors gain market share as a result of new technologies, commercialization strategies or otherwise.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Reimbursements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful commercialization of our products depends, in part, on the availability of third-party payer reimbursement for the cost of such products and related treatments and medical services in the markets where we sell our products. Government health authorities, private health insurers and other organizations generally provide reimbursement. As our products mature, private insurers and government payers often reduce the amount they will reimburse patients for these products, which increases pressure on us to reduce prices. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory actions affecting government prescription drug procurement and reimbursement programs occur relatively frequently. For example, in September 2020, FDA issued a final rule implementing a pathway for the importation of certain prescription drugs from Canada. This rule is subject to ongoing litigation. In addition, in November 2020, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) issued an interim final rule that would substantially alter the Medicare Part B reimbursement system for physician-administered medicines as of January 1, 2021. This rule is subject to ongoing litigation and CMS has been preliminarily enjoined from implementing the rule. We may be adversely impacted by any such legislative and regulatory actions, though it is difficult to predict the impact, if any, on the use and reimbursement of our products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Pricing, Discounts and Rebates</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the European Union and other significant or potentially significant markets for our products and product candidates, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services. In the United States, the volume of drug pricing-related bills has dramatically increased in recent years. For example, Congress has proposed bills to require the Department of Health and Human Services to negotiate prices for certain drugs, change the Medicare Part B and D benefit to impose an inflation-based rebate when list prices for drugs grow faster than inflation, increase manufacturer contributions in some or all of the Medicare Part D benefit phases and require manufacturer refunds on discarded drug from single-use vials. In addition, many state legislatures are considering, or have already passed into law, legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as requiring manufacturers to publicly report proprietary pricing information, creating review boards for prices to state agencies, and encouraging the use of generic drugs. Such initiatives and legislation may cause added pricing pressures on our products, and the resulting impact on our business is uncertain. Many countries outside the United States, including the European Union member states, have established complex and lengthy procedures to obtain price approvals, coverage reimbursement and periodically review their pricing and reimbursement decisions. The outcome of this review cannot be predicted and could have an adverse effect on the pricing and reimbursement of our medicinal products in the European Union member states. Reductions in the pricing of our medicinal products in one member state could affect the price in other member states and have a negative impact on our financial results. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our product sales is subject to significant discounts from list price, including rebates that we may be required to pay state Medicaid agencies and discounts provided to 340B covered entities. Changes to the 340B program or the Medicaid program at the federal or state level could have a material adverse effect on our business. For example, in December 2020, CMS issued a final rule that will make certain changes to the calculation of rebates under the Medicaid Drug Rebate Program. Among other changes, effective January 1, 2023, the final rule will change the requirements for excluding manufacturer co-pay coupons from the Medicaid &#8220;best price.&#8221; These changes are subject to ongoing litigation. If these changes go into effect, they could substantially increase our Medicaid rebate obligations and decrease the prices we charge 340B covered entities. The continued growth of the 340B program also limits the prices we may charge on an increasing percentage of sales.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, standard reimbursement structures may not adequately reimburse for innovative therapies. For example, beginning in fiscal year 2021, CMS established a new severity adjusted diagnosis related group (&#8220;DRG&#8221;) 018 for Medicare inpatient reimbursement of CAR T products such as Yescarta and Tecartus. While the new DRG has a significantly higher base payment amount than the prior DRG 016, the payment available may not be sufficient to reimburse some hospitals for their cost of care for patients receiving Yescarta and Tecartus. When reimbursement is not aligned well to account for treatment costs, Medicare beneficiaries may be denied access as this misalignment could impact the willingness of some hospitals to offer the therapy and of doctors to recommend the therapy. Additionally, in the European Union, there are barriers to reimbursement in individual countries that could limit the uptake of Yescarta and Tecartus.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we estimate the rebates we will be required to pay in connection with sales during a particular quarter based on claims data from prior quarters. In the United States, actual rebate claims are typically made by payers one to three quarters in arrears. Actual claims and payments may vary significantly from our estimates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may experience adverse impacts resulting from imports from countries where our products are available at lower prices or the unlawful distribution of generic or counterfeit versions of our products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices for our products are based on local market economics and competition and sometimes differ from country to country. Our sales in countries with relatively higher prices may be reduced if products can be imported and resold into those countries from lower price markets. For example, U.S. sales could also be affected if FDA permits importation of drugs from Canada. We have entered into agreements with generic drug manufacturers as well as licensing agreements with the Medicines Patent Pool, a United Nations-backed public health organization, which allows generic drug manufacturers to manufacture generic versions of certain of our products for distribution in certain low- and middle-income countries. We may be adversely affected if any generic versions of our products, whether or not produced and/or distributed under these agreements, are exported to the United States, Europe or markets with higher prices. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, we are required to permit products purchased in one European Union member state to be sold in another member state. Purchases of our products in countries where our selling prices are relatively low for resale in countries in which our selling prices are relatively high can affect the inventory level held by our wholesalers and can cause the relative sales levels in the various countries to fluctuate from quarter to quarter and not reflect the actual consumer demand in any given quarter. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, diverted products may be used in countries where they have not been approved and patients may source the diverted products outside the legitimate supply chain. These diverted products may be handled, shipped and stored inappropriately, which may affect the efficacy of the products and could harm patients, and adversely impact us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also aware of the existence of various &#8220;Buyers Clubs&#8221; around the world that promote the personal importation of our products and generic versions of our products that have not been approved for use in the countries into which they are imported. As a result, patients may be at risk of taking unapproved medications that may not be what they purport to be, may not have the potency they claim to have or may contain harmful substances, which could adversely impact us. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, third parties have illegally distributed and sold, and may continue to illegally distribute and sell, illegally diverted and counterfeit versions of our medicines, which do not meet the rigorous quality standards of our manufacturing and supply chain. Illegally diverted and counterfeit medicines pose a serious risk to patient health and safety and may raise the risk of product recalls. Our actions to stop or prevent the distribution and sale of illegally diverted and counterfeit versions of our medicines around the world may be costly and not successful, which may adversely affect our business, including our product revenues and financial results.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product Development and Supply Chain Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to demonstrate the safety and efficacy of products that we develop for each intended use through extensive preclinical studies and clinical trials. The results from preclinical and early clinical studies do not always accurately predict results in later, large-scale clinical trials. Even successfully completed large-scale clinical trials may not result in marketable products. If any of our product candidates fails to achieve its primary endpoint in clinical trials, if safety issues arise or if the results from our clinical trials are otherwise inadequate to support regulatory approval of our product candidates, commercialization of that product candidate could be delayed or halted. In addition, we may also face challenges in clinical trial protocol design.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be adversely impacted if the clinical trials for any of the product candidates in our pipeline are delayed or terminated. We face numerous risks and uncertainties with our product candidates that could prevent completion of development of these product candidates. These risks include our ability to enroll patients in clinical trials, the possibility of unfavorable results of our clinical trials, the need to modify or delay our clinical trials or to perform additional trials and the risk of failing to obtain FDA and other regulatory agency approvals. As a result, our product candidates may never be successfully commercialized. Further, we may make a strategic decision to discontinue development of our product candidates if, for example, we believe commercialization will be difficult relative to other opportunities in our pipeline. We may be adversely impacted if we do not have favorable results from clinical studies and other programs in our pipeline cannot be completed on a timely basis or at all. In addition, clinical trials involving our commercial products could raise new safety issues for our existing products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we extensively outsource our clinical trial activities and usually perform only a small portion of the start-up activities in-house. We rely on independent third-party contract research organizations (&#8220;CROs&#8221;) to perform most of our clinical studies, including document preparation, site identification, screening and preparation, pre-study visits, training, program management, patient enrollment, ongoing monitoring, site management and bioanalytical analysis. Many important aspects of the services performed for us by the CROs are out of our direct control. If there is any dispute or disruption in our relationship with our CROs, our clinical trials may be delayed. Moreover, in our regulatory submissions, we rely on the quality and validity of the clinical work performed by third-party CROs. If any of our CROs&#8217; processes, methodologies or results were determined to be invalid or inadequate, our own clinical data and results and related regulatory approvals may be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products, which are manufactured at our own facilities or by third-party manufacturers and corporate partners, are the result of complex, highly regulated manufacturing processes. We depend on third-party manufacturers and corporate partners to perform manufacturing activities effectively and on a timely basis for the majority of our active pharmaceutical ingredients and drug products. These third parties are independent entities subject to their own unique operational and financial risks that are out of our control. We and our third-party manufacturers and corporate partners are subject to Good Manufacturing Practices (&#8220;GMP&#8221;), which are extensive regulations governing manufacturing processes, stability testing, record keeping and quality standards as defined by FDA and the European Medicines Agency (&#8220;EMA&#8221;), as well as comparable regulations in other jurisdictions. Manufacturing operations are also subject to routine inspections by regulatory agencies.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting or resulting from our manufacturing operations or the operations of our third-party manufacturers and corporate partners may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also need to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications and quality standards, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share and damage our reputation. In addition, manufacturing issues may cause delays in our clinical trials and applications for regulatory approval. For example, if we are unable to remedy any deficiencies cited by FDA or other regulatory agencies in their inspections, our existing products and the timing of regulatory approval of product candidates in development could be adversely affected. Further, there is risk that regulatory agencies in other countries where marketing applications are pending will undertake similar additional reviews or apply a heightened standard of review, which could delay the regulatory approvals for products in those countries. Our business may be adversely affected if approval of any of our product candidates were delayed or if production of our products were interrupted.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufacture and sell our products, which could limit our ability to generate revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need access to certain supplies and products to conduct our clinical trials and to manufacture and sell our products. If we are unable to purchase sufficient quantities of these materials or find suitable alternative materials in a timely manner, our development efforts for our product candidates may be delayed or our ability to manufacture and sell our products could be limited.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suppliers of key components and materials must be named in the new drug application or marketing authorization application filed with the regulatory authority for any product candidate for which we are seeking marketing approval, and significant delays can occur if the qualification of a new supplier is required. Even after a manufacturer is qualified by the regulatory authority, the manufacturer must continue to expend time, money and effort in the area of production and quality control to maintain full compliance with GMP. Manufacturers are subject to regular periodic inspections by regulatory authorities following initial approval. If, as a result of these inspections, a regulatory authority determines that the equipment, facilities, laboratories or processes do not comply with applicable regulations and conditions of product approval, the regulatory authority may suspend the manufacturing operations. If the manufacturing operations of any of the single suppliers for our products are suspended, we may be unable to generate sufficient quantities of commercial or clinical supplies of product to meet market demand. In addition, if deliveries of materials from our suppliers were interrupted for any reason, we may be unable to ship certain of our products for commercial supply or to supply our product candidates in development for clinical trials. Also, some of our products and the materials that we utilize in our operations are manufactured by only one supplier or at only one facility, which we may not be able to replace in a timely manner and on commercially reasonable terms, or at all. Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the raw materials and intermediates used to manufacture our antiviral products are supplied by third-party manufacturers and corporate partners outside of the United States. As a result, any political or economic factors in a specific country or region, including any changes in or interpretations of trade regulations, compliance requirements or tax legislation, that would limit or prevent third parties outside of the United States from supplying these materials could adversely affect our ability to manufacture and supply our antiviral products to meet market needs and have a material and adverse effect on our operating results.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to encounter any of these difficulties, our ability to conduct clinical trials on product candidates and to manufacture and sell our products could be impaired.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Regulatory and Other Legal Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our operations depend on compliance with complex FDA and comparable international regulations. Failure to obtain broad approvals on a timely basis or to maintain compliance could delay or halt commercialization of our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we develop must be approved for marketing and sale by regulatory authorities and, once approved, are subject to extensive regulation by FDA, EMA and comparable regulatory agencies in other countries. We have filed, and anticipate that we will file, for marketing approval in additional countries and for additional indications and products over the next several years. These and any future marketing applications we file may not be approved by the regulatory authorities on a timely basis, or at all. Even if marketing approval is granted for these products, there may be significant limitations on their use. We cannot state with certainty when or whether any of our product candidates under development will be approved or launched; whether we will be able to develop, license or acquire additional product candidates or products; or whether any products, once launched, will be commercially successful. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, how we manufacture and sell our products is subject to extensive regulation and review. For example, under FDA rules, we are often required to conduct post-approval clinical studies to assess a known serious risk, signals of serious risk or to identify an unexpected serious risk. In certain circumstances, we may be required to implement a Risk Evaluation and Mitigation Strategy program for our products, which could include a medication guide, patient package insert, a communication plan to healthcare providers, restrictions on distribution or use of a product and other elements FDA deems necessary to assure safe use of the drug. Discovery of previously unknown problems with our marketed products or product candidates, including serious safety, resistance or drug interaction issues, or problems with our manufacturing, safety reporting or promotional activities may result in regulatory approvals being delayed, denied or granted with significant restrictions on our products, including limitations on or the withdrawal of the products from the market. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these or other requirements imposed by FDA could result in significant civil monetary penalties, fines suspensions of regulatory approvals, product recalls, seizure of products and criminal prosecutions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the health care industry. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health care industry is subject to various federal, state and international laws and regulations pertaining to drug reimbursement, rebates, price reporting, health care fraud and abuse, and data privacy and security. In the United States, these laws include anti-kickback and false claims laws, laws and regulations relating to the Medicare and Medicaid programs and other federal and state programs, the Medicaid Rebate Statute, individual state laws relating to pricing and sales and marketing practices, the Health Insurance Portability and Accountability Act and other federal and state laws relating to the privacy and security of health information. Actual or alleged violations of these laws or any related regulations may be punishable by criminal and/or civil sanctions, including, in some instances, substantial fines, civil monetary penalties, exclusion from participation in federal and state health care programs, including Medicare, Medicaid and Department of Veterans Affairs and Department of Defense health programs, actions against executives overseeing our business and significant remediation measures, negative publicity or other consequences. These laws and regulations are broad in scope and subject to changing and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our sales or marketing practices. The resulting impact on our business is uncertain and could be material.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government price reporting and payment regulations are complex and we are continually assessing the methods by which we calculate and report pricing in accordance with these obligations. Our methodologies for calculations are inherently subjective and may be subject to review and challenge by various government agencies, which may disagree with our interpretation. If the government disagrees with our reported calculations, we may need to restate previously reported data and could be subject to additional financial and legal liability.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also continues to be enhanced scrutiny of company-sponsored patient assistance programs, including co-pay assistance programs, and manufacturer donations to third-party charities that provide such assistance. There has also been enhanced scrutiny by governments on reimbursement and other patient support offerings, clinical education programs and promotional speaker programs. If we, or our agents and vendors, are deemed to have failed to comply with laws, regulations or government guidance in any of these areas, we could be subject to criminal or civil sanctions. Any similar violations by our competitors could also negatively impact our industry reputation and increase scrutiny over our business and our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our government investigations and related litigation, Note 11. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to risks if significant safety issues arise for our marketed products or our product candidates.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As additional studies are conducted subsequent to obtaining marketing approval for our products, and as our products are used over longer periods of time by many patients, including patients with underlying health problems or patients taking other medicines, we expect to continue finding new issues related to safety, resistance or drug interactions. Any such issues may require changes to our product labels, such as additional warnings, contraindications or even narrowed indications, or to halt sales of a product.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities have been moving towards more active and transparent pharmacovigilance and are making greater amounts of stand-alone safety information and clinical trial data directly available to the public through websites and other means, such as periodic safety update report summaries, risk management plan summaries and various adverse event data. Safety information, without the appropriate context and expertise, may be misinterpreted and lead to misperception or legal action.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are very important to our business. As part of our business strategy, we actively seek patent protection both in the United States and internationally and file additional patent applications, when appropriate, to cover improvements in our compounds, products and technology. Our success depends to a significant degree on our ability to:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain patents and licenses to patent rights;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preserve trade secrets and internal know-how;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defend against infringement of our patents and efforts to invalidate them; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate without infringing on the intellectual property of others.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since patent applications are confidential for a period of time before a patent is issued, we may not know if our competitors filed patent applications for technology covered by our pending applications or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent applications. If competitors file patent applications covering our technology, we may have to participate in litigation, post-grant proceedings before the U.S. Patent and Trademark Office or other proceedings to determine the right to a patent or validity of any patent granted. Such litigation and proceedings are unpredictable and expensive, and could divert management attention from other operations, such that, even if we are ultimately successful, we may be adversely impacted. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic manufacturers have sought, and may continue to seek, FDA approval to market generic versions of our products through an abbreviated new drug application (&#8220;ANDA&#8221;), the application process typically used by manufacturers seeking approval of a generic drug. For a description of our ANDA litigation, see Note 11. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q. The entry of generic versions of our products has, and may in the future, lead to market share and price erosion. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to infringe the valid patents of third parties, we may be required to pay significant monetary damages or we may be prevented from commercializing products or may be required to obtain licenses from these third parties. We may not be able to obtain alternative technologies or any required license on commercially reasonable terms or at all. If we fail to obtain these licenses or alternative technologies, we may be unable to develop or commercialize some or all of our products. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that such parties may claim cover the use of sofosbuvir, axicabtagene ciloleucel or bictegravir, as well as certain uses of combinations of FTC and TDF or TAF. For example, in February 2018, ViiV Healthcare Company (&#8220;ViiV&#8221;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with TAF and FTC as Biktarvy, infringes on ViiV&#8217;s U.S. Patent No. 8,129,385 (the &#8220;&#8217;385 patent&#8221;), covering ViiV&#8217;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the &#8217;385 patent. The court has set a trial date of January 2022 for this lawsuit. ViiV is seeking billions of dollars for alleged damages comprised of ViiV&#8217;s lost profits and a royalty on sales of bictegravir from launch through the trial. In addition, should a court find that we are liable for infringement, we expect ViiV will seek a royalty on sales after the trial. ViiV calculates these damages based on the cumulative U.S. revenues from Biktarvy since launch, which have totaled $16.4 billion through September&#160;30, 2021. Although we cannot predict with certainty the ultimate outcome of this litigation, an adverse judgment could result in substantial monetary damages, including ViiV&#8217;s lost profits and royalties through trial, and a going-forward royalty stream on future sales. See a description of our litigation related to these and other matters in Note 11. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we also rely on unpatented trade secrets and improvements, unpatented internal know-how and technological innovation. For example, a great deal of our liposomal manufacturing expertise, which is a key component of our liposomal technology, is not covered by patents but is instead protected as a trade secret. We protect these rights mainly through confidentiality agreements with our corporate partners, employees, consultants and vendors. We cannot be certain that these parties will comply with these confidentiality agreements, that we have adequate remedies for any breach or that our trade secrets, internal know-how or technological innovation will not otherwise become known or be independently discovered by our competitors. Under some of our R&amp;D agreements, inventions become jointly owned by us and our corporate partner and in other cases become the exclusive property of one party. In certain circumstances, it can be difficult to determine who owns a particular invention and disputes could arise regarding those inventions. We could be adversely affected if our trade secrets, internal know-how, technological innovation or confidential information become known or independently discovered by competitors or if we enter into disputes over ownership of inventions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face potentially significant liability and increased expenses from litigation and government investigations relating to our products and operations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in a number of litigation, investigation and other dispute-related matters that require us to expend substantial internal and financial resources, including ongoing litigation with ViiV related to bictegravir in which ViiV is seeking billions of dollars of alleged damages in a trial scheduled to begin in January 2022. These matters could require us to pay significant monetary damages, including royalty payments for past and future sales. We expect these matters will continue to require a high level of internal and financial resources for the foreseeable future. These matters have reduced, and are expected to continue to reduce, our earnings and require significant management attention. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the testing, manufacturing, marketing and use of our commercial products, as well as product candidates in development, involve substantial risk of product liability claims. These claims may be made directly by consumers, healthcare providers, pharmaceutical companies or others. We have limited insurance for product liabilities that may arise and claims may exceed our coverage.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our litigation, investigation and other dispute-related matters, see Note 11. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q. The outcome of such legal proceedings or any other legal proceedings that may be brought against us, the investigations or any other investigations that may be initiated and any other dispute-related matters, are inherently uncertain, and adverse developments or outcomes can result in significant expenses, monetary damages, penalties or injunctive relief against us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operational Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business has been, and may in the future be, adversely affected by outbreaks of epidemic, pandemic or contagious diseases, including the ongoing COVID-19 outbreak.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual or threatened outbreaks of epidemic, pandemic or contagious diseases, such as COVID-19, may significantly disrupt our global operations and adversely affect our business, financial condition and results of operations. For example, the COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international markets and has resulted in increased risks and adverse impacts to our operations, including as described below. In addition to the developments discussed in Part I, Item 2 &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; we are monitoring a number of risks related to the pandemic, including the following:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Supply Chain: The pandemic could result in disruptions to our global supply chain and distribution in the future. For example, quarantines, shelter-in-place and other governmental orders and policies, travel restrictions, airline capacity and route reductions, safety guidelines and health impacts of the pandemic, could impact the availability or productivity of products and personnel at manufacturers, distributors, freight carriers and other necessary components of our supply chain. In addition, there may be unfavorable changes in the availability or cost of raw materials, intermediates and other materials necessary for production, which may result in higher costs, disruptions in our supply chain and interruptions in our distribution capabilities.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical Trials: This pandemic has adversely affected and may continue to adversely affect certain of our clinical trials, including our ability to initiate and complete our clinical trials within the anticipated timelines. For ongoing trials, clinical trial sites have imposed restrictions on patient visits to limit risks of possible COVID-19 exposure, and we may experience issues with participant compliance with clinical trial protocols as a result of quarantines, travel restrictions and interruptions to healthcare services. There is also a risk that closures at clinical sites may be necessary as the pandemic and related guidance and restrictions continue to evolve. For the foregoing reasons, we have experienced delays with new subject enrollment for most clinical trials during the course of the pandemic, and may continue to experience overall delays in our clinical trials. There is also the risk of biased data collection if only certain clinical trial sites remain open. As a result of these challenges, our anticipated filing and marketing timelines for certain products may be adversely impacted.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory Reviews: The operations of FDA, EMA or other regulatory agencies may be adversely affected. We may also experience delays in necessary interactions with regulatory authorities around the world, including with respect to any anticipated filing, which together with other factors resulting from the pandemic may adversely impact our ability to launch new commercial products.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Access to Healthcare Providers: The pandemic has limited patients&#8217; ability or willingness to access and seek care from healthcare providers and initiate or continue therapies, which has resulted in lower demand for our products during the course of the pandemic, particularly with respect to HIV treatment and prevention and hepatitis C virus (&#8220;HCV&#8221;) treatment. For example, we have seen a reduction in prescription refills for HIV treatment and prevention as a result of higher discontinuations. We have also observed lower levels of screening and diagnosis for HIV, resulting in fewer treatment initiations. In addition, with increased levels of unemployment during the course of the pandemic, we have experienced a shift in payer mix towards more government-funded coverage and the uninsured segment. Our field personnel have also had reduced access to healthcare personnel during the pandemic, including fewer in-person interactions, which has adversely impacted and may continue to adversely impact our commercial activities.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Employees: We face risks related to the health, safety, morale and productivity of our employees, including the safe occupancy of our sites during the pandemic. In the fourth quarter of 2021, we transitioned to a return-to-site phase for our U.S. employees. Our job site enhancements and risk protocols, which include health screenings and COVID-19 testing and vaccine requirements, do not guarantee that we can maintain the continued safe occupancy of our sites and may adversely impact employee recruitment and retention. On-site employees testing positive for COVID-19 could lead to mandatory quarantines and potential site shutdowns.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Financial: The pandemic has had, and may continue to have, an adverse financial impact in the short-term and potentially beyond. In particular, our HIV treatment and HCV businesses have been and continue to be adversely impacted. For example, we observed a reduction in the overall U.S. HIV treatment volume in the second half of 2020 and the first quarter of 2021, and it is uncertain when treatment volume will return to pre-pandemic levels. In HCV, patient starts have also remained below pre-pandemic levels. We may continue to experience fluctuating revenues as infection rates rise and fall and as pandemic restrictions are periodically tightened and eased. We have also experienced, and may continue to experience, volatility in our short-term revenues due to fluctuations in inventory channel purchases during the pandemic. We could also have additional unexpected expenses related to the pandemic, which could negatively affect our results of operations. These factors together with the overall uncertainty and disruption caused by the pandemic could result in increased volatility and decreased predictability in our results of operations and volatility in our stock price.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic has also amplified many of the other risks described throughout the &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q. The extent to which the pandemic impacts our business and results will depend on future developments, which are uncertain and cannot be predicted with confidence, including any potential future waves of the pandemic, new variants of the virus that impact the severity and duration of the pandemic, the development, distribution, effectiveness and public acceptance of vaccines, and any other ongoing and future actions taken to contain the pandemic.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face risks associated with our global operations.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operations are accompanied by certain financial, political, economic and other risks, including those listed below:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign Currency Exchange: For the nine months ended September 30, 2021, approximately 30% of our product sales were outside the United States. Because a significant percentage of our product sales is denominated in foreign currencies, primarily the Euro, we face exposure to adverse movements in foreign currency exchange rates. Overall, we are a net receiver of foreign currencies, and therefore, we benefit from a weaker U.S. dollar and are adversely affected by a stronger U.S. dollar. Our hedging program does not eliminate our exposure to currency fluctuations. We may be adversely impacted if the U.S. dollar appreciates significantly against certain currencies and our hedging program does not sufficiently offset the effects of such appreciation.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-Bribery: We are subject to the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws that govern our international operations with respect to payments to government officials. Our international operations are heavily regulated and require significant interaction with foreign officials. We operate in parts of the world that have experienced governmental corruption to some degree. In certain circumstances, strict compliance with anti-bribery laws may conflict with local customs and practices or may require us to interact with doctors and hospitals, some of which may be state controlled, in a manner that is different than local custom. It is possible that certain of our practices may be challenged under these laws. In addition, our internal control policies and procedures may not protect us from reckless or criminal acts committed by our employees and agents. Enforcement activities under anti-bribery laws could subject us to administrative and legal proceedings and actions, which could result in civil and criminal sanctions, including monetary penalties and exclusion from healthcare programs.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks inherent in conducting a global business include:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictive government actions against our intellectual property and other foreign assets such as nationalization, expropriation, the imposition of compulsory licenses or similar actions, including waiver of intellectual property protections.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Protective economic policies taken by foreign governments, such as trade protection measures and import and export licensing requirements, which may result in the imposition of trade sanctions or similar restrictions by the United States or other governments.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Business interruptions stemming from natural or man-made disasters, such as climate change, earthquakes, hurricanes, flooding, fires, extreme heat, drought or actual or threatened public health emergencies, or efforts taken by third parties to prevent or mitigate such disasters, such as public safety power shutoffs and facility shutdowns, for which we may be uninsured or inadequately insured. For example, our corporate headquarters in Foster City and certain R&amp;D and manufacturing facilities are located in California, a seismically active region. In the event of a major earthquake, we may not carry adequate earthquake insurance and significant recovery time could be required to resume operations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Political instability or disruption in a geographic region where we operate, regardless of cause, including war, terrorism, social unrest and political changes. For example, on January 31, 2020, the United Kingdom withdrew from the European Union, which initiated a renegotiation of the United Kingdom and the European Union&#8217;s future relationship. There continues to be uncertainty concerning any changes in the laws and regulations governing the conduct of clinical trials and marketing of medicinal products in the United Kingdom following the country&#8217;s exit from the European Union. This uncertainty may lead to significant complexity and risks for our company and our ability to research, develop and market medicinal products in the European Union and the United Kingdom.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our aspirations, goals and disclosures related to environmental, social and governance (&#8220;ESG&#8221;) matters expose us to numerous risks, including risks to our reputation and stock price.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Institutional and individual investors are increasingly using ESG screening criteria to determine whether Gilead qualifies for inclusion in their investment portfolios. We are frequently asked by investors and other stakeholders to set ambitious ESG goals and provide new and more robust disclosure on goals, progress toward goals and other matters of interest to ESG stakeholders. In response, we have adapted the tracking and reporting of our corporate responsibility program to various evolving ESG frameworks, and we have established and announced goals and other objectives related to ESG matters. These goal statements reflect our current plans and aspirations and are not guarantees that we will be able to achieve them. Our efforts to accomplish and accurately report on these goals and objectives present numerous operational, reputational, financial, legal and other risks, any of which could have a material negative impact, including on our reputation and stock price. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to achieve any goal or objective, including with respect to environmental and diversity initiatives, is subject to numerous risks, many of which are outside of our control. Examples of such risks include: (1) the availability and cost of low- or non-carbon-based energy sources and technologies, (2) evolving regulatory requirements affecting ESG standards or disclosures, (3) the availability of suppliers that can meet our sustainability, diversity and other standards, (4) our ability to recruit, develop and retain diverse talent in our labor markets, and (5) the impact of our organic growth and acquisitions or dispositions of businesses or operations. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standards for tracking and reporting on ESG matters are relatively new, have not been harmonized and continue to evolve. Our selection of disclosure frameworks that seek to align with various reporting standards may change from time to time and may result in a lack of consistent or meaningful comparative data from period to period. In addition, our processes and controls may not always comply with evolving standards for identifying, measuring and reporting ESG metrics, our interpretation of reporting standards may differ from those of others and such standards may change over time, any of which could result in significant revisions to our goals or reported progress in achieving such goals. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our ESG practices do not meet evolving investor or other stakeholder expectations and standards, then our reputation, our ability to attract or retain employees and our attractiveness as an investment, business partner or acquiror could be negatively impacted. Similarly, our failure or perceived failure to pursue or fulfill our goals, targets and objectives or to satisfy various reporting standards within the timelines we announce, or at all, could also have similar negative impacts and expose us to government enforcement actions and private litigation. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We depend on relationships with third parties for sales and marketing performance, technology, development, logistics and commercialization of products. Failure to maintain these relationships, poor performance by these companies or disputes with these third parties could negatively impact our business.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative relationships with third parties for our sales and marketing performance in certain territories. For example, we have collaboration arrangements with Janssen Sciences Ireland UC for Odefsey, Complera/Eviplera and Symtuza. In some countries, we rely on international distributors for sales of certain of our products. Some of these relationships also involve the clinical development of these products by our partners. Reliance on collaborative relationships poses a number of risks, including the risk that:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are unable to control the resources our corporate partners devote to our programs or products;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of rights to technology developed with our corporate partners;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with our corporate partners could cause delays in, or termination of, the research, development or commercialization of product candidates or result in litigation or arbitration;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contracts with our corporate partners may fail to provide significant protection or may fail to be effectively enforced if one of these partners fails to perform;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our corporate partners have considerable discretion in electing whether to pursue the development of any additional products and may pursue alternative technologies or products either on their own or in collaboration with our competitors;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our corporate partners with marketing rights may choose to pursue competing technologies or to devote fewer resources to the marketing of our products than they do to products of their own development; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our distributors and our corporate partners may be unable to pay us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is a great deal of uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Due to the specialized and technical nature of our business, the failure to attract, develop and retain highly qualified personnel could adversely impact us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success will depend in large part on our continued ability to attract, develop and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, governmental regulation and commercialization. Our ability to do so also depends in part on how well we maintain a strong workplace culture that is attractive to employees. In addition, competition for qualified personnel in the biopharmaceutical field is intense, and there is a limited pool of qualified potential employees to recruit. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. Additionally, changes to U.S. immigration and work authorization laws and regulations could make it more difficult for employees to work in or transfer to one of the jurisdictions in which we operate. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are dependent on information technology systems, infrastructure and data, which may be subject to cyberattacks, security breaches and legal claims.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent upon information technology systems, infrastructure and data, including our Kite Konnect platform, which is critical to maintain chain of identity and chain of custody of Yescarta and Tecartus. The multitude and complexity of our computer systems make them inherently vulnerable to service interruption or destruction, malicious intrusion and ransomware attack. Likewise, data privacy or security breaches by employees or others pose a risk that sensitive data, including our intellectual property or trade secrets or the personal information of our employees, patients, customers or other business partners may be exposed to unauthorized persons or to the public. Cyberattacks are increasing in their frequency, sophistication and intensity, including during the pandemic. Cyberattacks include, for example, the deployment of harmful malware, ransomware, denial-of-service, social engineering and other means to affect service reliability and threaten data confidentiality, integrity and availability. Our business and technology partners face similar risks and any security breach of their systems could adversely affect our security posture. There can be no assurance that our efforts, or the efforts of our partners and vendors, to invest in the protection of information technology infrastructure and data will prevent future service interruptions or identify breaches in our systems. Such interruptions or breaches could cause the loss of critical or sensitive information, including personal information. In addition, our insurance may not be sufficient in type or amount to cover the losses that may result from an interruption or breach of our systems.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators globally are also imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the General Data Protection Regulation (&#8220;GDPR&#8221;) that became effective in Europe in 2018 established regulations regarding the handling of personal data, and non-compliance with the GDPR may result in monetary penalties of up to four percent of worldwide revenue. In addition, new domestic data privacy and security laws, such as the California Consumer Privacy Act (&#8220;CCPA&#8221;) that became effective in January 2020, and the California Privacy Rights Act (the &#8220;CPRA&#8221;) that was approved by voters in November 2020, and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with CCPA, CPRA or other laws may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. The GDPR, CCPA, CPRA and other changes, or new laws or regulations associated with the enhanced protection of personal information, including in some cases healthcare data or other personal information, could greatly increase our cost of providing our products and services or even prevent us from offering certain services in jurisdictions in which we operate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Strategic and Financial Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to risks associated with engaging in business acquisitions, licensing arrangements, collaborations, options, equity investments, asset divestitures and other strategic transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have engaged in, and may in the future engage in, such transactions as part of our business strategy. We may not identify suitable transactions in the future and, if we do, we may not complete such transactions in a timely manner, on a cost-effective basis, or at all, and may not realize the expected benefits. If we are successful in making an acquisition or closing a licensing arrangement or collaboration, the products, intellectual property and technologies that are acquired or licensed may not be successful or may require significantly greater resources and investments than anticipated. As part of our annual impairment testing of our goodwill and other indefinite-lived intangible assets in the fourth quarter, and earlier if impairment indicators exist, as required under U.S. generally accepted accounting principles, we may need to recognize impairment charges if the products, intellectual property and technologies that are acquired or licensed are not successful. For option structured deals, there is no assurance that we will elect to exercise our option right, and it is possible that disagreements, uncertainties or other circumstances may arise, including with respect to whether our option rights have been appropriately triggered, which may hinder our ability to realize the expected benefits. For equity investments in our strategic transactions, such as in connection with our collaboration with Galapagos NV, the value of our equity investments may fluctuate and decline in value. If we are not successful in the execution or implementation of these transactions, our financial condition, cash flows and results of operations may be adversely affected, and our stock price could decline.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid substantial amounts of cash and incurred additional debt to finance our strategic transactions. Additional indebtedness and a lower cash balance could result in a downgrade of our credit ratings, limit our ability to borrow additional funds or refinance existing debt on favorable terms, increase our vulnerability to adverse economic or industry conditions, and reduce our financial flexibility to continue with our capital investments, stock repurchases and dividend payments. For example, as a result of the cash used and the debt issued in connection with our acquisition of Immunomedics in 2020, S&amp;P downgraded our credit rating. We may be adversely impacted by any failure to overcome these additional risks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in our effective income tax rate could reduce our earnings.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes and tax return audits and reviews in the United States and various foreign jurisdictions, including Germany and Ireland. Due to economic and political conditions, various countries are actively considering and have made changes to existing tax laws, and we cannot predict the form or timing of such changes. For example, the current U.S. Presidential administration has proposed to increase the U.S. corporate income tax rate from its current 21%, implement a minimum tax on book income and increase taxation of international business operations, among numerous other corporate tax reform proposals. There are differing interpretations of tax laws and regulations and, as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We may be adversely affected by the resolution of one or more of these exposures in any reporting period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, significant judgment is required in determining our worldwide provision for income taxes. Various factors may have favorable or unfavorable effects on our income tax rate including, but not limited to, our portion of the non-deductible annual branded prescription drug fee, the accounting for stock options and other share-based awards, mergers/acquisitions and restructurings, ability to maintain manufacturing and other operational activities in our Irish facilities, changes in the mix of earnings in the various tax jurisdictions in which we operate, changes in overall levels of pre-tax earnings, resolution of federal, state and foreign income tax audits. The impact on our income tax provision resulting from the above mentioned factors may be significant.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our stock repurchase activity for the three months ended September 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of Shares&#160;Purchased (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average&#160;Price&#160;Paid per Share (in dollars) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;Total Number of Shares Purchased as Part of Publicly Announced Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maximum&#160;Approximate Dollar&#160;Value of&#160;Shares that&#160;May&#160;Yet&#160;Be Purchased&#160;Under the Plans or Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> (in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1 - July 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.57&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,414&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 1 - August 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 1 - September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In the first quarter of 2016, our Board of Directors authorized a $12.0 billion share repurchase program (&#8220;2016 Program&#8221;). Shares purchased during the period were made under the 2016 Program. In January 2020, our Board of Directors authorized a new $5.0 billion stock repurchase program, which will commence upon the completion of the 2016 Program. Share repurchases under both programs may be made in the open market or in privately negotiated transactions. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program is due to shares of common stock withheld by us from employee restricted stock awards in order to satisfy applicable tax withholding obligations.</span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_118"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_121"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_124"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2c1b4d102d99434b956b3b8616d0836a_127"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made to the Exhibit Index included herein. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit Index </span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.909%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.588%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Exhibit<br/>Footnote</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000095010320017822/dp136480_ex0201.htm">Agreement and Plan of Merger, dated September 13, 2020, among Immunomedics, Inc., Gilead Sciences, Inc. and Maui Merger Sub, Inc.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465919028215/a19-9678_1ex3d2.htm">Restated Certificate of Incorporation of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465919028215/a19-9678_1ex3d3.htm">Amended and Restated Bylaws of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Reference is made to Exhibit 3.1 and Exhibit 3.2</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex41.htm">Indenture related to Senior Notes, dated as of March&#160;30, 2011, between Registrant and Wells Fargo, National Association, as Trustee</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex42.htm">First Supplemental Indenture related to Senior Notes, dated as of March 30, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including form of Senior Notes)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511339157/d269235dex41.htm">Second Supplemental Indenture related to Senior Notes, dated as of December 13, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2041 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514089047/d688498dex41.htm">Third Supplemental Indenture related to Senior Notes, dated as of March 7, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2024 Note and Form of 2044 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514415184/d821656dex41.htm">Fourth Supplemental Indenture related to Senior Notes, dated as of November 17, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2025 Note and Form of 2045 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312515319560/d68529dex41.htm">Fifth Supplemental Indenture, dated as of September 14, 2015, between Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2026 Note, Form of 2035 Note and Form of 2046 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312516714926/d259911dex41.htm">Sixth Supplemental Indenture, dated as of September 20, 2016, between Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2023 Note, Form of 2027 Note, Form of 2036 Note and Form of 2047 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920110185/tm2031940d2_ex4-1.htm">Eighth Supplemental Indenture, dated as of September 30, 2020, between the Company and Wells Fargo Bank, National Association, as Trustee (including form of notes)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/gild2019form10-kex49.htm">Description of Registrant&#8217;s Securities</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312517168672/d396034dex101.htm">Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(12)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000008/gild20ormex102amendmentto2.htm">Amendment No. 1 to Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511132405/dex1042.htm">Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex104.htm">Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex105.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex105.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.7*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex1072021employe.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants commencing in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312509165506/dex1019.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2009 through 2012)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000038/gildq21310-qex1043.htm">Form of non-employee director stock option agreement (U.S.) under 2004 Equity Incentive Plan (for grants made in 2013)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.10*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000038/gildq21310-qex1044.htm">Form of non-employee director stock option agreement (non-U.S.) under 2004 Equity Incentive Plan (for grants made in 2013)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.11*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209514000038/ex1045-stockoptionagreement.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2014 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.12*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm"> in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(21)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.13*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10112020no.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.14*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1012.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.15*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1013.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.16*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10162021psuagr.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.17*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1015.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.18*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1017.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.19*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10192021psuagr.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.20*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511132405/dex1057.htm">Form of employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.21*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1017.htm">Form of employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.22*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex1020.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.23*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1024.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.909%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.588%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.24*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10242021employ.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants commencing in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(21)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.25*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10262020no.htm">Form of non-employee director restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(21)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.26*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10272018eq.htm">Gilead Sciences, Inc. 2018 Equity Incentive Plan, amended and restated April 7, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(22) </span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.27*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209515000015/exhibit101-espp.htm">Gilead Sciences, Inc. Employee Stock Purchase Plan, amended and restated January 22, 2015</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.28*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1020.htm">Gilead Sciences, Inc. 2005 Deferred Compensation Plan, amended and restated April 19, 2016</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(21)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.29*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex1030severa.htm">Gilead Sciences, Inc. Severance Plan, amended and restated May 5, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.30*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1028.htm">Gilead Sciences, Inc. Corporate Annual Incentive Plan, amended and restated January 1, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(24)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.31*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465918072098/a18-41320_1ex99d2.htm">Offer Letter between Registrant and Daniel O&#8217;Day, dated November 30, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.32*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1027.htm">Stock option agreement for Daniel O&#8217;Day under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.33*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1028.htm">Performance share award agreement for Daniel O&#8217;Day (for TSR Goals in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.34*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1029.htm">Performance share award agreement for Daniel O&#8217;Day (for Revenue Goals in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.35*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1030.htm">Form of restricted stock unit issuance agreement for Daniel O&#8217;Day (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.36*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1026.htm">Offer Letter between Registrant and Johanna Mercier, dated May 21, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(21)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.37*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex1043housin.htm">Letter Agreement between Registrant and Johanna Mercier, dated May 4, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.38*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1040.htm">Global stock option agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.39*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1041.htm">Restricted stock unit issuance agreement for Johanna Mercier (for Performance Objectives in 2019-2020) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.40*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1042.htm">Global restricted stock unit issuance agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.41*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1043.htm">Offer Letter between Registrant and Merdad Parsey, dated September 29, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.42*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1044.htm">Global stock option agreement for Merdad Parsey (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.43*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1045.htm">Global restricted stock unit issuance agreement for Merdad Parsey (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(25)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.44*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Form of Indemnity Agreement entered into between Registrant and its directors and executive officers</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(25)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.45*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(26)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.46*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312507041203/dex103.htm">Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees (revised September&#160;2006)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(27)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.47</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amendment Agreement, dated October&#160;25, 1993, between Registrant, the Institute of Organic Chemistry and Biochemistry (IOCB) and Rega Stichting v.z.w. (REGA), together with the following exhibits: the License Agreement, dated December&#160;15, 1991, between Registrant, IOCB and REGA (the 1991 License Agreement); the License Agreement, dated October&#160;15, 1992, between Registrant, IOCB and REGA (the October 1992 License Agreement); and the License Agreement, dated December&#160;1, 1992, between Registrant, IOCB and REGA (the December 1992 License Agreement)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(28)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000091205701007841/a2041233zex-10_13.txt">Amendment Agreement between Registrant and IOCB/REGA, dated December&#160;27, 2000, amending the 1991 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(29)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312506223996/dex103.htm">Sixth Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated August&#160;18, 2006, amending the October 1992 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(30)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000046/q313form10-qxexhibit1078.htm">Seventh Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated July 1, 2013, amending the October 1992 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(31)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.51</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022622/000091205799003190/0000912057-99-003190.txt">Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University, dated May&#160;6, 1999</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(32)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312505216649/dex102.htm">Royalty Sale Agreement by and among Registrant, Emory University and Investors Trust &amp; Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July&#160;18, 2005</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(32)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.53</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312505216649/dex102.htm">Amended and Restated License Agreement by and between Registrant, Emory University and Investors Trust &amp; Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July&#160;21, 2005</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(33)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.54</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000008/gild2018form10-kaexhibit1042.htm">Amended and Restated EVG License Agreement by and between Japan Tobacco Inc. and Registrant, dated November 29, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(33)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.55</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000008/gild2018form10-kaexhibit1043.htm">Master Agreement by and between Registrant, Gilead Sciences K.K. and Japan Tobacco Inc., dated November 29, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(34)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.56</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209515000008/ex1076-arcollaborationagre.htm">Amended and Restated Collaboration Agreement by and among Registrant, Gilead Sciences Ireland UC (formerly Gilead Sciences Limited) and Janssen R&amp;D Ireland, dated December 23, 2014</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(35)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1510580/000119312514239257/d705296dex1017.htm">License Agreement by and among Kite Pharma, Inc., Cabaret Biotech Ltd. and Dr. Zelig Eshhar, dated December 12, 2013</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.58</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex1050.htm">Option, License and Collaboration Agreement by and between Galapagos NV and Registrant, dated July 14, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">31.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq32021ex311ceocertific.htm">Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.909%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.588%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">31.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq32021ex312cfocertific.htm">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">32***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq32021ex32section906ce.htm">Certifications of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule&#160;15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.INS**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.SCH**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.CAL**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.DEF**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.LAB**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.PRE**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cover Page Interactive Data File, formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 14, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 9, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on April&#160;1, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on December 13, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on March 7, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on November 17, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 14, 2015, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 20, 2016, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 30, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(11)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 12, 2017, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(12)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(14)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(15)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(16)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(17)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(18)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2009, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(19)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, and incorporated herein by reference</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(20)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(21)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(22)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 8, 2015, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(23)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(24)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on December 10, 2018, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(25)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Registration Statement on Form S-1 (No. 33-55680), as amended, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(26)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(27)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended March&#160;31, 1994, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(28)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2000, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(29)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2006, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(30)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(31)&#160;&#160;&#160;&#160;Filed as an exhibit to Triangle Pharmaceuticals, Inc.&#8217;s Quarterly Report on Form 10-Q/A filed on November&#160;3, 1999, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(32)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2005, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(33)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Amendment No. 1 to Annual Report on Form 10-K/A filed on April 18, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(34)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2014, and incorporated herein by reference.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(35)&#160;&#160;&#160;&#160;Filed as an exhibit to Kite Pharma, Inc.&#8217;s Registration Statement on Form S-1/A (No. 333-196081) filed on June 17, 2014, and incorporated herein by reference.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Filed herewith.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">***&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Certain confidential portions of this Exhibit were omitted by means of marking such portions with an asterisk (the Mark). This Exhibit has been filed separately with the Secretary of the Securities and Exchange Commission without the Mark pursuant to Registrant&#8217;s Application Requesting Confidential Treatment under Rule 24b-2 under the Securities Exchange Act of 1934, as amended.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Certain confidential portions of this Exhibit were omitted by means of marking such portions with the Mark because the identified confidential portions are (i) not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i2c1b4d102d99434b956b3b8616d0836a_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</span></div><div style="margin-top:9pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILEAD SCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ DANIEL P. O&#8217;DAY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daniel P. O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Day</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ANDREW D. DICKINSON</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br/>Chief Financial Officer<br/>(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>gildq32021ex311ceocertific.htm
<DESCRIPTION>CEO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie7923ad3caad4009a23b3aaab0bcd1df_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel P. O&#8217;Day, certify that&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this quarterly report on Form 10-Q of Gilead Sciences, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;3, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:8pt;padding-left:288pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.959%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Daniel P. O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8217;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Day</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>gildq32021ex312cfocertific.htm
<DESCRIPTION>CFO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i69ef2fb786b74162b6dd439d387c872e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Andrew D. Dickinson, certify that&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this quarterly report on Form 10-Q of Gilead Sciences, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;3, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:11pt;padding-left:252pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br>Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>gildq32021ex32section906ce.htm
<DESCRIPTION>SECTION 906 CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i05393bce18b3448cbfa9830650b29069_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. &#167; 1350, as adopted), Daniel P. O&#8217;Day, the Chairman and Chief Executive Officer of Gilead Sciences, Inc. (the Company), and Andrew D. Dickinson, the Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2021 (the Report) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;3, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Daniel P. O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8217;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Day</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br>Chief Financial Officer</font></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>gild-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f99a0a1f-0889-484d-b0ab-b227dc47b3c9,g:c9f039a1-0400-492d-bc3a-193c416450f4-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:gild="http://www.gilead.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.gilead.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.gilead.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>2403401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUES" roleURI="http://www.gilead.com/role/REVENUES">
        <link:definition>2104102 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESTables" roleURI="http://www.gilead.com/role/REVENUESTables">
        <link:definition>2305301 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESDisaggregationofRevenuesDetails" roleURI="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails">
        <link:definition>2406402 - Disclosure - REVENUES - Disaggregation of Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESRevenuesfromMajorCustomersDetails" roleURI="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails">
        <link:definition>2407403 - Disclosure - REVENUES - Revenues from Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESAdditionalInformationDetails" roleURI="http://www.gilead.com/role/REVENUESAdditionalInformationDetails">
        <link:definition>2408404 - Disclosure - REVENUES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>2109103 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>2310302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>2411405 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails">
        <link:definition>2412406 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Classification of Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAdditionalInformationDetails" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails">
        <link:definition>2413407 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails">
        <link:definition>2414408 - Disclosure - FAIR VALUE MEASUREMENTS - Equity Investment In Galapagos (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIES" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES">
        <link:definition>2115104 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESTables" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables">
        <link:definition>2316303 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails">
        <link:definition>2417409 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails">
        <link:definition>2418410 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails">
        <link:definition>2419411 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails">
        <link:definition>2420412 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTS" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS">
        <link:definition>2121105 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSTables" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables">
        <link:definition>2322304 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails">
        <link:definition>2423413 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails">
        <link:definition>2424414 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails">
        <link:definition>2425415 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails">
        <link:definition>2426416 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONS" roleURI="http://www.gilead.com/role/ACQUISITIONS">
        <link:definition>2127106 - Disclosure - ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSTables" roleURI="http://www.gilead.com/role/ACQUISITIONSTables">
        <link:definition>2328305 - Disclosure - ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSNarrativeDetails" roleURI="http://www.gilead.com/role/ACQUISITIONSNarrativeDetails">
        <link:definition>2429417 - Disclosure - ACQUISITIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2430418 - Disclosure - ACQUISITIONS - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETS" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS">
        <link:definition>2131107 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSTables" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables">
        <link:definition>2332306 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSGoodwillDetails" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails">
        <link:definition>2433419 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails">
        <link:definition>2434420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1">
        <link:definition>2434420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails">
        <link:definition>2435421 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails">
        <link:definition>2436422 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATION" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATION">
        <link:definition>2137108 - Disclosure - OTHER FINANCIAL INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONTables" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables">
        <link:definition>2338307 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails">
        <link:definition>2439423 - Disclosure - OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONInventoriesDetails" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails">
        <link:definition>2440424 - Disclosure - OTHER FINANCIAL INFORMATION - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONInventoriesDetails_1" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1">
        <link:definition>2440424 - Disclosure - OTHER FINANCIAL INFORMATION - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails">
        <link:definition>2441425 - Disclosure - OTHER FINANCIAL INFORMATION - Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONSANDOTHERARRANGEMENTS" roleURI="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS">
        <link:definition>2142109 - Disclosure - COLLABORATIONS AND OTHER ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONSANDOTHERARRANGEMENTSDetails" roleURI="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails">
        <link:definition>2443426 - Disclosure - COLLABORATIONS AND OTHER ARRANGEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIES" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIES">
        <link:definition>2144110 - Disclosure - DEBT AND CREDIT FACILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIESTables" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables">
        <link:definition>2345308 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails">
        <link:definition>2446427 - Disclosure - DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIESAdditionalInformationDetails" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails">
        <link:definition>2447428 - Disclosure - DEBT AND CREDIT FACILITIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2148111 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>2449429 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2150112 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>2351309 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYAdditionalInformationDetails" roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails">
        <link:definition>2452430 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2453431 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS" roleURI="http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS">
        <link:definition>2154113 - Disclosure - NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables" roleURI="http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables">
        <link:definition>2355310 - Disclosure - NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails" roleURI="http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails">
        <link:definition>2456432 - Disclosure - NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" roleURI="http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails">
        <link:definition>2457433 - Disclosure - NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.gilead.com/role/INCOMETAXES">
        <link:definition>2158114 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.gilead.com/role/INCOMETAXESTables">
        <link:definition>2359311 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDetails" roleURI="http://www.gilead.com/role/INCOMETAXESDetails">
        <link:definition>2460434 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="gild_PaymentsToAcquireAssetsNetOfCashAcquired" abstract="false" name="PaymentsToAcquireAssetsNetOfCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A260SeniorUnsecuredNotesDueOctober2040Member" abstract="true" name="A260SeniorUnsecuredNotesDueOctober2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsCompleraEvipleraMember" abstract="true" name="HIVProductsCompleraEvipleraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FortySevenIncMember" abstract="true" name="FortySevenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EuropeanPatentClaims2024ExpirationMember" abstract="true" name="EuropeanPatentClaims2024ExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ImmunomedicsIncMember" abstract="true" name="ImmunomedicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A365SeniorUnsecuredNotesDueMarch2026Member" abstract="true" name="A365SeniorUnsecuredNotesDueMarch2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A2020StockRepurchaseProgramMember" abstract="true" name="A2020StockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyMaterialTransferAgreementsNumber" abstract="false" name="LossContingencyMaterialTransferAgreementsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" abstract="true" name="CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AccountsReceivableCashDiscountsAndOtherCurrent" abstract="false" name="AccountsReceivableCashDiscountsAndOtherCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" abstract="true" name="A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsOdefseyMember" abstract="true" name="HIVProductsOdefseyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ProductsRevenueShareSymtuzaMember" abstract="true" name="ProductsRevenueShareSymtuzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyPartiesFilingOppositionNumber" abstract="false" name="LossContingencyPartiesFilingOppositionNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_AmerisourcebergenCorpMember" abstract="true" name="AmerisourcebergenCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" abstract="false" name="EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_A120SeniorUnsecuredNotesDueOctober2027Member" abstract="true" name="A120SeniorUnsecuredNotesDueOctober2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CellTherapyProductsTotalCellTherapyProductSalesMember" abstract="true" name="CellTherapyProductsTotalCellTherapyProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OralFormulationProductMember" abstract="true" name="OralFormulationProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" abstract="true" name="ThreeYearSeniorUnsecuredTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A565SeniorUnsecuredNotesDueDecember2041Member" abstract="true" name="A565SeniorUnsecuredNotesDueDecember2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquityinvestmentinGalapagosMember" abstract="true" name="EquityinvestmentinGalapagosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherProductsLetairisMember" abstract="true" name="OtherProductsLetairisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherProductsZydeligMember" abstract="true" name="OtherProductsZydeligMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PreExposureProphylaxisMember" abstract="true" name="PreExposureProphylaxisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsTruvadaMember" abstract="true" name="HIVProductsTruvadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A2016StockRepurchaseProgramMember" abstract="true" name="A2016StockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" abstract="true" name="JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_A075SeniorUnsecuredNotesDueSeptember2023Member" abstract="true" name="A075SeniorUnsecuredNotesDueSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherProductsTotalOtherProductSalesMember" abstract="true" name="OtherProductsTotalOtherProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MarketableSecuritiesNoncurrentMember" abstract="true" name="MarketableSecuritiesNoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_VariableTermLoanNoteDueOctober2023Member" abstract="true" name="VariableTermLoanNoteDueOctober2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyPartiesAppealedNumber" abstract="false" name="LossContingencyPartiesAppealedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetsGrossReclassified" abstract="false" name="FiniteLivedIntangibleAssetsGrossReclassified" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_CashPaymentsMadeRelatedToEquityInvestments" abstract="false" name="CashPaymentsMadeRelatedToEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A460SeniorUnsecuredNotesDueSeptember2035Member" abstract="true" name="A460SeniorUnsecuredNotesDueSeptember2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A415SeniorUnsecuredNotesDueMarch2047Member" abstract="true" name="A415SeniorUnsecuredNotesDueMarch2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A480SeniorUnsecuredNotesDueApril2044Member" abstract="true" name="A480SeniorUnsecuredNotesDueApril2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ViiVHealthcareCompanyMember" abstract="true" name="ViiVHealthcareCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_CollaborativeandOtherArrangementsAbstract" abstract="true" name="CollaborativeandOtherArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_InventoryNetAndInventoryNoncurrent" abstract="false" name="InventoryNetAndInventoryNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A280SeniorUnsecuredNotesDueOctober2050Member" abstract="true" name="A280SeniorUnsecuredNotesDueOctober2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIPurchasePeriod" abstract="false" name="EquitySecuritiesFVNIPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_JudgmentEnhancedDamagesOnPastSales" abstract="false" name="JudgmentEnhancedDamagesOnPastSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_CellTherapyProductsYescartaMember" abstract="true" name="CellTherapyProductsYescartaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A325SeniorUnsecuredNotesDueSeptember2022Member" abstract="true" name="A325SeniorUnsecuredNotesDueSeptember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_InjectableFormulationProductMember" abstract="true" name="InjectableFormulationProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HCVProductsLedipasvirSofosbuvirMember" abstract="true" name="HCVProductsLedipasvirSofosbuvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AccruedGovernmentAndOtherRebates" abstract="false" name="AccruedGovernmentAndOtherRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HIVProductsDescovyMember" abstract="true" name="HIVProductsDescovyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_IntangibleAssetMeasurementInput" abstract="false" name="IntangibleAssetMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="gild_QuiTamMember" abstract="true" name="QuiTamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A165SeniorUnsecuredNotesDueOctober2030Member" abstract="true" name="A165SeniorUnsecuredNotesDueOctober2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A350SeniorUnsecuredNotesDueFebruary2025Member" abstract="true" name="A350SeniorUnsecuredNotesDueFebruary2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HCVProductSalesMember" abstract="true" name="HCVProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_TrodelvyForMTNBCMember" abstract="true" name="TrodelvyForMTNBCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A195SeniorUnsecuredNotesDueMarch2022Member" abstract="true" name="A195SeniorUnsecuredNotesDueMarch2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CollaborationArrangementNetProductSalesThreshold" abstract="false" name="CollaborationArrangementNetProductSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HIVProductsGenvoyaMember" abstract="true" name="HIVProductsGenvoyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_ForeignCurrencyDerivativeContractsMember" abstract="true" name="ForeignCurrencyDerivativeContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A450SeniorUnsecuredNotesDueFebruary2045Member" abstract="true" name="A450SeniorUnsecuredNotesDueFebruary2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ProductLiabilityMember" abstract="true" name="ProductLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HCVProductsSofosbuvirVelpatasvirMember" abstract="true" name="HCVProductsSofosbuvirVelpatasvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AxicabtageneciloleucelDLBCLMember" abstract="true" name="AxicabtageneciloleucelDLBCLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" abstract="true" name="MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" abstract="true" name="A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EuropeanPatentClaims2032ExpirationMember" abstract="true" name="EuropeanPatentClaims2032ExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsAtriplaMember" abstract="true" name="HIVProductsAtriplaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepcludexForHDVMember" abstract="true" name="HepcludexForHDVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIRestrictionPeriod" abstract="false" name="EquitySecuritiesFVNIRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_CellTherapyProductsTecartusMember" abstract="true" name="CellTherapyProductsTecartusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductVireadMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNISharesAcquired" abstract="false" name="EquitySecuritiesFVNISharesAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" abstract="false" name="UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_TrodelvyMember" abstract="true" name="TrodelvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A440SeniorUnsecuredNotesDueDecember2021Member" abstract="true" name="A440SeniorUnsecuredNotesDueDecember2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ResidentialMortgageAndAssetBackedSecuritiesMember" abstract="true" name="ResidentialMortgageAndAssetBackedSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherProductsRanexaMember" abstract="true" name="OtherProductsRanexaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CollaborationArrangementPercentOfGlobalProductRevenues" abstract="false" name="CollaborationArrangementPercentOfGlobalProductRevenues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_ArcusBiosciencesIncMember" abstract="true" name="ArcusBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsStribildMember" abstract="true" name="HIVProductsStribildMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_GalapagosNVMember" abstract="true" name="GalapagosNVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AccountsReceivableChargebacksCurrent" abstract="false" name="AccountsReceivableChargebacksCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A475SeniorUnsecuredNotesDueMarch2046Member" abstract="true" name="A475SeniorUnsecuredNotesDueMarch2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_JudgmentRoyaltyRateOnFutureSales" abstract="false" name="JudgmentRoyaltyRateOnFutureSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_GileadFoundationMember" abstract="true" name="GileadFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_JudgmentRoyaltyRateFromOctober2017" abstract="false" name="JudgmentRoyaltyRateFromOctober2017" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_SeniorNotesAndMediumTermNotesMember" abstract="true" name="SeniorNotesAndMediumTermNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_DeferredCompensationPlanMember" abstract="true" name="DeferredCompensationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" abstract="false" name="LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_RoyaltyContractAndOtherMember" abstract="true" name="RoyaltyContractAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherCollaborationArrangementsMember" abstract="true" name="OtherCollaborationArrangementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherHepatitisCVirusProductsMember" abstract="true" name="OtherHepatitisCVirusProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A250SeniorUnsecuredNotesDueSeptember2023Member" abstract="true" name="A250SeniorUnsecuredNotesDueSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" abstract="false" name="CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" abstract="false" name="TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_MYRGmbHMember" abstract="true" name="MYRGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A295SeniorUnsecuredNotesDueMarch2027Member" abstract="true" name="A295SeniorUnsecuredNotesDueMarch2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CreditFacilityDueJune2025Member" abstract="true" name="CreditFacilityDueJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MckessonCorpMember" abstract="true" name="MckessonCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_IntangibleAssetSofosbuvirMember" abstract="true" name="IntangibleAssetSofosbuvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ProductsOtherHIVMember" abstract="true" name="ProductsOtherHIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" abstract="false" name="CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_A400SeniorUnsecuredNotesDueSeptember2036Member" abstract="true" name="A400SeniorUnsecuredNotesDueSeptember2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CollaborativeAndOtherArrangementsTextBlock" abstract="false" name="CollaborativeAndOtherArrangementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" abstract="false" name="LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_MarketableSecuritiesCurrentMember" abstract="true" name="MarketableSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EuropeanPatentClaims2027ExpirationMember" abstract="true" name="EuropeanPatentClaims2027ExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ArcusStockPurchaseAgreementMember" abstract="true" name="ArcusStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherProductsOtherMember" abstract="true" name="OtherProductsOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A450SeniorUnsecuredNotesDueApril2021Member" abstract="true" name="A450SeniorUnsecuredNotesDueApril2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EuropeanPatentClaims2026ExpirationMember" abstract="true" name="EuropeanPatentClaims2026ExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIShares" abstract="false" name="EquitySecuritiesFVNIShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gild_MerckMember" abstract="true" name="MerckMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_VekluryMember" abstract="true" name="VekluryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherInternationalMember" abstract="true" name="OtherInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesDonationMember" abstract="true" name="EquitySecuritiesDonationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_OtherProductsAmBisomeMember" abstract="true" name="OtherProductsAmBisomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HIVProductsBiktarvyMember" abstract="true" name="HIVProductsBiktarvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A370SeniorUnsecuredNotesDueApril2024Member" abstract="true" name="A370SeniorUnsecuredNotesDueApril2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductSalesMember" abstract="true" name="HIVProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>gild-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f99a0a1f-0889-484d-b0ab-b227dc47b3c9,g:c9f039a1-0400-492d-bc3a-193c416450f4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="gild-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ebfdf41c-297b-4caf-9b27-b1970467eb86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b1899941-7255-4566-a99c-955575136028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ebfdf41c-297b-4caf-9b27-b1970467eb86" xlink:to="loc_us-gaap_PreferredStockValue_b1899941-7255-4566-a99c-955575136028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8c49f6b0-5b13-4a25-b1fa-bffaa8ec5e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ebfdf41c-297b-4caf-9b27-b1970467eb86" xlink:to="loc_us-gaap_CommonStockValue_8c49f6b0-5b13-4a25-b1fa-bffaa8ec5e3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f214e24f-7bfe-490f-8065-364af66df69a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ebfdf41c-297b-4caf-9b27-b1970467eb86" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f214e24f-7bfe-490f-8065-364af66df69a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_84001671-4a44-4786-934d-fb15fc62ad72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ebfdf41c-297b-4caf-9b27-b1970467eb86" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_84001671-4a44-4786-934d-fb15fc62ad72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bac49559-ebf3-4b20-83c5-6c7d3c073a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ebfdf41c-297b-4caf-9b27-b1970467eb86" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bac49559-ebf3-4b20-83c5-6c7d3c073a9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_90289ef0-8409-45d6-9287-5c871c306bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8d51906d-4bc5-4428-a057-9028f263965c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_90289ef0-8409-45d6-9287-5c871c306bdf" xlink:to="loc_us-gaap_AccountsPayableCurrent_8d51906d-4bc5-4428-a057-9028f263965c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedGovernmentAndOtherRebates_bd3b9c37-75f6-4a9f-8ff7-b94daacfff9a" xlink:href="gild-20210930.xsd#gild_AccruedGovernmentAndOtherRebates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_90289ef0-8409-45d6-9287-5c871c306bdf" xlink:to="loc_gild_AccruedGovernmentAndOtherRebates_bd3b9c37-75f6-4a9f-8ff7-b94daacfff9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4abfca20-ec62-4477-b6b6-c67aba0c4880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_90289ef0-8409-45d6-9287-5c871c306bdf" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4abfca20-ec62-4477-b6b6-c67aba0c4880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_e6e2cfb5-dcc6-4e36-8953-7044eeb02294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_90289ef0-8409-45d6-9287-5c871c306bdf" xlink:to="loc_us-gaap_DebtCurrent_e6e2cfb5-dcc6-4e36-8953-7044eeb02294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff49fc50-cd4d-406e-9742-64cadf40b097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_988143d2-fe9f-462a-82a6-ee8c541d541e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff49fc50-cd4d-406e-9742-64cadf40b097" xlink:to="loc_us-gaap_StockholdersEquity_988143d2-fe9f-462a-82a6-ee8c541d541e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9f2da8fd-740e-4a4c-acd8-d9d5cf971e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff49fc50-cd4d-406e-9742-64cadf40b097" xlink:to="loc_us-gaap_MinorityInterest_9f2da8fd-740e-4a4c-acd8-d9d5cf971e2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d15a7327-5945-44b5-b97e-72a7ba6583d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_763ec338-6d8f-47ca-baa1-fb42b6a1783b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d15a7327-5945-44b5-b97e-72a7ba6583d8" xlink:to="loc_us-gaap_AssetsCurrent_763ec338-6d8f-47ca-baa1-fb42b6a1783b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ea32bbc8-fd5b-4d81-a274-89d65e097581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d15a7327-5945-44b5-b97e-72a7ba6583d8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ea32bbc8-fd5b-4d81-a274-89d65e097581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_de9381fc-dd98-4601-9a70-e32ba9ee8251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d15a7327-5945-44b5-b97e-72a7ba6583d8" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_de9381fc-dd98-4601-9a70-e32ba9ee8251" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e00c58d1-be63-403f-b011-efb43a19ddb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d15a7327-5945-44b5-b97e-72a7ba6583d8" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e00c58d1-be63-403f-b011-efb43a19ddb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_428b42e4-f91a-4b2a-a3e1-33fa92584a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d15a7327-5945-44b5-b97e-72a7ba6583d8" xlink:to="loc_us-gaap_Goodwill_428b42e4-f91a-4b2a-a3e1-33fa92584a57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b707deb5-cacd-4f7f-91ed-ac717fe381e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d15a7327-5945-44b5-b97e-72a7ba6583d8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b707deb5-cacd-4f7f-91ed-ac717fe381e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_98ff27d8-276e-4068-8b08-9f496e611271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a24f2f5a-6ef7-4162-9eb4-46c6336559e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_98ff27d8-276e-4068-8b08-9f496e611271" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a24f2f5a-6ef7-4162-9eb4-46c6336559e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_a7548927-7ae5-4aa1-b79d-1002807c0729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_98ff27d8-276e-4068-8b08-9f496e611271" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_a7548927-7ae5-4aa1-b79d-1002807c0729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d7303d36-1a76-4c72-8987-fd53915b552d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_98ff27d8-276e-4068-8b08-9f496e611271" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d7303d36-1a76-4c72-8987-fd53915b552d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8f4fbf2a-fcb4-42d9-9b7f-efb850fdce3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_98ff27d8-276e-4068-8b08-9f496e611271" xlink:to="loc_us-gaap_InventoryNet_8f4fbf2a-fcb4-42d9-9b7f-efb850fdce3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_84aaed45-25d7-43ff-b930-bf9be8f75bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_98ff27d8-276e-4068-8b08-9f496e611271" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_84aaed45-25d7-43ff-b930-bf9be8f75bc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e936e06-4873-4084-819c-6c568de4f75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1d1d5eab-69c6-4c31-8486-e4fe08bedcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e936e06-4873-4084-819c-6c568de4f75c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1d1d5eab-69c6-4c31-8486-e4fe08bedcc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_faf95965-970e-49f9-9764-9a430fd33f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e936e06-4873-4084-819c-6c568de4f75c" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_faf95965-970e-49f9-9764-9a430fd33f62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_442d9ff0-a452-49af-88f6-d497301b9294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e936e06-4873-4084-819c-6c568de4f75c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_442d9ff0-a452-49af-88f6-d497301b9294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_043dfbfb-df4b-488a-ad4e-1a5c93667817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e936e06-4873-4084-819c-6c568de4f75c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_043dfbfb-df4b-488a-ad4e-1a5c93667817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eae9f006-b85b-4572-a5dd-7d73ca0ddd82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e936e06-4873-4084-819c-6c568de4f75c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eae9f006-b85b-4572-a5dd-7d73ca0ddd82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4aa8f90c-d6d6-4151-9e83-5c912ddb77a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e936e06-4873-4084-819c-6c568de4f75c" xlink:to="loc_us-gaap_LiabilitiesCurrent_4aa8f90c-d6d6-4151-9e83-5c912ddb77a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d7cff264-b0fe-4687-be74-339933f94dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e936e06-4873-4084-819c-6c568de4f75c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d7cff264-b0fe-4687-be74-339933f94dd3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="gild-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e5f63431-9a91-4cd4-aeed-a13f95b30d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0940ee1f-fc25-4cde-aa04-762244eb4f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e5f63431-9a91-4cd4-aeed-a13f95b30d71" xlink:to="loc_us-gaap_CostsAndExpenses_0940ee1f-fc25-4cde-aa04-762244eb4f3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2a56f7d-2796-47f4-a5c4-ed5c52f81808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e5f63431-9a91-4cd4-aeed-a13f95b30d71" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2a56f7d-2796-47f4-a5c4-ed5c52f81808" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cb60f723-bd65-4e40-aea7-f15979bf83ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8dd71f07-1469-458e-9d45-56566b98424f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cb60f723-bd65-4e40-aea7-f15979bf83ad" xlink:to="loc_us-gaap_OperatingIncomeLoss_8dd71f07-1469-458e-9d45-56566b98424f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_cc43c5e0-3a8d-4ef5-8d1a-ef33e5ebdb77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cb60f723-bd65-4e40-aea7-f15979bf83ad" xlink:to="loc_us-gaap_InterestExpense_cc43c5e0-3a8d-4ef5-8d1a-ef33e5ebdb77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1f51c6a5-3f51-468a-9236-f6f69838c0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cb60f723-bd65-4e40-aea7-f15979bf83ad" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1f51c6a5-3f51-468a-9236-f6f69838c0e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8d7274e6-e534-4bf6-9961-dc3e2c53fa64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e0ed5b4e-9ffc-40f0-8644-7021e2c54cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8d7274e6-e534-4bf6-9961-dc3e2c53fa64" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e0ed5b4e-9ffc-40f0-8644-7021e2c54cdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9ac9817b-717a-459f-81cd-ab9fd97493a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8d7274e6-e534-4bf6-9961-dc3e2c53fa64" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9ac9817b-717a-459f-81cd-ab9fd97493a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f858ec22-61ae-4e08-8bb3-3d927caf8fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_dadd4315-f1ee-4cf9-a8a8-a4bc0a4e878c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f858ec22-61ae-4e08-8bb3-3d927caf8fbe" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_dadd4315-f1ee-4cf9-a8a8-a4bc0a4e878c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4a34d26a-8527-417c-8080-e96651929a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f858ec22-61ae-4e08-8bb3-3d927caf8fbe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4a34d26a-8527-417c-8080-e96651929a6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3fea034b-4a12-4e9c-a6b0-b59e8f89ece2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f858ec22-61ae-4e08-8bb3-3d927caf8fbe" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3fea034b-4a12-4e9c-a6b0-b59e8f89ece2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e0c19735-1a34-4dac-8a39-071be4472549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f858ec22-61ae-4e08-8bb3-3d927caf8fbe" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e0c19735-1a34-4dac-8a39-071be4472549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c41e4b00-7ba5-4bca-8104-91bb4948c3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_eb58ce35-8292-4847-989c-3bac5e7ecf35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c41e4b00-7ba5-4bca-8104-91bb4948c3fc" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_eb58ce35-8292-4847-989c-3bac5e7ecf35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bded722e-2973-42a1-a765-73a5e97b9a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c41e4b00-7ba5-4bca-8104-91bb4948c3fc" xlink:to="loc_us-gaap_ProfitLoss_bded722e-2973-42a1-a765-73a5e97b9a3a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="gild-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_acc1680b-1137-44c5-9f71-8831820fdab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_52ffddbf-5cdf-449b-8534-1d9717249f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_acc1680b-1137-44c5-9f71-8831820fdab2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_52ffddbf-5cdf-449b-8534-1d9717249f7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a367fcc9-1b95-4221-9f67-daac1a803532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_acc1680b-1137-44c5-9f71-8831820fdab2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a367fcc9-1b95-4221-9f67-daac1a803532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ce5fefc4-046d-4fd7-8540-750fa8cc9203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_acc1680b-1137-44c5-9f71-8831820fdab2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ce5fefc4-046d-4fd7-8540-750fa8cc9203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_670a7f8a-8754-45dc-bee5-a51c3fa3e0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_3517f590-0479-4029-81c6-c6ddccd0781b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_670a7f8a-8754-45dc-bee5-a51c3fa3e0fc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_3517f590-0479-4029-81c6-c6ddccd0781b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_dd151441-d191-4f09-893d-aaa1ad5c3326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_670a7f8a-8754-45dc-bee5-a51c3fa3e0fc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_dd151441-d191-4f09-893d-aaa1ad5c3326" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_843aead4-c2ba-4e59-abf4-bf8e0eb505b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ab3e1a5a-fbe8-4133-9a02-1f663083513e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_843aead4-c2ba-4e59-abf4-bf8e0eb505b8" xlink:to="loc_us-gaap_ProfitLoss_ab3e1a5a-fbe8-4133-9a02-1f663083513e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_eee0b6b3-d3b4-421a-82fb-2861b02ccb01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_843aead4-c2ba-4e59-abf4-bf8e0eb505b8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_eee0b6b3-d3b4-421a-82fb-2861b02ccb01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_4d93738a-c1ff-413d-b58c-4f5a6801fb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_a7f10596-a6fc-446a-9662-ded0a2aef574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_4d93738a-c1ff-413d-b58c-4f5a6801fb3f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_a7f10596-a6fc-446a-9662-ded0a2aef574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_3557bf90-6a81-4cef-af80-e57434e39e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_4d93738a-c1ff-413d-b58c-4f5a6801fb3f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_3557bf90-6a81-4cef-af80-e57434e39e61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c6f53159-adac-4462-ae7f-28a1e5e8e080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4e3cf07c-95f7-488f-8f6c-4e3c9c1e1495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c6f53159-adac-4462-ae7f-28a1e5e8e080" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4e3cf07c-95f7-488f-8f6c-4e3c9c1e1495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ca2f82b9-f365-4ce9-901e-1f16a249fe72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c6f53159-adac-4462-ae7f-28a1e5e8e080" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ca2f82b9-f365-4ce9-901e-1f16a249fe72" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gild-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c245b3d5-ba4a-4958-b4e2-c3d64719af25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4291b1b6-5058-449a-a88c-f61530279763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c245b3d5-ba4a-4958-b4e2-c3d64719af25" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4291b1b6-5058-449a-a88c-f61530279763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b88979a5-b0ad-4328-86b3-61ed8a74b6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c245b3d5-ba4a-4958-b4e2-c3d64719af25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b88979a5-b0ad-4328-86b3-61ed8a74b6dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_62b374f6-3b75-4c4b-b988-4a163a347461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c245b3d5-ba4a-4958-b4e2-c3d64719af25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_62b374f6-3b75-4c4b-b988-4a163a347461" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db9a9757-ae75-4d71-b4a6-06a7aa1cc337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c245b3d5-ba4a-4958-b4e2-c3d64719af25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db9a9757-ae75-4d71-b4a6-06a7aa1cc337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34cd66d6-5d45-462c-83da-57c827a59dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_8f7c2421-5611-4509-b66b-0700af229b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34cd66d6-5d45-462c-83da-57c827a59dc6" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_8f7c2421-5611-4509-b66b-0700af229b3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a9b2b775-bb3a-4b80-94c2-80f8ee3467ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34cd66d6-5d45-462c-83da-57c827a59dc6" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a9b2b775-bb3a-4b80-94c2-80f8ee3467ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3f940c01-dfc9-4862-b73c-f6be3de92a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34cd66d6-5d45-462c-83da-57c827a59dc6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3f940c01-dfc9-4862-b73c-f6be3de92a26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_058e70ca-3bf9-4acf-83ef-e88e5ba08e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34cd66d6-5d45-462c-83da-57c827a59dc6" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_058e70ca-3bf9-4acf-83ef-e88e5ba08e61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_38097e88-0aff-4c4b-86dc-0c1f9fab2914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34cd66d6-5d45-462c-83da-57c827a59dc6" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_38097e88-0aff-4c4b-86dc-0c1f9fab2914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_dfb6cdf1-442e-4316-8104-17b67310624a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34cd66d6-5d45-462c-83da-57c827a59dc6" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_dfb6cdf1-442e-4316-8104-17b67310624a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b1b58e24-9b4e-4c5f-97bd-0c5311e3f6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34cd66d6-5d45-462c-83da-57c827a59dc6" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b1b58e24-9b4e-4c5f-97bd-0c5311e3f6a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49a4d111-72da-4996-b9c0-26fa0af6ce91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_34d9630f-d7ea-4418-b287-fb2db33c984e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49a4d111-72da-4996-b9c0-26fa0af6ce91" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_34d9630f-d7ea-4418-b287-fb2db33c984e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_92d2d0bf-1ed4-4076-a54c-3cb5c249328d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49a4d111-72da-4996-b9c0-26fa0af6ce91" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_92d2d0bf-1ed4-4076-a54c-3cb5c249328d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_286d0c1f-0134-4877-beb2-4409aa65f1de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49a4d111-72da-4996-b9c0-26fa0af6ce91" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_286d0c1f-0134-4877-beb2-4409aa65f1de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_2a685471-2a96-4eee-b2ab-7e7e5d097504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49a4d111-72da-4996-b9c0-26fa0af6ce91" xlink:to="loc_us-gaap_AdjustmentForAmortization_2a685471-2a96-4eee-b2ab-7e7e5d097504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f9542798-0687-41d6-96a6-9295ca844a79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49a4d111-72da-4996-b9c0-26fa0af6ce91" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f9542798-0687-41d6-96a6-9295ca844a79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_51ee2851-a368-4aa5-b784-d8bcd3e6a2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49a4d111-72da-4996-b9c0-26fa0af6ce91" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_51ee2851-a368-4aa5-b784-d8bcd3e6a2b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1738a8fc-1d1d-452d-9fd8-24e0e7861c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49a4d111-72da-4996-b9c0-26fa0af6ce91" xlink:to="loc_us-gaap_Depreciation_1738a8fc-1d1d-452d-9fd8-24e0e7861c8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_47af413c-1473-451f-980e-0fd8daf19f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49a4d111-72da-4996-b9c0-26fa0af6ce91" xlink:to="loc_us-gaap_ShareBasedCompensation_47af413c-1473-451f-980e-0fd8daf19f91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4bf4d80c-848b-4f47-b9fc-9abf72bdb294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49a4d111-72da-4996-b9c0-26fa0af6ce91" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4bf4d80c-848b-4f47-b9fc-9abf72bdb294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2930d901-8ed1-4c62-b867-47353596bcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49a4d111-72da-4996-b9c0-26fa0af6ce91" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2930d901-8ed1-4c62-b867-47353596bcb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_695a2b62-9459-47a6-bbb2-9d42c70142b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49a4d111-72da-4996-b9c0-26fa0af6ce91" xlink:to="loc_us-gaap_ProfitLoss_695a2b62-9459-47a6-bbb2-9d42c70142b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_92f55da1-a0e8-4117-84ab-f28eab2d4ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49a4d111-72da-4996-b9c0-26fa0af6ce91" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_92f55da1-a0e8-4117-84ab-f28eab2d4ab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_67b9ddde-f4d4-4ac9-9d0f-d988fcdf7755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49a4d111-72da-4996-b9c0-26fa0af6ce91" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_67b9ddde-f4d4-4ac9-9d0f-d988fcdf7755" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_f5158199-c1e3-489d-ad9c-2e5ffd709236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49a4d111-72da-4996-b9c0-26fa0af6ce91" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_f5158199-c1e3-489d-ad9c-2e5ffd709236" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0086cfc8-f1d9-46ad-adce-558e453843b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c4aeff68-c4ab-4111-bffa-f43c915d1229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0086cfc8-f1d9-46ad-adce-558e453843b1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c4aeff68-c4ab-4111-bffa-f43c915d1229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_5e247b16-cbf5-4a9c-8d45-d6b4545f7af3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0086cfc8-f1d9-46ad-adce-558e453843b1" xlink:to="loc_us-gaap_PaymentsOfDividends_5e247b16-cbf5-4a9c-8d45-d6b4545f7af3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_199c7dda-152d-44c8-95aa-76ff069f3f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0086cfc8-f1d9-46ad-adce-558e453843b1" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_199c7dda-152d-44c8-95aa-76ff069f3f1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7849cadb-8b44-46d7-b1ce-f94090ae8af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0086cfc8-f1d9-46ad-adce-558e453843b1" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7849cadb-8b44-46d7-b1ce-f94090ae8af6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_2d7205b2-5239-4af4-81d2-39c838d63673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0086cfc8-f1d9-46ad-adce-558e453843b1" xlink:to="loc_us-gaap_RepaymentsOfDebt_2d7205b2-5239-4af4-81d2-39c838d63673" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_d6d8f894-9df5-4f2e-874d-f1904e8a1c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0086cfc8-f1d9-46ad-adce-558e453843b1" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_d6d8f894-9df5-4f2e-874d-f1904e8a1c3f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_c7840a4b-9418-441f-991d-6d78221603da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b531ea17-ffa9-4728-a392-d24011ce8776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_c7840a4b-9418-441f-991d-6d78221603da" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b531ea17-ffa9-4728-a392-d24011ce8776" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_b40f0be0-f2f2-4716-a106-d03c87ebd804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_c7840a4b-9418-441f-991d-6d78221603da" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_b40f0be0-f2f2-4716-a106-d03c87ebd804" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_c12cd7f3-52cc-459e-aed4-f74643d7f804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_c7840a4b-9418-441f-991d-6d78221603da" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_c12cd7f3-52cc-459e-aed4-f74643d7f804" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_175fb603-61f4-48d7-95b8-c4562d7de8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_c582ae14-9297-4002-a9e7-75c7f8052f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_175fb603-61f4-48d7-95b8-c4562d7de8f0" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_c582ae14-9297-4002-a9e7-75c7f8052f2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_4f087c73-a761-4f33-9cf3-70fbb21f195f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_175fb603-61f4-48d7-95b8-c4562d7de8f0" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_4f087c73-a761-4f33-9cf3-70fbb21f195f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e3fecfc4-d5ac-41bf-9df9-975f1354dd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_175fb603-61f4-48d7-95b8-c4562d7de8f0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e3fecfc4-d5ac-41bf-9df9-975f1354dd4e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_45413536-b88b-4922-bce7-5da0efeb2cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d4c3ac4f-9b73-4557-b406-5a00426a1ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_45413536-b88b-4922-bce7-5da0efeb2cbd" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d4c3ac4f-9b73-4557-b406-5a00426a1ea8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_676f70c2-6d0b-487f-9fc4-3d960a347282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7a7ce044-eaf4-4405-838a-8b24b2d2f0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_676f70c2-6d0b-487f-9fc4-3d960a347282" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7a7ce044-eaf4-4405-838a-8b24b2d2f0f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8c36dcaa-520f-4a5e-9710-c0b5aed03412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_676f70c2-6d0b-487f-9fc4-3d960a347282" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8c36dcaa-520f-4a5e-9710-c0b5aed03412" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_607ff742-db97-48b1-81a2-d5498128af0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_676f70c2-6d0b-487f-9fc4-3d960a347282" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_607ff742-db97-48b1-81a2-d5498128af0c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_01d2e8af-f5e8-4bd8-951d-ca3ef690af17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_10010439-1b69-4306-b98e-a70066192a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_01d2e8af-f5e8-4bd8-951d-ca3ef690af17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_10010439-1b69-4306-b98e-a70066192a73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_14131ab2-66b6-4ee9-a2df-26e4c93c48e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_01d2e8af-f5e8-4bd8-951d-ca3ef690af17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_14131ab2-66b6-4ee9-a2df-26e4c93c48e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_17f434b5-4f27-40c3-889e-e6f3f26ed410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_01d2e8af-f5e8-4bd8-951d-ca3ef690af17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_17f434b5-4f27-40c3-889e-e6f3f26ed410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_af23535e-6c13-4334-8dd1-f2f3388f9e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_6835e739-63ca-419a-866e-83dd2e59bba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_af23535e-6c13-4334-8dd1-f2f3388f9e64" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_6835e739-63ca-419a-866e-83dd2e59bba8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_098ed479-491d-4b46-9c0c-7109fce7df51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_af23535e-6c13-4334-8dd1-f2f3388f9e64" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_098ed479-491d-4b46-9c0c-7109fce7df51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_4cfb0699-1e33-4a54-ab39-3456cad86d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_af23535e-6c13-4334-8dd1-f2f3388f9e64" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_4cfb0699-1e33-4a54-ab39-3456cad86d94" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_e55daec8-d2a5-4839-a0dc-52e3f9508ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_27d4de6b-d07d-4439-a852-40f76fa16a07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_e55daec8-d2a5-4839-a0dc-52e3f9508ba5" xlink:to="loc_us-gaap_DerivativeLiabilities_27d4de6b-d07d-4439-a852-40f76fa16a07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_74ddcf80-813d-4c11-9daf-692b4eaaf0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_e55daec8-d2a5-4839-a0dc-52e3f9508ba5" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_74ddcf80-813d-4c11-9daf-692b4eaaf0b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_98256e14-e83e-48c8-8b75-042aacf618de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_e55daec8-d2a5-4839-a0dc-52e3f9508ba5" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_98256e14-e83e-48c8-8b75-042aacf618de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_505a821b-ba83-4063-9eb8-9e9fb6c73cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_11bc6807-a7a5-43c8-bceb-89d92514be9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_505a821b-ba83-4063-9eb8-9e9fb6c73cb6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_11bc6807-a7a5-43c8-bceb-89d92514be9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_4f234778-4b56-4ad5-b945-7d55cc703f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_505a821b-ba83-4063-9eb8-9e9fb6c73cb6" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_4f234778-4b56-4ad5-b945-7d55cc703f9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_2b70737c-d03b-4889-99d0-83c897cc99b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_fdbb0c6b-a763-46ee-a9ae-d79d1bac0af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_2b70737c-d03b-4889-99d0-83c897cc99b9" xlink:to="loc_us-gaap_DerivativeAssets_fdbb0c6b-a763-46ee-a9ae-d79d1bac0af2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_58f768ef-a0f2-44e9-8109-6c1903a9a551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_2b70737c-d03b-4889-99d0-83c897cc99b9" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_58f768ef-a0f2-44e9-8109-6c1903a9a551" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_73bb35a9-44d8-4f3b-8d6d-8bbdd5086b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_2b70737c-d03b-4889-99d0-83c897cc99b9" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_73bb35a9-44d8-4f3b-8d6d-8bbdd5086b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_4a502585-05c2-46cf-b193-6911d94b66e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_392c83f3-3070-4f73-b4c4-36c4dfffff5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_4a502585-05c2-46cf-b193-6911d94b66e7" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_392c83f3-3070-4f73-b4c4-36c4dfffff5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_97b86a80-ead6-4617-8740-d8b50f78b95f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_4a502585-05c2-46cf-b193-6911d94b66e7" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_97b86a80-ead6-4617-8740-d8b50f78b95f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_771eda83-747c-433f-b763-810c5ba3e0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_516aff8b-bae8-49fa-a013-079ed862c24e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_771eda83-747c-433f-b763-810c5ba3e0d2" xlink:to="loc_us-gaap_GoodwillGross_516aff8b-bae8-49fa-a013-079ed862c24e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a024a44b-93c6-439c-a755-d9061bcef8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_771eda83-747c-433f-b763-810c5ba3e0d2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a024a44b-93c6-439c-a755-d9061bcef8d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c144d9d3-8d6c-4f72-89c0-f0a68cba065e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_3e07f956-4417-4d24-9dc8-2f692e2406d9" xlink:href="gild-20210930.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c144d9d3-8d6c-4f72-89c0-f0a68cba065e" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_3e07f956-4417-4d24-9dc8-2f692e2406d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_48c22817-1df4-48b1-a7f8-3cbb05a6900e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c144d9d3-8d6c-4f72-89c0-f0a68cba065e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_48c22817-1df4-48b1-a7f8-3cbb05a6900e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_efdf000b-84c5-4d50-bf80-230823b9f736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c144d9d3-8d6c-4f72-89c0-f0a68cba065e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_efdf000b-84c5-4d50-bf80-230823b9f736" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_280cdae5-a4b9-46c9-8a8b-d06d6570a097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c144d9d3-8d6c-4f72-89c0-f0a68cba065e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_280cdae5-a4b9-46c9-8a8b-d06d6570a097" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_f7504067-a47f-4f80-bf5b-408e0ae3d27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c144d9d3-8d6c-4f72-89c0-f0a68cba065e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_f7504067-a47f-4f80-bf5b-408e0ae3d27a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_3422338b-e835-4315-b886-69fc084e1665" xlink:href="gild-20210930.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c144d9d3-8d6c-4f72-89c0-f0a68cba065e" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_3422338b-e835-4315-b886-69fc084e1665" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b9c8814f-de99-4fd2-9131-9ca3f52866f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c144d9d3-8d6c-4f72-89c0-f0a68cba065e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b9c8814f-de99-4fd2-9131-9ca3f52866f5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4f8e7235-313a-4b0b-bf47-02bc0b8580d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_abf8dec3-625d-4d64-abdf-f6e205c42291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4f8e7235-313a-4b0b-bf47-02bc0b8580d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_abf8dec3-625d-4d64-abdf-f6e205c42291" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5e1e4ff8-0965-434b-be42-e0c50d0d77aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4f8e7235-313a-4b0b-bf47-02bc0b8580d6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5e1e4ff8-0965-434b-be42-e0c50d0d77aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5ab7a083-957f-4a1f-b7a9-619613b13e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_23a6dd4a-6033-4215-a1fb-421227baad30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5ab7a083-957f-4a1f-b7a9-619613b13e66" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_23a6dd4a-6033-4215-a1fb-421227baad30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_f753fbd7-7c6f-4b25-a68e-bb041829af30" xlink:href="gild-20210930.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5ab7a083-957f-4a1f-b7a9-619613b13e66" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_f753fbd7-7c6f-4b25-a68e-bb041829af30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_edaa0579-7cc8-40c3-99f0-bb350926750b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5ab7a083-957f-4a1f-b7a9-619613b13e66" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_edaa0579-7cc8-40c3-99f0-bb350926750b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_fff91094-be9b-4c0b-82f0-2a8b605e4462" xlink:href="gild-20210930.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_bd30cdad-293f-44af-ba58-d22e6a2e9fad" xlink:href="gild-20210930.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_fff91094-be9b-4c0b-82f0-2a8b605e4462" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_bd30cdad-293f-44af-ba58-d22e6a2e9fad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_466d82cf-4e6d-4925-b58a-320528a1a923" xlink:href="gild-20210930.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_fff91094-be9b-4c0b-82f0-2a8b605e4462" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_466d82cf-4e6d-4925-b58a-320528a1a923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a7b51ff2-2be1-40c3-875a-ba60ebc06085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_731c4b74-fae8-4634-8692-6fd06ed7bb73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a7b51ff2-2be1-40c3-875a-ba60ebc06085" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_731c4b74-fae8-4634-8692-6fd06ed7bb73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0fc6c7a3-7833-4644-89aa-1e524b064467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a7b51ff2-2be1-40c3-875a-ba60ebc06085" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0fc6c7a3-7833-4644-89aa-1e524b064467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_66e06580-2eee-406f-a7e2-471f1f1a78ce" xlink:href="gild-20210930.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a7b51ff2-2be1-40c3-875a-ba60ebc06085" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_66e06580-2eee-406f-a7e2-471f1f1a78ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_d06e09b9-ebbe-4206-8bd3-ca0fcf32aafe" xlink:href="gild-20210930.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9be9f34a-8d27-479a-b037-21f5e3cfb03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_d06e09b9-ebbe-4206-8bd3-ca0fcf32aafe" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9be9f34a-8d27-479a-b037-21f5e3cfb03b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_6f2273bc-4032-4534-9084-81ebb09a8304" xlink:href="gild-20210930.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_d06e09b9-ebbe-4206-8bd3-ca0fcf32aafe" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_6f2273bc-4032-4534-9084-81ebb09a8304" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="gild-20210930.xsd#GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_266e1c6d-6092-4208-bb4c-4ded9a6c8614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bf745b40-6771-4bdb-807a-c474010ca68c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_266e1c6d-6092-4208-bb4c-4ded9a6c8614" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bf745b40-6771-4bdb-807a-c474010ca68c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_a8c88008-5cab-4479-ae9c-ca12ac954e0c" xlink:href="gild-20210930.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_266e1c6d-6092-4208-bb4c-4ded9a6c8614" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_a8c88008-5cab-4479-ae9c-ca12ac954e0c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ee729640-2a88-400b-b5e9-79f58330c926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_378a5224-b3d9-4922-a8c7-f5b5d39b6498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ee729640-2a88-400b-b5e9-79f58330c926" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_378a5224-b3d9-4922-a8c7-f5b5d39b6498" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0d61d839-6074-4487-9955-2c9cc5db9221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ee729640-2a88-400b-b5e9-79f58330c926" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0d61d839-6074-4487-9955-2c9cc5db9221" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8d110d2a-d528-4893-bc7f-f0f668e852dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ee729640-2a88-400b-b5e9-79f58330c926" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8d110d2a-d528-4893-bc7f-f0f668e852dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a250cdde-850b-4f1e-a5e0-ec2f6a22233d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ee729640-2a88-400b-b5e9-79f58330c926" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a250cdde-850b-4f1e-a5e0-ec2f6a22233d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_886a355a-6331-42b7-b7c3-fb528df68a0b" xlink:href="gild-20210930.xsd#gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ee729640-2a88-400b-b5e9-79f58330c926" xlink:to="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_886a355a-6331-42b7-b7c3-fb528df68a0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_cb0daff9-65cb-4faf-9faa-116818f8a0df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ee729640-2a88-400b-b5e9-79f58330c926" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_cb0daff9-65cb-4faf-9faa-116818f8a0df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_97d49b51-d636-4656-8b9c-ca237713579d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_5dea3124-59ea-402f-b138-b96b031c4ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_97d49b51-d636-4656-8b9c-ca237713579d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_5dea3124-59ea-402f-b138-b96b031c4ac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_50470134-ce8d-44b9-87b7-48ce197fdb39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_97d49b51-d636-4656-8b9c-ca237713579d" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_50470134-ce8d-44b9-87b7-48ce197fdb39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent_a0063cc3-f119-47ac-a560-599b4f5ff95b" xlink:href="gild-20210930.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_97d49b51-d636-4656-8b9c-ca237713579d" xlink:to="loc_gild_AccountsReceivableChargebacksCurrent_a0063cc3-f119-47ac-a560-599b4f5ff95b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_6e1111c3-a78b-4b74-a147-af607e723ba8" xlink:href="gild-20210930.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_97d49b51-d636-4656-8b9c-ca237713579d" xlink:to="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_6e1111c3-a78b-4b74-a147-af607e723ba8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#OTHERFINANCIALINFORMATIONInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_cc731cfa-2f2d-43c4-ac9f-9a6ff52055ac" xlink:href="gild-20210930.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_790dd3ed-a042-426c-ad9c-f298e9f4aae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_cc731cfa-2f2d-43c4-ac9f-9a6ff52055ac" xlink:to="loc_us-gaap_InventoryNet_790dd3ed-a042-426c-ad9c-f298e9f4aae0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_d1752fcd-e9fa-45d7-ae41-c75dfa8e165e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_cc731cfa-2f2d-43c4-ac9f-9a6ff52055ac" xlink:to="loc_us-gaap_InventoryNoncurrent_d1752fcd-e9fa-45d7-ae41-c75dfa8e165e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1" xlink:type="simple" xlink:href="gild-20210930.xsd#OTHERFINANCIALINFORMATIONInventoriesDetails_1"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_599c73fb-9126-4bad-bb12-a4912d139691" xlink:href="gild-20210930.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_dd7d1bb2-6d6f-43e3-b858-be4483f8d8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_599c73fb-9126-4bad-bb12-a4912d139691" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_dd7d1bb2-6d6f-43e3-b858-be4483f8d8d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a55c5059-779c-41e0-bb7a-9c63b9ad6f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_599c73fb-9126-4bad-bb12-a4912d139691" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a55c5059-779c-41e0-bb7a-9c63b9ad6f9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3f963b72-094b-4aba-ab2f-9058bf4e3284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_599c73fb-9126-4bad-bb12-a4912d139691" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3f963b72-094b-4aba-ab2f-9058bf4e3284" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_16b38414-33d0-4669-a138-6cadcca9c85c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2538e9cd-ba55-4029-820a-486bf096f810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_16b38414-33d0-4669-a138-6cadcca9c85c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2538e9cd-ba55-4029-820a-486bf096f810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_6e3259b9-64b5-44de-a2a9-66db5e49b0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_16b38414-33d0-4669-a138-6cadcca9c85c" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_6e3259b9-64b5-44de-a2a9-66db5e49b0d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_1fecfade-712b-4829-81f3-67ae3c5cdf47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_16b38414-33d0-4669-a138-6cadcca9c85c" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_1fecfade-712b-4829-81f3-67ae3c5cdf47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2a463fb9-e71e-43df-9f5c-349387e2775a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_16b38414-33d0-4669-a138-6cadcca9c85c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2a463fb9-e71e-43df-9f5c-349387e2775a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_714d4c7a-bb8b-4e98-92fb-f875f1f2af7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_60127ea2-24b1-48e6-b8bb-a901c86dad82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_714d4c7a-bb8b-4e98-92fb-f875f1f2af7f" xlink:to="loc_us-gaap_LongTermDebtCurrent_60127ea2-24b1-48e6-b8bb-a901c86dad82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9c1832d9-d864-4a5c-8a05-d91220cca86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_714d4c7a-bb8b-4e98-92fb-f875f1f2af7f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9c1832d9-d864-4a5c-8a05-d91220cca86c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d62a4da1-a51e-466c-9bea-ad049e5c15e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_c2d016e7-947f-4c9f-9b1c-6fff6a36473a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d62a4da1-a51e-466c-9bea-ad049e5c15e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_c2d016e7-947f-4c9f-9b1c-6fff6a36473a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c7d85afb-8235-495d-aa97-f1183d8ecca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d62a4da1-a51e-466c-9bea-ad049e5c15e7" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c7d85afb-8235-495d-aa97-f1183d8ecca6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1075e17d-f152-437a-8aca-d3631a168dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bbb760f0-19d2-48b0-a3b7-98f412b4db94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1075e17d-f152-437a-8aca-d3631a168dea" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bbb760f0-19d2-48b0-a3b7-98f412b4db94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1e6130b3-be89-40e2-9314-2b4f0fa99d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1075e17d-f152-437a-8aca-d3631a168dea" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1e6130b3-be89-40e2-9314-2b4f0fa99d11" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>gild-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f99a0a1f-0889-484d-b0ab-b227dc47b3c9,g:c9f039a1-0400-492d-bc3a-193c416450f4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="gild-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i153460ee1c81422cbb58450ac029425d_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8429803c-4bf9-451c-8a25-973ca0656973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_RevenuesAbstract_8429803c-4bf9-451c-8a25-973ca0656973" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a72c4a7-0906-41ac-a4e2-d6e542f2ff81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_8429803c-4bf9-451c-8a25-973ca0656973" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a72c4a7-0906-41ac-a4e2-d6e542f2ff81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_da874c42-cac6-42b4-a4bf-18cf0e6dc42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_da874c42-cac6-42b4-a4bf-18cf0e6dc42c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8acf907e-2465-4bee-8e6d-e080491f02af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_da874c42-cac6-42b4-a4bf-18cf0e6dc42c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8acf907e-2465-4bee-8e6d-e080491f02af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c374bb23-e760-4eb9-ae0a-42ea298a205d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_da874c42-cac6-42b4-a4bf-18cf0e6dc42c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c374bb23-e760-4eb9-ae0a-42ea298a205d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ad8c627f-a7ca-4795-bc77-074118495821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_da874c42-cac6-42b4-a4bf-18cf0e6dc42c" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ad8c627f-a7ca-4795-bc77-074118495821" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c2a14f92-f83a-4268-9b42-bb5353602c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_da874c42-cac6-42b4-a4bf-18cf0e6dc42c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c2a14f92-f83a-4268-9b42-bb5353602c81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4cd28d3b-6b47-4543-9527-3f921375e8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_da874c42-cac6-42b4-a4bf-18cf0e6dc42c" xlink:to="loc_us-gaap_CostsAndExpenses_4cd28d3b-6b47-4543-9527-3f921375e8f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0f676403-b212-444c-8536-bd2d621c7081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_OperatingIncomeLoss_0f676403-b212-444c-8536-bd2d621c7081" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f9be8000-dfd5-4ab6-897c-96f7334a7c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_InterestExpense_f9be8000-dfd5-4ab6-897c-96f7334a7c1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7cabfcc7-4f06-41ed-b610-8e099c1b7c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7cabfcc7-4f06-41ed-b610-8e099c1b7c32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a32013a7-2125-4bcb-93af-a463586654b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a32013a7-2125-4bcb-93af-a463586654b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_681506b1-f359-49e5-8484-37e6c7151cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_681506b1-f359-49e5-8484-37e6c7151cd8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_141618c2-d079-4875-b1f0-043b633fa1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_ProfitLoss_141618c2-d079-4875-b1f0-043b633fa1f7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8925ef95-8ae8-4ccc-ba9e-d76353b85e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8925ef95-8ae8-4ccc-ba9e-d76353b85e95" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5b3d1405-9b9c-4146-bfd5-5f4baba41555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_NetIncomeLoss_5b3d1405-9b9c-4146-bfd5-5f4baba41555" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ec15c255-022b-46f4-9029-3814de76b931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_EarningsPerShareBasic_ec15c255-022b-46f4-9029-3814de76b931" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_90307875-9c9a-4878-9864-20afa17af8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_90307875-9c9a-4878-9864-20afa17af8c8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8285ad79-a3e5-4ec7-ae25-456d5cc50abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8285ad79-a3e5-4ec7-ae25-456d5cc50abb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_46522c00-c691-4d21-bd6a-c8056ebed21d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_46522c00-c691-4d21-bd6a-c8056ebed21d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_36409ae8-4912-4693-98c5-b32941c1e478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_StatementTable_36409ae8-4912-4693-98c5-b32941c1e478" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6ff5a2ed-ae85-43e3-beb0-9f0852d2bd0d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_36409ae8-4912-4693-98c5-b32941c1e478" xlink:to="loc_srt_ProductOrServiceAxis_6ff5a2ed-ae85-43e3-beb0-9f0852d2bd0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ff5a2ed-ae85-43e3-beb0-9f0852d2bd0d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6ff5a2ed-ae85-43e3-beb0-9f0852d2bd0d" xlink:to="loc_srt_ProductsAndServicesDomain_6ff5a2ed-ae85-43e3-beb0-9f0852d2bd0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0e9efd1-3a1e-42d8-9cf3-cc348ef1f761" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6ff5a2ed-ae85-43e3-beb0-9f0852d2bd0d" xlink:to="loc_srt_ProductsAndServicesDomain_a0e9efd1-3a1e-42d8-9cf3-cc348ef1f761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a76cc213-aa0d-4e3e-aee9-a1f0d785319a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0e9efd1-3a1e-42d8-9cf3-cc348ef1f761" xlink:to="loc_us-gaap_ProductMember_a76cc213-aa0d-4e3e-aee9-a1f0d785319a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_ee075e74-c9e4-4822-b246-2792b78128f9" xlink:href="gild-20210930.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0e9efd1-3a1e-42d8-9cf3-cc348ef1f761" xlink:to="loc_gild_RoyaltyContractAndOtherMember_ee075e74-c9e4-4822-b246-2792b78128f9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gild-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="ide01eeca3ffe40f2a13e6c11e34bf0ad_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e45c4d03-4372-4c6c-8a09-4a86c531932f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e45c4d03-4372-4c6c-8a09-4a86c531932f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_82c4957b-9263-4a83-b23e-3060eb6f1774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_82c4957b-9263-4a83-b23e-3060eb6f1774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f854179c-830e-4201-a5c8-7073aab5c9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f854179c-830e-4201-a5c8-7073aab5c9cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_d4c9b2ef-6ef4-4adc-8c5c-316f488558ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_d4c9b2ef-6ef4-4adc-8c5c-316f488558ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c13754de-bd4d-476e-aaf3-c9f59df45f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_ProfitLoss_c13754de-bd4d-476e-aaf3-c9f59df45f7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_59b63639-cd50-4684-9227-745a0e9ce1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_59b63639-cd50-4684-9227-745a0e9ce1dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7dba1b2a-f354-4620-978b-aff894b7e6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7dba1b2a-f354-4620-978b-aff894b7e6fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0148a126-aa68-4666-862e-f72a2ce9a4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0148a126-aa68-4666-862e-f72a2ce9a4a0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2deadffd-cfa3-4c7d-9847-fa399090ff07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2deadffd-cfa3-4c7d-9847-fa399090ff07" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cd4ed547-ced5-4c26-a2eb-e2bd9c2205d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cd4ed547-ced5-4c26-a2eb-e2bd9c2205d4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6b4bfd2e-b281-435a-964a-1b9d6e8a57a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6b4bfd2e-b281-435a-964a-1b9d6e8a57a6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_71168a9f-df8e-413f-90d1-168c84c5e9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_71168a9f-df8e-413f-90d1-168c84c5e9d0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_1298ca85-21d6-4704-a3ca-71578f955007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_1298ca85-21d6-4704-a3ca-71578f955007" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_07bc9830-3168-4bd0-8776-db351b8132d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_Dividends_07bc9830-3168-4bd0-8776-db351b8132d5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_54ff0b78-4142-412b-bd2d-a311c914fc18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b71cc1cd-afc7-4e9e-ac2e-284a17095cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_49fe33d2-b031-4310-acbf-9ae11bb19323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e45c4d03-4372-4c6c-8a09-4a86c531932f" xlink:to="loc_us-gaap_StatementTable_49fe33d2-b031-4310-acbf-9ae11bb19323" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_65661aa2-27bb-4511-9518-ad6c6cde008c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_49fe33d2-b031-4310-acbf-9ae11bb19323" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_65661aa2-27bb-4511-9518-ad6c6cde008c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_65661aa2-27bb-4511-9518-ad6c6cde008c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_65661aa2-27bb-4511-9518-ad6c6cde008c" xlink:to="loc_us-gaap_EquityComponentDomain_65661aa2-27bb-4511-9518-ad6c6cde008c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2f9f01a4-8ff3-4ba7-acb7-7d4ecdc18c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_65661aa2-27bb-4511-9518-ad6c6cde008c" xlink:to="loc_us-gaap_EquityComponentDomain_2f9f01a4-8ff3-4ba7-acb7-7d4ecdc18c0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9a86ca80-54d4-469a-a2ce-9024f0f784ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f9f01a4-8ff3-4ba7-acb7-7d4ecdc18c0b" xlink:to="loc_us-gaap_CommonStockMember_9a86ca80-54d4-469a-a2ce-9024f0f784ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a557a259-eafa-4734-bc79-8c0b4709d56d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f9f01a4-8ff3-4ba7-acb7-7d4ecdc18c0b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a557a259-eafa-4734-bc79-8c0b4709d56d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6c302f8-ded8-4dd0-ae3a-e7612687a526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f9f01a4-8ff3-4ba7-acb7-7d4ecdc18c0b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6c302f8-ded8-4dd0-ae3a-e7612687a526" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_08dd36c2-b6d6-4f9a-8d19-547e5f939c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f9f01a4-8ff3-4ba7-acb7-7d4ecdc18c0b" xlink:to="loc_us-gaap_RetainedEarningsMember_08dd36c2-b6d6-4f9a-8d19-547e5f939c18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d722a1c6-5b16-4ef6-b8ec-4691804e8404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f9f01a4-8ff3-4ba7-acb7-7d4ecdc18c0b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d722a1c6-5b16-4ef6-b8ec-4691804e8404" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f313528c-9ab8-4fed-84a1-03852f2b7ea6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_49fe33d2-b031-4310-acbf-9ae11bb19323" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f313528c-9ab8-4fed-84a1-03852f2b7ea6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f313528c-9ab8-4fed-84a1-03852f2b7ea6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f313528c-9ab8-4fed-84a1-03852f2b7ea6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f313528c-9ab8-4fed-84a1-03852f2b7ea6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_47ea50b8-4ada-45a5-8274-a3089c55f3c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f313528c-9ab8-4fed-84a1-03852f2b7ea6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_47ea50b8-4ada-45a5-8274-a3089c55f3c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f709f04b-dfef-4159-9433-b7805e3bdce6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_47ea50b8-4ada-45a5-8274-a3089c55f3c7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f709f04b-dfef-4159-9433-b7805e3bdce6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#REVENUESDisaggregationofRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails" xlink:type="extended" id="i4f140cd1be754105a5306613c5be6537_REVENUESDisaggregationofRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b2cad9b7-3063-4885-a522-9b00a667d321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_afe09cea-da49-46e7-b9a9-24382b5a09c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b2cad9b7-3063-4885-a522-9b00a667d321" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_afe09cea-da49-46e7-b9a9-24382b5a09c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_25008da0-477a-409e-997f-db05b380ee1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b2cad9b7-3063-4885-a522-9b00a667d321" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_25008da0-477a-409e-997f-db05b380ee1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d84c1cee-8113-4991-89df-7922cd324e59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_25008da0-477a-409e-997f-db05b380ee1c" xlink:to="loc_srt_ProductOrServiceAxis_d84c1cee-8113-4991-89df-7922cd324e59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d84c1cee-8113-4991-89df-7922cd324e59_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d84c1cee-8113-4991-89df-7922cd324e59" xlink:to="loc_srt_ProductsAndServicesDomain_d84c1cee-8113-4991-89df-7922cd324e59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_71c63568-af6f-4649-a306-5cdb6a7b5e8d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d84c1cee-8113-4991-89df-7922cd324e59" xlink:to="loc_srt_ProductsAndServicesDomain_71c63568-af6f-4649-a306-5cdb6a7b5e8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_71c63568-af6f-4649-a306-5cdb6a7b5e8d" xlink:to="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:href="gild-20210930.xsd#gild_HIVProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:to="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsAtriplaMember_5ce2354d-49de-4ea6-9b11-768537deaeaa" xlink:href="gild-20210930.xsd#gild_HIVProductsAtriplaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsAtriplaMember_5ce2354d-49de-4ea6-9b11-768537deaeaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember_c8ac4984-c196-4cd2-a402-8451934b02fc" xlink:href="gild-20210930.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsBiktarvyMember_c8ac4984-c196-4cd2-a402-8451934b02fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember_e403e29e-6afd-4133-af8b-3cb15254cfcb" xlink:href="gild-20210930.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsCompleraEvipleraMember_e403e29e-6afd-4133-af8b-3cb15254cfcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember_e249511b-0233-47ec-bfbe-1abb45e1dd1c" xlink:href="gild-20210930.xsd#gild_HIVProductsDescovyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsDescovyMember_e249511b-0233-47ec-bfbe-1abb45e1dd1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember_0872033e-01ba-4662-991b-2a7dc4227884" xlink:href="gild-20210930.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsGenvoyaMember_0872033e-01ba-4662-991b-2a7dc4227884" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember_7ab1286b-3445-47c8-abb3-d3514ea3d01a" xlink:href="gild-20210930.xsd#gild_HIVProductsOdefseyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsOdefseyMember_7ab1286b-3445-47c8-abb3-d3514ea3d01a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember_323241cf-fcf4-4cb3-b756-a52e55cdf07a" xlink:href="gild-20210930.xsd#gild_HIVProductsStribildMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsStribildMember_323241cf-fcf4-4cb3-b756-a52e55cdf07a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember_17a17215-5883-4a0c-b153-d99975ab0917" xlink:href="gild-20210930.xsd#gild_HIVProductsTruvadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsTruvadaMember_17a17215-5883-4a0c-b153-d99975ab0917" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember_0d75a5b6-c4ac-42c1-907d-4619d73d77c2" xlink:href="gild-20210930.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_ProductsRevenueShareSymtuzaMember_0d75a5b6-c4ac-42c1-907d-4619d73d77c2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember_55758a4b-3bbe-4667-99d7-07e43ca57e06" xlink:href="gild-20210930.xsd#gild_ProductsOtherHIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_ProductsOtherHIVMember_55758a4b-3bbe-4667-99d7-07e43ca57e06" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember_bfb03870-4066-4eb0-a5f3-bf5f436ce8ab" xlink:href="gild-20210930.xsd#gild_HCVProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:to="loc_gild_HCVProductSalesMember_bfb03870-4066-4eb0-a5f3-bf5f436ce8ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember_710a6f07-bed3-4036-8b74-55ee183df1c9" xlink:href="gild-20210930.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_bfb03870-4066-4eb0-a5f3-bf5f436ce8ab" xlink:to="loc_gild_HCVProductsLedipasvirSofosbuvirMember_710a6f07-bed3-4036-8b74-55ee183df1c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_a70af30c-443e-4ba6-91d5-969268061c81" xlink:href="gild-20210930.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_bfb03870-4066-4eb0-a5f3-bf5f436ce8ab" xlink:to="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_a70af30c-443e-4ba6-91d5-969268061c81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHepatitisCVirusProductsMember_7b405275-6ef4-490f-8c01-a54e7a0e1c69" xlink:href="gild-20210930.xsd#gild_OtherHepatitisCVirusProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_bfb03870-4066-4eb0-a5f3-bf5f436ce8ab" xlink:to="loc_gild_OtherHepatitisCVirusProductsMember_7b405275-6ef4-490f-8c01-a54e7a0e1c69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_38e8edba-7ebe-48a4-b1af-61b86a456af4" xlink:href="gild-20210930.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_38e8edba-7ebe-48a4-b1af-61b86a456af4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_2770241c-5f23-4169-8274-b57f2c038486" xlink:href="gild-20210930.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_38e8edba-7ebe-48a4-b1af-61b86a456af4" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_2770241c-5f23-4169-8274-b57f2c038486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_78440bc1-4255-4aca-97cb-e03d32bc476e" xlink:href="gild-20210930.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_38e8edba-7ebe-48a4-b1af-61b86a456af4" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_78440bc1-4255-4aca-97cb-e03d32bc476e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_335d030e-aae5-4998-a348-3348cc84fedb" xlink:href="gild-20210930.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_38e8edba-7ebe-48a4-b1af-61b86a456af4" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_335d030e-aae5-4998-a348-3348cc84fedb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember_be4d0786-9a3b-402d-9964-10065f4fe557" xlink:href="gild-20210930.xsd#gild_VekluryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:to="loc_gild_VekluryMember_be4d0786-9a3b-402d-9964-10065f4fe557" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ecc50b88-bb35-450b-ad06-b113a6189dae" xlink:href="gild-20210930.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:to="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ecc50b88-bb35-450b-ad06-b113a6189dae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember_9671bbd1-1137-4571-8f92-98d97d2f2d29" xlink:href="gild-20210930.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ecc50b88-bb35-450b-ad06-b113a6189dae" xlink:to="loc_gild_CellTherapyProductsTecartusMember_9671bbd1-1137-4571-8f92-98d97d2f2d29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsYescartaMember_92543cb0-e2a7-479c-8dae-396d1d8667ec" xlink:href="gild-20210930.xsd#gild_CellTherapyProductsYescartaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ecc50b88-bb35-450b-ad06-b113a6189dae" xlink:to="loc_gild_CellTherapyProductsYescartaMember_92543cb0-e2a7-479c-8dae-396d1d8667ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_3eb1681e-751f-414d-b81a-de02133e01af" xlink:href="gild-20210930.xsd#gild_TrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:to="loc_gild_TrodelvyMember_3eb1681e-751f-414d-b81a-de02133e01af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember_5573ece5-611f-47ec-a324-5711a183fdb0" xlink:href="gild-20210930.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:to="loc_gild_OtherProductsTotalOtherProductSalesMember_5573ece5-611f-47ec-a324-5711a183fdb0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember_a92d3e92-a439-46fc-bc7b-b336ae9751c1" xlink:href="gild-20210930.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_5573ece5-611f-47ec-a324-5711a183fdb0" xlink:to="loc_gild_OtherProductsAmBisomeMember_a92d3e92-a439-46fc-bc7b-b336ae9751c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember_6309089a-82fb-4a43-a4e7-22ecbc2913d9" xlink:href="gild-20210930.xsd#gild_OtherProductsLetairisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_5573ece5-611f-47ec-a324-5711a183fdb0" xlink:to="loc_gild_OtherProductsLetairisMember_6309089a-82fb-4a43-a4e7-22ecbc2913d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsRanexaMember_6ac6a406-d142-4ee2-80d9-60f9e351b227" xlink:href="gild-20210930.xsd#gild_OtherProductsRanexaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_5573ece5-611f-47ec-a324-5711a183fdb0" xlink:to="loc_gild_OtherProductsRanexaMember_6ac6a406-d142-4ee2-80d9-60f9e351b227" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsZydeligMember_6332db23-7168-4c22-bd30-4c7fd660902b" xlink:href="gild-20210930.xsd#gild_OtherProductsZydeligMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_5573ece5-611f-47ec-a324-5711a183fdb0" xlink:to="loc_gild_OtherProductsZydeligMember_6332db23-7168-4c22-bd30-4c7fd660902b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember_356e628d-b400-4b0e-a72b-15b4370cb473" xlink:href="gild-20210930.xsd#gild_OtherProductsOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_5573ece5-611f-47ec-a324-5711a183fdb0" xlink:to="loc_gild_OtherProductsOtherMember_356e628d-b400-4b0e-a72b-15b4370cb473" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_6aad704d-df6a-4f88-8ac1-9511e2539780" xlink:href="gild-20210930.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_71c63568-af6f-4649-a306-5cdb6a7b5e8d" xlink:to="loc_gild_RoyaltyContractAndOtherMember_6aad704d-df6a-4f88-8ac1-9511e2539780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_013d27df-fd61-4f5e-8d70-70af749a44bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_25008da0-477a-409e-997f-db05b380ee1c" xlink:to="loc_srt_StatementGeographicalAxis_013d27df-fd61-4f5e-8d70-70af749a44bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_013d27df-fd61-4f5e-8d70-70af749a44bf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_013d27df-fd61-4f5e-8d70-70af749a44bf" xlink:to="loc_srt_SegmentGeographicalDomain_013d27df-fd61-4f5e-8d70-70af749a44bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_124a2b6c-1553-436d-ad57-f61b8f2b412f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_013d27df-fd61-4f5e-8d70-70af749a44bf" xlink:to="loc_srt_SegmentGeographicalDomain_124a2b6c-1553-436d-ad57-f61b8f2b412f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e2a2d3a6-81c0-4eba-a72d-1459b264699c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_124a2b6c-1553-436d-ad57-f61b8f2b412f" xlink:to="loc_country_US_e2a2d3a6-81c0-4eba-a72d-1459b264699c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_b3e99c45-0684-473f-8c61-6ba6fb97775d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_124a2b6c-1553-436d-ad57-f61b8f2b412f" xlink:to="loc_srt_EuropeMember_b3e99c45-0684-473f-8c61-6ba6fb97775d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember_d298578c-3b22-47a6-bd6c-d4597fd3e0f7" xlink:href="gild-20210930.xsd#gild_OtherInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_124a2b6c-1553-436d-ad57-f61b8f2b412f" xlink:to="loc_gild_OtherInternationalMember_d298578c-3b22-47a6-bd6c-d4597fd3e0f7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#REVENUESRevenuesfromMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails" xlink:type="extended" id="i35ef8dab8ca94edc9f7dd5536fdaad5d_REVENUESRevenuesfromMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3054ea2e-5850-40e7-95cf-0373f6bc3f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ffc46628-8b23-454b-a037-238602e0cad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3054ea2e-5850-40e7-95cf-0373f6bc3f55" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ffc46628-8b23-454b-a037-238602e0cad5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_89f94986-e561-4d01-a3e3-dd5ff2313cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3054ea2e-5850-40e7-95cf-0373f6bc3f55" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_89f94986-e561-4d01-a3e3-dd5ff2313cfa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_14f602c2-9d51-4911-963a-c255a5cd46ae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_89f94986-e561-4d01-a3e3-dd5ff2313cfa" xlink:to="loc_srt_MajorCustomersAxis_14f602c2-9d51-4911-963a-c255a5cd46ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_14f602c2-9d51-4911-963a-c255a5cd46ae_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_14f602c2-9d51-4911-963a-c255a5cd46ae" xlink:to="loc_srt_NameOfMajorCustomerDomain_14f602c2-9d51-4911-963a-c255a5cd46ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b0df3301-b71a-40b0-9f38-c2848537363f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_14f602c2-9d51-4911-963a-c255a5cd46ae" xlink:to="loc_srt_NameOfMajorCustomerDomain_b0df3301-b71a-40b0-9f38-c2848537363f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember_e3dbc62b-1833-41c4-8512-d01839fdcfb4" xlink:href="gild-20210930.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b0df3301-b71a-40b0-9f38-c2848537363f" xlink:to="loc_gild_AmerisourcebergenCorpMember_e3dbc62b-1833-41c4-8512-d01839fdcfb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember_f3c2d6de-9f9a-4252-b402-ce67f68e71e7" xlink:href="gild-20210930.xsd#gild_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b0df3301-b71a-40b0-9f38-c2848537363f" xlink:to="loc_gild_CardinalHealthIncMember_f3c2d6de-9f9a-4252-b402-ce67f68e71e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember_83acc641-0adf-475c-a71a-cbae939d6ab0" xlink:href="gild-20210930.xsd#gild_MckessonCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b0df3301-b71a-40b0-9f38-c2848537363f" xlink:to="loc_gild_MckessonCorpMember_83acc641-0adf-475c-a71a-cbae939d6ab0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f2e8171f-6d1b-40e5-9dab-bb986ab060c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_89f94986-e561-4d01-a3e3-dd5ff2313cfa" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f2e8171f-6d1b-40e5-9dab-bb986ab060c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f2e8171f-6d1b-40e5-9dab-bb986ab060c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f2e8171f-6d1b-40e5-9dab-bb986ab060c2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f2e8171f-6d1b-40e5-9dab-bb986ab060c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_becb7c45-b5f8-48a7-88da-dd5e76338626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f2e8171f-6d1b-40e5-9dab-bb986ab060c2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_becb7c45-b5f8-48a7-88da-dd5e76338626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_3e639b8a-546a-4386-a501-45033b654f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_becb7c45-b5f8-48a7-88da-dd5e76338626" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_3e639b8a-546a-4386-a501-45033b654f80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_bb82a7d6-b417-4a37-b590-95f03f9e8f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_89f94986-e561-4d01-a3e3-dd5ff2313cfa" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_bb82a7d6-b417-4a37-b590-95f03f9e8f28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_bb82a7d6-b417-4a37-b590-95f03f9e8f28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_bb82a7d6-b417-4a37-b590-95f03f9e8f28" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_bb82a7d6-b417-4a37-b590-95f03f9e8f28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f51d6d13-fd15-4e2f-8430-34a04bd9a12f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_bb82a7d6-b417-4a37-b590-95f03f9e8f28" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f51d6d13-fd15-4e2f-8430-34a04bd9a12f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_eb8a93b7-8152-4253-a64d-49f80600d318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f51d6d13-fd15-4e2f-8430-34a04bd9a12f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_eb8a93b7-8152-4253-a64d-49f80600d318" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#REVENUESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/REVENUESAdditionalInformationDetails" xlink:type="extended" id="ibb89868513e84872b857890c0bbc9105_REVENUESAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ad30d284-aea6-459a-b89c-93c47ada64b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_709869d1-3335-4227-b430-a343ffd1c600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad30d284-aea6-459a-b89c-93c47ada64b4" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_709869d1-3335-4227-b430-a343ffd1c600" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_bc9ca0c8-c77c-4be2-84ff-0932499223c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad30d284-aea6-459a-b89c-93c47ada64b4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_bc9ca0c8-c77c-4be2-84ff-0932499223c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_cc48b917-0988-4c18-9fc0-052c2e523c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad30d284-aea6-459a-b89c-93c47ada64b4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_cc48b917-0988-4c18-9fc0-052c2e523c84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c2c9a208-8418-4e8f-a657-1b71f100f491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad30d284-aea6-459a-b89c-93c47ada64b4" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c2c9a208-8418-4e8f-a657-1b71f100f491" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_82a3491c-0ba1-4cdc-a04e-1e4cc2836aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad30d284-aea6-459a-b89c-93c47ada64b4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_82a3491c-0ba1-4cdc-a04e-1e4cc2836aa9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c1183b3-f2b0-437e-be49-3d1cb718d785" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_82a3491c-0ba1-4cdc-a04e-1e4cc2836aa9" xlink:to="loc_srt_ProductOrServiceAxis_8c1183b3-f2b0-437e-be49-3d1cb718d785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c1183b3-f2b0-437e-be49-3d1cb718d785_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8c1183b3-f2b0-437e-be49-3d1cb718d785" xlink:to="loc_srt_ProductsAndServicesDomain_8c1183b3-f2b0-437e-be49-3d1cb718d785_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_017885a4-4af1-49f3-bdc5-b67332ab2c08" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8c1183b3-f2b0-437e-be49-3d1cb718d785" xlink:to="loc_srt_ProductsAndServicesDomain_017885a4-4af1-49f3-bdc5-b67332ab2c08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_1e46087f-6e2f-4544-beac-b34a88f354cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_017885a4-4af1-49f3-bdc5-b67332ab2c08" xlink:to="loc_us-gaap_RoyaltyMember_1e46087f-6e2f-4544-beac-b34a88f354cb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="i3daa7a4b05a14713b2e334f80f3b0e38_FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b725a1a2-44e3-4952-97a4-22c0b51cb30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_93c39bf0-9cd0-4091-adde-ad883c39e504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b725a1a2-44e3-4952-97a4-22c0b51cb30d" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_93c39bf0-9cd0-4091-adde-ad883c39e504" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2260ba81-065c-471a-b6a3-d0bd8b62cd47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93c39bf0-9cd0-4091-adde-ad883c39e504" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2260ba81-065c-471a-b6a3-d0bd8b62cd47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_3928af8b-8d94-4d18-83b9-d83c8659044b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93c39bf0-9cd0-4091-adde-ad883c39e504" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_3928af8b-8d94-4d18-83b9-d83c8659044b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_35ccc40b-cf9b-43c1-8b28-e79a5b8827c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93c39bf0-9cd0-4091-adde-ad883c39e504" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_35ccc40b-cf9b-43c1-8b28-e79a5b8827c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7474c8da-5a46-4ef3-a8b3-c64dd2891d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93c39bf0-9cd0-4091-adde-ad883c39e504" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7474c8da-5a46-4ef3-a8b3-c64dd2891d7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_943f4107-a993-4920-8911-b6deedcb6ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b725a1a2-44e3-4952-97a4-22c0b51cb30d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_943f4107-a993-4920-8911-b6deedcb6ea8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_57a101cb-b80c-42ae-88e0-0b1b528bbd75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_943f4107-a993-4920-8911-b6deedcb6ea8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_57a101cb-b80c-42ae-88e0-0b1b528bbd75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_792c9707-1f37-41d0-8d28-f3f70f636596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_943f4107-a993-4920-8911-b6deedcb6ea8" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_792c9707-1f37-41d0-8d28-f3f70f636596" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_9462e4dd-5722-45a0-8b6e-4bdaacdb0504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_943f4107-a993-4920-8911-b6deedcb6ea8" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_9462e4dd-5722-45a0-8b6e-4bdaacdb0504" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_96a0b3b0-6e33-43ef-84d7-0e5361217e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_943f4107-a993-4920-8911-b6deedcb6ea8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_96a0b3b0-6e33-43ef-84d7-0e5361217e17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b725a1a2-44e3-4952-97a4-22c0b51cb30d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d1aa7ac1-029e-4a61-8e3f-b562a62a2e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d1aa7ac1-029e-4a61-8e3f-b562a62a2e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d1aa7ac1-029e-4a61-8e3f-b562a62a2e99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d1aa7ac1-029e-4a61-8e3f-b562a62a2e99" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d1aa7ac1-029e-4a61-8e3f-b562a62a2e99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a103ead-8116-4dc7-b5c0-197f2a9b904c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d1aa7ac1-029e-4a61-8e3f-b562a62a2e99" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a103ead-8116-4dc7-b5c0-197f2a9b904c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f1f38806-f134-43a0-8bc2-f075db8832ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a103ead-8116-4dc7-b5c0-197f2a9b904c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f1f38806-f134-43a0-8bc2-f075db8832ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9e88de33-e5ce-45ad-860f-83e0bab3112c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9e88de33-e5ce-45ad-860f-83e0bab3112c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e88de33-e5ce-45ad-860f-83e0bab3112c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9e88de33-e5ce-45ad-860f-83e0bab3112c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9e88de33-e5ce-45ad-860f-83e0bab3112c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ceb4682-49d7-4cde-93ca-009eab4b03f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9e88de33-e5ce-45ad-860f-83e0bab3112c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ceb4682-49d7-4cde-93ca-009eab4b03f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6d25d45e-5fc6-4c0a-b106-a7ce4c45db53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ceb4682-49d7-4cde-93ca-009eab4b03f8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6d25d45e-5fc6-4c0a-b106-a7ce4c45db53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6bc3b25b-c6a5-492f-a4b5-4782b6e8824b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ceb4682-49d7-4cde-93ca-009eab4b03f8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6bc3b25b-c6a5-492f-a4b5-4782b6e8824b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2741d616-7d94-471e-96cb-2bf07cc022ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ceb4682-49d7-4cde-93ca-009eab4b03f8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2741d616-7d94-471e-96cb-2bf07cc022ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_fb6d343a-fb08-4b4f-ac0f-6e54b390870d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_fb6d343a-fb08-4b4f-ac0f-6e54b390870d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fb6d343a-fb08-4b4f-ac0f-6e54b390870d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_fb6d343a-fb08-4b4f-ac0f-6e54b390870d" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fb6d343a-fb08-4b4f-ac0f-6e54b390870d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_304e6b23-c665-4e85-b83f-263487d4a14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_fb6d343a-fb08-4b4f-ac0f-6e54b390870d" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_304e6b23-c665-4e85-b83f-263487d4a14a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_470d1b56-14eb-4281-8269-250b79093994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_304e6b23-c665-4e85-b83f-263487d4a14a" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_470d1b56-14eb-4281-8269-250b79093994" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c94b80b1-13b2-43c4-bd97-f561ab942768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_470d1b56-14eb-4281-8269-250b79093994" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c94b80b1-13b2-43c4-bd97-f561ab942768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_26496da8-e3a6-4642-9d15-d3582a57be3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_26496da8-e3a6-4642-9d15-d3582a57be3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_26496da8-e3a6-4642-9d15-d3582a57be3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_26496da8-e3a6-4642-9d15-d3582a57be3c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_26496da8-e3a6-4642-9d15-d3582a57be3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_26496da8-e3a6-4642-9d15-d3582a57be3c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_55132303-f4de-493e-bb2b-d7e0b48abea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_55132303-f4de-493e-bb2b-d7e0b48abea9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0411ec94-33de-4ebb-a0f1-2573a730f006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0411ec94-33de-4ebb-a0f1-2573a730f006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_0c5d397b-0c1a-4355-83ca-44d2b171aedf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_0c5d397b-0c1a-4355-83ca-44d2b171aedf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_21f2ccf1-2563-4068-a768-b360866a1ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_us-gaap_CertificatesOfDepositMember_21f2ccf1-2563-4068-a768-b360866a1ee7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_af0c3f45-783b-4914-aca7-63b09d6f2177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_af0c3f45-783b-4914-aca7-63b09d6f2177" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_9e48648b-7ff9-46f8-8051-0a110e92095d" xlink:href="gild-20210930.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_9e48648b-7ff9-46f8-8051-0a110e92095d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_42fa102c-f67d-4578-ac35-27d54b919540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_us-gaap_MoneyMarketFundsMember_42fa102c-f67d-4578-ac35-27d54b919540" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityinvestmentinGalapagosMember_0c49cc5d-666d-47dc-9a23-e5ae8f5b51b3" xlink:href="gild-20210930.xsd#gild_EquityinvestmentinGalapagosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_gild_EquityinvestmentinGalapagosMember_0c49cc5d-666d-47dc-9a23-e5ae8f5b51b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_aa08be4a-f2ee-4929-b049-b735ebb0ba12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_us-gaap_EquitySecuritiesMember_aa08be4a-f2ee-4929-b049-b735ebb0ba12" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_85d3bc48-e60f-41fb-873c-cbd1b23bf33a" xlink:href="gild-20210930.xsd#gild_DeferredCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_gild_DeferredCompensationPlanMember_85d3bc48-e60f-41fb-873c-cbd1b23bf33a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember_5a0952cb-6758-4c49-b077-79ac935c3af3" xlink:href="gild-20210930.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_gild_ForeignCurrencyDerivativeContractsMember_5a0952cb-6758-4c49-b077-79ac935c3af3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_289a0c64-dc0f-4406-bc31-632f061324af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_289a0c64-dc0f-4406-bc31-632f061324af" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_289a0c64-dc0f-4406-bc31-632f061324af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_289a0c64-dc0f-4406-bc31-632f061324af" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_289a0c64-dc0f-4406-bc31-632f061324af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ecf6a42f-d0c4-45cb-831c-4595599106db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_289a0c64-dc0f-4406-bc31-632f061324af" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ecf6a42f-d0c4-45cb-831c-4595599106db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_3091b8c3-0114-459d-973c-7f1be24fca66" xlink:href="gild-20210930.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ecf6a42f-d0c4-45cb-831c-4595599106db" xlink:to="loc_gild_MYRGmbHMember_3091b8c3-0114-459d-973c-7f1be24fca66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5bb84315-6f7f-489c-b026-9bd49e0752f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5bb84315-6f7f-489c-b026-9bd49e0752f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5bb84315-6f7f-489c-b026-9bd49e0752f5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5bb84315-6f7f-489c-b026-9bd49e0752f5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5bb84315-6f7f-489c-b026-9bd49e0752f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_67b6d0dd-a657-4bbb-b2f0-fd68912e81af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5bb84315-6f7f-489c-b026-9bd49e0752f5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_67b6d0dd-a657-4bbb-b2f0-fd68912e81af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_2bae35fd-b2b9-47bf-902a-a822a118e862" xlink:href="gild-20210930.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_67b6d0dd-a657-4bbb-b2f0-fd68912e81af" xlink:to="loc_gild_ArcusBiosciencesIncMember_2bae35fd-b2b9-47bf-902a-a822a118e862" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails" xlink:type="extended" id="ie798b39a75604f28a31f403bcc6cea81_FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7dd1b30-51cf-426b-9115-9acc7e09e86a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_1f57d13c-e02f-4e2c-9e5d-73c5706cb063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7dd1b30-51cf-426b-9115-9acc7e09e86a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_1f57d13c-e02f-4e2c-9e5d-73c5706cb063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_97c0d657-9224-4849-8284-594c0dc24d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7dd1b30-51cf-426b-9115-9acc7e09e86a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_97c0d657-9224-4849-8284-594c0dc24d73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f613334-a6e9-44f0-bce3-92739f997cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7dd1b30-51cf-426b-9115-9acc7e09e86a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f613334-a6e9-44f0-bce3-92739f997cb1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_951b8eed-7648-4717-8426-80a069e5c2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f613334-a6e9-44f0-bce3-92739f997cb1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_951b8eed-7648-4717-8426-80a069e5c2f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_951b8eed-7648-4717-8426-80a069e5c2f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_951b8eed-7648-4717-8426-80a069e5c2f4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_951b8eed-7648-4717-8426-80a069e5c2f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_572e96ff-ebbf-418b-b626-dfad1ff4e34e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_951b8eed-7648-4717-8426-80a069e5c2f4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_572e96ff-ebbf-418b-b626-dfad1ff4e34e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_cdd8816c-66cf-49c7-94a9-98c0ecd39d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_572e96ff-ebbf-418b-b626-dfad1ff4e34e" xlink:to="loc_us-gaap_EquitySecuritiesMember_cdd8816c-66cf-49c7-94a9-98c0ecd39d0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_98e68185-daa5-4199-9b25-2ec4b043e4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f613334-a6e9-44f0-bce3-92739f997cb1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_98e68185-daa5-4199-9b25-2ec4b043e4f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_98e68185-daa5-4199-9b25-2ec4b043e4f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_98e68185-daa5-4199-9b25-2ec4b043e4f2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_98e68185-daa5-4199-9b25-2ec4b043e4f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b292c96e-d12a-4d59-a414-9f7a3892a39d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_98e68185-daa5-4199-9b25-2ec4b043e4f2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b292c96e-d12a-4d59-a414-9f7a3892a39d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_13995b69-3923-4c68-9490-ab5ec4640940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b292c96e-d12a-4d59-a414-9f7a3892a39d" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_13995b69-3923-4c68-9490-ab5ec4640940" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_e985c7ee-02e3-4769-8964-a45669696ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b292c96e-d12a-4d59-a414-9f7a3892a39d" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_e985c7ee-02e3-4769-8964-a45669696ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_87f11c26-b0ed-489c-be4c-70e2908547a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b292c96e-d12a-4d59-a414-9f7a3892a39d" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_87f11c26-b0ed-489c-be4c-70e2908547a4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#FAIRVALUEMEASUREMENTSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="extended" id="ifb8a21068fe14f60abdf59ea6e559b9f_FAIRVALUEMEASUREMENTSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_cf18ec26-4d38-4675-854a-3246e5debd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_cf18ec26-4d38-4675-854a-3246e5debd6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_dfd00d19-5e29-4311-96df-f42a4c5cf11e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_dfd00d19-5e29-4311-96df-f42a4c5cf11e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7e4be219-5c3c-4b47-98ac-b9dbfaa15aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7e4be219-5c3c-4b47-98ac-b9dbfaa15aba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_d950865e-b6d3-4730-bd86-f2785bced6de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_d950865e-b6d3-4730-bd86-f2785bced6de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_429b596d-48a7-4c2a-b3a4-358b7062cd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:to="loc_us-gaap_LongTermDebtFairValue_429b596d-48a7-4c2a-b3a4-358b7062cd2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_19892b09-25aa-4e2c-a446-0c008708c161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_19892b09-25aa-4e2c-a446-0c008708c161" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3db64155-ce06-4c7f-9135-07b7a680c619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3db64155-ce06-4c7f-9135-07b7a680c619" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_d73f1da1-bd4d-4195-aa50-c5c9d631a844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_d73f1da1-bd4d-4195-aa50-c5c9d631a844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d73f1da1-bd4d-4195-aa50-c5c9d631a844_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_d73f1da1-bd4d-4195-aa50-c5c9d631a844" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d73f1da1-bd4d-4195-aa50-c5c9d631a844_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a8360787-fe9e-4bb0-a225-4539f9745aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_d73f1da1-bd4d-4195-aa50-c5c9d631a844" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a8360787-fe9e-4bb0-a225-4539f9745aec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesDonationMember_bc160e0e-ccc6-49c2-b8b9-8cd1602ad6f2" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesDonationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a8360787-fe9e-4bb0-a225-4539f9745aec" xlink:to="loc_gild_EquitySecuritiesDonationMember_bc160e0e-ccc6-49c2-b8b9-8cd1602ad6f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4ea64550-3e12-4f96-afeb-13042ea2b253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4ea64550-3e12-4f96-afeb-13042ea2b253" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4ea64550-3e12-4f96-afeb-13042ea2b253_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4ea64550-3e12-4f96-afeb-13042ea2b253" xlink:to="loc_us-gaap_RelatedPartyDomain_4ea64550-3e12-4f96-afeb-13042ea2b253_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b1b2b844-bc95-4dea-90f8-d288147e5089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4ea64550-3e12-4f96-afeb-13042ea2b253" xlink:to="loc_us-gaap_RelatedPartyDomain_b1b2b844-bc95-4dea-90f8-d288147e5089" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadFoundationMember_02a4aba5-ced8-4fa6-ba3c-b41a7dff8b93" xlink:href="gild-20210930.xsd#gild_GileadFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b1b2b844-bc95-4dea-90f8-d288147e5089" xlink:to="loc_gild_GileadFoundationMember_02a4aba5-ced8-4fa6-ba3c-b41a7dff8b93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_7fd66470-ec27-4514-8fae-ee93e1d685ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_7fd66470-ec27-4514-8fae-ee93e1d685ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_7fd66470-ec27-4514-8fae-ee93e1d685ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_7fd66470-ec27-4514-8fae-ee93e1d685ed" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_7fd66470-ec27-4514-8fae-ee93e1d685ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0bbc3b61-9829-45f3-8dc8-cdd85b85b467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_7fd66470-ec27-4514-8fae-ee93e1d685ed" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0bbc3b61-9829-45f3-8dc8-cdd85b85b467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5405fc6d-116c-4400-9f6c-3c2b71dfb84f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0bbc3b61-9829-45f3-8dc8-cdd85b85b467" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5405fc6d-116c-4400-9f6c-3c2b71dfb84f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_cb8834de-3221-4439-97a3-3d0a625b8eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5405fc6d-116c-4400-9f6c-3c2b71dfb84f" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_cb8834de-3221-4439-97a3-3d0a625b8eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6d6410d9-cabd-47b8-849e-39eccf181c93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5405fc6d-116c-4400-9f6c-3c2b71dfb84f" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6d6410d9-cabd-47b8-849e-39eccf181c93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ed210bcb-9864-4d10-aabb-f604eb2db996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ed210bcb-9864-4d10-aabb-f604eb2db996" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed210bcb-9864-4d10-aabb-f604eb2db996_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ed210bcb-9864-4d10-aabb-f604eb2db996" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed210bcb-9864-4d10-aabb-f604eb2db996_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_33172143-d893-41d8-99a0-01deffe6ca08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ed210bcb-9864-4d10-aabb-f604eb2db996" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_33172143-d893-41d8-99a0-01deffe6ca08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1b8074ab-9dab-43d0-9f12-76727dc708f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_33172143-d893-41d8-99a0-01deffe6ca08" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1b8074ab-9dab-43d0-9f12-76727dc708f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d58ea9b9-bb7e-436e-97dd-f1e4708a03ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_33172143-d893-41d8-99a0-01deffe6ca08" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d58ea9b9-bb7e-436e-97dd-f1e4708a03ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_38b4f25b-462e-445f-835c-8a5dff6c6b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_38b4f25b-462e-445f-835c-8a5dff6c6b3b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_38b4f25b-462e-445f-835c-8a5dff6c6b3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_38b4f25b-462e-445f-835c-8a5dff6c6b3b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_38b4f25b-462e-445f-835c-8a5dff6c6b3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b114b61e-eaaf-4f81-86c5-baeef97aa3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_38b4f25b-462e-445f-835c-8a5dff6c6b3b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b114b61e-eaaf-4f81-86c5-baeef97aa3a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_1a565de4-e67b-4d0d-bfac-605ca94537c6" xlink:href="gild-20210930.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b114b61e-eaaf-4f81-86c5-baeef97aa3a0" xlink:to="loc_gild_MYRGmbHMember_1a565de4-e67b-4d0d-bfac-605ca94537c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_932d3766-ba44-4555-b065-a4c4f51cfe7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_932d3766-ba44-4555-b065-a4c4f51cfe7d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_932d3766-ba44-4555-b065-a4c4f51cfe7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_932d3766-ba44-4555-b065-a4c4f51cfe7d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_932d3766-ba44-4555-b065-a4c4f51cfe7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1af9fd0-be52-448d-ae6b-08fdbf88f6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_932d3766-ba44-4555-b065-a4c4f51cfe7d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1af9fd0-be52-448d-ae6b-08fdbf88f6d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ad46f165-747e-457b-9188-488851c07f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1af9fd0-be52-448d-ae6b-08fdbf88f6d2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ad46f165-747e-457b-9188-488851c07f36" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails" xlink:type="extended" id="i88d9582f03d9451abfdfb377578b33ea_FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1d0274b2-937e-45e3-959c-280834defe8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_8ef2c9aa-825a-4a39-98d4-67610ad32b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1d0274b2-937e-45e3-959c-280834defe8a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_8ef2c9aa-825a-4a39-98d4-67610ad32b50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_206176ac-5067-4c54-9e68-f8014411c955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1d0274b2-937e-45e3-959c-280834defe8a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_206176ac-5067-4c54-9e68-f8014411c955" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c1461bc1-b39e-4ecd-83f0-1021ad06034e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_206176ac-5067-4c54-9e68-f8014411c955" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c1461bc1-b39e-4ecd-83f0-1021ad06034e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c1461bc1-b39e-4ecd-83f0-1021ad06034e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c1461bc1-b39e-4ecd-83f0-1021ad06034e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c1461bc1-b39e-4ecd-83f0-1021ad06034e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0594984b-5817-4c86-8fed-e775bd2ff08f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c1461bc1-b39e-4ecd-83f0-1021ad06034e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0594984b-5817-4c86-8fed-e775bd2ff08f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosNVMember_e87e4adf-365a-48c0-8a33-7ec0b0fac5d3" xlink:href="gild-20210930.xsd#gild_GalapagosNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0594984b-5817-4c86-8fed-e775bd2ff08f" xlink:to="loc_gild_GalapagosNVMember_e87e4adf-365a-48c0-8a33-7ec0b0fac5d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_223d3d9f-b6d7-42f2-9c1d-7f70f9a0523d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_206176ac-5067-4c54-9e68-f8014411c955" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_223d3d9f-b6d7-42f2-9c1d-7f70f9a0523d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_223d3d9f-b6d7-42f2-9c1d-7f70f9a0523d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_223d3d9f-b6d7-42f2-9c1d-7f70f9a0523d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_223d3d9f-b6d7-42f2-9c1d-7f70f9a0523d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6b97205c-5bfb-47b9-a689-2ee25683e176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_223d3d9f-b6d7-42f2-9c1d-7f70f9a0523d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6b97205c-5bfb-47b9-a689-2ee25683e176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0e86de85-2d77-451d-b923-ff9e0c765bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6b97205c-5bfb-47b9-a689-2ee25683e176" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0e86de85-2d77-451d-b923-ff9e0c765bd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_9e1a0bd4-16fb-4475-a566-9ac274fa93cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6b97205c-5bfb-47b9-a689-2ee25683e176" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_9e1a0bd4-16fb-4475-a566-9ac274fa93cb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended" id="i5969a0e87150410499140ff0d04c678c_AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10425dc4-fa30-4a3d-be00-3e0ff1b022fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_d7ef27f3-b22e-4cd8-a02d-4232e1c88c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10425dc4-fa30-4a3d-be00-3e0ff1b022fc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_d7ef27f3-b22e-4cd8-a02d-4232e1c88c5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2dd7dd80-9da0-46c2-9ee7-c6afd59f0ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10425dc4-fa30-4a3d-be00-3e0ff1b022fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2dd7dd80-9da0-46c2-9ee7-c6afd59f0ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2504a2be-c1f1-4474-9df7-2be1131c5f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10425dc4-fa30-4a3d-be00-3e0ff1b022fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2504a2be-c1f1-4474-9df7-2be1131c5f2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ccd1d3f1-dbe6-4bd9-a025-29e6b60cd6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10425dc4-fa30-4a3d-be00-3e0ff1b022fc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ccd1d3f1-dbe6-4bd9-a025-29e6b60cd6e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a68d1521-609c-497a-8263-63ca6a0a6ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10425dc4-fa30-4a3d-be00-3e0ff1b022fc" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a68d1521-609c-497a-8263-63ca6a0a6ef1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_22ed0db2-3500-4df8-bd16-210bc7da67d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a68d1521-609c-497a-8263-63ca6a0a6ef1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_22ed0db2-3500-4df8-bd16-210bc7da67d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22ed0db2-3500-4df8-bd16-210bc7da67d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_22ed0db2-3500-4df8-bd16-210bc7da67d0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22ed0db2-3500-4df8-bd16-210bc7da67d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_22ed0db2-3500-4df8-bd16-210bc7da67d0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_ee29101e-1f10-4c44-a54d-3aca8207ab2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_ee29101e-1f10-4c44-a54d-3aca8207ab2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4da411d1-b153-4d3c-abb9-a90c0b76e8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4da411d1-b153-4d3c-abb9-a90c0b76e8ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_bcf4d77d-555a-4794-9b8a-b1a1d66de94e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_bcf4d77d-555a-4794-9b8a-b1a1d66de94e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0a526c5f-67cb-4abd-a0e0-070391f8a732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0a526c5f-67cb-4abd-a0e0-070391f8a732" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9e6198b2-4131-431f-9681-3a88b30e5733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9e6198b2-4131-431f-9681-3a88b30e5733" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_2464156f-f985-4689-b725-65cbea2c5262" xlink:href="gild-20210930.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_2464156f-f985-4689-b725-65cbea2c5262" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended" id="i49ec3ec330eb483c8663b16fad20c3d8_AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05d3e2b4-f5ec-45d3-9200-181bbb7f59cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_303a82ce-abcb-45cd-9f78-adcb917bd71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05d3e2b4-f5ec-45d3-9200-181bbb7f59cb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_303a82ce-abcb-45cd-9f78-adcb917bd71f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f620e9b2-2859-4407-95ff-01d96091b9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05d3e2b4-f5ec-45d3-9200-181bbb7f59cb" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f620e9b2-2859-4407-95ff-01d96091b9ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_73444bd1-0161-4fd2-963d-2e90c9cf3154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f620e9b2-2859-4407-95ff-01d96091b9ec" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_73444bd1-0161-4fd2-963d-2e90c9cf3154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_73444bd1-0161-4fd2-963d-2e90c9cf3154_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_73444bd1-0161-4fd2-963d-2e90c9cf3154" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_73444bd1-0161-4fd2-963d-2e90c9cf3154_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_87513c01-f17d-4f48-b439-22a0955b7503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_73444bd1-0161-4fd2-963d-2e90c9cf3154" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_87513c01-f17d-4f48-b439-22a0955b7503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_db462885-d5fd-49a3-8918-1d1177ba7795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_87513c01-f17d-4f48-b439-22a0955b7503" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_db462885-d5fd-49a3-8918-1d1177ba7795" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember_cbd6655e-f965-4cfa-a51d-d41cf67f0a8f" xlink:href="gild-20210930.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_87513c01-f17d-4f48-b439-22a0955b7503" xlink:to="loc_gild_MarketableSecuritiesCurrentMember_cbd6655e-f965-4cfa-a51d-d41cf67f0a8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember_49d196c7-bfcf-4104-97c5-5c3dbb12598c" xlink:href="gild-20210930.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_87513c01-f17d-4f48-b439-22a0955b7503" xlink:to="loc_gild_MarketableSecuritiesNoncurrentMember_49d196c7-bfcf-4104-97c5-5c3dbb12598c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="extended" id="icfce6ef55766408db0687ada18991ad5_DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a50480c9-e5e3-4971-87f3-ef9d022b4b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_ab3b4c6d-4acd-43ff-a8f5-d850be1b663b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a50480c9-e5e3-4971-87f3-ef9d022b4b77" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_ab3b4c6d-4acd-43ff-a8f5-d850be1b663b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_0aee8cdb-2914-4f2b-b6e2-76d57e02160e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a50480c9-e5e3-4971-87f3-ef9d022b4b77" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_0aee8cdb-2914-4f2b-b6e2-76d57e02160e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_3bc89064-75a2-40b4-a451-4f381b771470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a50480c9-e5e3-4971-87f3-ef9d022b4b77" xlink:to="loc_us-gaap_DerivativeNotionalAmount_3bc89064-75a2-40b4-a451-4f381b771470" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_a2525034-f39b-4a3e-99af-f3276f4b3ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a50480c9-e5e3-4971-87f3-ef9d022b4b77" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_a2525034-f39b-4a3e-99af-f3276f4b3ae2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f44a5042-72a7-430d-96b2-48799dfabd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_a50480c9-e5e3-4971-87f3-ef9d022b4b77" xlink:to="loc_us-gaap_DerivativeTable_f44a5042-72a7-430d-96b2-48799dfabd7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8ee77744-a859-4723-8112-64349a4e0565" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f44a5042-72a7-430d-96b2-48799dfabd7a" xlink:to="loc_srt_RangeAxis_8ee77744-a859-4723-8112-64349a4e0565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ee77744-a859-4723-8112-64349a4e0565_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8ee77744-a859-4723-8112-64349a4e0565" xlink:to="loc_srt_RangeMember_8ee77744-a859-4723-8112-64349a4e0565_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_efec2534-54cf-4e9b-a621-3e8682b18a74" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8ee77744-a859-4723-8112-64349a4e0565" xlink:to="loc_srt_RangeMember_efec2534-54cf-4e9b-a621-3e8682b18a74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d9095406-9e8e-48b0-a91f-5a494c558d1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_efec2534-54cf-4e9b-a621-3e8682b18a74" xlink:to="loc_srt_MaximumMember_d9095406-9e8e-48b0-a91f-5a494c558d1b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended" id="i2c52d0e7f3004c29a7a05b7f0aa801bd_DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_fd48e4e3-4cf0-4765-bd33-db536427ab8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_13b08b18-4060-4842-96c5-b90bf531d277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_fd48e4e3-4cf0-4765-bd33-db536427ab8f" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_13b08b18-4060-4842-96c5-b90bf531d277" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_5f5faf4c-3fde-4c3a-b406-c75f39d57047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_fd48e4e3-4cf0-4765-bd33-db536427ab8f" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_5f5faf4c-3fde-4c3a-b406-c75f39d57047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_963c95ae-d333-461d-8672-f72721f9b5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_fd48e4e3-4cf0-4765-bd33-db536427ab8f" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_963c95ae-d333-461d-8672-f72721f9b5fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6f5dbde2-5d83-4c2e-b8b5-b461ab335174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_963c95ae-d333-461d-8672-f72721f9b5fe" xlink:to="loc_us-gaap_HedgingDesignationAxis_6f5dbde2-5d83-4c2e-b8b5-b461ab335174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6f5dbde2-5d83-4c2e-b8b5-b461ab335174_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_6f5dbde2-5d83-4c2e-b8b5-b461ab335174" xlink:to="loc_us-gaap_HedgingDesignationDomain_6f5dbde2-5d83-4c2e-b8b5-b461ab335174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d5de5cec-f779-4d3a-9f6e-70c6a5d4eec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_6f5dbde2-5d83-4c2e-b8b5-b461ab335174" xlink:to="loc_us-gaap_HedgingDesignationDomain_d5de5cec-f779-4d3a-9f6e-70c6a5d4eec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f0cbaa21-7302-4628-ba7b-95504950ad7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_d5de5cec-f779-4d3a-9f6e-70c6a5d4eec4" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f0cbaa21-7302-4628-ba7b-95504950ad7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5b858a66-a610-4a75-bae9-e2319b3208aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_d5de5cec-f779-4d3a-9f6e-70c6a5d4eec4" xlink:to="loc_us-gaap_NondesignatedMember_5b858a66-a610-4a75-bae9-e2319b3208aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4ec16c4f-c1d5-4444-8b71-6947247fbe55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_963c95ae-d333-461d-8672-f72721f9b5fe" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4ec16c4f-c1d5-4444-8b71-6947247fbe55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4ec16c4f-c1d5-4444-8b71-6947247fbe55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4ec16c4f-c1d5-4444-8b71-6947247fbe55" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4ec16c4f-c1d5-4444-8b71-6947247fbe55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e53e74a5-fc99-4c2b-a867-09cf599574c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4ec16c4f-c1d5-4444-8b71-6947247fbe55" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e53e74a5-fc99-4c2b-a867-09cf599574c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_f0a461b5-6b41-4220-b772-1e3a4cc3680a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e53e74a5-fc99-4c2b-a867-09cf599574c2" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_f0a461b5-6b41-4220-b772-1e3a4cc3680a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_efd8baf9-4291-4a5d-80ad-fb9ef318f9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e53e74a5-fc99-4c2b-a867-09cf599574c2" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_efd8baf9-4291-4a5d-80ad-fb9ef318f9bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_2e65f6a1-7546-4c52-9373-5186aa515763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e53e74a5-fc99-4c2b-a867-09cf599574c2" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_2e65f6a1-7546-4c52-9373-5186aa515763" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a1b8a3ea-393c-4a75-9203-7b4685e837d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e53e74a5-fc99-4c2b-a867-09cf599574c2" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a1b8a3ea-393c-4a75-9203-7b4685e837d2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended" id="i655886deab3640eeba9ce15e6c174377_ACQUISITIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9e5a0445-3e99-4c13-a487-b8ee153087ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9e5a0445-3e99-4c13-a487-b8ee153087ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6cf199c1-4907-4cf7-9888-171bafa138b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6cf199c1-4907-4cf7-9888-171bafa138b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3437dfb9-5479-48ea-980c-315eb178a5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3437dfb9-5479-48ea-980c-315eb178a5a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_6d2ba343-d8bb-4818-bcf6-38cf701bfc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_6d2ba343-d8bb-4818-bcf6-38cf701bfc2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_4e7abd10-cd09-49a8-b216-305de7bca408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_4e7abd10-cd09-49a8-b216-305de7bca408" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetMeasurementInput_60d555ca-a9ba-4b0d-8f2c-9545a9004310" xlink:href="gild-20210930.xsd#gild_IntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_gild_IntangibleAssetMeasurementInput_60d555ca-a9ba-4b0d-8f2c-9545a9004310" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8ba309a2-e1f1-4640-9e0e-ce700484ce22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8ba309a2-e1f1-4640-9e0e-ce700484ce22" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_10d606b9-612c-417f-8fbb-274cf284ac62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_10d606b9-612c-417f-8fbb-274cf284ac62" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_1438a203-d0ad-4d1e-8af5-c577dba02699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_GoodwillGross_1438a203-d0ad-4d1e-8af5-c577dba02699" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_b9204395-38b1-4ac3-b09f-86b27af422ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_b9204395-38b1-4ac3-b09f-86b27af422ca" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_50d39bf5-acd3-42d7-85c3-805c280d64db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_50d39bf5-acd3-42d7-85c3-805c280d64db" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired_bcf5fd0d-1ca7-4eab-a074-af14e2e1b2d8" xlink:href="gild-20210930.xsd#gild_PaymentsToAcquireAssetsNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired_bcf5fd0d-1ca7-4eab-a074-af14e2e1b2d8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_21ff5368-76fc-473d-9701-cce43155ac24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_21ff5368-76fc-473d-9701-cce43155ac24" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_94a3fc29-3150-4ac8-8951-19da26c26368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_94a3fc29-3150-4ac8-8951-19da26c26368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94a3fc29-3150-4ac8-8951-19da26c26368_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_94a3fc29-3150-4ac8-8951-19da26c26368" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94a3fc29-3150-4ac8-8951-19da26c26368_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a6cd1c5b-f618-47b8-80a6-3be01c8a99ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_94a3fc29-3150-4ac8-8951-19da26c26368" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a6cd1c5b-f618-47b8-80a6-3be01c8a99ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_81f6ce5b-9e8e-47a8-88ff-fcb62998cac9" xlink:href="gild-20210930.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a6cd1c5b-f618-47b8-80a6-3be01c8a99ac" xlink:to="loc_gild_MYRGmbHMember_81f6ce5b-9e8e-47a8-88ff-fcb62998cac9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_a5555aa7-531e-413c-90dc-cd3ea36c5fd6" xlink:href="gild-20210930.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a6cd1c5b-f618-47b8-80a6-3be01c8a99ac" xlink:to="loc_gild_ImmunomedicsIncMember_a5555aa7-531e-413c-90dc-cd3ea36c5fd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4f2e2b5a-1ab4-4bbc-9448-37b7762e43eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4f2e2b5a-1ab4-4bbc-9448-37b7762e43eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4f2e2b5a-1ab4-4bbc-9448-37b7762e43eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4f2e2b5a-1ab4-4bbc-9448-37b7762e43eb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4f2e2b5a-1ab4-4bbc-9448-37b7762e43eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ceaa413a-c4cc-4bd2-a1e3-cf29445af79d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4f2e2b5a-1ab4-4bbc-9448-37b7762e43eb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ceaa413a-c4cc-4bd2-a1e3-cf29445af79d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a97bee6b-cea6-4aee-ac95-4d3254ad99c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ceaa413a-c4cc-4bd2-a1e3-cf29445af79d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a97bee6b-cea6-4aee-ac95-4d3254ad99c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f5b2cdc-bab0-4718-b6d5-8ad189b51862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f5b2cdc-bab0-4718-b6d5-8ad189b51862" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3f5b2cdc-bab0-4718-b6d5-8ad189b51862_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f5b2cdc-bab0-4718-b6d5-8ad189b51862" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3f5b2cdc-bab0-4718-b6d5-8ad189b51862_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7aa9c2e1-ca23-4b6f-8e3b-3c8530e369f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f5b2cdc-bab0-4718-b6d5-8ad189b51862" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7aa9c2e1-ca23-4b6f-8e3b-3c8530e369f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexForHDVMember_baa0a938-4790-4e35-937a-bd99299c0c16" xlink:href="gild-20210930.xsd#gild_HepcludexForHDVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7aa9c2e1-ca23-4b6f-8e3b-3c8530e369f4" xlink:to="loc_gild_HepcludexForHDVMember_baa0a938-4790-4e35-937a-bd99299c0c16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f38b3191-6c39-496a-9ea9-98469c3dace4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_DebtInstrumentAxis_f38b3191-6c39-496a-9ea9-98469c3dace4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f38b3191-6c39-496a-9ea9-98469c3dace4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f38b3191-6c39-496a-9ea9-98469c3dace4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f38b3191-6c39-496a-9ea9-98469c3dace4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_85fcd240-20db-4f27-999d-156b3f47722e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f38b3191-6c39-496a-9ea9-98469c3dace4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_85fcd240-20db-4f27-999d-156b3f47722e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_be4dfc39-02d2-42ab-9bc2-37b74cd5c6e6" xlink:href="gild-20210930.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_85fcd240-20db-4f27-999d-156b3f47722e" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_be4dfc39-02d2-42ab-9bc2-37b74cd5c6e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d000489b-f99d-4c11-865c-38aa3e79a678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d000489b-f99d-4c11-865c-38aa3e79a678" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d000489b-f99d-4c11-865c-38aa3e79a678_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d000489b-f99d-4c11-865c-38aa3e79a678" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d000489b-f99d-4c11-865c-38aa3e79a678_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_45817684-4325-4e96-a9bf-02dc342993f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d000489b-f99d-4c11-865c-38aa3e79a678" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_45817684-4325-4e96-a9bf-02dc342993f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_2aad6db7-8877-4769-b44b-cf55ccce2161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_45817684-4325-4e96-a9bf-02dc342993f1" xlink:to="loc_us-gaap_MediumTermNotesMember_2aad6db7-8877-4769-b44b-cf55ccce2161" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_12fd73d7-0028-49e8-86a2-82d1aaace3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_12fd73d7-0028-49e8-86a2-82d1aaace3f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_12fd73d7-0028-49e8-86a2-82d1aaace3f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_12fd73d7-0028-49e8-86a2-82d1aaace3f2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_12fd73d7-0028-49e8-86a2-82d1aaace3f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a975dc9c-990f-4e5e-ba13-da8e6289e000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_12fd73d7-0028-49e8-86a2-82d1aaace3f2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a975dc9c-990f-4e5e-ba13-da8e6289e000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_58623964-13c1-4146-9916-ca81212f0853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a975dc9c-990f-4e5e-ba13-da8e6289e000" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_58623964-13c1-4146-9916-ca81212f0853" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6e16b0da-39dc-4fd0-876b-e03262cf8b15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_srt_RangeAxis_6e16b0da-39dc-4fd0-876b-e03262cf8b15" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e16b0da-39dc-4fd0-876b-e03262cf8b15_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6e16b0da-39dc-4fd0-876b-e03262cf8b15" xlink:to="loc_srt_RangeMember_6e16b0da-39dc-4fd0-876b-e03262cf8b15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d824bef-0f64-4d7a-96ed-a9273902fc65" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6e16b0da-39dc-4fd0-876b-e03262cf8b15" xlink:to="loc_srt_RangeMember_1d824bef-0f64-4d7a-96ed-a9273902fc65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_90123f7e-6557-477e-96ed-83dffe0cc261" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1d824bef-0f64-4d7a-96ed-a9273902fc65" xlink:to="loc_srt_MaximumMember_90123f7e-6557-477e-96ed-83dffe0cc261" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_d8d935f5-3cf1-494a-a43c-3f491b3ec446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_AssetAcquisitionAxis_d8d935f5-3cf1-494a-a43c-3f491b3ec446" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_d8d935f5-3cf1-494a-a43c-3f491b3ec446_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_d8d935f5-3cf1-494a-a43c-3f491b3ec446" xlink:to="loc_us-gaap_AssetAcquisitionDomain_d8d935f5-3cf1-494a-a43c-3f491b3ec446_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c4c941f9-1cd2-445e-8a68-499ac3a2ee0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_d8d935f5-3cf1-494a-a43c-3f491b3ec446" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c4c941f9-1cd2-445e-8a68-499ac3a2ee0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_ad3b0dbb-cb7f-45e0-a865-2f76278dfb10" xlink:href="gild-20210930.xsd#gild_FortySevenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c4c941f9-1cd2-445e-8a68-499ac3a2ee0d" xlink:to="loc_gild_FortySevenIncMember_ad3b0dbb-cb7f-45e0-a865-2f76278dfb10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_457420cd-dcee-45b7-9be9-b6af248ff98f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_457420cd-dcee-45b7-9be9-b6af248ff98f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_457420cd-dcee-45b7-9be9-b6af248ff98f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_457420cd-dcee-45b7-9be9-b6af248ff98f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_457420cd-dcee-45b7-9be9-b6af248ff98f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9089ca44-b3a1-4c4c-848a-761207ebe2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_457420cd-dcee-45b7-9be9-b6af248ff98f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9089ca44-b3a1-4c4c-848a-761207ebe2b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b938d4bb-ce9a-488d-984f-184eea518f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9089ca44-b3a1-4c4c-848a-761207ebe2b1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b938d4bb-ce9a-488d-984f-184eea518f11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_901d5a7c-1da8-48aa-8825-4c76b09608d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_901d5a7c-1da8-48aa-8825-4c76b09608d7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_901d5a7c-1da8-48aa-8825-4c76b09608d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_901d5a7c-1da8-48aa-8825-4c76b09608d7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_901d5a7c-1da8-48aa-8825-4c76b09608d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ab624944-12b0-4c6c-b6d3-f16fb8fc74d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_901d5a7c-1da8-48aa-8825-4c76b09608d7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ab624944-12b0-4c6c-b6d3-f16fb8fc74d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_dabe0043-5f89-4b51-a4e5-d3be2688a8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ab624944-12b0-4c6c-b6d3-f16fb8fc74d8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_dabe0043-5f89-4b51-a4e5-d3be2688a8bc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i03d6395bfa9f409b8ed007f544162552_ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_71c10f09-0ad2-437e-9943-fb95bfd35d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_71c10f09-0ad2-437e-9943-fb95bfd35d52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_55c06a35-3e14-4e0a-8d13-cfef7d2ce760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_55c06a35-3e14-4e0a-8d13-cfef7d2ce760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_415e2c13-e03b-4084-9828-8c327f0724ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_415e2c13-e03b-4084-9828-8c327f0724ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_20ac2424-d1a3-4d32-b074-1a8767e82c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_415e2c13-e03b-4084-9828-8c327f0724ea" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_20ac2424-d1a3-4d32-b074-1a8767e82c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_05e8a827-92f5-4fb2-98ed-21ff5bccb4df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_415e2c13-e03b-4084-9828-8c327f0724ea" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_05e8a827-92f5-4fb2-98ed-21ff5bccb4df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3f1cfbd3-f60c-4e6a-b5ae-680bdf6e70cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3f1cfbd3-f60c-4e6a-b5ae-680bdf6e70cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_1ab8f4eb-d217-4637-aeb5-0babf7de7be7" xlink:href="gild-20210930.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_1ab8f4eb-d217-4637-aeb5-0babf7de7be7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_28b165b5-9571-4342-b162-91332ec6d567" xlink:href="gild-20210930.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_28b165b5-9571-4342-b162-91332ec6d567" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e21a71b1-f8d0-4017-b7d5-c2ba13f3b3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e21a71b1-f8d0-4017-b7d5-c2ba13f3b3bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_f68110ed-b537-48cd-823c-8390a6b6ca19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_us-gaap_GoodwillGross_f68110ed-b537-48cd-823c-8390a6b6ca19" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9ab2de3d-55d4-459b-9cec-27a263dabeef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9ab2de3d-55d4-459b-9cec-27a263dabeef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_fe7b57da-d641-41c6-a653-829d2becf87d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_fe7b57da-d641-41c6-a653-829d2becf87d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_74256089-f77d-4b62-9cba-66a42210ae24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_fe7b57da-d641-41c6-a653-829d2becf87d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_74256089-f77d-4b62-9cba-66a42210ae24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74256089-f77d-4b62-9cba-66a42210ae24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_74256089-f77d-4b62-9cba-66a42210ae24" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74256089-f77d-4b62-9cba-66a42210ae24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a05707d2-7603-4339-b059-0b42105e4d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_74256089-f77d-4b62-9cba-66a42210ae24" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a05707d2-7603-4339-b059-0b42105e4d7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_2e6dca0a-fe54-472a-a87e-af9bebb8c19e" xlink:href="gild-20210930.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a05707d2-7603-4339-b059-0b42105e4d7e" xlink:to="loc_gild_MYRGmbHMember_2e6dca0a-fe54-472a-a87e-af9bebb8c19e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_45caeaec-b810-4d80-a091-f507623552b1" xlink:href="gild-20210930.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a05707d2-7603-4339-b059-0b42105e4d7e" xlink:to="loc_gild_ImmunomedicsIncMember_45caeaec-b810-4d80-a091-f507623552b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c434c632-5f8c-4567-9d91-00792d0681fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_fe7b57da-d641-41c6-a653-829d2becf87d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c434c632-5f8c-4567-9d91-00792d0681fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c434c632-5f8c-4567-9d91-00792d0681fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c434c632-5f8c-4567-9d91-00792d0681fa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c434c632-5f8c-4567-9d91-00792d0681fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c2e220c-3014-4bd2-8a20-fb622ab142a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c434c632-5f8c-4567-9d91-00792d0681fa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c2e220c-3014-4bd2-8a20-fb622ab142a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyForMTNBCMember_2c90607e-0040-44f4-8da1-7b560b93db0b" xlink:href="gild-20210930.xsd#gild_TrodelvyForMTNBCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c2e220c-3014-4bd2-8a20-fb622ab142a1" xlink:to="loc_gild_TrodelvyForMTNBCMember_2c90607e-0040-44f4-8da1-7b560b93db0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_9e745140-04ce-4380-bd4b-848027cbde21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c2e220c-3014-4bd2-8a20-fb622ab142a1" xlink:to="loc_us-gaap_LicensingAgreementsMember_9e745140-04ce-4380-bd4b-848027cbde21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a3d5cd9e-ad10-4325-b8bc-5018a0265fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_fe7b57da-d641-41c6-a653-829d2becf87d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a3d5cd9e-ad10-4325-b8bc-5018a0265fad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a3d5cd9e-ad10-4325-b8bc-5018a0265fad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a3d5cd9e-ad10-4325-b8bc-5018a0265fad" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a3d5cd9e-ad10-4325-b8bc-5018a0265fad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_def79baa-51d0-4d4d-a0b7-5835fc131af4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a3d5cd9e-ad10-4325-b8bc-5018a0265fad" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_def79baa-51d0-4d4d-a0b7-5835fc131af4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_0bb7f6e0-d6e3-4753-8817-7d7db1ceeb33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_def79baa-51d0-4d4d-a0b7-5835fc131af4" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_0bb7f6e0-d6e3-4753-8817-7d7db1ceeb33" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="extended" id="icc9057ecae6c4aec9c5a7a2d20764ced_GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5abec81a-147b-4eec-9b68-5f923b30eed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5abec81a-147b-4eec-9b68-5f923b30eed5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9fdb478a-a999-4f04-b696-5e3cf5546ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9fdb478a-a999-4f04-b696-5e3cf5546ba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_5ac8f253-84f9-4cb0-af15-d867d69f29d6" xlink:href="gild-20210930.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_5ac8f253-84f9-4cb0-af15-d867d69f29d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aeac85cc-b026-44f0-ae1c-daa9fe92a0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aeac85cc-b026-44f0-ae1c-daa9fe92a0fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac6dce0e-51e8-4e6d-acf0-718fa7fcaade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac6dce0e-51e8-4e6d-acf0-718fa7fcaade" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_408e858b-1efb-43b7-af30-d1bc6ae26ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac6dce0e-51e8-4e6d-acf0-718fa7fcaade" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_408e858b-1efb-43b7-af30-d1bc6ae26ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_e3d03778-43ed-46d8-995a-5e3713c91124" xlink:href="gild-20210930.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac6dce0e-51e8-4e6d-acf0-718fa7fcaade" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_e3d03778-43ed-46d8-995a-5e3713c91124" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_d2f914c4-0149-4b2b-87d0-d44f6ff4a199" xlink:href="gild-20210930.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac6dce0e-51e8-4e6d-acf0-718fa7fcaade" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_d2f914c4-0149-4b2b-87d0-d44f6ff4a199" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_74cf751a-01a1-4251-acda-3087f328fda3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_74cf751a-01a1-4251-acda-3087f328fda3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_23842d6e-4dfe-4792-a07f-be2fe9e369a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_74cf751a-01a1-4251-acda-3087f328fda3" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_23842d6e-4dfe-4792-a07f-be2fe9e369a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ebe51acb-5270-41de-81ab-b898ad1ec6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_741a717a-7907-4ae8-b8a8-cb896276f2b0" xlink:href="gild-20210930.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_74cf751a-01a1-4251-acda-3087f328fda3" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_741a717a-7907-4ae8-b8a8-cb896276f2b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_64df8d90-8acf-44dd-8ab0-8584cafe27a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_74cf751a-01a1-4251-acda-3087f328fda3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_64df8d90-8acf-44dd-8ab0-8584cafe27a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_12281629-5d42-40bb-ba68-8845f8a36425" xlink:href="gild-20210930.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_12281629-5d42-40bb-ba68-8845f8a36425" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_635fad9d-14ee-4b16-9733-91493e88606e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_635fad9d-14ee-4b16-9733-91493e88606e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f625b4f7-0bb0-459b-9b87-997e989704ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f625b4f7-0bb0-459b-9b87-997e989704ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4c7c17e1-aa6b-470c-904a-1073ca48bfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f625b4f7-0bb0-459b-9b87-997e989704ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4c7c17e1-aa6b-470c-904a-1073ca48bfd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4c7c17e1-aa6b-470c-904a-1073ca48bfd1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4c7c17e1-aa6b-470c-904a-1073ca48bfd1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4c7c17e1-aa6b-470c-904a-1073ca48bfd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4c7c17e1-aa6b-470c-904a-1073ca48bfd1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember_2348c0fe-d750-4728-aa38-7cfb0f233981" xlink:href="gild-20210930.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:to="loc_gild_IntangibleAssetSofosbuvirMember_2348c0fe-d750-4728-aa38-7cfb0f233981" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember_44df7c46-b36d-46e8-bfb2-f875e2a3e724" xlink:href="gild-20210930.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:to="loc_gild_AxicabtageneciloleucelDLBCLMember_44df7c46-b36d-46e8-bfb2-f875e2a3e724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_3edf182f-5d4f-4571-9353-7c16733ed052" xlink:href="gild-20210930.xsd#gild_TrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:to="loc_gild_TrodelvyMember_3edf182f-5d4f-4571-9353-7c16733ed052" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexForHDVMember_3715e2e0-7846-4708-ac58-c359f1d21edd" xlink:href="gild-20210930.xsd#gild_HepcludexForHDVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:to="loc_gild_HepcludexForHDVMember_3715e2e0-7846-4708-ac58-c359f1d21edd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_e9245a48-68be-4e7a-a11a-9c0b5ea33ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_e9245a48-68be-4e7a-a11a-9c0b5ea33ec1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember_cd7a4d47-e56b-49c1-9c20-9b857dae2a56" xlink:href="gild-20210930.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:to="loc_gild_CellTherapyProductsTecartusMember_cd7a4d47-e56b-49c1-9c20-9b857dae2a56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ca84ee67-0c55-4381-8664-5106ad9a03cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f625b4f7-0bb0-459b-9b87-997e989704ba" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ca84ee67-0c55-4381-8664-5106ad9a03cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ca84ee67-0c55-4381-8664-5106ad9a03cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ca84ee67-0c55-4381-8664-5106ad9a03cd" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ca84ee67-0c55-4381-8664-5106ad9a03cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e028ba6-b9c0-4ce0-b1fe-72ab1fb87752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ca84ee67-0c55-4381-8664-5106ad9a03cd" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e028ba6-b9c0-4ce0-b1fe-72ab1fb87752" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_1040f977-80ce-43da-8566-c98f08c602ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e028ba6-b9c0-4ce0-b1fe-72ab1fb87752" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_1040f977-80ce-43da-8566-c98f08c602ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_259ed976-081d-42c6-938e-cd869eaa7ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f625b4f7-0bb0-459b-9b87-997e989704ba" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_259ed976-081d-42c6-938e-cd869eaa7ff6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_259ed976-081d-42c6-938e-cd869eaa7ff6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_259ed976-081d-42c6-938e-cd869eaa7ff6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_259ed976-081d-42c6-938e-cd869eaa7ff6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de5acc1a-542a-46a2-aa2d-d60c3d25752a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_259ed976-081d-42c6-938e-cd869eaa7ff6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de5acc1a-542a-46a2-aa2d-d60c3d25752a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_7788a720-2091-4c62-9b5d-1069f7a6379a" xlink:href="gild-20210930.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de5acc1a-542a-46a2-aa2d-d60c3d25752a" xlink:to="loc_gild_MYRGmbHMember_7788a720-2091-4c62-9b5d-1069f7a6379a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_78df642f-ecd4-47b1-97d9-883120f77445" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f625b4f7-0bb0-459b-9b87-997e989704ba" xlink:to="loc_srt_StatementScenarioAxis_78df642f-ecd4-47b1-97d9-883120f77445" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_78df642f-ecd4-47b1-97d9-883120f77445_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_78df642f-ecd4-47b1-97d9-883120f77445" xlink:to="loc_srt_ScenarioUnspecifiedDomain_78df642f-ecd4-47b1-97d9-883120f77445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b3529761-c673-4dcd-ac1e-4ae118fa9f7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_78df642f-ecd4-47b1-97d9-883120f77445" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b3529761-c673-4dcd-ac1e-4ae118fa9f7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_77a1e83d-09a5-4b04-bc48-a5c4eb3b11ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_b3529761-c673-4dcd-ac1e-4ae118fa9f7e" xlink:to="loc_srt_ScenarioForecastMember_77a1e83d-09a5-4b04-bc48-a5c4eb3b11ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_48b81c5c-08b8-49bc-8341-8d0d9c34bc38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f625b4f7-0bb0-459b-9b87-997e989704ba" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_48b81c5c-08b8-49bc-8341-8d0d9c34bc38" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_48b81c5c-08b8-49bc-8341-8d0d9c34bc38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_48b81c5c-08b8-49bc-8341-8d0d9c34bc38" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_48b81c5c-08b8-49bc-8341-8d0d9c34bc38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_65c55c51-cd7f-4b93-8732-bd705c3abbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_48b81c5c-08b8-49bc-8341-8d0d9c34bc38" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_65c55c51-cd7f-4b93-8732-bd705c3abbd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f788f60f-176c-42fe-b76a-3cdb71058411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_65c55c51-cd7f-4b93-8732-bd705c3abbd2" xlink:to="loc_us-gaap_SubsequentEventMember_f788f60f-176c-42fe-b76a-3cdb71058411" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#COLLABORATIONSANDOTHERARRANGEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="extended" id="i12590cf4109e45fc8c6fea35099b91c2_COLLABORATIONSANDOTHERARRANGEMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_e9f78d1a-ad69-4708-a7cc-4a59a1a590f6" xlink:href="gild-20210930.xsd#gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_e9f78d1a-ad69-4708-a7cc-4a59a1a590f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementNetProductSalesThreshold_9007a29a-bff9-4e95-987b-b39d05748ad1" xlink:href="gild-20210930.xsd#gild_CollaborationArrangementNetProductSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_CollaborationArrangementNetProductSalesThreshold_9007a29a-bff9-4e95-987b-b39d05748ad1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_66f9cae8-bbe3-4515-ba69-220f8707e9f9" xlink:href="gild-20210930.xsd#gild_CollaborationArrangementPercentOfGlobalProductRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_66f9cae8-bbe3-4515-ba69-220f8707e9f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_3ac03974-bd54-4743-a8eb-827720cacfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_3ac03974-bd54-4743-a8eb-827720cacfcc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_2485b42c-1ce7-4b25-b4ba-7322cfe47db4" xlink:href="gild-20210930.xsd#gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_2485b42c-1ce7-4b25-b4ba-7322cfe47db4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIPurchasePeriod_debd40fc-3fc4-47e3-afa6-ca1c04a197aa" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesFVNIPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_EquitySecuritiesFVNIPurchasePeriod_debd40fc-3fc4-47e3-afa6-ca1c04a197aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_773285a8-9141-42f5-ba72-bed69c4875ed" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_773285a8-9141-42f5-ba72-bed69c4875ed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_0875433f-bd1c-4bbf-b37a-bf2f5667d1e4" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesFVNIRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_0875433f-bd1c-4bbf-b37a-bf2f5667d1e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNISharesAcquired_77d485c3-0e78-4ac0-80b5-3f037612957e" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesFVNISharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_EquitySecuritiesFVNISharesAcquired_77d485c3-0e78-4ac0-80b5-3f037612957e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_833e83be-fb32-4002-9912-9163656b67bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_833e83be-fb32-4002-9912-9163656b67bf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIShares_d17a466f-3397-4134-9ebe-0ae0a3ce72ef" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesFVNIShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_EquitySecuritiesFVNIShares_d17a466f-3397-4134-9ebe-0ae0a3ce72ef" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_53f78c9c-40c3-44d4-9313-e26a78f026cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_53f78c9c-40c3-44d4-9313-e26a78f026cb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_f3a3015b-d64c-4aa2-b7d4-12fa262fbeed" xlink:href="gild-20210930.xsd#gild_CashPaymentsMadeRelatedToEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_f3a3015b-d64c-4aa2-b7d4-12fa262fbeed" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements_89e58976-0123-4741-88b2-89e60ac3017f" xlink:href="gild-20210930.xsd#gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements_89e58976-0123-4741-88b2-89e60ac3017f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f48bef7f-1bf7-42ca-b550-5d5567a980ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f48bef7f-1bf7-42ca-b550-5d5567a980ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c6af447-bf2d-4ef2-be38-f5f7c4980205" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f48bef7f-1bf7-42ca-b550-5d5567a980ad" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c6af447-bf2d-4ef2-be38-f5f7c4980205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8c6af447-bf2d-4ef2-be38-f5f7c4980205_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c6af447-bf2d-4ef2-be38-f5f7c4980205" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8c6af447-bf2d-4ef2-be38-f5f7c4980205_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_79ae0f68-6fe3-4acb-9f05-f02f5f42977c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c6af447-bf2d-4ef2-be38-f5f7c4980205" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_79ae0f68-6fe3-4acb-9f05-f02f5f42977c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_9f904396-1f6f-4fcb-a729-45ad88407f5b" xlink:href="gild-20210930.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_79ae0f68-6fe3-4acb-9f05-f02f5f42977c" xlink:to="loc_gild_ArcusBiosciencesIncMember_9f904396-1f6f-4fcb-a729-45ad88407f5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4ed51a0c-44c1-4b02-8ab2-955bd4ac7051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f48bef7f-1bf7-42ca-b550-5d5567a980ad" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4ed51a0c-44c1-4b02-8ab2-955bd4ac7051" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ed51a0c-44c1-4b02-8ab2-955bd4ac7051_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4ed51a0c-44c1-4b02-8ab2-955bd4ac7051" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ed51a0c-44c1-4b02-8ab2-955bd4ac7051_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd64f763-5f72-41b5-a9f8-f5a0be281980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4ed51a0c-44c1-4b02-8ab2-955bd4ac7051" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd64f763-5f72-41b5-a9f8-f5a0be281980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_04cc9ec7-7c60-4ca8-b47e-c06beefe04de" xlink:href="gild-20210930.xsd#gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd64f763-5f72-41b5-a9f8-f5a0be281980" xlink:to="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_04cc9ec7-7c60-4ca8-b47e-c06beefe04de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusStockPurchaseAgreementMember_d74d849f-8367-4a21-b3ad-aece72ac7001" xlink:href="gild-20210930.xsd#gild_ArcusStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd64f763-5f72-41b5-a9f8-f5a0be281980" xlink:to="loc_gild_ArcusStockPurchaseAgreementMember_d74d849f-8367-4a21-b3ad-aece72ac7001" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember_469f92be-16f9-4090-a7b2-d74515815ca8" xlink:href="gild-20210930.xsd#gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd64f763-5f72-41b5-a9f8-f5a0be281980" xlink:to="loc_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember_469f92be-16f9-4090-a7b2-d74515815ca8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherCollaborationArrangementsMember_63d5a119-4e2e-4e2a-996f-037c85cf1955" xlink:href="gild-20210930.xsd#gild_OtherCollaborationArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd64f763-5f72-41b5-a9f8-f5a0be281980" xlink:to="loc_gild_OtherCollaborationArrangementsMember_63d5a119-4e2e-4e2a-996f-037c85cf1955" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_f447fee1-357b-4d83-b971-05004b3b03ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f48bef7f-1bf7-42ca-b550-5d5567a980ad" xlink:to="loc_srt_OwnershipAxis_f447fee1-357b-4d83-b971-05004b3b03ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f447fee1-357b-4d83-b971-05004b3b03ec_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_f447fee1-357b-4d83-b971-05004b3b03ec" xlink:to="loc_srt_OwnershipDomain_f447fee1-357b-4d83-b971-05004b3b03ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1398fed7-e834-4cff-aa76-770650c293b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_f447fee1-357b-4d83-b971-05004b3b03ec" xlink:to="loc_srt_OwnershipDomain_1398fed7-e834-4cff-aa76-770650c293b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_82f2fdce-6939-42f3-a5b8-cc9f371e1831" xlink:href="gild-20210930.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1398fed7-e834-4cff-aa76-770650c293b6" xlink:to="loc_gild_ArcusBiosciencesIncMember_82f2fdce-6939-42f3-a5b8-cc9f371e1831" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2d26956c-567a-4060-ab59-c2deef6583ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f48bef7f-1bf7-42ca-b550-5d5567a980ad" xlink:to="loc_srt_ProductOrServiceAxis_2d26956c-567a-4060-ab59-c2deef6583ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2d26956c-567a-4060-ab59-c2deef6583ba_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2d26956c-567a-4060-ab59-c2deef6583ba" xlink:to="loc_srt_ProductsAndServicesDomain_2d26956c-567a-4060-ab59-c2deef6583ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dd6b40f2-91e3-42fe-97aa-b4e95abaefc8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2d26956c-567a-4060-ab59-c2deef6583ba" xlink:to="loc_srt_ProductsAndServicesDomain_dd6b40f2-91e3-42fe-97aa-b4e95abaefc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OralFormulationProductMember_96965f37-4f88-4795-9c3c-817acd1347dc" xlink:href="gild-20210930.xsd#gild_OralFormulationProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dd6b40f2-91e3-42fe-97aa-b4e95abaefc8" xlink:to="loc_gild_OralFormulationProductMember_96965f37-4f88-4795-9c3c-817acd1347dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InjectableFormulationProductMember_b4ab468a-2831-43ba-b7ed-35c21c5aed1e" xlink:href="gild-20210930.xsd#gild_InjectableFormulationProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dd6b40f2-91e3-42fe-97aa-b4e95abaefc8" xlink:to="loc_gild_InjectableFormulationProductMember_b4ab468a-2831-43ba-b7ed-35c21c5aed1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_858cafad-fbd9-49b2-8add-d070456f7e42" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f48bef7f-1bf7-42ca-b550-5d5567a980ad" xlink:to="loc_dei_LegalEntityAxis_858cafad-fbd9-49b2-8add-d070456f7e42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_858cafad-fbd9-49b2-8add-d070456f7e42_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_858cafad-fbd9-49b2-8add-d070456f7e42" xlink:to="loc_dei_EntityDomain_858cafad-fbd9-49b2-8add-d070456f7e42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_928356b9-c3ee-4794-8551-6ccb1395c6dd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_858cafad-fbd9-49b2-8add-d070456f7e42" xlink:to="loc_dei_EntityDomain_928356b9-c3ee-4794-8551-6ccb1395c6dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckMember_ffb19fa5-9b3e-4c2a-899c-59dac3e8a3b2" xlink:href="gild-20210930.xsd#gild_MerckMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_928356b9-c3ee-4794-8551-6ccb1395c6dd" xlink:to="loc_gild_MerckMember_ffb19fa5-9b3e-4c2a-899c-59dac3e8a3b2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="extended" id="ic1bedae58f2f402bb299b9ae95dc7b9e_DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_54195b80-dbc3-46f2-83f7-8ec07d5a7329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b1ee0ec0-a74d-4132-8327-10d791096486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_54195b80-dbc3-46f2-83f7-8ec07d5a7329" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b1ee0ec0-a74d-4132-8327-10d791096486" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_53665a2d-efd3-48a8-9d40-ffe87856a40d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_54195b80-dbc3-46f2-83f7-8ec07d5a7329" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_53665a2d-efd3-48a8-9d40-ffe87856a40d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_efd8e3aa-c430-4d19-8782-7be1a1a94516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_54195b80-dbc3-46f2-83f7-8ec07d5a7329" xlink:to="loc_us-gaap_LongTermDebt_efd8e3aa-c430-4d19-8782-7be1a1a94516" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_afe2a0e6-77ad-4fa8-a2eb-b0b0c3c44aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_54195b80-dbc3-46f2-83f7-8ec07d5a7329" xlink:to="loc_us-gaap_LongTermDebtCurrent_afe2a0e6-77ad-4fa8-a2eb-b0b0c3c44aa6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_710a5d7e-fba1-4587-8c6b-cb9aa3c0227a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_54195b80-dbc3-46f2-83f7-8ec07d5a7329" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_710a5d7e-fba1-4587-8c6b-cb9aa3c0227a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b1809c63-af37-4cf1-9e1e-f664e34353c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_54195b80-dbc3-46f2-83f7-8ec07d5a7329" xlink:to="loc_us-gaap_DebtInstrumentTable_b1809c63-af37-4cf1-9e1e-f664e34353c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d239fff3-c43c-4b78-a07d-240b5a46208b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b1809c63-af37-4cf1-9e1e-f664e34353c0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d239fff3-c43c-4b78-a07d-240b5a46208b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d239fff3-c43c-4b78-a07d-240b5a46208b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d239fff3-c43c-4b78-a07d-240b5a46208b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d239fff3-c43c-4b78-a07d-240b5a46208b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_db4a8809-8d92-462e-a2a7-cdda084ae3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d239fff3-c43c-4b78-a07d-240b5a46208b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_db4a8809-8d92-462e-a2a7-cdda084ae3ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember_30cfdf34-5961-4a41-9efa-b503787f8662" xlink:href="gild-20210930.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_db4a8809-8d92-462e-a2a7-cdda084ae3ed" xlink:to="loc_gild_SeniorNotesAndMediumTermNotesMember_30cfdf34-5961-4a41-9efa-b503787f8662" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e5604989-0d8e-44d0-84c5-05d9561efd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember_30cfdf34-5961-4a41-9efa-b503787f8662" xlink:to="loc_us-gaap_SeniorNotesMember_e5604989-0d8e-44d0-84c5-05d9561efd7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_e7339889-d776-472f-9786-5239dcf7871d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember_30cfdf34-5961-4a41-9efa-b503787f8662" xlink:to="loc_us-gaap_MediumTermNotesMember_e7339889-d776-472f-9786-5239dcf7871d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_b386f38a-c98d-4208-962c-b86845a9912e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_db4a8809-8d92-462e-a2a7-cdda084ae3ed" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_b386f38a-c98d-4208-962c-b86845a9912e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1d5cbbab-ad6d-4b0c-b6e7-dda21b4b354a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b1809c63-af37-4cf1-9e1e-f664e34353c0" xlink:to="loc_us-gaap_DebtInstrumentAxis_1d5cbbab-ad6d-4b0c-b6e7-dda21b4b354a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1d5cbbab-ad6d-4b0c-b6e7-dda21b4b354a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1d5cbbab-ad6d-4b0c-b6e7-dda21b4b354a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1d5cbbab-ad6d-4b0c-b6e7-dda21b4b354a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1d5cbbab-ad6d-4b0c-b6e7-dda21b4b354a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member_999886d3-dafd-420e-bc7f-3a8965c83205" xlink:href="gild-20210930.xsd#gild_A450SeniorUnsecuredNotesDueApril2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member_999886d3-dafd-420e-bc7f-3a8965c83205" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_159a92e5-b173-4895-8c8d-abfaa6a8d952" xlink:href="gild-20210930.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_159a92e5-b173-4895-8c8d-abfaa6a8d952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member_669d1bbf-c3b3-46f8-97f8-cd4832e44e45" xlink:href="gild-20210930.xsd#gild_A440SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member_669d1bbf-c3b3-46f8-97f8-cd4832e44e45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_cd0d1b78-af3f-4121-95c2-ac730b90042b" xlink:href="gild-20210930.xsd#gild_A195SeniorUnsecuredNotesDueMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_cd0d1b78-af3f-4121-95c2-ac730b90042b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_9003989c-bb25-4ff0-81e9-e70d5c78154e" xlink:href="gild-20210930.xsd#gild_A325SeniorUnsecuredNotesDueSeptember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_9003989c-bb25-4ff0-81e9-e70d5c78154e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_2c86d1b7-40a7-4333-893f-1d2f4b2cf334" xlink:href="gild-20210930.xsd#gild_A250SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_2c86d1b7-40a7-4333-893f-1d2f4b2cf334" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_1ab07474-8828-4d27-bcdf-4cec1b8e9d56" xlink:href="gild-20210930.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_1ab07474-8828-4d27-bcdf-4cec1b8e9d56" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_7f64175c-ed51-43ba-a5fd-2d6a047be221" xlink:href="gild-20210930.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_7f64175c-ed51-43ba-a5fd-2d6a047be221" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VariableTermLoanNoteDueOctober2023Member_aececa57-d94c-441c-9ee0-91fdb60ffee4" xlink:href="gild-20210930.xsd#gild_VariableTermLoanNoteDueOctober2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_VariableTermLoanNoteDueOctober2023Member_aececa57-d94c-441c-9ee0-91fdb60ffee4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_a8201061-942c-4e1a-bda2-5b2152ebb098" xlink:href="gild-20210930.xsd#gild_A370SeniorUnsecuredNotesDueApril2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_a8201061-942c-4e1a-bda2-5b2152ebb098" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_ca52c789-77fb-4362-aca9-eae9ad321cb9" xlink:href="gild-20210930.xsd#gild_A350SeniorUnsecuredNotesDueFebruary2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_ca52c789-77fb-4362-aca9-eae9ad321cb9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_8aef4beb-e10b-42dc-acb2-22e530436ab8" xlink:href="gild-20210930.xsd#gild_A365SeniorUnsecuredNotesDueMarch2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_8aef4beb-e10b-42dc-acb2-22e530436ab8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_105a40c9-7304-41a1-8ebb-2ba0a7353937" xlink:href="gild-20210930.xsd#gild_A295SeniorUnsecuredNotesDueMarch2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_105a40c9-7304-41a1-8ebb-2ba0a7353937" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_4cbc9de2-e493-42af-97b7-20f26bc48f12" xlink:href="gild-20210930.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_4cbc9de2-e493-42af-97b7-20f26bc48f12" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_2b4ebafc-2f2d-4b11-9be8-7429277434fd" xlink:href="gild-20210930.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_2b4ebafc-2f2d-4b11-9be8-7429277434fd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_e80fcb56-a045-4186-afc3-fc4776959598" xlink:href="gild-20210930.xsd#gild_A460SeniorUnsecuredNotesDueSeptember2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_e80fcb56-a045-4186-afc3-fc4776959598" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_700780fa-c708-40da-90f3-2bac8a0b5c6f" xlink:href="gild-20210930.xsd#gild_A400SeniorUnsecuredNotesDueSeptember2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_700780fa-c708-40da-90f3-2bac8a0b5c6f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_091ba7c0-316a-4510-9784-e706386fd321" xlink:href="gild-20210930.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_091ba7c0-316a-4510-9784-e706386fd321" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_23305ef9-4a22-4562-8d8c-56d2b7785855" xlink:href="gild-20210930.xsd#gild_A565SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_23305ef9-4a22-4562-8d8c-56d2b7785855" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_7cbe26f8-9786-44e6-91c0-4a8c9e0b2ea6" xlink:href="gild-20210930.xsd#gild_A480SeniorUnsecuredNotesDueApril2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_7cbe26f8-9786-44e6-91c0-4a8c9e0b2ea6" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_10505841-1928-4eee-b573-0b0ca4e43513" xlink:href="gild-20210930.xsd#gild_A450SeniorUnsecuredNotesDueFebruary2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_10505841-1928-4eee-b573-0b0ca4e43513" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_186afbc8-6a64-4b2d-9d7b-94eb2ec0921f" xlink:href="gild-20210930.xsd#gild_A475SeniorUnsecuredNotesDueMarch2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_186afbc8-6a64-4b2d-9d7b-94eb2ec0921f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_8df67e84-8e4d-431c-9a13-0ec41fbbab1c" xlink:href="gild-20210930.xsd#gild_A415SeniorUnsecuredNotesDueMarch2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_8df67e84-8e4d-431c-9a13-0ec41fbbab1c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_909fb878-7e71-4ef2-96f2-21aaae3784fa" xlink:href="gild-20210930.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_909fb878-7e71-4ef2-96f2-21aaae3784fa" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_44c0ad82-8303-4963-95fe-9e2af1f5fb44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b1809c63-af37-4cf1-9e1e-f664e34353c0" xlink:to="loc_us-gaap_VariableRateAxis_44c0ad82-8303-4963-95fe-9e2af1f5fb44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_44c0ad82-8303-4963-95fe-9e2af1f5fb44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_44c0ad82-8303-4963-95fe-9e2af1f5fb44" xlink:to="loc_us-gaap_VariableRateDomain_44c0ad82-8303-4963-95fe-9e2af1f5fb44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_012a84c4-5a1e-4a8c-974d-9c1d70f6fc45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_44c0ad82-8303-4963-95fe-9e2af1f5fb44" xlink:to="loc_us-gaap_VariableRateDomain_012a84c4-5a1e-4a8c-974d-9c1d70f6fc45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d17e7a36-806b-4293-a33d-5130f4d3335c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_012a84c4-5a1e-4a8c-974d-9c1d70f6fc45" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d17e7a36-806b-4293-a33d-5130f4d3335c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#DEBTANDCREDITFACILITIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="extended" id="ic56fcbb516dc40b9a497cd159aee7230_DEBTANDCREDITFACILITIESAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c2b3484c-cf77-4844-8fa5-d9031d0e625b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c2b3484c-cf77-4844-8fa5-d9031d0e625b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt_c9fc686b-0117-42b6-8525-c0f98d1a70c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:to="loc_us-gaap_RepaymentsOfUnsecuredDebt_c9fc686b-0117-42b6-8525-c0f98d1a70c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_96054628-5c73-4da2-953d-dad8e314c320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:to="loc_us-gaap_DebtInstrumentTerm_96054628-5c73-4da2-953d-dad8e314c320" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4a810dc5-7fa6-4d69-a5a0-d0aae4f68cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4a810dc5-7fa6-4d69-a5a0-d0aae4f68cbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_e3da6dba-8876-42f2-bf32-f0bbe792ab29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_e3da6dba-8876-42f2-bf32-f0bbe792ab29" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_2c2c8c38-9cc0-43bb-81ff-76e86fd7f7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:to="loc_us-gaap_LineOfCredit_2c2c8c38-9cc0-43bb-81ff-76e86fd7f7d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_353560d0-4232-4338-a5af-85d50ae279ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_353560d0-4232-4338-a5af-85d50ae279ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_be5d30f4-1bc1-466b-b168-f91e0cb9203d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:to="loc_us-gaap_DebtInstrumentTable_be5d30f4-1bc1-466b-b168-f91e0cb9203d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_08e6253d-1958-40fd-92a9-6619d930cbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_be5d30f4-1bc1-466b-b168-f91e0cb9203d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_08e6253d-1958-40fd-92a9-6619d930cbc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_08e6253d-1958-40fd-92a9-6619d930cbc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_08e6253d-1958-40fd-92a9-6619d930cbc8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_08e6253d-1958-40fd-92a9-6619d930cbc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7be84519-46e2-451c-877a-aa47cddae845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_08e6253d-1958-40fd-92a9-6619d930cbc8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7be84519-46e2-451c-877a-aa47cddae845" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_eb813b51-4ab7-4d3a-82de-cca91a1929b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7be84519-46e2-451c-877a-aa47cddae845" xlink:to="loc_us-gaap_SeniorNotesMember_eb813b51-4ab7-4d3a-82de-cca91a1929b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_91829302-c236-4614-9024-71e9d1fab5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7be84519-46e2-451c-877a-aa47cddae845" xlink:to="loc_us-gaap_MediumTermNotesMember_91829302-c236-4614-9024-71e9d1fab5b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ebbe9f93-552e-4a8e-892d-a0124ee62ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_be5d30f4-1bc1-466b-b168-f91e0cb9203d" xlink:to="loc_us-gaap_CreditFacilityAxis_ebbe9f93-552e-4a8e-892d-a0124ee62ab7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ebbe9f93-552e-4a8e-892d-a0124ee62ab7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_ebbe9f93-552e-4a8e-892d-a0124ee62ab7" xlink:to="loc_us-gaap_CreditFacilityDomain_ebbe9f93-552e-4a8e-892d-a0124ee62ab7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_72f17c95-86e9-489c-a671-bf090ef104bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_ebbe9f93-552e-4a8e-892d-a0124ee62ab7" xlink:to="loc_us-gaap_CreditFacilityDomain_72f17c95-86e9-489c-a671-bf090ef104bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e285d193-c545-4514-ac0d-a232d3ddb223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_72f17c95-86e9-489c-a671-bf090ef104bd" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e285d193-c545-4514-ac0d-a232d3ddb223" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4d161fc1-ee4a-49c4-b725-0f271704ae1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_be5d30f4-1bc1-466b-b168-f91e0cb9203d" xlink:to="loc_us-gaap_DebtInstrumentAxis_4d161fc1-ee4a-49c4-b725-0f271704ae1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4d161fc1-ee4a-49c4-b725-0f271704ae1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4d161fc1-ee4a-49c4-b725-0f271704ae1f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4d161fc1-ee4a-49c4-b725-0f271704ae1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4d161fc1-ee4a-49c4-b725-0f271704ae1f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member_16bbdec2-875b-40ad-a53d-964a16c862d9" xlink:href="gild-20210930.xsd#gild_A450SeniorUnsecuredNotesDueApril2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:to="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member_16bbdec2-875b-40ad-a53d-964a16c862d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member_4091b8a4-c1f3-4cd7-9585-3b8f4fd4aafa" xlink:href="gild-20210930.xsd#gild_A440SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:to="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member_4091b8a4-c1f3-4cd7-9585-3b8f4fd4aafa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_611863d7-31fd-4c4b-9dd2-bb7a79c5c448" xlink:href="gild-20210930.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_611863d7-31fd-4c4b-9dd2-bb7a79c5c448" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_da860532-4c8a-403d-8c86-d2ad0b631b4a" xlink:href="gild-20210930.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:to="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_da860532-4c8a-403d-8c86-d2ad0b631b4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_8631238d-c220-41c4-8bd0-e4cbae16e4b1" xlink:href="gild-20210930.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:to="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_8631238d-c220-41c4-8bd0-e4cbae16e4b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_5cadbc13-c0cf-4aa4-8941-b9cdbbcccd9d" xlink:href="gild-20210930.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_5cadbc13-c0cf-4aa4-8941-b9cdbbcccd9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member_59872e17-ab94-4b0c-816c-a838607459a1" xlink:href="gild-20210930.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:to="loc_gild_CreditFacilityDueJune2025Member_59872e17-ab94-4b0c-816c-a838607459a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8c0c4c4d-9306-4ebc-b0fd-53c936fc2578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_be5d30f4-1bc1-466b-b168-f91e0cb9203d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8c0c4c4d-9306-4ebc-b0fd-53c936fc2578" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8c0c4c4d-9306-4ebc-b0fd-53c936fc2578_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8c0c4c4d-9306-4ebc-b0fd-53c936fc2578" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8c0c4c4d-9306-4ebc-b0fd-53c936fc2578_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c16f7188-0054-4e73-8b45-1ddd8b2ad7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8c0c4c4d-9306-4ebc-b0fd-53c936fc2578" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c16f7188-0054-4e73-8b45-1ddd8b2ad7ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a1974f31-66dd-460e-98b1-490e24a40537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c16f7188-0054-4e73-8b45-1ddd8b2ad7ea" xlink:to="loc_us-gaap_SubsequentEventMember_a1974f31-66dd-460e-98b1-490e24a40537" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="icfc76df37d4a425ab6323445e58b278e_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_2c7dd9ef-9173-43d4-a2d8-ef8ba0bd3223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_2c7dd9ef-9173-43d4-a2d8-ef8ba0bd3223" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_1f0c66d3-ded3-4890-b34c-87d7e116f09c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_1f0c66d3-ded3-4890-b34c-87d7e116f09c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017_af753dd5-8b9f-4739-8883-f2a28fda81e3" xlink:href="gild-20210930.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_JudgmentRoyaltyRateFromOctober2017_af753dd5-8b9f-4739-8883-f2a28fda81e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesOnPastSales_d3a2d9c2-8acd-4810-82ba-3529c12ed1ed" xlink:href="gild-20210930.xsd#gild_JudgmentEnhancedDamagesOnPastSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_JudgmentEnhancedDamagesOnPastSales_d3a2d9c2-8acd-4810-82ba-3529c12ed1ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales_9039320b-53f0-4d83-82e3-dc7eead7f48a" xlink:href="gild-20210930.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_JudgmentRoyaltyRateOnFutureSales_9039320b-53f0-4d83-82e3-dc7eead7f48a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_a9355b64-e3ec-4e67-a1a5-333940e615b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_a9355b64-e3ec-4e67-a1a5-333940e615b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber_6134f7a8-c6d5-4ff0-b95c-42271eae7a50" xlink:href="gild-20210930.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_LossContingencyMaterialTransferAgreementsNumber_6134f7a8-c6d5-4ff0-b95c-42271eae7a50" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_fde627dc-aec9-4532-99aa-5e0d43942485" xlink:href="gild-20210930.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_fde627dc-aec9-4532-99aa-5e0d43942485" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_d1c29907-92cb-4810-80d0-4fd114f7dccb" xlink:href="gild-20210930.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_d1c29907-92cb-4810-80d0-4fd114f7dccb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber_04948fba-1ef5-45a6-bde5-fedc1b2f9072" xlink:href="gild-20210930.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_LossContingencyPartiesAppealedNumber_04948fba-1ef5-45a6-bde5-fedc1b2f9072" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesFilingOppositionNumber_ee2094f0-88e2-4470-8c41-635d15775642" xlink:href="gild-20210930.xsd#gild_LossContingencyPartiesFilingOppositionNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_LossContingencyPartiesFilingOppositionNumber_ee2094f0-88e2-4470-8c41-635d15775642" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_6ac488b0-b6ac-4577-a796-0ad5ddd72e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_6ac488b0-b6ac-4577-a796-0ad5ddd72e32" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_43535282-6c52-4373-99e8-c1e710ac8723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_43535282-6c52-4373-99e8-c1e710ac8723" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_494c6b88-5384-4103-8963-b9503f449bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_us-gaap_LossContingenciesTable_494c6b88-5384-4103-8963-b9503f449bf6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c43791de-9d66-4ea3-a022-4d1666329c3f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_494c6b88-5384-4103-8963-b9503f449bf6" xlink:to="loc_srt_LitigationCaseAxis_c43791de-9d66-4ea3-a022-4d1666329c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c43791de-9d66-4ea3-a022-4d1666329c3f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_c43791de-9d66-4ea3-a022-4d1666329c3f" xlink:to="loc_srt_LitigationCaseTypeDomain_c43791de-9d66-4ea3-a022-4d1666329c3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_c43791de-9d66-4ea3-a022-4d1666329c3f" xlink:to="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_880f1d4d-e369-42a9-bdf1-f25c64c36a84" xlink:href="gild-20210930.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_880f1d4d-e369-42a9-bdf1-f25c64c36a84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ViiVHealthcareCompanyMember_89dbf39d-e849-4600-88f2-c63518e44881" xlink:href="gild-20210930.xsd#gild_ViiVHealthcareCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_ViiVHealthcareCompanyMember_89dbf39d-e849-4600-88f2-c63518e44881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember_bbc52267-808c-4385-88d4-e56750568414" xlink:href="gild-20210930.xsd#gild_PreExposureProphylaxisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_PreExposureProphylaxisMember_bbc52267-808c-4385-88d4-e56750568414" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2024ExpirationMember_a769facf-b60e-4c05-a690-8580ad268597" xlink:href="gild-20210930.xsd#gild_EuropeanPatentClaims2024ExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_EuropeanPatentClaims2024ExpirationMember_a769facf-b60e-4c05-a690-8580ad268597" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2026ExpirationMember_39aa2041-04c0-49df-a4bf-2dd99b39ff45" xlink:href="gild-20210930.xsd#gild_EuropeanPatentClaims2026ExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_EuropeanPatentClaims2026ExpirationMember_39aa2041-04c0-49df-a4bf-2dd99b39ff45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2032ExpirationMember_4b509981-ff34-4117-8570-fdbbe49d6db6" xlink:href="gild-20210930.xsd#gild_EuropeanPatentClaims2032ExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_EuropeanPatentClaims2032ExpirationMember_4b509981-ff34-4117-8570-fdbbe49d6db6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2027ExpirationMember_ead997ec-badb-472c-ae1f-93bcbbf54b98" xlink:href="gild-20210930.xsd#gild_EuropeanPatentClaims2027ExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_EuropeanPatentClaims2027ExpirationMember_ead997ec-badb-472c-ae1f-93bcbbf54b98" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember_9d9bada2-0412-4c14-bd55-35a6f28379a0" xlink:href="gild-20210930.xsd#gild_ProductLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_ProductLiabilityMember_9d9bada2-0412-4c14-bd55-35a6f28379a0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_QuiTamMember_de294572-e797-477e-afc4-0d33bc151e39" xlink:href="gild-20210930.xsd#gild_QuiTamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_QuiTamMember_de294572-e797-477e-afc4-0d33bc151e39" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_5f352d36-09b2-4824-9c2f-38d5a04c53c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_494c6b88-5384-4103-8963-b9503f449bf6" xlink:to="loc_us-gaap_LitigationStatusAxis_5f352d36-09b2-4824-9c2f-38d5a04c53c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_5f352d36-09b2-4824-9c2f-38d5a04c53c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_5f352d36-09b2-4824-9c2f-38d5a04c53c9" xlink:to="loc_us-gaap_LitigationStatusDomain_5f352d36-09b2-4824-9c2f-38d5a04c53c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_de4f7ddd-1585-4953-a29c-e8d820b4f120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_5f352d36-09b2-4824-9c2f-38d5a04c53c9" xlink:to="loc_us-gaap_LitigationStatusDomain_de4f7ddd-1585-4953-a29c-e8d820b4f120" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_1c08d5a9-a506-4324-9ce5-65441ffc396c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_de4f7ddd-1585-4953-a29c-e8d820b4f120" xlink:to="loc_us-gaap_PendingLitigationMember_1c08d5a9-a506-4324-9ce5-65441ffc396c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="extended" id="i31853ab7f3c345ad8a45052e9404541c_STOCKHOLDERSEQUITYAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d987bb86-6a5f-4e61-a839-ab81f2bd7b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_862d71e5-b912-4e83-8372-9ba064cdc063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d987bb86-6a5f-4e61-a839-ab81f2bd7b65" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_862d71e5-b912-4e83-8372-9ba064cdc063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_444f0ebd-16f5-4182-a1fe-da451ed80f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d987bb86-6a5f-4e61-a839-ab81f2bd7b65" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_444f0ebd-16f5-4182-a1fe-da451ed80f35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_919ba129-fbaa-4d90-92f8-78015e3ee1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d987bb86-6a5f-4e61-a839-ab81f2bd7b65" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_919ba129-fbaa-4d90-92f8-78015e3ee1ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_36a4a6aa-154f-4754-9a3a-547f0a6638cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d987bb86-6a5f-4e61-a839-ab81f2bd7b65" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_36a4a6aa-154f-4754-9a3a-547f0a6638cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a6f36093-fd35-4129-b6c0-ba03939937e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d987bb86-6a5f-4e61-a839-ab81f2bd7b65" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a6f36093-fd35-4129-b6c0-ba03939937e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_292a62aa-44a7-47f9-943e-14ff9dacdac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a6f36093-fd35-4129-b6c0-ba03939937e6" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_292a62aa-44a7-47f9-943e-14ff9dacdac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_292a62aa-44a7-47f9-943e-14ff9dacdac9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_292a62aa-44a7-47f9-943e-14ff9dacdac9" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_292a62aa-44a7-47f9-943e-14ff9dacdac9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_a62c3e69-b4a9-4f1a-ad0e-3f3069a3b9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_292a62aa-44a7-47f9-943e-14ff9dacdac9" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_a62c3e69-b4a9-4f1a-ad0e-3f3069a3b9a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember_1203964d-1026-4818-8cb8-424688a25ae3" xlink:href="gild-20210930.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a62c3e69-b4a9-4f1a-ad0e-3f3069a3b9a2" xlink:to="loc_gild_A2016StockRepurchaseProgramMember_1203964d-1026-4818-8cb8-424688a25ae3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember_a987354c-9db9-4404-8e99-95847b7a14ed" xlink:href="gild-20210930.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a62c3e69-b4a9-4f1a-ad0e-3f3069a3b9a2" xlink:to="loc_gild_A2020StockRepurchaseProgramMember_a987354c-9db9-4404-8e99-95847b7a14ed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i0a369107b9624c678724972ed60dda71_STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8216a926-9f54-401a-83e7-7108c65e1dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fb2a2796-9a9a-47ad-8d12-66cc3bd19287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8216a926-9f54-401a-83e7-7108c65e1dea" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fb2a2796-9a9a-47ad-8d12-66cc3bd19287" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1aef90bf-1070-4136-a6c6-4bd15c932d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fb2a2796-9a9a-47ad-8d12-66cc3bd19287" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1aef90bf-1070-4136-a6c6-4bd15c932d58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_7344ca96-6122-4df7-acc1-82f6bed137b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fb2a2796-9a9a-47ad-8d12-66cc3bd19287" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_7344ca96-6122-4df7-acc1-82f6bed137b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_5080f307-aa6d-4249-b8d8-bd518afbf0be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fb2a2796-9a9a-47ad-8d12-66cc3bd19287" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_5080f307-aa6d-4249-b8d8-bd518afbf0be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_15333437-72b2-4785-bc38-233b2c047579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fb2a2796-9a9a-47ad-8d12-66cc3bd19287" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_15333437-72b2-4785-bc38-233b2c047579" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d0bf010b-1deb-49ef-a2d3-25fb357b6d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c6d516bf-64f3-41a3-b93a-16a4a1b07824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8216a926-9f54-401a-83e7-7108c65e1dea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c6d516bf-64f3-41a3-b93a-16a4a1b07824" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2f4e6fd2-889d-49f9-88c1-b737cc301e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c6d516bf-64f3-41a3-b93a-16a4a1b07824" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2f4e6fd2-889d-49f9-88c1-b737cc301e4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2f4e6fd2-889d-49f9-88c1-b737cc301e4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2f4e6fd2-889d-49f9-88c1-b737cc301e4b" xlink:to="loc_us-gaap_EquityComponentDomain_2f4e6fd2-889d-49f9-88c1-b737cc301e4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5f4c7cfb-3587-4f2d-bf32-b75123c548d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2f4e6fd2-889d-49f9-88c1-b737cc301e4b" xlink:to="loc_us-gaap_EquityComponentDomain_5f4c7cfb-3587-4f2d-bf32-b75123c548d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e3fa2930-fcf8-4278-a918-743156359cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5f4c7cfb-3587-4f2d-bf32-b75123c548d7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e3fa2930-fcf8-4278-a918-743156359cbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6ec4dd39-04ee-4bb4-8386-e58b5edfddc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e3fa2930-fcf8-4278-a918-743156359cbd" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6ec4dd39-04ee-4bb4-8386-e58b5edfddc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_bddcdeeb-e9b2-4e26-8f01-0663379be49b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e3fa2930-fcf8-4278-a918-743156359cbd" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_bddcdeeb-e9b2-4e26-8f01-0663379be49b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_27c2311b-caae-4c08-9ee1-2cdd845e17d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e3fa2930-fcf8-4278-a918-743156359cbd" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_27c2311b-caae-4c08-9ee1-2cdd845e17d1" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>gild-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f99a0a1f-0889-484d-b0ab-b227dc47b3c9,g:c9f039a1-0400-492d-bc3a-193c416450f4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_bc741983-9a42-40ad-8911-8988f542b286_terseLabel_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - sofosbuvir</link:label>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_label_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset - Sofosbuvir [Member]</link:label>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_documentation_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sofosbuvir [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember" xlink:href="gild-20210930.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IntangibleAssetSofosbuvirMember" xlink:to="lab_gild_IntangibleAssetSofosbuvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bd4796b2-4418-4488-a897-9f349e9a43da_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized amount under stock repurchase program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_b63471d1-498a-43e6-8ef7-70af6a20fc2e_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_8d116685-3bde-4929-bfad-adb7192dd301_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8ddaf16d-6a12-4e34-ae6e-e73bdc1c3d10_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fd5fbb25-0979-4231-bce2-ec64394ab2e2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_fb759063-89eb-495d-9a92-a32c5782bf97_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents challenged, scenario two</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_label_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_documentation_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:href="gild-20210930.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:to="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_87fb834d-8386-4217-8822-a8dd0bc68f2a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1fa5490c-3c79-4d3b-8a2e-6f0d55e56f63_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8a6abeaf-8768-43f3-bd81-45cf61002ab8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_999d8424-4078-401d-9aaf-9cfbd307a440_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_5f36cbfa-b1af-49d1-afba-6e34c92794e8_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_19dd8730-86d3-4342-a0b9-2ca079498110_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2d9e26dc-a208-4007-9393-3bbe3309261d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_25ab92b6-fd50-4579-9e2c-0ef7747255d8_terseLabel_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Running royalty rate on future sales</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_label_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate on Future Sales</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_documentation_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate on Future Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales" xlink:href="gild-20210930.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentRoyaltyRateOnFutureSales" xlink:to="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_371f9f6c-821f-4d5a-924a-f45caa668a67_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a1beda63-293b-4b3b-b980-929ca61f2d3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_bf93e96a-c560-4534-b764-75eabfb74587_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_71713bd7-b4f9-4bf4-b9b7-0b966e609cf9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_5f566bf9-b76b-43b3-bbe0-c11e7617f134_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_db8d1564-9862-4a56-90db-0b234ecfa79e_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cell Therapy</link:label>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Total Cell Therapy Product Sales [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Total Cell Therapy Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:href="gild-20210930.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:to="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_b2560882-6317-469c-8f5e-90f1410219ac_terseLabel_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of material transfer agreements</link:label>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_label_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Material Transfer Agreements, Number</link:label>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Material Transfer Agreements, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:href="gild-20210930.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:to="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_a856d47f-c840-4988-8d1c-10dea54ce910_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_0f5c8f02-8de8-4849-8c88-2aa06a017688_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_8bd8b640-3d8d-4e33-a34a-463bdf807a9d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_9c28e51c-ca7a-4edc-bcd9-2106f0267535_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_2595a0c4-528d-4d3a-bf79-5c905bb40588_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_aa4a820d-44ae-4927-a4f7-534cd264c8b7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_3b129e73-51ab-404e-a919-7f4babfa3e52_terseLabel_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Repurchase Program</link:label>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_label_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember" xlink:href="gild-20210930.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A2020StockRepurchaseProgramMember" xlink:to="lab_gild_A2020StockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_215f0ed0-f0be-49e9-b2d5-43301ef4e768_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_47078b6d-4a13-45c0-aad9-24944c249dfb_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InjectableFormulationProductMember_4cb88acf-d93d-4ca5-bc59-4450aa1c4403_terseLabel_en-US" xlink:label="lab_gild_InjectableFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Injectable Formulation Product</link:label>
    <link:label id="lab_gild_InjectableFormulationProductMember_label_en-US" xlink:label="lab_gild_InjectableFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Injectable Formulation Product [Member]</link:label>
    <link:label id="lab_gild_InjectableFormulationProductMember_documentation_en-US" xlink:label="lab_gild_InjectableFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Injectable Formulation Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InjectableFormulationProductMember" xlink:href="gild-20210930.xsd#gild_InjectableFormulationProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InjectableFormulationProductMember" xlink:to="lab_gild_InjectableFormulationProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_ae34e2ae-f42f-467c-a8eb-4dd2c4e3b64a_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_23b98ee8-660d-480e-950f-4885d91a397c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_93f2504c-f12b-43ac-b955-bed1916c1ecd_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HBV/HBD</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Other [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:href="gild-20210930.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6b4f2807-63cd-4fa7-98b6-d32f7acefcf4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_f5502dce-55f7-4f3b-90ef-f8aa7884049a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_2480e8bd-a6e4-4b7c-a6ef-c2f20c30b289_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_64464def-c099-4d65-9733-4dd91d796370_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_dd591174-4d12-4c30-8db8-e07af939c523_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Classification of Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_e4eafe44-2f45-414c-8ab3-719d63ef95e0_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_4a2e878b-78e1-4f29-9c6e-2727aac1ffc1_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents challenged, scenario one</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_label_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario One</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_documentation_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:href="gild-20210930.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:to="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4eb975bf-b646-409f-8d42-953338eb982d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_b677124d-93aa-4515-bf60-bc0059e4b8f3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_bf147338-1a37-41f0-afa9-c66e2b952e38_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_01659586-b46d-4ee3-b47a-d50509072347_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amortization expense related to finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_4975f5d0-7c92-40a0-b359-f5b340a8a13a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a0603d18-44bb-41b5-bae5-d4e5dcd60536_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b5e47c2e-1718-4004-ad32-98aec27e94b5_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized repurchase amount under stock repurchase programs</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_61dd95e3-487d-479a-a8ce-2582e5ee455e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Collateral Received/ Pledged</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Obligation to Return Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:to="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7acf13a3-d9e5-44d1-9ea1-13e99bf3973d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from earnings per share computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4a5f7ede-c08c-4ef7-822a-b2512a866340_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_30542138-10b8-44ca-a5b1-95f0562ebfe7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_b1a1c120-a538-4221-ab5d-3b578b50be37_terseLabel_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmBisome</link:label>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_label_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, AmBisome [Member]</link:label>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_documentation_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, AmBisome [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember" xlink:href="gild-20210930.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsAmBisomeMember" xlink:to="lab_gild_OtherProductsAmBisomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquityinvestmentinGalapagosMember_029e4ae7-c742-42c4-a899-0bac048b552d_terseLabel_en-US" xlink:label="lab_gild_EquityinvestmentinGalapagosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment in Galapagos</link:label>
    <link:label id="lab_gild_EquityinvestmentinGalapagosMember_label_en-US" xlink:label="lab_gild_EquityinvestmentinGalapagosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment in Galapagos [Member]</link:label>
    <link:label id="lab_gild_EquityinvestmentinGalapagosMember_documentation_en-US" xlink:label="lab_gild_EquityinvestmentinGalapagosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment in Galapagos [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityinvestmentinGalapagosMember" xlink:href="gild-20210930.xsd#gild_EquityinvestmentinGalapagosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquityinvestmentinGalapagosMember" xlink:to="lab_gild_EquityinvestmentinGalapagosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_95740c91-31a1-4f93-a5b3-465c556953d6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MerckMember_a8d7c123-6a8c-41b7-8cc4-f6ec12d83c26_terseLabel_en-US" xlink:label="lab_gild_MerckMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck</link:label>
    <link:label id="lab_gild_MerckMember_label_en-US" xlink:label="lab_gild_MerckMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_gild_MerckMember_documentation_en-US" xlink:label="lab_gild_MerckMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckMember" xlink:href="gild-20210930.xsd#gild_MerckMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MerckMember" xlink:to="lab_gild_MerckMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0996701a-2ae6-4f97-aee8-6dfb80f95b7f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_71309a6e-e511-4dfb-ac27-99ddfb43552b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) recognized in Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_135ad3d5-c960-4599-9062-34b87fdcc662_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_1a89ae5e-30a0-498b-be55-53ae51882eb5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_ccbebe08-a735-49f7-ad42-294619e2a2f5_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductSalesMember_968b9eb4-9f58-4372-b237-596a0dee105c_terseLabel_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HIV</link:label>
    <link:label id="lab_gild_HIVProductSalesMember_label_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Product Sales [Member]</link:label>
    <link:label id="lab_gild_HIVProductSalesMember_documentation_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember" xlink:href="gild-20210930.xsd#gild_HIVProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductSalesMember" xlink:to="lab_gild_HIVProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5bc2bd70-e9be-4ddf-8350-dbd22fcb8863_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_ca1c4810-8413-4d11-ace9-c72ce93d7a29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Available-for-Sale Debt Securities from Cost Basis to Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member_74c57bd4-198f-487e-a1d4-57a50f478f3d_terseLabel_en-US" xlink:label="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.65% Senior Unsecured Notes Due March 2026</link:label>
    <link:label id="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member_label_en-US" xlink:label="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.65% Senior Unsecured Notes Due March 2026 [Member]</link:label>
    <link:label id="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member_documentation_en-US" xlink:label="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.65% Senior Unsecured Notes Due March 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:href="gild-20210930.xsd#gild_A365SeniorUnsecuredNotesDueMarch2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:to="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_ca570daa-04d9-4c40-84da-3a9eafee4541_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DERIVATIVE FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_054cca45-d204-417b-86b0-58bb5d6a98ff_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Debt Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_06abc2fd-832e-4c1b-ac31-a973ea219770_terseLabel_en-US" xlink:label="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Senior Unsecured Notes Due September 2036</link:label>
    <link:label id="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_label_en-US" xlink:label="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Senior Unsecured Notes Due September 2036 [Member]</link:label>
    <link:label id="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_documentation_en-US" xlink:label="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Senior Unsecured Notes Due September 2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:href="gild-20210930.xsd#gild_A400SeniorUnsecuredNotesDueSeptember2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:to="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5045667f-d8e7-4bf6-8a91-b6cfa0980c5f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0094a0f0-24d7-4722-ab9f-299918c34cc1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL AND INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_79a9f6b9-484e-4920-bada-fde22a641c66_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_016f2a0c-44fa-4ca9-aa92-18c607ed79d4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsRanexaMember_82219c6d-de25-4015-8caa-60d7375f9741_terseLabel_en-US" xlink:label="lab_gild_OtherProductsRanexaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranexa</link:label>
    <link:label id="lab_gild_OtherProductsRanexaMember_label_en-US" xlink:label="lab_gild_OtherProductsRanexaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Ranexa [Member]</link:label>
    <link:label id="lab_gild_OtherProductsRanexaMember_documentation_en-US" xlink:label="lab_gild_OtherProductsRanexaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Ranexa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsRanexaMember" xlink:href="gild-20210930.xsd#gild_OtherProductsRanexaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsRanexaMember" xlink:to="lab_gild_OtherProductsRanexaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MckessonCorpMember_2a2b1704-8122-407f-82e2-e4db4aad08cf_terseLabel_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_gild_MckessonCorpMember_label_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corp [Member]</link:label>
    <link:label id="lab_gild_MckessonCorpMember_documentation_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember" xlink:href="gild-20210930.xsd#gild_MckessonCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MckessonCorpMember" xlink:to="lab_gild_MckessonCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c8d8cdf5-01f8-416b-90eb-1c3b8f7e41cd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_59f65b3e-dc5c-49c6-a87e-bd1f33164b4b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c148c1ab-1920-4aa2-993d-cb93ebcbcb1a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_902c3c34-65ca-420c-add6-d0f70cfcd081_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e0732276-8d37-4288-b5cd-9ad1bf434447_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_03b294af-6842-49bd-a2be-0e61a686db64_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_803ae571-f13e-4cde-b994-a96cfece8510_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_bf21cd66-c3de-41d6-b101-6d4009e7cd12_terseLabel_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: chargebacks</link:label>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_label_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Chargebacks, Current</link:label>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_documentation_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Chargebacks, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent" xlink:href="gild-20210930.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccountsReceivableChargebacksCurrent" xlink:to="lab_gild_AccountsReceivableChargebacksCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_d1f9949d-1922-42f9-8425-fdba7eac5db3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e44d8c8b-4b19-43f6-b47d-243bb7c8dcd3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_a916c324-7ec6-4d0d-a89b-89cbf2d116b4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares repurchased and retired</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_460407ed-e957-4700-b98c-ac3dc53e60d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member_4a13ea56-1414-4d1a-b1e1-b6bb33bef97e_terseLabel_en-US" xlink:label="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.95% Senior Unsecured Notes Due March 2022</link:label>
    <link:label id="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member_label_en-US" xlink:label="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.95% Senior Unsecured Notes Due March 2022 [Member]</link:label>
    <link:label id="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member_documentation_en-US" xlink:label="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.95% Senior Unsecured Notes Due March 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:href="gild-20210930.xsd#gild_A195SeniorUnsecuredNotesDueMarch2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:to="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_232c41a4-4490-4233-b44f-ab3079a12406_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIRestrictionPeriod_d41f4810-6a57-4bc1-99fc-61c44624051b_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restriction period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIRestrictionPeriod_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restriction Period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIRestrictionPeriod_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesFVNIRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:to="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_556de3a2-8b43-4c94-a042-9bd34bfa164e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_fb932b95-fea0-4fd2-bc29-4128849a712f_terseLabel_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20210930.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4a73952f-141c-4cd6-bcd1-a7335ee78d35_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_85923bef-f9ab-4298-8b87-01464d3aa701_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_3b653214-231d-4b3d-93b4-2889b402bb25_terseLabel_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_label_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corp [Member]</link:label>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_documentation_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember" xlink:href="gild-20210930.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AmerisourcebergenCorpMember" xlink:to="lab_gild_AmerisourcebergenCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_20b14697-69eb-48b3-b0fd-c35745f3b5e2_terseLabel_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genvoya</link:label>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_label_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Genvoya [Member]</link:label>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Genvoya [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember" xlink:href="gild-20210930.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsGenvoyaMember" xlink:to="lab_gild_HIVProductsGenvoyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7b83cee5-ce9b-485c-81f0-16bd65b8e6a6_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusStockPurchaseAgreementMember_72e27138-1754-4d87-855a-74bd12ba78ce_terseLabel_en-US" xlink:label="lab_gild_ArcusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus stock purchase agreement</link:label>
    <link:label id="lab_gild_ArcusStockPurchaseAgreementMember_label_en-US" xlink:label="lab_gild_ArcusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_gild_ArcusStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_gild_ArcusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusStockPurchaseAgreementMember" xlink:href="gild-20210930.xsd#gild_ArcusStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusStockPurchaseAgreementMember" xlink:to="lab_gild_ArcusStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_aab0cfec-862d-4c63-a9d6-bffc8ccdf6dd_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_87559d8a-1173-4315-b6b1-764aebedf7e4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share attributable to Gilead common stockholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_efdd5c4d-7e34-49d9-a80a-4cc85f0a7054_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsOtherMember_2f5ad0bd-d107-4f41-b858-1867e4edbd0d_terseLabel_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_gild_OtherProductsOtherMember_label_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Other [Member]</link:label>
    <link:label id="lab_gild_OtherProductsOtherMember_documentation_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember" xlink:href="gild-20210930.xsd#gild_OtherProductsOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsOtherMember" xlink:to="lab_gild_OtherProductsOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_53c995c8-4038-4a1c-8fb0-9e69dcdb3537_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1cef99fe-befe-4754-9e33-aa1d560a8dd9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_937b7aea-0c59-4d7f-96f8-3a1d5f56b5f7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_33c261e3-bed4-4ba3-af15-a6ef6529e9c7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2c1a4b79-8e10-410e-ab12-2140b243bb10_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_d9bdb3df-c875-4cb3-81d9-0aa68927b589_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_aa1e98b9-3b99-4193-aba5-8be669bfd053_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized&#160;Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_75d1b1cc-a78f-4cbd-b57d-db34b3c76a2b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_9e5cee1f-766a-4b38-ba4b-145351da1422_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2e41c7d1-e39b-47b1-ae98-2e4281861461_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2e6a5e80-04f8-42e7-8e81-188788f9b2b2_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_bee95aa7-e3c6-406d-b2c1-98e4c2b9cae1_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect from the adoption of new accounting standard</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_7463d461-cc73-4228-a4c8-3ba5514bcb1d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_e93058df-4064-4fb1-b7fb-2a5c701b4bc2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts of Recognized Assets/Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_23f4e209-ad72-4740-ab40-e3cd5ad5aa76_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs involved</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_af7cc4e3-55b2-498b-ad73-4df620d35c60_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimate of variable consideration</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member_6486209e-918a-4a12-97df-10821fea84f4_terseLabel_en-US" xlink:label="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Senior Unsecured Notes Due April 2024</link:label>
    <link:label id="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member_label_en-US" xlink:label="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Senior Unsecured Notes Due April 2024 [Member]</link:label>
    <link:label id="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member_documentation_en-US" xlink:label="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Senior Unsecured Notes Due April 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:href="gild-20210930.xsd#gild_A370SeniorUnsecuredNotesDueApril2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:to="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_eaa792e9-6b08-4771-bbad-a024e71fddc2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time estimate for gains (losses) to be reclassified from AOCI to product sales</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_735fff5d-2a64-488c-93d1-61cf638a7896_terseLabel_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030</link:label>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_label_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030 [Member]</link:label>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_documentation_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:href="gild-20210930.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:to="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_5ef615ab-7de8-4bb7-847c-2c12ce9c71b0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_9f9c8326-86fa-46d8-ba4a-e4663e6c3090_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired_812bdf80-1b0a-4ba4-84a1-b6852054f918_terseLabel_en-US" xlink:label="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration, net of acquired cash</link:label>
    <link:label id="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired_label_en-US" xlink:label="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Assets, Net Of Cash Acquired</link:label>
    <link:label id="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired_documentation_en-US" xlink:label="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Assets, Net Of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:href="gild-20210930.xsd#gild_PaymentsToAcquireAssetsNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:to="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_ba9ebd24-11ed-494a-8f2a-be22a581942f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_545c89eb-40b5-4565-aeea-1302f60258b3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term debt, carrying values</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TrodelvyMember_29b9ab5c-b551-4a5f-a25f-4cf140c047e9_terseLabel_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy</link:label>
    <link:label id="lab_gild_TrodelvyMember_6da7f62a-175c-44b4-ad5e-1bc007e8ddd2_verboseLabel_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - Trodelvy</link:label>
    <link:label id="lab_gild_TrodelvyMember_label_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy [Member]</link:label>
    <link:label id="lab_gild_TrodelvyMember_documentation_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember" xlink:href="gild-20210930.xsd#gild_TrodelvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TrodelvyMember" xlink:to="lab_gild_TrodelvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_VariableTermLoanNoteDueOctober2023Member_e5ca9830-77b7-474b-96dd-df8d584e7925_terseLabel_en-US" xlink:label="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Term Loan Note Due October 2023</link:label>
    <link:label id="lab_gild_VariableTermLoanNoteDueOctober2023Member_label_en-US" xlink:label="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Term Loan Note Due October 2023 [Member]</link:label>
    <link:label id="lab_gild_VariableTermLoanNoteDueOctober2023Member_documentation_en-US" xlink:label="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Term Loan Note Due October 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VariableTermLoanNoteDueOctober2023Member" xlink:href="gild-20210930.xsd#gild_VariableTermLoanNoteDueOctober2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_VariableTermLoanNoteDueOctober2023Member" xlink:to="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_cbdd43d6-c252-4a8f-af79-b1f767f7e85b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_e380388c-7ec2-49e8-8168-7971f13b1d76_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_95419707-52e0-433f-97a2-e69ee9d6bdf7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsAbstract_label_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsAbstract_documentation_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsAbstract" xlink:href="gild-20210930.xsd#gild_CollaborativeandOtherArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeandOtherArrangementsAbstract" xlink:to="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ce9a392c-2e3f-46dd-a67a-58ad1025c23b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2cb38dca-8bc3-47ad-9bdc-fd6c39ae42fe_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0f1955bf-50f7-4af3-81dd-f551cc13966a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_b762e1ac-499f-420b-b145-ae6a8279c4ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_927b04ac-11b1-4880-b0de-c92dcf9f9670_terseLabel_en-US" xlink:label="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.60% Senior Unsecured Notes Due September 2035</link:label>
    <link:label id="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_label_en-US" xlink:label="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.60% Senior Unsecured Notes Due September 2035 [Member]</link:label>
    <link:label id="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_documentation_en-US" xlink:label="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.60% Senior Unsecured Notes Due September 2035</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:href="gild-20210930.xsd#gild_A460SeniorUnsecuredNotesDueSeptember2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:to="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_7116ae87-0ef3-4db8-9d2f-2ef584079bef_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_62f1b688-392b-49b4-87dd-76085ef6aabf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_82d42751-35d6-43c0-a815-df76dd7aca96_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1659b946-f7b7-4831-9bd8-489429f85248_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_e3f207a8-914c-41e8-81e1-bac8396a70a6_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_db08a7a7-90c8-4347-8e11-11c822e73ba1_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_eee8baf1-e88e-49d7-b757-1e7358c3e37d_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GalapagosNVMember_d6c1c4ba-f41d-471e-bb34-775f9f5918ca_terseLabel_en-US" xlink:label="lab_gild_GalapagosNVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos NV</link:label>
    <link:label id="lab_gild_GalapagosNVMember_label_en-US" xlink:label="lab_gild_GalapagosNVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos NV [Member]</link:label>
    <link:label id="lab_gild_GalapagosNVMember_documentation_en-US" xlink:label="lab_gild_GalapagosNVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos NV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosNVMember" xlink:href="gild-20210930.xsd#gild_GalapagosNVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GalapagosNVMember" xlink:to="lab_gild_GalapagosNVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_3b1c16e1-4b98-4855-8c5e-d23256ac074b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_de86f6e0-f756-4af9-92d4-903ca23f0181_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agencies securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_66e4ee7d-6cc2-44d9-9572-da780c3023d3_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount (Legal Offset)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_61fa9e00-ef63-4d5e-b410-b752dda22f0b_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20210930.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ac56eb45-1ebe-4243-879e-de6b2e79d4df_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d99e479a-b951-482f-971a-0edb129b352f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_7c271a96-fb59-428c-a6be-faac66b83387_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_1de5f6b1-0926-40bc-888a-40d697079246_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_847212ef-76a4-403e-b430-9edf1f0251a2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_893be457-d449-4a17-b304-5d51455b9091_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_e5d71016-740b-4eae-a985-54a4d246ffa7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER FINANCIAL INFORMATION</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_08d407eb-7b94-4d1a-9a9e-831de20e2eea_terseLabel_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue share - Symtuza</link:label>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_label_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Revenue Share-Symtuza [Member]</link:label>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_documentation_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Revenue Share-Symtuza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember" xlink:href="gild-20210930.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductsRevenueShareSymtuzaMember" xlink:to="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherInternationalMember_3a9fd903-12fb-4ea7-889d-349d5262339d_terseLabel_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International</link:label>
    <link:label id="lab_gild_OtherInternationalMember_label_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International [Member]</link:label>
    <link:label id="lab_gild_OtherInternationalMember_documentation_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember" xlink:href="gild-20210930.xsd#gild_OtherInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherInternationalMember" xlink:to="lab_gild_OtherInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_ebf64800-a4df-4480-908f-626c8b389296_terseLabel_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets (and liabilities), net</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_label_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_documentation_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:href="gild-20210930.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:to="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_1bc8aead-5d95-49bf-a208-fb3aa2efda95_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_000c6bd3-1087-40eb-a72f-18d9b2eca359_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts outstanding under revolving credit facilities</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e273bbe0-fdb5-4e98-900a-e62cafdcd5ef_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_2243b4cd-c1b3-49c2-a008-8ea85c48e070_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_fafc69cc-839f-4373-8ace-295d95f53416_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsTruvadaMember_295b9173-468d-4950-94ef-e37541071e95_terseLabel_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Truvada</link:label>
    <link:label id="lab_gild_HIVProductsTruvadaMember_label_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Truvada [Member]</link:label>
    <link:label id="lab_gild_HIVProductsTruvadaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Truvada [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember" xlink:href="gild-20210930.xsd#gild_HIVProductsTruvadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsTruvadaMember" xlink:to="lab_gild_HIVProductsTruvadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_c37b5ec5-69c8-4454-9dab-100eaf4d7755_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6f1b844b-f924-4144-8e17-b02d729c0c01_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6bd14190-30ab-41f6-870e-781a4b69a55d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_37db7060-6131-4635-9918-3947760ed6a1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPartiesFilingOppositionNumber_1684d043-ece9-4a8a-a0d6-38ea085cf099_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of parties filing opposition</link:label>
    <link:label id="lab_gild_LossContingencyPartiesFilingOppositionNumber_label_en-US" xlink:label="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Filing Opposition, Number</link:label>
    <link:label id="lab_gild_LossContingencyPartiesFilingOppositionNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Filing Opposition, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesFilingOppositionNumber" xlink:href="gild-20210930.xsd#gild_LossContingencyPartiesFilingOppositionNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPartiesFilingOppositionNumber" xlink:to="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7e388add-60f1-48f4-bb86-3f6cccb86041_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember_9c6dd6de-f48a-4a63-a0fa-3201c9e2f079_terseLabel_en-US" xlink:label="lab_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The &#8220;Stock Purchase Agreements&#8221;</link:label>
    <link:label id="lab_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember_label_en-US" xlink:label="lab_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement and Investor Rights Agreement [Member]</link:label>
    <link:label id="lab_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember_documentation_en-US" xlink:label="lab_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement and Investor Rights Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" xlink:href="gild-20210930.xsd#gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" xlink:to="lab_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_964ba1c9-5dd5-4b6e-a3d7-c16023f33e75_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_96e3f289-68c1-4989-b9e3-db783d003e2c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period Of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsTecartusMember_a90bda27-f697-4aa1-b9a4-574811d3352c_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tecartus</link:label>
    <link:label id="lab_gild_CellTherapyProductsTecartusMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Tecartus [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsTecartusMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Tecartus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember" xlink:href="gild-20210930.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsTecartusMember" xlink:to="lab_gild_CellTherapyProductsTecartusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_269c24a6-31f7-4696-84a9-cb21fad1f814_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol(s)</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_9db31ef0-2934-4246-acfa-c8831d5c6c37_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages amount</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_04cdaf8a-86ba-4ad9-b8e4-c9072479a4d0_terseLabel_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040</link:label>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_label_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040 [Member]</link:label>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_documentation_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:href="gild-20210930.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:to="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MYRGmbHMember_5326ac04-5546-4231-9ffb-3b0529d1c068_terseLabel_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH</link:label>
    <link:label id="lab_gild_MYRGmbHMember_label_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH [Member]</link:label>
    <link:label id="lab_gild_MYRGmbHMember_documentation_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember" xlink:href="gild-20210930.xsd#gild_MYRGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MYRGmbHMember" xlink:to="lab_gild_MYRGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f631a0d0-7f65-4c89-98b2-c61cf0f833ad_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_QuiTamMember_7b5a10c4-0726-4294-b975-88322d0d01a7_terseLabel_en-US" xlink:label="lab_gild_QuiTamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qui Tam</link:label>
    <link:label id="lab_gild_QuiTamMember_label_en-US" xlink:label="lab_gild_QuiTamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qui Tam [Member]</link:label>
    <link:label id="lab_gild_QuiTamMember_documentation_en-US" xlink:label="lab_gild_QuiTamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qui Tam</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_QuiTamMember" xlink:href="gild-20210930.xsd#gild_QuiTamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_QuiTamMember" xlink:to="lab_gild_QuiTamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_a45ceb82-610c-49fb-ab76-cce0f9ce08aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Accelerated Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fa1a12fb-10d6-4329-829e-04c835f33524_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, including in-process research and development, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_6c262102-63ac-4271-ba22-89a7e21a23c1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_18716dba-d7de-4c23-8cc8-d27274f7b439_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT AND CREDIT FACILITIES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherHepatitisCVirusProductsMember_696fbe41-0969-44c0-beb3-4306b0550a96_terseLabel_en-US" xlink:label="lab_gild_OtherHepatitisCVirusProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HCV</link:label>
    <link:label id="lab_gild_OtherHepatitisCVirusProductsMember_label_en-US" xlink:label="lab_gild_OtherHepatitisCVirusProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Hepatitis C Virus Products [Member]</link:label>
    <link:label id="lab_gild_OtherHepatitisCVirusProductsMember_documentation_en-US" xlink:label="lab_gild_OtherHepatitisCVirusProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Hepatitis C Virus Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHepatitisCVirusProductsMember" xlink:href="gild-20210930.xsd#gild_OtherHepatitisCVirusProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherHepatitisCVirusProductsMember" xlink:to="lab_gild_OtherHepatitisCVirusProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_79eaa86d-5713-402b-b2a9-d31e4ca848a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_d2bf6218-e892-4bcf-a019-1bcc6eb07839_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_0d54d1eb-8264-4aee-9275-a4d12556c3f0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_93f60446-cd70-4f2a-8f05-4c07b82a9622_terseLabel_en-US" xlink:label="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% Senior Unsecured Notes Due September 2023</link:label>
    <link:label id="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_label_en-US" xlink:label="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% Senior Unsecured Notes Due September 2023 [Member]</link:label>
    <link:label id="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% Senior Unsecured Notes Due September 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:href="gild-20210930.xsd#gild_A250SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:to="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductLiabilityMember_d27cbbe5-7904-4302-8c89-1d5681cc74f0_terseLabel_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:label id="lab_gild_ProductLiabilityMember_label_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability [Member]</link:label>
    <link:label id="lab_gild_ProductLiabilityMember_documentation_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember" xlink:href="gild-20210930.xsd#gild_ProductLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductLiabilityMember" xlink:to="lab_gild_ProductLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_bff0ae0e-03f9-4b0b-a0e1-4621d79cb2ce_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Donation expense</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_a85cc8d3-ff6b-4100-be1a-e2f29954e8fc_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_bb020db5-8ebb-4070-a508-36cb05154b35_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_29b02f99-a8b7-43cd-8c72-830ec4d55bfd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_425278b4-5a08-4800-96cc-09966fe687ff_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. government securities</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_46bfde63-446a-4fc3-ac04-b907640d2d2c_terseLabel_en-US" xlink:label="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Sharp &amp; Dohme Corp agreement</link:label>
    <link:label id="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Sharp &amp; Dohme Corp License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Sharp &amp; Dohme Corp License And Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:href="gild-20210930.xsd#gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:to="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_27eff07e-7af4-4168-bfde-66d9b2927bf9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.001 per share; 5,600 shares authorized; 1,255 and 1,254 shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EuropeanPatentClaims2027ExpirationMember_a65a0449-7a46-4ee9-8ef4-9ac8045df440_terseLabel_en-US" xlink:label="lab_gild_EuropeanPatentClaims2027ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2027 Expiration</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2027ExpirationMember_label_en-US" xlink:label="lab_gild_EuropeanPatentClaims2027ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2027 Expiration [Member]</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2027ExpirationMember_documentation_en-US" xlink:label="lab_gild_EuropeanPatentClaims2027ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2027 Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2027ExpirationMember" xlink:href="gild-20210930.xsd#gild_EuropeanPatentClaims2027ExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EuropeanPatentClaims2027ExpirationMember" xlink:to="lab_gild_EuropeanPatentClaims2027ExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_153c900a-2d45-43be-85ed-b404ea5c7d59_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_4a603e87-f4bb-4e25-a18a-7ce019f534f0_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_321325a0-73f0-4964-89a7-dcb652d2a3a8_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_5b345a71-43a8-4e88-a91e-871a25dcac2e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill resulting from the acquisition of MYR</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d130a6cd-40bf-4948-a36c-2631c7b57d9c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_39d053af-341f-47e9-980b-2820c7921089_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EuropeanPatentClaims2024ExpirationMember_9f8517b4-23b7-4fed-98e6-25e9a353048b_terseLabel_en-US" xlink:label="lab_gild_EuropeanPatentClaims2024ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2024 Expiration</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2024ExpirationMember_label_en-US" xlink:label="lab_gild_EuropeanPatentClaims2024ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2024 Expiration [Member]</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2024ExpirationMember_documentation_en-US" xlink:label="lab_gild_EuropeanPatentClaims2024ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2024 Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2024ExpirationMember" xlink:href="gild-20210930.xsd#gild_EuropeanPatentClaims2024ExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EuropeanPatentClaims2024ExpirationMember" xlink:to="lab_gild_EuropeanPatentClaims2024ExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementNetProductSalesThreshold_5377dc25-fddb-4d0a-a6ea-542f622f6fab_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales threshold</link:label>
    <link:label id="lab_gild_CollaborationArrangementNetProductSalesThreshold_label_en-US" xlink:label="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Net Product Sales Threshold</link:label>
    <link:label id="lab_gild_CollaborationArrangementNetProductSalesThreshold_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Net Product Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementNetProductSalesThreshold" xlink:href="gild-20210930.xsd#gild_CollaborationArrangementNetProductSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementNetProductSalesThreshold" xlink:to="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1b855f72-59b5-4e3d-93f6-b5a87a72c079_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_ef48f179-a3f4-471b-8d53-024e6db86fa9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Classification of Equity Securities</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_6c820127-bbd4-439a-afcd-998294c09391_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowances for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_f6137648-8bcd-4d8f-b844-9b71cb01513d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt financing, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MediumTermNotesMember_4fa4c6e2-a3f0-4d95-a7b8-19190f736fca_terseLabel_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medium-term Notes</link:label>
    <link:label id="lab_us-gaap_MediumTermNotesMember_label_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medium-term Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MediumTermNotesMember" xlink:to="lab_us-gaap_MediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_4bcd687e-d73d-45b0-8701-c990be5f4128_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_c2e76b07-3d8e-48ae-9795-593f2533b8a7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_21187aa2-4643-45b5-b951-4dcb499f9adf_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HBV/HDV</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:href="gild-20210930.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_03cf264c-c036-447c-99bd-0936cdee98f2_terseLabel_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash discounts and other</link:label>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_label_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Cash Discounts and Other, Current</link:label>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_documentation_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Cash Discounts and Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:href="gild-20210930.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:to="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_8643f535-065e-4123-9484-a6309fdd8f40_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issued</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsAtriplaMember_daaa9e48-9612-4783-a5e1-2d0a7fe485de_terseLabel_en-US" xlink:label="lab_gild_HIVProductsAtriplaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Atripla</link:label>
    <link:label id="lab_gild_HIVProductsAtriplaMember_label_en-US" xlink:label="lab_gild_HIVProductsAtriplaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Atripla [Member]</link:label>
    <link:label id="lab_gild_HIVProductsAtriplaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsAtriplaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Atripla [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsAtriplaMember" xlink:href="gild-20210930.xsd#gild_HIVProductsAtriplaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsAtriplaMember" xlink:to="lab_gild_HIVProductsAtriplaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_f9089caf-4e65-456f-a971-66c49f692e80_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccruedGovernmentAndOtherRebates_1cec20a2-c630-4614-95f5-aa437ab2ff33_terseLabel_en-US" xlink:label="lab_gild_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued government and other rebates</link:label>
    <link:label id="lab_gild_AccruedGovernmentAndOtherRebates_label_en-US" xlink:label="lab_gild_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Government And Other Rebates</link:label>
    <link:label id="lab_gild_AccruedGovernmentAndOtherRebates_documentation_en-US" xlink:label="lab_gild_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Government And Other Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedGovernmentAndOtherRebates" xlink:href="gild-20210930.xsd#gild_AccruedGovernmentAndOtherRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccruedGovernmentAndOtherRebates" xlink:to="lab_gild_AccruedGovernmentAndOtherRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2534394b-afac-4b66-9ff4-4c8cdfd2df20_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1863ffef-0e67-4e87-aa75-ba337980efc5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVAILABLE-FOR-SALE DEBT SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6a13bfca-d283-47bf-8a99-ada19d0c9b1f_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of stock options and equivalents (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member_a0bd8e01-607f-4118-9846-557754df970e_terseLabel_en-US" xlink:label="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% Senior Unsecured Notes Due December 2041</link:label>
    <link:label id="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member_label_en-US" xlink:label="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% Senior Unsecured Notes Due December 2041 [Member]</link:label>
    <link:label id="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member_documentation_en-US" xlink:label="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% Senior Unsecured Notes Due December 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:href="gild-20210930.xsd#gild_A565SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:to="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_39171f63-fbdb-4bb1-8d70-6d3dc9f63d29_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1cdb019d-251b-41d9-9aca-214ecb12d223_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeAndOtherArrangementsTextBlock_4f997483-07b1-4b5f-a71a-e14a0a70fb60_terseLabel_en-US" xlink:label="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATIONS AND OTHER ARRANGEMENTS</link:label>
    <link:label id="lab_gild_CollaborativeAndOtherArrangementsTextBlock_label_en-US" xlink:label="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative And Other Arrangements [Text Block]</link:label>
    <link:label id="lab_gild_CollaborativeAndOtherArrangementsTextBlock_documentation_en-US" xlink:label="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:href="gild-20210930.xsd#gild_CollaborativeAndOtherArrangementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:to="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_57d85393-6ac0-4eeb-bb04-18d09fc5f2f4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_6a81cc4b-479b-4031-8317-a9a0345dc03b_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_8a2abfe0-2f83-4904-8076-ef9288a0ae27_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InventoryNetAndInventoryNoncurrent_a73e970a-a4e0-4f73-a6c2-b9f0683d01c0_totalLabel_en-US" xlink:label="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_gild_InventoryNetAndInventoryNoncurrent_label_en-US" xlink:label="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:label id="lab_gild_InventoryNetAndInventoryNoncurrent_documentation_en-US" xlink:label="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent" xlink:href="gild-20210930.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent" xlink:to="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1442832d-1fba-444c-bf5b-e535e636fca5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_87f121f6-3aa0-4b07-bec4-731edeb0e8a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from equity securities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5a62dec7-f10e-4e00-843e-c5b1fa6086d9_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_4a0d2544-3931-43f4-a51c-9630d735341a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value&#160;</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_92ac829b-a486-43b1-8f0c-b830fb669ff2_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_15586bcd-468f-4154-b58b-32b4c86796d1_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_96541192-81e5-47df-b9a5-fb63facc50f8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_fba5eb2f-3e2a-4b79-8f9c-3d663ad7dd1e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f63eb6fe-8bc4-48f5-8bcb-79b7e03b15d3_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_054a558e-770b-40c9-b41c-6d8054d6ed37_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_b9d58857-2781-40ca-9514-580930ba1a4c_terseLabel_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due February 2045</link:label>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_label_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due February 2045 [Member]</link:label>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_documentation_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due February 2045 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:href="gild-20210930.xsd#gild_A450SeniorUnsecuredNotesDueFebruary2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:to="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified_4df8c2b6-9837-41a6-83aa-198728c1e1ac_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassified amounts</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross, Reclassified</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross, Reclassified</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:href="gild-20210930.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:to="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_d4c80e08-272b-43ed-83ea-3d767259b85c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8ee7ee12-a80a-4ac2-9c3a-32ab7835ac5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_0666ff03-9b0c-4efe-8d6f-8fa79e3072a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_64d0706f-a135-49ef-8fe4-2888c439f349_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_606969ac-48f8-4a87-b79e-6c97eb8a4033_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_056f14ef-e22d-4135-9734-0f03a8f8582e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_f3f9b6b6-dd48-4719-8db4-8a067ed9cfe7_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7206e658-41d5-4085-88f4-55628308604c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsYescartaMember_889dd4f8-1ce6-4e96-9925-7923c48f839f_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yescarta</link:label>
    <link:label id="lab_gild_CellTherapyProductsYescartaMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Yescarta [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsYescartaMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Yescarta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsYescartaMember" xlink:href="gild-20210930.xsd#gild_CellTherapyProductsYescartaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsYescartaMember" xlink:to="lab_gild_CellTherapyProductsYescartaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_18da4b45-08f6-4c34-8638-4cfcc28a5ccd_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_20a440eb-b3be-428d-b42c-fada785d8d5c_terseLabel_en-US" xlink:label="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% Senior Unsecured Notes Due September 2022</link:label>
    <link:label id="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_label_en-US" xlink:label="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% Senior Unsecured Notes Due September 2022 [Member]</link:label>
    <link:label id="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_documentation_en-US" xlink:label="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% Senior Unsecured Notes Due September 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:href="gild-20210930.xsd#gild_A325SeniorUnsecuredNotesDueSeptember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:to="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_74b7abb4-3efc-4d79-9584-0b446f2950e0_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_84b5a9d7-4a72-4464-bd2f-e64264e7bf39_terseLabel_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_label_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current [Member]</link:label>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember" xlink:href="gild-20210930.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MarketableSecuritiesCurrentMember" xlink:to="lab_gild_MarketableSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b20863e7-657d-440a-9693-fd483a2719bc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock&#160;</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_eb7ecb0c-ebb4-41cb-ae7c-b98b3b479d52_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_e826054c-498f-4a31-861f-63b476809296_totalLabel_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Indefinite Lived Intangible Assets Excluding Goodwill</link:label>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_documentation_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="gild-20210930.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a41becfc-e071-4b4f-8ef2-af14915d795e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_441ee0a0-6977-454b-8aa8-2efebe002d64_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_992a5268-4857-41a3-9728-ae28492ad532_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_138389b8-a619-4365-b6d7-df1d6a001523_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e455b3e0-4b2f-4f58-add0-6d9c7af39d50_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_d53cc81d-5edd-4421-937c-b8a4ecfd9cae_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_VekluryMember_aab98cec-c494-44cd-b0bc-86be9049d5e8_terseLabel_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury</link:label>
    <link:label id="lab_gild_VekluryMember_label_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury [Member]</link:label>
    <link:label id="lab_gild_VekluryMember_documentation_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember" xlink:href="gild-20210930.xsd#gild_VekluryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_VekluryMember" xlink:to="lab_gild_VekluryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e0a70221-a19c-49ef-9730-ecaf719feaa0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3b97e8dd-686b-4fc5-8159-4022d9bbc3b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_7bc172c6-cc82-422e-8e5f-89092d11b599_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_ef7b5e3a-72e7-41e1-911b-771b5a94d243_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c5d9cc47-892e-4a2b-8fdc-240417f50910_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_a569a8ff-ec0f-44a0-a4b8-9edebed60b9f_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FortySevenIncMember_018c1aaf-0f04-47f3-b34f-65cb7cda690f_terseLabel_en-US" xlink:label="lab_gild_FortySevenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Seven, Inc.</link:label>
    <link:label id="lab_gild_FortySevenIncMember_label_en-US" xlink:label="lab_gild_FortySevenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Seven, Inc. [Member]</link:label>
    <link:label id="lab_gild_FortySevenIncMember_documentation_en-US" xlink:label="lab_gild_FortySevenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Seven, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember" xlink:href="gild-20210930.xsd#gild_FortySevenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FortySevenIncMember" xlink:to="lab_gild_FortySevenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_25bca441-4409-476c-97cf-d62b0c07f4c5_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt and other obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_7a1a5fcb-954e-4e7d-8436-f1971b06fb18_terseLabel_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_label_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent [Member]</link:label>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_documentation_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember" xlink:href="gild-20210930.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MarketableSecuritiesNoncurrentMember" xlink:to="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_a41e1302-53c4-40e5-a3ec-d68352b411c8_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5d2cf6d4-cd87-48b4-8667-f7763261d78b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_315fd061-74f2-4e38-9553-17b628ed7a08_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c2a3e14-c646-4e23-9352-bfe5e07699dd_verboseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A440SeniorUnsecuredNotesDueDecember2021Member_f7461c6a-63ea-4a24-9b74-a35bcb43b699_terseLabel_en-US" xlink:label="lab_gild_A440SeniorUnsecuredNotesDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% Senior Unsecured Notes Due December 2021</link:label>
    <link:label id="lab_gild_A440SeniorUnsecuredNotesDueDecember2021Member_label_en-US" xlink:label="lab_gild_A440SeniorUnsecuredNotesDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% Senior Unsecured Notes Due December 2021 [Member]</link:label>
    <link:label id="lab_gild_A440SeniorUnsecuredNotesDueDecember2021Member_documentation_en-US" xlink:label="lab_gild_A440SeniorUnsecuredNotesDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% Senior Unsecured Notes Due December 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member" xlink:href="gild-20210930.xsd#gild_A440SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member" xlink:to="lab_gild_A440SeniorUnsecuredNotesDueDecember2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_42ba72a3-6142-4cb8-8356-3ab09b1a9f49_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_42a98697-2843-44c5-a741-9b8734bfcab1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductsOtherHIVMember_3e04e838-0e78-4714-9ced-571d94e23d68_terseLabel_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HIV</link:label>
    <link:label id="lab_gild_ProductsOtherHIVMember_label_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Other HIV [Member]</link:label>
    <link:label id="lab_gild_ProductsOtherHIVMember_documentation_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Other HIV [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember" xlink:href="gild-20210930.xsd#gild_ProductsOtherHIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductsOtherHIVMember" xlink:to="lab_gild_ProductsOtherHIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_297fb4df-8e9d-49d4-9702-3a3df3a604ea_negatedTerseLabel_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_label_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_documentation_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:href="gild-20210930.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:to="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_3e98a851-ed94-4613-aa3b-1cb680b6ea3c_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased and retired (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6fe2217b-ad86-406b-bc22-e2902def1191_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e587f979-472b-450f-a726-5652622bc819_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_4f275b65-0f31-4152-8381-633149228c26_terseLabel_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Repurchase Program</link:label>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_label_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember" xlink:href="gild-20210930.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A2016StockRepurchaseProgramMember" xlink:to="lab_gild_A2016StockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d6ce6055-4f21-449f-bfd5-b40587362490_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_5dd30350-44d0-4238-ae58-0fbc2607db52_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_b1f02396-8900-4433-a821-f517dbc5ec58_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsZydeligMember_34192a27-07c1-4de5-85bf-06e137b7595f_terseLabel_en-US" xlink:label="lab_gild_OtherProductsZydeligMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zydelig</link:label>
    <link:label id="lab_gild_OtherProductsZydeligMember_label_en-US" xlink:label="lab_gild_OtherProductsZydeligMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Zydelig [Member]</link:label>
    <link:label id="lab_gild_OtherProductsZydeligMember_documentation_en-US" xlink:label="lab_gild_OtherProductsZydeligMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Zydelig [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsZydeligMember" xlink:href="gild-20210930.xsd#gild_OtherProductsZydeligMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsZydeligMember" xlink:to="lab_gild_OtherProductsZydeligMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_9ecad9dd-fb85-4bf4-9eee-4e2378d4b7e9_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c2982eb4-41ce-4f64-a380-5ea813157c72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_fd43d384-e566-4831-9c6d-c268507755d1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_78001ba8-dc4e-477e-b5cb-246d716d439c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_3c6854f4-532c-4c11-8054-3e2f9b48c93f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_61f70125-7520-4f99-b428-6decf3fbe534_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from Major Customers</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_57c2aba7-918e-4c5d-a3dc-d0ec80c3bce4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gilead stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0bd4ea98-9fd2-429e-8f32-fdf3ea7f4d9c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements_89c59bfb-abfa-4ff3-a1de-a9d0d5657f28_terseLabel_en-US" xlink:label="lab_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront collaboration expenses related to other collaborative arrangements</link:label>
    <link:label id="lab_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements_label_en-US" xlink:label="lab_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Collaboration Expenses Related To Other Collaborative Arrangements</link:label>
    <link:label id="lab_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements_documentation_en-US" xlink:label="lab_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Collaboration Expenses Related To Other Collaborative Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" xlink:href="gild-20210930.xsd#gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" xlink:to="lab_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member_0ecdc8f8-1bec-4ea4-b6b5-171ad9c2c05a_terseLabel_en-US" xlink:label="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80% Senior Unsecured Notes Due April 2044</link:label>
    <link:label id="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member_label_en-US" xlink:label="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80% Senior Unsecured Notes Due April 2044 [Member]</link:label>
    <link:label id="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member_documentation_en-US" xlink:label="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80% Senior Unsecured Notes Due April 2044 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:href="gild-20210930.xsd#gild_A480SeniorUnsecuredNotesDueApril2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:to="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_498a35c4-e89e-4598-9df8-e3a5b751c0be_terseLabel_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The "2020 Revolving Credit Facility"</link:label>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_label_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025 [Member]</link:label>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_documentation_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member" xlink:href="gild-20210930.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CreditFacilityDueJune2025Member" xlink:to="lab_gild_CreditFacilityDueJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a28b331d-4fed-4a45-b9ff-0ba4a0782cca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_b8b1a160-dab0-4f9a-b2af-cac73c3a61ae_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_a33693f3-35ce-4b55-9a88-0aa952a8082f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e688be97-af29-4547-9aa3-2af68e0d3450_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_de7ee1a6-e54b-4618-8154-a1fe483c2fa5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4247253f-5983-4c8d-9ce5-21f862bf3599_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_85e707f6-751c-41d2-a591-202dccdcc7fb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, performance obligation satisfied in previous period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_1389d014-4ed5-4a4a-8b71-432fd32bdaa7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_c122cb72-062e-4749-b7c8-517afa7c6aaf_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_545ccd0c-822a-42ab-bda8-2bbfa64c9b25_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EuropeanPatentClaims2026ExpirationMember_93a7e363-4be2-441f-b31c-bcc3f00c4d2c_terseLabel_en-US" xlink:label="lab_gild_EuropeanPatentClaims2026ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2026 Expiration</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2026ExpirationMember_label_en-US" xlink:label="lab_gild_EuropeanPatentClaims2026ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2026 Expiration [Member]</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2026ExpirationMember_documentation_en-US" xlink:label="lab_gild_EuropeanPatentClaims2026ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2026 Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2026ExpirationMember" xlink:href="gild-20210930.xsd#gild_EuropeanPatentClaims2026ExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EuropeanPatentClaims2026ExpirationMember" xlink:to="lab_gild_EuropeanPatentClaims2026ExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNISharesAcquired_c502ed26-fda0-4eb1-b326-ee240549a7fb_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities acquired (in shares)</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNISharesAcquired_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares Acquired</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNISharesAcquired_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNISharesAcquired" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesFVNISharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNISharesAcquired" xlink:to="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_b544caec-74b0-40db-9ec1-fde5845e6401_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_31821594-c8ca-4dca-82fe-c6946f9a56df_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outlicense contract</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c05a9266-f5bc-4815-85d5-e3bc565616dc_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_07d8048c-d396-4260-bdec-f186ace4d78f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsAbstract" xlink:to="lab_us-gaap_DerivativeAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3560063f-5ad7-4bf7-a120-471c7a5115a5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0e198fcf-522a-4873-a725-eb724690ef4c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_56f6bdd3-18e7-4c72-96e8-5bea0c696ac7_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_5d5788e2-427b-495a-b2c0-aacb5c6d0cc0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7cea1c23-c7e1-4739-8356-492409d63920_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_4944beef-d738-4394-ad75-ce9c47175014_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_f33fa52c-422f-42e8-8eff-c613ef1413de_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_309abf6b-15cf-499b-880b-e394873eb87e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_10490790-a0d2-493d-86a7-6f5c20faea3f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment recognized</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_304f71f0-5144-4ef2-bb73-bcd9a3a0c995_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Effect of Foreign Currency Exchange Contracts</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_d2131a4d-2616-4110-9c47-01eaf26939a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_006584ba-0ee0-4a87-b40f-67ce26d918c8_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_7c037ee6-0bbf-475b-a43a-ae20f7929282_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_bf40f590-e071-4980-a23e-33bb91b117f2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_62b94bde-4f53-4cd7-a87d-173c47d31264_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9387b03c-6bf8-45ee-ae0e-5c8ee4cbe9b7_verboseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fbefbeb2-ef11-4cdb-b790-cdc478b57fb4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_97275772-d09e-41e7-afb7-aa30d682b728_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ac12e38f-9ecf-459e-8f03-30294201f881_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_ee4d6929-92ca-43f9-9e48-e7f415061e66_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50f53756-7ac2-4f83-9592-b5af9d5b5009_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2d277da1-4dc5-4104-a6ae-4a4c1c364a3e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7cdaef2a-4add-479a-8810-0799e62e0552_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ad34da68-75d8-4777-a6b5-476b25d6330b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1e4a21ef-8345-435a-9ece-1ed6f7a8f020_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentEnhancedDamagesOnPastSales_3c9f9e6d-c54b-46e4-84fa-74a74f0e51b2_terseLabel_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enhancement rate on past damages</link:label>
    <link:label id="lab_gild_JudgmentEnhancedDamagesOnPastSales_label_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Enhanced Damages On Past Sales</link:label>
    <link:label id="lab_gild_JudgmentEnhancedDamagesOnPastSales_documentation_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Enhanced Damages On Past Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesOnPastSales" xlink:href="gild-20210930.xsd#gild_JudgmentEnhancedDamagesOnPastSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentEnhancedDamagesOnPastSales" xlink:to="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e9656cea-a9ab-46ff-ad12-aa6c9503bade_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_98cc4e7e-0216-45f0-83c3-590ee096d5a2_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_7f9d7274-b676-4b25-b510-480378f24af4_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a591fb3e-953c-497d-a111-4d8f8fe73dce_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_b90ca93a-c7a5-473d-8cfa-d203d79fb35a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_21a051b5-4735-4337-b4e9-1d5153a04902_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_1efed373-064b-4526-bf37-f5c385ce8b30_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_b304e949-2fc7-4454-acef-0291fd9e9a45_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_10b366e0-6f50-4532-a510-86580aea1cef_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_a00b731f-725f-4475-ade5-ef033b3f521f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_96a92574-c97d-427c-8868-bcf93052acc1_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_28d800ce-8900-47c7-9623-666c7ef4173b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_1428ca60-9b4a-4077-bb24-5e75e227c912_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bcb70c49-4990-431a-bfef-e4f728668b76_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_2296946e-297c-4de9-a175-43e52e5d21d0_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c5f6db38-7933-4d74-9de0-5bb8a539ff5f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1a7e24ac-0a85-4ff6-b34c-9d2c860319db_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c5299cbc-1dd2-43ab-b6e4-c523f2444503_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_dc58e4b0-d441-4902-8672-eb85d2a35fef_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion of long-term debt and other obligations, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_74469944-b64e-4bcf-b11c-dbe8e901b4ad_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_71e85008-bd56-4b09-a99a-63f5a5f1b9d5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8ddd7606-d622-45a3-b62c-8480baa3b2a4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_6088c08c-7a58-4816-b07e-30c5f8853dad_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d1b676fa-7c5e-4c7f-b179-1f7d900cd15e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_212faa03-b213-437c-aeae-e6164569ad71_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option period to license</link:label>
    <link:label id="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_label_en-US" xlink:label="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period</link:label>
    <link:label id="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:href="gild-20210930.xsd#gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:to="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OralFormulationProductMember_4ee5ab60-cf00-45ee-9a7d-c46a98dc0941_terseLabel_en-US" xlink:label="lab_gild_OralFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Formulation Product</link:label>
    <link:label id="lab_gild_OralFormulationProductMember_label_en-US" xlink:label="lab_gild_OralFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Formulation Product [Member]</link:label>
    <link:label id="lab_gild_OralFormulationProductMember_documentation_en-US" xlink:label="lab_gild_OralFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Formulation Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OralFormulationProductMember" xlink:href="gild-20210930.xsd#gild_OralFormulationProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OralFormulationProductMember" xlink:to="lab_gild_OralFormulationProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_d5b8ff82-2bd7-45d8-915e-76763a700865_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of outstanding stock allowed to be purchased (up to)</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:to="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_47fcb44d-e22f-419a-8ce8-5fc62a6df9e8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f4a92677-ac0d-4741-a793-e3b253b78f9a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance under equity incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_29b8940c-98bf-429c-b053-d6471440df44_terseLabel_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract" xlink:href="gild-20210930.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherFinancialInformationAbstract" xlink:to="lab_gild_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_b01f186a-12c2-4e43-befb-7016cc2e1bc4_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_40b82343-7bc5-4503-8261-6bab636126da_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_b5b45f21-ebae-4ed6-a038-1005c500463b_terseLabel_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complera/Eviplera</link:label>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_label_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Complera/Eviplera [Member]</link:label>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_documentation_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Complera/Eviplera [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember" xlink:href="gild-20210930.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsCompleraEvipleraMember" xlink:to="lab_gild_HIVProductsCompleraEvipleraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_aa4ca6d1-4487-4450-be1d-f2f8154beda1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible IPR&amp;D charges</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_8517b383-79db-424f-a0d6-58ec33b46907_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_3af15dc0-6d3e-4374-a5c7-e1034616dc8e_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_48479c4d-df3f-4482-aa69-376c04d47e3d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_2a34de76-303d-41d2-8c0f-3793fa44a7af_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_0e84a5d3-edd0-49e6-b826-77f42abb8d92_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIPurchasePeriod_b3ef5627-4ce8-4475-afed-323d0ab79fcd_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIPurchasePeriod_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Purchase Period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIPurchasePeriod_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesFVNIPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:to="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_630d6262-160e-473d-8664-f3a8aee71618_terseLabel_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Running royalty rate from October 2017</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_label_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate from October 2017</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_documentation_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate from October 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017" xlink:href="gild-20210930.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentRoyaltyRateFromOctober2017" xlink:to="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_054f684f-79b1-476d-99fb-7b65e15e52b5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_eff8426b-c37b-4415-b09c-7870b87d40fd_netLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_11425152-10ca-43c7-b33a-eb315c418e80_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_2aa25722-ecb7-4f48-bfe4-179f7095a01a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_15eb3fb9-249f-45bb-83d0-ae28a0a3cd80_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_21fe6d87-8538-463e-bec0-13e230a5cbe8_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7d883c0-8b13-43e6-8182-3489b349f494_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6e69e8d9-4aaf-4a98-9a90-6443b7e09199_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_18a79c1d-e863-4d11-9036-c7eda37175ab_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_c53d6bf5-6acc-4923-a7a1-5f88ee452ece_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f9da32b2-9c6c-4325-ad3f-95aa5a3f98f1_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies, Estimates and Judgments</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c2608cb9-5344-48f3-b565-1f2ba629d438_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Calculation of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_220e8044-b181-4d0b-b8dc-43a174742834_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_d1272405-164f-421f-a2df-2e7a09bf3975_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_181ccb76-6294-487d-9339-7e7470848f4c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_df00302a-b03a-41f0-94d3-727b8460cb3d_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_38fd2d3e-8a1b-4c41-bab0-7a6ad767ab0f_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of global development and commercialization costs</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_label_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Development And Commercialization Costs</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Development And Commercialization Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:href="gild-20210930.xsd#gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:to="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_b02324e7-c17d-48b9-a2d6-edc1f046fd56_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuances of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9f169056-2f1c-4369-977d-cbc9b090034c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_f3774470-ebf5-4f3f-a7b7-8ee2c41ea0bf_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a2ab963a-8e4c-4980-8894-45e2d1c1a35a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_3d4a0419-87eb-48d9-85cd-f30f2b90acd0_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_632df159-48a1-4a6f-b42e-9c2e0e998019_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesDonationMember_644a6e4b-8631-4d79-b9a5-aef45971f73a_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesDonationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Donation</link:label>
    <link:label id="lab_gild_EquitySecuritiesDonationMember_label_en-US" xlink:label="lab_gild_EquitySecuritiesDonationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Donation [Member]</link:label>
    <link:label id="lab_gild_EquitySecuritiesDonationMember_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesDonationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Donation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesDonationMember" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesDonationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesDonationMember" xlink:to="lab_gild_EquitySecuritiesDonationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_be1721e1-1319-44e8-8b71-fe8b5816d492_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_588dbfe9-6559-45d8-ad0b-7807123375ad_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_b6721c33-940c-4d51-b38e-3562f12e5a55_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PreExposureProphylaxisMember_a75c4833-eb6d-4480-8b17-1cb084428f95_terseLabel_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis</link:label>
    <link:label id="lab_gild_PreExposureProphylaxisMember_label_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis [Member]</link:label>
    <link:label id="lab_gild_PreExposureProphylaxisMember_documentation_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember" xlink:href="gild-20210930.xsd#gild_PreExposureProphylaxisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PreExposureProphylaxisMember" xlink:to="lab_gild_PreExposureProphylaxisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_75bc8fef-b1f2-40a3-b1d5-ada579189a72_terseLabel_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_label_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_documentation_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember" xlink:href="gild-20210930.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusBiosciencesIncMember" xlink:to="lab_gild_ArcusBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_45bb92bc-2751-4420-8a12-df771277e25a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_fe1d1e19-05d6-4856-90a6-e79141a4063c_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_5889ac7a-b9a6-4b40-a1c0-5a8e8c5ad7a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_59e1a0dc-ede9-46cf-8922-0d195200d046_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount (Legal Offset)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c3a3b15a-a279-4abd-8df9-15184e30941e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_df07256a-ae1e-4850-b73f-bc2e28629e13_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsDescovyMember_7ccf4171-3e1e-4de9-9d53-32ae316f5b60_terseLabel_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Descovy</link:label>
    <link:label id="lab_gild_HIVProductsDescovyMember_label_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Descovy [Member]</link:label>
    <link:label id="lab_gild_HIVProductsDescovyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Descovy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember" xlink:href="gild-20210930.xsd#gild_HIVProductsDescovyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsDescovyMember" xlink:to="lab_gild_HIVProductsDescovyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_6cd60665-91e3-473a-a6fe-4c3b53cdfe73_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_36989674-ff91-4e65-ac48-7cb70cc39a91_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for sales returns</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ImmunomedicsIncMember_79f5e0e6-0c1f-47fb-b92f-14f43a9ceb60_terseLabel_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics</link:label>
    <link:label id="lab_gild_ImmunomedicsIncMember_label_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc. [Member]</link:label>
    <link:label id="lab_gild_ImmunomedicsIncMember_documentation_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc. (&#8220;Immunomedics&#8221;), a leading company in antibody-drug conjugate (&#8220;ADC&#8221;) technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember" xlink:href="gild-20210930.xsd#gild_ImmunomedicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ImmunomedicsIncMember" xlink:to="lab_gild_ImmunomedicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_c8629119-ef4d-4e46-b4a3-1ee0abccdd5a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_15e50442-27f5-4339-a05a-b0483221c5a8_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period Of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_cb731a7e-3cd7-4200-8e96-4fa47f0912f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b63a7b9f-1573-4b74-b960-06a5a830e5b0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_3aee6aef-0dba-4b43-b1b0-2fd34ee7d680_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_3c754357-6eb9-4e55-a10a-b0b29e9f1bfa_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_12d29d69-2b55-491c-bcdd-39012f51d71d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Debt Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_184fb207-dd90-4eea-863c-e4e55a606952_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_03909d9d-18d6-4d0f-a4e6-038f23743304_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_31012404-30d4-47cb-b192-659ca713cbfe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e9c58c14-4cfa-4732-ab87-c9a10eb7ee9c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_acee26f1-d6be-4f34-86f7-99cf42e254fc_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_295cf4c3-528f-4ed2-bc74-0403cee3bee4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_06cb1e34-8138-4eb7-9c02-f33e610df05f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share attributable to Gilead common stockholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bc4b773b-2e90-421f-95a9-274a94c04191_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_70696e9a-9cf9-4b1b-a53c-cb4a8f633643_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_fa757e40-7780-4ddf-9f5f-c1dd6665ff13_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_39323ea7-fce8-4335-8987-8536a83e76eb_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_7e84a17b-3212-4730-b236-ea8935c2fc59_terseLabel_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center</link:label>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_label_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center [Member]</link:label>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_documentation_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:href="gild-20210930.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:to="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_5d00fc0f-dc1b-4cf5-bb39-da107980962d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments not measured at fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_29efecc3-06e4-482d-91ac-26bb48533c73_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Collateral Received/ Pledged</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Right to Reclaim Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_86fbf0b9-e2c1-4519-bf0b-8dc490f774bf_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_24b944c3-5969-4810-be74-8fc0caa86cc0_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9591dcc2-4475-4034-bfb2-1be9a811fc96_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_1d62d941-45dc-434d-be9c-e538c148015e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_e1a33c4a-8c26-49a8-a854-d325b5181e0d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected tax deductible goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_06ba9d4d-367e-4346-9292-29ce2c3d3c2b_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinuances of cash flow hedges</link:label>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_label_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Discontinuation of Foreign Currency Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:to="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5e555121-4162-4629-a197-5a797c908ce7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6f9cc408-2fc4-4e6f-bad4-8f69e3455d66_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_a63a00b4-f83b-4886-9b58-98c11acc42a9_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_9af099ad-8897-44b1-999f-9969d846a7d1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GileadFoundationMember_f33f190c-1fcc-45d5-bd0d-f4bb0a38bca7_terseLabel_en-US" xlink:label="lab_gild_GileadFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Foundation</link:label>
    <link:label id="lab_gild_GileadFoundationMember_label_en-US" xlink:label="lab_gild_GileadFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Foundation [Member]</link:label>
    <link:label id="lab_gild_GileadFoundationMember_documentation_en-US" xlink:label="lab_gild_GileadFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Foundation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadFoundationMember" xlink:href="gild-20210930.xsd#gild_GileadFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GileadFoundationMember" xlink:to="lab_gild_GileadFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_5fa9b5c2-e197-45e4-a287-5062b288ea90_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;long-term&#160;obligations</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_58797e40-c7e7-4c39-8b26-212cab83533d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_94a197c8-b01e-48d7-8e47-1b8604db6716_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vemlidy</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:href="gild-20210930.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member_42e38215-ecd4-414e-b887-bf6d2c1164c0_terseLabel_en-US" xlink:label="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Unsecured Notes Due March 2027</link:label>
    <link:label id="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member_label_en-US" xlink:label="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Unsecured Notes Due March 2027 [Member]</link:label>
    <link:label id="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member_documentation_en-US" xlink:label="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Unsecured Notes Due March 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:href="gild-20210930.xsd#gild_A295SeniorUnsecuredNotesDueMarch2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:to="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_a08e897e-7e4b-4eed-975f-bdf95a93865c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_963458da-4453-44d2-91bc-3c88986c4526_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_52058a8c-f0d0-4d6d-b841-73e03a23cbe1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TrodelvyForMTNBCMember_8dad082d-645c-4b65-9cb6-65becb9b7a41_terseLabel_en-US" xlink:label="lab_gild_TrodelvyForMTNBCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset</link:label>
    <link:label id="lab_gild_TrodelvyForMTNBCMember_label_en-US" xlink:label="lab_gild_TrodelvyForMTNBCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy for mTNBC [Member]</link:label>
    <link:label id="lab_gild_TrodelvyForMTNBCMember_documentation_en-US" xlink:label="lab_gild_TrodelvyForMTNBCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy for mTNBC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyForMTNBCMember" xlink:href="gild-20210930.xsd#gild_TrodelvyForMTNBCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TrodelvyForMTNBCMember" xlink:to="lab_gild_TrodelvyForMTNBCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2b2d1a43-e639-4da3-8d5f-cf6e62608cf0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_d0da8cec-649e-4932-b87e-f87ef02eb309_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_d215276e-766f-4cf6-9908-40e48293f223_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EuropeanPatentClaims2032ExpirationMember_f7499fa0-6b15-45aa-aa7e-9fe0c956f518_terseLabel_en-US" xlink:label="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2032 Expiration</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2032ExpirationMember_label_en-US" xlink:label="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2032 Expiration [Member]</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2032ExpirationMember_documentation_en-US" xlink:label="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2032 Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2032ExpirationMember" xlink:href="gild-20210930.xsd#gild_EuropeanPatentClaims2032ExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EuropeanPatentClaims2032ExpirationMember" xlink:to="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_12458ef7-9015-45c8-a83e-b8b3af48044f_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7e973044-92f1-48fe-97d0-759bbf59636d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_582023d0-921e-408d-ab12-1cbd4cb6d17a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_43eee51d-54c1-4e05-a6bf-d7fc2a92603a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing from senior unsecured term loan facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fad436a0-0cdf-4a12-9643-0e184f5251b5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a16c160d-02f7-4893-8cd9-30142eb51d24_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_bc1652a3-b3f7-440e-a22a-824dd67cf953_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_58954932-c3a8-4709-9c9c-7b330ab155c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_0e50c5ad-6488-4677-87da-e303e451d788_terseLabel_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_label_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Contracts [Member]</link:label>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_documentation_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember" xlink:href="gild-20210930.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ForeignCurrencyDerivativeContractsMember" xlink:to="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_9ae52a71-06f5-4be4-a65f-4c2fd74a2b29_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_7082d421-6453-4a18-b269-93b061719065_terseLabel_en-US" xlink:label="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.52% LIBOR Senior Unsecured Notes Due September 2023</link:label>
    <link:label id="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_label_en-US" xlink:label="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.52% LIBOR Senior Unsecured Notes Due September 2023 [Member]</link:label>
    <link:label id="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.52% LIBOR Senior Unsecured Notes Due September 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:href="gild-20210930.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:to="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7d03e63d-02e8-4fc0-97e3-08a11a4784a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b61fdb76-df20-4bd1-b5eb-d00cc4ce6c80_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a60c0568-3c37-4b76-865d-f1dea399e057_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_457fe4b9-e36a-47cc-b677-c8fe66e7cd4c_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_6b078f4a-6609-49bd-90ef-777536e0d43f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_0d6f605c-ff6a-46e7-a209-4e617b56a5cf_terseLabel_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027</link:label>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_label_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027 [Member]</link:label>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_documentation_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:href="gild-20210930.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:to="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_6b5ee6a6-83e8-4304-9250-eb3c7e7006ae_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_c703515d-8ced-4ffd-8be1-fed6e39da9bd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_54ba859d-c257-4096-bfde-12c3d82be69a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_feac3c40-a2d7-483b-892f-ac4f37d0dc9e_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueApril2021Member_d35873e4-5242-40a4-917e-76ff8b331941_terseLabel_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueApril2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due April 2021</link:label>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueApril2021Member_label_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueApril2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due April 2021 [Member]</link:label>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueApril2021Member_documentation_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueApril2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due April 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member" xlink:href="gild-20210930.xsd#gild_A450SeniorUnsecuredNotesDueApril2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member" xlink:to="lab_gild_A450SeniorUnsecuredNotesDueApril2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_8f0d74ba-c0ed-4f63-844f-78ee5d29a036_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f14f32e-57e2-4000-b576-2cdd12fb9cd6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0693a139-ae02-4035-b7a4-7c00197810d4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfUnsecuredDebt_2312b397-e70e-403f-8e67-a50f6b70aab9_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of senior unsecured notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfUnsecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Unsecured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfUnsecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues_eb1e6259-263d-4e99-885a-036d91fe112f_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of global product revenues</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues_label_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Product Revenues</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Product Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:href="gild-20210930.xsd#gild_CollaborationArrangementPercentOfGlobalProductRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:to="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_a7e5387b-caea-42e6-ba12-a0a1dc680177_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b1879c9b-374f-4d22-83d4-20621a2ae257_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DeferredCompensationPlanMember_2bc05cb1-f82b-44dd-b7aa-9b6e120af36b_terseLabel_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan</link:label>
    <link:label id="lab_gild_DeferredCompensationPlanMember_label_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan [Member]</link:label>
    <link:label id="lab_gild_DeferredCompensationPlanMember_documentation_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember" xlink:href="gild-20210930.xsd#gild_DeferredCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DeferredCompensationPlanMember" xlink:to="lab_gild_DeferredCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a4f92c7c-55c4-40bc-b5cb-422f4430ae12_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherCollaborationArrangementsMember_abfab6f8-e5e4-4c7a-8de8-59ab51e07588_terseLabel_en-US" xlink:label="lab_gild_OtherCollaborationArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaboration arrangements</link:label>
    <link:label id="lab_gild_OtherCollaborationArrangementsMember_label_en-US" xlink:label="lab_gild_OtherCollaborationArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Arrangements [Member]</link:label>
    <link:label id="lab_gild_OtherCollaborationArrangementsMember_documentation_en-US" xlink:label="lab_gild_OtherCollaborationArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherCollaborationArrangementsMember" xlink:href="gild-20210930.xsd#gild_OtherCollaborationArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherCollaborationArrangementsMember" xlink:to="lab_gild_OtherCollaborationArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_681d55f6-ac76-4b7f-8af5-6e877ae44de9_terseLabel_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes and Medium-Term Notes</link:label>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_label_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes And Medium-Term Notes [Member]</link:label>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_documentation_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes And Medium-Term Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember" xlink:href="gild-20210930.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember" xlink:to="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_dcb4180d-effa-43b1-9fb0-38c620ad0dd4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts Offset on our Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsStribildMember_0bdf713e-44f1-4c70-8cc6-177dc3f5dfec_terseLabel_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stribild</link:label>
    <link:label id="lab_gild_HIVProductsStribildMember_label_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Stribild [Member]</link:label>
    <link:label id="lab_gild_HIVProductsStribildMember_documentation_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Stribild [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember" xlink:href="gild-20210930.xsd#gild_HIVProductsStribildMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsStribildMember" xlink:to="lab_gild_HIVProductsStribildMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_4fed8bf1-6f37-4a3c-b60b-4457d156b44a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_17ff3538-38fb-45f4-9ab5-dab6853d2f55_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_f922bd57-474f-48df-866b-3684a85d80d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b4682b34-0a4a-4fd2-a514-a12903ebe0cc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_12b93786-41ce-4030-ad83-5e0d198b23bf_terseLabel_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biktarvy</link:label>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_label_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Biktarvy [Member]</link:label>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Biktarvy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember" xlink:href="gild-20210930.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsBiktarvyMember" xlink:to="lab_gild_HIVProductsBiktarvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_a8878465-f040-4afb-9a26-b3383235066d_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_1278f36b-5f62-48f9-ad1c-0a64b23d0c05_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_72c4bd3e-b6df-492d-9b54-5f6c88c08be7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_8f212b77-0a68-4d0e-9450-3293417f0d13_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_cc595895-ef2a-49cc-8eaa-5c4261f05fd4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income (loss)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_9471621e-b2b0-4e7c-9045-bedbdc03a3b1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts Offset on our Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_ce1417c7-eb41-4b50-82b3-9607ea6b1f12_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductSalesMember_d6714c5c-86bb-4f50-8991-36831ec65864_terseLabel_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HCV</link:label>
    <link:label id="lab_gild_HCVProductSalesMember_label_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Product Sales [Member]</link:label>
    <link:label id="lab_gild_HCVProductSalesMember_documentation_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember" xlink:href="gild-20210930.xsd#gild_HCVProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductSalesMember" xlink:to="lab_gild_HCVProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_13a944d6-e738-45d8-9026-d3929cec8f64_terseLabel_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage and asset-backed securities</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_935e2a89-343f-4c8a-869a-65235bcfcb23_verboseLabel_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage and asset-backed securities</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_label_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage And Asset-Backed Securities [Member]</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_documentation_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage And Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:href="gild-20210930.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:to="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIShares_1bd8ea7b-1c72-4223-9721-88b64bd1adb5_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities (in shares)</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIShares_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIShares_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIShares" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesFVNIShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIShares" xlink:to="lab_gild_EquitySecuritiesFVNIShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_a5ee4067-62b8-4f74-b03d-a649ad6efbe4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_f0ce3206-fefb-4b63-a6dd-14841698942d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0231814d-6886-4b56-ad59-0990d68efe94_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_9dd1409d-7156-4f3d-af65-098d0c4978b7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsOdefseyMember_8922053a-46a9-4549-b234-621abbad4520_terseLabel_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Odefsey</link:label>
    <link:label id="lab_gild_HIVProductsOdefseyMember_label_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Odefsey [Member]</link:label>
    <link:label id="lab_gild_HIVProductsOdefseyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Odefsey [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember" xlink:href="gild-20210930.xsd#gild_HIVProductsOdefseyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsOdefseyMember" xlink:to="lab_gild_HIVProductsOdefseyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_11937443-952e-4226-9e97-caf7946b89f8_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_801a04ba-71ef-4737-a5bc-d8907997aac6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions held in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_a3565194-35a4-4ac3-8f61-ae13fad94d33_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_f4e82d9e-9af0-4ef6-911b-d28360913612_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_357107c5-0f5b-464a-9116-e0f3a8bcda27_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IntangibleAssetMeasurementInput_12fa57b9-f980-4fb9-8925-37f652c9bac2_terseLabel_en-US" xlink:label="lab_gild_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_gild_IntangibleAssetMeasurementInput_label_en-US" xlink:label="lab_gild_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:label id="lab_gild_IntangibleAssetMeasurementInput_documentation_en-US" xlink:label="lab_gild_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetMeasurementInput" xlink:href="gild-20210930.xsd#gild_IntangibleAssetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IntangibleAssetMeasurementInput" xlink:to="lab_gild_IntangibleAssetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_ba300a71-201e-445c-8629-372de94417cf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CardinalHealthIncMember_c42903ac-6bb3-4420-872a-6d84a03bc7a8_terseLabel_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc.</link:label>
    <link:label id="lab_gild_CardinalHealthIncMember_label_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:label id="lab_gild_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember" xlink:href="gild-20210930.xsd#gild_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CardinalHealthIncMember" xlink:to="lab_gild_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_de71fe92-7034-424a-8c5e-06fd9f233e56_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_485c46eb-5bff-4ed6-bc57-8ee919f9b382_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by noncontrolling owners</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b4a919fe-82d8-4b61-ab26-6c584b4ca858_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_783297e9-d66c-4b35-80a2-8e486ea7a96d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ViiVHealthcareCompanyMember_e847e7c2-0a0e-4242-9bc2-15599db4cee2_terseLabel_en-US" xlink:label="lab_gild_ViiVHealthcareCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Company</link:label>
    <link:label id="lab_gild_ViiVHealthcareCompanyMember_label_en-US" xlink:label="lab_gild_ViiVHealthcareCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Company [Member]</link:label>
    <link:label id="lab_gild_ViiVHealthcareCompanyMember_documentation_en-US" xlink:label="lab_gild_ViiVHealthcareCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Company (&#8220;ViiV&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ViiVHealthcareCompanyMember" xlink:href="gild-20210930.xsd#gild_ViiVHealthcareCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ViiVHealthcareCompanyMember" xlink:to="lab_gild_ViiVHealthcareCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_547a2ff6-9aa3-48e9-b782-5cfddfb55673_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_6e05c41b-ace1-4a07-b1a9-a382088b065f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_577d7bc3-066f-4d15-9df2-f92aa22938de_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_66aee93c-666d-4146-8aee-5e2fc71e265a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt and other obligations, net</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_ada9bba8-1928-4cd6-853a-59b6cfbfff28_terseLabel_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ledipasvir/Sofosbuvir</link:label>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_label_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Ledipasvir/Sofosbuvir [Member]</link:label>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_documentation_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Ledipasvir/Sofosbuvir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:href="gild-20210930.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:to="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_dec1ecae-4a50-46b2-9c00-f97de5101bda_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_81b1e553-45c6-4d55-abde-585b1ddc04f2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_39317939-4d3f-44b6-866e-c7055256e3d8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ee796c2-5878-4c11-b684-5ea17ee320e8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_b783d37e-93a2-4349-b7fc-9e4a1a53fae9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Potential Effect of Offsetting Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_5eb070f2-be90-487f-9cf9-9eabd47b8429_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_4ca9d17a-41da-4b91-8d46-1b49b1ddff7a_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_95d2f55c-a427-44cc-9b58-bdcad3379e0a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_bfb64251-446f-43c1-89ad-23df51bbed29_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_595d3c75-c01f-4c8c-bab1-8e3a6366dd9d_terseLabel_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050</link:label>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_label_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050 [Member]</link:label>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_documentation_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:href="gild-20210930.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:to="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a5e43740-9ca1-488b-88b1-6e3a7cc68c2a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2f6f9fd5-1f49-40b2-8741-efb9fcf4b8f5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3ddd97da-ad47-4e4c-9008-757a70a14877_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_b9d33fc1-d06d-4d6e-bf64-fcf5a62175b1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_33c12c4e-fd35-4bc0-981b-0b0620898ccb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ac1c36e6-52c1-4d75-8650-3a986d8295d9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_44bbf055-70f9-47c7-9f09-c73dfe4c513b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_3f9eb4e5-6caf-4f91-86ea-db75490a1de9_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_282f8299-48d1-4509-980c-97da65fca257_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_885d973b-388a-4e4a-9819-2a1e60024cce_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_819528b4-d2d6-444e-be8f-0c2eb564968d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_6a5c36ad-b36e-4e08-8a2a-a42ea3f2a880_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9b5bd867-7d01-4ac1-ba3b-189713587983_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cdf64232-aa5b-4e23-863e-938a0b2d3508_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_20994a82-5e24-43aa-b8f8-f915ad3d6baa_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f5ab390c-89ec-42dd-90ab-e89f4bc8039c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_ad7b0ee6-8589-4b4c-9718-d16e1f9162cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_4c689949-d754-4f5b-a489-cab9b87b2c8d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_c31d2599-12c2-48c9-a77b-eb125fd33a48_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_99af7381-ff32-49f2-b611-f6aa92888a75_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member_9b62fb21-9643-4041-a63c-d8093cb469b8_terseLabel_en-US" xlink:label="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Unsecured Notes Due March 2046</link:label>
    <link:label id="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member_label_en-US" xlink:label="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Unsecured Notes Due March 2046 [Member]</link:label>
    <link:label id="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member_documentation_en-US" xlink:label="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Unsecured Notes Due March 2046 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:href="gild-20210930.xsd#gild_A475SeniorUnsecuredNotesDueMarch2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:to="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_b6a89e3b-bd4a-4d86-8810-dedf2777340e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_bfa8788b-10f0-47fc-a117-0eafdf2275fe_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8f2d794e-7a71-4d3f-8fc7-d660837e4efb_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6890ffb9-04cc-433f-94ef-033e361b0833_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate, variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2870d5b1-7436-461f-9196-64a0bdb6971b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_e8447223-1886-4c1f-8010-87c24ad50f47_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs charged against allowance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_c02b50c3-5a17-49a8-bc96-3ed97fdbe65f_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viread</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:href="gild-20210930.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_b68da550-4d9b-47d6-a026-c7970e40d84c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_0886a225-8c60-4472-9013-f03c060070ec_terseLabel_en-US" xlink:label="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three-Year Senior Term Loan Facility</link:label>
    <link:label id="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_label_en-US" xlink:label="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Year Senior Unsecured Term Loan Facility [Member]</link:label>
    <link:label id="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_documentation_en-US" xlink:label="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Year Senior Unsecured Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:href="gild-20210930.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:to="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_fe64dec4-9089-4847-896a-e657bcbe6f30_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_feb57944-5633-40ba-878f-6cad433cf59d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsLetairisMember_7954e866-fc62-40b6-bbfe-d3a45b0b69f0_terseLabel_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letairis</link:label>
    <link:label id="lab_gild_OtherProductsLetairisMember_label_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Letairis [Member]</link:label>
    <link:label id="lab_gild_OtherProductsLetairisMember_documentation_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Letairis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember" xlink:href="gild-20210930.xsd#gild_OtherProductsLetairisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsLetairisMember" xlink:to="lab_gild_OtherProductsLetairisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e2317ffa-37c3-4fe0-ba2b-e273056ee141_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CashPaymentsMadeRelatedToEquityInvestments_6f8794ed-80a6-43e1-82ef-e58a7c6d2ee9_terseLabel_en-US" xlink:label="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments made related to equity investments</link:label>
    <link:label id="lab_gild_CashPaymentsMadeRelatedToEquityInvestments_label_en-US" xlink:label="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payments Made Related to Equity Investments</link:label>
    <link:label id="lab_gild_CashPaymentsMadeRelatedToEquityInvestments_documentation_en-US" xlink:label="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payments Made Related to Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:href="gild-20210930.xsd#gild_CashPaymentsMadeRelatedToEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:to="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_d9c3e021-20b8-4659-91c0-16bf0435b42c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_61356fec-9cb3-4eec-bcec-fdb24bdd1728_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_234f4783-615b-44ef-9917-fd818d939f39_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_978852d9-7cf9-4710-9292-4e58b8859812_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_d330cca5-9d0c-4953-a31c-bb85c71a71cc_terseLabel_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due September 2023</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_label_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due September 2023 [Member]</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due in September 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:href="gild-20210930.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:to="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0d8fe2f7-d758-45d4-9b75-7881f627276b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_d4b97564-7f98-45ed-888e-9967fd2d7dd0_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b521fa95-43e5-4751-b19c-f6bbea7e76e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9bbbfef7-84ee-4c39-a41f-126a8ad259b9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c61f9089-8ade-4a69-904c-f7771aa359f1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_4dd4d87b-28a0-48d7-8e08-9fdb5da95655_terseLabel_en-US" xlink:label="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% LIBOR Senior Unsecured Notes Due September 2021</link:label>
    <link:label id="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_label_en-US" xlink:label="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% LIBOR Senior Unsecured Notes Due September 2021 [Member]</link:label>
    <link:label id="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_documentation_en-US" xlink:label="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% LIBOR Senior Unsecured Notes Due September 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:href="gild-20210930.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:to="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e6a991b8-c0bc-44bc-9dad-ad92187cf93f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_dd002d7e-23de-4bcb-844b-000724229be6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_70249924-0f1b-4db3-8c2b-c18de3a658e0_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of parties appealed</link:label>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_label_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Appealed, Number</link:label>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Appealed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber" xlink:href="gild-20210930.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPartiesAppealedNumber" xlink:to="lab_gild_LossContingencyPartiesAppealedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_1113e8fc-8804-425b-82d5-f92ba1724fcb_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3000c3da-252e-445d-b19e-0a26eeecc987_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_bf2fb31a-26e9-4a46-a2ec-3fed06f6cef1_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_8047c585-9fbc-47bb-9eb7-0e618949962e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0a396b11-9c4e-42c5-ae4d-92c6e9474ffa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_b457d6d0-eddb-4143-8727-d9758bb448ca_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f93f69b4-f279-40e9-b15b-5f5e10045ede_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_445266cd-0727-40c8-bbd3-67bdc184e7fa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_27c2ae65-e2cf-4199-9218-0bb802e15348_totalLabel_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20210930.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8383629a-5e96-40e6-aafa-63a86bb8a0f8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepcludexForHDVMember_6e3f8da1-57cf-4b52-a84e-0e43adf229fe_terseLabel_en-US" xlink:label="lab_gild_HepcludexForHDVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex For HDV</link:label>
    <link:label id="lab_gild_HepcludexForHDVMember_8ed979fc-0d4d-4871-af1c-c08c7390c96d_verboseLabel_en-US" xlink:label="lab_gild_HepcludexForHDVMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - Hepcludex</link:label>
    <link:label id="lab_gild_HepcludexForHDVMember_label_en-US" xlink:label="lab_gild_HepcludexForHDVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex For HDV [Member]</link:label>
    <link:label id="lab_gild_HepcludexForHDVMember_documentation_en-US" xlink:label="lab_gild_HepcludexForHDVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex For HDV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexForHDVMember" xlink:href="gild-20210930.xsd#gild_HepcludexForHDVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepcludexForHDVMember" xlink:to="lab_gild_HepcludexForHDVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2255f972-3113-4901-ab7b-d3e47cde9ab1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f8dd5e78-4f2e-4da7-a9e4-ba20af4d3504_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27e5cf7f-1de8-4882-8618-a789264f80d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_2b50923b-1e61-4e85-8788-e7066d27f9bb_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="gild-20210930.xsd#gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_3d1b473e-ea75-4b1d-a309-922e46c3be42_terseLabel_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - axicabtagene ciloleucel</link:label>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_label_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">axicabtagene ciloleucel (DLBCL) [Member]</link:label>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_documentation_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">axicabtagene ciloleucel (DLBCL) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember" xlink:href="gild-20210930.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AxicabtageneciloleucelDLBCLMember" xlink:to="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0c4776c6-4309-4cac-97a2-d55568c66c92_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member_bb58b413-1e82-46f6-a03b-6a6a35c9775c_terseLabel_en-US" xlink:label="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Senior Unsecured Notes Due March 2047</link:label>
    <link:label id="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member_label_en-US" xlink:label="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Senior Unsecured Notes Due March 2047 [Member]</link:label>
    <link:label id="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member_documentation_en-US" xlink:label="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Senior Unsecured Notes Due March 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:href="gild-20210930.xsd#gild_A415SeniorUnsecuredNotesDueMarch2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:to="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_0bf593f5-f94e-46e8-9189-4407cc75c613_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of class action lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_963664b8-548c-48fa-bcea-9d867cfe4583_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_f2937ffd-bdd5-4cdb-97c1-e7b7e470e3b9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts of Recognized Assets/Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_75729984-7c77-4d7b-afbe-1c29afdda604_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_cc335fa4-af17-4449-bef4-cc7d452a7377_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_bb83e177-07ae-4960-aa55-eb5a5c3246f3_terseLabel_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sofosbuvir/Velpatasvir</link:label>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_label_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Sofosbuvir/Velpatasvir [Member]</link:label>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_documentation_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Sofosbuvir/Velpatasvir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:href="gild-20210930.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:to="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e3d189da-bfd4-4daa-b6bc-81abe6460fcc_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_c3134f12-06ec-41b0-a8e9-e8f4a70f475b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:to="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9abd7a26-1faa-4dcd-a513-f897ba11d99a_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_5e08b79b-206c-425a-b131-066652f12e7a_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_98cddd25-a0a6-4e45-977e-ab4fe4b8c94b_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_e9e957b2-0117-4f21-937d-951b7bd9b82d_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_e6a27b7c-30e7-47d1-b00f-40c2a9a38e78_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) reclassified from AOCI into product sales</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_7ed8f52b-412c-4364-ab6d-063e1280a31f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_3414df5b-f6f6-4728-8e24-df3b57dbbe88_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_8931b7b0-7eba-4cb7-82b4-d3a7b80adf7e_terseLabel_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other</link:label>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_label_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Total Other product sales [Member]</link:label>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_documentation_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Total Other product sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember" xlink:href="gild-20210930.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember" xlink:to="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_06707004-070e-4523-9cf6-80d281ebea75_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_44dcc159-f37a-457a-83d8-c30c9261c1e2_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_bde77312-478c-472f-a8ea-4dd5bd6eaf17_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8662670d-f5c5-483f-b5da-ea908db84448_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_5f4bb1b7-ec1f-40a2-8a9e-9cf5edae41ec_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_585eca6c-5434-4c1f-a16f-6eb414302f47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Classification and Fair Value of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fc292c24-1176-43cf-a2bb-4ead2efd5c41_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_6d130679-3f5d-4343-8765-ec3b7f42c30a_terseLabel_en-US" xlink:label="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Unsecured Notes Due February 2025</link:label>
    <link:label id="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_label_en-US" xlink:label="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Unsecured Notes Due February 2025 [Member]</link:label>
    <link:label id="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_documentation_en-US" xlink:label="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Unsecured Notes Due February 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:href="gild-20210930.xsd#gild_A350SeniorUnsecuredNotesDueFebruary2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:to="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_560a584b-9a02-4c60-b2cf-6b997348f25a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_f96457bc-aee7-4d68-a436-7477f359a859_terseLabel_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, contract and other revenues</link:label>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_label_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Contract, And Other [Member]</link:label>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_documentation_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Contract, And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember" xlink:href="gild-20210930.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_RoyaltyContractAndOtherMember" xlink:to="lab_gild_RoyaltyContractAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_67e11e29-e884-4cf4-af8f-07a597b44920_negatedLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation accrual reversed</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3a72de76-13b8-4eea-a310-6b2028264cc1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_9d52eded-30f8-4e40-9dd8-f722b2db607e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>gild-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f99a0a1f-0889-484d-b0ab-b227dc47b3c9,g:c9f039a1-0400-492d-bc3a-193c416450f4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gilead.com/role/CoverPage" xlink:type="simple" xlink:href="gild-20210930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2584785d-58ab-4480-b17f-4aee9ffc3887" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_DocumentType_2584785d-58ab-4480-b17f-4aee9ffc3887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_fd9eb246-cfe7-4b37-bad7-a3d4010d87ad" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_DocumentQuarterlyReport_fd9eb246-cfe7-4b37-bad7-a3d4010d87ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_23a6d914-0037-4dca-b7f8-ad1ee2ea3720" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_DocumentPeriodEndDate_23a6d914-0037-4dca-b7f8-ad1ee2ea3720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_5a95db9b-e5ff-4b97-a2c6-15ec9209a9de" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_DocumentTransitionReport_5a95db9b-e5ff-4b97-a2c6-15ec9209a9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_af399f95-68c4-4de6-82dd-fe98b0dda0d7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntityFileNumber_af399f95-68c4-4de6-82dd-fe98b0dda0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4a7e378d-bef2-4d56-94f7-268252b6b7a2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntityRegistrantName_4a7e378d-bef2-4d56-94f7-268252b6b7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5bbe4ccc-bf25-41bb-af15-07ebaa9ffc8c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5bbe4ccc-bf25-41bb-af15-07ebaa9ffc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c4b67be0-66f7-456b-90c1-02b6170927d3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntityTaxIdentificationNumber_c4b67be0-66f7-456b-90c1-02b6170927d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_13b11481-074e-408e-8cef-0ca97ff346e3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntityAddressAddressLine1_13b11481-074e-408e-8cef-0ca97ff346e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0506cbe0-e03e-415f-b1ff-6b2aa79e3bb0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntityAddressCityOrTown_0506cbe0-e03e-415f-b1ff-6b2aa79e3bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a95c17be-51cd-424a-bd15-ce84198ff5d5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntityAddressStateOrProvince_a95c17be-51cd-424a-bd15-ce84198ff5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4365c982-521b-4505-be2a-56aac5f6c5ce" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntityAddressPostalZipCode_4365c982-521b-4505-be2a-56aac5f6c5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_be2ac6b9-72f5-463b-a99d-67cb6100eb05" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_CityAreaCode_be2ac6b9-72f5-463b-a99d-67cb6100eb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_df83ab3a-3eea-4895-8c41-a58edb3f6ab5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_LocalPhoneNumber_df83ab3a-3eea-4895-8c41-a58edb3f6ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ec4411ef-bcd0-4cb6-9567-5ea0f018029b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_Security12bTitle_ec4411ef-bcd0-4cb6-9567-5ea0f018029b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f389332b-5feb-48ed-a008-394f75671808" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_TradingSymbol_f389332b-5feb-48ed-a008-394f75671808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dcef50b7-1b31-49c2-b624-615d6ff47cbb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_SecurityExchangeName_dcef50b7-1b31-49c2-b624-615d6ff47cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_de0f9860-216c-4bf5-806b-a86c2e5c3ac0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntityCurrentReportingStatus_de0f9860-216c-4bf5-806b-a86c2e5c3ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b515b17a-f58b-426e-b698-202071c846ae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntityInteractiveDataCurrent_b515b17a-f58b-426e-b698-202071c846ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d1097866-cda6-4731-83af-6466898d51d9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntityFilerCategory_d1097866-cda6-4731-83af-6466898d51d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_67ff4746-77cd-446a-b8fb-69814ffd6eac" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntitySmallBusiness_67ff4746-77cd-446a-b8fb-69814ffd6eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_366123ea-6be0-4e7b-8b08-0dbd0bd99423" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntityEmergingGrowthCompany_366123ea-6be0-4e7b-8b08-0dbd0bd99423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3f2e6bdd-9235-4220-a1bf-2401cb2523ff" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntityShellCompany_3f2e6bdd-9235-4220-a1bf-2401cb2523ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_cdf1a075-2a60-4b24-bc66-f5703e2e0f86" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_cdf1a075-2a60-4b24-bc66-f5703e2e0f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_212c4fe0-4e07-4528-bfef-ff9728448a6c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_EntityCentralIndexKey_212c4fe0-4e07-4528-bfef-ff9728448a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e0b93f79-dfad-4386-aec9-f7f6d7dc6805" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_CurrentFiscalYearEndDate_e0b93f79-dfad-4386-aec9-f7f6d7dc6805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4f16533a-d653-4d3c-a734-de4761f444ec" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_DocumentFiscalYearFocus_4f16533a-d653-4d3c-a734-de4761f444ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_37fd49dc-e80f-4e0e-8259-68cd92e29eba" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_37fd49dc-e80f-4e0e-8259-68cd92e29eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5fb48b3d-830e-4f6b-b816-97f289d8dc19" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5fc38902-8ddc-489f-90b5-cdc3c4d108a7" xlink:to="loc_dei_AmendmentFlag_5fb48b3d-830e-4f6b-b816-97f289d8dc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="gild-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b2e273da-4d0c-4368-91ef-3d6b093f7997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_acd06b01-379c-4be2-8b77-0accb2c57f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b2e273da-4d0c-4368-91ef-3d6b093f7997" xlink:to="loc_us-gaap_AssetsAbstract_acd06b01-379c-4be2-8b77-0accb2c57f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2a195c1c-277d-452d-bdda-d55424c86a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_acd06b01-379c-4be2-8b77-0accb2c57f88" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2a195c1c-277d-452d-bdda-d55424c86a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8f41937-2d30-4ce7-89aa-e0ef53396614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2a195c1c-277d-452d-bdda-d55424c86a20" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8f41937-2d30-4ce7-89aa-e0ef53396614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_69b9fba7-2c89-4be3-8770-7fad64ca0595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2a195c1c-277d-452d-bdda-d55424c86a20" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_69b9fba7-2c89-4be3-8770-7fad64ca0595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bd16c60f-cde4-46b7-9000-2b2606928bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2a195c1c-277d-452d-bdda-d55424c86a20" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bd16c60f-cde4-46b7-9000-2b2606928bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_eab3f154-d6cd-44f7-9f7e-db130caf3614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2a195c1c-277d-452d-bdda-d55424c86a20" xlink:to="loc_us-gaap_InventoryNet_eab3f154-d6cd-44f7-9f7e-db130caf3614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7b28576-5a1d-4554-bac5-1f7890311864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2a195c1c-277d-452d-bdda-d55424c86a20" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7b28576-5a1d-4554-bac5-1f7890311864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8d77d8f3-aa73-4139-936a-135d0a69c8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2a195c1c-277d-452d-bdda-d55424c86a20" xlink:to="loc_us-gaap_AssetsCurrent_8d77d8f3-aa73-4139-936a-135d0a69c8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0cf96f63-dc78-4731-8236-9053219bb819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_acd06b01-379c-4be2-8b77-0accb2c57f88" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0cf96f63-dc78-4731-8236-9053219bb819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_0ec1b7ea-ccbb-4c7b-b85e-7ecd8a304390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_acd06b01-379c-4be2-8b77-0accb2c57f88" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_0ec1b7ea-ccbb-4c7b-b85e-7ecd8a304390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dcfc6c14-0431-4217-9262-679a5e22f9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_acd06b01-379c-4be2-8b77-0accb2c57f88" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dcfc6c14-0431-4217-9262-679a5e22f9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_66fb35d6-3b6e-42a4-b3e2-69b112fd1336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_acd06b01-379c-4be2-8b77-0accb2c57f88" xlink:to="loc_us-gaap_Goodwill_66fb35d6-3b6e-42a4-b3e2-69b112fd1336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1a04c1e6-eabc-480e-b30e-70c93600fd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_acd06b01-379c-4be2-8b77-0accb2c57f88" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1a04c1e6-eabc-480e-b30e-70c93600fd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1dda98e7-d923-4b44-9e68-01491fcb1ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_acd06b01-379c-4be2-8b77-0accb2c57f88" xlink:to="loc_us-gaap_Assets_1dda98e7-d923-4b44-9e68-01491fcb1ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a34c697-1d7d-4b2e-ad83-30199ef423ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b2e273da-4d0c-4368-91ef-3d6b093f7997" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a34c697-1d7d-4b2e-ad83-30199ef423ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_798e3da4-1a73-41ba-b268-249f8c99276a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a34c697-1d7d-4b2e-ad83-30199ef423ee" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_798e3da4-1a73-41ba-b268-249f8c99276a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_42196505-2870-452e-ad8a-22862fdcb03d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_798e3da4-1a73-41ba-b268-249f8c99276a" xlink:to="loc_us-gaap_AccountsPayableCurrent_42196505-2870-452e-ad8a-22862fdcb03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedGovernmentAndOtherRebates_76cacc18-748d-4863-85b1-25044c34d9a1" xlink:href="gild-20210930.xsd#gild_AccruedGovernmentAndOtherRebates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_798e3da4-1a73-41ba-b268-249f8c99276a" xlink:to="loc_gild_AccruedGovernmentAndOtherRebates_76cacc18-748d-4863-85b1-25044c34d9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5dd4e5ff-8d4d-45d9-8695-d2e38827e777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_798e3da4-1a73-41ba-b268-249f8c99276a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5dd4e5ff-8d4d-45d9-8695-d2e38827e777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_5432bf04-5c2b-4f1e-abc3-e580c3392b07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_798e3da4-1a73-41ba-b268-249f8c99276a" xlink:to="loc_us-gaap_DebtCurrent_5432bf04-5c2b-4f1e-abc3-e580c3392b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9363d221-48c1-4d66-9d08-1f11cd284a65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_798e3da4-1a73-41ba-b268-249f8c99276a" xlink:to="loc_us-gaap_LiabilitiesCurrent_9363d221-48c1-4d66-9d08-1f11cd284a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c89f4a07-5b78-4a19-91ff-0f21d96880e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a34c697-1d7d-4b2e-ad83-30199ef423ee" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c89f4a07-5b78-4a19-91ff-0f21d96880e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_bcd23c3e-7c5d-4451-8e07-c23d35037630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a34c697-1d7d-4b2e-ad83-30199ef423ee" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_bcd23c3e-7c5d-4451-8e07-c23d35037630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0dc2c1cd-2b23-418e-ab09-dc69a7bacbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a34c697-1d7d-4b2e-ad83-30199ef423ee" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0dc2c1cd-2b23-418e-ab09-dc69a7bacbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_afe39462-1a1c-42b9-9549-f8ac820ebad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a34c697-1d7d-4b2e-ad83-30199ef423ee" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_afe39462-1a1c-42b9-9549-f8ac820ebad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7147de38-5f3b-4aa6-b343-d22b3dd2a921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a34c697-1d7d-4b2e-ad83-30199ef423ee" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7147de38-5f3b-4aa6-b343-d22b3dd2a921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8a926912-7a07-4e47-8b89-0cc226894340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a34c697-1d7d-4b2e-ad83-30199ef423ee" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8a926912-7a07-4e47-8b89-0cc226894340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_fcd75eda-5bbc-4b82-83c9-ea682f8526d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8a926912-7a07-4e47-8b89-0cc226894340" xlink:to="loc_us-gaap_PreferredStockValue_fcd75eda-5bbc-4b82-83c9-ea682f8526d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3b79dfdc-14e8-48f1-84d7-9afc5ac1a360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8a926912-7a07-4e47-8b89-0cc226894340" xlink:to="loc_us-gaap_CommonStockValue_3b79dfdc-14e8-48f1-84d7-9afc5ac1a360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4bcc642b-71cd-4d5b-9711-31508f8b9dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8a926912-7a07-4e47-8b89-0cc226894340" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4bcc642b-71cd-4d5b-9711-31508f8b9dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cab81647-90e5-4d53-a165-7d0a7c211bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8a926912-7a07-4e47-8b89-0cc226894340" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cab81647-90e5-4d53-a165-7d0a7c211bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ddbbe229-b063-40b1-9e04-999c60348903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8a926912-7a07-4e47-8b89-0cc226894340" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ddbbe229-b063-40b1-9e04-999c60348903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6c962b28-f8a9-41b3-b06b-bad3ae4d33c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8a926912-7a07-4e47-8b89-0cc226894340" xlink:to="loc_us-gaap_StockholdersEquity_6c962b28-f8a9-41b3-b06b-bad3ae4d33c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_4ff51649-e825-44ff-8901-ede1903cb8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8a926912-7a07-4e47-8b89-0cc226894340" xlink:to="loc_us-gaap_MinorityInterest_4ff51649-e825-44ff-8901-ede1903cb8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87a2b065-4bc6-4048-9b90-65de7f058376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8a926912-7a07-4e47-8b89-0cc226894340" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87a2b065-4bc6-4048-9b90-65de7f058376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3d0ed084-1c6e-4b5f-8e6a-a47ab18bc24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a34c697-1d7d-4b2e-ad83-30199ef423ee" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3d0ed084-1c6e-4b5f-8e6a-a47ab18bc24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="gild-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_dea07ec0-e313-4f59-95f0-aba4a693d4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_047740ac-a0f0-44ff-bb02-13a67d706fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dea07ec0-e313-4f59-95f0-aba4a693d4b5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_047740ac-a0f0-44ff-bb02-13a67d706fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f21d14d-31f4-4902-b094-ca3acb5d45b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_047740ac-a0f0-44ff-bb02-13a67d706fe7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f21d14d-31f4-4902-b094-ca3acb5d45b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_535856aa-0c5b-4d8e-94ec-2a3ea191828a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f21d14d-31f4-4902-b094-ca3acb5d45b7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_535856aa-0c5b-4d8e-94ec-2a3ea191828a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_eec03cb2-1912-4978-8d77-fe7da86d03c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f21d14d-31f4-4902-b094-ca3acb5d45b7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_eec03cb2-1912-4978-8d77-fe7da86d03c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4ff80e6e-abc4-44ce-bb59-c91a4e3d8933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f21d14d-31f4-4902-b094-ca3acb5d45b7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4ff80e6e-abc4-44ce-bb59-c91a4e3d8933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_26e1d2c5-7c7a-48f3-828b-35fb6a61ee09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f21d14d-31f4-4902-b094-ca3acb5d45b7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_26e1d2c5-7c7a-48f3-828b-35fb6a61ee09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7595cca6-547f-47dd-abc2-3d4564fbebb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f21d14d-31f4-4902-b094-ca3acb5d45b7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7595cca6-547f-47dd-abc2-3d4564fbebb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0c571c38-79ea-4be0-b032-7a8c7eb5771d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f21d14d-31f4-4902-b094-ca3acb5d45b7" xlink:to="loc_us-gaap_CommonStockSharesIssued_0c571c38-79ea-4be0-b032-7a8c7eb5771d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_94e2f4e1-3e20-4ca5-bb60-bef46aaf15e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f21d14d-31f4-4902-b094-ca3acb5d45b7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_94e2f4e1-3e20-4ca5-bb60-bef46aaf15e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="gild-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4e3f5559-5602-4df3-a1f7-1aa18544329b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_36409ae8-4912-4693-98c5-b32941c1e478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3f5559-5602-4df3-a1f7-1aa18544329b" xlink:to="loc_us-gaap_StatementTable_36409ae8-4912-4693-98c5-b32941c1e478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6ff5a2ed-ae85-43e3-beb0-9f0852d2bd0d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_36409ae8-4912-4693-98c5-b32941c1e478" xlink:to="loc_srt_ProductOrServiceAxis_6ff5a2ed-ae85-43e3-beb0-9f0852d2bd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0e9efd1-3a1e-42d8-9cf3-cc348ef1f761" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6ff5a2ed-ae85-43e3-beb0-9f0852d2bd0d" xlink:to="loc_srt_ProductsAndServicesDomain_a0e9efd1-3a1e-42d8-9cf3-cc348ef1f761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a76cc213-aa0d-4e3e-aee9-a1f0d785319a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0e9efd1-3a1e-42d8-9cf3-cc348ef1f761" xlink:to="loc_us-gaap_ProductMember_a76cc213-aa0d-4e3e-aee9-a1f0d785319a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_ee075e74-c9e4-4822-b246-2792b78128f9" xlink:href="gild-20210930.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0e9efd1-3a1e-42d8-9cf3-cc348ef1f761" xlink:to="loc_gild_RoyaltyContractAndOtherMember_ee075e74-c9e4-4822-b246-2792b78128f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_36409ae8-4912-4693-98c5-b32941c1e478" xlink:to="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8429803c-4bf9-451c-8a25-973ca0656973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_RevenuesAbstract_8429803c-4bf9-451c-8a25-973ca0656973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a72c4a7-0906-41ac-a4e2-d6e542f2ff81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8429803c-4bf9-451c-8a25-973ca0656973" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a72c4a7-0906-41ac-a4e2-d6e542f2ff81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_da874c42-cac6-42b4-a4bf-18cf0e6dc42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_da874c42-cac6-42b4-a4bf-18cf0e6dc42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8acf907e-2465-4bee-8e6d-e080491f02af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_da874c42-cac6-42b4-a4bf-18cf0e6dc42c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8acf907e-2465-4bee-8e6d-e080491f02af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c374bb23-e760-4eb9-ae0a-42ea298a205d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_da874c42-cac6-42b4-a4bf-18cf0e6dc42c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c374bb23-e760-4eb9-ae0a-42ea298a205d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ad8c627f-a7ca-4795-bc77-074118495821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_da874c42-cac6-42b4-a4bf-18cf0e6dc42c" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ad8c627f-a7ca-4795-bc77-074118495821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c2a14f92-f83a-4268-9b42-bb5353602c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_da874c42-cac6-42b4-a4bf-18cf0e6dc42c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c2a14f92-f83a-4268-9b42-bb5353602c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4cd28d3b-6b47-4543-9527-3f921375e8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_da874c42-cac6-42b4-a4bf-18cf0e6dc42c" xlink:to="loc_us-gaap_CostsAndExpenses_4cd28d3b-6b47-4543-9527-3f921375e8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0f676403-b212-444c-8536-bd2d621c7081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_OperatingIncomeLoss_0f676403-b212-444c-8536-bd2d621c7081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f9be8000-dfd5-4ab6-897c-96f7334a7c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_InterestExpense_f9be8000-dfd5-4ab6-897c-96f7334a7c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7cabfcc7-4f06-41ed-b610-8e099c1b7c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7cabfcc7-4f06-41ed-b610-8e099c1b7c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a32013a7-2125-4bcb-93af-a463586654b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a32013a7-2125-4bcb-93af-a463586654b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_681506b1-f359-49e5-8484-37e6c7151cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_681506b1-f359-49e5-8484-37e6c7151cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_141618c2-d079-4875-b1f0-043b633fa1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_ProfitLoss_141618c2-d079-4875-b1f0-043b633fa1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8925ef95-8ae8-4ccc-ba9e-d76353b85e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8925ef95-8ae8-4ccc-ba9e-d76353b85e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5b3d1405-9b9c-4146-bfd5-5f4baba41555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_NetIncomeLoss_5b3d1405-9b9c-4146-bfd5-5f4baba41555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ec15c255-022b-46f4-9029-3814de76b931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_EarningsPerShareBasic_ec15c255-022b-46f4-9029-3814de76b931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_90307875-9c9a-4878-9864-20afa17af8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_90307875-9c9a-4878-9864-20afa17af8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8285ad79-a3e5-4ec7-ae25-456d5cc50abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8285ad79-a3e5-4ec7-ae25-456d5cc50abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_46522c00-c691-4d21-bd6a-c8056ebed21d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_421b5a52-a661-4394-8b9c-6aa94bb92c6f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_46522c00-c691-4d21-bd6a-c8056ebed21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="gild-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dcd82be6-f0a2-482a-8e91-028ee66454dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f1bf5db8-3fcd-4b72-be27-8f162cf7af98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dcd82be6-f0a2-482a-8e91-028ee66454dd" xlink:to="loc_us-gaap_ProfitLoss_f1bf5db8-3fcd-4b72-be27-8f162cf7af98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a4f96868-5e9a-479a-8403-bea389f41dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dcd82be6-f0a2-482a-8e91-028ee66454dd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a4f96868-5e9a-479a-8403-bea389f41dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f76a7609-8651-402c-9c8e-fb19267f1b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a4f96868-5e9a-479a-8403-bea389f41dc5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f76a7609-8651-402c-9c8e-fb19267f1b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_f4da4880-7096-4e67-80ae-cbf2731e648f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a4f96868-5e9a-479a-8403-bea389f41dc5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_f4da4880-7096-4e67-80ae-cbf2731e648f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_3eb90612-87f5-4d6a-9ab2-d4ca916f0546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_f4da4880-7096-4e67-80ae-cbf2731e648f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_3eb90612-87f5-4d6a-9ab2-d4ca916f0546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1b7e5703-0860-493a-bd06-9173fa3fed05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_f4da4880-7096-4e67-80ae-cbf2731e648f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1b7e5703-0860-493a-bd06-9173fa3fed05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b97ae3c2-1782-4b81-b3d2-298d6ef57554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_f4da4880-7096-4e67-80ae-cbf2731e648f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b97ae3c2-1782-4b81-b3d2-298d6ef57554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_44d14383-57d5-4171-99bf-825e264db161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a4f96868-5e9a-479a-8403-bea389f41dc5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_44d14383-57d5-4171-99bf-825e264db161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_d1f8d62f-9bb4-4cbd-a957-16f7b1b6fd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_44d14383-57d5-4171-99bf-825e264db161" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_d1f8d62f-9bb4-4cbd-a957-16f7b1b6fd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_2a5cb252-c61f-47cc-8d99-c5a07026b41b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_44d14383-57d5-4171-99bf-825e264db161" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_2a5cb252-c61f-47cc-8d99-c5a07026b41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1550ff94-d063-454c-900c-64c55ebcb421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_44d14383-57d5-4171-99bf-825e264db161" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1550ff94-d063-454c-900c-64c55ebcb421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3b888cbc-5b63-47d9-a4ed-d0d330634c62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a4f96868-5e9a-479a-8403-bea389f41dc5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3b888cbc-5b63-47d9-a4ed-d0d330634c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_794da0a8-f713-4b8c-8768-b624ad094a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dcd82be6-f0a2-482a-8e91-028ee66454dd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_794da0a8-f713-4b8c-8768-b624ad094a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ea3827e2-a3b7-4eae-85a4-e2b49f71bc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dcd82be6-f0a2-482a-8e91-028ee66454dd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ea3827e2-a3b7-4eae-85a4-e2b49f71bc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a26fb428-55e6-4b49-9709-90308eacc171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dcd82be6-f0a2-482a-8e91-028ee66454dd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a26fb428-55e6-4b49-9709-90308eacc171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gild-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_416185c3-05f4-4447-9cbe-bae79d4b4092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_49fe33d2-b031-4310-acbf-9ae11bb19323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_416185c3-05f4-4447-9cbe-bae79d4b4092" xlink:to="loc_us-gaap_StatementTable_49fe33d2-b031-4310-acbf-9ae11bb19323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_65661aa2-27bb-4511-9518-ad6c6cde008c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_49fe33d2-b031-4310-acbf-9ae11bb19323" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_65661aa2-27bb-4511-9518-ad6c6cde008c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2f9f01a4-8ff3-4ba7-acb7-7d4ecdc18c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_65661aa2-27bb-4511-9518-ad6c6cde008c" xlink:to="loc_us-gaap_EquityComponentDomain_2f9f01a4-8ff3-4ba7-acb7-7d4ecdc18c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9a86ca80-54d4-469a-a2ce-9024f0f784ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f9f01a4-8ff3-4ba7-acb7-7d4ecdc18c0b" xlink:to="loc_us-gaap_CommonStockMember_9a86ca80-54d4-469a-a2ce-9024f0f784ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a557a259-eafa-4734-bc79-8c0b4709d56d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f9f01a4-8ff3-4ba7-acb7-7d4ecdc18c0b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a557a259-eafa-4734-bc79-8c0b4709d56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6c302f8-ded8-4dd0-ae3a-e7612687a526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f9f01a4-8ff3-4ba7-acb7-7d4ecdc18c0b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6c302f8-ded8-4dd0-ae3a-e7612687a526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_08dd36c2-b6d6-4f9a-8d19-547e5f939c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f9f01a4-8ff3-4ba7-acb7-7d4ecdc18c0b" xlink:to="loc_us-gaap_RetainedEarningsMember_08dd36c2-b6d6-4f9a-8d19-547e5f939c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d722a1c6-5b16-4ef6-b8ec-4691804e8404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f9f01a4-8ff3-4ba7-acb7-7d4ecdc18c0b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d722a1c6-5b16-4ef6-b8ec-4691804e8404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f313528c-9ab8-4fed-84a1-03852f2b7ea6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_49fe33d2-b031-4310-acbf-9ae11bb19323" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f313528c-9ab8-4fed-84a1-03852f2b7ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_47ea50b8-4ada-45a5-8274-a3089c55f3c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f313528c-9ab8-4fed-84a1-03852f2b7ea6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_47ea50b8-4ada-45a5-8274-a3089c55f3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f709f04b-dfef-4159-9433-b7805e3bdce6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_47ea50b8-4ada-45a5-8274-a3089c55f3c7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f709f04b-dfef-4159-9433-b7805e3bdce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e45c4d03-4372-4c6c-8a09-4a86c531932f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_49fe33d2-b031-4310-acbf-9ae11bb19323" xlink:to="loc_us-gaap_StatementLineItems_e45c4d03-4372-4c6c-8a09-4a86c531932f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e45c4d03-4372-4c6c-8a09-4a86c531932f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_82c4957b-9263-4a83-b23e-3060eb6f1774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_82c4957b-9263-4a83-b23e-3060eb6f1774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f854179c-830e-4201-a5c8-7073aab5c9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f854179c-830e-4201-a5c8-7073aab5c9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_d4c9b2ef-6ef4-4adc-8c5c-316f488558ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_d4c9b2ef-6ef4-4adc-8c5c-316f488558ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c13754de-bd4d-476e-aaf3-c9f59df45f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_ProfitLoss_c13754de-bd4d-476e-aaf3-c9f59df45f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_59b63639-cd50-4684-9227-745a0e9ce1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_59b63639-cd50-4684-9227-745a0e9ce1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7dba1b2a-f354-4620-978b-aff894b7e6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7dba1b2a-f354-4620-978b-aff894b7e6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0148a126-aa68-4666-862e-f72a2ce9a4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0148a126-aa68-4666-862e-f72a2ce9a4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2deadffd-cfa3-4c7d-9847-fa399090ff07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2deadffd-cfa3-4c7d-9847-fa399090ff07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cd4ed547-ced5-4c26-a2eb-e2bd9c2205d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cd4ed547-ced5-4c26-a2eb-e2bd9c2205d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6b4bfd2e-b281-435a-964a-1b9d6e8a57a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6b4bfd2e-b281-435a-964a-1b9d6e8a57a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_71168a9f-df8e-413f-90d1-168c84c5e9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_71168a9f-df8e-413f-90d1-168c84c5e9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_1298ca85-21d6-4704-a3ca-71578f955007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_1298ca85-21d6-4704-a3ca-71578f955007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_07bc9830-3168-4bd0-8776-db351b8132d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_Dividends_07bc9830-3168-4bd0-8776-db351b8132d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_54ff0b78-4142-412b-bd2d-a311c914fc18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_54ff0b78-4142-412b-bd2d-a311c914fc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b71cc1cd-afc7-4e9e-ac2e-284a17095cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67bed946-4a0e-4b44-af7b-ef2c596a5edf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b71cc1cd-afc7-4e9e-ac2e-284a17095cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="gild-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_bf880128-ee08-4e9a-a51d-98e561043c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_26130a27-2301-4702-a38a-a7d5c1b760a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_bf880128-ee08-4e9a-a51d-98e561043c6f" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_26130a27-2301-4702-a38a-a7d5c1b760a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gild-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ab63e072-0999-4d0b-8749-f040d9b2dd85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_507425f9-8fd4-4b2e-8eee-c9cbe10db817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab63e072-0999-4d0b-8749-f040d9b2dd85" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_507425f9-8fd4-4b2e-8eee-c9cbe10db817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7ec81b7d-12b9-4a62-8433-da26dc6261f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_507425f9-8fd4-4b2e-8eee-c9cbe10db817" xlink:to="loc_us-gaap_ProfitLoss_7ec81b7d-12b9-4a62-8433-da26dc6261f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8971c3d-1357-48b0-bd06-de48d0d9401a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_507425f9-8fd4-4b2e-8eee-c9cbe10db817" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8971c3d-1357-48b0-bd06-de48d0d9401a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2a7fab65-3df6-453c-9d9d-e1bdf96f3997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8971c3d-1357-48b0-bd06-de48d0d9401a" xlink:to="loc_us-gaap_Depreciation_2a7fab65-3df6-453c-9d9d-e1bdf96f3997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_4eb59620-2968-4e83-ac89-f0e8d9090cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8971c3d-1357-48b0-bd06-de48d0d9401a" xlink:to="loc_us-gaap_AdjustmentForAmortization_4eb59620-2968-4e83-ac89-f0e8d9090cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_923e1b28-4ed5-4e4d-ab1a-47a7c8e8e76a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8971c3d-1357-48b0-bd06-de48d0d9401a" xlink:to="loc_us-gaap_ShareBasedCompensation_923e1b28-4ed5-4e4d-ab1a-47a7c8e8e76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_14274671-84c3-4a69-9e81-d58f8f97bdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8971c3d-1357-48b0-bd06-de48d0d9401a" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_14274671-84c3-4a69-9e81-d58f8f97bdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0e8093ae-2c80-467a-8916-3c4197c154a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8971c3d-1357-48b0-bd06-de48d0d9401a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0e8093ae-2c80-467a-8916-3c4197c154a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_5da542e0-a9db-40a4-8b0e-6fa73518d4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8971c3d-1357-48b0-bd06-de48d0d9401a" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_5da542e0-a9db-40a4-8b0e-6fa73518d4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_25164d4a-913d-48bf-abb4-254ddb0c3850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8971c3d-1357-48b0-bd06-de48d0d9401a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_25164d4a-913d-48bf-abb4-254ddb0c3850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d550982-9086-464b-8d9a-00dab886d154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_507425f9-8fd4-4b2e-8eee-c9cbe10db817" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d550982-9086-464b-8d9a-00dab886d154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_23dc5c6f-1c9a-4a99-8b44-db9db8c26a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d550982-9086-464b-8d9a-00dab886d154" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_23dc5c6f-1c9a-4a99-8b44-db9db8c26a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_47bdb58f-5e3d-4f83-9ac7-5bb505dae4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d550982-9086-464b-8d9a-00dab886d154" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_47bdb58f-5e3d-4f83-9ac7-5bb505dae4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7fe72f20-ee12-4063-aed5-62dd487725f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d550982-9086-464b-8d9a-00dab886d154" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7fe72f20-ee12-4063-aed5-62dd487725f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d22b44b2-4529-4d5c-88e3-2ebfd40f52f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d550982-9086-464b-8d9a-00dab886d154" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d22b44b2-4529-4d5c-88e3-2ebfd40f52f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_5e9882cd-3fa6-4e6c-ad8c-62fb84ee9652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d550982-9086-464b-8d9a-00dab886d154" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_5e9882cd-3fa6-4e6c-ad8c-62fb84ee9652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e281c1a1-3db1-42e9-a6dc-3aea3580adf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0d550982-9086-464b-8d9a-00dab886d154" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e281c1a1-3db1-42e9-a6dc-3aea3580adf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2f7d2d0b-9a0a-4dc7-b5f3-1ac7bb7cb803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_507425f9-8fd4-4b2e-8eee-c9cbe10db817" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2f7d2d0b-9a0a-4dc7-b5f3-1ac7bb7cb803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_555820a6-a7d4-4c27-8441-fd774d485ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab63e072-0999-4d0b-8749-f040d9b2dd85" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_555820a6-a7d4-4c27-8441-fd774d485ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b111c13c-55f5-4c8c-8128-196ad1091db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_555820a6-a7d4-4c27-8441-fd774d485ac9" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b111c13c-55f5-4c8c-8128-196ad1091db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_78a6561c-9313-4635-a659-db1af9a62ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_555820a6-a7d4-4c27-8441-fd774d485ac9" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_78a6561c-9313-4635-a659-db1af9a62ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_f6fc2fa8-72bb-4229-bcf3-7497ea40e205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_555820a6-a7d4-4c27-8441-fd774d485ac9" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_f6fc2fa8-72bb-4229-bcf3-7497ea40e205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_103bf0a9-bd17-4d41-b0ff-00371321e669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_555820a6-a7d4-4c27-8441-fd774d485ac9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_103bf0a9-bd17-4d41-b0ff-00371321e669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_c17572de-cce9-4dd4-a3a0-6953eb7dc8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_555820a6-a7d4-4c27-8441-fd774d485ac9" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_c17572de-cce9-4dd4-a3a0-6953eb7dc8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a79209b1-2138-478a-a8af-f21cf369bcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_555820a6-a7d4-4c27-8441-fd774d485ac9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a79209b1-2138-478a-a8af-f21cf369bcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6788ce02-599b-4068-aa6e-2e6442c6dcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_555820a6-a7d4-4c27-8441-fd774d485ac9" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6788ce02-599b-4068-aa6e-2e6442c6dcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3c04e826-50cd-4eac-bcf0-eb5629f0c0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_555820a6-a7d4-4c27-8441-fd774d485ac9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3c04e826-50cd-4eac-bcf0-eb5629f0c0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ea14ec1-6b18-4e02-b242-1782b30b1d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab63e072-0999-4d0b-8749-f040d9b2dd85" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ea14ec1-6b18-4e02-b242-1782b30b1d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_0820f6a7-fdfa-43a4-b615-5d2fdda4787e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ea14ec1-6b18-4e02-b242-1782b30b1d4d" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_0820f6a7-fdfa-43a4-b615-5d2fdda4787e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_640357fc-546c-4779-a571-f863488d1f00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ea14ec1-6b18-4e02-b242-1782b30b1d4d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_640357fc-546c-4779-a571-f863488d1f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_20171a61-e5b4-4275-95e8-bb11a859d5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ea14ec1-6b18-4e02-b242-1782b30b1d4d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_20171a61-e5b4-4275-95e8-bb11a859d5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_b16c206e-a03a-41a0-b2a4-ce54a5f12561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ea14ec1-6b18-4e02-b242-1782b30b1d4d" xlink:to="loc_us-gaap_RepaymentsOfDebt_b16c206e-a03a-41a0-b2a4-ce54a5f12561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_3cc0d304-6330-4731-b1df-25747c3aadb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ea14ec1-6b18-4e02-b242-1782b30b1d4d" xlink:to="loc_us-gaap_PaymentsOfDividends_3cc0d304-6330-4731-b1df-25747c3aadb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6928b163-fd65-4dff-bce2-f03c28e17c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ea14ec1-6b18-4e02-b242-1782b30b1d4d" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6928b163-fd65-4dff-bce2-f03c28e17c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_98f9af1c-55de-471b-b88d-cafd1c32b954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ea14ec1-6b18-4e02-b242-1782b30b1d4d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_98f9af1c-55de-471b-b88d-cafd1c32b954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_57d76fc7-c64f-4bb2-8e98-235edbdc0b66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab63e072-0999-4d0b-8749-f040d9b2dd85" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_57d76fc7-c64f-4bb2-8e98-235edbdc0b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39505311-f779-4abf-ab00-d3d1ccfaac25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab63e072-0999-4d0b-8749-f040d9b2dd85" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39505311-f779-4abf-ab00-d3d1ccfaac25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_064e17b0-3150-45e5-b006-99083f536219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab63e072-0999-4d0b-8749-f040d9b2dd85" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_064e17b0-3150-45e5-b006-99083f536219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29e99130-b2fa-4b40-ad31-a2327733ca55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab63e072-0999-4d0b-8749-f040d9b2dd85" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29e99130-b2fa-4b40-ad31-a2327733ca55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="gild-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_07aad282-4818-4163-877c-45be5e3c0184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0c7cd1da-94ff-47ce-9f18-ad7cf7b02ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07aad282-4818-4163-877c-45be5e3c0184" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0c7cd1da-94ff-47ce-9f18-ad7cf7b02ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="gild-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e4d4a785-8082-47f6-b57d-92b2fe8f6eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_df14967a-cac9-457a-b061-e012e0cbdc97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4d4a785-8082-47f6-b57d-92b2fe8f6eb1" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_df14967a-cac9-457a-b061-e012e0cbdc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_29d0d284-6eea-4991-8b01-fdb6b58f81d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4d4a785-8082-47f6-b57d-92b2fe8f6eb1" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_29d0d284-6eea-4991-8b01-fdb6b58f81d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e1192a1f-1d09-4cfb-bb3d-caadbb9882e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4d4a785-8082-47f6-b57d-92b2fe8f6eb1" xlink:to="loc_us-gaap_UseOfEstimates_e1192a1f-1d09-4cfb-bb3d-caadbb9882e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_c9285d6f-1315-4363-a254-4e4c443101f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4d4a785-8082-47f6-b57d-92b2fe8f6eb1" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_c9285d6f-1315-4363-a254-4e4c443101f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_2ac3bf98-9134-4ad4-93c1-4f5044a017bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4d4a785-8082-47f6-b57d-92b2fe8f6eb1" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_2ac3bf98-9134-4ad4-93c1-4f5044a017bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_616ac948-e1a6-44f1-afed-edb65733cb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e7a2c7a3-b5c1-4af2-90bd-c710547f7717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_616ac948-e1a6-44f1-afed-edb65733cb1b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e7a2c7a3-b5c1-4af2-90bd-c710547f7717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_c87eea8b-bf8c-4d6e-b5ce-48911d997b76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_616ac948-e1a6-44f1-afed-edb65733cb1b" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_c87eea8b-bf8c-4d6e-b5ce-48911d997b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUES" xlink:type="simple" xlink:href="gild-20210930.xsd#REVENUES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eb601657-9ac8-4c9d-8e57-29bffb84880d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_029544aa-0059-410a-a3a7-c20a01b3cb69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eb601657-9ac8-4c9d-8e57-29bffb84880d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_029544aa-0059-410a-a3a7-c20a01b3cb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESTables" xlink:type="simple" xlink:href="gild-20210930.xsd#REVENUESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_434cd1ad-cbda-4a97-b14b-ae3bd4da2c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3e24d9bc-aa12-4a0f-acc5-59a51896b00b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_434cd1ad-cbda-4a97-b14b-ae3bd4da2c1d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3e24d9bc-aa12-4a0f-acc5-59a51896b00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_051a113e-0fbb-4fd9-afd3-cf7cea74a99c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_434cd1ad-cbda-4a97-b14b-ae3bd4da2c1d" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_051a113e-0fbb-4fd9-afd3-cf7cea74a99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#REVENUESDisaggregationofRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_34d84add-d13a-4607-9d09-b6f1ac7fc1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_25008da0-477a-409e-997f-db05b380ee1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_34d84add-d13a-4607-9d09-b6f1ac7fc1e0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_25008da0-477a-409e-997f-db05b380ee1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d84c1cee-8113-4991-89df-7922cd324e59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_25008da0-477a-409e-997f-db05b380ee1c" xlink:to="loc_srt_ProductOrServiceAxis_d84c1cee-8113-4991-89df-7922cd324e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_71c63568-af6f-4649-a306-5cdb6a7b5e8d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d84c1cee-8113-4991-89df-7922cd324e59" xlink:to="loc_srt_ProductsAndServicesDomain_71c63568-af6f-4649-a306-5cdb6a7b5e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_71c63568-af6f-4649-a306-5cdb6a7b5e8d" xlink:to="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:href="gild-20210930.xsd#gild_HIVProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:to="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsAtriplaMember_5ce2354d-49de-4ea6-9b11-768537deaeaa" xlink:href="gild-20210930.xsd#gild_HIVProductsAtriplaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsAtriplaMember_5ce2354d-49de-4ea6-9b11-768537deaeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember_c8ac4984-c196-4cd2-a402-8451934b02fc" xlink:href="gild-20210930.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsBiktarvyMember_c8ac4984-c196-4cd2-a402-8451934b02fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember_e403e29e-6afd-4133-af8b-3cb15254cfcb" xlink:href="gild-20210930.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsCompleraEvipleraMember_e403e29e-6afd-4133-af8b-3cb15254cfcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember_e249511b-0233-47ec-bfbe-1abb45e1dd1c" xlink:href="gild-20210930.xsd#gild_HIVProductsDescovyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsDescovyMember_e249511b-0233-47ec-bfbe-1abb45e1dd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember_0872033e-01ba-4662-991b-2a7dc4227884" xlink:href="gild-20210930.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsGenvoyaMember_0872033e-01ba-4662-991b-2a7dc4227884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember_7ab1286b-3445-47c8-abb3-d3514ea3d01a" xlink:href="gild-20210930.xsd#gild_HIVProductsOdefseyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsOdefseyMember_7ab1286b-3445-47c8-abb3-d3514ea3d01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember_323241cf-fcf4-4cb3-b756-a52e55cdf07a" xlink:href="gild-20210930.xsd#gild_HIVProductsStribildMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsStribildMember_323241cf-fcf4-4cb3-b756-a52e55cdf07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember_17a17215-5883-4a0c-b153-d99975ab0917" xlink:href="gild-20210930.xsd#gild_HIVProductsTruvadaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_HIVProductsTruvadaMember_17a17215-5883-4a0c-b153-d99975ab0917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember_0d75a5b6-c4ac-42c1-907d-4619d73d77c2" xlink:href="gild-20210930.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_ProductsRevenueShareSymtuzaMember_0d75a5b6-c4ac-42c1-907d-4619d73d77c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember_55758a4b-3bbe-4667-99d7-07e43ca57e06" xlink:href="gild-20210930.xsd#gild_ProductsOtherHIVMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_1d04649f-1c12-47bb-897e-eea7caedf8d8" xlink:to="loc_gild_ProductsOtherHIVMember_55758a4b-3bbe-4667-99d7-07e43ca57e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember_bfb03870-4066-4eb0-a5f3-bf5f436ce8ab" xlink:href="gild-20210930.xsd#gild_HCVProductSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:to="loc_gild_HCVProductSalesMember_bfb03870-4066-4eb0-a5f3-bf5f436ce8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember_710a6f07-bed3-4036-8b74-55ee183df1c9" xlink:href="gild-20210930.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_bfb03870-4066-4eb0-a5f3-bf5f436ce8ab" xlink:to="loc_gild_HCVProductsLedipasvirSofosbuvirMember_710a6f07-bed3-4036-8b74-55ee183df1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_a70af30c-443e-4ba6-91d5-969268061c81" xlink:href="gild-20210930.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_bfb03870-4066-4eb0-a5f3-bf5f436ce8ab" xlink:to="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_a70af30c-443e-4ba6-91d5-969268061c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHepatitisCVirusProductsMember_7b405275-6ef4-490f-8c01-a54e7a0e1c69" xlink:href="gild-20210930.xsd#gild_OtherHepatitisCVirusProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_bfb03870-4066-4eb0-a5f3-bf5f436ce8ab" xlink:to="loc_gild_OtherHepatitisCVirusProductsMember_7b405275-6ef4-490f-8c01-a54e7a0e1c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_38e8edba-7ebe-48a4-b1af-61b86a456af4" xlink:href="gild-20210930.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_38e8edba-7ebe-48a4-b1af-61b86a456af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_2770241c-5f23-4169-8274-b57f2c038486" xlink:href="gild-20210930.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_38e8edba-7ebe-48a4-b1af-61b86a456af4" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_2770241c-5f23-4169-8274-b57f2c038486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_78440bc1-4255-4aca-97cb-e03d32bc476e" xlink:href="gild-20210930.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_38e8edba-7ebe-48a4-b1af-61b86a456af4" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_78440bc1-4255-4aca-97cb-e03d32bc476e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_335d030e-aae5-4998-a348-3348cc84fedb" xlink:href="gild-20210930.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_38e8edba-7ebe-48a4-b1af-61b86a456af4" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_335d030e-aae5-4998-a348-3348cc84fedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember_be4d0786-9a3b-402d-9964-10065f4fe557" xlink:href="gild-20210930.xsd#gild_VekluryMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:to="loc_gild_VekluryMember_be4d0786-9a3b-402d-9964-10065f4fe557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ecc50b88-bb35-450b-ad06-b113a6189dae" xlink:href="gild-20210930.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:to="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ecc50b88-bb35-450b-ad06-b113a6189dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember_9671bbd1-1137-4571-8f92-98d97d2f2d29" xlink:href="gild-20210930.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ecc50b88-bb35-450b-ad06-b113a6189dae" xlink:to="loc_gild_CellTherapyProductsTecartusMember_9671bbd1-1137-4571-8f92-98d97d2f2d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsYescartaMember_92543cb0-e2a7-479c-8dae-396d1d8667ec" xlink:href="gild-20210930.xsd#gild_CellTherapyProductsYescartaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ecc50b88-bb35-450b-ad06-b113a6189dae" xlink:to="loc_gild_CellTherapyProductsYescartaMember_92543cb0-e2a7-479c-8dae-396d1d8667ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_3eb1681e-751f-414d-b81a-de02133e01af" xlink:href="gild-20210930.xsd#gild_TrodelvyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:to="loc_gild_TrodelvyMember_3eb1681e-751f-414d-b81a-de02133e01af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember_5573ece5-611f-47ec-a324-5711a183fdb0" xlink:href="gild-20210930.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_a89f92df-fdcd-4263-9af3-b299de1e5d74" xlink:to="loc_gild_OtherProductsTotalOtherProductSalesMember_5573ece5-611f-47ec-a324-5711a183fdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember_a92d3e92-a439-46fc-bc7b-b336ae9751c1" xlink:href="gild-20210930.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_5573ece5-611f-47ec-a324-5711a183fdb0" xlink:to="loc_gild_OtherProductsAmBisomeMember_a92d3e92-a439-46fc-bc7b-b336ae9751c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember_6309089a-82fb-4a43-a4e7-22ecbc2913d9" xlink:href="gild-20210930.xsd#gild_OtherProductsLetairisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_5573ece5-611f-47ec-a324-5711a183fdb0" xlink:to="loc_gild_OtherProductsLetairisMember_6309089a-82fb-4a43-a4e7-22ecbc2913d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsRanexaMember_6ac6a406-d142-4ee2-80d9-60f9e351b227" xlink:href="gild-20210930.xsd#gild_OtherProductsRanexaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_5573ece5-611f-47ec-a324-5711a183fdb0" xlink:to="loc_gild_OtherProductsRanexaMember_6ac6a406-d142-4ee2-80d9-60f9e351b227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsZydeligMember_6332db23-7168-4c22-bd30-4c7fd660902b" xlink:href="gild-20210930.xsd#gild_OtherProductsZydeligMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_5573ece5-611f-47ec-a324-5711a183fdb0" xlink:to="loc_gild_OtherProductsZydeligMember_6332db23-7168-4c22-bd30-4c7fd660902b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember_356e628d-b400-4b0e-a72b-15b4370cb473" xlink:href="gild-20210930.xsd#gild_OtherProductsOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_5573ece5-611f-47ec-a324-5711a183fdb0" xlink:to="loc_gild_OtherProductsOtherMember_356e628d-b400-4b0e-a72b-15b4370cb473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_6aad704d-df6a-4f88-8ac1-9511e2539780" xlink:href="gild-20210930.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_71c63568-af6f-4649-a306-5cdb6a7b5e8d" xlink:to="loc_gild_RoyaltyContractAndOtherMember_6aad704d-df6a-4f88-8ac1-9511e2539780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_013d27df-fd61-4f5e-8d70-70af749a44bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_25008da0-477a-409e-997f-db05b380ee1c" xlink:to="loc_srt_StatementGeographicalAxis_013d27df-fd61-4f5e-8d70-70af749a44bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_124a2b6c-1553-436d-ad57-f61b8f2b412f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_013d27df-fd61-4f5e-8d70-70af749a44bf" xlink:to="loc_srt_SegmentGeographicalDomain_124a2b6c-1553-436d-ad57-f61b8f2b412f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e2a2d3a6-81c0-4eba-a72d-1459b264699c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_124a2b6c-1553-436d-ad57-f61b8f2b412f" xlink:to="loc_country_US_e2a2d3a6-81c0-4eba-a72d-1459b264699c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_b3e99c45-0684-473f-8c61-6ba6fb97775d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_124a2b6c-1553-436d-ad57-f61b8f2b412f" xlink:to="loc_srt_EuropeMember_b3e99c45-0684-473f-8c61-6ba6fb97775d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember_d298578c-3b22-47a6-bd6c-d4597fd3e0f7" xlink:href="gild-20210930.xsd#gild_OtherInternationalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_124a2b6c-1553-436d-ad57-f61b8f2b412f" xlink:to="loc_gild_OtherInternationalMember_d298578c-3b22-47a6-bd6c-d4597fd3e0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b2cad9b7-3063-4885-a522-9b00a667d321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_25008da0-477a-409e-997f-db05b380ee1c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b2cad9b7-3063-4885-a522-9b00a667d321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_afe09cea-da49-46e7-b9a9-24382b5a09c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b2cad9b7-3063-4885-a522-9b00a667d321" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_afe09cea-da49-46e7-b9a9-24382b5a09c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#REVENUESRevenuesfromMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e3fbc5d1-4754-45d9-a212-e3b627391305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_89f94986-e561-4d01-a3e3-dd5ff2313cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e3fbc5d1-4754-45d9-a212-e3b627391305" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_89f94986-e561-4d01-a3e3-dd5ff2313cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_14f602c2-9d51-4911-963a-c255a5cd46ae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_89f94986-e561-4d01-a3e3-dd5ff2313cfa" xlink:to="loc_srt_MajorCustomersAxis_14f602c2-9d51-4911-963a-c255a5cd46ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b0df3301-b71a-40b0-9f38-c2848537363f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_14f602c2-9d51-4911-963a-c255a5cd46ae" xlink:to="loc_srt_NameOfMajorCustomerDomain_b0df3301-b71a-40b0-9f38-c2848537363f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember_e3dbc62b-1833-41c4-8512-d01839fdcfb4" xlink:href="gild-20210930.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b0df3301-b71a-40b0-9f38-c2848537363f" xlink:to="loc_gild_AmerisourcebergenCorpMember_e3dbc62b-1833-41c4-8512-d01839fdcfb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember_f3c2d6de-9f9a-4252-b402-ce67f68e71e7" xlink:href="gild-20210930.xsd#gild_CardinalHealthIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b0df3301-b71a-40b0-9f38-c2848537363f" xlink:to="loc_gild_CardinalHealthIncMember_f3c2d6de-9f9a-4252-b402-ce67f68e71e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember_83acc641-0adf-475c-a71a-cbae939d6ab0" xlink:href="gild-20210930.xsd#gild_MckessonCorpMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b0df3301-b71a-40b0-9f38-c2848537363f" xlink:to="loc_gild_MckessonCorpMember_83acc641-0adf-475c-a71a-cbae939d6ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f2e8171f-6d1b-40e5-9dab-bb986ab060c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_89f94986-e561-4d01-a3e3-dd5ff2313cfa" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f2e8171f-6d1b-40e5-9dab-bb986ab060c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_becb7c45-b5f8-48a7-88da-dd5e76338626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f2e8171f-6d1b-40e5-9dab-bb986ab060c2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_becb7c45-b5f8-48a7-88da-dd5e76338626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_3e639b8a-546a-4386-a501-45033b654f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_becb7c45-b5f8-48a7-88da-dd5e76338626" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_3e639b8a-546a-4386-a501-45033b654f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_bb82a7d6-b417-4a37-b590-95f03f9e8f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_89f94986-e561-4d01-a3e3-dd5ff2313cfa" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_bb82a7d6-b417-4a37-b590-95f03f9e8f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f51d6d13-fd15-4e2f-8430-34a04bd9a12f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_bb82a7d6-b417-4a37-b590-95f03f9e8f28" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f51d6d13-fd15-4e2f-8430-34a04bd9a12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_eb8a93b7-8152-4253-a64d-49f80600d318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f51d6d13-fd15-4e2f-8430-34a04bd9a12f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_eb8a93b7-8152-4253-a64d-49f80600d318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3054ea2e-5850-40e7-95cf-0373f6bc3f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_89f94986-e561-4d01-a3e3-dd5ff2313cfa" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3054ea2e-5850-40e7-95cf-0373f6bc3f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ffc46628-8b23-454b-a037-238602e0cad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3054ea2e-5850-40e7-95cf-0373f6bc3f55" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ffc46628-8b23-454b-a037-238602e0cad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#REVENUESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8ba7e487-341a-4233-a3fd-56bb91eb19fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_82a3491c-0ba1-4cdc-a04e-1e4cc2836aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8ba7e487-341a-4233-a3fd-56bb91eb19fd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_82a3491c-0ba1-4cdc-a04e-1e4cc2836aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c1183b3-f2b0-437e-be49-3d1cb718d785" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_82a3491c-0ba1-4cdc-a04e-1e4cc2836aa9" xlink:to="loc_srt_ProductOrServiceAxis_8c1183b3-f2b0-437e-be49-3d1cb718d785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_017885a4-4af1-49f3-bdc5-b67332ab2c08" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8c1183b3-f2b0-437e-be49-3d1cb718d785" xlink:to="loc_srt_ProductsAndServicesDomain_017885a4-4af1-49f3-bdc5-b67332ab2c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_1e46087f-6e2f-4544-beac-b34a88f354cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_017885a4-4af1-49f3-bdc5-b67332ab2c08" xlink:to="loc_us-gaap_RoyaltyMember_1e46087f-6e2f-4544-beac-b34a88f354cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ad30d284-aea6-459a-b89c-93c47ada64b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_82a3491c-0ba1-4cdc-a04e-1e4cc2836aa9" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ad30d284-aea6-459a-b89c-93c47ada64b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_709869d1-3335-4227-b430-a343ffd1c600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad30d284-aea6-459a-b89c-93c47ada64b4" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_709869d1-3335-4227-b430-a343ffd1c600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_bc9ca0c8-c77c-4be2-84ff-0932499223c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad30d284-aea6-459a-b89c-93c47ada64b4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_bc9ca0c8-c77c-4be2-84ff-0932499223c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_cc48b917-0988-4c18-9fc0-052c2e523c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad30d284-aea6-459a-b89c-93c47ada64b4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_cc48b917-0988-4c18-9fc0-052c2e523c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c2c9a208-8418-4e8f-a657-1b71f100f491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad30d284-aea6-459a-b89c-93c47ada64b4" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c2c9a208-8418-4e8f-a657-1b71f100f491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="gild-20210930.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dc60db1c-5284-428a-b483-dba7a2db634e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c1d62a39-c4cd-4fb0-805f-ceb52858aaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dc60db1c-5284-428a-b483-dba7a2db634e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c1d62a39-c4cd-4fb0-805f-ceb52858aaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="gild-20210930.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e54ea346-1a94-4de6-bb06-4a5f5e942bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_432d05ee-448f-4363-93fe-8e3b5fbc8ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e54ea346-1a94-4de6-bb06-4a5f5e942bd6" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_432d05ee-448f-4363-93fe-8e3b5fbc8ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_7ca4ff4c-7936-41f8-9301-11113480e663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e54ea346-1a94-4de6-bb06-4a5f5e942bd6" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_7ca4ff4c-7936-41f8-9301-11113480e663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_760730c9-04df-44b0-8a5b-b03154c0ef81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e54ea346-1a94-4de6-bb06-4a5f5e942bd6" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_760730c9-04df-44b0-8a5b-b03154c0ef81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_365a2887-19ab-43ae-952f-02cb62e71e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_365a2887-19ab-43ae-952f-02cb62e71e4b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d1aa7ac1-029e-4a61-8e3f-b562a62a2e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d1aa7ac1-029e-4a61-8e3f-b562a62a2e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a103ead-8116-4dc7-b5c0-197f2a9b904c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d1aa7ac1-029e-4a61-8e3f-b562a62a2e99" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a103ead-8116-4dc7-b5c0-197f2a9b904c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f1f38806-f134-43a0-8bc2-f075db8832ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9a103ead-8116-4dc7-b5c0-197f2a9b904c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f1f38806-f134-43a0-8bc2-f075db8832ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9e88de33-e5ce-45ad-860f-83e0bab3112c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9e88de33-e5ce-45ad-860f-83e0bab3112c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ceb4682-49d7-4cde-93ca-009eab4b03f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9e88de33-e5ce-45ad-860f-83e0bab3112c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ceb4682-49d7-4cde-93ca-009eab4b03f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6d25d45e-5fc6-4c0a-b106-a7ce4c45db53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ceb4682-49d7-4cde-93ca-009eab4b03f8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6d25d45e-5fc6-4c0a-b106-a7ce4c45db53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6bc3b25b-c6a5-492f-a4b5-4782b6e8824b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ceb4682-49d7-4cde-93ca-009eab4b03f8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6bc3b25b-c6a5-492f-a4b5-4782b6e8824b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2741d616-7d94-471e-96cb-2bf07cc022ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ceb4682-49d7-4cde-93ca-009eab4b03f8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2741d616-7d94-471e-96cb-2bf07cc022ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_fb6d343a-fb08-4b4f-ac0f-6e54b390870d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_fb6d343a-fb08-4b4f-ac0f-6e54b390870d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_304e6b23-c665-4e85-b83f-263487d4a14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_fb6d343a-fb08-4b4f-ac0f-6e54b390870d" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_304e6b23-c665-4e85-b83f-263487d4a14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_470d1b56-14eb-4281-8269-250b79093994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_304e6b23-c665-4e85-b83f-263487d4a14a" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_470d1b56-14eb-4281-8269-250b79093994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c94b80b1-13b2-43c4-bd97-f561ab942768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_470d1b56-14eb-4281-8269-250b79093994" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c94b80b1-13b2-43c4-bd97-f561ab942768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_26496da8-e3a6-4642-9d15-d3582a57be3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_26496da8-e3a6-4642-9d15-d3582a57be3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_26496da8-e3a6-4642-9d15-d3582a57be3c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_55132303-f4de-493e-bb2b-d7e0b48abea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_55132303-f4de-493e-bb2b-d7e0b48abea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0411ec94-33de-4ebb-a0f1-2573a730f006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0411ec94-33de-4ebb-a0f1-2573a730f006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_0c5d397b-0c1a-4355-83ca-44d2b171aedf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_0c5d397b-0c1a-4355-83ca-44d2b171aedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_21f2ccf1-2563-4068-a768-b360866a1ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_us-gaap_CertificatesOfDepositMember_21f2ccf1-2563-4068-a768-b360866a1ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_af0c3f45-783b-4914-aca7-63b09d6f2177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_af0c3f45-783b-4914-aca7-63b09d6f2177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_9e48648b-7ff9-46f8-8051-0a110e92095d" xlink:href="gild-20210930.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_9e48648b-7ff9-46f8-8051-0a110e92095d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_42fa102c-f67d-4578-ac35-27d54b919540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_us-gaap_MoneyMarketFundsMember_42fa102c-f67d-4578-ac35-27d54b919540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityinvestmentinGalapagosMember_0c49cc5d-666d-47dc-9a23-e5ae8f5b51b3" xlink:href="gild-20210930.xsd#gild_EquityinvestmentinGalapagosMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_gild_EquityinvestmentinGalapagosMember_0c49cc5d-666d-47dc-9a23-e5ae8f5b51b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_aa08be4a-f2ee-4929-b049-b735ebb0ba12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_us-gaap_EquitySecuritiesMember_aa08be4a-f2ee-4929-b049-b735ebb0ba12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_85d3bc48-e60f-41fb-873c-cbd1b23bf33a" xlink:href="gild-20210930.xsd#gild_DeferredCompensationPlanMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_gild_DeferredCompensationPlanMember_85d3bc48-e60f-41fb-873c-cbd1b23bf33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember_5a0952cb-6758-4c49-b077-79ac935c3af3" xlink:href="gild-20210930.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_861239ec-6cda-4224-96d1-6849677b2958" xlink:to="loc_gild_ForeignCurrencyDerivativeContractsMember_5a0952cb-6758-4c49-b077-79ac935c3af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_289a0c64-dc0f-4406-bc31-632f061324af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_289a0c64-dc0f-4406-bc31-632f061324af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ecf6a42f-d0c4-45cb-831c-4595599106db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_289a0c64-dc0f-4406-bc31-632f061324af" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ecf6a42f-d0c4-45cb-831c-4595599106db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_3091b8c3-0114-459d-973c-7f1be24fca66" xlink:href="gild-20210930.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ecf6a42f-d0c4-45cb-831c-4595599106db" xlink:to="loc_gild_MYRGmbHMember_3091b8c3-0114-459d-973c-7f1be24fca66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5bb84315-6f7f-489c-b026-9bd49e0752f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5bb84315-6f7f-489c-b026-9bd49e0752f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_67b6d0dd-a657-4bbb-b2f0-fd68912e81af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5bb84315-6f7f-489c-b026-9bd49e0752f5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_67b6d0dd-a657-4bbb-b2f0-fd68912e81af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_2bae35fd-b2b9-47bf-902a-a822a118e862" xlink:href="gild-20210930.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_67b6d0dd-a657-4bbb-b2f0-fd68912e81af" xlink:to="loc_gild_ArcusBiosciencesIncMember_2bae35fd-b2b9-47bf-902a-a822a118e862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b725a1a2-44e3-4952-97a4-22c0b51cb30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c362df5-b794-4665-9f88-704cdc148000" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b725a1a2-44e3-4952-97a4-22c0b51cb30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_93c39bf0-9cd0-4091-adde-ad883c39e504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b725a1a2-44e3-4952-97a4-22c0b51cb30d" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_93c39bf0-9cd0-4091-adde-ad883c39e504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2260ba81-065c-471a-b6a3-d0bd8b62cd47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93c39bf0-9cd0-4091-adde-ad883c39e504" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2260ba81-065c-471a-b6a3-d0bd8b62cd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_3928af8b-8d94-4d18-83b9-d83c8659044b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93c39bf0-9cd0-4091-adde-ad883c39e504" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_3928af8b-8d94-4d18-83b9-d83c8659044b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_35ccc40b-cf9b-43c1-8b28-e79a5b8827c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93c39bf0-9cd0-4091-adde-ad883c39e504" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_35ccc40b-cf9b-43c1-8b28-e79a5b8827c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7474c8da-5a46-4ef3-a8b3-c64dd2891d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93c39bf0-9cd0-4091-adde-ad883c39e504" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7474c8da-5a46-4ef3-a8b3-c64dd2891d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_943f4107-a993-4920-8911-b6deedcb6ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b725a1a2-44e3-4952-97a4-22c0b51cb30d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_943f4107-a993-4920-8911-b6deedcb6ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_57a101cb-b80c-42ae-88e0-0b1b528bbd75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_943f4107-a993-4920-8911-b6deedcb6ea8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_57a101cb-b80c-42ae-88e0-0b1b528bbd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_792c9707-1f37-41d0-8d28-f3f70f636596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_943f4107-a993-4920-8911-b6deedcb6ea8" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_792c9707-1f37-41d0-8d28-f3f70f636596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_9462e4dd-5722-45a0-8b6e-4bdaacdb0504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_943f4107-a993-4920-8911-b6deedcb6ea8" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_9462e4dd-5722-45a0-8b6e-4bdaacdb0504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_96a0b3b0-6e33-43ef-84d7-0e5361217e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_943f4107-a993-4920-8911-b6deedcb6ea8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_96a0b3b0-6e33-43ef-84d7-0e5361217e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0083562a-517b-421b-b08e-a8abdc6ecbef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f613334-a6e9-44f0-bce3-92739f997cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0083562a-517b-421b-b08e-a8abdc6ecbef" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f613334-a6e9-44f0-bce3-92739f997cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_951b8eed-7648-4717-8426-80a069e5c2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f613334-a6e9-44f0-bce3-92739f997cb1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_951b8eed-7648-4717-8426-80a069e5c2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_572e96ff-ebbf-418b-b626-dfad1ff4e34e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_951b8eed-7648-4717-8426-80a069e5c2f4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_572e96ff-ebbf-418b-b626-dfad1ff4e34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_cdd8816c-66cf-49c7-94a9-98c0ecd39d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_572e96ff-ebbf-418b-b626-dfad1ff4e34e" xlink:to="loc_us-gaap_EquitySecuritiesMember_cdd8816c-66cf-49c7-94a9-98c0ecd39d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_98e68185-daa5-4199-9b25-2ec4b043e4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f613334-a6e9-44f0-bce3-92739f997cb1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_98e68185-daa5-4199-9b25-2ec4b043e4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b292c96e-d12a-4d59-a414-9f7a3892a39d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_98e68185-daa5-4199-9b25-2ec4b043e4f2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b292c96e-d12a-4d59-a414-9f7a3892a39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_13995b69-3923-4c68-9490-ab5ec4640940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b292c96e-d12a-4d59-a414-9f7a3892a39d" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_13995b69-3923-4c68-9490-ab5ec4640940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_e985c7ee-02e3-4769-8964-a45669696ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b292c96e-d12a-4d59-a414-9f7a3892a39d" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_e985c7ee-02e3-4769-8964-a45669696ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_87f11c26-b0ed-489c-be4c-70e2908547a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b292c96e-d12a-4d59-a414-9f7a3892a39d" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_87f11c26-b0ed-489c-be4c-70e2908547a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7dd1b30-51cf-426b-9115-9acc7e09e86a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f613334-a6e9-44f0-bce3-92739f997cb1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7dd1b30-51cf-426b-9115-9acc7e09e86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_1f57d13c-e02f-4e2c-9e5d-73c5706cb063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7dd1b30-51cf-426b-9115-9acc7e09e86a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_1f57d13c-e02f-4e2c-9e5d-73c5706cb063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_97c0d657-9224-4849-8284-594c0dc24d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7dd1b30-51cf-426b-9115-9acc7e09e86a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_97c0d657-9224-4849-8284-594c0dc24d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#FAIRVALUEMEASUREMENTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fc0c0c1a-5ae8-4564-be0d-754b8ec4ca88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fc0c0c1a-5ae8-4564-be0d-754b8ec4ca88" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_d73f1da1-bd4d-4195-aa50-c5c9d631a844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_d73f1da1-bd4d-4195-aa50-c5c9d631a844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a8360787-fe9e-4bb0-a225-4539f9745aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_d73f1da1-bd4d-4195-aa50-c5c9d631a844" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a8360787-fe9e-4bb0-a225-4539f9745aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesDonationMember_bc160e0e-ccc6-49c2-b8b9-8cd1602ad6f2" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesDonationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a8360787-fe9e-4bb0-a225-4539f9745aec" xlink:to="loc_gild_EquitySecuritiesDonationMember_bc160e0e-ccc6-49c2-b8b9-8cd1602ad6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4ea64550-3e12-4f96-afeb-13042ea2b253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4ea64550-3e12-4f96-afeb-13042ea2b253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b1b2b844-bc95-4dea-90f8-d288147e5089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4ea64550-3e12-4f96-afeb-13042ea2b253" xlink:to="loc_us-gaap_RelatedPartyDomain_b1b2b844-bc95-4dea-90f8-d288147e5089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadFoundationMember_02a4aba5-ced8-4fa6-ba3c-b41a7dff8b93" xlink:href="gild-20210930.xsd#gild_GileadFoundationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b1b2b844-bc95-4dea-90f8-d288147e5089" xlink:to="loc_gild_GileadFoundationMember_02a4aba5-ced8-4fa6-ba3c-b41a7dff8b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_7fd66470-ec27-4514-8fae-ee93e1d685ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_7fd66470-ec27-4514-8fae-ee93e1d685ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0bbc3b61-9829-45f3-8dc8-cdd85b85b467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_7fd66470-ec27-4514-8fae-ee93e1d685ed" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0bbc3b61-9829-45f3-8dc8-cdd85b85b467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5405fc6d-116c-4400-9f6c-3c2b71dfb84f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0bbc3b61-9829-45f3-8dc8-cdd85b85b467" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5405fc6d-116c-4400-9f6c-3c2b71dfb84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_cb8834de-3221-4439-97a3-3d0a625b8eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5405fc6d-116c-4400-9f6c-3c2b71dfb84f" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_cb8834de-3221-4439-97a3-3d0a625b8eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6d6410d9-cabd-47b8-849e-39eccf181c93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5405fc6d-116c-4400-9f6c-3c2b71dfb84f" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6d6410d9-cabd-47b8-849e-39eccf181c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ed210bcb-9864-4d10-aabb-f604eb2db996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ed210bcb-9864-4d10-aabb-f604eb2db996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_33172143-d893-41d8-99a0-01deffe6ca08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ed210bcb-9864-4d10-aabb-f604eb2db996" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_33172143-d893-41d8-99a0-01deffe6ca08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1b8074ab-9dab-43d0-9f12-76727dc708f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_33172143-d893-41d8-99a0-01deffe6ca08" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1b8074ab-9dab-43d0-9f12-76727dc708f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d58ea9b9-bb7e-436e-97dd-f1e4708a03ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_33172143-d893-41d8-99a0-01deffe6ca08" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d58ea9b9-bb7e-436e-97dd-f1e4708a03ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_38b4f25b-462e-445f-835c-8a5dff6c6b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_38b4f25b-462e-445f-835c-8a5dff6c6b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b114b61e-eaaf-4f81-86c5-baeef97aa3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_38b4f25b-462e-445f-835c-8a5dff6c6b3b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b114b61e-eaaf-4f81-86c5-baeef97aa3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_1a565de4-e67b-4d0d-bfac-605ca94537c6" xlink:href="gild-20210930.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b114b61e-eaaf-4f81-86c5-baeef97aa3a0" xlink:to="loc_gild_MYRGmbHMember_1a565de4-e67b-4d0d-bfac-605ca94537c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_932d3766-ba44-4555-b065-a4c4f51cfe7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_932d3766-ba44-4555-b065-a4c4f51cfe7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1af9fd0-be52-448d-ae6b-08fdbf88f6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_932d3766-ba44-4555-b065-a4c4f51cfe7d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1af9fd0-be52-448d-ae6b-08fdbf88f6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ad46f165-747e-457b-9188-488851c07f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1af9fd0-be52-448d-ae6b-08fdbf88f6d2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ad46f165-747e-457b-9188-488851c07f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f4d984-0e94-4635-b4ad-5f46e2e5e373" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_cf18ec26-4d38-4675-854a-3246e5debd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_cf18ec26-4d38-4675-854a-3246e5debd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_dfd00d19-5e29-4311-96df-f42a4c5cf11e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_dfd00d19-5e29-4311-96df-f42a4c5cf11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7e4be219-5c3c-4b47-98ac-b9dbfaa15aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7e4be219-5c3c-4b47-98ac-b9dbfaa15aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_d950865e-b6d3-4730-bd86-f2785bced6de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_d950865e-b6d3-4730-bd86-f2785bced6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_429b596d-48a7-4c2a-b3a4-358b7062cd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:to="loc_us-gaap_LongTermDebtFairValue_429b596d-48a7-4c2a-b3a4-358b7062cd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_19892b09-25aa-4e2c-a446-0c008708c161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_19892b09-25aa-4e2c-a446-0c008708c161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3db64155-ce06-4c7f-9135-07b7a680c619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4754d6f3-9d3a-4688-b036-01fce8209794" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3db64155-ce06-4c7f-9135-07b7a680c619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b3b5212c-220f-4120-961d-a8d199f746c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_206176ac-5067-4c54-9e68-f8014411c955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b3b5212c-220f-4120-961d-a8d199f746c0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_206176ac-5067-4c54-9e68-f8014411c955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c1461bc1-b39e-4ecd-83f0-1021ad06034e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_206176ac-5067-4c54-9e68-f8014411c955" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c1461bc1-b39e-4ecd-83f0-1021ad06034e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0594984b-5817-4c86-8fed-e775bd2ff08f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c1461bc1-b39e-4ecd-83f0-1021ad06034e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0594984b-5817-4c86-8fed-e775bd2ff08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosNVMember_e87e4adf-365a-48c0-8a33-7ec0b0fac5d3" xlink:href="gild-20210930.xsd#gild_GalapagosNVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0594984b-5817-4c86-8fed-e775bd2ff08f" xlink:to="loc_gild_GalapagosNVMember_e87e4adf-365a-48c0-8a33-7ec0b0fac5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_223d3d9f-b6d7-42f2-9c1d-7f70f9a0523d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_206176ac-5067-4c54-9e68-f8014411c955" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_223d3d9f-b6d7-42f2-9c1d-7f70f9a0523d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6b97205c-5bfb-47b9-a689-2ee25683e176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_223d3d9f-b6d7-42f2-9c1d-7f70f9a0523d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6b97205c-5bfb-47b9-a689-2ee25683e176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0e86de85-2d77-451d-b923-ff9e0c765bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6b97205c-5bfb-47b9-a689-2ee25683e176" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0e86de85-2d77-451d-b923-ff9e0c765bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_9e1a0bd4-16fb-4475-a566-9ac274fa93cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6b97205c-5bfb-47b9-a689-2ee25683e176" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_9e1a0bd4-16fb-4475-a566-9ac274fa93cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1d0274b2-937e-45e3-959c-280834defe8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_206176ac-5067-4c54-9e68-f8014411c955" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1d0274b2-937e-45e3-959c-280834defe8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_8ef2c9aa-825a-4a39-98d4-67610ad32b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1d0274b2-937e-45e3-959c-280834defe8a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_8ef2c9aa-825a-4a39-98d4-67610ad32b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES" xlink:type="simple" xlink:href="gild-20210930.xsd#AVAILABLEFORSALEDEBTSECURITIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_10339681-0f44-46e8-a03e-1303dbf706bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f2c81b13-cdf0-4070-8330-09d3b14a4e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_10339681-0f44-46e8-a03e-1303dbf706bf" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f2c81b13-cdf0-4070-8330-09d3b14a4e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables" xlink:type="simple" xlink:href="gild-20210930.xsd#AVAILABLEFORSALEDEBTSECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f331ad2a-8965-4ad6-a400-b18cafa82b52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_25df78f1-eea2-451b-81d8-53f2818eaa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f331ad2a-8965-4ad6-a400-b18cafa82b52" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_25df78f1-eea2-451b-81d8-53f2818eaa1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_715e484f-9811-4261-ac7d-071523fb9610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f331ad2a-8965-4ad6-a400-b18cafa82b52" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_715e484f-9811-4261-ac7d-071523fb9610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_34360b6c-fa95-475a-aad1-e23c519ea799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f331ad2a-8965-4ad6-a400-b18cafa82b52" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_34360b6c-fa95-475a-aad1-e23c519ea799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_16968064-0440-4689-ac1d-2d90e8ab349f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a68d1521-609c-497a-8263-63ca6a0a6ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_16968064-0440-4689-ac1d-2d90e8ab349f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a68d1521-609c-497a-8263-63ca6a0a6ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_22ed0db2-3500-4df8-bd16-210bc7da67d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a68d1521-609c-497a-8263-63ca6a0a6ef1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_22ed0db2-3500-4df8-bd16-210bc7da67d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_22ed0db2-3500-4df8-bd16-210bc7da67d0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_ee29101e-1f10-4c44-a54d-3aca8207ab2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_ee29101e-1f10-4c44-a54d-3aca8207ab2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4da411d1-b153-4d3c-abb9-a90c0b76e8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4da411d1-b153-4d3c-abb9-a90c0b76e8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_bcf4d77d-555a-4794-9b8a-b1a1d66de94e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_bcf4d77d-555a-4794-9b8a-b1a1d66de94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0a526c5f-67cb-4abd-a0e0-070391f8a732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0a526c5f-67cb-4abd-a0e0-070391f8a732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9e6198b2-4131-431f-9681-3a88b30e5733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9e6198b2-4131-431f-9681-3a88b30e5733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_2464156f-f985-4689-b725-65cbea2c5262" xlink:href="gild-20210930.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b6e725ae-1022-409c-a05d-5d9ef1947964" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_2464156f-f985-4689-b725-65cbea2c5262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10425dc4-fa30-4a3d-be00-3e0ff1b022fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a68d1521-609c-497a-8263-63ca6a0a6ef1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10425dc4-fa30-4a3d-be00-3e0ff1b022fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_d7ef27f3-b22e-4cd8-a02d-4232e1c88c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10425dc4-fa30-4a3d-be00-3e0ff1b022fc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_d7ef27f3-b22e-4cd8-a02d-4232e1c88c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2dd7dd80-9da0-46c2-9ee7-c6afd59f0ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10425dc4-fa30-4a3d-be00-3e0ff1b022fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2dd7dd80-9da0-46c2-9ee7-c6afd59f0ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2504a2be-c1f1-4474-9df7-2be1131c5f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10425dc4-fa30-4a3d-be00-3e0ff1b022fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2504a2be-c1f1-4474-9df7-2be1131c5f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ccd1d3f1-dbe6-4bd9-a025-29e6b60cd6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10425dc4-fa30-4a3d-be00-3e0ff1b022fc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ccd1d3f1-dbe6-4bd9-a025-29e6b60cd6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0e61cf3f-85b2-4159-9efe-cfa72e2e492f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f620e9b2-2859-4407-95ff-01d96091b9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0e61cf3f-85b2-4159-9efe-cfa72e2e492f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f620e9b2-2859-4407-95ff-01d96091b9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_73444bd1-0161-4fd2-963d-2e90c9cf3154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f620e9b2-2859-4407-95ff-01d96091b9ec" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_73444bd1-0161-4fd2-963d-2e90c9cf3154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_87513c01-f17d-4f48-b439-22a0955b7503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_73444bd1-0161-4fd2-963d-2e90c9cf3154" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_87513c01-f17d-4f48-b439-22a0955b7503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_db462885-d5fd-49a3-8918-1d1177ba7795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_87513c01-f17d-4f48-b439-22a0955b7503" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_db462885-d5fd-49a3-8918-1d1177ba7795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember_cbd6655e-f965-4cfa-a51d-d41cf67f0a8f" xlink:href="gild-20210930.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_87513c01-f17d-4f48-b439-22a0955b7503" xlink:to="loc_gild_MarketableSecuritiesCurrentMember_cbd6655e-f965-4cfa-a51d-d41cf67f0a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember_49d196c7-bfcf-4104-97c5-5c3dbb12598c" xlink:href="gild-20210930.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_87513c01-f17d-4f48-b439-22a0955b7503" xlink:to="loc_gild_MarketableSecuritiesNoncurrentMember_49d196c7-bfcf-4104-97c5-5c3dbb12598c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05d3e2b4-f5ec-45d3-9200-181bbb7f59cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f620e9b2-2859-4407-95ff-01d96091b9ec" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05d3e2b4-f5ec-45d3-9200-181bbb7f59cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_303a82ce-abcb-45cd-9f78-adcb917bd71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05d3e2b4-f5ec-45d3-9200-181bbb7f59cb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_303a82ce-abcb-45cd-9f78-adcb917bd71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_73508b98-34fa-437c-b45e-8918d6da02ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_d975a21e-726d-48db-9be2-7d4b04ea8416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_73508b98-34fa-437c-b45e-8918d6da02ce" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_d975a21e-726d-48db-9be2-7d4b04ea8416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_f170740f-bf30-4fdc-bba8-c7915a87a0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_d975a21e-726d-48db-9be2-7d4b04ea8416" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_f170740f-bf30-4fdc-bba8-c7915a87a0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c140414b-e236-4345-af18-cf9b507e031a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_d975a21e-726d-48db-9be2-7d4b04ea8416" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c140414b-e236-4345-af18-cf9b507e031a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_614cb56b-c7da-4ebe-9fe3-7c6cbf4bd15e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_d975a21e-726d-48db-9be2-7d4b04ea8416" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_614cb56b-c7da-4ebe-9fe3-7c6cbf4bd15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_766160ad-92b4-49de-83f7-7fa93fe8ad5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_d975a21e-726d-48db-9be2-7d4b04ea8416" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_766160ad-92b4-49de-83f7-7fa93fe8ad5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_267de9b4-287e-41f7-a760-6ba18ca15ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_73508b98-34fa-437c-b45e-8918d6da02ce" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_267de9b4-287e-41f7-a760-6ba18ca15ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_31742472-bca5-4bae-a238-21d84be3aeee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_267de9b4-287e-41f7-a760-6ba18ca15ad7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_31742472-bca5-4bae-a238-21d84be3aeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d3c9abf5-88be-44fd-a3e3-f877cc9bf4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_267de9b4-287e-41f7-a760-6ba18ca15ad7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d3c9abf5-88be-44fd-a3e3-f877cc9bf4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_4cb7243c-4ad4-4d19-8cbd-62dd311c875d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_267de9b4-287e-41f7-a760-6ba18ca15ad7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_4cb7243c-4ad4-4d19-8cbd-62dd311c875d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_df4720bd-1bb6-4041-ac27-90c98b405a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_267de9b4-287e-41f7-a760-6ba18ca15ad7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_df4720bd-1bb6-4041-ac27-90c98b405a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_10007245-766e-4043-8489-3f2697ae1530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_c0de3519-948a-4b16-9171-ea3f4647b6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_10007245-766e-4043-8489-3f2697ae1530" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_c0de3519-948a-4b16-9171-ea3f4647b6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_d888f8a4-129d-4e44-ad2d-40e7949f282b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_10007245-766e-4043-8489-3f2697ae1530" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_d888f8a4-129d-4e44-ad2d-40e7949f282b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="gild-20210930.xsd#DERIVATIVEFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5ae96a2d-1d48-4d37-9d01-2c7997516b76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5ad0ea0f-d1c2-4cd2-90be-670cc1a6ab69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5ae96a2d-1d48-4d37-9d01-2c7997516b76" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5ad0ea0f-d1c2-4cd2-90be-670cc1a6ab69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="gild-20210930.xsd#DERIVATIVEFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5fbb5b1e-b6bc-4167-a223-3d06a40d9d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_9917991f-1e0a-403b-b509-7c30599003fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5fbb5b1e-b6bc-4167-a223-3d06a40d9d56" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_9917991f-1e0a-403b-b509-7c30599003fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_f7811bfa-8410-45c6-bb71-a964e751eb94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5fbb5b1e-b6bc-4167-a223-3d06a40d9d56" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_f7811bfa-8410-45c6-bb71-a964e751eb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_42a54a09-a3aa-4013-82f7-95d48a0696c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5fbb5b1e-b6bc-4167-a223-3d06a40d9d56" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_42a54a09-a3aa-4013-82f7-95d48a0696c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a7e446db-b610-4f4e-8369-e0039f726681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f44a5042-72a7-430d-96b2-48799dfabd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a7e446db-b610-4f4e-8369-e0039f726681" xlink:to="loc_us-gaap_DerivativeTable_f44a5042-72a7-430d-96b2-48799dfabd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8ee77744-a859-4723-8112-64349a4e0565" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f44a5042-72a7-430d-96b2-48799dfabd7a" xlink:to="loc_srt_RangeAxis_8ee77744-a859-4723-8112-64349a4e0565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_efec2534-54cf-4e9b-a621-3e8682b18a74" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8ee77744-a859-4723-8112-64349a4e0565" xlink:to="loc_srt_RangeMember_efec2534-54cf-4e9b-a621-3e8682b18a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d9095406-9e8e-48b0-a91f-5a494c558d1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_efec2534-54cf-4e9b-a621-3e8682b18a74" xlink:to="loc_srt_MaximumMember_d9095406-9e8e-48b0-a91f-5a494c558d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a50480c9-e5e3-4971-87f3-ef9d022b4b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f44a5042-72a7-430d-96b2-48799dfabd7a" xlink:to="loc_us-gaap_DerivativeLineItems_a50480c9-e5e3-4971-87f3-ef9d022b4b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_ab3b4c6d-4acd-43ff-a8f5-d850be1b663b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a50480c9-e5e3-4971-87f3-ef9d022b4b77" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_ab3b4c6d-4acd-43ff-a8f5-d850be1b663b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_0aee8cdb-2914-4f2b-b6e2-76d57e02160e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a50480c9-e5e3-4971-87f3-ef9d022b4b77" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_0aee8cdb-2914-4f2b-b6e2-76d57e02160e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_3bc89064-75a2-40b4-a451-4f381b771470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a50480c9-e5e3-4971-87f3-ef9d022b4b77" xlink:to="loc_us-gaap_DerivativeNotionalAmount_3bc89064-75a2-40b4-a451-4f381b771470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_a2525034-f39b-4a3e-99af-f3276f4b3ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a50480c9-e5e3-4971-87f3-ef9d022b4b77" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_a2525034-f39b-4a3e-99af-f3276f4b3ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2e2e4357-8125-4c60-8717-1a0a7215caf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_963c95ae-d333-461d-8672-f72721f9b5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2e2e4357-8125-4c60-8717-1a0a7215caf9" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_963c95ae-d333-461d-8672-f72721f9b5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6f5dbde2-5d83-4c2e-b8b5-b461ab335174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_963c95ae-d333-461d-8672-f72721f9b5fe" xlink:to="loc_us-gaap_HedgingDesignationAxis_6f5dbde2-5d83-4c2e-b8b5-b461ab335174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d5de5cec-f779-4d3a-9f6e-70c6a5d4eec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_6f5dbde2-5d83-4c2e-b8b5-b461ab335174" xlink:to="loc_us-gaap_HedgingDesignationDomain_d5de5cec-f779-4d3a-9f6e-70c6a5d4eec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f0cbaa21-7302-4628-ba7b-95504950ad7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_d5de5cec-f779-4d3a-9f6e-70c6a5d4eec4" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f0cbaa21-7302-4628-ba7b-95504950ad7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5b858a66-a610-4a75-bae9-e2319b3208aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_d5de5cec-f779-4d3a-9f6e-70c6a5d4eec4" xlink:to="loc_us-gaap_NondesignatedMember_5b858a66-a610-4a75-bae9-e2319b3208aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4ec16c4f-c1d5-4444-8b71-6947247fbe55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_963c95ae-d333-461d-8672-f72721f9b5fe" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4ec16c4f-c1d5-4444-8b71-6947247fbe55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e53e74a5-fc99-4c2b-a867-09cf599574c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4ec16c4f-c1d5-4444-8b71-6947247fbe55" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e53e74a5-fc99-4c2b-a867-09cf599574c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_f0a461b5-6b41-4220-b772-1e3a4cc3680a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e53e74a5-fc99-4c2b-a867-09cf599574c2" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_f0a461b5-6b41-4220-b772-1e3a4cc3680a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_efd8baf9-4291-4a5d-80ad-fb9ef318f9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e53e74a5-fc99-4c2b-a867-09cf599574c2" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_efd8baf9-4291-4a5d-80ad-fb9ef318f9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_2e65f6a1-7546-4c52-9373-5186aa515763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e53e74a5-fc99-4c2b-a867-09cf599574c2" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_2e65f6a1-7546-4c52-9373-5186aa515763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a1b8a3ea-393c-4a75-9203-7b4685e837d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e53e74a5-fc99-4c2b-a867-09cf599574c2" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a1b8a3ea-393c-4a75-9203-7b4685e837d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_fd48e4e3-4cf0-4765-bd33-db536427ab8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_963c95ae-d333-461d-8672-f72721f9b5fe" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_fd48e4e3-4cf0-4765-bd33-db536427ab8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_13b08b18-4060-4842-96c5-b90bf531d277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_fd48e4e3-4cf0-4765-bd33-db536427ab8f" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_13b08b18-4060-4842-96c5-b90bf531d277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_5f5faf4c-3fde-4c3a-b406-c75f39d57047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_fd48e4e3-4cf0-4765-bd33-db536427ab8f" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_5f5faf4c-3fde-4c3a-b406-c75f39d57047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_791babc1-16f2-4e5b-a89d-a9a8671e28de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_562259c5-50f3-412c-aca1-16069cf698ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_791babc1-16f2-4e5b-a89d-a9a8671e28de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_562259c5-50f3-412c-aca1-16069cf698ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_7e22fa9e-2749-4e4b-b595-804f7fa7cc30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_791babc1-16f2-4e5b-a89d-a9a8671e28de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_7e22fa9e-2749-4e4b-b595-804f7fa7cc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4e474906-2c2b-4aaf-b5dd-85176c7d5d64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_791babc1-16f2-4e5b-a89d-a9a8671e28de" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4e474906-2c2b-4aaf-b5dd-85176c7d5d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_96f02151-f626-43cc-b3de-43699ee7af52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract_c95bfbd8-518d-448c-a6d8-ea3e7bea937d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_96f02151-f626-43cc-b3de-43699ee7af52" xlink:to="loc_us-gaap_DerivativeAssetsAbstract_c95bfbd8-518d-448c-a6d8-ea3e7bea937d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8040f4f4-37cb-48a2-b8cb-463f03e6a797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_c95bfbd8-518d-448c-a6d8-ea3e7bea937d" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8040f4f4-37cb-48a2-b8cb-463f03e6a797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_b7792d40-6707-438b-a69b-cfd8ab799652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_c95bfbd8-518d-448c-a6d8-ea3e7bea937d" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_b7792d40-6707-438b-a69b-cfd8ab799652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_40e4fb23-f3e9-4a5f-8e6a-098fa967a81c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_c95bfbd8-518d-448c-a6d8-ea3e7bea937d" xlink:to="loc_us-gaap_DerivativeAssets_40e4fb23-f3e9-4a5f-8e6a-098fa967a81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_da3960b4-05dd-4fb4-b276-3a1500b8cfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_c95bfbd8-518d-448c-a6d8-ea3e7bea937d" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_da3960b4-05dd-4fb4-b276-3a1500b8cfd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_63b1c254-9f38-458a-9797-3685152abd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_c95bfbd8-518d-448c-a6d8-ea3e7bea937d" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_63b1c254-9f38-458a-9797-3685152abd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_6a75ac37-e8a0-4554-8917-a45245e52a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_c95bfbd8-518d-448c-a6d8-ea3e7bea937d" xlink:to="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_6a75ac37-e8a0-4554-8917-a45245e52a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract_ab956075-df1d-4747-9e96-2ad97e6847b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_96f02151-f626-43cc-b3de-43699ee7af52" xlink:to="loc_us-gaap_DerivativeLiabilitiesAbstract_ab956075-df1d-4747-9e96-2ad97e6847b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_53a4f201-e99f-4af5-8a4e-17580252b64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_ab956075-df1d-4747-9e96-2ad97e6847b4" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_53a4f201-e99f-4af5-8a4e-17580252b64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_6b928b0e-9c14-4e34-a590-f42cf79b10ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_ab956075-df1d-4747-9e96-2ad97e6847b4" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_6b928b0e-9c14-4e34-a590-f42cf79b10ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_afaf7a78-343b-4975-95c8-216acb5113e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_ab956075-df1d-4747-9e96-2ad97e6847b4" xlink:to="loc_us-gaap_DerivativeLiabilities_afaf7a78-343b-4975-95c8-216acb5113e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_dc827f28-dd4f-4e18-a781-9e0c0e0a38cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_ab956075-df1d-4747-9e96-2ad97e6847b4" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_dc827f28-dd4f-4e18-a781-9e0c0e0a38cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_977ee15d-4fe8-4695-ba06-4c894af48fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_ab956075-df1d-4747-9e96-2ad97e6847b4" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_977ee15d-4fe8-4695-ba06-4c894af48fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_2b7ebebc-bd56-4fca-ad37-ec7e6b223aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_ab956075-df1d-4747-9e96-2ad97e6847b4" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_2b7ebebc-bd56-4fca-ad37-ec7e6b223aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="gild-20210930.xsd#ACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0a03b577-f4ad-43ee-a13d-390427fa8fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f66a795c-7f6d-497f-a0aa-5f7573281713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0a03b577-f4ad-43ee-a13d-390427fa8fec" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f66a795c-7f6d-497f-a0aa-5f7573281713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="gild-20210930.xsd#ACQUISITIONSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ACQUISITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9b0757d6-5d45-4233-8546-0dfb4a0cb034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1ce4850d-22ab-4894-8cdb-441bb4ed2c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9b0757d6-5d45-4233-8546-0dfb4a0cb034" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1ce4850d-22ab-4894-8cdb-441bb4ed2c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8c9434c3-c844-405f-bc3d-77c136ed9748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8c9434c3-c844-405f-bc3d-77c136ed9748" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_94a3fc29-3150-4ac8-8951-19da26c26368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_94a3fc29-3150-4ac8-8951-19da26c26368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a6cd1c5b-f618-47b8-80a6-3be01c8a99ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_94a3fc29-3150-4ac8-8951-19da26c26368" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a6cd1c5b-f618-47b8-80a6-3be01c8a99ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_81f6ce5b-9e8e-47a8-88ff-fcb62998cac9" xlink:href="gild-20210930.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a6cd1c5b-f618-47b8-80a6-3be01c8a99ac" xlink:to="loc_gild_MYRGmbHMember_81f6ce5b-9e8e-47a8-88ff-fcb62998cac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_a5555aa7-531e-413c-90dc-cd3ea36c5fd6" xlink:href="gild-20210930.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a6cd1c5b-f618-47b8-80a6-3be01c8a99ac" xlink:to="loc_gild_ImmunomedicsIncMember_a5555aa7-531e-413c-90dc-cd3ea36c5fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4f2e2b5a-1ab4-4bbc-9448-37b7762e43eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4f2e2b5a-1ab4-4bbc-9448-37b7762e43eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ceaa413a-c4cc-4bd2-a1e3-cf29445af79d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4f2e2b5a-1ab4-4bbc-9448-37b7762e43eb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ceaa413a-c4cc-4bd2-a1e3-cf29445af79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a97bee6b-cea6-4aee-ac95-4d3254ad99c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ceaa413a-c4cc-4bd2-a1e3-cf29445af79d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a97bee6b-cea6-4aee-ac95-4d3254ad99c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f5b2cdc-bab0-4718-b6d5-8ad189b51862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f5b2cdc-bab0-4718-b6d5-8ad189b51862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7aa9c2e1-ca23-4b6f-8e3b-3c8530e369f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f5b2cdc-bab0-4718-b6d5-8ad189b51862" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7aa9c2e1-ca23-4b6f-8e3b-3c8530e369f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexForHDVMember_baa0a938-4790-4e35-937a-bd99299c0c16" xlink:href="gild-20210930.xsd#gild_HepcludexForHDVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7aa9c2e1-ca23-4b6f-8e3b-3c8530e369f4" xlink:to="loc_gild_HepcludexForHDVMember_baa0a938-4790-4e35-937a-bd99299c0c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f38b3191-6c39-496a-9ea9-98469c3dace4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_DebtInstrumentAxis_f38b3191-6c39-496a-9ea9-98469c3dace4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_85fcd240-20db-4f27-999d-156b3f47722e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f38b3191-6c39-496a-9ea9-98469c3dace4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_85fcd240-20db-4f27-999d-156b3f47722e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_be4dfc39-02d2-42ab-9bc2-37b74cd5c6e6" xlink:href="gild-20210930.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_85fcd240-20db-4f27-999d-156b3f47722e" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_be4dfc39-02d2-42ab-9bc2-37b74cd5c6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d000489b-f99d-4c11-865c-38aa3e79a678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d000489b-f99d-4c11-865c-38aa3e79a678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_45817684-4325-4e96-a9bf-02dc342993f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d000489b-f99d-4c11-865c-38aa3e79a678" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_45817684-4325-4e96-a9bf-02dc342993f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_2aad6db7-8877-4769-b44b-cf55ccce2161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_45817684-4325-4e96-a9bf-02dc342993f1" xlink:to="loc_us-gaap_MediumTermNotesMember_2aad6db7-8877-4769-b44b-cf55ccce2161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_12fd73d7-0028-49e8-86a2-82d1aaace3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_12fd73d7-0028-49e8-86a2-82d1aaace3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a975dc9c-990f-4e5e-ba13-da8e6289e000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_12fd73d7-0028-49e8-86a2-82d1aaace3f2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a975dc9c-990f-4e5e-ba13-da8e6289e000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_58623964-13c1-4146-9916-ca81212f0853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a975dc9c-990f-4e5e-ba13-da8e6289e000" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_58623964-13c1-4146-9916-ca81212f0853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6e16b0da-39dc-4fd0-876b-e03262cf8b15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_srt_RangeAxis_6e16b0da-39dc-4fd0-876b-e03262cf8b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d824bef-0f64-4d7a-96ed-a9273902fc65" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6e16b0da-39dc-4fd0-876b-e03262cf8b15" xlink:to="loc_srt_RangeMember_1d824bef-0f64-4d7a-96ed-a9273902fc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_90123f7e-6557-477e-96ed-83dffe0cc261" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1d824bef-0f64-4d7a-96ed-a9273902fc65" xlink:to="loc_srt_MaximumMember_90123f7e-6557-477e-96ed-83dffe0cc261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_d8d935f5-3cf1-494a-a43c-3f491b3ec446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_AssetAcquisitionAxis_d8d935f5-3cf1-494a-a43c-3f491b3ec446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c4c941f9-1cd2-445e-8a68-499ac3a2ee0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_d8d935f5-3cf1-494a-a43c-3f491b3ec446" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c4c941f9-1cd2-445e-8a68-499ac3a2ee0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_ad3b0dbb-cb7f-45e0-a865-2f76278dfb10" xlink:href="gild-20210930.xsd#gild_FortySevenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c4c941f9-1cd2-445e-8a68-499ac3a2ee0d" xlink:to="loc_gild_FortySevenIncMember_ad3b0dbb-cb7f-45e0-a865-2f76278dfb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_457420cd-dcee-45b7-9be9-b6af248ff98f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_457420cd-dcee-45b7-9be9-b6af248ff98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9089ca44-b3a1-4c4c-848a-761207ebe2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_457420cd-dcee-45b7-9be9-b6af248ff98f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9089ca44-b3a1-4c4c-848a-761207ebe2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b938d4bb-ce9a-488d-984f-184eea518f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9089ca44-b3a1-4c4c-848a-761207ebe2b1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b938d4bb-ce9a-488d-984f-184eea518f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_901d5a7c-1da8-48aa-8825-4c76b09608d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_901d5a7c-1da8-48aa-8825-4c76b09608d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ab624944-12b0-4c6c-b6d3-f16fb8fc74d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_901d5a7c-1da8-48aa-8825-4c76b09608d7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ab624944-12b0-4c6c-b6d3-f16fb8fc74d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_dabe0043-5f89-4b51-a4e5-d3be2688a8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ab624944-12b0-4c6c-b6d3-f16fb8fc74d8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_dabe0043-5f89-4b51-a4e5-d3be2688a8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_7a4d0fb2-d6a7-4589-8c98-4c1112b6cae7" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9e5a0445-3e99-4c13-a487-b8ee153087ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9e5a0445-3e99-4c13-a487-b8ee153087ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6cf199c1-4907-4cf7-9888-171bafa138b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6cf199c1-4907-4cf7-9888-171bafa138b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3437dfb9-5479-48ea-980c-315eb178a5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3437dfb9-5479-48ea-980c-315eb178a5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_6d2ba343-d8bb-4818-bcf6-38cf701bfc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_6d2ba343-d8bb-4818-bcf6-38cf701bfc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_4e7abd10-cd09-49a8-b216-305de7bca408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_4e7abd10-cd09-49a8-b216-305de7bca408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetMeasurementInput_60d555ca-a9ba-4b0d-8f2c-9545a9004310" xlink:href="gild-20210930.xsd#gild_IntangibleAssetMeasurementInput"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_gild_IntangibleAssetMeasurementInput_60d555ca-a9ba-4b0d-8f2c-9545a9004310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8ba309a2-e1f1-4640-9e0e-ce700484ce22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8ba309a2-e1f1-4640-9e0e-ce700484ce22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_10d606b9-612c-417f-8fbb-274cf284ac62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_10d606b9-612c-417f-8fbb-274cf284ac62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_1438a203-d0ad-4d1e-8af5-c577dba02699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_GoodwillGross_1438a203-d0ad-4d1e-8af5-c577dba02699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_b9204395-38b1-4ac3-b09f-86b27af422ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_b9204395-38b1-4ac3-b09f-86b27af422ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_50d39bf5-acd3-42d7-85c3-805c280d64db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_50d39bf5-acd3-42d7-85c3-805c280d64db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired_bcf5fd0d-1ca7-4eab-a074-af14e2e1b2d8" xlink:href="gild-20210930.xsd#gild_PaymentsToAcquireAssetsNetOfCashAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired_bcf5fd0d-1ca7-4eab-a074-af14e2e1b2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_21ff5368-76fc-473d-9701-cce43155ac24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_6feae24c-4909-42d3-87db-e1efe5b2d975" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_21ff5368-76fc-473d-9701-cce43155ac24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3db7f1fb-7bdf-44c5-ac73-46c2580f426e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_fe7b57da-d641-41c6-a653-829d2becf87d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3db7f1fb-7bdf-44c5-ac73-46c2580f426e" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_fe7b57da-d641-41c6-a653-829d2becf87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_74256089-f77d-4b62-9cba-66a42210ae24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_fe7b57da-d641-41c6-a653-829d2becf87d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_74256089-f77d-4b62-9cba-66a42210ae24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a05707d2-7603-4339-b059-0b42105e4d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_74256089-f77d-4b62-9cba-66a42210ae24" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a05707d2-7603-4339-b059-0b42105e4d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_2e6dca0a-fe54-472a-a87e-af9bebb8c19e" xlink:href="gild-20210930.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a05707d2-7603-4339-b059-0b42105e4d7e" xlink:to="loc_gild_MYRGmbHMember_2e6dca0a-fe54-472a-a87e-af9bebb8c19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_45caeaec-b810-4d80-a091-f507623552b1" xlink:href="gild-20210930.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a05707d2-7603-4339-b059-0b42105e4d7e" xlink:to="loc_gild_ImmunomedicsIncMember_45caeaec-b810-4d80-a091-f507623552b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c434c632-5f8c-4567-9d91-00792d0681fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_fe7b57da-d641-41c6-a653-829d2becf87d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c434c632-5f8c-4567-9d91-00792d0681fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c2e220c-3014-4bd2-8a20-fb622ab142a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c434c632-5f8c-4567-9d91-00792d0681fa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c2e220c-3014-4bd2-8a20-fb622ab142a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyForMTNBCMember_2c90607e-0040-44f4-8da1-7b560b93db0b" xlink:href="gild-20210930.xsd#gild_TrodelvyForMTNBCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c2e220c-3014-4bd2-8a20-fb622ab142a1" xlink:to="loc_gild_TrodelvyForMTNBCMember_2c90607e-0040-44f4-8da1-7b560b93db0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_9e745140-04ce-4380-bd4b-848027cbde21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c2e220c-3014-4bd2-8a20-fb622ab142a1" xlink:to="loc_us-gaap_LicensingAgreementsMember_9e745140-04ce-4380-bd4b-848027cbde21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a3d5cd9e-ad10-4325-b8bc-5018a0265fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_fe7b57da-d641-41c6-a653-829d2becf87d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a3d5cd9e-ad10-4325-b8bc-5018a0265fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_def79baa-51d0-4d4d-a0b7-5835fc131af4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a3d5cd9e-ad10-4325-b8bc-5018a0265fad" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_def79baa-51d0-4d4d-a0b7-5835fc131af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_0bb7f6e0-d6e3-4753-8817-7d7db1ceeb33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_def79baa-51d0-4d4d-a0b7-5835fc131af4" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_0bb7f6e0-d6e3-4753-8817-7d7db1ceeb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_fe7b57da-d641-41c6-a653-829d2becf87d" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_71c10f09-0ad2-437e-9943-fb95bfd35d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_71c10f09-0ad2-437e-9943-fb95bfd35d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_55c06a35-3e14-4e0a-8d13-cfef7d2ce760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_55c06a35-3e14-4e0a-8d13-cfef7d2ce760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_415e2c13-e03b-4084-9828-8c327f0724ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_415e2c13-e03b-4084-9828-8c327f0724ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_20ac2424-d1a3-4d32-b074-1a8767e82c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_415e2c13-e03b-4084-9828-8c327f0724ea" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_20ac2424-d1a3-4d32-b074-1a8767e82c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_05e8a827-92f5-4fb2-98ed-21ff5bccb4df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_415e2c13-e03b-4084-9828-8c327f0724ea" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_05e8a827-92f5-4fb2-98ed-21ff5bccb4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3f1cfbd3-f60c-4e6a-b5ae-680bdf6e70cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3f1cfbd3-f60c-4e6a-b5ae-680bdf6e70cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_1ab8f4eb-d217-4637-aeb5-0babf7de7be7" xlink:href="gild-20210930.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_1ab8f4eb-d217-4637-aeb5-0babf7de7be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_28b165b5-9571-4342-b162-91332ec6d567" xlink:href="gild-20210930.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_28b165b5-9571-4342-b162-91332ec6d567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e21a71b1-f8d0-4017-b7d5-c2ba13f3b3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e21a71b1-f8d0-4017-b7d5-c2ba13f3b3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_f68110ed-b537-48cd-823c-8390a6b6ca19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_us-gaap_GoodwillGross_f68110ed-b537-48cd-823c-8390a6b6ca19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9ab2de3d-55d4-459b-9cec-27a263dabeef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_48b5b97d-cd38-493f-b655-92855b1526fb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9ab2de3d-55d4-459b-9cec-27a263dabeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="simple" xlink:href="gild-20210930.xsd#GOODWILLANDINTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_47507529-0f2a-4fa2-9e3f-2d7d803a2c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_714af18b-3126-4025-9f70-9d5c692439ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_47507529-0f2a-4fa2-9e3f-2d7d803a2c57" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_714af18b-3126-4025-9f70-9d5c692439ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="gild-20210930.xsd#GOODWILLANDINTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cc6a62f9-0238-418b-93c5-690bdbbaedfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_b22ef0e1-98d2-4e75-a071-94db3673594b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cc6a62f9-0238-418b-93c5-690bdbbaedfa" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_b22ef0e1-98d2-4e75-a071-94db3673594b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_b8b00d39-543a-4bb3-9c30-3bb4a17b4363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cc6a62f9-0238-418b-93c5-690bdbbaedfa" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_b8b00d39-543a-4bb3-9c30-3bb4a17b4363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_bc87d8b5-bc2a-47ae-b708-0df0b4c61b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cc6a62f9-0238-418b-93c5-690bdbbaedfa" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_bc87d8b5-bc2a-47ae-b708-0df0b4c61b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f98e5ecc-828e-42f3-b3cd-47edf492df2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cc6a62f9-0238-418b-93c5-690bdbbaedfa" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f98e5ecc-828e-42f3-b3cd-47edf492df2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#GOODWILLANDINTANGIBLEASSETSGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6fb13cf5-c1ac-4a12-933c-9f8dd8f76c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_623a2d2a-0c6a-43c6-a378-b49c915abdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6fb13cf5-c1ac-4a12-933c-9f8dd8f76c8f" xlink:to="loc_us-gaap_GoodwillRollForward_623a2d2a-0c6a-43c6-a378-b49c915abdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_237d0f3e-804f-45b1-b6eb-0ac8abb1f8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_623a2d2a-0c6a-43c6-a378-b49c915abdbf" xlink:to="loc_us-gaap_Goodwill_237d0f3e-804f-45b1-b6eb-0ac8abb1f8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_c29a22d0-1bdb-436e-89a3-9c22d619cd12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_623a2d2a-0c6a-43c6-a378-b49c915abdbf" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_c29a22d0-1bdb-436e-89a3-9c22d619cd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_ee2d1773-13ec-49e9-8054-2d7447533d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_623a2d2a-0c6a-43c6-a378-b49c915abdbf" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_ee2d1773-13ec-49e9-8054-2d7447533d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a2b456ca-a9af-46f2-af6b-fc8c12c86ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_623a2d2a-0c6a-43c6-a378-b49c915abdbf" xlink:to="loc_us-gaap_Goodwill_a2b456ca-a9af-46f2-af6b-fc8c12c86ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0ab16137-0e87-4f16-b186-5b82ee132e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f625b4f7-0bb0-459b-9b87-997e989704ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0ab16137-0e87-4f16-b186-5b82ee132e39" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f625b4f7-0bb0-459b-9b87-997e989704ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4c7c17e1-aa6b-470c-904a-1073ca48bfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f625b4f7-0bb0-459b-9b87-997e989704ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4c7c17e1-aa6b-470c-904a-1073ca48bfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4c7c17e1-aa6b-470c-904a-1073ca48bfd1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember_2348c0fe-d750-4728-aa38-7cfb0f233981" xlink:href="gild-20210930.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:to="loc_gild_IntangibleAssetSofosbuvirMember_2348c0fe-d750-4728-aa38-7cfb0f233981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember_44df7c46-b36d-46e8-bfb2-f875e2a3e724" xlink:href="gild-20210930.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:to="loc_gild_AxicabtageneciloleucelDLBCLMember_44df7c46-b36d-46e8-bfb2-f875e2a3e724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_3edf182f-5d4f-4571-9353-7c16733ed052" xlink:href="gild-20210930.xsd#gild_TrodelvyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:to="loc_gild_TrodelvyMember_3edf182f-5d4f-4571-9353-7c16733ed052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexForHDVMember_3715e2e0-7846-4708-ac58-c359f1d21edd" xlink:href="gild-20210930.xsd#gild_HepcludexForHDVMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:to="loc_gild_HepcludexForHDVMember_3715e2e0-7846-4708-ac58-c359f1d21edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_e9245a48-68be-4e7a-a11a-9c0b5ea33ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_e9245a48-68be-4e7a-a11a-9c0b5ea33ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember_cd7a4d47-e56b-49c1-9c20-9b857dae2a56" xlink:href="gild-20210930.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2414433c-c1f1-428d-934c-732f1b4bea7f" xlink:to="loc_gild_CellTherapyProductsTecartusMember_cd7a4d47-e56b-49c1-9c20-9b857dae2a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ca84ee67-0c55-4381-8664-5106ad9a03cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f625b4f7-0bb0-459b-9b87-997e989704ba" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ca84ee67-0c55-4381-8664-5106ad9a03cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e028ba6-b9c0-4ce0-b1fe-72ab1fb87752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ca84ee67-0c55-4381-8664-5106ad9a03cd" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e028ba6-b9c0-4ce0-b1fe-72ab1fb87752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_1040f977-80ce-43da-8566-c98f08c602ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e028ba6-b9c0-4ce0-b1fe-72ab1fb87752" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_1040f977-80ce-43da-8566-c98f08c602ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_259ed976-081d-42c6-938e-cd869eaa7ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f625b4f7-0bb0-459b-9b87-997e989704ba" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_259ed976-081d-42c6-938e-cd869eaa7ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de5acc1a-542a-46a2-aa2d-d60c3d25752a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_259ed976-081d-42c6-938e-cd869eaa7ff6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de5acc1a-542a-46a2-aa2d-d60c3d25752a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_7788a720-2091-4c62-9b5d-1069f7a6379a" xlink:href="gild-20210930.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de5acc1a-542a-46a2-aa2d-d60c3d25752a" xlink:to="loc_gild_MYRGmbHMember_7788a720-2091-4c62-9b5d-1069f7a6379a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_78df642f-ecd4-47b1-97d9-883120f77445" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f625b4f7-0bb0-459b-9b87-997e989704ba" xlink:to="loc_srt_StatementScenarioAxis_78df642f-ecd4-47b1-97d9-883120f77445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b3529761-c673-4dcd-ac1e-4ae118fa9f7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_78df642f-ecd4-47b1-97d9-883120f77445" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b3529761-c673-4dcd-ac1e-4ae118fa9f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_77a1e83d-09a5-4b04-bc48-a5c4eb3b11ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_b3529761-c673-4dcd-ac1e-4ae118fa9f7e" xlink:to="loc_srt_ScenarioForecastMember_77a1e83d-09a5-4b04-bc48-a5c4eb3b11ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_48b81c5c-08b8-49bc-8341-8d0d9c34bc38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f625b4f7-0bb0-459b-9b87-997e989704ba" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_48b81c5c-08b8-49bc-8341-8d0d9c34bc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_65c55c51-cd7f-4b93-8732-bd705c3abbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_48b81c5c-08b8-49bc-8341-8d0d9c34bc38" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_65c55c51-cd7f-4b93-8732-bd705c3abbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f788f60f-176c-42fe-b76a-3cdb71058411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_65c55c51-cd7f-4b93-8732-bd705c3abbd2" xlink:to="loc_us-gaap_SubsequentEventMember_f788f60f-176c-42fe-b76a-3cdb71058411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f625b4f7-0bb0-459b-9b87-997e989704ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5abec81a-147b-4eec-9b68-5f923b30eed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5abec81a-147b-4eec-9b68-5f923b30eed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9fdb478a-a999-4f04-b696-5e3cf5546ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9fdb478a-a999-4f04-b696-5e3cf5546ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_5ac8f253-84f9-4cb0-af15-d867d69f29d6" xlink:href="gild-20210930.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_5ac8f253-84f9-4cb0-af15-d867d69f29d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aeac85cc-b026-44f0-ae1c-daa9fe92a0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aeac85cc-b026-44f0-ae1c-daa9fe92a0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac6dce0e-51e8-4e6d-acf0-718fa7fcaade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac6dce0e-51e8-4e6d-acf0-718fa7fcaade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_408e858b-1efb-43b7-af30-d1bc6ae26ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac6dce0e-51e8-4e6d-acf0-718fa7fcaade" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_408e858b-1efb-43b7-af30-d1bc6ae26ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_e3d03778-43ed-46d8-995a-5e3713c91124" xlink:href="gild-20210930.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac6dce0e-51e8-4e6d-acf0-718fa7fcaade" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_e3d03778-43ed-46d8-995a-5e3713c91124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_d2f914c4-0149-4b2b-87d0-d44f6ff4a199" xlink:href="gild-20210930.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac6dce0e-51e8-4e6d-acf0-718fa7fcaade" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_d2f914c4-0149-4b2b-87d0-d44f6ff4a199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_74cf751a-01a1-4251-acda-3087f328fda3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_74cf751a-01a1-4251-acda-3087f328fda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_23842d6e-4dfe-4792-a07f-be2fe9e369a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_74cf751a-01a1-4251-acda-3087f328fda3" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_23842d6e-4dfe-4792-a07f-be2fe9e369a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ebe51acb-5270-41de-81ab-b898ad1ec6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_74cf751a-01a1-4251-acda-3087f328fda3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ebe51acb-5270-41de-81ab-b898ad1ec6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_741a717a-7907-4ae8-b8a8-cb896276f2b0" xlink:href="gild-20210930.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_74cf751a-01a1-4251-acda-3087f328fda3" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_741a717a-7907-4ae8-b8a8-cb896276f2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_64df8d90-8acf-44dd-8ab0-8584cafe27a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_74cf751a-01a1-4251-acda-3087f328fda3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_64df8d90-8acf-44dd-8ab0-8584cafe27a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_12281629-5d42-40bb-ba68-8845f8a36425" xlink:href="gild-20210930.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_12281629-5d42-40bb-ba68-8845f8a36425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_635fad9d-14ee-4b16-9733-91493e88606e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_15a1733a-a0fa-4911-bd51-cdad366a6f69" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_635fad9d-14ee-4b16-9733-91493e88606e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="gild-20210930.xsd#GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3f0d261-180b-475f-9adc-412b6d91b819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_58a4baf5-f237-4ac1-a696-c132784f0843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3f0d261-180b-475f-9adc-412b6d91b819" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_58a4baf5-f237-4ac1-a696-c132784f0843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_74a3645c-f5b7-412d-84e9-ac02d3cf1187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e348a7b5-546f-4434-9d73-e87e79335e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_74a3645c-f5b7-412d-84e9-ac02d3cf1187" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e348a7b5-546f-4434-9d73-e87e79335e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5c7c9a57-ec54-4dcb-ab43-20224d27fd40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_74a3645c-f5b7-412d-84e9-ac02d3cf1187" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5c7c9a57-ec54-4dcb-ab43-20224d27fd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fa7389c1-f1b7-4c91-bdec-1474688f249d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_74a3645c-f5b7-412d-84e9-ac02d3cf1187" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fa7389c1-f1b7-4c91-bdec-1474688f249d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_999329da-6f8b-4790-92b5-f6a77d6a2fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_74a3645c-f5b7-412d-84e9-ac02d3cf1187" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_999329da-6f8b-4790-92b5-f6a77d6a2fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ca263d74-0b57-436b-a1ac-121cbdd07a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_74a3645c-f5b7-412d-84e9-ac02d3cf1187" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ca263d74-0b57-436b-a1ac-121cbdd07a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_6ecdc3e9-2085-47e1-9458-7fbcb9a57221" xlink:href="gild-20210930.xsd#gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_74a3645c-f5b7-412d-84e9-ac02d3cf1187" xlink:to="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_6ecdc3e9-2085-47e1-9458-7fbcb9a57221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3c122747-830c-4da8-aa0d-6e5e1f73778a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_74a3645c-f5b7-412d-84e9-ac02d3cf1187" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3c122747-830c-4da8-aa0d-6e5e1f73778a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATION" xlink:type="simple" xlink:href="gild-20210930.xsd#OTHERFINANCIALINFORMATION"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_5addf313-6241-4d85-894c-839d17c22758" xlink:href="gild-20210930.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_9b5049f2-24a2-4f58-b2c3-02d43e21214f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_5addf313-6241-4d85-894c-839d17c22758" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_9b5049f2-24a2-4f58-b2c3-02d43e21214f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="gild-20210930.xsd#OTHERFINANCIALINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_d33172ca-0ed6-407c-829f-ee0c13ead5f4" xlink:href="gild-20210930.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_7a7a848f-d1a9-4a43-a99e-5f9c2df9b423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d33172ca-0ed6-407c-829f-ee0c13ead5f4" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_7a7a848f-d1a9-4a43-a99e-5f9c2df9b423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1e9cd170-9349-4d14-a185-8ffeb1884770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d33172ca-0ed6-407c-829f-ee0c13ead5f4" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1e9cd170-9349-4d14-a185-8ffeb1884770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5fa6f42b-989b-4189-a786-71967da05beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d33172ca-0ed6-407c-829f-ee0c13ead5f4" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5fa6f42b-989b-4189-a786-71967da05beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_b1de8c37-b935-4285-8d03-4e272b88b8b3" xlink:href="gild-20210930.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_6999089e-eac0-4361-9207-6c36f262c6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_b1de8c37-b935-4285-8d03-4e272b88b8b3" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_6999089e-eac0-4361-9207-6c36f262c6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent_1c5062ff-bd50-4900-88ce-3b3a4e46604c" xlink:href="gild-20210930.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_b1de8c37-b935-4285-8d03-4e272b88b8b3" xlink:to="loc_gild_AccountsReceivableChargebacksCurrent_1c5062ff-bd50-4900-88ce-3b3a4e46604c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_b8cc1fc4-72d5-4ab9-9ef1-1641dfab6507" xlink:href="gild-20210930.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_b1de8c37-b935-4285-8d03-4e272b88b8b3" xlink:to="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_b8cc1fc4-72d5-4ab9-9ef1-1641dfab6507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_34cb2f14-6579-4a41-a46a-ba149761b852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_b1de8c37-b935-4285-8d03-4e272b88b8b3" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_34cb2f14-6579-4a41-a46a-ba149761b852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a6c2edd6-1db2-42a4-925a-5e64324425f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_b1de8c37-b935-4285-8d03-4e272b88b8b3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a6c2edd6-1db2-42a4-925a-5e64324425f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#OTHERFINANCIALINFORMATIONInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_31f94103-635c-4679-ad63-599759fe0eaf" xlink:href="gild-20210930.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e5e9e35f-b60a-4a66-8117-5dbafca8608e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_31f94103-635c-4679-ad63-599759fe0eaf" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e5e9e35f-b60a-4a66-8117-5dbafca8608e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_798edf64-b724-408d-86eb-8c9537382cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_31f94103-635c-4679-ad63-599759fe0eaf" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_798edf64-b724-408d-86eb-8c9537382cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_1c892d22-0951-4635-8e2a-0fe55f999c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_31f94103-635c-4679-ad63-599759fe0eaf" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_1c892d22-0951-4635-8e2a-0fe55f999c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_9571bc00-b6f7-4c26-99b5-758fedd1d23f" xlink:href="gild-20210930.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_31f94103-635c-4679-ad63-599759fe0eaf" xlink:to="loc_gild_InventoryNetAndInventoryNoncurrent_9571bc00-b6f7-4c26-99b5-758fedd1d23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0bebe604-fcef-49e9-95f4-fa8cebd1d4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_31f94103-635c-4679-ad63-599759fe0eaf" xlink:to="loc_us-gaap_InventoryNet_0bebe604-fcef-49e9-95f4-fa8cebd1d4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_4381afb4-9deb-4432-ab67-3a91b35391f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_31f94103-635c-4679-ad63-599759fe0eaf" xlink:to="loc_us-gaap_InventoryNoncurrent_4381afb4-9deb-4432-ab67-3a91b35391f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_3e47071c-3406-4132-94e6-ae35d921e65a" xlink:href="gild-20210930.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1" xlink:type="simple" xlink:href="gild-20210930.xsd#OTHERFINANCIALINFORMATIONInventoriesDetails_1"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_34f10b4f-715e-413a-841b-8ea4d51eedb1" xlink:href="gild-20210930.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3bc6b2e5-4729-4f8e-a7df-0e400fac148d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_34f10b4f-715e-413a-841b-8ea4d51eedb1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3bc6b2e5-4729-4f8e-a7df-0e400fac148d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_ee728ff3-b9cd-4768-9416-c789b15ad0de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_34f10b4f-715e-413a-841b-8ea4d51eedb1" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_ee728ff3-b9cd-4768-9416-c789b15ad0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_b1139fcd-eb68-41bb-b3b4-4b4a523b84a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_34f10b4f-715e-413a-841b-8ea4d51eedb1" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_b1139fcd-eb68-41bb-b3b4-4b4a523b84a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8377aff7-5666-4bdd-9368-fe0c6694ab21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_34f10b4f-715e-413a-841b-8ea4d51eedb1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8377aff7-5666-4bdd-9368-fe0c6694ab21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d1583bbc-e1f2-4dd3-97ee-ff3a608822d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_34f10b4f-715e-413a-841b-8ea4d51eedb1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d1583bbc-e1f2-4dd3-97ee-ff3a608822d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS" xlink:type="simple" xlink:href="gild-20210930.xsd#COLLABORATIONSANDOTHERARRANGEMENTS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsAbstract_6b78a9e1-70e9-46ed-af29-0dda5bca0a39" xlink:href="gild-20210930.xsd#gild_CollaborativeandOtherArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAndOtherArrangementsTextBlock_1732184d-f2b9-4820-8971-d4a32f00d2bd" xlink:href="gild-20210930.xsd#gild_CollaborativeAndOtherArrangementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CollaborativeandOtherArrangementsAbstract_6b78a9e1-70e9-46ed-af29-0dda5bca0a39" xlink:to="loc_gild_CollaborativeAndOtherArrangementsTextBlock_1732184d-f2b9-4820-8971-d4a32f00d2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#COLLABORATIONSANDOTHERARRANGEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsAbstract_8a91c573-b1c1-40c7-a14a-d1a7a0d6c7d4" xlink:href="gild-20210930.xsd#gild_CollaborativeandOtherArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f48bef7f-1bf7-42ca-b550-5d5567a980ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CollaborativeandOtherArrangementsAbstract_8a91c573-b1c1-40c7-a14a-d1a7a0d6c7d4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f48bef7f-1bf7-42ca-b550-5d5567a980ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c6af447-bf2d-4ef2-be38-f5f7c4980205" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f48bef7f-1bf7-42ca-b550-5d5567a980ad" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c6af447-bf2d-4ef2-be38-f5f7c4980205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_79ae0f68-6fe3-4acb-9f05-f02f5f42977c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c6af447-bf2d-4ef2-be38-f5f7c4980205" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_79ae0f68-6fe3-4acb-9f05-f02f5f42977c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_9f904396-1f6f-4fcb-a729-45ad88407f5b" xlink:href="gild-20210930.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_79ae0f68-6fe3-4acb-9f05-f02f5f42977c" xlink:to="loc_gild_ArcusBiosciencesIncMember_9f904396-1f6f-4fcb-a729-45ad88407f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4ed51a0c-44c1-4b02-8ab2-955bd4ac7051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f48bef7f-1bf7-42ca-b550-5d5567a980ad" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4ed51a0c-44c1-4b02-8ab2-955bd4ac7051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd64f763-5f72-41b5-a9f8-f5a0be281980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4ed51a0c-44c1-4b02-8ab2-955bd4ac7051" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd64f763-5f72-41b5-a9f8-f5a0be281980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_04cc9ec7-7c60-4ca8-b47e-c06beefe04de" xlink:href="gild-20210930.xsd#gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd64f763-5f72-41b5-a9f8-f5a0be281980" xlink:to="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_04cc9ec7-7c60-4ca8-b47e-c06beefe04de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusStockPurchaseAgreementMember_d74d849f-8367-4a21-b3ad-aece72ac7001" xlink:href="gild-20210930.xsd#gild_ArcusStockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd64f763-5f72-41b5-a9f8-f5a0be281980" xlink:to="loc_gild_ArcusStockPurchaseAgreementMember_d74d849f-8367-4a21-b3ad-aece72ac7001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember_469f92be-16f9-4090-a7b2-d74515815ca8" xlink:href="gild-20210930.xsd#gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd64f763-5f72-41b5-a9f8-f5a0be281980" xlink:to="loc_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember_469f92be-16f9-4090-a7b2-d74515815ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherCollaborationArrangementsMember_63d5a119-4e2e-4e2a-996f-037c85cf1955" xlink:href="gild-20210930.xsd#gild_OtherCollaborationArrangementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd64f763-5f72-41b5-a9f8-f5a0be281980" xlink:to="loc_gild_OtherCollaborationArrangementsMember_63d5a119-4e2e-4e2a-996f-037c85cf1955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_f447fee1-357b-4d83-b971-05004b3b03ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f48bef7f-1bf7-42ca-b550-5d5567a980ad" xlink:to="loc_srt_OwnershipAxis_f447fee1-357b-4d83-b971-05004b3b03ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1398fed7-e834-4cff-aa76-770650c293b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_f447fee1-357b-4d83-b971-05004b3b03ec" xlink:to="loc_srt_OwnershipDomain_1398fed7-e834-4cff-aa76-770650c293b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_82f2fdce-6939-42f3-a5b8-cc9f371e1831" xlink:href="gild-20210930.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1398fed7-e834-4cff-aa76-770650c293b6" xlink:to="loc_gild_ArcusBiosciencesIncMember_82f2fdce-6939-42f3-a5b8-cc9f371e1831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2d26956c-567a-4060-ab59-c2deef6583ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f48bef7f-1bf7-42ca-b550-5d5567a980ad" xlink:to="loc_srt_ProductOrServiceAxis_2d26956c-567a-4060-ab59-c2deef6583ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dd6b40f2-91e3-42fe-97aa-b4e95abaefc8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2d26956c-567a-4060-ab59-c2deef6583ba" xlink:to="loc_srt_ProductsAndServicesDomain_dd6b40f2-91e3-42fe-97aa-b4e95abaefc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OralFormulationProductMember_96965f37-4f88-4795-9c3c-817acd1347dc" xlink:href="gild-20210930.xsd#gild_OralFormulationProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dd6b40f2-91e3-42fe-97aa-b4e95abaefc8" xlink:to="loc_gild_OralFormulationProductMember_96965f37-4f88-4795-9c3c-817acd1347dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InjectableFormulationProductMember_b4ab468a-2831-43ba-b7ed-35c21c5aed1e" xlink:href="gild-20210930.xsd#gild_InjectableFormulationProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dd6b40f2-91e3-42fe-97aa-b4e95abaefc8" xlink:to="loc_gild_InjectableFormulationProductMember_b4ab468a-2831-43ba-b7ed-35c21c5aed1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_858cafad-fbd9-49b2-8add-d070456f7e42" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f48bef7f-1bf7-42ca-b550-5d5567a980ad" xlink:to="loc_dei_LegalEntityAxis_858cafad-fbd9-49b2-8add-d070456f7e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_928356b9-c3ee-4794-8551-6ccb1395c6dd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_858cafad-fbd9-49b2-8add-d070456f7e42" xlink:to="loc_dei_EntityDomain_928356b9-c3ee-4794-8551-6ccb1395c6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckMember_ffb19fa5-9b3e-4c2a-899c-59dac3e8a3b2" xlink:href="gild-20210930.xsd#gild_MerckMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_928356b9-c3ee-4794-8551-6ccb1395c6dd" xlink:to="loc_gild_MerckMember_ffb19fa5-9b3e-4c2a-899c-59dac3e8a3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f48bef7f-1bf7-42ca-b550-5d5567a980ad" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_e9f78d1a-ad69-4708-a7cc-4a59a1a590f6" xlink:href="gild-20210930.xsd#gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_e9f78d1a-ad69-4708-a7cc-4a59a1a590f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementNetProductSalesThreshold_9007a29a-bff9-4e95-987b-b39d05748ad1" xlink:href="gild-20210930.xsd#gild_CollaborationArrangementNetProductSalesThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_CollaborationArrangementNetProductSalesThreshold_9007a29a-bff9-4e95-987b-b39d05748ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_66f9cae8-bbe3-4515-ba69-220f8707e9f9" xlink:href="gild-20210930.xsd#gild_CollaborationArrangementPercentOfGlobalProductRevenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_66f9cae8-bbe3-4515-ba69-220f8707e9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_3ac03974-bd54-4743-a8eb-827720cacfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_3ac03974-bd54-4743-a8eb-827720cacfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_2485b42c-1ce7-4b25-b4ba-7322cfe47db4" xlink:href="gild-20210930.xsd#gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_2485b42c-1ce7-4b25-b4ba-7322cfe47db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIPurchasePeriod_debd40fc-3fc4-47e3-afa6-ca1c04a197aa" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesFVNIPurchasePeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_EquitySecuritiesFVNIPurchasePeriod_debd40fc-3fc4-47e3-afa6-ca1c04a197aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_773285a8-9141-42f5-ba72-bed69c4875ed" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_773285a8-9141-42f5-ba72-bed69c4875ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_0875433f-bd1c-4bbf-b37a-bf2f5667d1e4" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesFVNIRestrictionPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_0875433f-bd1c-4bbf-b37a-bf2f5667d1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNISharesAcquired_77d485c3-0e78-4ac0-80b5-3f037612957e" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesFVNISharesAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_EquitySecuritiesFVNISharesAcquired_77d485c3-0e78-4ac0-80b5-3f037612957e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_833e83be-fb32-4002-9912-9163656b67bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_833e83be-fb32-4002-9912-9163656b67bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIShares_d17a466f-3397-4134-9ebe-0ae0a3ce72ef" xlink:href="gild-20210930.xsd#gild_EquitySecuritiesFVNIShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_EquitySecuritiesFVNIShares_d17a466f-3397-4134-9ebe-0ae0a3ce72ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_53f78c9c-40c3-44d4-9313-e26a78f026cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_53f78c9c-40c3-44d4-9313-e26a78f026cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_f3a3015b-d64c-4aa2-b7d4-12fa262fbeed" xlink:href="gild-20210930.xsd#gild_CashPaymentsMadeRelatedToEquityInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_f3a3015b-d64c-4aa2-b7d4-12fa262fbeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements_89e58976-0123-4741-88b2-89e60ac3017f" xlink:href="gild-20210930.xsd#gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9160d366-6259-49c3-93ce-5c5b5fe61fbc" xlink:to="loc_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements_89e58976-0123-4741-88b2-89e60ac3017f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIES" xlink:type="simple" xlink:href="gild-20210930.xsd#DEBTANDCREDITFACILITIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_95443b7d-c823-4f65-9c6a-4fab1a5f0dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_59601612-88cc-4a22-8a29-1fe2d56a8d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_95443b7d-c823-4f65-9c6a-4fab1a5f0dfc" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_59601612-88cc-4a22-8a29-1fe2d56a8d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables" xlink:type="simple" xlink:href="gild-20210930.xsd#DEBTANDCREDITFACILITIESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_50437a3f-1408-4a66-8739-a7b3c104d76e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_25a463ec-5f04-4e1c-95c2-885d0a9a78a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_50437a3f-1408-4a66-8739-a7b3c104d76e" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_25a463ec-5f04-4e1c-95c2-885d0a9a78a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_eeab195e-a879-4769-b5e1-d1f44874b6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b1809c63-af37-4cf1-9e1e-f664e34353c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_eeab195e-a879-4769-b5e1-d1f44874b6e2" xlink:to="loc_us-gaap_DebtInstrumentTable_b1809c63-af37-4cf1-9e1e-f664e34353c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d239fff3-c43c-4b78-a07d-240b5a46208b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b1809c63-af37-4cf1-9e1e-f664e34353c0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d239fff3-c43c-4b78-a07d-240b5a46208b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_db4a8809-8d92-462e-a2a7-cdda084ae3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d239fff3-c43c-4b78-a07d-240b5a46208b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_db4a8809-8d92-462e-a2a7-cdda084ae3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember_30cfdf34-5961-4a41-9efa-b503787f8662" xlink:href="gild-20210930.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_db4a8809-8d92-462e-a2a7-cdda084ae3ed" xlink:to="loc_gild_SeniorNotesAndMediumTermNotesMember_30cfdf34-5961-4a41-9efa-b503787f8662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e5604989-0d8e-44d0-84c5-05d9561efd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember_30cfdf34-5961-4a41-9efa-b503787f8662" xlink:to="loc_us-gaap_SeniorNotesMember_e5604989-0d8e-44d0-84c5-05d9561efd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_e7339889-d776-472f-9786-5239dcf7871d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember_30cfdf34-5961-4a41-9efa-b503787f8662" xlink:to="loc_us-gaap_MediumTermNotesMember_e7339889-d776-472f-9786-5239dcf7871d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_b386f38a-c98d-4208-962c-b86845a9912e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_db4a8809-8d92-462e-a2a7-cdda084ae3ed" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_b386f38a-c98d-4208-962c-b86845a9912e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1d5cbbab-ad6d-4b0c-b6e7-dda21b4b354a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b1809c63-af37-4cf1-9e1e-f664e34353c0" xlink:to="loc_us-gaap_DebtInstrumentAxis_1d5cbbab-ad6d-4b0c-b6e7-dda21b4b354a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1d5cbbab-ad6d-4b0c-b6e7-dda21b4b354a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member_999886d3-dafd-420e-bc7f-3a8965c83205" xlink:href="gild-20210930.xsd#gild_A450SeniorUnsecuredNotesDueApril2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member_999886d3-dafd-420e-bc7f-3a8965c83205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_159a92e5-b173-4895-8c8d-abfaa6a8d952" xlink:href="gild-20210930.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_159a92e5-b173-4895-8c8d-abfaa6a8d952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member_669d1bbf-c3b3-46f8-97f8-cd4832e44e45" xlink:href="gild-20210930.xsd#gild_A440SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member_669d1bbf-c3b3-46f8-97f8-cd4832e44e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_cd0d1b78-af3f-4121-95c2-ac730b90042b" xlink:href="gild-20210930.xsd#gild_A195SeniorUnsecuredNotesDueMarch2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_cd0d1b78-af3f-4121-95c2-ac730b90042b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_9003989c-bb25-4ff0-81e9-e70d5c78154e" xlink:href="gild-20210930.xsd#gild_A325SeniorUnsecuredNotesDueSeptember2022Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_9003989c-bb25-4ff0-81e9-e70d5c78154e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_2c86d1b7-40a7-4333-893f-1d2f4b2cf334" xlink:href="gild-20210930.xsd#gild_A250SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_2c86d1b7-40a7-4333-893f-1d2f4b2cf334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_1ab07474-8828-4d27-bcdf-4cec1b8e9d56" xlink:href="gild-20210930.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_1ab07474-8828-4d27-bcdf-4cec1b8e9d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_7f64175c-ed51-43ba-a5fd-2d6a047be221" xlink:href="gild-20210930.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_7f64175c-ed51-43ba-a5fd-2d6a047be221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VariableTermLoanNoteDueOctober2023Member_aececa57-d94c-441c-9ee0-91fdb60ffee4" xlink:href="gild-20210930.xsd#gild_VariableTermLoanNoteDueOctober2023Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_VariableTermLoanNoteDueOctober2023Member_aececa57-d94c-441c-9ee0-91fdb60ffee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_a8201061-942c-4e1a-bda2-5b2152ebb098" xlink:href="gild-20210930.xsd#gild_A370SeniorUnsecuredNotesDueApril2024Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_a8201061-942c-4e1a-bda2-5b2152ebb098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_ca52c789-77fb-4362-aca9-eae9ad321cb9" xlink:href="gild-20210930.xsd#gild_A350SeniorUnsecuredNotesDueFebruary2025Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_ca52c789-77fb-4362-aca9-eae9ad321cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_8aef4beb-e10b-42dc-acb2-22e530436ab8" xlink:href="gild-20210930.xsd#gild_A365SeniorUnsecuredNotesDueMarch2026Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_8aef4beb-e10b-42dc-acb2-22e530436ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_105a40c9-7304-41a1-8ebb-2ba0a7353937" xlink:href="gild-20210930.xsd#gild_A295SeniorUnsecuredNotesDueMarch2027Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_105a40c9-7304-41a1-8ebb-2ba0a7353937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_4cbc9de2-e493-42af-97b7-20f26bc48f12" xlink:href="gild-20210930.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_4cbc9de2-e493-42af-97b7-20f26bc48f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_2b4ebafc-2f2d-4b11-9be8-7429277434fd" xlink:href="gild-20210930.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_2b4ebafc-2f2d-4b11-9be8-7429277434fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_e80fcb56-a045-4186-afc3-fc4776959598" xlink:href="gild-20210930.xsd#gild_A460SeniorUnsecuredNotesDueSeptember2035Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_e80fcb56-a045-4186-afc3-fc4776959598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_700780fa-c708-40da-90f3-2bac8a0b5c6f" xlink:href="gild-20210930.xsd#gild_A400SeniorUnsecuredNotesDueSeptember2036Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_700780fa-c708-40da-90f3-2bac8a0b5c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_091ba7c0-316a-4510-9784-e706386fd321" xlink:href="gild-20210930.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_091ba7c0-316a-4510-9784-e706386fd321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_23305ef9-4a22-4562-8d8c-56d2b7785855" xlink:href="gild-20210930.xsd#gild_A565SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_23305ef9-4a22-4562-8d8c-56d2b7785855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_7cbe26f8-9786-44e6-91c0-4a8c9e0b2ea6" xlink:href="gild-20210930.xsd#gild_A480SeniorUnsecuredNotesDueApril2044Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_7cbe26f8-9786-44e6-91c0-4a8c9e0b2ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_10505841-1928-4eee-b573-0b0ca4e43513" xlink:href="gild-20210930.xsd#gild_A450SeniorUnsecuredNotesDueFebruary2045Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_10505841-1928-4eee-b573-0b0ca4e43513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_186afbc8-6a64-4b2d-9d7b-94eb2ec0921f" xlink:href="gild-20210930.xsd#gild_A475SeniorUnsecuredNotesDueMarch2046Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_186afbc8-6a64-4b2d-9d7b-94eb2ec0921f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_8df67e84-8e4d-431c-9a13-0ec41fbbab1c" xlink:href="gild-20210930.xsd#gild_A415SeniorUnsecuredNotesDueMarch2047Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_8df67e84-8e4d-431c-9a13-0ec41fbbab1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_909fb878-7e71-4ef2-96f2-21aaae3784fa" xlink:href="gild-20210930.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e13b5f1-02bd-4dfb-a200-143cbca50dda" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_909fb878-7e71-4ef2-96f2-21aaae3784fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_44c0ad82-8303-4963-95fe-9e2af1f5fb44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b1809c63-af37-4cf1-9e1e-f664e34353c0" xlink:to="loc_us-gaap_VariableRateAxis_44c0ad82-8303-4963-95fe-9e2af1f5fb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_012a84c4-5a1e-4a8c-974d-9c1d70f6fc45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_44c0ad82-8303-4963-95fe-9e2af1f5fb44" xlink:to="loc_us-gaap_VariableRateDomain_012a84c4-5a1e-4a8c-974d-9c1d70f6fc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d17e7a36-806b-4293-a33d-5130f4d3335c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_012a84c4-5a1e-4a8c-974d-9c1d70f6fc45" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d17e7a36-806b-4293-a33d-5130f4d3335c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_54195b80-dbc3-46f2-83f7-8ec07d5a7329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b1809c63-af37-4cf1-9e1e-f664e34353c0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_54195b80-dbc3-46f2-83f7-8ec07d5a7329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b1ee0ec0-a74d-4132-8327-10d791096486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_54195b80-dbc3-46f2-83f7-8ec07d5a7329" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b1ee0ec0-a74d-4132-8327-10d791096486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_53665a2d-efd3-48a8-9d40-ffe87856a40d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_54195b80-dbc3-46f2-83f7-8ec07d5a7329" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_53665a2d-efd3-48a8-9d40-ffe87856a40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_efd8e3aa-c430-4d19-8782-7be1a1a94516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_54195b80-dbc3-46f2-83f7-8ec07d5a7329" xlink:to="loc_us-gaap_LongTermDebt_efd8e3aa-c430-4d19-8782-7be1a1a94516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_afe2a0e6-77ad-4fa8-a2eb-b0b0c3c44aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_54195b80-dbc3-46f2-83f7-8ec07d5a7329" xlink:to="loc_us-gaap_LongTermDebtCurrent_afe2a0e6-77ad-4fa8-a2eb-b0b0c3c44aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_710a5d7e-fba1-4587-8c6b-cb9aa3c0227a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_54195b80-dbc3-46f2-83f7-8ec07d5a7329" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_710a5d7e-fba1-4587-8c6b-cb9aa3c0227a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#DEBTANDCREDITFACILITIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e313af01-7e1e-4e0e-af71-4a8ef3ab272b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_be5d30f4-1bc1-466b-b168-f91e0cb9203d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e313af01-7e1e-4e0e-af71-4a8ef3ab272b" xlink:to="loc_us-gaap_DebtInstrumentTable_be5d30f4-1bc1-466b-b168-f91e0cb9203d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_08e6253d-1958-40fd-92a9-6619d930cbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_be5d30f4-1bc1-466b-b168-f91e0cb9203d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_08e6253d-1958-40fd-92a9-6619d930cbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7be84519-46e2-451c-877a-aa47cddae845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_08e6253d-1958-40fd-92a9-6619d930cbc8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7be84519-46e2-451c-877a-aa47cddae845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_eb813b51-4ab7-4d3a-82de-cca91a1929b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7be84519-46e2-451c-877a-aa47cddae845" xlink:to="loc_us-gaap_SeniorNotesMember_eb813b51-4ab7-4d3a-82de-cca91a1929b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_91829302-c236-4614-9024-71e9d1fab5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7be84519-46e2-451c-877a-aa47cddae845" xlink:to="loc_us-gaap_MediumTermNotesMember_91829302-c236-4614-9024-71e9d1fab5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ebbe9f93-552e-4a8e-892d-a0124ee62ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_be5d30f4-1bc1-466b-b168-f91e0cb9203d" xlink:to="loc_us-gaap_CreditFacilityAxis_ebbe9f93-552e-4a8e-892d-a0124ee62ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_72f17c95-86e9-489c-a671-bf090ef104bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_ebbe9f93-552e-4a8e-892d-a0124ee62ab7" xlink:to="loc_us-gaap_CreditFacilityDomain_72f17c95-86e9-489c-a671-bf090ef104bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e285d193-c545-4514-ac0d-a232d3ddb223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_72f17c95-86e9-489c-a671-bf090ef104bd" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e285d193-c545-4514-ac0d-a232d3ddb223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4d161fc1-ee4a-49c4-b725-0f271704ae1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_be5d30f4-1bc1-466b-b168-f91e0cb9203d" xlink:to="loc_us-gaap_DebtInstrumentAxis_4d161fc1-ee4a-49c4-b725-0f271704ae1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4d161fc1-ee4a-49c4-b725-0f271704ae1f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member_16bbdec2-875b-40ad-a53d-964a16c862d9" xlink:href="gild-20210930.xsd#gild_A450SeniorUnsecuredNotesDueApril2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:to="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member_16bbdec2-875b-40ad-a53d-964a16c862d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member_4091b8a4-c1f3-4cd7-9585-3b8f4fd4aafa" xlink:href="gild-20210930.xsd#gild_A440SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:to="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member_4091b8a4-c1f3-4cd7-9585-3b8f4fd4aafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_611863d7-31fd-4c4b-9dd2-bb7a79c5c448" xlink:href="gild-20210930.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_611863d7-31fd-4c4b-9dd2-bb7a79c5c448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_da860532-4c8a-403d-8c86-d2ad0b631b4a" xlink:href="gild-20210930.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:to="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_da860532-4c8a-403d-8c86-d2ad0b631b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_8631238d-c220-41c4-8bd0-e4cbae16e4b1" xlink:href="gild-20210930.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:to="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_8631238d-c220-41c4-8bd0-e4cbae16e4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_5cadbc13-c0cf-4aa4-8941-b9cdbbcccd9d" xlink:href="gild-20210930.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_5cadbc13-c0cf-4aa4-8941-b9cdbbcccd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member_59872e17-ab94-4b0c-816c-a838607459a1" xlink:href="gild-20210930.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a4fcf04-7f41-44bd-afbc-bab5d481c14c" xlink:to="loc_gild_CreditFacilityDueJune2025Member_59872e17-ab94-4b0c-816c-a838607459a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8c0c4c4d-9306-4ebc-b0fd-53c936fc2578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_be5d30f4-1bc1-466b-b168-f91e0cb9203d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8c0c4c4d-9306-4ebc-b0fd-53c936fc2578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c16f7188-0054-4e73-8b45-1ddd8b2ad7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8c0c4c4d-9306-4ebc-b0fd-53c936fc2578" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c16f7188-0054-4e73-8b45-1ddd8b2ad7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a1974f31-66dd-460e-98b1-490e24a40537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c16f7188-0054-4e73-8b45-1ddd8b2ad7ea" xlink:to="loc_us-gaap_SubsequentEventMember_a1974f31-66dd-460e-98b1-490e24a40537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_be5d30f4-1bc1-466b-b168-f91e0cb9203d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c2b3484c-cf77-4844-8fa5-d9031d0e625b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c2b3484c-cf77-4844-8fa5-d9031d0e625b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt_c9fc686b-0117-42b6-8525-c0f98d1a70c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:to="loc_us-gaap_RepaymentsOfUnsecuredDebt_c9fc686b-0117-42b6-8525-c0f98d1a70c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_96054628-5c73-4da2-953d-dad8e314c320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:to="loc_us-gaap_DebtInstrumentTerm_96054628-5c73-4da2-953d-dad8e314c320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4a810dc5-7fa6-4d69-a5a0-d0aae4f68cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4a810dc5-7fa6-4d69-a5a0-d0aae4f68cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_e3da6dba-8876-42f2-bf32-f0bbe792ab29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_e3da6dba-8876-42f2-bf32-f0bbe792ab29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_2c2c8c38-9cc0-43bb-81ff-76e86fd7f7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:to="loc_us-gaap_LineOfCredit_2c2c8c38-9cc0-43bb-81ff-76e86fd7f7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_353560d0-4232-4338-a5af-85d50ae279ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f288965b-d01d-44a9-9889-f34a0d9fc1e7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_353560d0-4232-4338-a5af-85d50ae279ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="gild-20210930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_10b8a005-735f-440e-8af5-b35f45a0968e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_24a576a0-0efd-42cb-a1e8-2cbd5f16ffe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_10b8a005-735f-440e-8af5-b35f45a0968e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_24a576a0-0efd-42cb-a1e8-2cbd5f16ffe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ef110448-6014-4b80-80b0-8f2246f35950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_494c6b88-5384-4103-8963-b9503f449bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ef110448-6014-4b80-80b0-8f2246f35950" xlink:to="loc_us-gaap_LossContingenciesTable_494c6b88-5384-4103-8963-b9503f449bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c43791de-9d66-4ea3-a022-4d1666329c3f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_494c6b88-5384-4103-8963-b9503f449bf6" xlink:to="loc_srt_LitigationCaseAxis_c43791de-9d66-4ea3-a022-4d1666329c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_c43791de-9d66-4ea3-a022-4d1666329c3f" xlink:to="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_880f1d4d-e369-42a9-bdf1-f25c64c36a84" xlink:href="gild-20210930.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_880f1d4d-e369-42a9-bdf1-f25c64c36a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ViiVHealthcareCompanyMember_89dbf39d-e849-4600-88f2-c63518e44881" xlink:href="gild-20210930.xsd#gild_ViiVHealthcareCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_ViiVHealthcareCompanyMember_89dbf39d-e849-4600-88f2-c63518e44881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember_bbc52267-808c-4385-88d4-e56750568414" xlink:href="gild-20210930.xsd#gild_PreExposureProphylaxisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_PreExposureProphylaxisMember_bbc52267-808c-4385-88d4-e56750568414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2024ExpirationMember_a769facf-b60e-4c05-a690-8580ad268597" xlink:href="gild-20210930.xsd#gild_EuropeanPatentClaims2024ExpirationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_EuropeanPatentClaims2024ExpirationMember_a769facf-b60e-4c05-a690-8580ad268597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2026ExpirationMember_39aa2041-04c0-49df-a4bf-2dd99b39ff45" xlink:href="gild-20210930.xsd#gild_EuropeanPatentClaims2026ExpirationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_EuropeanPatentClaims2026ExpirationMember_39aa2041-04c0-49df-a4bf-2dd99b39ff45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2032ExpirationMember_4b509981-ff34-4117-8570-fdbbe49d6db6" xlink:href="gild-20210930.xsd#gild_EuropeanPatentClaims2032ExpirationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_EuropeanPatentClaims2032ExpirationMember_4b509981-ff34-4117-8570-fdbbe49d6db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2027ExpirationMember_ead997ec-badb-472c-ae1f-93bcbbf54b98" xlink:href="gild-20210930.xsd#gild_EuropeanPatentClaims2027ExpirationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_EuropeanPatentClaims2027ExpirationMember_ead997ec-badb-472c-ae1f-93bcbbf54b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember_9d9bada2-0412-4c14-bd55-35a6f28379a0" xlink:href="gild-20210930.xsd#gild_ProductLiabilityMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_ProductLiabilityMember_9d9bada2-0412-4c14-bd55-35a6f28379a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_QuiTamMember_de294572-e797-477e-afc4-0d33bc151e39" xlink:href="gild-20210930.xsd#gild_QuiTamMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e2116f6a-d769-4dac-99b6-49901d37d620" xlink:to="loc_gild_QuiTamMember_de294572-e797-477e-afc4-0d33bc151e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_5f352d36-09b2-4824-9c2f-38d5a04c53c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_494c6b88-5384-4103-8963-b9503f449bf6" xlink:to="loc_us-gaap_LitigationStatusAxis_5f352d36-09b2-4824-9c2f-38d5a04c53c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_de4f7ddd-1585-4953-a29c-e8d820b4f120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_5f352d36-09b2-4824-9c2f-38d5a04c53c9" xlink:to="loc_us-gaap_LitigationStatusDomain_de4f7ddd-1585-4953-a29c-e8d820b4f120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_1c08d5a9-a506-4324-9ce5-65441ffc396c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_de4f7ddd-1585-4953-a29c-e8d820b4f120" xlink:to="loc_us-gaap_PendingLitigationMember_1c08d5a9-a506-4324-9ce5-65441ffc396c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_494c6b88-5384-4103-8963-b9503f449bf6" xlink:to="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_2c7dd9ef-9173-43d4-a2d8-ef8ba0bd3223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_2c7dd9ef-9173-43d4-a2d8-ef8ba0bd3223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_1f0c66d3-ded3-4890-b34c-87d7e116f09c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_1f0c66d3-ded3-4890-b34c-87d7e116f09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017_af753dd5-8b9f-4739-8883-f2a28fda81e3" xlink:href="gild-20210930.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_JudgmentRoyaltyRateFromOctober2017_af753dd5-8b9f-4739-8883-f2a28fda81e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesOnPastSales_d3a2d9c2-8acd-4810-82ba-3529c12ed1ed" xlink:href="gild-20210930.xsd#gild_JudgmentEnhancedDamagesOnPastSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_JudgmentEnhancedDamagesOnPastSales_d3a2d9c2-8acd-4810-82ba-3529c12ed1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales_9039320b-53f0-4d83-82e3-dc7eead7f48a" xlink:href="gild-20210930.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_JudgmentRoyaltyRateOnFutureSales_9039320b-53f0-4d83-82e3-dc7eead7f48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_a9355b64-e3ec-4e67-a1a5-333940e615b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_a9355b64-e3ec-4e67-a1a5-333940e615b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber_6134f7a8-c6d5-4ff0-b95c-42271eae7a50" xlink:href="gild-20210930.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_LossContingencyMaterialTransferAgreementsNumber_6134f7a8-c6d5-4ff0-b95c-42271eae7a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_fde627dc-aec9-4532-99aa-5e0d43942485" xlink:href="gild-20210930.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_fde627dc-aec9-4532-99aa-5e0d43942485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_d1c29907-92cb-4810-80d0-4fd114f7dccb" xlink:href="gild-20210930.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_d1c29907-92cb-4810-80d0-4fd114f7dccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber_04948fba-1ef5-45a6-bde5-fedc1b2f9072" xlink:href="gild-20210930.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_LossContingencyPartiesAppealedNumber_04948fba-1ef5-45a6-bde5-fedc1b2f9072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesFilingOppositionNumber_ee2094f0-88e2-4470-8c41-635d15775642" xlink:href="gild-20210930.xsd#gild_LossContingencyPartiesFilingOppositionNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_gild_LossContingencyPartiesFilingOppositionNumber_ee2094f0-88e2-4470-8c41-635d15775642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_6ac488b0-b6ac-4577-a796-0ad5ddd72e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_6ac488b0-b6ac-4577-a796-0ad5ddd72e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_43535282-6c52-4373-99e8-c1e710ac8723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_eaacf2d6-a1a7-4019-88da-d481242c8fd4" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_43535282-6c52-4373-99e8-c1e710ac8723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gild-20210930.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_680d9c85-2d64-4478-beb0-79b32511b034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_437ba285-165a-4207-9894-de6b14cbb9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_680d9c85-2d64-4478-beb0-79b32511b034" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_437ba285-165a-4207-9894-de6b14cbb9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="gild-20210930.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_db7267a3-863e-410d-954c-58488c191364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_2219b31b-a1f2-442d-ad18-314ace4e28ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_db7267a3-863e-410d-954c-58488c191364" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_2219b31b-a1f2-442d-ad18-314ace4e28ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_db376f88-51a5-4a7a-aec1-5f8fd7526092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a6f36093-fd35-4129-b6c0-ba03939937e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_db376f88-51a5-4a7a-aec1-5f8fd7526092" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a6f36093-fd35-4129-b6c0-ba03939937e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_292a62aa-44a7-47f9-943e-14ff9dacdac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a6f36093-fd35-4129-b6c0-ba03939937e6" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_292a62aa-44a7-47f9-943e-14ff9dacdac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_a62c3e69-b4a9-4f1a-ad0e-3f3069a3b9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_292a62aa-44a7-47f9-943e-14ff9dacdac9" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_a62c3e69-b4a9-4f1a-ad0e-3f3069a3b9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember_1203964d-1026-4818-8cb8-424688a25ae3" xlink:href="gild-20210930.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a62c3e69-b4a9-4f1a-ad0e-3f3069a3b9a2" xlink:to="loc_gild_A2016StockRepurchaseProgramMember_1203964d-1026-4818-8cb8-424688a25ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember_a987354c-9db9-4404-8e99-95847b7a14ed" xlink:href="gild-20210930.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a62c3e69-b4a9-4f1a-ad0e-3f3069a3b9a2" xlink:to="loc_gild_A2020StockRepurchaseProgramMember_a987354c-9db9-4404-8e99-95847b7a14ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d987bb86-6a5f-4e61-a839-ab81f2bd7b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a6f36093-fd35-4129-b6c0-ba03939937e6" xlink:to="loc_us-gaap_ClassOfStockLineItems_d987bb86-6a5f-4e61-a839-ab81f2bd7b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_862d71e5-b912-4e83-8372-9ba064cdc063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d987bb86-6a5f-4e61-a839-ab81f2bd7b65" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_862d71e5-b912-4e83-8372-9ba064cdc063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_444f0ebd-16f5-4182-a1fe-da451ed80f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d987bb86-6a5f-4e61-a839-ab81f2bd7b65" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_444f0ebd-16f5-4182-a1fe-da451ed80f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_919ba129-fbaa-4d90-92f8-78015e3ee1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d987bb86-6a5f-4e61-a839-ab81f2bd7b65" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_919ba129-fbaa-4d90-92f8-78015e3ee1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_36a4a6aa-154f-4754-9a3a-547f0a6638cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d987bb86-6a5f-4e61-a839-ab81f2bd7b65" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_36a4a6aa-154f-4754-9a3a-547f0a6638cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_223939c7-c967-4a0a-8e5d-79a12a2914e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c6d516bf-64f3-41a3-b93a-16a4a1b07824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_223939c7-c967-4a0a-8e5d-79a12a2914e7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c6d516bf-64f3-41a3-b93a-16a4a1b07824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2f4e6fd2-889d-49f9-88c1-b737cc301e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c6d516bf-64f3-41a3-b93a-16a4a1b07824" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2f4e6fd2-889d-49f9-88c1-b737cc301e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5f4c7cfb-3587-4f2d-bf32-b75123c548d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2f4e6fd2-889d-49f9-88c1-b737cc301e4b" xlink:to="loc_us-gaap_EquityComponentDomain_5f4c7cfb-3587-4f2d-bf32-b75123c548d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e3fa2930-fcf8-4278-a918-743156359cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5f4c7cfb-3587-4f2d-bf32-b75123c548d7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e3fa2930-fcf8-4278-a918-743156359cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6ec4dd39-04ee-4bb4-8386-e58b5edfddc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e3fa2930-fcf8-4278-a918-743156359cbd" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6ec4dd39-04ee-4bb4-8386-e58b5edfddc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_bddcdeeb-e9b2-4e26-8f01-0663379be49b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e3fa2930-fcf8-4278-a918-743156359cbd" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_bddcdeeb-e9b2-4e26-8f01-0663379be49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_27c2311b-caae-4c08-9ee1-2cdd845e17d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e3fa2930-fcf8-4278-a918-743156359cbd" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_27c2311b-caae-4c08-9ee1-2cdd845e17d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8216a926-9f54-401a-83e7-7108c65e1dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c6d516bf-64f3-41a3-b93a-16a4a1b07824" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8216a926-9f54-401a-83e7-7108c65e1dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fb2a2796-9a9a-47ad-8d12-66cc3bd19287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8216a926-9f54-401a-83e7-7108c65e1dea" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fb2a2796-9a9a-47ad-8d12-66cc3bd19287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1aef90bf-1070-4136-a6c6-4bd15c932d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fb2a2796-9a9a-47ad-8d12-66cc3bd19287" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1aef90bf-1070-4136-a6c6-4bd15c932d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_7344ca96-6122-4df7-acc1-82f6bed137b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fb2a2796-9a9a-47ad-8d12-66cc3bd19287" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_7344ca96-6122-4df7-acc1-82f6bed137b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_5080f307-aa6d-4249-b8d8-bd518afbf0be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fb2a2796-9a9a-47ad-8d12-66cc3bd19287" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_5080f307-aa6d-4249-b8d8-bd518afbf0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_15333437-72b2-4785-bc38-233b2c047579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fb2a2796-9a9a-47ad-8d12-66cc3bd19287" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_15333437-72b2-4785-bc38-233b2c047579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d0bf010b-1deb-49ef-a2d3-25fb357b6d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fb2a2796-9a9a-47ad-8d12-66cc3bd19287" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d0bf010b-1deb-49ef-a2d3-25fb357b6d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS" xlink:type="simple" xlink:href="gild-20210930.xsd#NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6ff46f0d-dc29-40af-8982-7c3124652f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_6a79ccd2-ef23-44b6-8ecb-9c5c4764792d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6ff46f0d-dc29-40af-8982-7c3124652f9c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_6a79ccd2-ef23-44b6-8ecb-9c5c4764792d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables" xlink:type="simple" xlink:href="gild-20210930.xsd#NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ea437cf6-9049-44c6-926a-40782ce6f4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f4b329ee-960d-4ce6-8a75-d7741fa2bcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ea437cf6-9049-44c6-926a-40782ce6f4c1" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f4b329ee-960d-4ce6-8a75-d7741fa2bcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cba32dd5-d550-4812-94de-b930d4c5c379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c9d5615b-e0b2-4c43-8460-3005024a6afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cba32dd5-d550-4812-94de-b930d4c5c379" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c9d5615b-e0b2-4c43-8460-3005024a6afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1b09e59f-14d9-4f2c-8152-13fe346ea1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_18c928d2-aee2-4d5c-81d9-4ec9a3a7c761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b09e59f-14d9-4f2c-8152-13fe346ea1c9" xlink:to="loc_us-gaap_NetIncomeLoss_18c928d2-aee2-4d5c-81d9-4ec9a3a7c761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_60fe924c-a73a-430e-8750-4513e4b0c67b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b09e59f-14d9-4f2c-8152-13fe346ea1c9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_60fe924c-a73a-430e-8750-4513e4b0c67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_abcaa12e-d9a7-41e9-8637-a52333ccaf14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b09e59f-14d9-4f2c-8152-13fe346ea1c9" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_abcaa12e-d9a7-41e9-8637-a52333ccaf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a016f460-2316-4fcc-bf73-565f20a143fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b09e59f-14d9-4f2c-8152-13fe346ea1c9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a016f460-2316-4fcc-bf73-565f20a143fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_34c2af5e-9025-46d2-8fe9-6bdb4e6b79ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b09e59f-14d9-4f2c-8152-13fe346ea1c9" xlink:to="loc_us-gaap_EarningsPerShareBasic_34c2af5e-9025-46d2-8fe9-6bdb4e6b79ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_aa8b190d-be3b-4a12-9117-65969333adb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b09e59f-14d9-4f2c-8152-13fe346ea1c9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_aa8b190d-be3b-4a12-9117-65969333adb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXES" xlink:type="simple" xlink:href="gild-20210930.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_889c37e3-8ebb-45d4-887a-dec5ceedbb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_b3416725-b829-40d4-8fcd-709e02ecd2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_889c37e3-8ebb-45d4-887a-dec5ceedbb9b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_b3416725-b829-40d4-8fcd-709e02ecd2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="gild-20210930.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_eb6769a7-1a09-41d8-9d40-9fb9305bfe7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_138a5eae-4448-4e56-8906-cdec68ee96df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eb6769a7-1a09-41d8-9d40-9fb9305bfe7a" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_138a5eae-4448-4e56-8906-cdec68ee96df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="gild-20210930.xsd#INCOMETAXESDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INCOMETAXESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1cc5292a-dd99-4e0a-8021-d1941a0d8449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_533471a1-5a70-4d2d-95c0-0fa236231198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1cc5292a-dd99-4e0a-8021-d1941a0d8449" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_533471a1-5a70-4d2d-95c0-0fa236231198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_aadc3eef-cb1b-4b08-8fba-2a0e48443a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1cc5292a-dd99-4e0a-8021-d1941a0d8449" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_aadc3eef-cb1b-4b08-8fba-2a0e48443a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_335e492a-16a1-43b5-9c09-04b18a16794d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1cc5292a-dd99-4e0a-8021-d1941a0d8449" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_335e492a-16a1-43b5-9c09-04b18a16794d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_1a72012f-802c-43e3-906c-3c5197eb6b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1cc5292a-dd99-4e0a-8021-d1941a0d8449" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_1a72012f-802c-43e3-906c-3c5197eb6b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>gild-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:gild="http://www.gilead.com/20210930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gild-20210930.xsd" xlink:type="simple"/>
    <context id="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3eac3303cc9649e2a0b0fd67ca07ce16_I20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0300f6dad76745ceafff278866806c16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifcc4638e68b041b3aed502ac0da98085_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i113f7696af45458ba1c6270ba2e89d75_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib7a2ec8073884bc5881bfa3d3afda11c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4666b276ec7d40ea86d10c4ded816760_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if593c50c51de4ecab2682f502e43fe0b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i80719b1e7cda4bf6adddc01b671e7d5f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9a47277681854c0eaa992a6c02b6acb3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i528488c905dd4c8da2e5a1389a8b0a59_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6780596b267f474480b87b8ce4471b81_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if7cadd9af8cb4d648ad69a6bf5f40afb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic320c878f7da497289eedfe7777dbd63_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i47c2e7921e224837ab97ee0fe6c8f222_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i51b36b57f62a4b6f9933e96a8a774a03_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0ce088514657437793db4cb212d85fa9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i93cee50aef154d89907a30e4b6fe3dad_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i38550fb4b8e545b6933ed2239c97d37d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic9a23e1ecf384ef8854c99561d634f7b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia4232b9569ef4dc784f4c812cd10758a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i47d05e5d8c89426f941e19ac183a993e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib3c507e951f04b82bce9764e6f829c9b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifcc67220f43e4bb097d163125b104986_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6a7f62ba5efc4ba2a75848977dcd0f28_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic607fe5efeb4462ba677a36d66cea69e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i07b01e048e144df19a994cf3c542a026_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3db1326cef2b4443b8901640d2a96bc8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i67dfd12ea224410a8e53fd74958a0afb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4708079b07443c7a62480f7e6915098_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i68c8176bb4194abc96d3c13de341cd01_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if83cc5f617644ec28eca6ba9626e3244_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40898fd2e2e842e88088320ba442b8f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4751784eb024137a55a00f62297811b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa59bbe2a2154f068815ed93165ba107_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibdca6d608af14f87aeafba62f5b528f1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i71ab8e199657427eb6e86e9e2a9be3a8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i33c2cfa2e7ec445881cec30e9eed5e76_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if91124405d414b9dba81e4453951813a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i79f810b4c15c48908cf2409474335f75_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id36e5ff34aee4ca1a00a4a484c912ba8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic03e12a879694340bc9fdc68aa15f297_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i44d0ae25eecf499fb680c4e796d4bbaf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i740e8f78f6c348b0b796258c902c6df7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idf9c8e7ee0794bd18997a355702704fd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i68393aa2cad140b0813dae42d797b81c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4276333617e7401db14493cc3da842ae_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id9f4a9c842e640eb850df6488920516c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2310959eb5074abf916d6715b8aa87fc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib82a8b96d9074a4fb728c152000179b2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3ca43e6b419249ee89f9dcf2bf9735ed_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1eb53663397049a380603edf12d76c3a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibb7e694d30cd45e3a1e9103b0b1e82e1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i377473f7a7634d6cba9a5bb6603d6547_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i05bfa65a7fdd430ea5429b49909dff6d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i19f0cbf8e15f44e3a8bf106f16ddf237_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i863402769fcf4a3abffd39d64a185584_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i188cf2bc805343608e1a7c9417d2404d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie2552479e6ff476e92abd17114269cd7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0f3b569ef25240f1a155a0024e7b8e90_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3c214ead3cf04a2e9fc7bc2b14bdaf84_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic4e29df1f11f450ca7eb2e638244a8d1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaaae18a74fca47d1b00b45a50b94910d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1a3a3fc257534802a47360ab1e00d78c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i65979baffae041ae8ddc09c614f2ebb8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id3bd1b11f59e45f4ad008ef2737fcd81_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i57db840e2919481eb28184ec2cbb0a50_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i612f84efa15449cc9787e2a73fa82064_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia55ca9423cea4d12b888483189b2ac1f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie8aa096b135f48158580b40a60e33019_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i36a8c27aca7b4c4eb248168068a32aa5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia9c91fbfc86b4896a3a819c4d77bdb7d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie6111ed4b4e34cc0938dc6143421bf29_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i846bb97183f648a1a345c7417b016402_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idde4cb31f8274161ba1a860f8c484f38_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib4c0f1a209914347a5e69fa51270ee29_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i768c3bc1ec8c43ddad2162082a96cd6c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8b9a118513ef49819b2577666b0ec096_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i733e5fef29374d46b413dee54bb19109_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i90b02afac5b7406d9c151b1f25da49ab_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iba9d39a80c434949bcf4d4dbaa9759d7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i63ca5be4690f44a7bf33e1db73a1d060_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie0257f3a298140fc84dee8d53d699670_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4f7a64d9f59c4811a20101fd386ee115_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i417036899f4b4ba6a942d6c89d2cf9b8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie4e1d6d95b2c4d2a920c8653b06216b5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i83e6d6c2611b4c2e8c4aecf466648862_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7bfa430609e94754b5309dcbd1f54afa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i524768e71ccf4918b463a9f11d0b12ad_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4bbd970a4b1c41ac826211b086ec75c6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i585135633c624761b4c1a83f8fb3835f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifcda312d5cda40abbb9ac037d9a20f64_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if6c13cff5ea440d6856dd460e75e1cce_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i972c68c99d2b48aa9f0ab252eaded219_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9bcac0500428449ba45e660bcf11a22e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3b5f64fafefb476897c670520ef3e684_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieb444609f3c343faae5bc31dc0f2969a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i11b21909ece24606afb19d200d6cbf45_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie64f24cc49d2461993b4706f48070582_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia581ec4341004cacbe1676f4824925d5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0beeedfff0ab464dacc2dfe91fea027f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifda373a4474d4fddbe280b1ceeb9773b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa5ff99375b246b19d9a454b2bfcd5c4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib6072428678a4c13b3bc2cefe46e2367_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5830a8e44aad42d6b4e5c07745f1a654_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if2499d0efe544c88b850f4e06d6d0fe2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3df12d48d77f444687886781f8f13ce0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9021fb6917c34472a60654a134736f11_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i340ad048883f42aa821f43d0819810b8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i593cc1643d3b4cffbe6c45b7b951be8b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if96b216119514bd5b34e404efd229b24_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9fd1cab9c1fd4ca68901a86b57b2fb99_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3484ed15b64c4fc291da3be7d9248674_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3f663d9f8f284b539edc2448996d7698_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i121ea362bc6448bc8bed2159e95e89b0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0a9823f6159647fb992be0b7838c2a93_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifb9dfdb77c104c9ca832bcf98a8246d3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i75b44da404f64237881a6460aa4636ca_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9ab0ac7cc574410790fabeb761d1d174_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i38e2ac5333234a66b3903412e42f3e68_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i75c03337a48d4a949b4288448d18a1cb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idca8d358805f479b89d1fb6e6719e857_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i52e40c6015764bd69ee9cbf82d281820_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7a28cac4b61d41f5b9356a0b6aac960f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifd6bc5b0bed743c29791702bead202bb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id310e22cdbef4eb1baca5c55f8b8fa02_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i65d60a8d39b34372a1be78e500f813c3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id6a580919a214b2d895ab413f26c8880_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i71a7ae2ad394446693596affca1e12ab_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i754a2616edfb4f3fb575bf9a85114f6a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i48939703477c47fe9550c4f92c6ba557_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie40a71d15ea447a2ae8f68926fced7a6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5e606e91fa3e46acac32b0de0f54dbd0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4c941e621c4b4cb1a5e4e5d4ba5a859a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icee57962d9df495e8b9f2cbabe1f503e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifb5b96718e3d479492237b8214637bd9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie0ca8a58c2d94581bcfdc60a41cf40ec_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i864044e4908b498e881e97143cb3166e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i51ab94a8ddba44f79cfe371276e8f9bf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia93c6c5c009b4c31b3fa92708b8d815b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3b348befa53e4159bedea795454be27c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iab1615ced09e40b1aa3cc44738550dd1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if20f435a41c348cbbdc43f245ac16861_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i73bf790cd1a346988b368c7d3cde8b8f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8612d631840e48e895d251930e52c4b9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i76968fb55cbc4ae28307471f0cccfdd7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i10ab46addd4942a0b01ed1d3a2011f31_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i47709a114cd148c0838a562496cab936_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4c463d05c4ab40cdb9e847fd0f510bea_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i171565ffc87743c1aba490024359250a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ied3ad8d00ec64e84b7f987b2ba29eabb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i78b9c2f39bff448a95abbd58f45d0fd8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib86391bc6dae4373b89bd8ab38605880_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8ad4a6158ebe4dff890142a1696e812f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5dffca717ae24d34a470d8d9a38dc095_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i61275390a7e640b2897c50f960fc2caa_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia61446b694c74e7d9f5a65b521566c20_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib982a6b7a5ef409bb13733f8c74abbbc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8e3676630be045daad191ec0e8486184_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a702cd0f2e242db85b30aa6ce77bd11_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i99d0c47edbf149b4b42fcf95a60ac88b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i82bf2e8a84c54403aff0f3a4e0827765_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i529a378d1a634502932448df5c7dfc96_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id5c2caa8a7da4d24a4facd4e5589dff4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i28240f36b37149c0aebeb17174beff82_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6a5536e23c6241a49f1464d8fe7455fc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie1a32343f5754479b35423074bb85146_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7520be9c8c2b44299328cc6ffba5984a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i505f00cc79eb434fab41a8fc651c07bb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia266f177505e46e1bf32006d610309d5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i871de7451e1745a0a07ed808518e7b3d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99b5ce6646c74d90aff700749d2e8cfb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iceedaa27c5974485aef9d4d3a5782af9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i554974bf2ebf487c9a569c72bf26081f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6cbc708d4b1a44a7a2159db8585b1eee_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2ac3e5d698614f858c14ebe4eb398eb7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5b6ded5571864ffd9ce7c0d50dc74892_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1b63f63cabe44e2585bbadd57fa354b1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac3caa38232a4a51a8ab79f61e2251ff_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieffd3dd156194386848193bc49944ee6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i83a6dddb7daa4a5ca29ac5484a6fd6e7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i83f0238d623444989439cf7baaffa508_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i45562ada92804faaba94694bf0efa14a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i826c955d2db24a8fac6267b635be2cde_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia73efd497975415fa3b80207050da730_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibc2ba5e907414bfd8ea65cf2a73b82dd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic82244d6f2a444548484e7aec01540b2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i19aa5a3f35bf4604808d9f2e3a8da3d0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieb7d7312714a49a0a36fa523e3b8b0a4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0baa0f95e2af4393a1730300142cc581_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i88742fc2c2b34f5ea2b9520a011826a8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idf9b1de4fa0b4462bd3dc919628df7de_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1115a331568c4809844ce0028077a85a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8837076c1a0d4dfc86bd66bf5152de38_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i444db132af094e4bbf54b5614246e999_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5a81a8e5d9974ac7bde5d42f5a4fc336_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaa8b523c2e824076a748ebd245595664_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id70ba4cf64c94219a9e327880de4ffb7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5f05f61614c147efa464532642700a6e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i93f53d3fb034456b9a305a7ed3d3e66e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7a017e3308ef4cbb9b933e55ec090998_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iea639de29d0e4d668506abf5fe3550ad_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ife19093e97a54f5c9eb24677048ec618_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5266ed380c4d492c9019fc51f76cefd0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9eb9b983d1b54d55beb90a63dddb2c59_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaf984fd7000f4775a945b8b0f7942e2a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i29ec2e59c50f41ca958a6fac1402679d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4f4e484bfe8744e48ad91049bec90979_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie3732c23942243a9a941c7c4e278892a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i877e24c5d0694819b01d486f5d882659_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icf1741a698e64669b6b86f03281e3c65_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8a1dce33288a4302aaad5691f38a09dc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i80097a5080c0445eb9773bcbbb99bc1c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i19103f7ddbeb423abb4a6bb401db7fff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ica155088076646c3a5bd1588f0bceb4b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia812590aed6d4ab39be1d578c15c1486_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3e007c33751b4a5c978064214accac0e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i33137ec5b6634022892adaf4e137ea2b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i02900307815d45ee8652b90be7d1be4c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieba46f08b484419da5dcf2ea9265939b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2f89bf00ca354d5bb864b9f0cd155397_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2e029ac4bf384381be5a78e8fb2e5178_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifd034ba2efa44a2db164c8aea8825436_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i04bfbceaa25142cc84ac6378009c15a3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i992039dc5c0441c5b5f6174dce19c781_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0ae99aee62f846139d54de729834ff14_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i678692608fbd4c1fa178eabaae64217c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3b6c99a3b9fb41af94b2683664d43cb7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieec0b95176c043cfbbc5a9f6fa983587_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0507455b49474b93a38ead6ff2615419_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i12ee4d5996924966837c8c99c967f51a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic78827f1965b425dba08fd9f4c2e4d58_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i39b4ec9525e44e808926dba562992f53_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5113443b36744e9e982775ec8eddc113_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i736b122cf29c43ee95e28299d9a585f1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5c967382fd7e4043b63ff0da2d1242a2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie85528a66b46438d9ef9265272241283_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idb5dc4dc454649c4a9f9a11210acdf30_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0c45e550d01b429cb2b091b9902532c0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i35a4693d3cc04b62b20fbe12a1d5a54c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie9751f0cadc8491e945ca44b0b80b126_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia4395e1c88544cc4b60097ece5543cd3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia30e8d354ab04f3a97abc398675713dd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id953d64ac7fc4fccbf566a8d9a4e880e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie6ecbe4c2b2d407793fd3b236408f12a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0b07ea93a6f54fd0a91bf6672ff04b65_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i73b68324728248e48095f5acec992615_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic8f3b797b0784b5e98a1ebecc9731bc1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4c6152e617b143c19295e79115efbfde_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i55ce6c803e5044689d6f072466cdb84a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icbb1331a5dd2469fae50b0f82ccdc186_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i32399ea9bc584449a570a053a33d5913_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b87fa8d5dc94c15bba720f6e25ca2c4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id317edd4885848da96375a5d6890f972_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic5d1c49fd62e488a9d8f1b1bf40b098e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3c6dddbd6632497799ce67bce0d386c2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id2a5f3cc54f848f1a10d35d090a03387_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4fb67792ca1a4e87a11d779d955afe4c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i71818c2f40544a51bd97f8265ec8d26e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia8d2d00f525545e0bfeaff95a0d0fbae_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iffba5b40986f41988004b66efa3262e3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie950ff8a161b4f3cb591feb0c61f2b65_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i014ae1acc1a0400cb0833dd1ec4d8c95_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i248f6f4d0b1743b8ac49ee8a4893a138_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idb48adf7671d4b5095439fa1db112f98_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6dea3ee0ff204b6a859461e1d1f6d8ef_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i98dbae32b00044609d015af32ec98ca2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibb6c3fd5a3c7472f93e4bcc1e14205f1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i93a4e05cc8d84ef193edc737f58313f3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4c4a3efb665a4e32b3fab9bc46d0e840_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i07b88223ff894ebeb782ba78c923b80f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6ef52ca9d6a84708adf4f8bd716acb1b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia60d842da95f4557a472db9a4f20944c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i312af34f38c3480f92c1180516ce4b2f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i69497b92cda24b32bb318450db656d59_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2c83f4a3e9804930b2a2b194201c1c9a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b526ba862f347ec9e038db912732159_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic8674bb821a143ffbf0e7c0a4bbc23f5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1f44e89624524a3f85af2769737da0e9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i106ed528aea94b3e84e167881f011048_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i06672ac481ba4a9bb5bd08dacfe71e88_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie0753fdb7e8f479fa676298a44c409a3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i84e6d6f192a24ac8b2f45a194dfc508a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i86eebf78b2f54e5789f05f6de57a33ff_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i90831c4bec134c3d9479dc73821bd890_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1f950f4a2a1943729bd08af5465b17bc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i00d836d842884745a9b0c054d60b3106_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i94d80d18f64348a6952ff66466587e5e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i420349f096da42faa5a1507cb5af2bac_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5c028e5643ea425b858bce273dbb43ff_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0f15774b1a2c46f9849e41b07da947da_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibfa297463bca43108958d1bc0d817e62_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i801113c804f84bf68a7ce7874e0fdfff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i22120ea38a6f43808c0a51b6b42c907a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0dd65b051c3c43a09723cf00754a0d11_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7ee5d0fa9bc243609b1326fffc9420dc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i64edf3f2b52641b0b8963f1e7ecaf35e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibcd113a548354e83adbc4e684d0b7c6b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0ad59f43c9584895b43102b96b356bf6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8e7dca62ce034df2965648995f1e45c3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ide81ff472a904e96bd7c11cfb160bb5a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1c657737c9a44da0bd9a0a0ed937b77a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i761660c0e36b44119d0a377956dca1fa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i42344c7afe36415a9346e765e883f109_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i780ad9f4faff41188b82d5ee6efad1c7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i771dc583a85d484996619f6a24a1e310_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i12d2e276cf194b249b5381b7c0d564e7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a788a5a397c4d3c9c4273e20cb2eaaa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaf04a6872a2045d9aba3f8ee749ef8cd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i89aba37ab3bb4d6f995db3f1ef7313fb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib47fccef93064956b207fbf3f4b0c07b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5c6ae907411a40a09a29dc2bf329268a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibea8c08b19a845a7bc3ab84d8743dac6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idbbee8f040784dbbbba5f6f7708c8260_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i06591e9d784f4725a4a3f560f9165fdf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic63411681ae343ee931a1ef0fa134389_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7017bfe2cca74515a9c77805ce3e685c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if87c9a9443ac49bbbc5f60c80bdb0cf5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i34a4aea2fb6941c9b82af8675d2a96d6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic38c735785bf4de499f546ffb3cbbafb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if590ab24b0d24195a1751c7e37eda7d6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i86322bce038342589d4f3d411cce6b67_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i122291e0c90149469fe7f534977d4bd1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7be015c2d53f492face1090466f96194_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i41905ceca0e14646bdbb966a276724c5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i96b919aa74e64ed8953496faef33cead_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id55d71c6943b41688ba0c99c12c4b0a0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib74e3480706c4ceea2eeaa33e8a29a04_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia50f0d178a34403ba582f4fd7b081032_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1125817792a24e229eac03cff110ec3d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3b4c349c2ec345e9b842096c5ccaf53e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i175a2429ab0a4e3b8b1e75f43911073d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9bb3ecdf995d4d6d812e8c4cbd7c50e7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie1b6b1928d21482d9b69713fe3e4a90b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia342fd853fbe4fafbfdb82fc8f51be9c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i23e096ae4d344ee6812e02f2cc006dcb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic8bdd6612962405a995125b9413576f2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i028a2e4438b44cd584805fb7db0521f3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie8cf4df7cb3b4e0b86839f9b4fc78b33_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icfac141d6cd44e59b0b264ad26f95be5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4522ce1c0acc43ec92a475e4619c9ded_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic5f3f15ae4734085be8c32af347a19ab_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id78d2215b759479ba1d4220802e6d2d0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2ec8a9a644aa4b0ebccca4dab9dca43c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8af2ad96fab4466bb054d82d939ab1e0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id37247af540b49ffb68edae4f0e29c75_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9fb751dac07449418c170631d9d26c50_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5761b86071f3408392639773ba999d6c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibf1124b457b6443b9adc6d3bca56384b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i21c3ea05d2d6469bb4402a1e7bc7b6ea_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaf14c77718b943c99cce1bd3bf1a1bb8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i985f8bd1a9864259bc024e136e98165e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib17bea95dcb84138abe482f8fe033d2e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i721ea7e79a674506888fa965f545242b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id19b27572f12412498a2fbdc8b6f03d3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i294f1f3217554943bc9e24fd2f2d7b62_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i71ecaf56026f4bd5be46fe08dedcfbad_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i74defff37d6741aea5e3b56c22443253_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i27247f779d88460f9b4a30781c8e204e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i621eef6cf69b42cb94aae8c92e1e958f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7e09c9fb52974397863d698886f2e887_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ida707d8753fe48d2aeba73c027150355_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie768d1c6a00b48d5bda81338c8079975_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9708db6e96ec46d5880ab00e9b04a81e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id562523bafee46199bfba4a84d9ab6f7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3c6bd8c13db64a3ab7f8eb8574846b45_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie8899f03cb424167ad78b89040f1a538_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i21d311bd075f4f02b44de6feb4ab37f9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7979efe4ac394083a361addf3d2a49be_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3a303146ddae40fdbd9eede2a54e5625_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i036eac2d8114497bb332d3456f541e87_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i17d484b178dd4b64b7766ad74bfc4575_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9283b98610164ee6bf6bb05476c6b514_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaf92e99dbb2140f493dd3d8fb8410ba5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8d74d0421c60403c8a6f350e1d3b261f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i76d962d727ea437a9d9bf778a9145642_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iab1b92b6f4ea4a199a439cefdcf33eb4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieaad6f61dc4d43cb950a28292948294a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5dadedf4a3a0408cb0d1d97265933589_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0d7e5fc9e484420c99dbd9d31335006d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i94648f1cf2334fd39189ddd5a2526fea_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i87770df84d314b2d9aad501ce6c1d18e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i03ba162945dc41be8591b11496c129d2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i42e31f17d8bd4d23b055d34e97fc4ca7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7bc60dcceb644702ad795c8522e3f1fc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieff814faff8a4823a581ff8c22875f06_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i898ffefc3e8041be98cde4df6be2c6c8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i41d525086d2940c8bc5faa039d023674_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie975ec0d59844df5ba2bc20d9d8ed6d0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iade9dfaea73c44d59d5ed5c0b2478333_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie07906aa3788456f883989affdbca674_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6a36ba79c6f545ebae95e83233deca01_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i73a607992c5c4d25ad9c3ac39d2b5086_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i87e96b04266246398a423cbb059ca43a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0314692dcb914529b1c58577b2b23a0d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i68a023cfdfda4020ad80e31bfc9b887a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8af6b5ba80b548de8cc9f594408ecc5e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6362737d64e24ccf8210a3c52840afb6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1b03fbb1ad6b40f19a144436859a94f2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4bdb0af715f34b249428381e9aecddf7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i086ee71ea26941e88d86269d05ffe0da_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5ad8c8ce385e48069566ed761014713d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6462e169d53f4b4fa0ce56f4c177fbec_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icb8274f710244001811907e50cd4649f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia087c8100b6442799b592343e8d561ee_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2963d1dc4f004cde8fd58fc8adeb9698_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1cb3a52c0f00489082cde7485cbe447c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8cb8226c97a04cce9da6c55eaa7cbf5c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i66452d493a694b09b553e49d6ab26de1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie00c38ed5e114e7c9b2c757c827e0138_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i41eae22e9d694cdfbbc45e5052d09e8f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i896a5a5651944bfe84bb61cec75fe4ed_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i96c7b41d05fe44dc98629f17bcb23c36_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i14cb743958c641659fbba039af3651c2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i130fc4df5c3a4447ad6bafc4c36d9a70_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i743f436a82f046efabc844f2f53f0827_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5636e6fa99514854be00d8ce0f92da0f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i089d7a7d04eb4354a426b6f111e8c9a1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i97fd886a21164803a5ecfb1a6ca689a2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib9f9350bc75c442d91a688c62b89b6e1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5763ac2ae7874bc3949baeefcb466bb9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic843439826b2471ba7693acebb1e44f4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i952a37c342574b4fb556d2cb998f1dbf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia3bbe012fe22423491ec35738ee162d6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie50a6de3cd234635ab5eef79157b0e1e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2c55fd7299a240adbf6d39bdf17aa7cc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i96ab85ae6a2d499f8162d50d3fe1dde3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ief5bc9a6130945279a3ed73051e33bdd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idc475161995042e1b32b3447cfd8372a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifa3ddd3a8d67413d8ccc8f4f45930641_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iabb8e6fba8504ecf8c222643ff4b5f9b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic0a5589d4d564f57bd7d3624c5dadb39_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0891181a1f1841c3ac6a145676585a41_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9b86819db2a34c97be76a722a5625303_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e952d3e460445a9baeec1dcc88eb745_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie3a2d6364e6440d2be0d03705fab3cff_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifb620cd6eaf04c1c8f121fab54f876c5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if09794c214e347d6bea03f6a5b211ada_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4a9462d61d0f479b9fd7e5b189d86696_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if7fa3912b241402d8cd650313d3c7018_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icf0e9011b3d24494816bcc206c0c68f6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i30b2167174a94caf9d1f6bb56760edcd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i20212de8e88345cd81a0017d04adec4d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icc4680796da146cb8f0e19e816cc8a1a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i20583fb976024f8f8e57d6812ece8f46_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i06b5d4b507e1433ca2793f5756b1393c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia59084cd434e42fbafd89bb8ba03f4cd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1678eb4959ea4499b972f90192b36d19_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8c6ce327bc5a423fa9c0482e0ab2581c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if50b052e699145cb95a035c96c0cbee3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i54a055cd7cae4d1c9803fa1d5c85d26c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i323ac2db963e406abe6b6c72a52169c4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i306cc17766184506a102f49dd753f257_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9f7ccddf15fb48a6ad13341a6b918c1f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id66d30a90b1d4991894bd9de74896ac3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie93d3106744048369cdab984d1705db3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibb480f4f198e4b9bbf94fe25b67eb48c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i350d04c2a6974b8d81fb176e56b5a2e5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i72f473445dae45a5ba0d6b6eb575f11d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac82bc33803743e89507ebfd8155528b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9e01dfafe5e548d9960d2188b833a39f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie071dc0e5b3949d9839bd24e374990ea_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i912fe4ab93f14a9f8e6b580172900315_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3c166e53abf24fc9af7b888824f5bb49_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id99eff088b5d453b929c3d11f5802852_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i663bd657772843f4ab8018e6a76865dd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8c90a17fa3db439e94799030d2aa841e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib095572329c649af806dff6bf6648e2e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i52882de359e54c22ae4f7a72a8137b42_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5eb10e809c404f009423263342e5e7ec_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i59f4724ec2d14aad8052c7338d1e1a70_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i539e9d57820a4905bcab08d23c1fcdb6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i414c554b9ef34e0b9825b306a35bc339_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i41352f9abff2460ea53c3161faa76af2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i15f5acec533141a6afaedf118bb678bd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i974c2dbea9c44cadbbed8b52fc7f0508_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iba449c38763d4a5bb15ee5d3583e8506_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5ea474d996994c7cbaa07eff099c4759_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie3414950d11449a089e780e1462c6861_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i98ce7e4d4685422fbdf942d3bd865108_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib600ed3308d64a8b946e889611b8cf20_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib31f6766705e412abe5b95c86b77a3bf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i375d592d929047a993e6735cac3e7524_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i25802e2404924e7bb626581d9cdcd76e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i485672b302d740d299e2875e2d04bb74_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ida399d53d569435ca887d4b734cbe214_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9518115801fa4a4e943fb879f5bf25ba_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i51826c7e75b64381862b2f02fb933540_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ife3535d931384c729359473d5f8a4507_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1d1b980a3c9844768bbe2d46b8be2e7d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6aeebdc4428e44828acedd57caa0faca_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib41e7dc04b7148b4bfbba74683bb45cd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1b6f5dee9cac47efba1d637a42bd0f68_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id530903404aa44608666ca2ea201cad0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i53bbf05572d84302be77973d5913a305_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4505c57940594da1a6edc651f9236d9e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i704f5a35c74142ebb14940a3a4fc0d89_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0b5618b046614ad186793fefd8dcf5bd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6081efd3f9744514a207bf9f739d1607_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ide124041bcd946b29f470c0a14b6de2d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaadc71dd3a2547cea41b38c3c9ce7424_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i52a87250c5f446d8ab703b837cedde5b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if4b70689a9f142a9bd885d142547defc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i17f4e1512b3f4a6a988b52b2020f402c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i93ca470d7fdc4eb5bdee6dda889e6593_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i91affe4ed5b44ccc8baafb617adf2e9e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3a57a9c4342a4d129d4b551d06423da8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3f55f5d973df4988979569a529db6926_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if5e801c7e1af45b1ad4f62e390c18253_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i887c3ef61a3a45dbb40ba7652320c71b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i431029e24f704dde9b7df67fe1ba94ee_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i067f537de5404b9dba9eae8cc5fe8ba2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i040023fa9ea949e99260ae268fb58313_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2d85864fc37443df93104eb46275dfb2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie785b0f49c10443fb9de1408de71f21e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifb0b8d70240b45f9af68a14c1bc14401_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifc055133d0cf433781d778bd29bcf851_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5b7dd3e6b3fb460b8f290204f2ad10aa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4342f00fa51e4687acb11f09198af17a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i60da582576d74709b9d1fabc050be19e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaba56c135c2949f5a73bf185229f9d9c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id250fc6f2b094e5a9eaae0b8f02e6283_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6e8e47a466d34118bfe22a1393d5b447_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8b0094bc7ae7468e8f94517cdc8d4c16_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0c9cf81f27044e40ae5a06b91f4fed65_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i832adea04eeb4821973a36b8d8054b28_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia5defc88095b45f88cbef65982c863b2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i74e9b2ae35f94059a42f289e242fd5d6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib5d4f53a05ed4cf9a3c013c511bb6d57_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib495e1983c7d43ad954d6982a1acc6df_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia65f96edddf14125a0ceff48dd6ce529_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2ac5d731345b49a89e720e60b2bd6179_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1472bae377ce48de85232d1f7e78a6f1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if9da54dcd88e46a7a00d599ef8199f51_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifa2fa3fc25c348288b3ec143881904ce_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iae77bc715f014b6abd4b797b309ecbd3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1b06166a143f46ac8b776fcfa056152c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3b1c82a1c7814ef0bae95b14cd89caa3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i833340a21ed94b68a7b86f7be0fdf2ab_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i513c462b957b48c38384730437388578_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6a22bab8816347da9de17b819770d4a1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i156443fab6604e7abefd184b681ac88f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icd0453ae248b4871a513cc0481e0ba95_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i88b9b3ecee864a188d3318a7b3b10134_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i79b02c41c5dd4f85b666bb73366db6a9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i664b0e413d3e45a1b02ea0aca6fa69a3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i61127c264a134cadac4433659a4b2a07_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i73ed798ddb0d4b829c8f9df19472898e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i70ccbeb9d2904b8494fcca05b0e0aabe_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3cb505b42a7d41d197183c8cbc88fa17_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id7c7645be0b7483282e2fa48a952ce6a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9aaff90d56d04403ab9bcbaf508a1fb9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7d2ca052afdd41308acfee42874d16bc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1c6f15ef048940a2ba4ba7ff83b36db4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8e56043c08ff44629cc394d2f686ed56_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i98bd71b2478e4a04916636f59012d953_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i13822eeebaf946b9a83f2a817987763e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibc2e5f8264194107aa51706375b167fd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i794e4f01cf834ef6b6cb3fac8633384e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide78b4b7f0d04153ad16104b60a2684f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i69842657a0724c8bb9baf66aa7591fe5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0b7e271684784d7dae794919a0acb56b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i61a064a1cde64b1196d2dce7960e85f5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i34484c2dc9304341be78db8166e621e3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3ca680e493e94c14a2d7345742f31836_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i092466e16cdb43f4bb4f2f9191a72a85_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9e494a218a634591bd5ed5db40a1c47f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5f12c7af337245d5afb3786a6258a024_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3bb2f8457d7b431ea9f1c47d5413415c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifc4cacc943a04c45aa40ab1aca412a24_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6a6bf17320054464a3bc267f3849d5c1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i40c1afde566a44a2b60890f7234a9889_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5f0226418aa141e08a04b3292d3d6a3b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i69b2aa2945ce4106a4fcf5c0bdca8f28_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib2a8467fbacf40c38e699b24ac162d3a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5f9291215372429da56d3bf18442238f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie89b30127587468d9e71733bf07d5081_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iedd6b57e5ee3433abe93e62847e14d87_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if6546a28c4524eaab7537c0d6bf777fc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i21718856cc7648018662a2e392cd71a4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i74a16f60814741f98bcabd2ce43bcb36_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iac98ca2d21064f81a59741305eb998b4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic0f301d0c0aa40ab958148e4f5814aa1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia1f131cf4a5b4202aa0a668ee3ad2bc5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if33c4729f0e84f61be8298fc81de60ff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i348e70f83b254e66adb00f1a55a6328e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4979a9738ed14d44a7fc44641a6b295b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i44900a3d2ba94688bb7a0dfade50db90_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8f07727060b14c0d872f5f929cc9fdf2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i30f8590a90374b4fbc764b63834fe5ed_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0e302cf42eb74c9a84eab7578f54195e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i92825af11f15411da7e658f2ec15da12_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic35f4c541e614d33a6437788299fdc0c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i45e0d18c597e4ca2ae01fdfbd7881c3a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibfaa631e8e95431a9bdfa133e0488d8a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id69559bfdfb948d1a4ffa643418f21c9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie3548698f1b14ba68822ef5950d4915a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c690fe00ac54cd0a140a27f890f5c48_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i824f7d8e5c4243208069c78b91bbb9a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27bd677e9c7f4ab69c1c65c4a2154029_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8e5aea4693e4a208fbfbf2e410e5c40_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4c621536eda94c6f8d03472cdac1cc35_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic59f42fcfdbc43379e5b44f081585c47_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i780e0de404214dc29d45580e7b2531b8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i41956a7c7b7a4ab299edca9f380ca798_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79c41df237804e668c0da56a46ee0085_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c07df65da1d41098cd48baa32f21d8a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide714ebff4fb46809c7b477daae2d962_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifce16fa84c314d2d8b2732c6bf0d57e1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idf10f2216a934d5b9d20de4fa33c7e6f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i86ec4abb19ae49f0b238c47892dd4df4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1839e6fac09a4a4d9210d56808c687d5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i54f21829201d45aa939df14dd7b96c21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa7361567a884284b89e7bf5a20638a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i549d3edb71ed44988ab49d3637f8cf90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i36270f186c97490e84c4d0dd8788d411_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd9e6e86e84a497aa1ba2c847b3e7767_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i22c6271275734808a0ff96495b000a60_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2217b0ea8f50482aa528fde408cb76e3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icfea4630e695464ea306f7481b6e32ec_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0fbed77deabb4de589efde4d54035191_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i961ed43970894b70b047d465504721d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d59baf4935e4b848a146a795052db24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84eee8925bd946b48b71e527c679a789_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic665639028ad4946b03ef3d0a7ca3192_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3960deda1f4d454eb5bece595f0566f3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i897098b154ce4014a6261d31477a3023_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0adcb1eef7cb452f847c13e9842de931_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i25b8ac7aca374e42ba0903e04a423882_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idab563e4309c42b6991e40459e65c9bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i484390e670d3449786a771db7ab9ade5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i526c131b580f42bc9d870f04c6d8d5b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i926b7e069399438cb0fa7f1d96f3e3e0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i68a0012537fe46c5969295f09f2f6dd4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2ee3cd97581a4d2abdb377c19e3ebfc0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ide347640da714f3395ba489a540c603a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i276c9ea2224d4affa06277ba327a2d61_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72a95ff7958c4fb7ac5a1798d4dce9cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3136714317f0456c977067551e4bd81f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8a7c2c25d974d61a8013b71288affd0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44d10b847f5e406db45e5ac1953efe55_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i14621646e10c4fd1b6c4a65065d514ab_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id3b775bacbe44316aae442a85d447f1c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ide0afddf10ce4f31895aad1d16c1d85c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4c1629420b3f4c80b65c3eb9d05ee4ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96153a6dea77431eb98e9c8200e6181a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f662a891d89402584dcecd95385ff8e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4532563975f4635bce45eb0d2ae51f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i78c02433e66541af99b97939d39e23a0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8e8d9e0325a1434c858eb9522b968441_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic21fe9fe9de1442b89efde9577f52f46_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4b838d5587cb496093b251362509ac97_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic1f0e139c0cd44a6b90716186d108008_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0fe330b4018048f1898231a7f4ff4ecb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b84e22ee5ab4a49ba427501bba85dd7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b4898fa0a764d7aafa5e9a1d6d72ef3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf1508526e8c4ee1b4e7b2a680bad4c4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia9769a32b3db420e9bd1bec55f864b91_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i316acb6201d34cd8b84ad4bc0a229326_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i29435eace9144606b96eee2d02e381a8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibbabaed951aa4295ae68d516beb80338_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a4501dcb7b04327b30565529b2d48aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i799dd8cb5a934a67aad9f2247cd1f8b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb74d6dc685f4234af1aa0e61f985bf7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia380e72b9e514a0dbc10fa47a96a37b9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia0202af8459b4f3789926f58b9cf9752_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i42edfdab86c9426e93701ffdc0c7fe94_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4c80ed86b032450995903fbe43ad034e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i54901c86be024d34813c278457433dd1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c04316279d5406ebb97ec435e024e2d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1502ee19eaa24b0992c9886bfc77cb5b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib15e0bfd36234157af17a4ce20b77d43_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if364edca58da421d9d61dae9fcad7914_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i40461f1ac8b940ce8fec799328c0881a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iefe2d6409bd5447b881a310ce4725db2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i87d5b42f92744945842d42ff308f0e20_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib6428c6244bd40588e98b0566fc843e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b69704c2d87477fa4c4e048aef6c84a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28c7735eb6934c9290f2ee14fb060da0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iba8e7f03185947608f3762d7182fac94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icccb697c433d4ec09b49c19f13ab8a83_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i373b78381e234c3ca41660182ac003fe_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2e9cc0b50d7c4ab6bc2905f65769e3b1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie8a9ceaf8e034398898fc7c7ed8656c9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5ee81b72feb64a13bb9b256646717944_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ccfe72a95f54aa78e87fe00e6420d4a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e7f4d6bbc524f168c63679b9a7e91fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91039368c3bd4bfb910457fd3dd4c000_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i989d63bf16b04e01a3d9b072d85d1ba9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i31da5834b4314564824f60b82ecae0f1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i35eec1666a264bd3b71436f39b919d85_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib3e238999bb54c4099da8e86105699dc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0cd694a407d04faab683d1cd31f7d8a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c237a39755447a48b076df315f9ace7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i48f04e6cd6d84fc3bb90b473f068279d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5faee6f594734e2eadc6353454b6d927_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72ccac9d876f460bb41bf5ff8f83566d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i176ff44bb5764e3b809a6d1ac92b4178_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib6ef3db73cbc4509905d24a522ce5757_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0da35341d6714931bc1689adaba0f122_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4da087316a0f42869c52cd83bef39303_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie1511de451544838b5b9f248bbe33b1a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94f9fa2675c74baf9fc13fcaa1d41e1f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id37cb24882ef449585ce764d602b950d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1be5d0f90b94ff6beab639c85963cc9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iff3127bd77e544569634499a4cf507c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice6cc9ca3679429daa7ddad7be3b18f8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i823c5759f91342788099a4a119a8361f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ccaa167281f4a20b66d52b3c71f1dae_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8dcf510e014b414ea7b2dc9b96ebd136_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i78a2c5f5c07343a095efd1f37fda91fd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4df9dcc40c9941ea8c7e26f4f58967e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7dfebbffea394aacba0aba288b9dc053_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gild:EquitySecuritiesDonationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gild:GileadFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0b50cb54d91f4e6c99676d255fa29fad_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic6a9dc16a8a0426d985e8a948bb5bfb1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4da7a64c618429d8996f9b339ac38a8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6c6903daf0954d94b44190d9b3e1b5ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76c056d0bef64de1a20dc89b76c1fa78_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie5d7dd3905d64e28ac9327a66e603863_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icd2639a9859c40faa55868710c142818_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i48f52dc3cab841a3809ef785e4e66ca3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i03b29e17a2c248719dab9a52b28f2838_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib9848c60df524b6d8597f27a5c2348a7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie1b6844083d54dd6b01c081a66abc0ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf1a2f42beca4dbfb5c2042c0e6ec2c9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i91b301a386454cff8a23c0f9d5802e0b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9edacacd9fed40b19c21f8c9a2d1066a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibdd06b56ab884773b9a6d59b91979118_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4d28e4219744460aa5d638f0e4748d7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icb6a3f0759ad4433953398e7ad344fd5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4fcdeab4094c40bc957aa0ac494ab157_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8aa08afccd2c4c3c920afbf679603457_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie91dfb2ea1ff4696bbe46980e5074985_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i36fc4c8f965c42f091bfa62e48d5188c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77ef7763dceb461d8ba101eedb3ec351_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2a621708b219448a9f522102302751fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i358d5e6dcfe74eb2bd53d281984be1b6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibd2b0d3a5d754eba9ec5ab61ab8a496c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iba883e2763fc4f24aa849f2ba1b18762_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i441b41e448e24773b07474571334d688_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic68b8c1df06a4e9ebf5ecc3162d4e91b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i41080ff3b0f84bb6ac2d71f26d888ae3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9de9bbb3a16148ef822890fed3ae38df_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4f577e7ed1d9420a854f73986479f887_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2a621ab557e54d8aae26f9664ee66d03_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0316527653e540b79aaa8ffd4daeb2e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idcc66a969998454596abd65746688f8d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33df3af625fb41ae885fec733687b6cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if2c72fc1463e44eb96aabd7dae05dad7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a2c8de705884a04944f9028afb662e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07a3a9b39d3f40068ad241a4bf584ecf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d9378e46bcd49c1aeccf6c8f61de218_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3efa4fc2e80425d911786fe90f0577e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i318a011bf49b49c3a79192b82583bb57_D20210304-20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="ib5181ad1c63c4deeb36365ffdce5e584_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i59fefc5ad8ec413db93d451131df6e85_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i352358e211a34a23b9dc88776f5a0076_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i7d953182d7f349f7880aa6b8782ddbea_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i46f837bb32354303808450010f541cf2_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i6d0182ee77884d308f972ee3ac8635f4_D20210304-20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="i91c7b3ebdf1649509a1e026f30a65baa_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i0680e69caed6418b9c239d0f897aa373_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8a84de62d1ec4a0db403459b92a7debd_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="if38c0f756f6945658b15ba7c6e9bb284_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i15facb5b1aa5415199d533abd8de3199_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="ie94f540fb43d41c2a993dcfcce7e6d9e_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="ic7a6d7dbc5194ce3a5c2c451b949a083_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i90be553f64364971a7f334cad33d512f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5e6bdf7f4837439c93c50b528a400b0e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i59fc30c6ac6b49d88f04a9291366fc62_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id248063645c14c6ca92fb1d761be74e4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ice9f0c8cd2fc4c7ebfd9c7829f4948e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica281eb0ea274e8fbe28117ec9397184_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i423d39bed9384081904c47d75b0d641a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a0f810172a14dfaa8af6a1edfc4646b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i25358862393f4ca4b14b4364da42d681_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie35fe5b3532249fbaa1d215c6cea8f90_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3a065190f73644d7a438667b54161f4e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26cf0458992d429ba5ed5fb92c5a2436_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5a12c46bb79a4f2797fb774367f4f73d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1922554024b64cb8898c1f3fd434e8da_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i969a0f7a4e6f4d7bb52b87c7b652a57b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i097e3a84fba5476487ee41ea9a26f8b0_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i58f39982e7154710a0e9bffb98d87c09_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i186934b8fe964624a8c713e57b5bc48a_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i0f1396f1bd31451bb640de4f9f3638b4_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i5af10497a26b467daee57d68cbd93a36_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic84bc582b1d04652bd6754bb4901989d_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i856f386d4aa44a00a2c20f4010d3fbc5_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i199d5ca3470540be922bc9d2707767c8_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="ida214684d6f748fa94820133c41fb9cb_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gild:MerckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="ic4b2d0d8fb10491f844ccbf3c9d99659_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OralFormulationProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="i7a7ea0a008d44d19aeaba7ea8a234a79_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:InjectableFormulationProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="i4fbddaa5defd43eda896eb3f45f893de_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i94b469d6b3cb4b1cae15cc21665e0bbb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idcb33e823a4c4f73a7d1f634b45cee94_D20200527-20200527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-27</startDate>
            <endDate>2020-05-27</endDate>
        </period>
    </context>
    <context id="i3878c6df63be4399a67430941e5732c7_D20200527-20200527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:CommonStockPurchaseAgreementAndInvestorRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-27</startDate>
            <endDate>2020-05-27</endDate>
        </period>
    </context>
    <context id="i7e4ffaa955f9435b9bf6dff41e50e726_D20200529-20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-29</startDate>
            <endDate>2020-05-29</endDate>
        </period>
    </context>
    <context id="i18ae4cc7725f4c96842b14bc9e4daf0e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i48dadb586c444781b30fb3c1b0888939_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i819ce30a96d84a66915bb6c431c7a737_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iaeaa95ca088c4fe285e88b406cff5320_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibcaa35425c334e66adfe9c0143a54cc5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i36771d101b1945cd9d9de5fa0410171b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2084f6bcb60540018e9a4b1e4715c369_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i075533c7d37d491793ebc09f561f12c8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1beee1ec406146d38e3211fa2933708d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43c2519105dc4bfdb185e7ebc59a5a2a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7b6417210f0c45cab95af5ede847f506_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic250ebc316ec45b1bbe84636770ce814_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a816c3a555a4fa08e58b54a04015ffb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A440SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie2fd7afacc2446fdb2b73b021c7ec4c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A440SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c2641db1ef947ebb5c2e598d80af8b7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A195SeniorUnsecuredNotesDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i047f7d6efaab4949ba75985dec2bd448_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A195SeniorUnsecuredNotesDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b207ad1f4604e47bf243a142f719c3d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A325SeniorUnsecuredNotesDueSeptember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ide3713760e2f406f87de6a771c56330c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A325SeniorUnsecuredNotesDueSeptember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i378aa93017824e3e9bd151f32b47c054_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4ebf78ad2ccb4d43a991df3fd307bba9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iafda4276088e42e3a214977fd3664e77_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie2c0f1bb661849bbafaaac95aa413df7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i718060d949f64ee2b8c966d8822e9de3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd18b3372b0d4339ba7e932b3bcfb631_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3a673086504e43c08aba24aa7d8a2fb6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie39bf03ca3dd4c7eaf82c5f3247707e0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i96e9697694914c628eb31495e561618f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if73fdd4a8341456487fd2dedf6c2e9d7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i81c97bf760b64de9bbdde1c94a7b8ae2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4ac5b7017d1476fb5bcd16b536f43e8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifb213534bbcd45118c1bb26b41e1e907_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia58159b24bd345179d097a8c8fa338da_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6a046019e56c4f54b51b48b7aa1d9d88_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3836e4ff9f5545ad88927b7ccfe6ce9a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic4cd61c4d420435f8f8a47a822a2fb94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia75a4a1f883644e593643caeeb64e8c8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i831cf307aaac48e3a4f36b76c1ae6821_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia606b7a94a2a4a27be3bac90bae27db7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i033466f65d06435daaf05ce68cdea42a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26def8fc057343cea1511af0a42bbd82_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i793861fc864b4d84a4d7675fd3879f56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i334415af3e3b4544a67d9d7fca63abc9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iab18c39cd70d4664b5614e5d608d97f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3a50f56b0a243339131abb7a4e8302f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3aab6acda6824604a29d697a10699b89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56cf1e78acd541bf8bda7634c9734818_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2d8992e066ac492e96f9427867db1b37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id18ba93f1f954ea7825f560783159641_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i47bdb44a5bf54303b2b1c5d712c9b5f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69e5c28f892a4699b116990ce04af8d5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ida4a76b2bb9c486ab32b0ed960911667_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c9e673628f24f989a48a76bc085f8ad_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib475552eda99433d86c1a416ace1cc9a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i063be5049ee1464b8b050a5513490bf2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3282c94d1c174c6ea5efa7ab36b47b19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1bfce21e9994d52bbeedde558474519_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i729835fd97c847689dae526ba4c3f80f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09bfaa553aa8422b9801e9811d4f84ff_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i31b25ed89c604903b3ab2cb0f953dae9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacd82538440946f2b5a64f02e99bd78e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4ecfcc11f2b44bee8fc31ff744993188_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i20624e63c9d342039f2acd0aa0e221dc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia5e1397cca1b4612bda3fec5029c7caa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A440SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4a838956d382494aa01dce9ce9a74af3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4f517572134b4e7bb737cffba5c07c94_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i50cd74cb77d0435b838bbc259636ca23_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i755d8293c829458682df87bc82180dd0_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="iaf9f1c5fb1234d22a178a74091f99dd1_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i6198bb2c3e1b4f7a86b03b31b9a31291_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ife22d5290cb340d48c49cda6ebce356c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia55d69200ead47739810b75c12b1c289_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i294c3dd1a0044d64b2a2c206819a4787_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i08188eab1c8f48659c9fb097dbfa6ad9_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i1e74f009f33c41a1b3024e5689146bb1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i40650c0325e24e0db701d2ab8acfe659_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:PreExposureProphylaxisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ie57e22e42a844c1c934bc94bfc2e2e72_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic6c268206d494d42a3e01744ecb78d28_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2024ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i842ab5644f88423ea3fb5a3f08f81d21_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2026ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie5c2c8d7ed2c407cb3c28ad661f37190_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2032ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib144fc19e2424cdea1de575c395ea438_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2027ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i32e0f49607724a678979d40a5566567c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2027ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i50d725ee8e5d42e8b1d6a84547e3f2dc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if347b8e9f0f441978924331eb15b50e0_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:QuiTamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i86e5d209900446c0b30dc2880295f243_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2016StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="id644c4f270bd409c8d4eb7dbc0893a59_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2020StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2a5998ee4b384480a72487be18641c7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c3d265770c244a0a765e499a4ee7cb9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c0ff94d0a674ceabb8a179fc4e48905_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45325645469947adb3cc8720858aa852_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2b5cc9befb344284aed69e9c8209aba9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if101dcd8b89a438ab7ac5691e108990a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia8bee7f2d6524b07b87afe756d78590e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4990ffc169374b34bdd3f918810fc418_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i79d0985dca0949ec872d8eb72624d97f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i414821821100441394f7829f268ffe4e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0cf07b371d2f4766b8d9469daa886de3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3e4e4f7365f94609beeaed0a72a5533b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i967254dd024046df825693124da51c02_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id89abf1e3aba470fbcbb850fec50b11b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i216f4d250c4d49e19ca6cf3b0d5a5818_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i54fe2a88a4c14a76a2d768cacc3e0995_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i20b67d0bcd224fc9a3adb44b3d27fd5b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5cf587a459224feaac6e5a4412d46585_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3ce0a2da343c4d92b5c1b28c7b50805f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>gild:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="position">
        <measure>gild:position</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="agreement">
        <measure>gild:agreement</measure>
    </unit>
    <unit id="patent">
        <measure>gild:patent</measure>
    </unit>
    <unit id="opposingparty">
        <measure>gild:opposingParty</measure>
    </unit>
    <unit id="party">
        <measure>gild:party</measure>
    </unit>
    <unit id="lawsuit">
        <measure>gild:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>gild:plaintiff</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80L2ZyYWc6ZTkzZjUzZjY5NzNjNGJmN2JmNDlkZWJlNjQzYTZmZTQvdGFibGU6ZDlkZjE5ZWFkMTZlNDVhMzgwODRiNWQ1ZWQ1ZTE4MTQvdGFibGVyYW5nZTpkOWRmMTllYWQxNmU0NWEzODA4NGI1ZDVlZDVlMTgxNF80LTEtMS0xLTA_c06cf68a-0df1-4b81-ad97-72d84e081397">0000882095</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80L2ZyYWc6ZTkzZjUzZjY5NzNjNGJmN2JmNDlkZWJlNjQzYTZmZTQvdGFibGU6ZDlkZjE5ZWFkMTZlNDVhMzgwODRiNWQ1ZWQ1ZTE4MTQvdGFibGVyYW5nZTpkOWRmMTllYWQxNmU0NWEzODA4NGI1ZDVlZDVlMTgxNF81LTEtMS0xLTA_9519a0f5-a985-487d-a40f-06b88d936db2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80L2ZyYWc6ZTkzZjUzZjY5NzNjNGJmN2JmNDlkZWJlNjQzYTZmZTQvdGFibGU6ZDlkZjE5ZWFkMTZlNDVhMzgwODRiNWQ1ZWQ1ZTE4MTQvdGFibGVyYW5nZTpkOWRmMTllYWQxNmU0NWEzODA4NGI1ZDVlZDVlMTgxNF85LTEtMS0xLTA_107b9f75-ad6d-4494-9dda-0c07bddc5caa">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80L2ZyYWc6ZTkzZjUzZjY5NzNjNGJmN2JmNDlkZWJlNjQzYTZmZTQvdGFibGU6ZDlkZjE5ZWFkMTZlNDVhMzgwODRiNWQ1ZWQ1ZTE4MTQvdGFibGVyYW5nZTpkOWRmMTllYWQxNmU0NWEzODA4NGI1ZDVlZDVlMTgxNF8xMC0xLTEtMS0w_31c3ecc7-6f25-4d88-9402-5f9635997df3">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80L2ZyYWc6ZTkzZjUzZjY5NzNjNGJmN2JmNDlkZWJlNjQzYTZmZTQvdGFibGU6ZDlkZjE5ZWFkMTZlNDVhMzgwODRiNWQ1ZWQ1ZTE4MTQvdGFibGVyYW5nZTpkOWRmMTllYWQxNmU0NWEzODA4NGI1ZDVlZDVlMTgxNF8xMy0xLTEtMS0w_75130ee1-5412-4a23-8f08-cc0b7dcc7393">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM184OA_d7f163ba-83c5-4a9c-86fc-a55a9c0b261d">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGFibGU6NDMzMzkwMWQ5MWU1NGQzMWEyYjBkZTlhMTZmMjAwNDkvdGFibGVyYW5nZTo0MzMzOTAxZDkxZTU0ZDMxYTJiMGRlOWExNmYyMDA0OV8wLTAtMS0xLTA_b7d104ea-54c6-40cc-8973-b49dd177fd6f">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18xMDY_a4d6cfbe-306d-4685-8032-96839821c4fe">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGFibGU6YjQyMDU5NmFkNjgzNDczMWJhMDQ3N2NlZTBkYjM1YWQvdGFibGVyYW5nZTpiNDIwNTk2YWQ2ODM0NzMxYmEwNDc3Y2VlMGRiMzVhZF8wLTAtMS0xLTA_165c8b72-3a3b-4f99-b1bb-168425085bfc">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18xOTM_f866df4c-22e0-42c3-9c1e-64330e563ce8">0-19731</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yMDE_40197ec0-d025-4c76-a2e6-4a09e0e52868">GILEAD SCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGFibGU6NzZkMGFmOGZiY2QzNGM0OWEyZTkyZTNhMmZmNjAwY2YvdGFibGVyYW5nZTo3NmQwYWY4ZmJjZDM0YzQ5YTJlOTJlM2EyZmY2MDBjZl8wLTAtMS0xLTA_8db0d471-6d73-41a2-b47d-d4ba7f45d481">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGFibGU6NzZkMGFmOGZiY2QzNGM0OWEyZTkyZTNhMmZmNjAwY2YvdGFibGVyYW5nZTo3NmQwYWY4ZmJjZDM0YzQ5YTJlOTJlM2EyZmY2MDBjZl8wLTEtMS0xLTA_2b423a58-8525-404e-a3f2-8bd6ae7a54e3">94-3047598</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yNjU_b544f0ea-2db1-4a3b-acf3-852427b54621">333 Lakeside Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yNjk_84339777-84d1-4f40-bc53-571820aa5f86">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yNzM_609966ac-4509-41fd-97a6-ad1ebe3efffa">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yNzY_74b96839-a04d-43dc-aaa7-2bd2b81843c0">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18zMzI_38f42e47-ad30-4ea7-a294-9bfa3465c102">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18zMzU_f15260cd-4373-4787-95ff-5b829872f1ed">574-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGFibGU6ZTg3Nzg3OTU4Yjc4NDUzMWJmOGU2MjhjMzY2MjExZWMvdGFibGVyYW5nZTplODc3ODc5NThiNzg0NTMxYmY4ZTYyOGMzNjYyMTFlY18xLTAtMS0xLTA_28a5d219-616c-4387-a68f-c704be315487">Common Stock, par value, $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGFibGU6ZTg3Nzg3OTU4Yjc4NDUzMWJmOGU2MjhjMzY2MjExZWMvdGFibGVyYW5nZTplODc3ODc5NThiNzg0NTMxYmY4ZTYyOGMzNjYyMTFlY18xLTItMS0xLTA_13e33f68-446a-4325-9c1a-cacbf51593af">GILD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGFibGU6ZTg3Nzg3OTU4Yjc4NDUzMWJmOGU2MjhjMzY2MjExZWMvdGFibGVyYW5nZTplODc3ODc5NThiNzg0NTMxYmY4ZTYyOGMzNjYyMTFlY18xLTQtMS0xLTA_9bec9a5c-e7a8-4968-b2fb-dbee330e522e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM184MDM_db43193d-70f4-4164-ac39-b562c5cd53b7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18xMTIy_1d07015e-d6ed-4fba-900b-008f446f0d74">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yMDgz_46b14de5-2afe-406f-9860-d1d449a2b264">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yMDg0_8ac63091-d201-4957-a351-fcbb992cb255">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yMDg1_22ed2acb-a724-428d-881a-41d3d5067ac7">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yMDg2_99b9ccfa-b8fb-4e44-b109-94ba49c9801b">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i3eac3303cc9649e2a0b0fd67ca07ce16_I20211029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xL2ZyYWc6ZjIyMmQzMDM0MzllNDZlOWEwNDVjMWY5ZmI2MGU4YTMvdGV4dHJlZ2lvbjpmMjIyZDMwMzQzOWU0NmU5YTA0NWMxZjlmYjYwZThhM18yMDgw_3baa4bba-e01a-4ba2-add6-719f3249c84c"
      unitRef="shares">1254383522</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMy0yLTEtMS0w_acf7e619-54ae-4f7c-8489-179b17eb8644"
      unitRef="usd">4362000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMy00LTEtMS0w_c7be5e97-21d7-4377-bf7b-5ca97eedfa4f"
      unitRef="usd">5997000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNC0yLTEtMS0w_cbaacc94-3133-4362-a620-2c45e90a129d"
      unitRef="usd">1376000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNC00LTEtMS0w_7d656edb-5a43-44e7-8a41-18a860fc8ba8"
      unitRef="usd">1411000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNS0yLTEtMS0w_c1c9221a-b1b2-45cb-bce8-568a444b0420"
      unitRef="usd">4566000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNS00LTEtMS0w_b6b9d9b5-938e-4997-b9a7-f8cd3e08997e"
      unitRef="usd">4892000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNi0yLTEtMS0w_bc51ffc9-f735-4f79-8b58-86e21905abcf"
      unitRef="usd">1676000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNi00LTEtMS0w_cbeb2af3-d33e-419a-bcd2-ac8b0035de6d"
      unitRef="usd">1683000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNy0yLTEtMS0w_a51fa232-f35e-457b-9af8-0de7063eda35"
      unitRef="usd">2011000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfNy00LTEtMS0w_95df602b-17ac-4ddd-a841-ba453cf2f699"
      unitRef="usd">2013000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfOC0yLTEtMS0w_d9fc7487-1627-4edc-a198-6e2a4b664a62"
      unitRef="usd">13991000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfOC00LTEtMS0w_5746a1e3-9295-4147-90cf-ac8cf3d914c9"
      unitRef="usd">15996000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfOS0yLTEtMS0w_4299a45f-f7ab-478b-bcce-737d6fbff379"
      unitRef="usd">5037000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfOS00LTEtMS0w_4b6acb07-c9e3-432f-a1b9-0eea98c3c11e"
      unitRef="usd">4967000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTAtMi0xLTEtMA_21a3ddd1-90c6-41b6-a8b9-75b159f6d49f"
      unitRef="usd">1099000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTAtNC0xLTEtMA_b6e867b8-62a8-40bc-be2f-4cceb62be1d4"
      unitRef="usd">502000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTEtMi0xLTEtMA_deeeddf7-c331-4f1d-a45e-8b2a4444ef92"
      unitRef="usd">33900000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTEtNC0xLTEtMA_67f8d0a3-30c1-4bef-a5d5-a8a4aaab1ae1"
      unitRef="usd">33126000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTItMi0xLTEtMA_6610c622-ea66-4d60-96c0-c97db83beccc"
      unitRef="usd">8332000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTItNC0xLTEtMA_d4eec289-38af-43d7-bb31-1421728c8101"
      unitRef="usd">8108000000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTMtMi0xLTEtMA_3391c752-df97-4219-ae06-ef8a5c46c11a"
      unitRef="usd">4739000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTMtNC0xLTEtMA_fedd686a-9211-4273-8f2a-29af2cf26dba"
      unitRef="usd">5708000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTQtMi0xLTEtMA_21de837a-c693-40a6-af10-a817a59a4258"
      unitRef="usd">67098000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTQtNC0xLTEtMA_bef9c0da-d66f-4566-ba6b-d555c8f20705"
      unitRef="usd">68407000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTctMi0xLTEtMA_7955f049-888d-426d-91bd-28eda0fc746b"
      unitRef="usd">585000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTctNC0xLTEtMA_b11c4c0f-0429-41e7-aff0-819e2fa93c5c"
      unitRef="usd">844000000</us-gaap:AccountsPayableCurrent>
    <gild:AccruedGovernmentAndOtherRebates
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTgtMi0xLTEtMA_6fcc587e-fd61-4cbd-808a-b4e3b780a92b"
      unitRef="usd">3368000000</gild:AccruedGovernmentAndOtherRebates>
    <gild:AccruedGovernmentAndOtherRebates
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTgtNC0xLTEtMA_4e6183fd-0a48-4cb0-9dbf-b88ae1fd9660"
      unitRef="usd">3460000000</gild:AccruedGovernmentAndOtherRebates>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTktMi0xLTEtMA_726efd7e-2404-426d-8548-270c2dbd490d"
      unitRef="usd">3781000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMTktNC0xLTEtMA_b3c64286-c825-4bf2-ac9a-3948bcc953f4"
      unitRef="usd">4336000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjAtMi0xLTEtMA_eef6f5c3-18aa-4b39-aa25-89a23118c439"
      unitRef="usd">2511000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjAtNC0xLTEtMA_43085672-022f-42ed-9f82-cc9ef0645730"
      unitRef="usd">2757000000</us-gaap:DebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjEtMi0xLTEtMA_155c053f-5c0b-4be9-9568-226acfab3acb"
      unitRef="usd">10245000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjEtNC0xLTEtMA_164a79ea-a3a7-4009-87e9-12a273f00f46"
      unitRef="usd">11397000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjItMi0xLTEtMA_3981c46d-7599-477b-b65c-4591211412a8"
      unitRef="usd">25175000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjItNC0xLTEtMA_22739a13-0968-47a1-bf24-903511706e64"
      unitRef="usd">28645000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjMtMi0xLTEtMA_b56e6918-2774-45a2-9dd3-a47acdd23c5f"
      unitRef="usd">4642000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjMtNC0xLTEtMA_a3179c13-e77a-408c-83f0-f72ac42b80d4"
      unitRef="usd">5016000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjQtMi0xLTEtMA_8d96c6d9-9a46-48e3-bed7-960713131f7d"
      unitRef="usd">4603000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjQtNC0xLTEtMA_b825c2e3-4217-4168-aaca-6c2fbd2b43d3"
      unitRef="usd">3914000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjUtMi0xLTEtMA_cadd006d-6a53-478e-a640-f09bcf7e579f"
      unitRef="usd">962000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjUtNC0xLTEtMA_65001a10-1a23-4b71-84b3-10d89f4dc3cf"
      unitRef="usd">1214000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjYtMi0xLTEtMA_c160dfa1-8b92-48c6-98a8-7fed549d9ccc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjYtNC0xLTEtMA_d5155486-a7de-43a7-a297-f0b38c2718a2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjVlMTViODMwNjFhNDQ4YmI4ZTQzMmY3YTcyZDNiYTQ5XzMx_713ce8ca-558a-4f2c-b9bd-ac02050402af"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjVlMTViODMwNjFhNDQ4YmI4ZTQzMmY3YTcyZDNiYTQ5XzMx_da316f45-1c30-4428-9125-4c25fe36a7fa"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjVlMTViODMwNjFhNDQ4YmI4ZTQzMmY3YTcyZDNiYTQ5XzQ1_9c1bd033-c7f8-49a3-848b-4e2e73c16afd"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjVlMTViODMwNjFhNDQ4YmI4ZTQzMmY3YTcyZDNiYTQ5XzQ1_fe3e7b5a-4a65-4b01-83fc-d10623ef5f91"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjVlMTViODMwNjFhNDQ4YmI4ZTQzMmY3YTcyZDNiYTQ5XzY3_08762b48-24ab-402c-8fc9-c2716add2c9f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjVlMTViODMwNjFhNDQ4YmI4ZTQzMmY3YTcyZDNiYTQ5XzY3_32ce2d2c-273c-4e3c-8d90-00030d597e23"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtMi0xLTEtMA_83f3152b-1f73-4cb1-bab8-596bc3ec7a6e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjgtNC0xLTEtMA_6cc1d84a-8d17-4e09-ae96-112c2ddf9816"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzI4_1418abb8-f304-4727-be2e-b6081bf6d1cb"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzI4_1e5a973a-e563-4531-95d1-b86880ea99f8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzQy_3a153e5b-0682-4838-933a-631ddd624486"
      unitRef="shares">5600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzQy_caafc6f1-3c4b-466b-8900-b37117bf59c8"
      unitRef="shares">5600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzY0_067fe071-15ec-457e-834a-660c9c25e035"
      unitRef="shares">1255000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzY0_aed738fd-5cb7-4873-8778-8ce89b9617d3"
      unitRef="shares">1255000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzE2NDkyNjc0NDE3ODk_04cc31d9-8fd1-4065-b2a9-4a03b6944629"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmNjMTc5NmE1MTFlYjQ2YTFhYzA3Mjg0MmNhNDk4YTRjXzE2NDkyNjc0NDE3ODk_5b74f9f2-0c9c-4775-aadf-7b81feb40d08"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktMi0xLTEtMA_1648b7ac-e9e0-411d-8ccf-73b0fe7568c8"
      unitRef="usd">1000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMjktNC0xLTEtMA_ea6e86bf-09c7-4a22-b037-2129648ec134"
      unitRef="usd">1000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzAtMi0xLTEtMA_f08075c0-1e51-488e-ac79-1682996c90dc"
      unitRef="usd">4492000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzAtNC0xLTEtMA_e29541cd-8a4b-448b-9537-a6f756b7db35"
      unitRef="usd">3880000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzEtMi0xLTEtMA_0e5272a5-d526-4d75-b167-6ce3624663cb"
      unitRef="usd">74000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzEtNC0xLTEtMA_5194a20b-e362-4c65-8ada-a00cc216fe6f"
      unitRef="usd">-60000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzItMi0xLTEtMA_b142aba4-95f4-42b0-9fa7-d15635971351"
      unitRef="usd">16903000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzItNC0xLTEtMA_0b0dde27-f085-4702-b64b-864b56d3e906"
      unitRef="usd">14381000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzMtMi0xLTEtMA_30da2aba-157f-426c-869e-4744ce2d2b0e"
      unitRef="usd">21470000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzMtNC0xLTEtMA_ffc22a8a-7704-4afa-a028-abc32f19db7d"
      unitRef="usd">18202000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzQtMi0xLTEtMA_d4c7cf5a-5b2a-4c87-8318-bea77b69d62c"
      unitRef="usd">1000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzQtNC0xLTEtMA_b6d79273-ba5a-4faf-bf93-054a6698116a"
      unitRef="usd">19000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzUtMi0xLTEtMA_6beca6ba-a5e9-4859-9db3-916a9df0877b"
      unitRef="usd">21471000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzUtNC0xLTEtMA_76faec9e-7105-49f9-9950-33f20127adea"
      unitRef="usd">18221000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzYtMi0xLTEtMA_dad3058c-3c06-48c2-adc6-7e2d55e7fc82"
      unitRef="usd">67098000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xNi9mcmFnOjJkNzdmMjZiMGU2OTQ1NjlhN2FiNGQ0YzE3YmIxYzMxL3RhYmxlOmFhZTE1M2IyMDc4ZjQ4MzI4MWM4ZWViYzNkYzM2YzczL3RhYmxlcmFuZ2U6YWFlMTUzYjIwNzhmNDgzMjgxYzhlZWJjM2RjMzZjNzNfMzYtNC0xLTEtMA_52f4fa92-f983-48b1-8be3-40a02bce3e3c"
      unitRef="usd">68407000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcc4638e68b041b3aed502ac0da98085_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNC0yLTEtMS0w_778d90d7-743f-447d-b10c-78910fce8647"
      unitRef="usd">7356000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i113f7696af45458ba1c6270ba2e89d75_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNC00LTEtMS0w_cde0eaea-80aa-4077-93e4-eb46150ed084"
      unitRef="usd">6493000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7a2ec8073884bc5881bfa3d3afda11c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNC02LTEtMS0w_c1e30d6a-10e3-4f05-bc02-9b05d35efeb7"
      unitRef="usd">19848000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4666b276ec7d40ea86d10c4ded816760_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNC04LTEtMS0w_bf0ebbef-f3a1-411d-b54d-8a1de1b7fd21"
      unitRef="usd">17027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if593c50c51de4ecab2682f502e43fe0b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNS0yLTEtMS0w_5aba8e30-8408-4e44-b1bc-c175f291be7b"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80719b1e7cda4bf6adddc01b671e7d5f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNS00LTEtMS0w_2938e66c-2272-4def-85a2-cde3a9a32186"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a47277681854c0eaa992a6c02b6acb3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNS02LTEtMS0w_b839332b-4105-4c6f-8af4-d151518e5546"
      unitRef="usd">213000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i528488c905dd4c8da2e5a1389a8b0a59_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNS04LTEtMS0w_3a1cce88-5bf4-4b66-917b-78f8f9351108"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNi0yLTEtMS0w_6a693999-0855-4092-8465-bde662d6a2f7"
      unitRef="usd">7421000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNi00LTEtMS0w_4321661c-2f8b-458e-88b2-b9a4071a4b6b"
      unitRef="usd">6577000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNi02LTEtMS0w_c59fc90c-1b94-46d3-8c74-68745f2f26e1"
      unitRef="usd">20061000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfNi04LTEtMS0w_1b6e1eb0-be89-40c3-a037-31e3ae1f871c"
      unitRef="usd">17268000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOC0yLTEtMS0w_f3a223b9-9f2f-4438-aa4a-518552568b88"
      unitRef="usd">1223000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOC00LTEtMS0w_d2efbe11-714e-4b81-88e6-4a19baa33766"
      unitRef="usd">1141000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOC02LTEtMS0w_e2ef5ce3-64b1-4f42-8b30-95e11bc9e9c0"
      unitRef="usd">3974000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOC04LTEtMS0w_5337637b-5080-4f20-930d-c6433d384782"
      unitRef="usd">3174000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOS0yLTEtMS0w_b505774c-811e-43d0-a993-4c4f0abeb340"
      unitRef="usd">1147000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOS00LTEtMS0w_b214193e-c853-490b-bf45-6cef4377ff08"
      unitRef="usd">1158000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOS02LTEtMS0w_c19b5327-4264-4367-ba23-a1b1f15ab490"
      unitRef="usd">3336000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfOS04LTEtMS0w_91f18296-9268-445f-b18c-0cbb3a62360e"
      unitRef="usd">3461000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTAtMi0xLTEtMA_efdd920e-8b9f-4c6e-b4d4-2fdf9928656a"
      unitRef="usd">19000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTAtNC0xLTEtMA_f026f8a5-3494-4b08-8982-27a0a585170b"
      unitRef="usd">1171000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTAtNi0xLTEtMA_c12dd00e-79ef-4ca7-9e7e-f40df9b0cda6"
      unitRef="usd">177000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTAtOC0xLTEtMA_f3195434-76fb-492f-ac7b-4f40115d8af0"
      unitRef="usd">5792000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTEtMi0xLTEtMA_0458e2e3-815e-44bd-a2b5-3725f73f5512"
      unitRef="usd">1190000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTEtNC0xLTEtMA_b6fe8f2d-0332-499a-a370-9bbcf10726c7"
      unitRef="usd">1106000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTEtNi0xLTEtMA_46371e09-6942-4b32-9690-5124cb7b9ed2"
      unitRef="usd">3596000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTEtOC0xLTEtMA_8144184b-6265-4795-bc38-58308e627a15"
      unitRef="usd">3421000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTItMi0xLTEtMA_e3ef2ce8-6710-40e3-8192-924c201fb5a8"
      unitRef="usd">3579000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTItNC0xLTEtMA_05ac4b4e-4d42-4d23-a012-546fa5f6d4e2"
      unitRef="usd">4576000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTItNi0xLTEtMA_4ac7ed3b-ef78-4e37-91fb-bc4748431b49"
      unitRef="usd">11083000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTItOC0xLTEtMA_ac55e62a-f4c7-4242-8ce7-93745d219ebe"
      unitRef="usd">15848000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTMtMi0xLTEtMA_5a20458c-c129-47e5-8add-f9c67741f160"
      unitRef="usd">3842000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTMtNC0xLTEtMA_415e5e15-a329-4384-8de8-03c5f13ca740"
      unitRef="usd">2001000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTMtNi0xLTEtMA_02fc6761-68ca-4b51-a5d3-452cf1cf56ae"
      unitRef="usd">8978000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTMtOC0xLTEtMA_a44b0e8f-9a61-418c-a80b-23ef0b25f11f"
      unitRef="usd">1420000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTQtMi0xLTEtMA_2b2c34ec-6caf-4f95-989c-a3fce9f71df1"
      unitRef="usd">250000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTQtNC0xLTEtMA_507c9f55-3465-44a6-b32a-2ca04979c48f"
      unitRef="usd">236000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTQtNi0xLTEtMA_6355c2c2-4829-45eb-bda5-898bf2a9fa18"
      unitRef="usd">763000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTQtOC0xLTEtMA_a51b51b0-5733-4b52-b5ad-6f9c5f03a580"
      unitRef="usd">717000000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTUtMi0xLTEtMA_807f2eda-dd9d-4dee-9c43-95fc42005985"
      unitRef="usd">-154000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTUtNC0xLTEtMA_e166eb9d-bb33-42e6-a3e8-324087b5028e"
      unitRef="usd">-940000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTUtNi0xLTEtMA_eed1fafe-f996-490d-8b40-bc08789bb3cc"
      unitRef="usd">-696000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTUtOC0xLTEtMA_819a2f7c-ca4e-4b52-85ad-dd6b52084ab2"
      unitRef="usd">-848000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTYtMi0xLTEtMA_c0f1cedd-4c62-4504-894e-7eefdca5190a"
      unitRef="usd">3438000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTYtNC0xLTEtMA_a56b9641-1ce3-494e-a175-8cf605cf57a0"
      unitRef="usd">825000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTYtNi0xLTEtMA_1c722f21-6020-46f6-b702-e020c6c8c9c0"
      unitRef="usd">7519000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTYtOC0xLTEtMA_da3022a1-b718-4531-8fa2-a345a27b5be3"
      unitRef="usd">-145000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTctMi0xLTEtMA_a739ce53-4f96-4153-8951-72935364c9eb"
      unitRef="usd">852000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTctNC0xLTEtMA_b5d7c797-e715-40a7-935f-481f179b605f"
      unitRef="usd">472000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTctNi0xLTEtMA_09d911e5-2d90-4d5f-a4af-4f421ca32902"
      unitRef="usd">1694000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTctOC0xLTEtMA_15ad47df-33bb-49cb-8941-eed6fec54dd9"
      unitRef="usd">1310000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTgtMi0xLTEtMA_1a6df507-318e-4441-8ce0-285aa5d2058f"
      unitRef="usd">2586000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTgtNC0xLTEtMA_79756a0c-9642-41e5-a52c-d2588200a970"
      unitRef="usd">353000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTgtNi0xLTEtMA_dc22c516-1109-45f0-a992-735d404769b7"
      unitRef="usd">5825000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTgtOC0xLTEtMA_180d5d34-a378-4fb3-849d-a8f3a01284e4"
      unitRef="usd">-1455000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTktMi0xLTEtMA_c3551425-fc69-41db-ac63-d5cad1a45215"
      unitRef="usd">-6000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTktNC0xLTEtMA_6a06d42e-cf15-49fa-b8d6-8ecb95fbe179"
      unitRef="usd">-7000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTktNi0xLTEtMA_b5487b12-00e7-4727-a099-6250968c3101"
      unitRef="usd">-18000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMTktOC0xLTEtMA_4b8ab49c-7d8f-44f9-84e5-b9a37c4e74e1"
      unitRef="usd">-27000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjAtMi0xLTEtMA_2ae7cead-ef05-4ba5-88dc-033def53f9fa"
      unitRef="usd">2592000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjAtNC0xLTEtMA_619513d8-4af8-4e7a-accd-ae0fb4fe598f"
      unitRef="usd">360000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjAtNi0xLTEtMA_7b614bec-7c63-40dd-b5a9-5560a2691c8a"
      unitRef="usd">5843000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjAtOC0xLTEtMA_3d575997-8a51-45f0-b1de-9b8a973661dd"
      unitRef="usd">-1428000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjEtMi0xLTEtMA_57cb18e4-86cd-42b9-b9c6-e8ae752c1e01"
      unitRef="usdPerShare">2.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjEtNC0xLTEtMA_4a639e4d-44dd-45e5-8d17-24cb56f74acb"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjEtNi0xLTEtMA_510e00ca-66e9-40a6-8ccf-6fdecc9c22ea"
      unitRef="usdPerShare">4.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjEtOC0xLTEtMA_1e58b78f-9d8b-44d1-b26f-eda768b91943"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjItMi0xLTEtMA_44418776-8607-4130-bdf9-7e7e3203f6c1"
      unitRef="shares">1256000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjItNC0xLTEtMA_76a94e61-8fd2-4cc5-8634-ede928b1fd95"
      unitRef="shares">1255000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjItNi0xLTEtMA_7b56f8da-b6d7-44f9-90f4-d0f1ff58dfe9"
      unitRef="shares">1256000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjItOC0xLTEtMA_221edcfc-0899-4c56-9ab1-96ed8f3dcc9a"
      unitRef="shares">1257000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjMtMi0xLTEtMA_277950c8-cf9a-45af-ace0-d655273d9efa"
      unitRef="usdPerShare">2.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjMtNC0xLTEtMA_ed69da37-78d1-4c11-94b5-68260ef74e68"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjMtNi0xLTEtMA_2429d6fa-2dec-4550-a254-6fd6573da824"
      unitRef="usdPerShare">4.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjMtOC0xLTEtMA_50288d8f-aed1-4ad1-9a6f-f3d78414a826"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjQtMi0xLTEtMA_e6e2e7bf-eff0-4479-b189-94cb7314ba21"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjQtNC0xLTEtMA_95089e6c-0866-41fe-8fc7-e795462e9866"
      unitRef="shares">1261000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjQtNi0xLTEtMA_98fa3a04-308f-40b3-8d88-1b8742e4c78b"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8xOS9mcmFnOjgxZjkxNmNhY2QwMzRhZDY4YTJhN2U1NDhiYzI5YWY3L3RhYmxlOjA3YjJmZTBjMjc5MzQ2YmFhMGM4YTY0MDUxMTBmZTg5L3RhYmxlcmFuZ2U6MDdiMmZlMGMyNzkzNDZiYWEwYzhhNjQwNTExMGZlODlfMjQtOC0xLTEtMA_5ad4b668-41f1-4829-b27a-5e559ce2308f"
      unitRef="shares">1257000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMy0yLTEtMS0w_1a6df507-318e-4441-8ce0-285aa5d2058f"
      unitRef="usd">2586000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMy00LTEtMS0w_79756a0c-9642-41e5-a52c-d2588200a970"
      unitRef="usd">353000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMy02LTEtMS0w_2d563853-221d-4f57-812d-5eb7d1a67c6b"
      unitRef="usd">5825000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMy04LTEtMS0w_e3bd1109-9eeb-4230-ab23-5d135688bc02"
      unitRef="usd">-1455000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNS0yLTEtMS0w_904b7040-dd56-4c8e-9bad-9d248fc137f2"
      unitRef="usd">-20000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNS00LTEtMS0w_66ca8aa3-8131-45d4-996e-2693205b6151"
      unitRef="usd">23000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNS02LTEtMS0w_ece42b32-9b68-4237-8f77-04947d1a6575"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNS04LTEtMS0w_6832c359-9f7a-45c5-8492-e2032e431db3"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNy0yLTEtMS0w_37784c25-4c76-48f3-a5df-a0cec22d1617"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNy00LTEtMS0w_1af78750-9daa-44fb-8119-98e2fc018b51"
      unitRef="usd">-9000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNy02LTEtMS0w_c9e1b346-02c0-4e64-827c-09399ff6c530"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfNy04LTEtMS0w_60cb4782-6ed6-451c-ba0b-5458f8ae3f49"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOC0yLTEtMS0w_cfc23036-173b-4536-9eea-fe5d88b4d877"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOC00LTEtMS0w_2620e223-64c5-43e5-ad52-eb2db155ec72"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOC02LTEtMS0w_780cd31d-de3a-4be0-98f9-b9b1aa499c86"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOC04LTEtMS0w_b825c797-74e8-4112-86aa-cf739481ae8e"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOS0yLTEtMS0w_e0eb4422-6489-42a8-b8f0-67dd8117b88e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOS00LTEtMS0w_855be1b2-10e7-4bd1-b198-457110e55025"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOS02LTEtMS0w_8354f63e-b30b-4703-ae9d-a4a5093d370f"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfOS04LTEtMS0w_48a0d992-69bd-4670-a29d-16cf9fb6f4cd"
      unitRef="usd">25000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTEtMi0xLTEtMA_712efb03-259c-421e-aa22-60a5f335f790"
      unitRef="usd">37000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTEtNC0xLTEtMA_79656257-186a-4bad-ab05-9a0863d53b82"
      unitRef="usd">-46000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTEtNi0xLTEtMA_54c0d36c-2525-4205-a247-cbac5e460a92"
      unitRef="usd">92000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTEtOC0xLTEtMA_0a4069bc-1dc0-45b4-9bfc-fb083704972a"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTItMi0xLTEtMA_74313866-3f9b-4f6f-a8e0-67c65fc4c119"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTItNC0xLTEtMA_11057d5e-2d63-4b97-b900-4d7544a641ba"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTItNi0xLTEtMA_a5063f8e-9009-4816-99dd-8b97d5c1dd5a"
      unitRef="usd">-60000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTItOC0xLTEtMA_702b4372-29df-4709-8ed2-136e50147d3a"
      unitRef="usd">50000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTMtMi0xLTEtMA_0868b7b4-a6eb-4e7d-b94c-266acc0b6c5f"
      unitRef="usd">55000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTMtNC0xLTEtMA_276fec76-b687-434a-9479-940a506cf080"
      unitRef="usd">-57000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTMtNi0xLTEtMA_0d20213f-1700-436c-b7db-bf9977546ba0"
      unitRef="usd">152000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTMtOC0xLTEtMA_9b240957-1e95-4a43-91d5-2ccd199cec56"
      unitRef="usd">-75000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTQtMi0xLTEtMA_3b7d34d2-c338-4bde-8888-99caf0959780"
      unitRef="usd">35000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTQtNC0xLTEtMA_8308ec40-72f1-424d-afa4-013ea5abcbf9"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTQtNi0xLTEtMA_f9463994-14da-4204-84a7-0ea7c1fc75fb"
      unitRef="usd">134000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTQtOC0xLTEtMA_e81ada15-973e-4653-878b-ed5e13824b7a"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTUtMi0xLTEtMA_52b9d48e-00f6-4144-a0f6-000606e2f2f2"
      unitRef="usd">2621000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTUtNC0xLTEtMA_9a2afd7e-5d5e-4041-95a9-96f5a20183ce"
      unitRef="usd">306000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTUtNi0xLTEtMA_e4772ad1-9b82-4cba-a7d3-ba809b9d72aa"
      unitRef="usd">5959000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTUtOC0xLTEtMA_c424abf0-09d0-4d21-8e95-e82ede957a3a"
      unitRef="usd">-1517000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTYtMi0xLTEtMA_25abed72-ce97-44d6-875d-c1be02dcbd9b"
      unitRef="usd">-6000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTYtNC0xLTEtMA_f93c84d9-59a4-4a8b-931f-d131f2f3213c"
      unitRef="usd">-7000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTYtNi0xLTEtMA_17582e2a-6d25-4b67-8465-84afce4128f3"
      unitRef="usd">-18000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTYtOC0xLTEtMA_d8981612-948f-4064-b449-519a630e627b"
      unitRef="usd">-27000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTctMi0xLTEtMA_3db29321-269d-4dbb-a790-c63adaf36215"
      unitRef="usd">2627000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTctNC0xLTEtMA_a4acbe03-332b-49b4-b3b7-2d1d87442b90"
      unitRef="usd">313000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTctNi0xLTEtMA_9c1792cf-3f9d-4cab-a6a3-8c63bbcdcbd3"
      unitRef="usd">5977000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yMi9mcmFnOmY1ZjI2M2QxMDAyYTRkYmE4OGIzNDE1ZDAzZjU2M2Y2L3RhYmxlOmUxODY3MzZjYjFlMjQyMDk5NjI1ZjczNDNjMTA1YjdiL3RhYmxlcmFuZ2U6ZTE4NjczNmNiMWUyNDIwOTk2MjVmNzM0M2MxMDViN2JfMTctOC0xLTEtMA_658c6d84-4e22-4dff-9cc6-fed349fbb886"
      unitRef="usd">-1490000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if7cadd9af8cb4d648ad69a6bf5f40afb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNC0yLTEtMS0w_683bb819-890e-4c49-b11b-6189ddd80dc9"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7cadd9af8cb4d648ad69a6bf5f40afb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNC00LTEtMS0w_af798078-99c5-41f8-8e4a-680fe1dec87b"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic320c878f7da497289eedfe7777dbd63_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNC02LTEtMS0w_a548c4ae-7eec-4bc4-83fe-9ff1f808a929"
      unitRef="usd">4271000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47c2e7921e224837ab97ee0fe6c8f222_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNC04LTEtMS0w_06da1080-df22-4050-9283-aff0fface1d5"
      unitRef="usd">39000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i51b36b57f62a4b6f9933e96a8a774a03_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNC0xMC0xLTEtMA_ac71638e-6731-4467-a5fd-e84422515c5f"
      unitRef="usd">15392000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ce088514657437793db4cb212d85fa9_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNC0xMi0xLTEtMA_ad19653b-f7c0-4d6d-952a-10afb14048b9"
      unitRef="usd">7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93cee50aef154d89907a30e4b6fe3dad_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNC0xNC0xLTEtMA_83a060da-ad24-4151-9010-b780e3e89146"
      unitRef="usd">19710000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i38550fb4b8e545b6933ed2239c97d37d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNS0xMC0xLTEtMA_7dfbfa6f-fe14-4d55-8c12-bfb4f12587e1"
      unitRef="usd">2592000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic9a23e1ecf384ef8854c99561d634f7b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNS0xMi0xLTEtMA_4d06163d-dc8a-45a6-bc58-87d3e63de72a"
      unitRef="usd">-6000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNS0xNC0xLTEtMA_2be80482-2536-4828-a8b6-f5364dba7cbb"
      unitRef="usd">2586000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia4232b9569ef4dc784f4c812cd10758a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNi04LTEtMS0w_bb3e6bc7-8eaf-46eb-ad5c-5ce92d38c2b2"
      unitRef="usd">35000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNi0xNC0xLTEtMA_d97ef09c-e05f-4852-a616-76f57dfc8813"
      unitRef="usd">35000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i47d05e5d8c89426f941e19ac183a993e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNy0yLTEtMS00NTg0NQ_7ceb1f68-5ef5-425a-9f35-75c204b16fe0"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib3c507e951f04b82bce9764e6f829c9b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNy02LTEtMS00NTg0NQ_4df0655e-5569-4b2c-a15a-a8b7c95f0c83"
      unitRef="usd">35000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNy0xNC0xLTEtNDU4NDU_ee4ef760-5d72-4ad8-b6f5-04ebe5b1d5a2"
      unitRef="usd">35000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i47d05e5d8c89426f941e19ac183a993e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNy0yLTEtMS0w_3aebb3d1-2422-4c7b-8f08-13b22cfe892b"
      unitRef="shares">3000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib3c507e951f04b82bce9764e6f829c9b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNy02LTEtMS0w_fda52b73-4e84-4378-928a-ddffc27b14fe"
      unitRef="usd">22000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfNy0xNC0xLTEtMA_c514c8c4-2847-4fb4-afaa-12374a663afb"
      unitRef="usd">22000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib3c507e951f04b82bce9764e6f829c9b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfOC02LTEtMS0w_114fb092-821a-48bf-85dc-69880a96d5fd"
      unitRef="usd">171000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfOC0xNC0xLTEtMA_b67e6a26-23b3-46ac-96d2-298b7f59200d"
      unitRef="usd">171000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i47d05e5d8c89426f941e19ac183a993e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfOS0yLTEtMS0w_a80f375e-0f30-46b5-90e1-c66d001b1a97"
      unitRef="shares">3000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ib3c507e951f04b82bce9764e6f829c9b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfOS02LTEtMS0w_15fc2e1d-93d8-4bfd-a771-73e1481c0392"
      unitRef="usd">7000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i38550fb4b8e545b6933ed2239c97d37d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfOS0xMC0xLTEtMA_6fb8fab2-52d4-49ce-86e7-d58ea1971f08"
      unitRef="usd">176000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfOS0xNC0xLTEtMA_5e1e8a92-0ef9-402b-9498-c64f693a0e3c"
      unitRef="usd">183000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOmE4ZWE4ZTU0ZTBlZjQ1OWM4YmM4NmI3OWNkNDI1MjRmXzI0_6ca31a94-53a5-40aa-93b9-8d72889899f1"
      unitRef="usdPerShare">0.71</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i38550fb4b8e545b6933ed2239c97d37d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTAtMTAtMS0xLTA_5f5422aa-2bc9-464a-9a61-61d5f6629eff"
      unitRef="usd">905000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTAtMTQtMS0xLTA_88c6727d-6dd9-47a6-adda-cfa910b7210a"
      unitRef="usd">905000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifcc67220f43e4bb097d163125b104986_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTEtMi0xLTEtMA_0ec45b3d-cc8e-4cce-9ddf-5395641d62ea"
      unitRef="shares">1255000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifcc67220f43e4bb097d163125b104986_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTEtNC0xLTEtMA_274a74a3-e49b-4cd2-bf9b-f8e6294cc7ba"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a7f62ba5efc4ba2a75848977dcd0f28_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTEtNi0xLTEtMA_09ecd1c6-cd10-40c7-bd41-cee28819adfa"
      unitRef="usd">4492000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic607fe5efeb4462ba677a36d66cea69e_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTEtOC0xLTEtMA_d2ef5de0-79b3-44e7-9a9d-aefc8085a4f8"
      unitRef="usd">74000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i07b01e048e144df19a994cf3c542a026_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTEtMTAtMS0xLTA_e02fcdd2-4973-4e2d-aff2-b1d89b86f8d3"
      unitRef="usd">16903000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3db1326cef2b4443b8901640d2a96bc8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTEtMTItMS0xLTA_9e6dec0e-1f32-4722-b7fd-9055452a7df8"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjMyZGYwMzQ2ODM5ZjQyYzFiZmI4OTg1NzhmNjVmNDgwL3RhYmxlcmFuZ2U6MzJkZjAzNDY4MzlmNDJjMWJmYjg5ODU3OGY2NWY0ODBfMTEtMTQtMS0xLTA_b4d0028f-a82f-4828-ab57-1f0f8d0835f3"
      unitRef="usd">21471000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i67dfd12ea224410a8e53fd74958a0afb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNC0yLTEtMS0w_ce37a7b3-f349-4ed4-9643-588bb467d586"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67dfd12ea224410a8e53fd74958a0afb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNC00LTEtMS0w_371a101b-aa6a-4ce8-932c-f9a16de81a93"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4708079b07443c7a62480f7e6915098_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNC02LTEtMS0w_c05e6620-e800-4246-9884-b5244ae2d2f8"
      unitRef="usd">3880000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i68c8176bb4194abc96d3c13de341cd01_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNC04LTEtMS0w_ddcb312a-a2c7-49fa-9849-b0aed6915424"
      unitRef="usd">-60000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if83cc5f617644ec28eca6ba9626e3244_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNC0xMC0xLTEtMA_81ce1bb0-b29a-436f-870c-7fd7bc57df8e"
      unitRef="usd">14381000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40898fd2e2e842e88088320ba442b8f2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNC0xMi0xLTEtMA_79919359-2fca-43c7-a00f-c16aa40b3e51"
      unitRef="usd">19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNC0xNC0xLTEtMA_65f6fa3f-e6ce-4c7b-a577-3e8b36dbfa77"
      unitRef="usd">18221000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ic4751784eb024137a55a00f62297811b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNS0xMC0xLTEtMA_ab07cb4e-b673-4432-b6cd-d6f8a771cb76"
      unitRef="usd">5843000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifa59bbe2a2154f068815ed93165ba107_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNS0xMi0xLTEtMA_7a70f5cc-99f5-465c-bd41-7cad3df2ae59"
      unitRef="usd">-18000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNS0xNC0xLTEtMA_5e23150e-0036-479c-87a9-d72022310666"
      unitRef="usd">5825000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibdca6d608af14f87aeafba62f5b528f1_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNi04LTEtMS0w_cb51d21b-5076-4613-b037-100ac7be4ae5"
      unitRef="usd">134000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNi0xNC0xLTEtMA_366cdc24-6131-42d1-bdaa-fe69ee149eeb"
      unitRef="usd">134000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i71ab8e199657427eb6e86e9e2a9be3a8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNy0yLTEtMS0w_56fd44b0-e85d-40ff-85f7-c00ec21fb2cc"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i33c2cfa2e7ec445881cec30e9eed5e76_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNy02LTEtMS0w_b0a93e41-b870-4e28-b534-fa0e1a0e3839"
      unitRef="usd">111000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfNy0xNC0xLTEtMA_0c96106d-6448-4265-af90-dbbcc8d20664"
      unitRef="usd">111000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i71ab8e199657427eb6e86e9e2a9be3a8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfOC0yLTEtMS0w_d1fdf602-3510-4eac-be4a-5596c85b243d"
      unitRef="shares">9000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i33c2cfa2e7ec445881cec30e9eed5e76_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfOC02LTEtMS0w_d2fdf099-43e8-49ff-aeb5-eaf6514b9631"
      unitRef="usd">46000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfOC0xNC0xLTEtMA_846bdb8e-abcc-4c5d-bb51-ddaa9140d017"
      unitRef="usd">46000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i33c2cfa2e7ec445881cec30e9eed5e76_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfOS02LTEtMS0w_3505f9ac-5dba-4ba6-91ae-31a312544198"
      unitRef="usd">479000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfOS0xNC0xLTEtMA_d5a586df-25a0-4660-90bc-a5ae2bc77798"
      unitRef="usd">479000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i71ab8e199657427eb6e86e9e2a9be3a8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTAtMi0xLTEtMA_41b2e2de-42c4-4f05-a652-24f6bf69eecb"
      unitRef="shares">10000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i33c2cfa2e7ec445881cec30e9eed5e76_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTAtNi0xLTEtMA_3ea6ef19-d157-467d-987c-0a4ce2c2d285"
      unitRef="usd">24000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic4751784eb024137a55a00f62297811b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTAtMTAtMS0xLTA_192eb70e-fd2e-47f8-befa-81cff91a3454"
      unitRef="usd">607000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTAtMTQtMS0xLTA_4d1cd8bd-8a93-4649-a15b-a6acc1c76586"
      unitRef="usd">631000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOmE0MjkyODY3YjJkNzQ1MDc5NDIxZWM1YmYyODM2ODFiXzI0_0c9a20bb-7760-4096-9d48-bbad84f4b47d"
      unitRef="usdPerShare">2.13</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="ic4751784eb024137a55a00f62297811b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTEtMTAtMS0xLTA_2b51b99a-bfc4-484e-9ed0-fda792117298"
      unitRef="usd">2714000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTEtMTQtMS0xLTA_26ec88be-1afa-4ea1-a240-f5258a449b10"
      unitRef="usd">2714000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifcc67220f43e4bb097d163125b104986_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTItMi0xLTEtMA_0a4eb44e-fd12-4f4a-8d75-59bc6eddffb8"
      unitRef="shares">1255000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifcc67220f43e4bb097d163125b104986_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTItNC0xLTEtMA_38fc40e9-20d3-41f5-b6ef-87f1aa4392c7"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a7f62ba5efc4ba2a75848977dcd0f28_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTItNi0xLTEtMA_c0829cb4-0490-4b4d-b80f-b3ac63ee80b2"
      unitRef="usd">4492000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic607fe5efeb4462ba677a36d66cea69e_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTItOC0xLTEtMA_585288ee-59d6-43db-bc8b-167fe4531688"
      unitRef="usd">74000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i07b01e048e144df19a994cf3c542a026_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTItMTAtMS0xLTA_cab40b8e-a9ba-4fd0-a395-b806ccec3b37"
      unitRef="usd">16903000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3db1326cef2b4443b8901640d2a96bc8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTItMTItMS0xLTA_ee817bde-5042-4aa7-9f44-6fc6d9fd4690"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOjJjZWRjNTI0ZjA3NzRmNGRhYjM4OWE2ZDc5OTBkNjdmL3RhYmxlcmFuZ2U6MmNlZGM1MjRmMDc3NGY0ZGFiMzg5YTZkNzk5MGQ2N2ZfMTItMTQtMS0xLTA_6cc68c0f-d7f1-402a-a32b-9e3210fc1a42"
      unitRef="usd">21471000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if91124405d414b9dba81e4453951813a_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNC0yLTEtMS0w_9b13403a-2c07-4659-8355-6436bc6f8c76"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if91124405d414b9dba81e4453951813a_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNC00LTEtMS0w_0c89ad3c-9eef-43b5-a047-c3c0d6ca75c2"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79f810b4c15c48908cf2409474335f75_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNC02LTEtMS0w_05b69d38-c5df-4e0c-8209-dd99a60e582e"
      unitRef="usd">3511000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id36e5ff34aee4ca1a00a4a484c912ba8_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNC04LTEtMS0w_f5159f61-3491-44b2-8c87-3f5f4b398c4b"
      unitRef="usd">70000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic03e12a879694340bc9fdc68aa15f297_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNC0xMC0xLTEtMA_516a1c1d-e650-45f7-9984-accad3827e7b"
      unitRef="usd">14445000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44d0ae25eecf499fb680c4e796d4bbaf_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNC0xMi0xLTEtMA_b900946d-0e10-4a2b-89d9-82bb9215d7f6"
      unitRef="usd">115000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i740e8f78f6c348b0b796258c902c6df7_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNC0xNC0xLTEtMA_7e860cb8-dabc-4a3c-af86-3bc16bc8769f"
      unitRef="usd">18142000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="idf9c8e7ee0794bd18997a355702704fd_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNS0xMi0xLTEtMA_ea66586f-d8ae-456b-bda1-5e9bd7445900"
      unitRef="usd">-82000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNS0xNC0xLTEtMA_c1bd6370-9a82-455e-b0cc-e19190a46def"
      unitRef="usd">-82000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:ProfitLoss
      contextRef="i68393aa2cad140b0813dae42d797b81c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNi0xMC0xLTEtMA_5c192d24-2155-4d9e-89c7-ae055528a36d"
      unitRef="usd">360000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idf9c8e7ee0794bd18997a355702704fd_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNi0xMi0xLTEtMA_8b9d67b2-498e-48ce-99ac-91a198cc1307"
      unitRef="usd">-7000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNi0xNC0xLTEtMA_1b450576-432e-4555-9ee4-e47c49cf1d3a"
      unitRef="usd">353000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4276333617e7401db14493cc3da842ae_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNy02LTEtMS0w_4897f390-236f-4e19-a727-c17680b7959f"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id9f4a9c842e640eb850df6488920516c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNy04LTEtMS0w_2f78214c-7f94-4683-8b00-42906b642a80"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i68393aa2cad140b0813dae42d797b81c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNy0xMC0xLTEtMA_8f7bb01d-2544-4925-84ec-09cdd25275a8"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfNy0xNC0xLTEtMA_29e58cb7-68d5-421b-83bc-923564f43a5c"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i2310959eb5074abf916d6715b8aa87fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOC0yLTEtMS0xMTU_fc88ab1a-a50b-40b2-8867-7849d2e19477"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4276333617e7401db14493cc3da842ae_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOC02LTEtMS0xMTU_54bad866-769a-4bb3-8614-7334ac87b634"
      unitRef="usd">34000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOC0xNC0xLTEtMTE1_0d0a9019-0517-42d5-8b4d-eee4ba6469bd"
      unitRef="usd">34000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2310959eb5074abf916d6715b8aa87fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOC0yLTEtMS0w_cef16e71-7e61-4142-ba58-e59400e5f413"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4276333617e7401db14493cc3da842ae_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOC02LTEtMS0w_b91239ad-b273-4fb4-865f-2bb8be00ff8e"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOC0xNC0xLTEtMA_05b96706-35dd-40de-b081-78437b29f92b"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4276333617e7401db14493cc3da842ae_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOS02LTEtMS0w_150f0253-2411-4c0c-a19f-a209b2de4205"
      unitRef="usd">173000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfOS0xNC0xLTEtMA_99df4da5-156f-4b27-b5f7-59967bea3b25"
      unitRef="usd">173000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i2310959eb5074abf916d6715b8aa87fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTAtMi0xLTEtMA_7e2c05ac-0d9a-40c1-a601-5c8a69a4a569"
      unitRef="shares">4000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i4276333617e7401db14493cc3da842ae_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTAtNi0xLTEtMA_2398e6ec-ad68-46f5-8e7d-669f3ba3b14a"
      unitRef="usd">9000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i68393aa2cad140b0813dae42d797b81c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTAtMTAtMS0xLTA_a4411456-3521-4eb3-a913-b46b8ba09eea"
      unitRef="usd">229000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTAtMTQtMS0xLTA_fac97fcd-b5df-4b9a-b5ef-61e7a07b75a8"
      unitRef="usd">238000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRkYzA5ZTBmYWIyYTRmNGVhZDQ5YmZkYWY3ODY1ZTgxXzI0_511765df-8709-4887-8a47-18d64789b64e"
      unitRef="usdPerShare">0.68</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i68393aa2cad140b0813dae42d797b81c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTEtMTAtMS0xLTA_97d18302-9959-4f47-bebf-c745fd594e4b"
      unitRef="usd">866000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTEtMTQtMS0xLTA_6551fee9-d458-488d-abc9-77efebfa30cf"
      unitRef="usd">866000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib82a8b96d9074a4fb728c152000179b2_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTItMi0xLTEtMA_ae5aed8e-ff4c-4e02-aa4c-033baac542e5"
      unitRef="shares">1253000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib82a8b96d9074a4fb728c152000179b2_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTItNC0xLTEtMA_d9c4bdb1-29fd-4395-9485-bf85a198fa72"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ca43e6b419249ee89f9dcf2bf9735ed_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTItNi0xLTEtMA_71addef3-6499-40b9-a9dc-705cd1eaf6a9"
      unitRef="usd">3712000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1eb53663397049a380603edf12d76c3a_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTItOC0xLTEtMA_fbc4857a-fa60-4350-9f72-6494967ee0b1"
      unitRef="usd">23000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibb7e694d30cd45e3a1e9103b0b1e82e1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTItMTAtMS0xLTA_aa0fec1d-41d7-45c0-8e30-ad367bbf464d"
      unitRef="usd">13709000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i377473f7a7634d6cba9a5bb6603d6547_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTItMTItMS0xLTA_78406e96-cd17-4f19-93b8-70fa3d27e275"
      unitRef="usd">26000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i05bfa65a7fdd430ea5429b49909dff6d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmE3YWMxNmMwYTU2MzQ1NmZhNzQ1ZmQzZTZkYzVkMGY5L3RhYmxlcmFuZ2U6YTdhYzE2YzBhNTYzNDU2ZmE3NDVmZDNlNmRjNWQwZjlfMTItMTQtMS0xLTA_c93b769f-d309-4f30-85d8-d82d4ab4f966"
      unitRef="usd">17471000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i19f0cbf8e15f44e3a8bf106f16ddf237_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNC0yLTEtMS0w_76de0af4-f49d-403c-8ae1-fe81fff336ed"
      unitRef="shares">1266000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i19f0cbf8e15f44e3a8bf106f16ddf237_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNC00LTEtMS0w_4f64090a-a435-4b6d-96bb-4e62f894825a"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i863402769fcf4a3abffd39d64a185584_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNC02LTEtMS0w_f4b20847-9ffb-4291-a840-45fcc6e2bcaf"
      unitRef="usd">3051000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i188cf2bc805343608e1a7c9417d2404d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNC04LTEtMS0w_2b17f1fc-40fd-4906-b5d9-cd6879148255"
      unitRef="usd">85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2552479e6ff476e92abd17114269cd7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNC0xMC0xLTEtMA_62f37c18-b30a-4a51-81a7-718a20ca9c2e"
      unitRef="usd">19388000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f3b569ef25240f1a155a0024e7b8e90_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNC0xMi0xLTEtMA_c47c1bb6-c5c2-4cab-8ef3-66bd0aaa5ce1"
      unitRef="usd">125000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3c214ead3cf04a2e9fc7bc2b14bdaf84_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNC0xNC0xLTEtMA_006e6d11-b4ae-49f8-9b4b-14780ac1f071"
      unitRef="usd">22650000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic4e29df1f11f450ca7eb2e638244a8d1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNS0xMC0xLTEtMA_9239f280-bb69-4dae-8a0d-7d3d875ff65e"
      unitRef="usd">-7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaaae18a74fca47d1b00b45a50b94910d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNS0xNC0xLTEtMA_0a69a55c-136c-4561-8fba-c0563b0c966c"
      unitRef="usd">-7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i1a3a3fc257534802a47360ab1e00d78c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNi0xMi0xLTEtMA_f3ba9ae9-c24f-4ba0-9a0e-136dc6412e6c"
      unitRef="usd">-72000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNi0xNC0xLTEtMA_76aa338e-a4b5-4cc1-93fb-e7d1670a587a"
      unitRef="usd">-72000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:ProfitLoss
      contextRef="i65979baffae041ae8ddc09c614f2ebb8_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNy0xMC0xLTEtMA_9aa1fc29-7101-43c4-b3b1-a753e3f1f47b"
      unitRef="usd">-1428000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1a3a3fc257534802a47360ab1e00d78c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNy0xMi0xLTEtMA_c8886453-49b2-4e36-a76f-724a8a3252fc"
      unitRef="usd">-27000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfNy0xNC0xLTEtMA_a7bf51e1-171f-4fec-9d39-2644f142ef51"
      unitRef="usd">-1455000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id3bd1b11f59e45f4ad008ef2737fcd81_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfOC02LTEtMS0w_cb80eadc-cd75-46dd-8062-833df3ac9607"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i57db840e2919481eb28184ec2cbb0a50_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfOC04LTEtMS0w_066072b5-ce80-4db2-86a8-ef952d1f4af2"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i65979baffae041ae8ddc09c614f2ebb8_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfOC0xMC0xLTEtMA_091cddbe-1e98-41e6-9a24-c27d1204a48d"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfOC0xNC0xLTEtMA_82fc8232-933d-455d-9591-69ba27bc2ded"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i612f84efa15449cc9787e2a73fa82064_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfOS0yLTEtMS0w_2dc3f4c0-a63e-4ca9-b5ca-2100596b3ffd"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id3bd1b11f59e45f4ad008ef2737fcd81_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfOS02LTEtMS0w_9ca1564b-f8f8-4f81-b435-122e891a02c3"
      unitRef="usd">100000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfOS0xNC0xLTEtMA_109e0389-6c30-497e-b909-68dead4719c2"
      unitRef="usd">100000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i612f84efa15449cc9787e2a73fa82064_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTAtMi0xLTEtMA_f0d861bb-2a89-41d4-9285-a01f25818644"
      unitRef="shares">10000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id3bd1b11f59e45f4ad008ef2737fcd81_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTAtNi0xLTEtMA_6a481c55-e3b4-49b2-8412-1ce85d708310"
      unitRef="usd">148000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTAtMTQtMS0xLTA_fadfcefb-ef50-495e-b90d-0da09c341864"
      unitRef="usd">148000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id3bd1b11f59e45f4ad008ef2737fcd81_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTEtNi0xLTEtMA_c1f9fb55-f503-4c80-a1e8-a3c1e0f0e682"
      unitRef="usd">482000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTEtMTQtMS0xLTA_a003d93a-b5b3-419b-96f3-cb4291d95b4c"
      unitRef="usd">482000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i612f84efa15449cc9787e2a73fa82064_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTItMi0xLTEtMA_9816afd2-0ac4-4f37-a6e4-dc27dab74103"
      unitRef="shares">25000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id3bd1b11f59e45f4ad008ef2737fcd81_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTItNi0xLTEtMA_2e44a1d7-63b5-4729-8bef-7c71345abf62"
      unitRef="usd">70000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i65979baffae041ae8ddc09c614f2ebb8_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTItMTAtMS0xLTA_93a6782b-818d-4fe0-8a84-6e4026daf82b"
      unitRef="usd">1644000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTItMTQtMS0xLTA_eb577080-74f5-4502-8398-82fd8dfc801f"
      unitRef="usd">1714000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTMtMC0xLTEtMC90ZXh0cmVnaW9uOjE2NGU0NWMwYWQ4NDRlMDRiZmZlOTg2MzdiNzA2ZDY5XzI0_1c5c46ac-f5b4-4cbf-a10d-9b4eef540b07"
      unitRef="usdPerShare">2.04</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i65979baffae041ae8ddc09c614f2ebb8_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTMtMTAtMS0xLTA_6c29e802-1901-4515-b04c-bf3a889a3226"
      unitRef="usd">2599000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTMtMTQtMS0xLTA_86b8fce8-777d-4dcf-a9e9-7a6be7e75269"
      unitRef="usd">2599000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib82a8b96d9074a4fb728c152000179b2_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTQtMi0xLTEtMA_0221b73a-38eb-4f05-9ea7-cacf4ae74511"
      unitRef="shares">1253000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib82a8b96d9074a4fb728c152000179b2_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTQtNC0xLTEtMA_92c3f547-d40d-497a-967e-1678c7d51c68"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ca43e6b419249ee89f9dcf2bf9735ed_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTQtNi0xLTEtMA_e29023ca-8e4b-4fbe-aa84-6b9410dfdf1c"
      unitRef="usd">3712000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1eb53663397049a380603edf12d76c3a_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTQtOC0xLTEtMA_1eb5ba5c-8099-4d55-80dc-7a3a5eda2ca0"
      unitRef="usd">23000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibb7e694d30cd45e3a1e9103b0b1e82e1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTQtMTAtMS0xLTA_a6e00014-e01c-4107-9b03-c20fb383873d"
      unitRef="usd">13709000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i377473f7a7634d6cba9a5bb6603d6547_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTQtMTItMS0xLTA_6b76e31e-20bf-4fd2-b634-c8ea0e2e3015"
      unitRef="usd">26000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i05bfa65a7fdd430ea5429b49909dff6d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yNS9mcmFnOmYyZGEzMDkzNTQ2NTQ3OTBiYjQxYjQzYzhmZGIwMTc2L3RhYmxlOmFkNzMyNzAxNGExYTQ3OTNhYWQ0ZGE1YzUwMWQ3ZmEwL3RhYmxlcmFuZ2U6YWQ3MzI3MDE0YTFhNDc5M2FhZDRkYTVjNTAxZDdmYTBfMTQtMTQtMS0xLTA_76a71e20-22f7-4cbc-b4bd-e17e4a4c4fbe"
      unitRef="usd">17471000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNC0yLTEtMS0w_dc22c516-1109-45f0-a992-735d404769b7"
      unitRef="usd">5825000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNC00LTEtMS0w_180d5d34-a378-4fb3-849d-a8f3a01284e4"
      unitRef="usd">-1455000000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNi0yLTEtMS0w_d3beae80-9ee7-408f-96f1-2e6c81cba931"
      unitRef="usd">239000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNi00LTEtMS0w_7449b166-b821-42b9-a336-a57113ddea5b"
      unitRef="usd">209000000</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNy0yLTEtMS0w_8fce7abc-866b-4c2d-bca1-694a28dbd261"
      unitRef="usd">1276000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNy00LTEtMS0w_94fc6cc0-70f5-4181-bce8-b4bf92d59cfe"
      unitRef="usd">844000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfOC0yLTEtMS0w_10c6758e-3825-4a44-813a-d7aefd3283ab"
      unitRef="usd">476000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfOC00LTEtMS0w_665a5717-5848-4261-bd7e-d82dfa235443"
      unitRef="usd">482000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfOS0yLTEtMS0w_c87636cf-ebef-487e-8a72-d5d35be56474"
      unitRef="usd">177000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfOS00LTEtMS0w_eaa26349-b429-4c62-a42f-6836e9bccb84"
      unitRef="usd">5792000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTAtMi0xLTEtMA_23d18f72-b140-4ee9-9477-71671dfb27c4"
      unitRef="usd">243000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTAtNC0xLTEtMA_e607f813-dfb5-442e-92a3-c0a35c04fc1a"
      unitRef="usd">-12000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTEtMi0xLTEtMA_71295755-bc38-4462-b247-6273ea26b319"
      unitRef="usd">-667000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTEtNC0xLTEtMA_39636e45-a631-4724-8801-567f1dc18243"
      unitRef="usd">-1046000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTItMi0xLTEtMA_6ed22c58-1743-4a21-96fb-d90455d154d2"
      unitRef="usd">-601000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTItNC0xLTEtMA_15ec5a15-772a-40b8-b318-28e9d0be30ca"
      unitRef="usd">-210000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTQtMi0xLTEtMA_861be1b1-987c-44e9-8e23-003dfd380ef8"
      unitRef="usd">-272000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTQtNC0xLTEtMA_48a489d6-2ddd-4454-ba59-e757e9178654"
      unitRef="usd">334000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTUtMi0xLTEtMA_9e7772b6-087e-49ae-b622-4b7ee170a7f7"
      unitRef="usd">24000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTUtNC0xLTEtMA_feebc8f9-6824-4167-8e34-129a2148d4f9"
      unitRef="usd">48000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTYtMi0xLTEtMA_a007d44e-a1ba-48b8-928d-21dfd6713c69"
      unitRef="usd">17000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTYtNC0xLTEtMA_8e239059-3c12-450f-8b6f-011bcd850cee"
      unitRef="usd">-22000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTctMi0xLTEtMA_c7f67589-b61d-434e-8f6b-8df927a87369"
      unitRef="usd">-242000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTctNC0xLTEtMA_f14e5a77-126a-4b25-a810-2eb69f4ebd6f"
      unitRef="usd">-134000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTgtMi0xLTEtMA_87bd9cb0-24bb-4d12-92a5-65d0752b20ba"
      unitRef="usd">-463000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTgtNC0xLTEtMA_75cb65cc-e763-43ae-aba3-38dbe4f08a18"
      unitRef="usd">-428000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTktMi0xLTEtMA_d8b67d89-30ed-4722-a1b3-870084a1c095"
      unitRef="usd">-851000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMTktNC0xLTEtMA_e31fdf0e-723e-4a7f-a0ef-6df942c07794"
      unitRef="usd">58000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjAtMi0xLTEtMA_ca97cf50-9a23-4ac4-99d2-194f1f5282d0"
      unitRef="usd">8179000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjAtNC0xLTEtMA_07c7eaf5-c924-482f-9fad-fc44a1e20783"
      unitRef="usd">6252000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjItMi0xLTEtMA_c1da62ad-156e-436f-b57b-1006f105227f"
      unitRef="usd">2891000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjItNC0xLTEtMA_2e6c66a5-a130-457e-9b7c-bbedd2e48394"
      unitRef="usd">19809000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjMtMi0xLTEtMA_1731e512-ab5b-43cf-96cd-0b29572628d7"
      unitRef="usd">506000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjMtNC0xLTEtMA_af5306c1-2f18-4c73-9091-d53d52acfcfa"
      unitRef="usd">12367000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjQtMi0xLTEtMA_5f59a3be-7003-49af-a35d-f2d084b8403c"
      unitRef="usd">1808000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjQtNC0xLTEtMA_103e0567-4536-4a79-ad26-f864ebbb5c53"
      unitRef="usd">8528000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjUtMi0xLTEtMA_d73a737e-b238-49eb-8bb7-1dfed73fb7b1"
      unitRef="usd">1401000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjUtNC0xLTEtMA_79f3454e-f0c1-43ce-a97c-a60c9f54a186"
      unitRef="usd">5804000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjYtMi0xLTEtMA_2708411a-ea21-40bc-8c88-b8b2aebb3162"
      unitRef="usd">332000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjYtNC0xLTEtMA_e69d4da9-97bd-4031-b5ec-cc7a74442cee"
      unitRef="usd">388000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjctMi0xLTEtMA_6c5b30f2-3734-4da0-8cd7-2f00dcafe032"
      unitRef="usd">423000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjctNC0xLTEtMA_260307ef-aaa2-4783-ac3d-9e6852db3696"
      unitRef="usd">469000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjgtMi0xLTEtMA_ed826e4d-b3d4-4f14-affb-50ab27af6ee7"
      unitRef="usd">120000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjgtNC0xLTEtMA_083f749a-2edd-4007-9645-acb5cee8fc3e"
      unitRef="usd">63000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjktMi0xLTEtMA_af02a7cf-a99c-4c70-b493-0a19cf52ab7a"
      unitRef="usd">-2853000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMjktNC0xLTEtMA_57373ede-8f09-4a4b-96c4-55d61d6532e3"
      unitRef="usd">-5638000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzEtMi0xLTEtMTI3_88e24bb2-8d60-46c7-a57a-94509f933b3c"
      unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzEtNC0xLTEtMTI3_aada7063-0721-4c64-9c72-3e353540f2a7"
      unitRef="usd">7189000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzEtMi0xLTEtMA_d482648d-f91e-42b1-8bf1-278ba038ea3a"
      unitRef="usd">157000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzEtNC0xLTEtMA_8320871e-7d72-4c2a-8959-9c8f2f8c8c3f"
      unitRef="usd">248000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzItMi0xLTEtMA_403e72a7-b92c-4317-93f4-a3ad78f5b58b"
      unitRef="usd">497000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzItNC0xLTEtMA_6ff34848-9ec5-4c6c-b652-521842a4e13c"
      unitRef="usd">1583000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfDebt
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzMtMi0xLTEtMA_57a98dca-f952-4853-86f5-af23494f4cf6"
      unitRef="usd">3750000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzMtNC0xLTEtMA_7c8e65a9-964f-4009-b044-495d89dd5769"
      unitRef="usd">2500000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsOfDividends
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzQtMi0xLTEtMA_f45d4dc0-0323-486d-9359-bddc11bd6331"
      unitRef="usd">2711000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzQtNC0xLTEtMA_7172a580-e262-47c2-823a-94e222a8ea16"
      unitRef="usd">2591000000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzUtMi0xLTEtMA_a2d6bcfc-1683-47b5-9130-0f2db46d4c64"
      unitRef="usd">-134000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzUtNC0xLTEtMA_73e056e8-5f9b-4500-843c-522ecc02fea9"
      unitRef="usd">-124000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzYtMi0xLTEtMA_febdf105-6ec5-4fda-aff9-25764462bd2e"
      unitRef="usd">-6935000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzYtNC0xLTEtMA_d9808276-619d-4bd5-8fc7-91b058d491fb"
      unitRef="usd">639000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzctMi0xLTEtMA_c99fcf02-b1a3-4112-be8a-a15c1a12a341"
      unitRef="usd">-26000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzctNC0xLTEtMA_f79c4a0e-1f18-4b6b-8eef-2a2bbe4fe99d"
      unitRef="usd">2000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzgtMi0xLTEtMA_5163b52c-d71b-42d3-98b3-89fd119cda95"
      unitRef="usd">-1635000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzgtNC0xLTEtMA_7f9b8ed2-0eb1-454d-b907-d07c7aa26986"
      unitRef="usd">1255000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzktMi0xLTEtMA_1a4d0c33-ecd1-4ca6-9741-3cad623b4e97"
      unitRef="usd">5997000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3c214ead3cf04a2e9fc7bc2b14bdaf84_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfMzktNC0xLTEtMA_a1561ee6-69b6-4d6e-86b4-aa7ad3871f5a"
      unitRef="usd">11631000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNDAtMi0xLTEtMA_c4ae238b-938a-49c3-a46c-eef94d40dff8"
      unitRef="usd">4362000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i05bfa65a7fdd430ea5429b49909dff6d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8yOC9mcmFnOjM4MTYzMmRlMTZiMzRjMzhiNDFhMmMwZjE3N2Q1MDY4L3RhYmxlOjZkNjZkYTZiOGVmYzQ5ZDJhNWQ1MjMxODI5OGFmYWI2L3RhYmxlcmFuZ2U6NmQ2NmRhNmI4ZWZjNDlkMmE1ZDUyMzE4Mjk4YWZhYjZfNDAtNC0xLTEtMA_b24b76ff-f3e8-4c24-b54e-df307d2f1ce6"
      unitRef="usd">12886000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTc5Mw_f9710ffe-f76b-482a-a4c8-c1d799c9a868">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (&#x201c;Gilead,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and a variable interest entity (&#x201c;VIE&#x201d;) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We did not have any material VIEs as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one operating segment, which focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#x201c;CODM&#x201d;), manages and allocates resources to the operations of the company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#x201c;R&amp;amp;D&#x201d;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;amp;D portfolio and external opportunities to best support the long-term growth of our business. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies, Estimates and Judgments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these Condensed Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the coronavirus disease 2019 (&#x201c;COVID-19&#x201d;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. &lt;/span&gt;&lt;/div&gt;We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States and Europe. There were no material write-offs charged against the allowance for the three and nine months ended September 30, 2021 and 2020.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTc4OA_46ab677d-cce7-4c50-ac63-d782cee6b839">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (&#x201c;Gilead,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and a variable interest entity (&#x201c;VIE&#x201d;) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We did not have any material VIEs as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTgxNw_440cac44-690a-42fb-8302-b75f287f3771">We have one operating segment, which focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#x201c;CODM&#x201d;), manages and allocates resources to the operations of the company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#x201c;R&amp;amp;D&#x201d;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;amp;D portfolio and external opportunities to best support the long-term growth of our business.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfMTgyOQ_690c6c66-eeb8-45cb-882b-f2e6688c5f09"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTc5Nw_9f853e44-6fca-4e20-8502-9c31bb98c33d">The preparation of these Condensed Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the coronavirus disease 2019 (&#x201c;COVID-19&#x201d;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTgyMQ_372467da-f00c-4425-92c9-af8a5d6effa9">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States and Europe. There were no material write-offs charged against the allowance for the three and nine months ended September 30, 2021 and 2020.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTA3OQ_210f55ba-57a5-482e-90a9-9a6999fcb939"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTA3OQ_33d5173f-192c-407f-a763-ce13b0bba8d0"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTA3OQ_8e10fac9-0b99-43cf-9ba7-ae607900a97b"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNC9mcmFnOjc2YTA1ZGFiMzYxYjQwMGE5OTlmZmM2ZWI0NTA1Njk4L3RleHRyZWdpb246NzZhMDVkYWIzNjFiNDAwYTk5OWZmYzZlYjQ1MDU2OThfNTA3OQ_923417c5-d79b-4c48-a305-751b470155b1"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMjUzMw_871e907f-3db7-4527-aff1-1ee489a67f11">REVENUES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Product Sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Atripla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HIV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Hepatitis C virus (&#x201c;HCV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ledipasvir/Sofosbuvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HCV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HCV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Hepatitis B virus (&#x201c;HBV&#x201d;) / Hepatitis Delta virus (&#x201c;HDV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HBV/HDV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HBV/HDV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Zydelig&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Product Sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Atripla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HIV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;HCV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ledipasvir/Sofosbuvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HCV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HCV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;HBV / HDV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HBV/HDV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HBV/HDV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ranexa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Zydelig&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#x201c;C&#x201d;), emtricitabine (&#x201c;FTC&#x201d;) and tenofovir alafenamide (&#x201c;TAF&#x201d;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues from Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(as a percentage of total revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues Recognized from Performance Obligations Satisfied in Prior Periods &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $190 million and $625 million for the three and nine months ended September 30, 2021, respectively, and $206 million and $618 million for the three and nine months ended September 30, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates for variable consideration related to sales made in prior years resulted in a $188 million and $661 million increase in revenues for the three and nine months ended September 30, 2021, respectively, and $13 million and $94 million increase in revenues for the three and nine months ended September 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $167 million and $198 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were $85&#160;million and $97&#160;million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. During the three and nine months ended September 30, 2021 and 2020, revenue recognized that was included in the contract liability balance as of the beginning of the respective years was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMjU0NQ_fb3a9a04-df7c-4339-919a-16fdddfb766d">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Product Sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Atripla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HIV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Hepatitis C virus (&#x201c;HCV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ledipasvir/Sofosbuvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HCV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HCV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Hepatitis B virus (&#x201c;HBV&#x201d;) / Hepatitis Delta virus (&#x201c;HDV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HBV/HDV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HBV/HDV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Zydelig&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Product Sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Atripla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HIV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;HCV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ledipasvir/Sofosbuvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HCV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HCV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;HBV / HDV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HBV/HDV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HBV/HDV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ranexa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Zydelig&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#x201c;C&#x201d;), emtricitabine (&#x201c;FTC&#x201d;) and tenofovir alafenamide (&#x201c;TAF&#x201d;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia55ca9423cea4d12b888483189b2ac1f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC0yLTEtMS0w_6d15e035-016f-43e7-b9a0-f60e674417f1"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8aa096b135f48158580b40a60e33019_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC00LTEtMS0w_beff4668-53bc-4743-a12b-1eee416b31bf"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36a8c27aca7b4c4eb248168068a32aa5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC02LTEtMS0w_757b1154-bae8-4602-817d-6ad0da5e4978"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9c91fbfc86b4896a3a819c4d77bdb7d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC04LTEtMS0w_485aff05-719f-40c8-9535-a89fd17eade5"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6111ed4b4e34cc0938dc6143421bf29_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC0xMC0xLTEtMA_1c50c3de-09e3-48c4-910d-ef844817346e"
      unitRef="usd">99000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i846bb97183f648a1a345c7417b016402_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC0xMi0xLTEtMA_37abecf6-72ee-4a2b-ab65-1be05e5f1897"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idde4cb31f8274161ba1a860f8c484f38_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC0xNC0xLTEtMA_46cef4b3-e45c-4ffe-ae30-896c18200497"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4c0f1a209914347a5e69fa51270ee29_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNC0xNi0xLTEtMA_ea02e353-c410-4354-85fa-31d265bfdbf2"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i768c3bc1ec8c43ddad2162082a96cd6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS0yLTEtMS0w_a22ba602-8a76-44e4-b68f-476d4783f76f"
      unitRef="usd">1875000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b9a118513ef49819b2577666b0ec096_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS00LTEtMS0w_6881a87c-2b67-4065-87c4-75699779d466"
      unitRef="usd">254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i733e5fef29374d46b413dee54bb19109_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS02LTEtMS0w_02004383-d01c-4367-aa96-50672a937012"
      unitRef="usd">147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90b02afac5b7406d9c151b1f25da49ab_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS04LTEtMS0w_3502b122-3a4f-4d50-8a7d-dba7d382f933"
      unitRef="usd">2276000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba9d39a80c434949bcf4d4dbaa9759d7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS0xMC0xLTEtMA_1a7ba771-3827-4215-83f4-d12949c8c87a"
      unitRef="usd">1584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63ca5be4690f44a7bf33e1db73a1d060_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS0xMi0xLTEtMA_f7d184ff-91f3-40b7-8873-6b2862687599"
      unitRef="usd">194000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0257f3a298140fc84dee8d53d699670_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS0xNC0xLTEtMA_dc40237a-a1da-42cf-932a-8f6c2c9c8a74"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f7a64d9f59c4811a20101fd386ee115_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNS0xNi0xLTEtMA_53ac2798-41e5-4e88-80fd-e981c7946bbf"
      unitRef="usd">1891000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i417036899f4b4ba6a942d6c89d2cf9b8_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi0yLTEtMS0w_4021fce1-7239-44ba-aa8b-a58834e7c145"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4e1d6d95b2c4d2a920c8653b06216b5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi00LTEtMS0w_b225343e-5fe9-446d-a805-2214d41aa318"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83e6d6c2611b4c2e8c4aecf466648862_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi02LTEtMS0w_7e1ce8ef-ca59-44c5-9212-5818e7c009df"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7bfa430609e94754b5309dcbd1f54afa_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi04LTEtMS0w_e4bd0bbf-5040-48a1-9245-f2104fcc1f93"
      unitRef="usd">64000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i524768e71ccf4918b463a9f11d0b12ad_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi0xMC0xLTEtMA_f8f4c68e-b936-43dc-a03f-5626981a7beb"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4bbd970a4b1c41ac826211b086ec75c6_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi0xMi0xLTEtMA_b98c9ab2-2173-452f-8226-5bf3eb79bef1"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i585135633c624761b4c1a83f8fb3835f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi0xNC0xLTEtMA_6e9156a0-8d30-4070-a7c7-b2cc5b333c32"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcda312d5cda40abbb9ac037d9a20f64_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNi0xNi0xLTEtMA_ff364812-35cc-4fad-8c82-71da3f801960"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6c13cff5ea440d6856dd460e75e1cce_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy0yLTEtMS0w_6b6cc507-99ae-4aaa-9f6c-5db6f3553e95"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i972c68c99d2b48aa9f0ab252eaded219_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy00LTEtMS0w_2eb0e089-b683-4ee0-a690-7ec173d06be2"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bcac0500428449ba45e660bcf11a22e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy02LTEtMS0w_355df11e-6f5a-4325-8fdf-b4bed2f5581d"
      unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b5f64fafefb476897c670520ef3e684_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy04LTEtMS0w_9b1de614-5516-45eb-be2e-3f1fb0c5acd7"
      unitRef="usd">433000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb444609f3c343faae5bc31dc0f2969a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy0xMC0xLTEtMA_be97978a-5663-41aa-941e-b7c9e9ca1b72"
      unitRef="usd">424000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11b21909ece24606afb19d200d6cbf45_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy0xMi0xLTEtMA_fb474e29-f623-4f09-b27b-cf8d3ef5417b"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie64f24cc49d2461993b4706f48070582_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy0xNC0xLTEtMA_5e11e7b4-fb78-447f-82f4-1fb03240d93d"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia581ec4341004cacbe1676f4824925d5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNy0xNi0xLTEtMA_63657381-d926-46c3-84e2-072a4977c3e2"
      unitRef="usd">508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0beeedfff0ab464dacc2dfe91fea027f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC0yLTEtMS0w_d08d3070-afa1-4dd1-a4b7-3cdf6a1eb09c"
      unitRef="usd">576000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifda373a4474d4fddbe280b1ceeb9773b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC00LTEtMS0w_40cc960b-3af1-495c-8616-88ed85b2f1f2"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa5ff99375b246b19d9a454b2bfcd5c4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC02LTEtMS0w_3908ff36-89a7-4a26-ace3-b3a70eb9adc8"
      unitRef="usd">68000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6072428678a4c13b3bc2cefe46e2367_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC04LTEtMS0w_52c6db33-a43d-4246-9a60-a6443b5453ed"
      unitRef="usd">744000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5830a8e44aad42d6b4e5c07745f1a654_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC0xMC0xLTEtMA_b0aa0a55-72d3-40e3-b739-dba053738aaa"
      unitRef="usd">669000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2499d0efe544c88b850f4e06d6d0fe2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC0xMi0xLTEtMA_99f818e7-99dd-4d3a-a2b9-7daa59b81add"
      unitRef="usd">116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3df12d48d77f444687886781f8f13ce0_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC0xNC0xLTEtMA_315d084a-d229-4cc9-b5e5-e0932282da68"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9021fb6917c34472a60654a134736f11_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOC0xNi0xLTEtMA_2c031ebb-9b42-44e5-ae4d-615cd9f001ea"
      unitRef="usd">846000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i340ad048883f42aa821f43d0819810b8_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS0yLTEtMS0w_36133d40-cf1f-4afe-bf49-9c24ea8d72f0"
      unitRef="usd">275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i593cc1643d3b4cffbe6c45b7b951be8b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS00LTEtMS0w_83d30979-564b-4ca8-b9ad-4aaeb659a587"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if96b216119514bd5b34e404efd229b24_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS02LTEtMS0w_14c73d51-24cc-4e47-8fc8-32165694fce3"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fd1cab9c1fd4ca68901a86b57b2fb99_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS04LTEtMS0w_553cc1bc-3bb8-4ea1-919e-c2a4ea76206d"
      unitRef="usd">399000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3484ed15b64c4fc291da3be7d9248674_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS0xMC0xLTEtMA_db996a34-d8c1-49e1-95bd-14ff23797502"
      unitRef="usd">309000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f663d9f8f284b539edc2448996d7698_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS0xMi0xLTEtMA_f6365c23-953a-4abe-ae61-a9f16c74b251"
      unitRef="usd">116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i121ea362bc6448bc8bed2159e95e89b0_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS0xNC0xLTEtMA_3747add7-0ed7-40fb-92ec-5eda8de26d89"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a9823f6159647fb992be0b7838c2a93_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfOS0xNi0xLTEtMA_92bba081-ccbf-4865-9a13-46371ce51a98"
      unitRef="usd">437000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb9dfdb77c104c9ca832bcf98a8246d3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtMi0xLTEtMA_ea26c46d-86cb-4aba-821c-90634301ac07"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75b44da404f64237881a6460aa4636ca_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtNC0xLTEtMA_efc92776-53a9-4b86-8e48-522f9f7d2579"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ab0ac7cc574410790fabeb761d1d174_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtNi0xLTEtMA_2066feb3-0cb6-42ab-9d55-93ca719a6b6f"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38e2ac5333234a66b3903412e42f3e68_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtOC0xLTEtMA_04198d76-68e9-4612-a282-b1444a193f47"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75c03337a48d4a949b4288448d18a1cb_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtMTAtMS0xLTA_a2ec1d73-6c0e-41ea-a69a-c30e11e7a4c3"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idca8d358805f479b89d1fb6e6719e857_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtMTItMS0xLTA_66abed2c-99e8-4748-a66e-4f90cb7d01ce"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52e40c6015764bd69ee9cbf82d281820_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtMTQtMS0xLTA_3ced7eec-0b84-4bac-b06f-5aa198a1fd14"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a28cac4b61d41f5b9356a0b6aac960f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTAtMTYtMS0xLTA_39c34bf2-dccc-4a59-b041-fa72f1a6f8d1"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd6bc5b0bed743c29791702bead202bb_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtMi0xLTEtMA_7d3f9a91-8e11-4b60-8aae-57c12d31ae8d"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id310e22cdbef4eb1baca5c55f8b8fa02_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtNC0xLTEtMA_d8ce5f24-f3b8-4790-8238-4136cbdf5661"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65d60a8d39b34372a1be78e500f813c3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtNi0xLTEtMA_b407e242-a9df-4eea-9eec-152db09d369e"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6a580919a214b2d895ab413f26c8880_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtOC0xLTEtMA_7f9cda84-0daf-414e-b84c-362a20fd9233"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71a7ae2ad394446693596affca1e12ab_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtMTAtMS0xLTA_a95a8c94-6b22-47f9-b5da-15d024048c1b"
      unitRef="usd">492000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i754a2616edfb4f3fb575bf9a85114f6a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtMTItMS0xLTA_1004f0b1-fb72-440c-84e7-e2c13b30c560"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48939703477c47fe9550c4f92c6ba557_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtMTQtMS0xLTA_70809368-e934-4c2b-b15b-ffd3ce5f47ec"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie40a71d15ea447a2ae8f68926fced7a6_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTEtMTYtMS0xLTA_4db0c86c-9595-49fd-972c-c33cc25bcf2a"
      unitRef="usd">509000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e606e91fa3e46acac32b0de0f54dbd0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItMi0xLTEtMA_4d9c6a0c-a725-4950-922e-db9d7e34f9cc"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c941e621c4b4cb1a5e4e5d4ba5a859a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItNC0xLTEtMA_29532596-c6b0-4c8d-af2e-597d3f671e0a"
      unitRef="usd">41000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icee57962d9df495e8b9f2cbabe1f503e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItNi0xLTEtMA_1a068d86-1dc0-47e8-8c31-90ef1ff801b2"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb5b96718e3d479492237b8214637bd9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItOC0xLTEtMA_e9e983a4-7292-4f2c-8a46-caa9cc75f142"
      unitRef="usd">130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0ca8a58c2d94581bcfdc60a41cf40ec_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItMTAtMS0xLTA_5ce706a3-0901-46be-8d7e-56e37aa9e1b9"
      unitRef="usd">82000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i864044e4908b498e881e97143cb3166e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItMTItMS0xLTA_9fe8b681-9b9d-4127-9383-2c1d0398999f"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51ab94a8ddba44f79cfe371276e8f9bf_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItMTQtMS0xLTA_b930fa54-9379-4ff3-9c39-fadbb3bec369"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia93c6c5c009b4c31b3fa92708b8d815b_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTItMTYtMS0xLTA_92a7374d-cb46-475f-8735-5ddc42ef8f23"
      unitRef="usd">118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b348befa53e4159bedea795454be27c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtMi0xLTEtNDI0NzY_108102e5-d685-41ab-a201-8a0a8b6026a2"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab1615ced09e40b1aa3cc44738550dd1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtNC0xLTEtNDI0NzY_3860c166-4481-48ae-9318-ef9246d6f1ea"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if20f435a41c348cbbdc43f245ac16861_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtNi0xLTEtNDI0NzY_f2213a41-0f7f-4326-b82f-405c923ec4d4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73bf790cd1a346988b368c7d3cde8b8f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtOC0xLTEtNDI0NzY_bca89de3-662a-4a0c-a6b5-745e9232e0bd"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8612d631840e48e895d251930e52c4b9_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtMTAtMS0xLTQyNDc2_2b63b1e4-8392-4a13-bc73-7629d439ccd4"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76968fb55cbc4ae28307471f0cccfdd7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtMTItMS0xLTQyNDc2_136ac9d8-1493-45fd-8c0d-ba1c1502e391"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10ab46addd4942a0b01ed1d3a2011f31_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtMTQtMS0xLTQyNDc2_1d3e6f85-ca02-4767-884d-67ddddd2d8eb"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47709a114cd148c0838a562496cab936_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTMtMTYtMS0xLTQyNDc2_5e23d6a3-6bb0-418a-aa89-bd75fea91c95"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c463d05c4ab40cdb9e847fd0f510bea_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtMi0xLTEtMA_6f6278e0-0032-44a6-8cb6-3e38fafcd85d"
      unitRef="usd">3302000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i171565ffc87743c1aba490024359250a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtNC0xLTEtMA_df307c8e-3f23-447e-8a79-c103fc1cec67"
      unitRef="usd">602000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied3ad8d00ec64e84b7f987b2ba29eabb_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtNi0xLTEtMA_018cfd61-f884-4992-8860-79443890c086"
      unitRef="usd">285000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78b9c2f39bff448a95abbd58f45d0fd8_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtOC0xLTEtMA_80d48b62-aefc-4096-b454-779b6d00667e"
      unitRef="usd">4189000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib86391bc6dae4373b89bd8ab38605880_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtMTAtMS0xLTA_a040216c-33bb-43d5-8653-dd998c930623"
      unitRef="usd">3722000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ad4a6158ebe4dff890142a1696e812f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtMTItMS0xLTA_c64b650e-cd7e-4f83-999d-f56882cbbc63"
      unitRef="usd">569000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5dffca717ae24d34a470d8d9a38dc095_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtMTQtMS0xLTA_f26f4701-988f-49d3-bccf-47149588d371"
      unitRef="usd">256000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61275390a7e640b2897c50f960fc2caa_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTQtMTYtMS0xLTA_12f68429-aa54-4df4-8ec4-99fc1893b382"
      unitRef="usd">4547000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia61446b694c74e7d9f5a65b521566c20_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtMi0xLTEtMA_ed638451-fe4a-4ebe-8756-c43445d420d2"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib982a6b7a5ef409bb13733f8c74abbbc_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtNC0xLTEtMA_77f2ea67-5d50-4fc3-ae15-d6fe88c1afd4"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e3676630be045daad191ec0e8486184_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtNi0xLTEtMA_39bd7519-91b2-4fb2-95a3-3367d0b764f3"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a702cd0f2e242db85b30aa6ce77bd11_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtOC0xLTEtMA_0fa134b8-11f5-4fc8-ba1c-e13c0089af3b"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99d0c47edbf149b4b42fcf95a60ac88b_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtMTAtMS0xLTA_98e26edb-0d7d-4463-a0de-cf15a9d1e52a"
      unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82bf2e8a84c54403aff0f3a4e0827765_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtMTItMS0xLTA_d98f5ef5-03cc-42b2-b672-2e9d30bfe735"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i529a378d1a634502932448df5c7dfc96_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtMTQtMS0xLTA_f75fce04-80e4-4d89-9025-5b7a6550c0e7"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5c2caa8a7da4d24a4facd4e5589dff4_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTYtMTYtMS0xLTA_45698578-aa22-40ef-85d0-747b4d36ae85"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28240f36b37149c0aebeb17174beff82_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctMi0xLTEtMA_1189b5c7-d3d6-442e-a082-1d75290ea488"
      unitRef="usd">173000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a5536e23c6241a49f1464d8fe7455fc_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctNC0xLTEtMA_02b73f71-5147-4ad7-bf10-8e50c581fc82"
      unitRef="usd">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1a32343f5754479b35423074bb85146_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctNi0xLTEtMA_b2f997ca-8807-4a00-b089-6ea014283fa6"
      unitRef="usd">82000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7520be9c8c2b44299328cc6ffba5984a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctOC0xLTEtMA_b83d4698-0cd7-44dd-ae43-1cdb9a6ce4a7"
      unitRef="usd">332000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i505f00cc79eb434fab41a8fc651c07bb_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctMTAtMS0xLTA_426c60b8-0b0f-49b3-966f-31b65815df08"
      unitRef="usd">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia266f177505e46e1bf32006d610309d5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctMTItMS0xLTA_d6975e35-3f9c-4f39-b3fe-9116913b19cb"
      unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i871de7451e1745a0a07ed808518e7b3d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctMTQtMS0xLTA_31270a3a-5d8d-48ad-ae76-b8f124a6cbce"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99b5ce6646c74d90aff700749d2e8cfb_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTctMTYtMS0xLTA_c3f2a20d-5765-4a1a-8541-f99c4d4aa581"
      unitRef="usd">330000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iceedaa27c5974485aef9d4d3a5782af9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtMi0xLTEtMA_5f452b87-9ad9-4ed6-994b-4f6d26e79fb9"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i554974bf2ebf487c9a569c72bf26081f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtNC0xLTEtMA_65e42ce4-e0ab-49a6-8237-2fb67024a510"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cbc708d4b1a44a7a2159db8585b1eee_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtNi0xLTEtMA_f49ec81b-edc6-4c13-96d4-b31e4e6d8687"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ac3e5d698614f858c14ebe4eb398eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtOC0xLTEtMA_b199883d-a119-4031-9943-b19db9a15df4"
      unitRef="usd">52000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b6ded5571864ffd9ce7c0d50dc74892_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtMTAtMS0xLTA_c76f29cb-2e8e-4344-b557-ec3f1c88cd8f"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b63f63cabe44e2585bbadd57fa354b1_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtMTItMS0xLTA_18faf89e-8213-4df9-981d-6180ce841a89"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac3caa38232a4a51a8ab79f61e2251ff_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtMTQtMS0xLTA_734fe6da-3d49-4fcf-8b91-f70fad805f9e"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieffd3dd156194386848193bc49944ee6_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTgtMTYtMS0xLTA_18f75d8e-b4c6-4f41-a15c-7fbaf2cad943"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83a6dddb7daa4a5ca29ac5484a6fd6e7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktMi0xLTEtMA_fa2c9b85-f9a7-4a69-8b5e-eccb3303db1d"
      unitRef="usd">224000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83f0238d623444989439cf7baaffa508_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktNC0xLTEtMA_d4366c48-094e-455b-b30f-798de0edb127"
      unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45562ada92804faaba94694bf0efa14a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktNi0xLTEtMA_32b6986a-3da1-4534-b551-bd525a71c51d"
      unitRef="usd">111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i826c955d2db24a8fac6267b635be2cde_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktOC0xLTEtMA_85c71a50-4a2b-403b-99be-683691f70d88"
      unitRef="usd">429000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia73efd497975415fa3b80207050da730_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktMTAtMS0xLTA_d5c1488c-62c1-4326-a058-2e3817ba4d27"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc2ba5e907414bfd8ea65cf2a73b82dd_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktMTItMS0xLTA_f1048073-5733-466d-a3e4-2fadc7329163"
      unitRef="usd">98000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic82244d6f2a444548484e7aec01540b2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktMTQtMS0xLTA_2ea53ee9-a16f-4f13-8c54-e5aa718a08b0"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19aa5a3f35bf4604808d9f2e3a8da3d0_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMTktMTYtMS0xLTA_0ba3185b-1c50-4c40-8326-a791b970d144"
      unitRef="usd">464000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb7d7312714a49a0a36fa523e3b8b0a4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtMi0xLTEtMA_2eefd392-c46c-4f10-b0ae-648101348d28"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0baa0f95e2af4393a1730300142cc581_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtNC0xLTEtMA_55e43fab-61a1-4999-8c76-8ca6ede77a81"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88742fc2c2b34f5ea2b9520a011826a8_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtNi0xLTEtMA_c97c710c-85e2-4687-a918-2c6af9c341e1"
      unitRef="usd">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf9b1de4fa0b4462bd3dc919628df7de_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtOC0xLTEtMA_7858af8e-d82a-45c0-8c28-51e984251631"
      unitRef="usd">208000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1115a331568c4809844ce0028077a85a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtMTAtMS0xLTA_3a8fbcac-24be-4f58-9e1e-a294a1643468"
      unitRef="usd">99000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8837076c1a0d4dfc86bd66bf5152de38_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtMTItMS0xLTA_60db4e0a-da84-4ff1-b873-b385a3e800fc"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i444db132af094e4bbf54b5614246e999_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtMTQtMS0xLTA_fd55813d-2d0c-4f19-bc0e-5b7d1ed7c838"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a81a8e5d9974ac7bde5d42f5a4fc336_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjEtMTYtMS0xLTA_72171d55-3cdc-4ba5-8fbe-20a363ade880"
      unitRef="usd">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa8b523c2e824076a748ebd245595664_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItMi0xLTEtMA_a8646aa7-4bc1-4ce0-b101-8724c7ee7f01"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id70ba4cf64c94219a9e327880de4ffb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItNC0xLTEtMA_ccfb6196-eada-41a4-bbd3-598706a5aff6"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f05f61614c147efa464532642700a6e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItNi0xLTEtMA_d397d51d-b07d-459b-bbd5-cd2b0e51e378"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93f53d3fb034456b9a305a7ed3d3e66e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItOC0xLTEtMA_e7ac6090-9bfd-442a-881e-6c4eecb7a4f9"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a017e3308ef4cbb9b933e55ec090998_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItMTAtMS0xLTA_32b30ebc-e1f8-4d67-8743-af32448ca060"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea639de29d0e4d668506abf5fe3550ad_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItMTItMS0xLTA_3ea461cd-7d21-4331-be91-a53c9d81115a"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife19093e97a54f5c9eb24677048ec618_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItMTQtMS0xLTA_bc512ae7-a976-456d-8462-a665684aa16c"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5266ed380c4d492c9019fc51f76cefd0_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjItMTYtMS0xLTA_8b6e99b8-5e5c-4846-9a91-3bd35252202b"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9eb9b983d1b54d55beb90a63dddb2c59_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtMi0xLTEtMA_3cd510c9-aca4-4c9f-9d39-5f9cbe0a491b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf984fd7000f4775a945b8b0f7942e2a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtNC0xLTEtMA_fce2e293-aad6-45e3-bcba-3b197a71a1d9"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29ec2e59c50f41ca958a6fac1402679d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtNi0xLTEtMA_0e73b5ee-399c-49ff-b51c-4c92bc6c54fa"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f4e484bfe8744e48ad91049bec90979_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtOC0xLTEtMA_8cde92ee-f6cc-4ac9-9d43-6ccf05c2a2dd"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3732c23942243a9a941c7c4e278892a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtMTAtMS0xLTA_0794001c-98c3-46cc-9a41-5aa19d5ee209"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i877e24c5d0694819b01d486f5d882659_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtMTItMS0xLTA_e9e98a00-94db-4973-8344-fb32dbacf60d"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf1741a698e64669b6b86f03281e3c65_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtMTQtMS0xLTA_6d6ec1d8-870a-4579-af19-be2fae4fa2eb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a1dce33288a4302aaad5691f38a09dc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjMtMTYtMS0xLTA_218c1f34-ad9a-4006-a729-abad2eaf149f"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80097a5080c0445eb9773bcbbb99bc1c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtMi0xLTEtMA_88dbafd4-3c41-483a-ab4f-549bb67d7520"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19103f7ddbeb423abb4a6bb401db7fff_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtNC0xLTEtMA_7716181c-2a4d-431a-b38b-6cf754f1fbf0"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica155088076646c3a5bd1588f0bceb4b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtNi0xLTEtMA_bd056b31-e302-4cbe-a0c7-084b05e27e18"
      unitRef="usd">114000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia812590aed6d4ab39be1d578c15c1486_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtOC0xLTEtMA_c4c3d1ba-a7b2-4bf0-b0fb-0dff985cd1d3"
      unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e007c33751b4a5c978064214accac0e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtMTAtMS0xLTA_043f0028-42a6-4cbc-b8a6-3fdc8fbc1646"
      unitRef="usd">102000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33137ec5b6634022892adaf4e137ea2b_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtMTItMS0xLTA_f3284b9b-04fc-4e07-813c-11cc25d08c08"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02900307815d45ee8652b90be7d1be4c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtMTQtMS0xLTA_2852efe0-74c1-45b1-b5b4-cea429dd5106"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieba46f08b484419da5dcf2ea9265939b_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjQtMTYtMS0xLTA_3ce1dea6-ef2a-42ee-aa6a-e6f62d6bde36"
      unitRef="usd">211000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f89bf00ca354d5bb864b9f0cd155397_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtMi0xLTEtMA_cae72440-97c1-4360-a18e-2de95ff9889c"
      unitRef="usd">1527000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e029ac4bf384381be5a78e8fb2e5178_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtNC0xLTEtMA_de0a61fd-6e22-421b-af95-9adb33cc06c5"
      unitRef="usd">109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd034ba2efa44a2db164c8aea8825436_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtNi0xLTEtMA_f6e02a78-364f-4abc-aac5-38b8c917a462"
      unitRef="usd">287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04bfbceaa25142cc84ac6378009c15a3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtOC0xLTEtMA_fd050680-b280-4e73-bfcd-1fb60480cbb4"
      unitRef="usd">1923000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i992039dc5c0441c5b5f6174dce19c781_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtMTAtMS0xLTA_5d047526-b6e5-4930-9607-2a8dee62365c"
      unitRef="usd">785000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ae99aee62f846139d54de729834ff14_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtMTItMS0xLTA_50bcfd4c-64a2-475d-a83a-b9072dbd1124"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i678692608fbd4c1fa178eabaae64217c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtMTQtMS0xLTA_9086f8a0-f5f0-45ae-9799-f2ce411440fb"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b6c99a3b9fb41af94b2683664d43cb7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjYtMTYtMS0xLTA_e15e29e5-7990-4f59-be9f-af601efa008e"
      unitRef="usd">873000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieec0b95176c043cfbbc5a9f6fa983587_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktMi0xLTEtMA_103b0d2e-9371-48b6-aa5d-7b0cd97f96e8"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0507455b49474b93a38ead6ff2615419_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktNC0xLTEtMA_6631dd96-3349-4c3e-8e8e-9b97d4b732f8"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12ee4d5996924966837c8c99c967f51a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktNi0xLTEtMA_db93037f-029f-4a1c-a896-affa02c54153"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic78827f1965b425dba08fd9f4c2e4d58_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktOC0xLTEtMA_4c63dc7c-6777-4893-ac9a-4ee594e6e7a9"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39b4ec9525e44e808926dba562992f53_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktMTAtMS0xLTA_a9a713b5-7fd0-48cf-88d0-5ea7fcd9f0f6"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5113443b36744e9e982775ec8eddc113_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktMTItMS0xLTA_fd7f7700-0194-4453-8e22-c520fbcfd1ce"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i736b122cf29c43ee95e28299d9a585f1_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktMTQtMS0xLTA_28f7ea69-87cc-4fe8-a55e-57d9886dfb14"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c967382fd7e4043b63ff0da2d1242a2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMjktMTYtMS0xLTA_efaf6c84-b7e2-4d84-91bd-a0384bc8e501"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie85528a66b46438d9ef9265272241283_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtMi0xLTEtMA_bbcb0d07-ddff-4b68-aba5-d32202dabbb3"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb5dc4dc454649c4a9f9a11210acdf30_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtNC0xLTEtMA_fddc56af-99b5-4e65-9f5b-665b6df2b0d2"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c45e550d01b429cb2b091b9902532c0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtNi0xLTEtMA_b189bc34-446b-4603-895b-5308138decc4"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35a4693d3cc04b62b20fbe12a1d5a54c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtOC0xLTEtMA_c06851cd-7c20-4435-a9f9-a33e94bb9e95"
      unitRef="usd">175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9751f0cadc8491e945ca44b0b80b126_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtMTAtMS0xLTA_b127352e-5a70-49d1-8974-cd81213c93b3"
      unitRef="usd">85000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4395e1c88544cc4b60097ece5543cd3_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtMTItMS0xLTA_8cc5b760-e26e-454b-8440-d6f0e2e8e24c"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia30e8d354ab04f3a97abc398675713dd_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtMTQtMS0xLTA_b6cb5c15-f9c3-4b0b-aa26-e2b2fb8c5d34"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id953d64ac7fc4fccbf566a8d9a4e880e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzAtMTYtMS0xLTA_efe3d617-e305-40ff-8f5b-5801c0c327a9"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6ecbe4c2b2d407793fd3b236408f12a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtMi0xLTEtMA_cb102291-bf2f-4799-8384-2fe7c0b6a4b7"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b07ea93a6f54fd0a91bf6672ff04b65_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtNC0xLTEtMA_9e8de06e-2f34-47bb-b833-f267a8b44756"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73b68324728248e48095f5acec992615_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtNi0xLTEtMA_18826e31-cba0-4958-8b9d-2eb2430c53b0"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8f3b797b0784b5e98a1ebecc9731bc1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtOC0xLTEtMA_5c460de9-6c89-4e03-b9a7-6a8e9d9ca582"
      unitRef="usd">222000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c6152e617b143c19295e79115efbfde_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtMTAtMS0xLTA_b3568c93-e434-4160-a3e5-516a83d31cb4"
      unitRef="usd">90000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55ce6c803e5044689d6f072466cdb84a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtMTItMS0xLTA_ebf7f012-0376-4189-bdde-fb0a1dbc10f1"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icbb1331a5dd2469fae50b0f82ccdc186_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtMTQtMS0xLTA_f568751c-dddc-4732-8369-364df1881595"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32399ea9bc584449a570a053a33d5913_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzEtMTYtMS0xLTA_38985e51-9211-4bc6-ad2b-2199ebb5c39a"
      unitRef="usd">147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b87fa8d5dc94c15bba720f6e25ca2c4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtMi0xLTEtMA_17ff3a44-394b-4b28-8b74-af6f0e0f132f"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id317edd4885848da96375a5d6890f972_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtNC0xLTEtMA_dcaca6da-8c2b-4957-94a8-7db1c60eab11"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5d1c49fd62e488a9d8f1b1bf40b098e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtNi0xLTEtMA_591cae46-d455-4a5b-a0f7-dfb475fbcad9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c6dddbd6632497799ce67bce0d386c2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtOC0xLTEtMA_7fc5d80a-4a01-493f-9638-f37a17b5bd0c"
      unitRef="usd">101000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2a5f3cc54f848f1a10d35d090a03387_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtMTAtMS0xLTA_9f56cdef-da1a-4fd5-a0b2-eb7cc3b76dff"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fb67792ca1a4e87a11d779d955afe4c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtMTItMS0xLTA_29eb1b93-d362-4688-9722-ff6238b71df5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71818c2f40544a51bd97f8265ec8d26e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtMTQtMS0xLTA_75b6ec97-e792-4f3d-a784-19d21db44ef6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8d2d00f525545e0bfeaff95a0d0fbae_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzMtMTYtMS0xLTA_fad5f5e2-76d0-4f38-8816-f6d0cfca2e69"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffba5b40986f41988004b66efa3262e3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtMi0xLTEtMA_5c069fdf-45ec-4ba1-9a00-10825953e7bc"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie950ff8a161b4f3cb591feb0c61f2b65_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtNC0xLTEtMA_8c8e863a-6e1e-4195-a7f3-032c2f810c04"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i014ae1acc1a0400cb0833dd1ec4d8c95_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtNi0xLTEtMA_821abfd4-5315-474b-b8ac-94ecb577a668"
      unitRef="usd">69000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i248f6f4d0b1743b8ac49ee8a4893a138_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtOC0xLTEtMA_baf681ff-3caa-4d1c-9ba2-8ba24cb6ac5c"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb48adf7671d4b5095439fa1db112f98_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtMTAtMS0xLTA_b97c00bc-813a-4446-b3ea-5b9567d30824"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6dea3ee0ff204b6a859461e1d1f6d8ef_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtMTItMS0xLTA_fc3578ac-2934-4b65-9bc9-4408066ddbfb"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98dbae32b00044609d015af32ec98ca2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtMTQtMS0xLTA_60b0ed0a-dbb4-4cd6-bfd9-4c1113dd1c14"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb6c3fd5a3c7472f93e4bcc1e14205f1_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzUtMTYtMS0xLTA_89409dc3-19a0-4b40-ace5-626660cbb00a"
      unitRef="usd">111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93a4e05cc8d84ef193edc737f58313f3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtMi0xLTEtMA_8d744c8d-7214-476b-b052-d810b9d87369"
      unitRef="usd">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c4a3efb665a4e32b3fab9bc46d0e840_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtNC0xLTEtMA_e116809d-7e23-4859-b501-0fcaf4f5cf72"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07b88223ff894ebeb782ba78c923b80f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtNi0xLTEtMA_5e3d40a0-961f-4fbe-9d40-5c6f02ce51aa"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ef52ca9d6a84708adf4f8bd716acb1b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtOC0xLTEtMA_639e4824-082a-4301-a43a-efbb88d1cc24"
      unitRef="usd">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia60d842da95f4557a472db9a4f20944c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtMTAtMS0xLTA_a01502c9-4f4a-4c0f-a17e-eb18f80604ba"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i312af34f38c3480f92c1180516ce4b2f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtMTItMS0xLTA_4c1e1a6c-cf09-4da6-862a-1956e4257e71"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69497b92cda24b32bb318450db656d59_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtMTQtMS0xLTA_3e56f783-5a92-46aa-a776-511801889f0d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c83f4a3e9804930b2a2b194201c1c9a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzYtMTYtMS0xLTA_1f2502ca-ba07-471a-8db3-73835d333ce3"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b526ba862f347ec9e038db912732159_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtMi0xLTEtMA_b7210307-2e7c-43b8-8ce4-61cdb70df498"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8674bb821a143ffbf0e7c0a4bbc23f5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtNC0xLTEtMA_e697bdc6-e799-4b7b-a56e-b2f1a823cab2"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f44e89624524a3f85af2769737da0e9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtNi0xLTEtMA_425370f9-8e91-46cd-95f0-1ce3a3e513eb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i106ed528aea94b3e84e167881f011048_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtOC0xLTEtMA_e8f7b489-4e41-4cd0-aeb5-dc3ea3776847"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06672ac481ba4a9bb5bd08dacfe71e88_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtMTAtMS0xLTA_e6a3418b-741b-4991-b21c-6fd46a58fffe"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0753fdb7e8f479fa676298a44c409a3_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtMTItMS0xLTA_934e4a1d-d9e2-41fc-846d-82a623f5c4e6"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84e6d6f192a24ac8b2f45a194dfc508a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtMTQtMS0xLTA_d48e7d5e-0884-4c2d-acec-3aa27f647652"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86eebf78b2f54e5789f05f6de57a33ff_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzgtMTYtMS0xLTA_3d0ea6f0-7b0c-4415-9946-6f8089eb7441"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90831c4bec134c3d9479dc73821bd890_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktMi0xLTEtMA_9719bebe-2359-4005-b36b-a03c258f241a"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f950f4a2a1943729bd08af5465b17bc_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktNC0xLTEtMA_cc63cf55-4590-4340-be3a-78ea6afb616a"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00d836d842884745a9b0c054d60b3106_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktNi0xLTEtMA_1954617b-597a-46a7-add8-b969995566dc"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94d80d18f64348a6952ff66466587e5e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktOC0xLTEtMA_523f15f7-58eb-4c21-a6fb-a03e4a24806b"
      unitRef="usd">43000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i420349f096da42faa5a1507cb5af2bac_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktMTAtMS0xLTA_2f64a6ba-fc16-4586-9185-181f8c9c14b7"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c028e5643ea425b858bce273dbb43ff_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktMTItMS0xLTA_ac764b8f-cf00-4fba-866d-2be1bd06126d"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f15774b1a2c46f9849e41b07da947da_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktMTQtMS0xLTA_fadbbf1c-190d-4084-becc-4d3f6fc76299"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibfa297463bca43108958d1bc0d817e62_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfMzktMTYtMS0xLTA_8d305cf1-a5fc-4ec8-86b4-e12c5715cae1"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i801113c804f84bf68a7ce7874e0fdfff_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtMi0xLTEtMA_db3d818a-fbc6-4ae2-8326-12189c329eb6"
      unitRef="usd">87000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22120ea38a6f43808c0a51b6b42c907a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtNC0xLTEtMA_11738258-bffc-4e65-a95f-881cf983304e"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dd65b051c3c43a09723cf00754a0d11_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtNi0xLTEtMA_bef5eb04-0b1b-45f1-8866-2c0423cb4248"
      unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ee5d0fa9bc243609b1326fffc9420dc_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtOC0xLTEtMA_a5e563fc-7935-4488-8452-e023f1cd9a0b"
      unitRef="usd">245000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64edf3f2b52641b0b8963f1e7ecaf35e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtMTAtMS0xLTA_c6f98c85-0a50-4392-8a0c-f8336546b6a1"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcd113a548354e83adbc4e684d0b7c6b_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtMTItMS0xLTA_cf03e04b-1225-434b-9068-620eb18a496a"
      unitRef="usd">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ad59f43c9584895b43102b96b356bf6_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtMTQtMS0xLTA_60d0433e-7970-444d-842d-300c8da605d2"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e7dca62ce034df2965648995f1e45c3_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDAtMTYtMS0xLTA_36decea2-54d1-4e33-a7cd-a0fd209d237d"
      unitRef="usd">251000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide81ff472a904e96bd7c11cfb160bb5a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtMi0xLTEtMA_a50b7e3a-377b-4cbb-b16e-b92d6a8b4559"
      unitRef="usd">5479000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c657737c9a44da0bd9a0a0ed937b77a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtNC0xLTEtMA_5d7d3f8a-ca97-4b4f-9449-2e4f41c9fe0d"
      unitRef="usd">997000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i761660c0e36b44119d0a377956dca1fa_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtNi0xLTEtMA_d7ff2c96-7085-49ff-9242-19ab74bca295"
      unitRef="usd">880000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcc4638e68b041b3aed502ac0da98085_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtOC0xLTEtMA_a8957ffd-a3f3-49d3-be4a-afb5c6846738"
      unitRef="usd">7356000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42344c7afe36415a9346e765e883f109_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtMTAtMS0xLTA_22984a6e-e582-43a7-b029-d570b002708f"
      unitRef="usd">5076000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i780ad9f4faff41188b82d5ee6efad1c7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtMTItMS0xLTA_151e2517-daa5-4782-870e-15e0b7a16f0e"
      unitRef="usd">877000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i771dc583a85d484996619f6a24a1e310_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtMTQtMS0xLTA_36db3f42-368a-4baa-a44d-a5c8469afac7"
      unitRef="usd">540000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i113f7696af45458ba1c6270ba2e89d75_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDEtMTYtMS0xLTA_85b9ff25-f257-416c-a7fb-452a8bb615ff"
      unitRef="usd">6493000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12d2e276cf194b249b5381b7c0d564e7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItMi0xLTEtMA_c9ec77b3-7963-440f-a640-1f4ef6b0be05"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a788a5a397c4d3c9c4273e20cb2eaaa_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItNC0xLTEtMA_3dbfe82d-a10b-4be4-8068-0862b742d12b"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf04a6872a2045d9aba3f8ee749ef8cd_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItNi0xLTEtMA_b85e797f-1c87-49ce-9a61-18a23c253a19"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if593c50c51de4ecab2682f502e43fe0b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItOC0xLTEtMA_b9b37025-93a4-4e13-bdaa-39dcf5cde7b8"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89aba37ab3bb4d6f995db3f1ef7313fb_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItMTAtMS0xLTA_c3260b5f-2b27-43e0-b3a0-ed801f07c5aa"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib47fccef93064956b207fbf3f4b0c07b_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItMTItMS0xLTA_bbbcde5b-5e34-4a0e-a0df-37ac7b0d173a"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c6ae907411a40a09a29dc2bf329268a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItMTQtMS0xLTA_a4870628-8f0c-4226-aa94-f5d37d765cec"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80719b1e7cda4bf6adddc01b671e7d5f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDItMTYtMS0xLTA_765848be-ef18-43dc-9c50-3b77356cf1f5"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibea8c08b19a845a7bc3ab84d8743dac6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtMi0xLTEtMA_7725d5c9-8ce6-4bda-b2c1-fc5d0e8b0d6c"
      unitRef="usd">5509000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbbee8f040784dbbbba5f6f7708c8260_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtNC0xLTEtMA_37eaf8dd-857d-4786-b0f0-36258d17271b"
      unitRef="usd">1031000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06591e9d784f4725a4a3f560f9165fdf_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtNi0xLTEtMA_e58d781d-2040-4c60-9699-f504ee96d52c"
      unitRef="usd">881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtOC0xLTEtMA_ba8e2db6-5d76-4108-b7ea-380bc4c2cab8"
      unitRef="usd">7421000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic63411681ae343ee931a1ef0fa134389_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtMTAtMS0xLTA_3346eed7-c48c-4f2b-82fe-91806e702513"
      unitRef="usd">5100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7017bfe2cca74515a9c77805ce3e685c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtMTItMS0xLTA_6aabcc19-68cc-4e91-8d10-4360f3e77075"
      unitRef="usd">937000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if87c9a9443ac49bbbc5f60c80bdb0cf5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtMTQtMS0xLTA_8fc676a9-f70d-439b-a7cc-087f821d221c"
      unitRef="usd">540000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjE1N2FmZjdlMDQxZDQ2Zjk4N2Q3NTkxYWM4N2Y2M2NmL3RhYmxlcmFuZ2U6MTU3YWZmN2UwNDFkNDZmOTg3ZDc1OTFhYzg3ZjYzY2ZfNDMtMTYtMS0xLTA_aece37be-197c-47a7-9297-7216131cead2"
      unitRef="usd">6577000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34a4aea2fb6941c9b82af8675d2a96d6_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC0yLTEtMS0w_b1d8494e-036a-4aed-8383-431be8c8d840"
      unitRef="usd">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic38c735785bf4de499f546ffb3cbbafb_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC00LTEtMS0w_e7bb3256-9ea8-44ed-9636-8679eefec17d"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if590ab24b0d24195a1751c7e37eda7d6_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC02LTEtMS0w_17fbe949-6195-4c90-be4d-741790e48b03"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86322bce038342589d4f3d411cce6b67_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC04LTEtMS0w_78e2d6bd-3675-4b76-9909-f9dafda2241d"
      unitRef="usd">118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i122291e0c90149469fe7f534977d4bd1_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC0xMC0xLTEtMA_bfe33f82-2853-4f02-b4e6-fb5c98335d01"
      unitRef="usd">275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7be015c2d53f492face1090466f96194_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC0xMi0xLTEtMA_329d150d-baba-4306-9826-f062cc9e8f05"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41905ceca0e14646bdbb966a276724c5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC0xNC0xLTEtMA_24d0621b-fd23-4a1c-9101-5c63874bf215"
      unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96b919aa74e64ed8953496faef33cead_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNC0xNi0xLTEtMA_d20b0f5d-8298-447c-b828-52438d9e6141"
      unitRef="usd">311000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id55d71c6943b41688ba0c99c12c4b0a0_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS0yLTEtMS0w_063cc84f-9837-471f-baeb-537339219e23"
      unitRef="usd">4926000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib74e3480706c4ceea2eeaa33e8a29a04_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS00LTEtMS0w_1c48650e-5a58-46b3-a7ec-017b42a4c562"
      unitRef="usd">707000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia50f0d178a34403ba582f4fd7b081032_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS02LTEtMS0w_b76d9461-4bca-4693-962e-e59654ea7f08"
      unitRef="usd">461000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1125817792a24e229eac03cff110ec3d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS04LTEtMS0w_7be0af88-e147-41c0-bbdb-db0e9fbf96f7"
      unitRef="usd">6094000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b4c349c2ec345e9b842096c5ccaf53e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS0xMC0xLTEtMA_2e5b3811-d67b-47ff-897b-ae2573c112dc"
      unitRef="usd">4346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i175a2429ab0a4e3b8b1e75f43911073d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS0xMi0xLTEtMA_18290232-947f-4e0e-be21-078130d4fccd"
      unitRef="usd">528000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bb3ecdf995d4d6d812e8c4cbd7c50e7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS0xNC0xLTEtMA_48fa7c5c-3199-45fb-80a1-b2105aacbb00"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1b6b1928d21482d9b69713fe3e4a90b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNS0xNi0xLTEtMA_83662abe-5005-4edc-acbc-9ea4db265ace"
      unitRef="usd">5188000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia342fd853fbe4fafbfdb82fc8f51be9c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi0yLTEtMS0w_eb7c9e02-50a2-4e73-9776-d320c82e5108"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23e096ae4d344ee6812e02f2cc006dcb_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi00LTEtMS0w_754fba5f-2df3-4c68-a460-52e81b282a02"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8bdd6612962405a995125b9413576f2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi02LTEtMS0w_4f5c1c5f-7798-47f8-ad46-01ea0ec60ccf"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i028a2e4438b44cd584805fb7db0521f3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi04LTEtMS0w_516a3151-238d-44a5-85fa-100184962adf"
      unitRef="usd">189000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8cf4df7cb3b4e0b86839f9b4fc78b33_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi0xMC0xLTEtMA_57248eaf-06cf-4738-b94c-1294eb619148"
      unitRef="usd">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfac141d6cd44e59b0b264ad26f95be5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi0xMi0xLTEtMA_d538ed04-22d4-4c30-a8b6-1970bf068ee1"
      unitRef="usd">124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4522ce1c0acc43ec92a475e4619c9ded_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi0xNC0xLTEtMA_352bc435-89e6-4806-b36f-09770ab0210d"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5f3f15ae4734085be8c32af347a19ab_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNi0xNi0xLTEtMA_a2a05522-458d-432c-ad45-007a02a46630"
      unitRef="usd">218000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id78d2215b759479ba1d4220802e6d2d0_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy0yLTEtMS0w_8f022bad-c1a8-4277-988c-200dbe87d8fe"
      unitRef="usd">994000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ec8a9a644aa4b0ebccca4dab9dca43c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy00LTEtMS0w_19ff6515-6e9c-452c-a8f2-883591c6790e"
      unitRef="usd">128000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8af2ad96fab4466bb054d82d939ab1e0_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy02LTEtMS0w_a1ad762f-67ac-4cf8-8ffe-22231cfeb0e1"
      unitRef="usd">105000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id37247af540b49ffb68edae4f0e29c75_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy04LTEtMS0w_9d9fde8e-0c7b-4997-b239-910ec289dc69"
      unitRef="usd">1227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fb751dac07449418c170631d9d26c50_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy0xMC0xLTEtMA_10bbc903-f7df-4b15-bdb3-e8ca2ac00e70"
      unitRef="usd">1124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5761b86071f3408392639773ba999d6c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy0xMi0xLTEtMA_b743b0f6-363f-42a2-ac9c-2799c968851c"
      unitRef="usd">156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf1124b457b6443b9adc6d3bca56384b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy0xNC0xLTEtMA_acc94b15-3f7a-4023-b20a-d5b8ce15608c"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21c3ea05d2d6469bb4402a1e7bc7b6ea_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNy0xNi0xLTEtMA_34724a72-cfbe-4695-a36c-64ac04903584"
      unitRef="usd">1383000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf14c77718b943c99cce1bd3bf1a1bb8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC0yLTEtMS0w_b0486f80-24d8-47fe-840d-5d77d4445e05"
      unitRef="usd">1633000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i985f8bd1a9864259bc024e136e98165e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC00LTEtMS0w_8222c2b3-1fc0-474b-96dd-dcc86f1191cd"
      unitRef="usd">306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib17bea95dcb84138abe482f8fe033d2e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC02LTEtMS0w_e8ed8497-4ea1-449c-aba5-eec98308b423"
      unitRef="usd">184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i721ea7e79a674506888fa965f545242b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC04LTEtMS0w_253c3dff-1ddb-47a7-8c98-bb3ee8f524f4"
      unitRef="usd">2123000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id19b27572f12412498a2fbdc8b6f03d3_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC0xMC0xLTEtMA_37ec5607-2bce-42e7-93fb-67df9f7ccdb0"
      unitRef="usd">1927000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i294f1f3217554943bc9e24fd2f2d7b62_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC0xMi0xLTEtMA_36d5369b-9f6c-4a13-bf2a-cfd01767b5b4"
      unitRef="usd">376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71ecaf56026f4bd5be46fe08dedcfbad_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC0xNC0xLTEtMA_5cdee1aa-d6d2-4585-b3a8-a1ba31d6fc95"
      unitRef="usd">183000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74defff37d6741aea5e3b56c22443253_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOC0xNi0xLTEtMA_2897ef8d-001e-4455-bba1-be6aa34f1cb4"
      unitRef="usd">2486000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27247f779d88460f9b4a30781c8e204e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS0yLTEtMS0w_d902682d-4794-4936-ba8f-0e7097e03e7a"
      unitRef="usd">773000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i621eef6cf69b42cb94aae8c92e1e958f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS00LTEtMS0w_ad70a236-2661-43e0-9161-084120729c82"
      unitRef="usd">336000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e09c9fb52974397863d698886f2e887_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS02LTEtMS0w_54481ca9-12b2-4afa-8a84-1f6461d14baa"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida707d8753fe48d2aeba73c027150355_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS04LTEtMS0w_75fb3060-26fd-4d02-ae7a-45bbeb6aabf4"
      unitRef="usd">1148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie768d1c6a00b48d5bda81338c8079975_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS0xMC0xLTEtMA_fa07416f-e8e4-4109-9a2f-0fd3f4792f05"
      unitRef="usd">851000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9708db6e96ec46d5880ab00e9b04a81e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS0xMi0xLTEtMA_fb6de3cf-c93e-4be3-85c6-b9ab8ec26c37"
      unitRef="usd">341000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id562523bafee46199bfba4a84d9ab6f7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS0xNC0xLTEtMA_f21c947c-9367-435f-bbfc-621657ebcfb5"
      unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c6bd8c13db64a3ab7f8eb8574846b45_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfOS0xNi0xLTEtMA_5e36df7e-dc33-45a9-954d-2005698d23de"
      unitRef="usd">1228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8899f03cb424167ad78b89040f1a538_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtMi0xLTEtMA_11276cb2-9b8a-4cd2-8b73-caef2f640297"
      unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21d311bd075f4f02b44de6feb4ab37f9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtNC0xLTEtMA_32388288-1ec8-43ae-9aa8-e5e4e18ec8a3"
      unitRef="usd">33000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7979efe4ac394083a361addf3d2a49be_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtNi0xLTEtMA_abf772d3-d591-425b-bb39-221e2ad7032f"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a303146ddae40fdbd9eede2a54e5625_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtOC0xLTEtMA_4cdd0967-cded-44e9-a29d-7456e5a412b5"
      unitRef="usd">139000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i036eac2d8114497bb332d3456f541e87_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtMTAtMS0xLTA_fd1ec560-c90d-41df-93ef-f1579cca4e5f"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17d484b178dd4b64b7766ad74bfc4575_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtMTItMS0xLTA_b132f13f-9275-4781-9db0-00e7e5e14054"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9283b98610164ee6bf6bb05476c6b514_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtMTQtMS0xLTA_4ded22ef-6bb9-4071-b395-360e6bac05dc"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf92e99dbb2140f493dd3d8fb8410ba5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTAtMTYtMS0xLTA_43ad8cd9-d9fe-45b9-a4b2-b86c29178df8"
      unitRef="usd">154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d74d0421c60403c8a6f350e1d3b261f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtMi0xLTEtMA_a8b7c3d5-0ae6-4683-925b-9cba23e38bbf"
      unitRef="usd">268000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76d962d727ea437a9d9bf778a9145642_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtNC0xLTEtMA_9c0bf2b8-0e92-43ad-9667-7f291500782b"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab1b92b6f4ea4a199a439cefdcf33eb4_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtNi0xLTEtMA_f3956cd5-fd7f-4fef-aae9-4e5095171f81"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieaad6f61dc4d43cb950a28292948294a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtOC0xLTEtMA_7e687e8f-2811-44fe-9f18-60a98733ff4f"
      unitRef="usd">310000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5dadedf4a3a0408cb0d1d97265933589_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtMTAtMS0xLTA_6dc6b238-92f4-4768-84db-c635c794d940"
      unitRef="usd">1245000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d7e5fc9e484420c99dbd9d31335006d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtMTItMS0xLTA_405de7d5-2d42-48ac-ad5e-02a8bf083d96"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94648f1cf2334fd39189ddd5a2526fea_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtMTQtMS0xLTA_9f6db3fd-c8b0-4852-9a21-fbd8d9ce8227"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87770df84d314b2d9aad501ce6c1d18e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTEtMTYtMS0xLTA_1ef5cd1f-f6e0-42d2-a2d2-dce7ad512e29"
      unitRef="usd">1302000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03ba162945dc41be8591b11496c129d2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMi0xLTEtNDI0MDg_e167e422-30b6-43cb-ad2f-c4ffffd9916b"
      unitRef="usd">261000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42e31f17d8bd4d23b055d34e97fc4ca7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItNC0xLTEtNDI0MDg_d0c4b603-e54e-4e4a-a814-336270d11422"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7bc60dcceb644702ad795c8522e3f1fc_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItNi0xLTEtNDI0MDg_8c2035a6-9297-4593-a451-b3c527466e5c"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieff814faff8a4823a581ff8c22875f06_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItOC0xLTEtNDI0MDg_3ac9b7e4-3c40-4bb5-abbe-daafda65c89f"
      unitRef="usd">394000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i898ffefc3e8041be98cde4df6be2c6c8_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTAtMS0xLTQyNDA4_99d97f3d-14fd-4057-a297-45c3f2dfe3b0"
      unitRef="usd">244000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41d525086d2940c8bc5faa039d023674_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTItMS0xLTQyNDA4_d6021cf7-bc3d-4cf0-b2e0-b672970e2d44"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie975ec0d59844df5ba2bc20d9d8ed6d0_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTQtMS0xLTQyNDA4_f1b4afa0-76a2-48a1-971a-d12d9d4a8eed"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iade9dfaea73c44d59d5ed5c0b2478333_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTYtMS0xLTQyNDA4_fb3b9056-02b3-48d1-ad98-eb39143d9d3e"
      unitRef="usd">362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie07906aa3788456f883989affdbca674_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMi0xLTEtMA_e6724924-8a41-4783-8ebe-48df0f963d0d"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a36ba79c6f545ebae95e83233deca01_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItNC0xLTEtMA_9752fdef-33b3-49ed-a751-50c281315786"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73a607992c5c4d25ad9c3ac39d2b5086_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItNi0xLTEtMA_700af084-d4cd-4a66-8cb2-ed05d3eb987b"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87e96b04266246398a423cbb059ca43a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItOC0xLTEtMA_59b650b9-401d-4bc6-b357-4ca2b9b2585e"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0314692dcb914529b1c58577b2b23a0d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTAtMS0xLTA_451ccd45-efe9-48ad-8300-15188e2e9097"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68a023cfdfda4020ad80e31bfc9b887a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTItMS0xLTA_58e46c18-b481-42af-896c-8a899a29cfb5"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8af6b5ba80b548de8cc9f594408ecc5e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTQtMS0xLTA_3c662caf-a3dd-4f49-a561-198b871cc95a"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6362737d64e24ccf8210a3c52840afb6_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTItMTYtMS0xLTA_e11e634a-6d4f-441e-afec-fb7bd2ccf34d"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b03fbb1ad6b40f19a144436859a94f2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtMi0xLTEtMA_5926af1b-e4a8-4d9e-9563-da7efb4fe90a"
      unitRef="usd">9132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4bdb0af715f34b249428381e9aecddf7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtNC0xLTEtMA_5ea68265-79dc-490d-97ec-3dd82a1f0d09"
      unitRef="usd">1776000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i086ee71ea26941e88d86269d05ffe0da_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtNi0xLTEtMA_dc6b1f50-040f-455b-be31-149282d17484"
      unitRef="usd">869000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ad8c8ce385e48069566ed761014713d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtOC0xLTEtMA_d2b42f31-a68f-4b09-b1ae-ff1eaa65aba8"
      unitRef="usd">11777000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6462e169d53f4b4fa0ce56f4c177fbec_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtMTAtMS0xLTA_d49264f0-7a23-414e-bd60-e0f1efbd3d0d"
      unitRef="usd">10213000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb8274f710244001811907e50cd4649f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtMTItMS0xLTA_47f6237f-1e7a-404c-857a-78656a553fef"
      unitRef="usd">1720000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia087c8100b6442799b592343e8d561ee_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtMTQtMS0xLTA_0f8aeace-bdf4-4263-9c70-8a73e6ca0765"
      unitRef="usd">748000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2963d1dc4f004cde8fd58fc8adeb9698_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTQtMTYtMS0xLTA_fd5faac5-ed25-4562-93e8-265301217ec2"
      unitRef="usd">12681000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cb3a52c0f00489082cde7485cbe447c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtMi0xLTEtMA_dbb9994a-e959-4b49-b5ec-542b3a907156"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cb8226c97a04cce9da6c55eaa7cbf5c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtNC0xLTEtMA_92cacec9-b274-4ee8-b88e-e8ee81f2e5eb"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66452d493a694b09b553e49d6ab26de1_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtNi0xLTEtMA_3a030ba4-da63-4374-81f3-75fb1e0c41d7"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie00c38ed5e114e7c9b2c757c827e0138_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtOC0xLTEtMA_de1399e1-f222-448f-9835-92fad2cc9a26"
      unitRef="usd">163000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41eae22e9d694cdfbbc45e5052d09e8f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtMTAtMS0xLTA_cfba95d0-e7fa-43a3-b3bf-e5ac93e062ef"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i896a5a5651944bfe84bb61cec75fe4ed_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtMTItMS0xLTA_ec7f01fa-ee35-42f3-b3e0-45a55192aab0"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96c7b41d05fe44dc98629f17bcb23c36_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtMTQtMS0xLTA_a2b82123-7535-4cf9-a4de-d8ae845b8233"
      unitRef="usd">124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14cb743958c641659fbba039af3651c2_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTYtMTYtMS0xLTA_bde6fb7a-a141-48f2-90cc-f49a52e52bd2"
      unitRef="usd">263000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i130fc4df5c3a4447ad6bafc4c36d9a70_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctMi0xLTEtMA_45c8ed25-69d5-4600-a44b-6f6db0d1b7fd"
      unitRef="usd">649000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i743f436a82f046efabc844f2f53f0827_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctNC0xLTEtMA_a0578fcb-a133-489e-98e4-4af8462d9e68"
      unitRef="usd">234000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5636e6fa99514854be00d8ce0f92da0f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctNi0xLTEtMA_b980b5ef-ce1a-4a2e-9212-3e0b17efe08a"
      unitRef="usd">272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i089d7a7d04eb4354a426b6f111e8c9a1_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctOC0xLTEtMA_c6875dce-0043-49b6-81f5-f42200c781b5"
      unitRef="usd">1155000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97fd886a21164803a5ecfb1a6ca689a2_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctMTAtMS0xLTA_9b0402b1-c50c-4ba3-b1d0-e28268b63b03"
      unitRef="usd">646000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9f9350bc75c442d91a688c62b89b6e1_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctMTItMS0xLTA_b1483531-d531-4934-8007-c35263d39a27"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5763ac2ae7874bc3949baeefcb466bb9_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctMTQtMS0xLTA_b0648063-f525-4bc5-890e-32438bf929c8"
      unitRef="usd">330000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic843439826b2471ba7693acebb1e44f4_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTctMTYtMS0xLTA_b02e751e-4c4d-4afe-920e-f3c1dcd69aea"
      unitRef="usd">1229000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i952a37c342574b4fb556d2cb998f1dbf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtMi0xLTEtMA_16259d67-a492-4648-b689-8af25bf0d3cd"
      unitRef="usd">97000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3bbe012fe22423491ec35738ee162d6_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtNC0xLTEtMA_786ba2fa-3478-486e-b0e1-286b628488a0"
      unitRef="usd">64000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie50a6de3cd234635ab5eef79157b0e1e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtNi0xLTEtMA_2bd1d135-5dd2-4077-ae3b-4f08e02dfa12"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c55fd7299a240adbf6d39bdf17aa7cc_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtOC0xLTEtMA_2a0ffee7-cfbf-4a69-8526-2550c955722a"
      unitRef="usd">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96ab85ae6a2d499f8162d50d3fe1dde3_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtMTAtMS0xLTA_a8cc9757-db93-4a59-b361-b6f3eeef2b86"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief5bc9a6130945279a3ed73051e33bdd_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtMTItMS0xLTA_7d82c037-cb57-47f2-986a-d153e321ba4d"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc475161995042e1b32b3447cfd8372a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtMTQtMS0xLTA_24f8ebfe-e10b-481e-95cf-768a624ab904"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa3ddd3a8d67413d8ccc8f4f45930641_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTgtMTYtMS0xLTA_c577603c-c36a-4f6d-9a99-9e2094f3b1f8"
      unitRef="usd">149000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabb8e6fba8504ecf8c222643ff4b5f9b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktMi0xLTEtMA_d37acbb8-e6e7-414d-addc-40bc7921de34"
      unitRef="usd">809000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0a5589d4d564f57bd7d3624c5dadb39_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktNC0xLTEtMA_f137f1c8-0743-4f27-acf4-f36584e81146"
      unitRef="usd">322000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0891181a1f1841c3ac6a145676585a41_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktNi0xLTEtMA_688da1c2-d0a7-42f5-bb25-cc078b91c2f9"
      unitRef="usd">357000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b86819db2a34c97be76a722a5625303_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktOC0xLTEtMA_75021970-1b6e-4e82-a785-6eb73eb81823"
      unitRef="usd">1488000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e952d3e460445a9baeec1dcc88eb745_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktMTAtMS0xLTA_4d4bc7ad-da2d-449c-90be-ea050c88949b"
      unitRef="usd">859000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3a2d6364e6440d2be0d03705fab3cff_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktMTItMS0xLTA_47fc174e-a692-44c1-aee9-9f3c100fd2ba"
      unitRef="usd">316000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb620cd6eaf04c1c8f121fab54f876c5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktMTQtMS0xLTA_d8722d9d-2853-4822-857d-53f141db5eb0"
      unitRef="usd">466000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if09794c214e347d6bea03f6a5b211ada_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMTktMTYtMS0xLTA_51bfd983-5331-4e16-995b-6faf1141ecfb"
      unitRef="usd">1641000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a9462d61d0f479b9fd7e5b189d86696_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtMi0xLTEtMA_10a51438-5cb9-4e93-8b33-cb11b5ab789b"
      unitRef="usd">266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7fa3912b241402d8cd650313d3c7018_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtNC0xLTEtMA_82dda43e-f2e2-4602-af70-e80460db14a5"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf0e9011b3d24494816bcc206c0c68f6_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtNi0xLTEtMA_fc7f374a-0a91-4cd5-b1fa-f6e2f7d2601e"
      unitRef="usd">298000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30b2167174a94caf9d1f6bb56760edcd_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtOC0xLTEtMA_fd9c669e-fb40-46fe-a36c-dd90a048bd6d"
      unitRef="usd">589000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20212de8e88345cd81a0017d04adec4d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtMTAtMS0xLTA_e7be0449-7bfe-4bd3-9f03-8a813835d8ab"
      unitRef="usd">248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc4680796da146cb8f0e19e816cc8a1a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtMTItMS0xLTA_62a2498d-d018-41d5-8513-f581bf06629d"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20583fb976024f8f8e57d6812ece8f46_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtMTQtMS0xLTA_d64c883e-cdbb-4e5d-a063-09461b3953e1"
      unitRef="usd">194000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06b5d4b507e1433ca2793f5756b1393c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjEtMTYtMS0xLTA_08ef5dbd-35ff-4b70-8392-9013b46618ba"
      unitRef="usd">464000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia59084cd434e42fbafd89bb8ba03f4cd_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItMi0xLTEtMA_e2b7ce82-ba88-4b61-b256-558f1dcfd64d"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1678eb4959ea4499b972f90192b36d19_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItNC0xLTEtMA_5d3502c3-5283-4659-93fc-bcb6cae1d7b6"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c6ce327bc5a423fa9c0482e0ab2581c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItNi0xLTEtMA_4578f2b1-e54e-4962-a0a0-a6bc0afd89b6"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if50b052e699145cb95a035c96c0cbee3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItOC0xLTEtMA_cbef0781-0847-4d02-85cb-d8a9c32dae8f"
      unitRef="usd">85000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54a055cd7cae4d1c9803fa1d5c85d26c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItMTAtMS0xLTA_9ec82d53-0121-4f8d-9c7e-66a488bf027b"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i323ac2db963e406abe6b6c72a52169c4_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItMTItMS0xLTA_5e4b36ba-4431-450d-8d16-2cfa19b85f8d"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i306cc17766184506a102f49dd753f257_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItMTQtMS0xLTA_3ed6fd80-8722-4d49-b609-b2e3bef42dd4"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f7ccddf15fb48a6ad13341a6b918c1f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjItMTYtMS0xLTA_a42d696e-971f-4f1b-98de-09e6590792c4"
      unitRef="usd">137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id66d30a90b1d4991894bd9de74896ac3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtMi0xLTEtMA_cfacf867-b501-461f-ac43-d096cee9cd3d"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie93d3106744048369cdab984d1705db3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtNC0xLTEtMA_e13ea09d-7e87-4937-ab13-cf29aac95b80"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb480f4f198e4b9bbf94fe25b67eb48c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtNi0xLTEtMA_d1135fe7-4a4e-41f2-b19e-dc9bd0caaa88"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i350d04c2a6974b8d81fb176e56b5a2e5_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtOC0xLTEtMA_3d3c611b-7967-4f53-ae3f-a2d2d349c275"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72f473445dae45a5ba0d6b6eb575f11d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtMTAtMS0xLTA_3c232076-0dea-4fa8-8fed-6de61f8196ba"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac82bc33803743e89507ebfd8155528b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtMTItMS0xLTA_1f0f44f9-36bb-4e0a-b1db-73abea3ff2e7"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e01dfafe5e548d9960d2188b833a39f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtMTQtMS0xLTA_7f021662-a5aa-49da-878c-6a2dfd959d4e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie071dc0e5b3949d9839bd24e374990ea_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjMtMTYtMS0xLTA_f16af153-078d-4770-a25a-44cb5d969264"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i912fe4ab93f14a9f8e6b580172900315_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtMi0xLTEtMA_2ab17d10-fa4b-4167-ad70-2c2567c2ecdb"
      unitRef="usd">275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c166e53abf24fc9af7b888824f5bb49_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtNC0xLTEtMA_3de395ad-4e07-4b1d-9ebc-49f11bd286d4"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id99eff088b5d453b929c3d11f5802852_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtNi0xLTEtMA_6321e896-6a5c-46e3-86cd-54e2e0c89ed9"
      unitRef="usd">353000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i663bd657772843f4ab8018e6a76865dd_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtOC0xLTEtMA_e34ff363-c598-449f-ab12-a90f7b5256e1"
      unitRef="usd">704000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c90a17fa3db439e94799030d2aa841e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtMTAtMS0xLTA_11c6e659-f96a-4f61-b102-b12b0f530b23"
      unitRef="usd">267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib095572329c649af806dff6bf6648e2e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtMTItMS0xLTA_59f8036b-7342-4e2b-9beb-15341ecbd0d4"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52882de359e54c22ae4f7a72a8137b42_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtMTQtMS0xLTA_3fc32638-04e5-488b-8eb4-adff38ff7d4b"
      unitRef="usd">294000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5eb10e809c404f009423263342e5e7ec_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjQtMTYtMS0xLTA_8d82ecb4-d471-4d4e-8338-d2b732a4fa2c"
      unitRef="usd">616000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59f4724ec2d14aad8052c7338d1e1a70_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtMi0xLTEtMA_0e11bd76-4494-45bf-8978-8aa03f265687"
      unitRef="usd">2763000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i539e9d57820a4905bcab08d23c1fcdb6_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtNC0xLTEtMA_d8c266f1-cba7-4f66-8bfa-49981e86e5c1"
      unitRef="usd">761000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i414c554b9ef34e0b9825b306a35bc339_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtNi0xLTEtMA_9cd0968a-6e9f-457f-9e09-f68dfeeee476"
      unitRef="usd">684000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41352f9abff2460ea53c3161faa76af2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtOC0xLTEtMA_400813c0-2036-43ca-9b57-09eb9d67af89"
      unitRef="usd">4208000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15f5acec533141a6afaedf118bb678bd_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtMTAtMS0xLTA_2e83c00e-48a6-4026-aa80-96324d3f10a0"
      unitRef="usd">785000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i974c2dbea9c44cadbbed8b52fc7f0508_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtMTItMS0xLTA_1e285d13-148c-4014-969a-db369b948b84"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba449c38763d4a5bb15ee5d3583e8506_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtMTQtMS0xLTA_d07b5346-8881-45af-a80c-94326af4afd7"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ea474d996994c7cbaa07eff099c4759_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjYtMTYtMS0xLTA_50baf287-1e42-42fc-8018-9959c1fd8029"
      unitRef="usd">873000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3414950d11449a089e780e1462c6861_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktMi0xLTEtMA_4bea5db0-04ed-46be-9ed7-1f94f85cb006"
      unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98ce7e4d4685422fbdf942d3bd865108_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktNC0xLTEtMA_65667959-639f-4541-ae52-5e81e0d977f3"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib600ed3308d64a8b946e889611b8cf20_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktNi0xLTEtMA_6a51f047-5111-425f-9952-3c90eced995a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib31f6766705e412abe5b95c86b77a3bf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktOC0xLTEtMA_3956f991-0b65-4b03-b0da-14ce51a09001"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i375d592d929047a993e6735cac3e7524_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktMTAtMS0xLTA_75c392e9-0ea9-48e8-878a-d98d77bc81ea"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25802e2404924e7bb626581d9cdcd76e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktMTItMS0xLTA_7b7ed709-2d2e-4f5c-91c6-133aa2ab1b03"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i485672b302d740d299e2875e2d04bb74_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktMTQtMS0xLTA_583300da-c990-4b51-9b03-bf115a67b7e1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida399d53d569435ca887d4b734cbe214_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMjktMTYtMS0xLTA_6992f988-e9a3-4337-82cf-3e4dfbb2577b"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9518115801fa4a4e943fb879f5bf25ba_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtMi0xLTEtMA_f0b87b19-fb7f-4ce3-830d-dde653334469"
      unitRef="usd">300000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51826c7e75b64381862b2f02fb933540_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtNC0xLTEtMA_f3e5e326-df84-4d67-a94c-9d55304fcbe3"
      unitRef="usd">188000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife3535d931384c729359473d5f8a4507_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtNi0xLTEtMA_e8d8ba19-90c9-4885-b2ee-64b05d4f98ab"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d1b980a3c9844768bbe2d46b8be2e7d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtOC0xLTEtMA_35b5fe18-9074-4bd9-9fc2-06fd6bb9ee3a"
      unitRef="usd">513000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6aeebdc4428e44828acedd57caa0faca_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtMTAtMS0xLTA_0223e6fd-d687-41d5-b4b2-e9b488875d48"
      unitRef="usd">283000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib41e7dc04b7148b4bfbba74683bb45cd_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtMTItMS0xLTA_320b8da2-d9c2-488d-8d54-dee01e73d9d6"
      unitRef="usd">144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b6f5dee9cac47efba1d637a42bd0f68_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtMTQtMS0xLTA_67b57507-4912-47a6-8969-887d937caaa7"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id530903404aa44608666ca2ea201cad0_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzAtMTYtMS0xLTA_480e4216-7276-4f2e-b072-5ea4f695af49"
      unitRef="usd">434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53bbf05572d84302be77973d5913a305_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtMi0xLTEtMA_38b429b0-c120-4c30-a0fd-b202affe86b8"
      unitRef="usd">394000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4505c57940594da1a6edc651f9236d9e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtNC0xLTEtMA_fa42827b-be6d-48b3-8757-760fb1d3de18"
      unitRef="usd">213000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i704f5a35c74142ebb14940a3a4fc0d89_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtNi0xLTEtMA_c01f8ee9-a0da-415c-bb00-8913697299b8"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b5618b046614ad186793fefd8dcf5bd_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtOC0xLTEtMA_9880c9e0-3c8f-43b3-93ba-34edf8cb768e"
      unitRef="usd">632000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6081efd3f9744514a207bf9f739d1607_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtMTAtMS0xLTA_0686b705-6ed1-4f8c-8fb8-6e20ebb67344"
      unitRef="usd">288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide124041bcd946b29f470c0a14b6de2d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtMTItMS0xLTA_fed3ca78-02f3-4c1b-932f-835147f9b40e"
      unitRef="usd">149000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaadc71dd3a2547cea41b38c3c9ce7424_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtMTQtMS0xLTA_f4a60339-201b-4588-88c8-d29b4bdfcbd8"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52a87250c5f446d8ab703b837cedde5b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzEtMTYtMS0xLTA_d5d0d8c2-ff05-4020-a6ca-0e3788bc73be"
      unitRef="usd">444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4b70689a9f142a9bd885d142547defc_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtMi0xLTEtMA_5c475227-b387-47e9-ae40-3737b045c11a"
      unitRef="usd">261000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17f4e1512b3f4a6a988b52b2020f402c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtNC0xLTEtMA_bd3f7543-bb6d-4d5f-94b2-76aaa471cefa"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93ca470d7fdc4eb5bdee6dda889e6593_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtNi0xLTEtMA_43b7f8e3-4961-4de7-8416-47fdf3b1d1eb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91affe4ed5b44ccc8baafb617adf2e9e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtOC0xLTEtMA_579ad3d7-597c-4233-b766-4bee91de3def"
      unitRef="usd">262000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a57a9c4342a4d129d4b551d06423da8_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtMTAtMS0xLTA_49e478ad-d927-4c24-97d0-17a32fd80872"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f55f5d973df4988979569a529db6926_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtMTItMS0xLTA_d6b63e1e-9fee-4e60-9b10-7dcb8a8bd96b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5e801c7e1af45b1ad4f62e390c18253_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtMTQtMS0xLTA_de3d3941-5e9e-4fe1-b173-d28583c91ae2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i887c3ef61a3a45dbb40ba7652320c71b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzMtMTYtMS0xLTA_1af0d4f1-2a93-4f6e-b7f1-1eef6258639c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i431029e24f704dde9b7df67fe1ba94ee_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtMi0xLTEtMA_6ed70f5e-3047-4098-a60b-2a7139ff3a9c"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i067f537de5404b9dba9eae8cc5fe8ba2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtNC0xLTEtMA_ad60af96-9a20-44d7-abc7-b27b5110af6e"
      unitRef="usd">202000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i040023fa9ea949e99260ae268fb58313_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtNi0xLTEtMA_37f557a1-ae20-436c-b7a2-41e2b09fc09d"
      unitRef="usd">186000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d85864fc37443df93104eb46275dfb2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtOC0xLTEtMA_266e64d1-a53a-4d2c-8fa3-11034817123b"
      unitRef="usd">420000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie785b0f49c10443fb9de1408de71f21e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtMTAtMS0xLTA_8059898a-43e0-4f38-9550-17a6d9980c59"
      unitRef="usd">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb0b8d70240b45f9af68a14c1bc14401_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtMTItMS0xLTA_25ce7a5b-d841-4767-85be-7d30716d9042"
      unitRef="usd">166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc055133d0cf433781d778bd29bcf851_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtMTQtMS0xLTA_c67c16f8-ea24-46c0-9793-0ef01df91d32"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b7dd3e6b3fb460b8f290204f2ad10aa_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzUtMTYtMS0xLTA_9c652b6a-4faf-4149-90f0-3a1060a8136a"
      unitRef="usd">325000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4342f00fa51e4687acb11f09198af17a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtMi0xLTEtMA_451f1cd5-a329-4c28-9b8c-deab7786bcdc"
      unitRef="usd">157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60da582576d74709b9d1fabc050be19e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtNC0xLTEtMA_383ee1ac-6391-42d9-9476-8551949741b8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaba56c135c2949f5a73bf185229f9d9c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtNi0xLTEtMA_cade3464-a880-4d6c-bff1-83274812d32d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id250fc6f2b094e5a9eaae0b8f02e6283_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtOC0xLTEtMA_e53693cb-2714-4670-aabf-c7bd003d0738"
      unitRef="usd">157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e8e47a466d34118bfe22a1393d5b447_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtMTAtMS0xLTA_305bff9b-cc33-4cec-bb54-aee3a5779a5f"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b0094bc7ae7468e8f94517cdc8d4c16_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtMTItMS0xLTA_ab875d00-c849-4db6-a9f1-b206a1d7ac01"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c9cf81f27044e40ae5a06b91f4fed65_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtMTQtMS0xLTA_dfa93dd8-6bed-4162-aed0-288fead22f59"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i832adea04eeb4821973a36b8d8054b28_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzYtMTYtMS0xLTA_531a3ee4-f195-472d-8722-6eb164c2bd7f"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5defc88095b45f88cbef65982c863b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctMi0xLTEtMA_d834f45e-c727-4e4d-bfab-9d384c5b302f"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74e9b2ae35f94059a42f289e242fd5d6_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctNC0xLTEtMA_552b4a17-0d9c-41e5-91bd-0c881da0af25"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5d4f53a05ed4cf9a3c013c511bb6d57_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctNi0xLTEtMA_dff1525a-24f3-4771-b5a8-2f95e4db9d0a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib495e1983c7d43ad954d6982a1acc6df_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctOC0xLTEtMA_283bbce1-ff29-46e6-acdd-44a406d18be6"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia65f96edddf14125a0ceff48dd6ce529_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctMTAtMS0xLTA_779da52e-cb3a-4513-ab25-f03fc52181b8"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ac5d731345b49a89e720e60b2bd6179_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctMTItMS0xLTA_05628e37-f0fc-4635-9b3e-e8655ea4d15d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1472bae377ce48de85232d1f7e78a6f1_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctMTQtMS0xLTA_090db458-d883-4387-b60f-b5498fb8a27e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9da54dcd88e46a7a00d599ef8199f51_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzctMTYtMS0xLTA_e52f382f-deb7-4795-92c4-f7e7528796a8"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa2fa3fc25c348288b3ec143881904ce_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtMi0xLTEtMA_014a22da-f7c7-482f-bf94-bc302770bf09"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae77bc715f014b6abd4b797b309ecbd3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtNC0xLTEtMA_6726915a-b5a8-4a1c-96a3-ac4792d7e19e"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b06166a143f46ac8b776fcfa056152c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtNi0xLTEtMA_60ae36f3-a82b-4034-814e-2398c4c94739"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b1c82a1c7814ef0bae95b14cd89caa3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtOC0xLTEtMA_34b1ca3c-d4fd-4792-a72a-f106b51c4d9e"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i833340a21ed94b68a7b86f7be0fdf2ab_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtMTAtMS0xLTA_f8ab2ddd-4002-4606-98b5-c54503856d80"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i513c462b957b48c38384730437388578_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtMTItMS0xLTA_6db2ba3d-f894-4689-935c-c158fa66355a"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a22bab8816347da9de17b819770d4a1_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtMTQtMS0xLTA_70c65a4b-f21e-4148-b381-416d14371cc0"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i156443fab6604e7abefd184b681ac88f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzgtMTYtMS0xLTA_6f9caa1f-e901-42c3-aa00-ec2f00935819"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd0453ae248b4871a513cc0481e0ba95_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktMi0xLTEtMA_886ab69a-e83e-4c88-bbb3-024be5f7f32a"
      unitRef="usd">82000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88b9b3ecee864a188d3318a7b3b10134_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktNC0xLTEtMA_e7079a31-bb85-4fc4-9c3c-7ff57a6320fa"
      unitRef="usd">41000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79b02c41c5dd4f85b666bb73366db6a9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktNi0xLTEtMA_4552568b-2714-42a9-bcbf-f717898782e3"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i664b0e413d3e45a1b02ea0aca6fa69a3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktOC0xLTEtMA_43695efb-3e98-49ac-9712-ac9dfde418eb"
      unitRef="usd">145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61127c264a134cadac4433659a4b2a07_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktMTAtMS0xLTA_30c97633-9f77-46c6-aa7c-d2b6c5356961"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73ed798ddb0d4b829c8f9df19472898e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktMTItMS0xLTA_0fc80ee6-5cb3-4787-8754-584e9323c87f"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70ccbeb9d2904b8494fcca05b0e0aabe_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktMTQtMS0xLTA_cfc9d4a2-e9ab-4b0f-a693-45aec32c5aac"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3cb505b42a7d41d197183c8cbc88fa17_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfMzktMTYtMS0xLTA_f937ac8d-031b-491f-b8a1-a3d848fc43d7"
      unitRef="usd">142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7c7645be0b7483282e2fa48a952ce6a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtMi0xLTEtMA_14268160-282f-4b2a-9c9b-f6182faed9c0"
      unitRef="usd">298000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9aaff90d56d04403ab9bcbaf508a1fb9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtNC0xLTEtMA_72d62533-541c-4076-8e8c-727c5b97e46e"
      unitRef="usd">270000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d2ca052afdd41308acfee42874d16bc_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtNi0xLTEtMA_95b8597d-133c-454e-9323-72620360dc2a"
      unitRef="usd">209000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c6f15ef048940a2ba4ba7ff83b36db4_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtOC0xLTEtMA_ed549d4d-4fa2-468b-996f-d03c74adc73f"
      unitRef="usd">777000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e56043c08ff44629cc394d2f686ed56_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtMTAtMS0xLTA_110929c7-df83-41e0-b775-0491d6ad6300"
      unitRef="usd">423000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98bd71b2478e4a04916636f59012d953_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtMTItMS0xLTA_445869d2-6f7a-4acf-9a4e-b5e7f63a6d61"
      unitRef="usd">228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13822eeebaf946b9a83f2a817987763e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtMTQtMS0xLTA_33064583-c1a3-4ccd-bc7f-616e928bc6a1"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc2e5f8264194107aa51706375b167fd_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDAtMTYtMS0xLTA_5daa4ef3-741c-46bb-83f7-36b629d966cb"
      unitRef="usd">772000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i794e4f01cf834ef6b6cb3fac8633384e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtMi0xLTEtMA_d080f96b-56cf-4368-9da7-93eb4a2b647e"
      unitRef="usd">13932000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide78b4b7f0d04153ad16104b60a2684f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtNC0xLTEtMA_5a0fb394-7198-4eff-a58a-62224a071313"
      unitRef="usd">3419000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69842657a0724c8bb9baf66aa7591fe5_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtNi0xLTEtMA_10e4ab47-0084-45d9-8b23-4fd1619e46da"
      unitRef="usd">2497000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7a2ec8073884bc5881bfa3d3afda11c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtOC0xLTEtMA_8ae01873-4ac3-4e20-8462-d99a9e4e4aac"
      unitRef="usd">19848000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b7e271684784d7dae794919a0acb56b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtMTAtMS0xLTA_02075981-41b0-4a32-a817-f3d695be3aa4"
      unitRef="usd">12835000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61a064a1cde64b1196d2dce7960e85f5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtMTItMS0xLTA_d1de43ab-703b-43f9-a79b-531ffafb0b0c"
      unitRef="usd">2528000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34484c2dc9304341be78db8166e621e3_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtMTQtMS0xLTA_db2509d2-fe57-4358-9bda-49d2d2626e13"
      unitRef="usd">1664000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4666b276ec7d40ea86d10c4ded816760_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDEtMTYtMS0xLTA_d4536e71-a539-4c68-b7a0-1b4992db341b"
      unitRef="usd">17027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ca680e493e94c14a2d7345742f31836_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItMi0xLTEtMA_5c29a200-8834-4e4f-922d-59c7fc794a7f"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i092466e16cdb43f4bb4f2f9191a72a85_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItNC0xLTEtMA_7e917a3f-a4fa-45a0-b39b-e34b19bf6e74"
      unitRef="usd">140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e494a218a634591bd5ed5db40a1c47f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItNi0xLTEtMA_878f9686-8d76-4be4-ba14-1345b537c357"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a47277681854c0eaa992a6c02b6acb3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItOC0xLTEtMA_5c8bdb3b-ea4b-4543-a37b-48485b4ba3d7"
      unitRef="usd">213000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f12c7af337245d5afb3786a6258a024_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItMTAtMS0xLTA_508b199e-cad6-492e-a57e-3798a32e15e2"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bb2f8457d7b431ea9f1c47d5413415c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItMTItMS0xLTA_0666a55a-4a06-498b-87e0-db22e886eb2f"
      unitRef="usd">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc4cacc943a04c45aa40ab1aca412a24_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItMTQtMS0xLTA_ca017402-4125-41b0-b099-3792b4c455eb"
      unitRef="usd">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i528488c905dd4c8da2e5a1389a8b0a59_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDItMTYtMS0xLTA_b7b4a38f-5ad0-451b-8b1b-c1cc487a4ef0"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a6bf17320054464a3bc267f3849d5c1_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtMi0xLTEtMA_f4c1c2d5-56c2-4280-b3f1-bdfa674671b2"
      unitRef="usd">14002000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40c1afde566a44a2b60890f7234a9889_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtNC0xLTEtMA_3bc9d5c6-81e9-438a-93d1-3e6d85b18507"
      unitRef="usd">3559000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f0226418aa141e08a04b3292d3d6a3b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtNi0xLTEtMA_7b42a17b-91d8-48ad-b05b-3f7528b6884d"
      unitRef="usd">2500000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtOC0xLTEtMA_2b253fed-cfe2-4d60-b4f5-67eae2f83ec1"
      unitRef="usd">20061000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69b2aa2945ce4106a4fcf5c0bdca8f28_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtMTAtMS0xLTA_93109ba2-e369-4c6a-8a41-41ff955787a1"
      unitRef="usd">12890000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2a8467fbacf40c38e699b24ac162d3a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtMTItMS0xLTA_62983fc0-c874-472d-9624-dc118af2867a"
      unitRef="usd">2698000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f9291215372429da56d3bf18442238f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtMTQtMS0xLTA_aaaeb5e2-4eac-46a8-96cb-4d66f10c469f"
      unitRef="usd">1680000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjg1MzFiYzQ1YjMwZTRiYTk5MzVlMDgwNGVlOGQ2ZjY2L3RhYmxlcmFuZ2U6ODUzMWJjNDViMzBlNGJhOTkzNWUwODA0ZWU4ZDZmNjZfNDMtMTYtMS0xLTA_d05a4b0c-b9dd-4294-898c-2914913301f1"
      unitRef="usd">17268000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMjUzNw_47060d27-4079-4384-a9f5-2da57c2c40fb">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(as a percentage of total revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie89b30127587468d9e71733bf07d5081_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfMy0yLTEtMS0w_a894ba42-fc28-4387-9627-a5d285c03a31"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iedd6b57e5ee3433abe93e62847e14d87_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfMy00LTEtMS0w_aa99b8e5-0c5e-4546-8193-161cc3efc4e1"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if6546a28c4524eaab7537c0d6bf777fc_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfMy02LTEtMS0w_a9fd6282-1a9c-43e8-aee5-54c22f8bb1d4"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i21718856cc7648018662a2e392cd71a4_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfMy04LTEtMS0w_4086f524-49b1-4c49-8b3a-cd52547e8617"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i74a16f60814741f98bcabd2ce43bcb36_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNC0yLTEtMS0w_17dd1606-02b4-4934-8f7e-1c56388e48f9"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iac98ca2d21064f81a59741305eb998b4_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNC00LTEtMS0w_7bf53fd2-cf66-4bef-914c-69437b39dc92"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic0f301d0c0aa40ab958148e4f5814aa1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNC02LTEtMS0w_d658eea3-3335-435c-8624-e9c04d6858d4"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia1f131cf4a5b4202aa0a668ee3ad2bc5_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNC04LTEtMS0w_97272760-1705-4e96-96d1-4e9211dd966d"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if33c4729f0e84f61be8298fc81de60ff_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNS0yLTEtMS0w_fdcea9cc-12b3-460e-921a-8e71f1d9f420"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i348e70f83b254e66adb00f1a55a6328e_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNS00LTEtMS0w_3b8238b0-10a5-427b-8ded-e10bf253f1b4"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4979a9738ed14d44a7fc44641a6b295b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNS02LTEtMS0w_54e6657d-66d9-4036-9cea-48f0a92890c3"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i44900a3d2ba94688bb7a0dfade50db90_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RhYmxlOjNmYTdkNjUyOWNjNDRjYWZiODQ0N2FiNzUyZGY3ZTUxL3RhYmxlcmFuZ2U6M2ZhN2Q2NTI5Y2M0NGNhZmI4NDQ3YWI3NTJkZjdlNTFfNS04LTEtMS0w_91595697-5f4d-4683-a7a6-711190e6c73a"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i8f07727060b14c0d872f5f929cc9fdf2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTE1Mg_204e5423-de5a-4910-816f-e5b144347355"
      unitRef="usd">190000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i30f8590a90374b4fbc764b63834fe5ed_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTE1OQ_6143d4a5-c8db-4408-8dfc-731607c631b4"
      unitRef="usd">625000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i0e302cf42eb74c9a84eab7578f54195e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTE5Mg_bca7ca10-1d02-4b36-bea7-2f9e73d98425"
      unitRef="usd">206000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i92825af11f15411da7e658f2ec15da12_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTE5OQ_c4edcd2a-68e4-421a-a589-088fe5fad85d"
      unitRef="usd">618000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTY3Mw_a64f49d4-974f-4435-8198-4e8f267eb13d"
      unitRef="usd">188000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTY4MA_2c51eb51-9fb9-4fd9-b9ff-3f207bd5e2a7"
      unitRef="usd">661000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTczNA_c94b3500-4912-44e5-9406-0785ba1ea6b3"
      unitRef="usd">13000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTc0MQ_a638aa86-7b5c-496f-a98b-4e8970f74b8e"
      unitRef="usd">94000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMTk5Nw_f1689b62-0674-4f8b-9076-be28a93c292a"
      unitRef="usd">167000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMjAwNA_900d4dd3-3444-46e7-9067-55fb538c8a58"
      unitRef="usd">198000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMjE2Mw_155592f3-b6ab-4cd7-95e1-10a79ef98b4d"
      unitRef="usd">85000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV8zNy9mcmFnOmI4NzM1MDY0ODI4NjRiOWQ5ZDExNTYxODA5MmFiYTMwL3RleHRyZWdpb246Yjg3MzUwNjQ4Mjg2NGI5ZDlkMTE1NjE4MDkyYWJhMzBfMjE3MA_04ec9e0e-2ae1-4e1f-b9b9-92b6fdc8c346"
      unitRef="usd">97000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNzcyMw_a1b36890-633a-4f7a-ba5f-d0f3a43fb20e">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 1 inputs include quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Galapagos&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other publicly traded equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for MYR GmbH (&#x201c;MYR&#x201d;) contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes our equity investment in Arcus Biosciences, Inc. (&#x201c;Arcus&#x201d;) of $482 million as of September&#160;30, 2021 recorded in Prepaid and other current assets and $212 million as of December&#160;31, 2020 recorded in Other long-term assets on our Condensed Consolidated Balance Sheets. See Note 9. Collaborations and Other Arrangements for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity securities measured at fair value on a recurring basis on our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;See the table under the Equity Investment in Galapagos NV (&#x201c;Galapagos&#x201d;) for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of equity securities resulted in net unrealized loss of $142&#160;million and $667&#160;million for the three and nine months ended September 30, 2021, respectively, and $964&#160;million and $1.0 billion for the three and nine months ended September 30, 2020, respectively, which were included in Other income (expense), net on our Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale debt securities are classified as cash equivalents, short-term marketable securities and long-term marketable securities in our Condensed Consolidated Balance Sheets. See Note 4. Available-For-Sale Debt Securities for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Investment in Galapagos&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity investment in Galapagos in our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We elected and applied the fair value option to account for our equity investment in Galapagos whereby the investment is marked to market through earnings each reporting period based on the market price of Galapagos shares. We believe the fair value option best reflects the underlying economics of the investment. The portion of the investment subject to long-term contractual lock-up provisions is classified within Other long-term assets and the remainder is classified as Prepaid and other current assets on our Condensed Consolidated Balance Sheets. In April 2021, we amended the Galapagos subscription agreement to extend the initial lock-up provision for certain Galapagos shares from August 2021 to August 2024. As of September&#160;30, 2021, all of our equity investment in Galapagos was classified as Other long-term assets on our Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments not measured at fair value and excluded from the above tables were limited partnerships and other equity method investments of $96 million and $58 million at September&#160;30, 2021 and December&#160;31, 2020, respectively, and other equity investments without readily determinable fair values of $211 million and $204 million at September&#160;30, 2021 and December&#160;31, 2020, respectively. These amounts were included in Other long-term assets on our Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related Party Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021, Gilead donated certain equity securities at fair value to the Gilead Foundation, a California nonprofit organization (the &#x201c;Foundation&#x201d;). The Foundation is a related party as certain officers of the Company also serve as directors of the Foundation. The donation expense of $212&#160;million was recorded within Selling, general and administrative expenses on our Condensed Consolidated Statements of Operations during the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair values of Level 2 financial instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;amp;P Global Ratings, Moody&#x2019;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates (&#x201c;LIBOR&#x201d;) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimated fair values of our aggregate short-term and long-term debt, determined using Level 2 inputs based on their quoted market values, were approximately $29.6 billion and $34.6 billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and the carrying values were $26.6&#160;billion and $30.3 billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3 Inputs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We measured assets acquired and liabilities assumed at fair value as of the acquisition on a nonrecurring basis, in connection with our first quarter 2021 acquisition of MYR. The liability for contingent consideration of $341 million as of the acquisition date is remeasured on a recurring basis. The estimated fair value of this contingent liability was $328&#160;million as of September&#160;30, 2021. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of Hepcludex. See Note 6. Acquisitions for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We measured assets acquired and liabilities assumed at fair value as of the acquisition on a nonrecurring basis, in connection with our fourth quarter 2020 acquisition of Immunomedics, Inc. (&#x201c;Immunomedics&#x201d;). The liability related to future royalties assumed is recorded at amortized cost, which approximated fair value as of September&#160;30, 2021 and December&#160;31, 2020. See Note 6. Acquisitions and Note 10. Debt and Credit Facilities for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNzcyNw_25a881c6-34c5-43be-a17d-dfc878375d2c">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 1 inputs include quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. &lt;/span&gt;&lt;/div&gt;Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair values of Level 2 financial instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;amp;P Global Ratings, Moody&#x2019;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates (&#x201c;LIBOR&#x201d;) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNzc0OQ_beced561-2c7d-4538-a3dc-bdfe40258274">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Galapagos&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other publicly traded equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for MYR GmbH (&#x201c;MYR&#x201d;) contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes our equity investment in Arcus Biosciences, Inc. (&#x201c;Arcus&#x201d;) of $482 million as of September&#160;30, 2021 recorded in Prepaid and other current assets and $212 million as of December&#160;31, 2020 recorded in Other long-term assets on our Condensed Consolidated Balance Sheets. See Note 9. Collaborations and Other Arrangements for further information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic35f4c541e614d33a6437788299fdc0c_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC0yLTEtMS0w_639ba40c-495e-4f78-8d56-f743d6de4bc8"
      unitRef="usd">360000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i45e0d18c597e4ca2ae01fdfbd7881c3a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC00LTEtMS0w_22856123-ed22-43d4-930e-037c71ca1d06"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibfaa631e8e95431a9bdfa133e0488d8a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC02LTEtMS0w_3d42ac2c-b1e7-456c-9427-49e62d2ec7ef"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id69559bfdfb948d1a4ffa643418f21c9_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC04LTEtMS0w_4e549a56-6d07-4171-acdc-05309346ee53"
      unitRef="usd">360000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie3548698f1b14ba68822ef5950d4915a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC0xMC0xLTEtMA_12b7bcb0-c12a-4d3b-90bd-eb338fd4325a"
      unitRef="usd">309000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c690fe00ac54cd0a140a27f890f5c48_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC0xMi0xLTEtMA_ba889682-9321-4a14-bf54-fc463a0afcd6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i824f7d8e5c4243208069c78b91bbb9a3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC0xNC0xLTEtMA_67822ef3-11cd-4df6-9a7d-7b0d0d8c75c1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i27bd677e9c7f4ab69c1c65c4a2154029_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNC0xNi0xLTEtMA_21cdb6d5-be88-4554-9968-ca5635b90b82"
      unitRef="usd">309000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if8e5aea4693e4a208fbfbf2e410e5c40_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi0yLTEtMS0w_2d2032fc-01ed-4732-bd9d-1feea1b323cc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4c621536eda94c6f8d03472cdac1cc35_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi00LTEtMS0w_cf85a004-2441-423e-bde2-d252433a41f3"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic59f42fcfdbc43379e5b44f081585c47_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi02LTEtMS0w_05236374-edb9-4f2e-a055-5e6322efbf9b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i780e0de404214dc29d45580e7b2531b8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi04LTEtMS0w_51f9508f-a173-444f-b2bb-a9363589da68"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i41956a7c7b7a4ab299edca9f380ca798_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi0xMC0xLTEtMA_74d5a12e-1037-4291-8a0a-10363b7a5f4e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79c41df237804e668c0da56a46ee0085_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi0xMi0xLTEtMA_d8996e46-ac58-4083-8a82-91a39240321a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c07df65da1d41098cd48baa32f21d8a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi0xNC0xLTEtMA_f6878097-4f8e-4fae-a37a-cd99d2dbb276"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide714ebff4fb46809c7b477daae2d962_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNi0xNi0xLTEtMA_5b5d0b1b-d641-49be-8da0-d179ead47581"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifce16fa84c314d2d8b2732c6bf0d57e1_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy0yLTEtMS0w_2ec54d03-3596-49cd-8a76-5b713a63e665"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idf10f2216a934d5b9d20de4fa33c7e6f_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy00LTEtMS0w_3223efd8-49eb-442f-a01c-1585bef10ec4"
      unitRef="usd">44000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i86ec4abb19ae49f0b238c47892dd4df4_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy02LTEtMS0w_4861e964-91a6-46f4-8a77-96376adfd7d8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1839e6fac09a4a4d9210d56808c687d5_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy04LTEtMS0w_332eb3b1-14e8-4067-9662-5bb3fcea2ee9"
      unitRef="usd">44000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i54f21829201d45aa939df14dd7b96c21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy0xMC0xLTEtMA_011f9153-ce1c-448b-9f2e-f11f6e46801f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa7361567a884284b89e7bf5a20638a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy0xMi0xLTEtMA_ad1d32e8-b2ee-48a3-b41b-53af99879766"
      unitRef="usd">43000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i549d3edb71ed44988ab49d3637f8cf90_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy0xNC0xLTEtMA_d3cfa027-fdce-47d2-92b6-c5b778185a0c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i36270f186c97490e84c4d0dd8788d411_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfNy0xNi0xLTEtMA_87f9f18e-a698-4270-881d-c05ef921021c"
      unitRef="usd">43000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibd9e6e86e84a497aa1ba2c847b3e7767_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0yLTEtMS00NjIzMw_afa05c7e-0111-44f4-bcdb-81f9c0b119fc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i22c6271275734808a0ff96495b000a60_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC00LTEtMS00NjIzMw_dc9811e0-e5a7-473b-aca7-4d0b507632dc"
      unitRef="usd">361000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2217b0ea8f50482aa528fde408cb76e3_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC02LTEtMS00NjIzMw_29be6d76-7064-4bea-837c-9feb9a22f010"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icfea4630e695464ea306f7481b6e32ec_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC04LTEtMS00NjIzMw_35533258-7092-4fe1-87ba-2d15c46818b0"
      unitRef="usd">361000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0fbed77deabb4de589efde4d54035191_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xMC0xLTEtNDYyMzM_bf3e34a7-42d8-4aaf-8ed3-853e3061fbd7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i961ed43970894b70b047d465504721d5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xMi0xLTEtNDYyMzM_ef91dfb1-263c-4e22-988a-65ce39640621"
      unitRef="usd">216000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d59baf4935e4b848a146a795052db24_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xNC0xLTEtNDYyMzM_94d2b3e2-59e6-4ebc-ba2d-46c91a1f1a2f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i84eee8925bd946b48b71e527c679a789_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xNi0xLTEtNDYyMzM_134bc098-1bb3-4aea-802a-626a7fe8a3aa"
      unitRef="usd">216000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic665639028ad4946b03ef3d0a7ca3192_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0yLTEtMS0w_c0a7e387-b507-4fe6-8a33-205e4344c803"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3960deda1f4d454eb5bece595f0566f3_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC00LTEtMS0w_5ea2509b-4944-41b5-a393-6bcbb69de1f0"
      unitRef="usd">1272000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i897098b154ce4014a6261d31477a3023_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC02LTEtMS0w_997a463a-89bf-46ea-bddd-505b43bad141"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0adcb1eef7cb452f847c13e9842de931_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC04LTEtMS0w_1e6873cc-9739-40ae-8847-35a3052c65db"
      unitRef="usd">1272000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i25b8ac7aca374e42ba0903e04a423882_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xMC0xLTEtMA_8a40d021-e0c6-4541-9ce2-2c0b91a62f5e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idab563e4309c42b6991e40459e65c9bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xMi0xLTEtMA_ef5d5b75-3b6e-4aeb-939d-afb755b4fa1b"
      unitRef="usd">1142000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i484390e670d3449786a771db7ab9ade5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xNC0xLTEtMA_43b3aeb9-979a-491e-9b72-9cfe65c0f876"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i526c131b580f42bc9d870f04c6d8d5b9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOC0xNi0xLTEtMA_697f0214-5e13-429c-b057-090c88716441"
      unitRef="usd">1142000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i926b7e069399438cb0fa7f1d96f3e3e0_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS0yLTEtMS0w_183218e7-acdd-448c-852e-ec6025579d00"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i68a0012537fe46c5969295f09f2f6dd4_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS00LTEtMS0w_37aef324-a255-4037-b5b2-25ab1b7fd239"
      unitRef="usd">447000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ee3cd97581a4d2abdb377c19e3ebfc0_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS02LTEtMS0w_2656c4bc-4c84-4ca8-a069-1eb6518396dc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide347640da714f3395ba489a540c603a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS04LTEtMS0w_12e1a152-61fb-4f8a-a163-dcf8e237f53c"
      unitRef="usd">447000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i276c9ea2224d4affa06277ba327a2d61_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS0xMC0xLTEtMA_778b83dc-b8c3-407f-8f1a-0ba8870dff9a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i72a95ff7958c4fb7ac5a1798d4dce9cf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS0xMi0xLTEtMA_bc792f0f-8b8b-4f9e-97b5-c32dbd77e786"
      unitRef="usd">316000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3136714317f0456c977067551e4bd81f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS0xNC0xLTEtMA_6cae3740-53db-461d-ad57-0b7048628c78"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if8a7c2c25d974d61a8013b71288affd0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfOS0xNi0xLTEtMA_38a67ef8-650d-45f3-8cab-43fc6c5166be"
      unitRef="usd">316000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i44d10b847f5e406db45e5ac1953efe55_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtMi0xLTEtMA_82bb1419-f8a9-4f77-8b5e-f3bebe22087b"
      unitRef="usd">2768000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i14621646e10c4fd1b6c4a65065d514ab_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtNC0xLTEtMA_c74a4170-63ed-42e1-980b-1c09b50875ea"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id3b775bacbe44316aae442a85d447f1c_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtNi0xLTEtMA_63f557ee-b5c3-4d7e-b5ca-35d5cd54e05e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ide0afddf10ce4f31895aad1d16c1d85c_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtOC0xLTEtMA_61d28987-d31b-4ff3-bab5-617e99bbfb79"
      unitRef="usd">2768000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4c1629420b3f4c80b65c3eb9d05ee4ec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtMTAtMS0xLTA_832f5d42-a676-4407-b429-1336d33856d8"
      unitRef="usd">4361000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i96153a6dea77431eb98e9c8200e6181a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtMTItMS0xLTA_c169eeed-33c2-467a-bd7b-82480e6c1659"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7f662a891d89402584dcecd95385ff8e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtMTQtMS0xLTA_5d9d726d-be84-42c4-8f7d-5e6005cf86f4"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id4532563975f4635bce45eb0d2ae51f2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTEtMTYtMS0xLTA_8968e4fc-2d9a-43ad-9183-521676f33e05"
      unitRef="usd">4361000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i78c02433e66541af99b97939d39e23a0_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItMi0xLTEtMA_e0736e63-4e51-444f-817f-8829e0a69c95"
      unitRef="usd">881000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8e8d9e0325a1434c858eb9522b968441_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItNC0xLTEtMA_f5ef8f33-cefb-43e4-b56b-d6eb8ff5c154"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic21fe9fe9de1442b89efde9577f52f46_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItNi0xLTEtMA_0f344dc4-2ce0-477f-b005-1817454acf73"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4b838d5587cb496093b251362509ac97_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItOC0xLTEtMA_e63f3da3-e02c-48bb-add7-a44252430b2d"
      unitRef="usd">881000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic1f0e139c0cd44a6b90716186d108008_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItMTAtMS0xLTA_ccb03fc0-1811-4e6a-8f1e-278f29187375"
      unitRef="usd">1648000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0fe330b4018048f1898231a7f4ff4ecb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItMTItMS0xLTA_0ebb0e2a-38fc-4304-ad97-9611180e3a15"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1b84e22ee5ab4a49ba427501bba85dd7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItMTQtMS0xLTA_be6bb57b-443f-43b0-9f18-3ad5dda3f021"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4b4898fa0a764d7aafa5e9a1d6d72ef3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTItMTYtMS0xLTA_ca402c8b-1f9f-4a9e-8c51-a3cf4ed95b0d"
      unitRef="usd">1648000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idf1508526e8c4ee1b4e7b2a680bad4c4_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtMi0xLTEtMA_682a124e-9403-4370-a9dd-7fdfb31bc7b0"
      unitRef="usd">876000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia9769a32b3db420e9bd1bec55f864b91_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtNC0xLTEtMA_f2ad278e-4783-457e-a35c-adb61893ee2a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i316acb6201d34cd8b84ad4bc0a229326_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtNi0xLTEtMA_8e81c75d-8b56-47e7-9eb0-9f07ea2ba55e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i29435eace9144606b96eee2d02e381a8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtOC0xLTEtMA_ddf3fb75-a4d5-4975-a925-13a54f5d4534"
      unitRef="usd">876000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibbabaed951aa4295ae68d516beb80338_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtMTAtMS0xLTA_b45891ca-be3b-4895-932a-255bafa95abc"
      unitRef="usd">743000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1a4501dcb7b04327b30565529b2d48aa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtMTItMS0xLTA_f3869f6d-cbcf-4607-9be6-d8eb2afde899"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i799dd8cb5a934a67aad9f2247cd1f8b6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtMTQtMS0xLTA_b9160050-b5d6-4f26-9fb4-a33bcd515070"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifb74d6dc685f4234af1aa0e61f985bf7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTMtMTYtMS0xLTA_68dde13d-7d22-43ea-be31-71efa86889e7"
      unitRef="usd">743000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia380e72b9e514a0dbc10fa47a96a37b9_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtMi0xLTEtMA_85b318af-424b-420f-a47a-5048a2569d77"
      unitRef="usd">249000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia0202af8459b4f3789926f58b9cf9752_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtNC0xLTEtMA_abb94cf4-36db-4490-91c4-804b9fbf134a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i42edfdab86c9426e93701ffdc0c7fe94_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtNi0xLTEtMA_d0151553-dfbf-4f14-afdc-e11d3ab8902d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4c80ed86b032450995903fbe43ad034e_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtOC0xLTEtMA_fc9b265f-cd64-4d8e-a66c-ab34aea4bd2f"
      unitRef="usd">249000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i54901c86be024d34813c278457433dd1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtMTAtMS0xLTA_da675228-2fce-425d-aaa3-e00e614aa9e4"
      unitRef="usd">218000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6c04316279d5406ebb97ec435e024e2d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtMTItMS0xLTA_16018e9b-60ff-4afc-bd43-8183ec3fcaa4"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1502ee19eaa24b0992c9886bfc77cb5b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtMTQtMS0xLTA_98871279-d090-45a9-949a-e3ef83ccb4ad"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib15e0bfd36234157af17a4ce20b77d43_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTQtMTYtMS0xLTA_bc725902-e269-4073-99f9-5dbc62bd9884"
      unitRef="usd">218000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="if364edca58da421d9d61dae9fcad7914_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtMi0xLTEtMA_b43a561a-81c0-4741-8bd8-d9a77c3fac26"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i40461f1ac8b940ce8fec799328c0881a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtNC0xLTEtMA_f8351ed3-6240-42e6-9872-5d4334252d51"
      unitRef="usd">55000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="iefe2d6409bd5447b881a310ce4725db2_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtNi0xLTEtMA_64c37eb6-5473-48a4-8db0-498084fd8a81"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i87d5b42f92744945842d42ff308f0e20_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtOC0xLTEtMA_c02fa321-8c05-47b1-b98b-f6429a4fcace"
      unitRef="usd">55000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ib6428c6244bd40588e98b0566fc843e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtMTAtMS0xLTA_bb83065b-c019-493a-a765-cd2024b1bccf"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i1b69704c2d87477fa4c4e048aef6c84a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtMTItMS0xLTA_de1e13d7-484b-4ede-8f04-1ea70433d8d1"
      unitRef="usd">12000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i28c7735eb6934c9290f2ee14fb060da0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtMTQtMS0xLTA_7efc2ccf-78aa-45ac-a7e5-690f14cedbf3"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="iba8e7f03185947608f3762d7182fac94_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTUtMTYtMS0xLTA_07546a11-6d9c-4fee-a25a-d384a8e02879"
      unitRef="usd">12000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icccb697c433d4ec09b49c19f13ab8a83_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtMi0xLTEtMA_89eff2b4-5938-4431-bb8d-5679e15ecbe1"
      unitRef="usd">5134000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i373b78381e234c3ca41660182ac003fe_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtNC0xLTEtMA_6ad49414-5f16-473a-a733-121515fa5208"
      unitRef="usd">2184000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2e9cc0b50d7c4ab6bc2905f65769e3b1_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtNi0xLTEtMA_0b5e9e50-07fa-4e07-970c-a8222506f5b5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie8a9ceaf8e034398898fc7c7ed8656c9_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtOC0xLTEtMA_d3a970c0-236a-46ad-af91-e12134b38568"
      unitRef="usd">7318000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5ee81b72feb64a13bb9b256646717944_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtMTAtMS0xLTA_6a4c8aef-525d-4962-96ee-cbb324078a30"
      unitRef="usd">7279000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8ccfe72a95f54aa78e87fe00e6420d4a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtMTItMS0xLTA_2ed9d347-ccd7-4d51-a2fe-99c433fe3cce"
      unitRef="usd">1729000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7e7f4d6bbc524f168c63679b9a7e91fb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtMTQtMS0xLTA_7dd217c0-7f84-4021-bc92-f88edb335d55"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i91039368c3bd4bfb910457fd3dd4c000_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTYtMTYtMS0xLTA_216be828-2e33-4e0a-942c-d48db885af5c"
      unitRef="usd">9008000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i989d63bf16b04e01a3d9b072d85d1ba9_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtMi0xLTEtMA_3c83b72a-2d5b-4bfa-b716-849a9969562a"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i31da5834b4314564824f60b82ecae0f1_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtNC0xLTEtMA_96226f68-dff5-4601-9f44-f24625bb118e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i35eec1666a264bd3b71436f39b919d85_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtNi0xLTEtMA_ca55942b-6480-42f8-a6d2-5e1bee2178af"
      unitRef="usd">328000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib3e238999bb54c4099da8e86105699dc_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtOC0xLTEtMA_358318fd-800c-4c3c-bb64-2480a76574fd"
      unitRef="usd">328000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0cd694a407d04faab683d1cd31f7d8a9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtMTAtMS0xLTA_7a9bf9ab-9875-463c-a646-97289de09a69"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6c237a39755447a48b076df315f9ace7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtMTItMS0xLTA_1fe30a36-3359-4057-8da6-d5083685d6e5"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i48f04e6cd6d84fc3bb90b473f068279d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtMTQtMS0xLTA_39e57879-2da6-4ddf-8738-8c0c82fddd10"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5faee6f594734e2eadc6353454b6d927_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTgtMTYtMS0xLTA_e3c382f5-8b25-4d09-ab47-f13d6c2b71ee"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ia380e72b9e514a0dbc10fa47a96a37b9_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktMi0xLTEtMA_eee08247-2c83-4fe5-b409-029363478627"
      unitRef="usd">249000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ia0202af8459b4f3789926f58b9cf9752_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktNC0xLTEtMA_07262822-7573-4eea-a0d9-24f1e70d3a71"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i42edfdab86c9426e93701ffdc0c7fe94_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktNi0xLTEtMA_e6da06ab-b76e-4f1a-b3e0-3ffade33ac7f"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i4c80ed86b032450995903fbe43ad034e_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktOC0xLTEtMA_91dc95e0-13fa-49c5-b086-47a9c9713101"
      unitRef="usd">249000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i54901c86be024d34813c278457433dd1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktMTAtMS0xLTA_bf2ca411-9102-4d1c-adaa-8ec096721efe"
      unitRef="usd">218000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i6c04316279d5406ebb97ec435e024e2d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktMTItMS0xLTA_be24060c-fa52-494b-ac34-84261cf2e7d8"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i1502ee19eaa24b0992c9886bfc77cb5b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktMTQtMS0xLTA_b72e2f2b-911c-456d-9943-4614b7b97085"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ib15e0bfd36234157af17a4ce20b77d43_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMTktMTYtMS0xLTA_d8a5e4bc-61d7-42ae-b21f-f277e78d2aaa"
      unitRef="usd">218000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="if364edca58da421d9d61dae9fcad7914_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtMi0xLTEtMA_1ed9c6af-42b5-46f8-abb0-a79f8836997a"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i40461f1ac8b940ce8fec799328c0881a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtNC0xLTEtMA_659a46a5-9c0e-44a4-b57f-552da794cc11"
      unitRef="usd">8000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="iefe2d6409bd5447b881a310ce4725db2_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtNi0xLTEtMA_5c6256e9-a50d-4cef-a2c4-5e7a5a04deb6"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i87d5b42f92744945842d42ff308f0e20_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtOC0xLTEtMA_82963863-f705-4750-8cb0-00ca33253253"
      unitRef="usd">8000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ib6428c6244bd40588e98b0566fc843e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtMTAtMS0xLTA_820bbd66-2a83-4f85-9b27-51450c96f79b"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i1b69704c2d87477fa4c4e048aef6c84a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtMTItMS0xLTA_dccbcba1-cf3a-4855-a3cc-b90568e3fdb4"
      unitRef="usd">121000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i28c7735eb6934c9290f2ee14fb060da0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtMTQtMS0xLTA_e81844ca-e336-4beb-82f7-ad8880bf278e"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="iba8e7f03185947608f3762d7182fac94_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjAtMTYtMS0xLTA_f509ecb5-5815-441a-bf22-99b516444149"
      unitRef="usd">121000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="icccb697c433d4ec09b49c19f13ab8a83_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtMi0xLTEtMA_e52ad917-2f96-43c0-8cde-e9b76319c681"
      unitRef="usd">249000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i373b78381e234c3ca41660182ac003fe_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtNC0xLTEtMA_5f33b6d9-482d-46d0-afe1-3a4343ed6e06"
      unitRef="usd">8000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2e9cc0b50d7c4ab6bc2905f65769e3b1_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtNi0xLTEtMA_1aafe058-0ab3-4ea9-ac16-1acf2410dad0"
      unitRef="usd">328000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie8a9ceaf8e034398898fc7c7ed8656c9_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtOC0xLTEtMA_1475fca8-ea38-40ee-9668-5ec90928b66c"
      unitRef="usd">585000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5ee81b72feb64a13bb9b256646717944_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtMTAtMS0xLTA_51fb3b79-b708-44b6-8b19-d0aa41e0072c"
      unitRef="usd">218000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8ccfe72a95f54aa78e87fe00e6420d4a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtMTItMS0xLTA_1a675994-f670-435a-831f-d6c68a373eea"
      unitRef="usd">121000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7e7f4d6bbc524f168c63679b9a7e91fb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtMTQtMS0xLTA_103a2cde-888e-42fe-ad11-d03ad0b36ab2"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i91039368c3bd4bfb910457fd3dd4c000_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjI3OGExYThlMTVjMjQzYTVhYTk0NWE3ZTkxMDEzYjFhL3RhYmxlcmFuZ2U6Mjc4YTFhOGUxNWMyNDNhNWFhOTQ1YTdlOTEwMTNiMWFfMjEtMTYtMS0xLTA_260e736e-51b2-4111-bc39-b6b79235f2f9"
      unitRef="usd">339000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i72ccac9d876f460bb41bf5ff8f83566d_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTA5OTUxMTY0NDk5Mw_6ba1ba31-ac10-4b88-8cfe-136e34e3906a"
      unitRef="usd">482000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i176ff44bb5764e3b809a6d1ac92b4178_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTA5OTUxMTY0NTAxMA_4cae37b3-bf41-4457-8844-c92b3ca567bd"
      unitRef="usd">212000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNzc0Ng_fa7cce93-e6e4-419b-8224-c659ce3183f7">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity securities measured at fair value on a recurring basis on our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;See the table under the Equity Investment in Galapagos NV (&#x201c;Galapagos&#x201d;) for more information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib6ef3db73cbc4509905d24a522ce5757_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfMS0yLTEtMS0w_d59c32f8-2dde-4959-a715-12d8040588ce"
      unitRef="usd">2768000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0da35341d6714931bc1689adaba0f122_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfMS00LTEtMS0w_b3823e92-9299-4536-bf68-e61fc56c615f"
      unitRef="usd">4361000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4da087316a0f42869c52cd83bef39303_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfMi0yLTEtMS0w_7681d917-23f9-4fc0-a110-688c3e16a615"
      unitRef="usd">871000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie1511de451544838b5b9f248bbe33b1a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfMi00LTEtMS0w_29b92c67-9ef6-4061-a746-3c3123e51dd4"
      unitRef="usd">853000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i94f9fa2675c74baf9fc13fcaa1d41e1f_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfMy0yLTEtMS0w_20687fa3-6bb6-4a95-92f4-e532a23f155f"
      unitRef="usd">1135000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id37cb24882ef449585ce764d602b950d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfMy00LTEtMS0w_515b1002-ad25-41eb-9807-cd138f849ca0"
      unitRef="usd">1756000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia1be5d0f90b94ff6beab639c85963cc9_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfNC0yLTEtMS0w_d207ea1f-db41-49c6-979c-9f1460e98026"
      unitRef="usd">4774000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iff3127bd77e544569634499a4cf507c8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOmNhYzdjYjcyNWRjOTQwYWJhYTEyMmYwMjA0ODliYTZhL3RhYmxlcmFuZ2U6Y2FjN2NiNzI1ZGM5NDBhYmFhMTIyZjAyMDQ4OWJhNmFfNC00LTEtMS0w_2400aa97-9128-448e-b45b-285ca3b93966"
      unitRef="usd">6970000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTY0OTI2NzQ0Mjg1NDE_553df822-7cfa-495b-8483-6eb9901453de"
      unitRef="usd">-142000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTY0OTI2NzQ1MzU3Ng_8a092c20-b2d0-4d18-a52e-863ca240ec69"
      unitRef="usd">-667000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTA5OTUxMTYyODY5MTU_a45d4ac5-c604-4f17-9846-6080ddba6862"
      unitRef="usd">-964000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTA5OTUxMTYzOTcwOQ_8f8e8cdd-93f2-4b50-80c5-8f867809e24b"
      unitRef="usd">-1000000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNTQ5NzU1ODE1MDgwNw_40fc1567-91c2-410c-8002-3cc97a92a63c">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity investment in Galapagos in our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ice6cc9ca3679429daa7ddad7be3b18f8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjlhNTI4ODZmN2FlZjQxMDI5MTUzYjM4MmEzMjA1YmNhL3RhYmxlcmFuZ2U6OWE1Mjg4NmY3YWVmNDEwMjkxNTNiMzgyYTMyMDViY2FfMS0yLTEtMS0zOTYwMQ_f2c0d649-dee7-4540-aa16-51d338a3e69d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i823c5759f91342788099a4a119a8361f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjlhNTI4ODZmN2FlZjQxMDI5MTUzYjM4MmEzMjA1YmNhL3RhYmxlcmFuZ2U6OWE1Mjg4NmY3YWVmNDEwMjkxNTNiMzgyYTMyMDViY2FfMS00LTEtMS0zOTYwMQ_b63e573c-7be5-4078-beeb-63cf3ec9f9e4"
      unitRef="usd">351000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4ccaa167281f4a20b66d52b3c71f1dae_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjlhNTI4ODZmN2FlZjQxMDI5MTUzYjM4MmEzMjA1YmNhL3RhYmxlcmFuZ2U6OWE1Mjg4NmY3YWVmNDEwMjkxNTNiMzgyYTMyMDViY2FfMi0yLTEtMS0zOTYwMQ_e1f0cdca-3020-4a3f-a582-f55bc0759336"
      unitRef="usd">881000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8dcf510e014b414ea7b2dc9b96ebd136_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjlhNTI4ODZmN2FlZjQxMDI5MTUzYjM4MmEzMjA1YmNhL3RhYmxlcmFuZ2U6OWE1Mjg4NmY3YWVmNDEwMjkxNTNiMzgyYTMyMDViY2FfMi00LTEtMS0zOTYwMQ_d53e3cc5-ea4d-40c9-a3e8-d4835cfdc1d7"
      unitRef="usd">1297000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i78a2c5f5c07343a095efd1f37fda91fd_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjlhNTI4ODZmN2FlZjQxMDI5MTUzYjM4MmEzMjA1YmNhL3RhYmxlcmFuZ2U6OWE1Mjg4NmY3YWVmNDEwMjkxNTNiMzgyYTMyMDViY2FfMy0yLTEtMS0zOTYwMQ_ba5e03bd-c9f0-43be-87c6-7a689f38f0c0"
      unitRef="usd">881000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4df9dcc40c9941ea8c7e26f4f58967e9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RhYmxlOjlhNTI4ODZmN2FlZjQxMDI5MTUzYjM4MmEzMjA1YmNhL3RhYmxlcmFuZ2U6OWE1Mjg4NmY3YWVmNDEwMjkxNTNiMzgyYTMyMDViY2FfMy00LTEtMS0zOTYwMQ_c31446ab-a888-4544-b557-0b473d377b9c"
      unitRef="usd">1648000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMzE5MQ_c8cf3e2f-9858-47f3-845f-0bcc2db60c12"
      unitRef="usd">96000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMzE5OA_737dc1c2-8332-4431-bb71-22e324104f68"
      unitRef="usd">58000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMzMwMg_3bf89603-6591-478b-b76f-c59f8fccb911"
      unitRef="usd">211000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMzMwOQ_ba23c6e4-b815-42d5-af1d-6a059d6fed5f"
      unitRef="usd">204000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="i7dfebbffea394aacba0aba288b9dc053_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNDE3Mg_24b833ad-212e-4297-b104-9f6c3ae064d1"
      unitRef="usd">212000000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:LongTermDebtFairValue
      contextRef="i0b50cb54d91f4e6c99676d255fa29fad_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNjY2MQ_124ca565-0da6-4359-94ff-1958e9b9e5f7"
      unitRef="usd">29600000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ic6a9dc16a8a0426d985e8a948bb5bfb1_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNjY2OA_a6a01d20-252b-4f5a-947b-c01fd4e8f7cd"
      unitRef="usd">34600000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia4da7a64c618429d8996f9b339ac38a8_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTY0OTI2NzQ0Mjg0NzI_61b99972-143f-43ed-9393-3fcc1801eb0f"
      unitRef="usd">26600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6c6903daf0954d94b44190d9b3e1b5ba_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNjczOA_0f233633-b04f-4c62-9140-6f4287e5a5a4"
      unitRef="usd">30300000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i76c056d0bef64de1a20dc89b76c1fa78_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfNzAyMg_1fad4322-36fa-4917-a4f2-08469b98003f"
      unitRef="usd">341000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i35eec1666a264bd3b71436f39b919d85_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80MC9mcmFnOmI4ZGZlNzZlMGFkZDQwZTY4Y2VhM2VkYzVhM2M0ODIxL3RleHRyZWdpb246YjhkZmU3NmUwYWRkNDBlNjhjZWEzZWRjNWEzYzQ4MjFfMTY0OTI2NzQ0Mjg0ODA_3853746e-f56d-4629-8292-255fad8547d3"
      unitRef="usd">328000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNzI1_ee89ce0e-c966-49ed-93f1-c948421a069f">AVAILABLE-FOR-SALE DEBT SECURITIES&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held a total of 214 and 208 positions which were in unrealized loss positions as of September&#160;30, 2021 and 2020, respectively. The unrealized losses were largely due to changes in interest rates. Aggregated gross unrealized losses on available-for-sale debt securities were not material for the three and nine months ended September 30, 2021 and 2020. No impairment was recognized for the three and nine months ended September 30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNzAw_8f0af4e6-f5bc-4d24-8112-bed4ad5033be">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ie5d7dd3905d64e28ac9327a66e603863_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi0yLTEtMS0w_57b08cc3-2afd-42cd-93e3-b1415e50914e"
      unitRef="usd">360000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie5d7dd3905d64e28ac9327a66e603863_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi00LTEtMS0w_c5c7424f-6b82-4349-8dbc-40e897626a85"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie5d7dd3905d64e28ac9327a66e603863_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi02LTEtMS0w_c571c0d4-3101-477a-a6b4-7184d41969a2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie5d7dd3905d64e28ac9327a66e603863_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi04LTEtMS0w_ea45cc56-3d4d-47c4-aa93-743346bffc1e"
      unitRef="usd">360000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="icd2639a9859c40faa55868710c142818_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi0xMC0xLTEtMA_3b6b3855-e52f-4ea3-8a48-c0b54cebb56e"
      unitRef="usd">308000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icd2639a9859c40faa55868710c142818_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi0xMi0xLTEtMA_2fe220d2-7ab4-4096-b5c2-e45f284804fc"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icd2639a9859c40faa55868710c142818_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi0xNC0xLTEtMA_f39e2c90-9b8e-42ad-9e08-a27e9d1053d6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="icd2639a9859c40faa55868710c142818_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfMi0xNi0xLTEtMA_dde58ebe-80ec-4068-bf87-75f7279f40a5"
      unitRef="usd">309000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i48f52dc3cab841a3809ef785e4e66ca3_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0yLTEtMS00NjI0MA_22d499c7-f02a-4427-b1b5-63e48d6822ea"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i48f52dc3cab841a3809ef785e4e66ca3_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC00LTEtMS00NjI0MA_7b15a10b-0079-48d1-884b-6b1a027f9e5b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i48f52dc3cab841a3809ef785e4e66ca3_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC02LTEtMS00NjI0MA_098b699b-7d80-4d4e-9f7b-afe4783325ba"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i48f52dc3cab841a3809ef785e4e66ca3_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC04LTEtMS00NjI0MA_529017e1-a2f6-41e9-8f85-c10242510338"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i03b29e17a2c248719dab9a52b28f2838_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xMC0xLTEtNDYyNDA_ccd8566e-aca5-4ef8-a17b-776905450d3d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i03b29e17a2c248719dab9a52b28f2838_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xMi0xLTEtNDYyNDA_d6b5364d-f27b-4b6f-872a-94c088dea1f2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i03b29e17a2c248719dab9a52b28f2838_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xNC0xLTEtNDYyNDA_1fa7aa5f-c945-44ed-b276-d4ca7421c72c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i03b29e17a2c248719dab9a52b28f2838_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xNi0xLTEtNDYyNDA_9baa8d1a-ba5f-4132-ac0e-1c1a0d3e4b82"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ib9848c60df524b6d8597f27a5c2348a7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0yLTEtMS0w_95d2eae0-028a-4776-8da4-286dd0cca4eb"
      unitRef="usd">44000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib9848c60df524b6d8597f27a5c2348a7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC00LTEtMS0w_db604131-7e15-4690-b645-4ca97e225579"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib9848c60df524b6d8597f27a5c2348a7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC02LTEtMS0w_940e2351-f4d7-4957-b4e8-3cd4b183755d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib9848c60df524b6d8597f27a5c2348a7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC04LTEtMS0w_5e25accc-7bd5-40f4-b39f-f5bf1449d7b8"
      unitRef="usd">44000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ie1b6844083d54dd6b01c081a66abc0ac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xMC0xLTEtMA_cb4d32d8-2f79-4f90-b2dc-25e50b04dbee"
      unitRef="usd">43000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie1b6844083d54dd6b01c081a66abc0ac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xMi0xLTEtMA_3d55acd4-4e69-4c46-9037-951fb28b1161"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie1b6844083d54dd6b01c081a66abc0ac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xNC0xLTEtMA_b6fece2e-2375-4a2b-8449-ed67080e64be"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie1b6844083d54dd6b01c081a66abc0ac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNC0xNi0xLTEtMA_89f98591-ac06-4bd6-9c7b-a3d7f8a4b2c0"
      unitRef="usd">43000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ibf1a2f42beca4dbfb5c2042c0e6ec2c9_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0yLTEtMS00NDcyNQ_6cea095e-4b7f-454d-85d4-74733d4727dd"
      unitRef="usd">361000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibf1a2f42beca4dbfb5c2042c0e6ec2c9_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS00LTEtMS00NDcyNQ_82b2b3ac-5c8b-408d-a88e-f4c3c611cc20"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibf1a2f42beca4dbfb5c2042c0e6ec2c9_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS02LTEtMS00NDcyNQ_a61e1ef3-1a63-4447-8414-fe6fa50d5ffa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ibf1a2f42beca4dbfb5c2042c0e6ec2c9_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS04LTEtMS00NDcyNQ_7bbe4505-2704-4386-a994-683e89dc2830"
      unitRef="usd">361000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i91b301a386454cff8a23c0f9d5802e0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xMC0xLTEtNDQ3MjU_cb8c3ed0-c7ad-4313-a1d3-fb386e2c789e"
      unitRef="usd">216000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i91b301a386454cff8a23c0f9d5802e0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xMi0xLTEtNDQ3MjU_5eab8282-2152-4d64-b93b-b7d6fc1577ff"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i91b301a386454cff8a23c0f9d5802e0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xNC0xLTEtNDQ3MjU_d7e069f1-bf72-4d68-8caf-4a1c73bb7700"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i91b301a386454cff8a23c0f9d5802e0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xNi0xLTEtNDQ3MjU_a155837a-8ea5-49d8-b297-089201e15d33"
      unitRef="usd">216000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i9edacacd9fed40b19c21f8c9a2d1066a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0yLTEtMS0w_fa930565-da52-47ab-ba99-210ba02f9037"
      unitRef="usd">1272000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9edacacd9fed40b19c21f8c9a2d1066a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS00LTEtMS0w_836b41b6-66c5-46d4-b3d7-54d9a4cf40e3"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9edacacd9fed40b19c21f8c9a2d1066a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS02LTEtMS0w_e513a913-bf77-47ef-b597-def46c85629d"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i9edacacd9fed40b19c21f8c9a2d1066a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS04LTEtMS0w_a9f4b923-0e25-4d6c-84cb-a03494383010"
      unitRef="usd">1272000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ibdd06b56ab884773b9a6d59b91979118_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xMC0xLTEtMA_4f6cd6a7-6bf3-42aa-bed0-6a7149201701"
      unitRef="usd">1140000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibdd06b56ab884773b9a6d59b91979118_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xMi0xLTEtMA_352ed836-c94a-4984-b30c-66957f91f5ac"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibdd06b56ab884773b9a6d59b91979118_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xNC0xLTEtMA_0f6fe123-bd9b-44ca-8016-80e6118fb6c0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ibdd06b56ab884773b9a6d59b91979118_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNS0xNi0xLTEtMA_963dea10-c41e-40f2-87b9-e0cc14184585"
      unitRef="usd">1142000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ie4d28e4219744460aa5d638f0e4748d7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi0yLTEtMS0w_df2a3233-2b72-45e9-a4c8-6f72a33f1d4a"
      unitRef="usd">447000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie4d28e4219744460aa5d638f0e4748d7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi00LTEtMS0w_766deef4-66fa-47c8-a804-e26d84d69872"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie4d28e4219744460aa5d638f0e4748d7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi02LTEtMS0w_308a8216-272f-4aab-a649-27809fd952fb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie4d28e4219744460aa5d638f0e4748d7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi04LTEtMS0w_abf769d9-a176-41b6-a9be-dad1b8448386"
      unitRef="usd">447000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="icb6a3f0759ad4433953398e7ad344fd5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi0xMC0xLTEtMA_7b69b41e-e2c4-496f-8691-c04c0917ec90"
      unitRef="usd">316000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icb6a3f0759ad4433953398e7ad344fd5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi0xMi0xLTEtMA_69151171-e850-40bf-945e-c3f48c0382eb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icb6a3f0759ad4433953398e7ad344fd5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi0xNC0xLTEtMA_d84f8f43-ee59-4869-8cea-f9ad7b750e8b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="icb6a3f0759ad4433953398e7ad344fd5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNi0xNi0xLTEtMA_c8ae022f-52d9-4059-93ee-33361ff6a090"
      unitRef="usd">316000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy0yLTEtMS0w_1e3a1697-ec33-49a7-b5d5-afc4a9dc36e2"
      unitRef="usd">2489000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy00LTEtMS0w_37f20232-ac49-441b-8bde-c5d072033d66"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy02LTEtMS0w_73b4f9bf-32cd-442d-a3ac-31cfc6b9e056"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy04LTEtMS0w_8d5d4269-b305-40b7-b131-e81a86c4f0a8"
      unitRef="usd">2489000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy0xMC0xLTEtMA_fd480d1b-1f76-44ef-b116-f4958b0d2be8"
      unitRef="usd">2023000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy0xMi0xLTEtMA_e664e801-7a6b-45d4-8859-d8da9f5fb323"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy0xNC0xLTEtMA_6ad4ab0c-8a44-48bf-a263-9e8c2f760249"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOjFhZDZhNDVkZTE5ZDQ4NWU4YTU5OTVhMTEwZWMwMjc2L3RhYmxlcmFuZ2U6MWFkNmE0NWRlMTlkNDg1ZThhNTk5NWExMTBlYzAyNzZfNy0xNi0xLTEtMA_49cddd0a-03a3-41a9-8f1a-5868b76d32c0"
      unitRef="usd">2026000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNjkx_20636eab-804a-4f23-af25-584a7bab3349">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i4fcdeab4094c40bc957aa0ac494ab157_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfMS0yLTEtMS0w_73d96e8c-016d-4f19-8523-51fc78c3430e"
      unitRef="usd">14000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8aa08afccd2c4c3c920afbf679603457_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfMS00LTEtMS0w_0f4aca6a-5f97-4c19-a37b-d005469a8481"
      unitRef="usd">113000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie91dfb2ea1ff4696bbe46980e5074985_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfMi0yLTEtMS0w_09501e32-2890-4b3c-ba17-edb27e9f046a"
      unitRef="usd">1376000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i36fc4c8f965c42f091bfa62e48d5188c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfMi00LTEtMS0w_cb61bb1e-01d8-46e8-a7e4-8aa808f08bd3"
      unitRef="usd">1411000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i77ef7763dceb461d8ba101eedb3ec351_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfMy0yLTEtMS0w_e38013d1-d50a-4ecc-8f03-19ad57874f49"
      unitRef="usd">1099000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2a621708b219448a9f522102302751fe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfMy00LTEtMS0w_5f6dd4a9-0379-4bf9-99e8-660af945dfc1"
      unitRef="usd">502000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfNC0yLTEtMS0w_a31da331-6623-4af1-b366-de60d505d0b9"
      unitRef="usd">2489000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY5YTA1YTNmMjQwOTRhNzk4NmZkOTQ5Yzg3NjJiMzY4L3RhYmxlcmFuZ2U6ZjlhMDVhM2YyNDA5NGE3OTg2ZmQ5NDljODc2MmIzNjhfNC00LTEtMS0w_68245248-f4a2-4a51-86a6-c5b947e593f3"
      unitRef="usd">2026000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNzIx_90839b99-73cf-45f5-ae1d-f25f56809bdd">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfMi0yLTEtMS0w_52c5404e-bfd8-4ffa-8861-9dde1263a504"
      unitRef="usd">1390000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfMi00LTEtMS0w_80b1f2bf-3a97-4f07-be88-00406ee76116"
      unitRef="usd">1390000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfMy0yLTEtMS0w_55ffbba5-4723-44e2-a848-ec63f1eadb11"
      unitRef="usd">1075000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfMy00LTEtMS0w_c907c04a-12ef-4b90-8959-d26ff52a7dfa"
      unitRef="usd">1075000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfNC0yLTEtMS0w_90d69536-362e-424c-8573-bfea9b408a1b"
      unitRef="usd">24000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfNC00LTEtMS0w_4e446658-5ca4-4307-920e-9b7606c22690"
      unitRef="usd">24000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfNS0yLTEtMS0w_db791e20-a5e7-4a3d-a306-8de5742bb807"
      unitRef="usd">2489000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RhYmxlOmY3ZGE1OTI1ZTg3MDRjN2Q5Njg2YmNlMDMyYmI3MTE5L3RhYmxlcmFuZ2U6ZjdkYTU5MjVlODcwNGM3ZDk2ODZiY2UwMzJiYjcxMTlfNS00LTEtMS0w_97a1bf8d-a2ed-4701-a2e8-0dfd1b5fcdc1"
      unitRef="usd">2489000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfMzA3_4a02f22f-34f6-4a48-bd6a-88c6e81c84a8"
      unitRef="position">214</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i05bfa65a7fdd430ea5429b49909dff6d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfMTA5OTUxMTYyNzg2MDU_4e17ec6c-d484-48db-bfb2-990fa70311a7"
      unitRef="position">208</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNTMz_027e6186-d1e3-4020-af5d-26c6595530e7"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNTMz_17db7020-4495-4388-a10c-cab1e4db1fa3"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNTMz_6962c841-cbd0-48b8-b1c9-2efd9acc1be1"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80My9mcmFnOjNlZjJjNTUzMGI4MDRiNWM5MmU3YjYxOTMwOWZmZmJmL3RleHRyZWdpb246M2VmMmM1NTMwYjgwNGI1YzkyZTdiNjE5MzA5ZmZmYmZfNTMz_80fd1033-2c1b-448a-8c24-59654afe5a5b"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzMzMg_cf6798ad-9283-4f49-9aa9-c78c31328c90">DERIVATIVE FINANCIAL INSTRUMENTS&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we may hedge a portion of our foreign currency exposure related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward or option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge our exposure to foreign currency exchange rate fluctuations for certain monetary assets and liabilities that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are not designated as hedges and, as a result, changes in their fair value are recorded in Other income (expense), net on our Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of 18 months or less. Upon executing a hedging contract and quarterly thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses in Accumulated other comprehensive income (&#x201c;AOCI&#x201d;) are reclassified into product sales when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of September&#160;30, 2021 are expected to be reclassified to product sales within 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash flow effects of our derivative contracts for the nine months ended September 30, 2021 and 2020 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had notional amounts on foreign currency exchange contracts outstanding of $3.0 billion and $2.4 billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. The following table summarizes the classification and fair values of derivative instruments on our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) reclassified from AOCI into product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) recognized in Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Condensed Consolidated Statements of Operations. There were no discontinuances of cash flow hedges for the three and nine months ended September 30, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and December&#160;31, 2020, we only held foreign currency exchange contracts. The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.899%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Amounts Not Offset &lt;br/&gt;on our Condensed &lt;br/&gt;Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Amounts&lt;br/&gt;&#160;of Recognized &lt;br/&gt;Assets/Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Amounts&lt;br/&gt;&#160;Offset on our &lt;br/&gt;Condensed &lt;br/&gt;Consolidated &lt;br/&gt;Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amounts of Assets/Liabilities Presented&lt;br/&gt;&#160;on our Condensed Consolidated&lt;br/&gt;Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Derivative &lt;br/&gt;Financial &lt;br/&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Cash Collateral &lt;br/&gt;Received/&lt;br/&gt;Pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;br/&gt;&#160;(Legal Offset)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i358d5e6dcfe74eb2bd53d281984be1b6_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMTg3Ng_5d4c6d0b-4eb8-4bcc-b94f-76c4c96824c7">P18M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1
      contextRef="i358d5e6dcfe74eb2bd53d281984be1b6_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMjM0MQ_ef713134-3936-476e-a1ea-24bedba7e4e8">P12M</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMjU2NQ_3336cfb5-fadd-4c3a-bd73-391ee9c330f8"
      unitRef="usd">3000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMjU3Mg_c6aaceb6-52d7-4b2e-8016-69b106264a38"
      unitRef="usd">2400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzMyNw_0e285158-7698-4148-8213-89dd699a6a6c">The following table summarizes the classification and fair values of derivative instruments on our Condensed Consolidated Balance Sheets:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="ibd2b0d3a5d754eba9ec5ab61ab8a496c_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfNC00LTEtMS0w_63c98b61-8f20-49d5-9bd0-69a28faaae9a"
      unitRef="usd">50000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="iba883e2763fc4f24aa849f2ba1b18762_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfNC04LTEtMS0w_ac6f7e94-0788-4e50-9073-54367b7b2922"
      unitRef="usd">8000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i441b41e448e24773b07474571334d688_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfNS00LTEtMS0w_241921f2-2dea-4fac-aa0b-d9043ac3f746"
      unitRef="usd">5000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="ic68b8c1df06a4e9ebf5ecc3162d4e91b_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfNS04LTEtMS0w_17f9575c-2545-4083-8b7b-3fc95c5ec3f8"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i41080ff3b0f84bb6ac2d71f26d888ae3_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfNi00LTEtMS0w_b341fb9a-271f-441a-b9d6-f37011d11cf3"
      unitRef="usd">55000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i41080ff3b0f84bb6ac2d71f26d888ae3_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfNi04LTEtMS0w_9caa9ae0-b942-4022-abaf-9d143503e009"
      unitRef="usd">8000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i9de9bbb3a16148ef822890fed3ae38df_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfOC00LTEtMS0w_a9290c22-b58a-4b80-88c6-b2a8e8fa3c50"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i4f577e7ed1d9420a854f73986479f887_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfOC04LTEtMS0w_549ea077-b2ad-4b19-9e20-699ac4687b1a"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i2a621ab557e54d8aae26f9664ee66d03_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfOS00LTEtMS0w_c2b54f85-c4b2-48b1-812c-67ead28b0017"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i2a621ab557e54d8aae26f9664ee66d03_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfOS04LTEtMS0w_dc98dc88-f6f5-462e-8c90-349dc53a2e16"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfMTAtNC0xLTEtMA_3de762c1-49fe-4dd5-903e-a4aa1687b5d6"
      unitRef="usd">55000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmUzM2M0YjY1MjllZjQ5Yjg5MWMyMzg5NzdkMWM5NmY0L3RhYmxlcmFuZ2U6ZTMzYzRiNjUyOWVmNDliODkxYzIzODk3N2QxYzk2ZjRfMTAtOC0xLTEtMA_d9704c6f-e19d-4048-a272-3f43f1878364"
      unitRef="usd">8000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i0316527653e540b79aaa8ffd4daeb2e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfNC00LTEtMS0w_c1c0848c-9f8c-4b4b-a448-07705b1d2e24"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="idcc66a969998454596abd65746688f8d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfNC04LTEtMS0w_72a40809-2cda-488a-88cf-e1bf8b46ad1c"
      unitRef="usd">113000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i33df3af625fb41ae885fec733687b6cf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfNS00LTEtMS0w_ca56b777-43b1-434e-8740-7c86a796a131"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="if2c72fc1463e44eb96aabd7dae05dad7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfNS04LTEtMS0w_042e7a34-6353-4fba-ac4d-b25eaa889d0a"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i8a2c8de705884a04944f9028afb662e6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfNi00LTEtMS0w_70c810b8-f828-49b4-9c5b-abc44ff51e25"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i8a2c8de705884a04944f9028afb662e6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfNi04LTEtMS0w_388bbd09-4404-42a5-bcc1-612b0978f1c8"
      unitRef="usd">120000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i07a3a9b39d3f40068ad241a4bf584ecf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfOC00LTEtMS0w_ad908818-e252-4c3c-9be8-ad4cd5ce47de"
      unitRef="usd">12000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i2d9378e46bcd49c1aeccf6c8f61de218_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfOC04LTEtMS0w_271ab4fe-e109-4ab1-b991-41b7ebcf8fba"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="if3efa4fc2e80425d911786fe90f0577e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfOS00LTEtMS0w_99040c3d-f43d-41b1-b400-95c577fe57a5"
      unitRef="usd">12000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="if3efa4fc2e80425d911786fe90f0577e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfOS04LTEtMS0w_035c3aed-e720-4306-81e8-856c8d210ccb"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfMTAtNC0xLTEtMA_e68b9fcc-affb-42cc-99d3-71019f2fbeff"
      unitRef="usd">12000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOjAxZDQxNjIxNzk0OTQ1NzI4OTRjNGJlNTBkNjMxM2YxL3RhYmxlcmFuZ2U6MDFkNDE2MjE3OTQ5NDU3Mjg5NGM0YmU1MGQ2MzEzZjFfMTAtOC0xLTEtMA_e18ec714-891d-41b8-b1ad-392e051f03c0"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzMxNw_246e81fb-252b-497e-86cd-fc0cdd4219aa">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) reclassified from AOCI into product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) recognized in Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNC0yLTEtMS0w_fcbc2900-6be9-4b3e-b100-c0c2c206c455"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNC00LTEtMS0w_eb981166-d392-4dc0-9638-164d6eea734a"
      unitRef="usd">-52000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNC02LTEtMS0w_aedabde2-5e98-44f8-89f4-4fe6196bb07f"
      unitRef="usd">104000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNC04LTEtMS0w_74875bfb-6057-44fa-9376-217c23d8a4f5"
      unitRef="usd">-28000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNS0yLTEtMS0w_1f977c66-7e7c-4025-a9be-bf1310bf5d60"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNS00LTEtMS0w_7cc5e41c-1a76-4b53-ba48-3a4d5651fd17"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNS02LTEtMS0w_fac0570e-0be5-45b2-a62a-5b0c37b09114"
      unitRef="usd">-69000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNS04LTEtMS0w_cd1619be-4c88-4ee7-ae96-d137b84f0f27"
      unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNy0yLTEtMS0w_d5e07564-1d72-4596-97ae-9b0d668bb42f"
      unitRef="usd">5000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNy00LTEtMS0w_ebe3b2a1-a3fe-4a55-97bd-40fdc225fecd"
      unitRef="usd">-13000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNy02LTEtMS0w_e84b0d9b-2405-4da6-a233-a9003b4bac69"
      unitRef="usd">24000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwNmQzYzlhMWY1MzRlNjc4NjFmMGZkNGM1NjIyZjM3L3RhYmxlcmFuZ2U6YzA2ZDNjOWExZjUzNGU2Nzg2MWYwZmQ0YzU2MjJmMzdfNy04LTEtMS0w_9d006894-7f34-44dd-a983-1a49492d737e"
      unitRef="usd">-10000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzA2OQ_544d91b8-9a11-44a9-ac83-2ab470b9bd96"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzA2OQ_6092d477-c552-48a0-b4d3-f2a35ec1af16"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzA2OQ_6c14782e-d768-42c6-a003-b17eccb14d99"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzA2OQ_8c61216a-a763-44de-8bfb-205d959a7fd4"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RleHRyZWdpb246M2MxMDAxZjQzMmE1NDliMGEyZWZlMzBiNWFjNDI2ZjNfMzM0OQ_0902b00e-f622-4ea4-85a3-63fac00e0da3">The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.899%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Amounts Not Offset &lt;br/&gt;on our Condensed &lt;br/&gt;Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Amounts&lt;br/&gt;&#160;of Recognized &lt;br/&gt;Assets/Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Amounts&lt;br/&gt;&#160;Offset on our &lt;br/&gt;Condensed &lt;br/&gt;Consolidated &lt;br/&gt;Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amounts of Assets/Liabilities Presented&lt;br/&gt;&#160;on our Condensed Consolidated&lt;br/&gt;Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Derivative &lt;br/&gt;Financial &lt;br/&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Cash Collateral &lt;br/&gt;Received/&lt;br/&gt;Pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;br/&gt;&#160;(Legal Offset)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNC0yLTEtMS0w_453529f6-c861-4b18-ad92-66fffe0d03f0"
      unitRef="usd">55000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNC00LTEtMS0w_c27b4cf6-9d5b-45ff-827a-17bd36fceb48"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNC02LTEtMS0w_2fd51f94-40a4-4031-8741-e70ba3a9ecdc"
      unitRef="usd">55000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNC04LTEtMS0w_3e63e440-ae40-4196-91e2-75f644b13e64"
      unitRef="usd">7000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNC0xMC0xLTEtMA_e13ee9a4-8d62-481b-84ce-7393705442db"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNC0xMi0xLTEtMA_a66d4c9f-e0ed-4abb-aad6-4d32e8065472"
      unitRef="usd">48000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNS0yLTEtMS0w_f857d3e9-395b-4dd1-83e8-744216e539ba"
      unitRef="usd">8000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNS00LTEtMS0w_88194b82-8519-4638-ab71-dcb85c0b31c8"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNS02LTEtMS0w_267b341e-2ebb-4979-97b5-296b319b67a0"
      unitRef="usd">8000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNS04LTEtMS0w_e561e3e4-1b44-4b72-945e-18eab1939e41"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNS0xMC0xLTEtMA_8ed8f914-a324-4ff2-a1ba-dc6d990ac31c"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNS0xMi0xLTEtMA_62422d3c-8478-4ce0-8007-d2c5c33c79e9"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNy0yLTEtMS0w_7b48140a-4109-453f-87d5-fbaca1deb74a"
      unitRef="usd">12000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNy00LTEtMS0w_f45c70dd-1636-450e-86c8-436f221503bf"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNy02LTEtMS0w_46a0112c-f91d-4b60-b742-42fc7fe9a107"
      unitRef="usd">12000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNy04LTEtMS0w_76a2a516-4e51-470f-ac65-685a64e6a233"
      unitRef="usd">12000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNy0xMC0xLTEtMA_9c2c442a-a02d-4f99-b388-4b75f8612b8d"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfNy0xMi0xLTEtMA_188797a2-3542-4a4a-a31d-ebc4b09f2a74"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfOC0yLTEtMS0w_30ddf171-34ab-46a8-ada1-6d033a2eaaf2"
      unitRef="usd">121000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfOC00LTEtMS0w_eed3cc21-b4b6-4555-a17e-df95d2468f7f"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfOC02LTEtMS0w_ff4aa29e-08f3-49f5-a974-de4f4a34a6e8"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfOC04LTEtMS0w_fed88dfd-0369-4059-8b9e-5c739c33e138"
      unitRef="usd">12000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfOC0xMC0xLTEtMA_74bfcdff-9bd1-4a6f-b22e-0fcb52ab1330"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80Ni9mcmFnOjNjMTAwMWY0MzJhNTQ5YjBhMmVmZTMwYjVhYzQyNmYzL3RhYmxlOmMwMTE2MTA4M2ZmNDRjZTc4YWMwNWRkNDM5NTliZWU0L3RhYmxlcmFuZ2U6YzAxMTYxMDgzZmY0NGNlNzhhYzA1ZGQ0Mzk1OWJlZTRfOC0xMi0xLTEtMA_bebd607c-0af9-4cd0-83e8-a28e0979277c"
      unitRef="usd">109000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNzE0OA_9d3ac2c7-a263-4c01-8e3d-fc7f40b1f712">ACQUISITIONS&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Condensed Consolidated Balance Sheets. Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. Transaction costs associated with business combinations are expensed as they are incurred. The first quarter 2021 acquisition of MYR and the fourth quarter 2020 acquisition of Immunomedics were accounted for as business combinations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets. For an asset acquisition, no goodwill is recorded and contingent consideration, such as payments upon achievement of various development, regulatory and commercial milestones, generally is not recognized as of the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;amp;D projects at the acquisition date and subsequent milestone payments are expensed unless there is an alternative future use. The second quarter 2020 acquisition of Forty Seven, Inc. (&#x201c;Forty Seven&#x201d;) was accounted for as an asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;MYR&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provided Gilead with Hepcludex, which was conditionally approved by the European Medicines Agency (&#x201c;EMA&#x201d;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. Upon closing, MYR became a wholly-owned subsidiary of Gilead. The financial results of MYR were included in our Condensed Consolidated Financial Statements from the date of the acquisition. Acquisition-related expenses were not material for the three and nine months ended September 30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate consideration for this acquisition of &#x20ac;1.3 billion (or $1.6 billion) primarily consists of &#x20ac;1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to &#x20ac;300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability-weighted scenarios for FDA approval, was $341 million as of the acquisition date and was initially recorded in Other long-term obligations on our Condensed Consolidated Balance Sheets. In the second quarter of 2021, the balance was reclassified to Accrued and other current liabilities on our Condensed Consolidated Balance Sheets. The estimated fair value of the contingent liability was $328&#160;million as of September&#160;30, 2021. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value estimates for the assets acquired and liabilities assumed were based upon valuations using information known and knowable as of the date of this filing. Changes to these assumptions and estimates could cause an impact to the valuation of assets acquired, including intangible assets, goodwill and the related tax impacts of the acquisition, as well as legal and other contingencies. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The finite-lived intangible asset of $845 million represents the estimated fair value of Hepcludex for HDV in Europe as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Hepcludex for HDV in Europe and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired intangible assets related to IPR&amp;amp;D consist of Hepcludex for HDV in all other regions without regulatory approval, including the United States. The estimated aggregate fair value of $1.2 billion as of the acquisition date was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to this asset and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the more significant assumptions inherent in the development of intangible asset fair values include: estimates of projected future cash flows including revenues and operating profits; probability of success; the discount rate selected; the life of the potential commercialized products and the risks related to the viability of and potential alternative treatments in any future target markets, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived assets until the completion or abandonment of the associated R&amp;amp;D efforts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The inputs used for valuing these identifiable intangibles are unobservable and considered Level 3 under the fair value measurement and disclosure guidance. See Note 3. Fair Value Measurements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net deferred tax liability was based upon the difference between the estimated book basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of MYR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $226 million was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for MYR is not expected to be deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no material measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the three and nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Immunomedics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2020, we completed the acquisition of Immunomedics, a company focused on the development of antibody-drug conjugate technology, for cash consideration of $20.6 billion. Upon closing, Immunomedics became a wholly-owned subsidiary of Gilead. The acquisition was financed with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $1.0 billion borrowing under a new senior unsecured term loan facility and cash on hand. During the nine months ended September 30, 2021, we repaid the borrowing under the senior unsecured term loan facility. See Note 10. Debt and Credit Facilities for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outlicense contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no material measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the three and nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Forty Seven&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2020, we completed the acquisition of Forty Seven, a clinical-stage immuno-oncology company focused on developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for total consideration of $4.7 billion, net of acquired cash. Upon closing, Forty Seven became a wholly-owned subsidiary of Gilead. During the nine months ended September 30, 2020, we recorded a $4.5 billion charge representing an acquired IPR&amp;amp;D asset with no alternative future use in Acquired in-process research and development expenses, and stock-based compensation expense of $144 million primarily in Research and development expenses on our Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i318a011bf49b49c3a79192b82583bb57_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMjAwMg_f31026fc-4284-479f-9fa6-605071c82789"
      unitRef="eur">1300000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i318a011bf49b49c3a79192b82583bb57_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMjAwOQ_69501c35-4654-415e-9667-84b49dd5edfc"
      unitRef="usd">1600000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i318a011bf49b49c3a79192b82583bb57_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMjAzNQ_292a9738-11fa-474c-9b88-0605af590f24"
      unitRef="eur">1000000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i318a011bf49b49c3a79192b82583bb57_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMjA1Ng_9ea8e0ce-3f1a-480b-89ae-93fc08f42c75"
      unitRef="usd">1200000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib5181ad1c63c4deeb36365ffdce5e584_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMjExNg_09067a39-e1ce-4500-9a0c-f3a8107730c7"
      unitRef="eur">300000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
      contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMjM1MA_3d85ea3b-dff3-4a19-b71c-b7dac437ef64"
      unitRef="usd">341000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i35eec1666a264bd3b71436f39b919d85_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNDM5ODA0NjUxODM3OQ_3853746e-f56d-4629-8292-255fad8547d3"
      unitRef="usd">328000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNzE0Ng_ebc66751-1940-45b5-8573-cd14c9503c0a">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outlicense contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjJmYWRhNmUwYzZmYjRlM2E4OWQ1ODAxYjA0NDI2ZDYzL3RhYmxlcmFuZ2U6MmZhZGE2ZTBjNmZiNGUzYTg5ZDU4MDFiMDQ0MjZkNjNfMi0yLTEtMS0w_adf8ad01-8e7c-4cab-b9c7-edfd2e2fe773"
      unitRef="usd">845000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i352358e211a34a23b9dc88776f5a0076_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjJmYWRhNmUwYzZmYjRlM2E4OWQ1ODAxYjA0NDI2ZDYzL3RhYmxlcmFuZ2U6MmZhZGE2ZTBjNmZiNGUzYTg5ZDU4MDFiMDQ0MjZkNjNfMy0yLTEtMS0w_f1b46bbc-534f-4ebf-84ad-5ece5c0d5757"
      unitRef="usd">1190000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjJmYWRhNmUwYzZmYjRlM2E4OWQ1ODAxYjA0NDI2ZDYzL3RhYmxlcmFuZ2U6MmZhZGE2ZTBjNmZiNGUzYTg5ZDU4MDFiMDQ0MjZkNjNfNC0yLTEtMS0w_a5bf74bf-dd7c-42b9-a42b-f0f9b58f498f"
      unitRef="usd">513000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet
      contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjJmYWRhNmUwYzZmYjRlM2E4OWQ1ODAxYjA0NDI2ZDYzL3RhYmxlcmFuZ2U6MmZhZGE2ZTBjNmZiNGUzYTg5ZDU4MDFiMDQ0MjZkNjNfNS0yLTEtMS0w_013da903-7b78-4a44-add4-f79229365e9a"
      unitRef="usd">-187000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjJmYWRhNmUwYzZmYjRlM2E4OWQ1ODAxYjA0NDI2ZDYzL3RhYmxlcmFuZ2U6MmZhZGE2ZTBjNmZiNGUzYTg5ZDU4MDFiMDQ0MjZkNjNfNi0yLTEtMS0w_24b6810f-3519-4e2b-8e82-c49d95833f47"
      unitRef="usd">1335000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillGross
      contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjJmYWRhNmUwYzZmYjRlM2E4OWQ1ODAxYjA0NDI2ZDYzL3RhYmxlcmFuZ2U6MmZhZGE2ZTBjNmZiNGUzYTg5ZDU4MDFiMDQ0MjZkNjNfNy0yLTEtMS0w_a848505b-c621-4e3e-b164-91b4c6e4a194"
      unitRef="usd">226000000</us-gaap:GoodwillGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjJmYWRhNmUwYzZmYjRlM2E4OWQ1ODAxYjA0NDI2ZDYzL3RhYmxlcmFuZ2U6MmZhZGE2ZTBjNmZiNGUzYTg5ZDU4MDFiMDQ0MjZkNjNfOC0yLTEtMS0w_91020b8d-84c8-46cb-b8cd-b73b254fa9f0"
      unitRef="usd">1561000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i7d953182d7f349f7880aa6b8782ddbea_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMzMwNA_f02ae5e3-eaa8-4a9e-a78f-f9654c1c7172"
      unitRef="usd">845000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <gild:IntangibleAssetMeasurementInput
      contextRef="i46f837bb32354303808450010f541cf2_I20210304"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMzYwNQ_4fa69033-7e3d-4568-9ed9-1711be5fc8e0"
      unitRef="number">0.12</gild:IntangibleAssetMeasurementInput>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i6d0182ee77884d308f972ee3ac8635f4_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfMzgwMw_863f00ce-9f70-4f71-ad2a-8936d32ed657">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i352358e211a34a23b9dc88776f5a0076_I20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNDAwMg_f1e7200b-8c72-4fe5-9256-7e85f3072227"
      unitRef="usd">1200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <gild:IntangibleAssetMeasurementInput
      contextRef="i91c7b3ebdf1649509a1e026f30a65baa_I20210304"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNDIwMw_a9c19c37-dd6d-41f8-b693-cd9dd13b1871"
      unitRef="number">0.12</gild:IntangibleAssetMeasurementInput>
    <us-gaap:GoodwillGross
      contextRef="i59fefc5ad8ec413db93d451131df6e85_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNTQ1NQ_d60c4fbe-3bb0-4545-ab1e-a538c03603e5"
      unitRef="usd">226000000</us-gaap:GoodwillGross>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i0680e69caed6418b9c239d0f897aa373_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNTY3Mw_2451aa22-20e7-4ea7-b424-ab58d450fd9a"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i8a84de62d1ec4a0db403459b92a7debd_D20201023-20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNjA1MQ_873d7850-5c64-41ad-9512-bff375d5f3a0"
      unitRef="usd">20600000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="if38c0f756f6945658b15ba7c6e9bb284_D20201001-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNjI2MA_d0dc1955-7a2f-4931-912c-84e8041f6e11"
      unitRef="usd">1000000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfMS0yLTEtMS0w_8c04612e-45d5-4a3d-a31f-dbc6a35034b9"
      unitRef="usd">726000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfMi0yLTEtMS0w_1ecd1a06-a263-4a1a-a02b-1e4aff3bcf9b"
      unitRef="usd">946000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i15facb5b1aa5415199d533abd8de3199_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfNC0yLTEtMS0w_fa59b474-8686-4cac-9c53-635ede3a47f6"
      unitRef="usd">4600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="ie94f540fb43d41c2a993dcfcce7e6d9e_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfNS0yLTEtMS0w_0467b6fd-db84-466c-8e79-ff08931e0ecf"
      unitRef="usd">15760000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ic7a6d7dbc5194ce3a5c2c451b949a083_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfNi0yLTEtMS0w_98b79569-9b78-4617-9f0c-0c6db798c606"
      unitRef="usd">175000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfNy0yLTEtMS0w_1cbe5b90-548f-407b-8c15-0e5ab0033f43"
      unitRef="usd">4565000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability
      contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfOC0yLTEtMS0w_dc61df67-5f10-4ad0-a26d-331087db2c5e"
      unitRef="usd">1100000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet
      contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfOS0yLTEtMS0w_40636703-6ae5-4721-8268-aa800c94e0a5"
      unitRef="usd">64000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfMTAtMi0xLTEtMA_ffa128bf-26b5-47ad-9840-4e5311e8498e"
      unitRef="usd">16606000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillGross
      contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfMTEtMi0xLTEtMA_34c4fcac-790c-49f5-95e7-2c89b4185acf"
      unitRef="usd">3991000000</us-gaap:GoodwillGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i361cbefd0d1a4aa2afdc5945396b9c62_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RhYmxlOjhkYTcxZGMyNWNlNjQ2NjhiYzE2MTE4NGMyNjJmZmZhL3RhYmxlcmFuZ2U6OGRhNzFkYzI1Y2U2NDY2OGJjMTYxMTg0YzI2MmZmZmFfMTItMi0xLTEtMA_d3c40446-29d1-4653-8556-5c1404da960d"
      unitRef="usd">20597000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <gild:PaymentsToAcquireAssetsNetOfCashAcquired
      contextRef="i90be553f64364971a7f334cad33d512f_D20200401-20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNjg2Ng_48a92268-d1c0-4eed-906a-2d1b95f04dac"
      unitRef="usd">4700000000</gild:PaymentsToAcquireAssetsNetOfCashAcquired>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i5e6bdf7f4837439c93c50b528a400b0e_D20200101-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNjk5MQ_e1d1f7a7-a43f-432f-bb4c-bb62a592c17a"
      unitRef="usd">4500000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="i59fc30c6ac6b49d88f04a9291366fc62_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV80OS9mcmFnOjYwMDY2NzkzMjFjYzRiZDA5YmRhM2UyMDM4YWQzNmM1L3RleHRyZWdpb246NjAwNjY3OTMyMWNjNGJkMDliZGEzZTIwMzhhZDM2YzVfNzExNg_998b2418-8091-4b6c-93b7-3a98bf61e1e5"
      unitRef="usd">144000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTMwOA_f38853d1-42cc-4fd8-917d-e5dee5fda17a">GOODWILL AND INTANGIBLE ASSETS&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from the acquisition of MYR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement period adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - axicabtagene ciloleucel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Trodelvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Hepcludex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,936)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)(2)(3)(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,936)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes $910&#160;million reclassified from indefinite-lived assets - IPR&amp;amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes Trodelvy for metastatic triple-negative breast cancer which was granted approval by FDA in April 2021 and Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer (&#x201c;UC&#x201d;) which was granted accelerated approval by FDA in April 2021. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&amp;amp;D.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes $1.2&#160;billion recognized from the first quarter 2021 acquisition of MYR. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200&#160;million will be reclassified to finite-lived assets in the fourth quarter of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate amortization expense related to finite-lived intangible assets was $441 million and $1.3 billion for the three and nine months ended September 30, 2021 and $281 million and $844 million for the three and nine months ended September 30, 2020, respectively, and was primarily included in Cost of goods sold on our Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTMzNw_a3a17490-9cdf-48e4-9c0b-b9dba716c63e">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from the acquisition of MYR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement period adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjdmMzlkOTNmNGU0NjRkZWE5NzI0OTNlOWViOWZjMGY3L3RhYmxlcmFuZ2U6N2YzOWQ5M2Y0ZTQ2NGRlYTk3MjQ5M2U5ZWI5ZmMwZjdfMS0yLTEtMS0w_8c0d525f-d1de-4b87-82a8-37b3ae51fcdb"
      unitRef="usd">8108000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjdmMzlkOTNmNGU0NjRkZWE5NzI0OTNlOWViOWZjMGY3L3RhYmxlcmFuZ2U6N2YzOWQ5M2Y0ZTQ2NGRlYTk3MjQ5M2U5ZWI5ZmMwZjdfMi0yLTEtMS0w_a072e4d1-37c9-4a6c-8df1-e3fa31e67335"
      unitRef="usd">226000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjdmMzlkOTNmNGU0NjRkZWE5NzI0OTNlOWViOWZjMGY3L3RhYmxlcmFuZ2U6N2YzOWQ5M2Y0ZTQ2NGRlYTk3MjQ5M2U5ZWI5ZmMwZjdfMy0yLTEtMS00MzY2Ng_ff371298-9c85-4995-9746-9a14ce5313e6"
      unitRef="usd">-2000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjdmMzlkOTNmNGU0NjRkZWE5NzI0OTNlOWViOWZjMGY3L3RhYmxlcmFuZ2U6N2YzOWQ5M2Y0ZTQ2NGRlYTk3MjQ5M2U5ZWI5ZmMwZjdfMy0yLTEtMS0w_721bf30a-ec74-4b76-834b-c2b688575503"
      unitRef="usd">8332000000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTMwMQ_77a8ce25-3e57-4319-8ec4-808a89c47fbd">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - axicabtagene ciloleucel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Trodelvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Hepcludex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,936)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)(2)(3)(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,936)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes $910&#160;million reclassified from indefinite-lived assets - IPR&amp;amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes Trodelvy for metastatic triple-negative breast cancer which was granted approval by FDA in April 2021 and Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer (&#x201c;UC&#x201d;) which was granted accelerated approval by FDA in April 2021. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&amp;amp;D.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes $1.2&#160;billion recognized from the first quarter 2021 acquisition of MYR. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;(4) &#160;&#160;&#160;&#160;In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200&#160;million will be reclassified to finite-lived assets in the fourth quarter of 2021.</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTMyNg_0867a553-f68f-46aa-9076-ca485dad69f1">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - axicabtagene ciloleucel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Trodelvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Hepcludex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,936)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)(2)(3)(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,936)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes $910&#160;million reclassified from indefinite-lived assets - IPR&amp;amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes Trodelvy for metastatic triple-negative breast cancer which was granted approval by FDA in April 2021 and Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer (&#x201c;UC&#x201d;) which was granted accelerated approval by FDA in April 2021. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&amp;amp;D.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes $1.2&#160;billion recognized from the first quarter 2021 acquisition of MYR. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;(4) &#160;&#160;&#160;&#160;In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200&#160;million will be reclassified to finite-lived assets in the fourth quarter of 2021.</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id248063645c14c6ca92fb1d761be74e4_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy0yLTEtMS0w_622ef743-28b8-43f6-a0de-f583170859a1"
      unitRef="usd">10720000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id248063645c14c6ca92fb1d761be74e4_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy00LTEtMS0w_c380de85-d518-42a8-b3b6-4572886f62f7"
      unitRef="usd">5477000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="id248063645c14c6ca92fb1d761be74e4_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy02LTEtMS0w_4ae80c0a-2e4f-47f2-8528-ffafb8c5e393"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id248063645c14c6ca92fb1d761be74e4_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy04LTEtMS0w_aa9bf4a8-23de-4f60-917b-a62975a11eb4"
      unitRef="usd">5243000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ice9f0c8cd2fc4c7ebfd9c7829f4948e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy0xMC0xLTEtMA_7fcb136c-6f61-455b-91d8-bf89c34dae4b"
      unitRef="usd">10720000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ice9f0c8cd2fc4c7ebfd9c7829f4948e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy0xMi0xLTEtMA_99c6d91a-c57d-4f31-9eca-72a597aa44f2"
      unitRef="usd">4952000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ice9f0c8cd2fc4c7ebfd9c7829f4948e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy0xNC0xLTEtMA_33253e19-ef25-482a-a60e-410718b5d116"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ice9f0c8cd2fc4c7ebfd9c7829f4948e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMy0xNi0xLTEtMA_2b477c04-11b3-48e5-80aa-efe9009d3271"
      unitRef="usd">5768000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ica281eb0ea274e8fbe28117ec9397184_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC0yLTEtMS0w_a978eac3-13eb-4ce9-a00e-37ded6947195"
      unitRef="usd">7110000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ica281eb0ea274e8fbe28117ec9397184_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC00LTEtMS0w_6ce90776-165c-4896-82dd-7785eb4eb1e0"
      unitRef="usd">1400000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ica281eb0ea274e8fbe28117ec9397184_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC02LTEtMS0w_121bc20b-13a5-44c0-a7ce-abc99094c090"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ica281eb0ea274e8fbe28117ec9397184_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC04LTEtMS0w_46dd2a5a-97d1-41be-b0fb-e2c02c3b4185"
      unitRef="usd">5710000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i423d39bed9384081904c47d75b0d641a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC0xMC0xLTEtMA_d9b92008-c6b2-4a35-9a50-8718e8067c04"
      unitRef="usd">6200000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i423d39bed9384081904c47d75b0d641a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC0xMi0xLTEtMA_b091e7d1-66d6-4ec4-8b6b-5c289f95fa0d"
      unitRef="usd">1105000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i423d39bed9384081904c47d75b0d641a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC0xNC0xLTEtMA_52870a4c-80dc-465d-86e6-5308a6f5bd73"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i423d39bed9384081904c47d75b0d641a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNC0xNi0xLTEtMA_de596e4d-f744-4448-af19-278c01ea57da"
      unitRef="usd">5095000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0a0f810172a14dfaa8af6a1edfc4646b_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS0yLTEtMS0w_ae4776ed-376b-4c77-973f-bbf7c11c4e2e"
      unitRef="usd">5630000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0a0f810172a14dfaa8af6a1edfc4646b_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS00LTEtMS0w_6f1c690b-a287-4519-bda3-6588cfb45b63"
      unitRef="usd">390000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i0a0f810172a14dfaa8af6a1edfc4646b_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS02LTEtMS0w_37578846-a169-4ec8-bc7f-82c346e80ec3"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0a0f810172a14dfaa8af6a1edfc4646b_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS04LTEtMS0w_8fee6984-01a6-4006-ac27-5925f8afcdc7"
      unitRef="usd">5240000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i25358862393f4ca4b14b4364da42d681_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS0xMC0xLTEtMA_5092764b-4ba2-4e8c-8fbc-96d6aa43a253"
      unitRef="usd">4600000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i25358862393f4ca4b14b4364da42d681_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS0xMi0xLTEtMA_36986866-f8cb-4a65-955b-90f426be9bf8"
      unitRef="usd">63000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i25358862393f4ca4b14b4364da42d681_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS0xNC0xLTEtMA_23f513f9-06c4-4e62-bef2-8938494cfc55"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i25358862393f4ca4b14b4364da42d681_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNS0xNi0xLTEtMA_46ceb507-e56a-48f2-98c1-f514488aac99"
      unitRef="usd">4537000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie35fe5b3532249fbaa1d215c6cea8f90_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi0yLTEtMS0w_c84e5061-87d8-4107-8fc0-0d631d30a470"
      unitRef="usd">845000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie35fe5b3532249fbaa1d215c6cea8f90_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi00LTEtMS0w_c903705b-10d6-4d7c-a163-56e9c2f9ccc5"
      unitRef="usd">50000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ie35fe5b3532249fbaa1d215c6cea8f90_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi02LTEtMS0w_aab64039-b1a8-49be-895c-39759b27f695"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie35fe5b3532249fbaa1d215c6cea8f90_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi04LTEtMS0w_316acc1b-7b7d-4baf-8618-1a4c481684cc"
      unitRef="usd">795000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3a065190f73644d7a438667b54161f4e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi0xMC0xLTEtMA_c606766e-cf00-4ae2-8ace-637b0b9db05a"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3a065190f73644d7a438667b54161f4e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi0xMi0xLTEtMA_37d68411-30ef-4ef2-b925-d76c505691ee"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i3a065190f73644d7a438667b54161f4e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi0xNC0xLTEtMA_451004f3-c7ae-4856-873e-dbe4ee340b6d"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3a065190f73644d7a438667b54161f4e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNi0xNi0xLTEtMA_4053643f-726e-45d4-82d7-900f25c77e72"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i26cf0458992d429ba5ed5fb92c5a2436_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy0yLTEtMS0w_95f289ac-893f-4d16-a51c-79a590d94f7e"
      unitRef="usd">1410000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i26cf0458992d429ba5ed5fb92c5a2436_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy00LTEtMS0w_a8f59efc-4d2b-4b2d-9c7e-8b506729cf60"
      unitRef="usd">619000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i26cf0458992d429ba5ed5fb92c5a2436_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy02LTEtMS0w_d8f79cca-1cf6-4517-b766-39ffa00b83e8"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i26cf0458992d429ba5ed5fb92c5a2436_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy04LTEtMS0w_314a7ab9-3851-4cec-bf86-05d44474d690"
      unitRef="usd">792000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5a12c46bb79a4f2797fb774367f4f73d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy0xMC0xLTEtMA_38be9613-0d7c-4f07-b0ef-d1f785f75a52"
      unitRef="usd">1377000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5a12c46bb79a4f2797fb774367f4f73d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy0xMi0xLTEtMA_ed3db778-6883-4167-81d8-85c56cc1b28d"
      unitRef="usd">540000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i5a12c46bb79a4f2797fb774367f4f73d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy0xNC0xLTEtMA_45aa79c1-6892-4d92-9840-0fdd48812a47"
      unitRef="usd">-1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5a12c46bb79a4f2797fb774367f4f73d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfNy0xNi0xLTEtMA_db75dee4-4695-4f94-bfc2-07b90fca4d0c"
      unitRef="usd">836000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC0yLTEtMS0w_68431871-f8b6-46f7-a6f5-47aa538d2683"
      unitRef="usd">25715000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC00LTEtMS0w_d8b2882b-0c5c-47e8-a90c-5db33d9eb6c2"
      unitRef="usd">7936000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC02LTEtMS0w_edecbfc4-c699-4285-ae15-d2063c9068e1"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC04LTEtMS0w_98e06492-86ab-49f7-b4f2-1216decfb930"
      unitRef="usd">17780000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC0xMC0xLTEtMA_bd37e552-1f21-4507-a1c0-d79451d69e1a"
      unitRef="usd">22897000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC0xMi0xLTEtMA_bb5a72d3-987f-4e57-95da-44abe01f5b0f"
      unitRef="usd">6660000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC0xNC0xLTEtMA_6a8b10d1-054e-4636-9371-0d16988812b3"
      unitRef="usd">-1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOC0xNi0xLTEtMA_1bf91b7f-c8eb-4ce2-967b-82c27b5c07a8"
      unitRef="usd">16236000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i1922554024b64cb8898c1f3fd434e8da_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOS0yLTEtMS0w_74bdd178-aae8-49c2-b320-a797ec2ad561"
      unitRef="usd">16120000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i1922554024b64cb8898c1f3fd434e8da_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOS02LTEtMS0w_113a9426-1a99-4500-819d-d36b2df18497"
      unitRef="usd">0</gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i1922554024b64cb8898c1f3fd434e8da_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOS04LTEtMS0w_9c2da3ac-3de3-4659-be96-ff8960cfbb79"
      unitRef="usd">16120000000</gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i969a0f7a4e6f4d7bb52b87c7b652a57b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOS0xMC0xLTEtMA_de1d9606-d6f4-4426-a735-b38cd916ab40"
      unitRef="usd">16890000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i969a0f7a4e6f4d7bb52b87c7b652a57b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOS0xNC0xLTEtMA_c9fb8c42-18c2-417e-b1e3-79a3ce48ee97"
      unitRef="usd">0</gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i969a0f7a4e6f4d7bb52b87c7b652a57b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfOS0xNi0xLTEtMA_9b38fdaa-4809-4de1-9ced-b0c86925b6f3"
      unitRef="usd">16890000000</gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtMi0xLTEtMA_6200c553-5ccd-4d6c-8f00-4a9b1a0dc219"
      unitRef="usd">41835000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtNC0xLTEtMA_e31c20f5-8932-4b8d-bfce-bdebf0cdd803"
      unitRef="usd">7936000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtNi0xLTEtMA_34960785-2fbf-4744-8e81-2a89ee4234ce"
      unitRef="usd">1000000</gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtOC0xLTEtMA_56d91385-2a51-4a9e-ad06-7dcb3c6a7181"
      unitRef="usd">33900000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtMTAtMS0xLTA_f5d8a00b-1edd-4ca5-bac6-b74f4a6a241f"
      unitRef="usd">39787000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtMTItMS0xLTA_5bee9620-ea19-45ea-94c1-0b3a1d7809d0"
      unitRef="usd">6660000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtMTQtMS0xLTA_78502d46-0c4b-4511-88ee-45656a40996b"
      unitRef="usd">-1000000</gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOjhjOTczYzU4OTUxNTRkMmNiMTQ4MGYwMzljZjQ5NTY0L3RhYmxlcmFuZ2U6OGM5NzNjNTg5NTE1NGQyY2IxNDgwZjAzOWNmNDk1NjRfMTAtMTYtMS0xLTA_16774e51-12c7-4ef3-a480-ad484f3d72f0"
      unitRef="usd">33126000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="i097e3a84fba5476487ee41ea9a26f8b0_D20210301-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMjM5_e2349b07-11ed-4e62-9034-f5ec580d856d"
      unitRef="usd">910000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="i58f39982e7154710a0e9bffb98d87c09_D20210301-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMjM5_fd546713-d978-421b-bd8d-78c969c7c1b4"
      unitRef="usd">-910000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="i186934b8fe964624a8c713e57b5bc48a_D20210401-20210430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfNzE2_3bebf781-8c50-4b54-8629-661007c1fcf5"
      unitRef="usd">-1000000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="i0f1396f1bd31451bb640de4f9f3638b4_D20210401-20210430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfNzE2_6ffae4e9-57f1-4190-8156-0a7daef8b677"
      unitRef="usd">1000000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i5af10497a26b467daee57d68cbd93a36_I20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfODgw_ec12cd6d-954f-4d0c-936b-ca7487b3ac12"
      unitRef="usd">1200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="ic84bc582b1d04652bd6754bb4901989d_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfNDM5ODA0NjUxMzMyMg_a39f5d69-a335-429e-b049-579685f3834c"
      unitRef="usd">200000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="i856f386d4aa44a00a2c20f4010d3fbc5_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfNDM5ODA0NjUxMzMyMg_f2e1aa22-7f2b-41e8-a100-a6201ff45e79"
      unitRef="usd">-200000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTA1OQ_94a2d68a-b35c-4b19-8825-5b9b903deb9c"
      unitRef="usd">441000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTA2Ng_b9b5aba8-0b6a-4506-8efa-2e58c3cca9bd"
      unitRef="usd">1300000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTA4NA_23de5dc7-9551-474c-b32a-3dc388fb30a2"
      unitRef="usd">281000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTA5MQ_8dcafd44-809d-4f31-a260-12b198acb7c7"
      unitRef="usd">844000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RleHRyZWdpb246ZTc1NjFhZTY2MGI0NDdjZGIxMDQzNGNmNjJlN2YwOTdfMTMxNw_92386bb6-b4e7-47db-9445-e721966c2cac">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOmIzNDBjZGYzMzEwYTRhMTZiNzI1YzA3M2E2YzcxYzY1L3RhYmxlcmFuZ2U6YjM0MGNkZjMzMTBhNGExNmI3MjVjMDczYTZjNzFjNjVfMS0yLTEtMS0w_56d39ad6-83bb-4fc5-9e00-bf69d59f1010"
      unitRef="usd">441000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOmIzNDBjZGYzMzEwYTRhMTZiNzI1YzA3M2E2YzcxYzY1L3RhYmxlcmFuZ2U6YjM0MGNkZjMzMTBhNGExNmI3MjVjMDczYTZjNzFjNjVfMi0yLTEtMS0w_3fbc5fe9-746a-4b12-9783-09985ef04c08"
      unitRef="usd">1764000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOmIzNDBjZGYzMzEwYTRhMTZiNzI1YzA3M2E2YzcxYzY1L3RhYmxlcmFuZ2U6YjM0MGNkZjMzMTBhNGExNmI3MjVjMDczYTZjNzFjNjVfMy0yLTEtMS0w_77cb31c4-59c2-4100-babe-dbbc94ea6348"
      unitRef="usd">1764000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOmIzNDBjZGYzMzEwYTRhMTZiNzI1YzA3M2E2YzcxYzY1L3RhYmxlcmFuZ2U6YjM0MGNkZjMzMTBhNGExNmI3MjVjMDczYTZjNzFjNjVfNC0yLTEtMS0w_176025c9-8b7a-4bf9-857c-4670ff5a975e"
      unitRef="usd">1764000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOmIzNDBjZGYzMzEwYTRhMTZiNzI1YzA3M2E2YzcxYzY1L3RhYmxlcmFuZ2U6YjM0MGNkZjMzMTBhNGExNmI3MjVjMDczYTZjNzFjNjVfNS0yLTEtMS0w_532cad19-bb13-4dfc-90c3-934c2c2900c3"
      unitRef="usd">1759000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <gild:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOmIzNDBjZGYzMzEwYTRhMTZiNzI1YzA3M2E2YzcxYzY1L3RhYmxlcmFuZ2U6YjM0MGNkZjMzMTBhNGExNmI3MjVjMDczYTZjNzFjNjVfNi0yLTEtMS0w_907ba036-9e68-493d-9650-88800e8ab4a0"
      unitRef="usd">10288000000</gild:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81Mi9mcmFnOmU3NTYxYWU2NjBiNDQ3Y2RiMTA0MzRjZjYyZTdmMDk3L3RhYmxlOmIzNDBjZGYzMzEwYTRhMTZiNzI1YzA3M2E2YzcxYzY1L3RhYmxlcmFuZ2U6YjM0MGNkZjMzMTBhNGExNmI3MjVjMDczYTZjNzFjNjVfNy0yLTEtMS0w_46a76cee-a6fe-4b90-bcaf-9466061114b7"
      unitRef="usd">17780000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RleHRyZWdpb246NDkyYWU5MmYwNTE2NDk2MmJiZjFlNWQwOTc1N2NlNDBfMTgy_85d31900-b3b2-4159-aa32-470c7d727f8d">OTHER FINANCIAL INFORMATION&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Accounts receivable, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash discounts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Inventories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued and other current liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of Accrued and other current liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RleHRyZWdpb246NDkyYWU5MmYwNTE2NDk2MmJiZjFlNWQwOTc1N2NlNDBfMTcw_670b7f14-83a1-4e9f-959c-7cb583c023ca">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Accounts receivable, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash discounts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfMS0yLTEtMS0w_6ab108a9-23d2-4629-9ce8-8a1b66d4b5e4"
      unitRef="usd">5284000000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfMS00LTEtMS0w_58587882-d19f-4e61-aee5-1a4d3a35822b"
      unitRef="usd">5560000000</us-gaap:AccountsReceivableGrossCurrent>
    <gild:AccountsReceivableChargebacksCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfMi0yLTEtMS0w_f116518f-505f-4104-95ca-e3851137d675"
      unitRef="usd">591000000</gild:AccountsReceivableChargebacksCurrent>
    <gild:AccountsReceivableChargebacksCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfMi00LTEtMS0w_e834391b-2f05-448f-bbf7-984ce4a4e524"
      unitRef="usd">552000000</gild:AccountsReceivableChargebacksCurrent>
    <gild:AccountsReceivableCashDiscountsAndOtherCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfMy0yLTEtMS0w_ee371d81-7da4-48bb-aa60-00bbc0d3c043"
      unitRef="usd">70000000</gild:AccountsReceivableCashDiscountsAndOtherCurrent>
    <gild:AccountsReceivableCashDiscountsAndOtherCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfMy00LTEtMS0w_09a3b71d-ee6a-4890-9c27-fb223c36a06d"
      unitRef="usd">72000000</gild:AccountsReceivableCashDiscountsAndOtherCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfNC0yLTEtMS0w_c0fae8e0-8c06-4b0e-a525-884c28009efd"
      unitRef="usd">57000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfNC00LTEtMS0w_5328d074-a115-4dcd-8885-98dbcb730386"
      unitRef="usd">44000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfNS0yLTEtMS0w_feef9abe-7e42-4662-8789-bda82b61da6d"
      unitRef="usd">4566000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjg2YmMwODI0ZGQ4ZjQ1Njk5NjgzYzdhZWZkMzIwOGQxL3RhYmxlcmFuZ2U6ODZiYzA4MjRkZDhmNDU2OTk2ODNjN2FlZmQzMjA4ZDFfNS00LTEtMS0w_5c435cb5-00ef-4e95-ae02-1dcb57e60b66"
      unitRef="usd">4892000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RleHRyZWdpb246NDkyYWU5MmYwNTE2NDk2MmJiZjFlNWQwOTc1N2NlNDBfMTc4_50d3928e-dc9e-41b4-afca-dab86041371a">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Inventories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfMS0yLTEtMS0w_f3a326ca-58aa-4281-8dce-04e281afc57f"
      unitRef="usd">1067000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfMS00LTEtMS0w_bfb91f96-4705-4f0c-b02b-46e0ff857154"
      unitRef="usd">1080000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfMi0yLTEtMS0w_ca8f8a35-329b-4bdc-92a3-ddaddbb2a3d7"
      unitRef="usd">727000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfMi00LTEtMS0w_d4cddbca-681b-4d2e-a1d4-46997e220507"
      unitRef="usd">976000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfMy0yLTEtMS0w_66b508e5-9356-4c28-925f-f177b38dbd0e"
      unitRef="usd">1003000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfMy00LTEtMS0w_41a038cb-c661-400a-a47f-f89819331305"
      unitRef="usd">958000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfNC0yLTEtMS0w_31f3ff0b-7490-47d4-8d64-42e9356ece17"
      unitRef="usd">2797000000</gild:InventoryNetAndInventoryNoncurrent>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfNC00LTEtMS0w_ceb38397-c8f9-497f-a66e-1b99324b2f11"
      unitRef="usd">3014000000</gild:InventoryNetAndInventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfNy0yLTEtMS0w_bc51ffc9-f735-4f79-8b58-86e21905abcf"
      unitRef="usd">1676000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfNy00LTEtMS0w_cbeb2af3-d33e-419a-bcd2-ac8b0035de6d"
      unitRef="usd">1683000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfOC0yLTEtMS0w_58500feb-2114-4687-b7d5-50f1cc09ff95"
      unitRef="usd">1121000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfOC00LTEtMS0w_91ebfb20-7513-4cdc-a0c6-9878907c94f4"
      unitRef="usd">1331000000</us-gaap:InventoryNoncurrent>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfOS0yLTEtMS0w_62d482e8-a509-4e2c-a897-f1a801a8657d"
      unitRef="usd">2797000000</gild:InventoryNetAndInventoryNoncurrent>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOjJkOGQ2MmJhOTM2NTRhMDdiMGQ1NGIyYTI0ZGQ5YTI4L3RhYmxlcmFuZ2U6MmQ4ZDYyYmE5MzY1NGEwN2IwZDU0YjJhMjRkZDlhMjhfOS00LTEtMS0w_29b71856-973a-4ec9-96c5-2119006a91dc"
      unitRef="usd">3014000000</gild:InventoryNetAndInventoryNoncurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RleHRyZWdpb246NDkyYWU5MmYwNTE2NDk2MmJiZjFlNWQwOTc1N2NlNDBfMTc2_4950a390-d634-4c73-99b8-10d5a4518ed9">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of Accrued and other current liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfMS0yLTEtMS0w_7121eb3b-c32a-47aa-b12c-d6b6eda53dfd"
      unitRef="usd">691000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfMS00LTEtMS0w_281e8a52-c2ad-4c11-af4b-e160bbcd2448"
      unitRef="usd">864000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfMi0yLTEtMS0w_d4d69b60-670a-4bc8-b48b-c0d59f0c7606"
      unitRef="usd">447000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfMi00LTEtMS0w_e44da9a4-210c-47b8-b791-12df86267e3a"
      unitRef="usd">598000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfMy0yLTEtMS0w_68780428-dbd7-41a8-8981-f6dd73528cd6"
      unitRef="usd">530000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfMy00LTEtMS0w_dd8eef50-6ce9-4718-bef3-3d2598afec17"
      unitRef="usd">587000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfNC0yLTEtMS0w_dc311bb3-48cb-4f4a-858b-1361580ea864"
      unitRef="usd">2113000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfNC00LTEtMS0w_1a916dd4-05e3-4a13-a3f9-2444467a8b00"
      unitRef="usd">2287000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfNS0yLTEtMS0w_507fdb3b-3f8b-4973-a168-febc2f56a800"
      unitRef="usd">3781000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81NS9mcmFnOjQ5MmFlOTJmMDUxNjQ5NjJiYmYxZTVkMDk3NTdjZTQwL3RhYmxlOmI1N2Y0ZTE1NDRmNjRjZjZhODhlNTRjNjI1MTA2ZDcyL3RhYmxlcmFuZ2U6YjU3ZjRlMTU0NGY2NGNmNmE4OGU1NGM2MjUxMDZkNzJfNS00LTEtMS0w_2bc9b3c2-f675-4026-8037-92d58b4f5e75"
      unitRef="usd">4336000000</us-gaap:AccruedLiabilitiesCurrent>
    <gild:CollaborativeAndOtherArrangementsTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNzA1NA_3c16ebb6-74ad-4984-bca6-6e3fb65fa52b">COLLABORATIONS AND OTHER ARRANGEMENTS&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continue to pursue licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements and cost-sharing arrangements. We also continue to pursue equity investments in third parties focused on the development and commercialization of products and product candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Merck Sharp &amp;amp; Dohme Corp. (&#x201c;Merck&#x201d;) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 13, 2021, we entered into a license and collaboration agreement with Merck, a subsidiary of Merck &amp;amp; Co., Inc. to jointly develop and commercialize long-acting investigational treatments in HIV that combine Gilead&#x2019;s investigational capsid inhibitor, lenacapavir, and Merck&#x2019;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The collaboration will initially focus on long-acting oral and injectable formulations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Gilead and Merck will share global development and commercialization costs at 60% and 40%, respectively, across the oral and injectable formulation programs. For long-acting oral products, Gilead will lead commercialization in the United States, and Merck will lead commercialization in the European Union (&#x201c;EU&#x201d;) and rest of the world. For long-acting injectable products, Merck will lead commercialization in the United States and Gilead will lead commercialization in the EU and rest of the world. Gilead and Merck will jointly promote the combination products in the United States and certain other major markets. We will share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $2.0 billion in net product sales for the oral combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Upon passing $3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Reimbursements of research and development costs to or from Merck are recorded within Research and development expenses on our Condensed Consolidated Statements of Operations. Expenses recognized under the agreement were not material for the three and nine months ended September 30, 2021. No revenues have been recognized under the agreement for the three and nine months ended September 30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will also have the option to license certain of Merck&#x2019;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#x2019;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for such investigational oral integrase inhibitor of the other company within the first five years after execution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt-out, in which case the non-exercising company will be paid a royalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Arcus&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On&#160;May 27, 2020, we entered into a transaction with Arcus, which included entry into an option, license and collaboration agreement (the &#x201c;Collaboration Agreement&#x201d;) and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended the &#x201c;Stock Purchase Agreements&#x201d;). Under the Stock Purchase Agreements, we have the right to purchase additional shares of Arcus from Arcus over the five-year period beginning on the closing of the Stock Purchase Agreements, up to a maximum of 35% of the outstanding voting stock. We are subject to a three-year standstill, which period began on the date the parties entered into the Stock Purchase Agreements, restricting our ability to acquire voting stock of Arcus exceeding more than 35% of the then issued and outstanding voting stock of Arcus, subject to certain exceptions. Additionally, we agreed not to dispose of any equity securities of Arcus prior to the second anniversary of the closing of the Stock Purchase Agreements without the prior consent of Arcus, subject to certain exceptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Collaboration Agreement and Stock Purchase Agreements which closed on July 13, 2020, and a separate secondary equity offering which closed on May 29, 2020, we acquired approximately 8.2&#160;million shares of Arcus common stock for approximately $261 million. In the first quarter of 2021, we amended and restated the common stock purchase agreement and acquired approximately 5.7&#160;million additional shares of Arcus common stock for $220 million. As a result, we currently own a total of 13.8&#160;million shares of Arcus, which represented approximately 19.5% of the issued and outstanding voting stock of Arcus immediately following the closing of the first quarter 2021 transaction. The amendment and restatement of the common stock purchase agreement in the first quarter of 2021 did not modify any of the terms above. We elected and applied the fair value option to account for our equity investment in Arcus whereby the investment is marked to market each reporting period based on the market price of Arcus shares. We believe the fair value option best reflects the underlying economics of the investment. Changes in fair value of the investment are recognized in Other income (expense), net on our Condensed Consolidated Statements of Operations. We initially recorded our equity investments in Arcus in Other long-term assets on our Condensed Consolidated Balance Sheets as the investments are subject to contractual lock-up provisions, subject to certain conditions. In the third quarter of 2021, we reclassified our equity investments in Arcus to Prepaid and other current assets on our Condensed Consolidated Balance Sheets as the contractual lock-up provisions will expire in July 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2021 and 2020, we entered into several collaborations, equity investments and licensing arrangements as well as other similar arrangements that we do not consider to be individually material. We recorded upfront collaboration expenses related to these arrangements within Acquired in-process research and development expenses on our Condensed Consolidated Statements of Operations. Upfront collaboration expenses and cash payments made related to our equity investments were not material for the three and nine months ended September 30, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the financial terms of these arrangements, we may be required to make payments upon achievement of developmental, regulatory and commercial milestones, which could be significant. Future milestone payments, if any, will be reflected in our Condensed Consolidated Statements of Operations when the corresponding events become probable. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.&lt;/span&gt;&lt;/div&gt;</gild:CollaborativeAndOtherArrangementsTextBlock>
    <gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts
      contextRef="i199d5ca3470540be922bc9d2707767c8_D20210313-20210313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMTU1Nw_8ec3e7a7-4713-4436-a2c1-0d180a734c80"
      unitRef="number">0.60</gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts>
    <gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts
      contextRef="ida214684d6f748fa94820133c41fb9cb_D20210313-20210313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMTU2NA_7bee1148-f1cd-4c8a-b132-1c8741f49928"
      unitRef="number">0.40</gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts>
    <gild:CollaborationArrangementNetProductSalesThreshold
      contextRef="ic4b2d0d8fb10491f844ccbf3c9d99659_D20210313-20210313"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMjI0OA_5626ef65-4f37-41a2-ac15-94577b1786df"
      unitRef="usd">2000000000</gild:CollaborationArrangementNetProductSalesThreshold>
    <gild:CollaborationArrangementPercentOfGlobalProductRevenues
      contextRef="ic4b2d0d8fb10491f844ccbf3c9d99659_D20210313-20210313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMjM2MQ_ac37e8ab-b5d5-4327-8bb4-306cd41e51bf"
      unitRef="number">0.65</gild:CollaborationArrangementPercentOfGlobalProductRevenues>
    <gild:CollaborationArrangementNetProductSalesThreshold
      contextRef="i7a7ea0a008d44d19aeaba7ea8a234a79_D20210313-20210313"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMjQzOA_1674c010-a517-4705-beb5-0b983cbac56a"
      unitRef="usd">3500000000</gild:CollaborationArrangementNetProductSalesThreshold>
    <gild:CollaborationArrangementPercentOfGlobalProductRevenues
      contextRef="i7a7ea0a008d44d19aeaba7ea8a234a79_D20210313-20210313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMjU1Nw_f66cf751-4879-44a0-86fc-6f2481ffc25e"
      unitRef="number">0.65</gild:CollaborationArrangementPercentOfGlobalProductRevenues>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i4fbddaa5defd43eda896eb3f45f893de_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMjc5MQ_314326bf-2e2c-4123-ab7d-d8241d586f35"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i94b469d6b3cb4b1cae15cc21665e0bbb_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfMjc5MQ_4f45d141-f322-40ec-946c-8dc676733b94"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <gild:CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod
      contextRef="i199d5ca3470540be922bc9d2707767c8_D20210313-20210313"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNzA1Mg_03ce3192-5ddf-4f65-9109-b43fe4221574">P5Y</gild:CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod>
    <gild:EquitySecuritiesFVNIPurchasePeriod
      contextRef="idcb33e823a4c4f73a7d1f634b45cee94_D20200527-20200527"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxNw_50c0cb34-9b66-4ee4-83d7-02a63a2c68dd">P5Y</gild:EquitySecuritiesFVNIPurchasePeriod>
    <gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
      contextRef="i3878c6df63be4399a67430941e5732c7_D20200527-20200527"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDM5ODA0NjUyMTY1MQ_80297e8e-7d7a-4e8f-b24a-f846527c02db"
      unitRef="number">0.35</gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased>
    <gild:EquitySecuritiesFVNIRestrictionPeriod
      contextRef="idcb33e823a4c4f73a7d1f634b45cee94_D20200527-20200527"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOA_6e8ed4b8-28c4-4dcf-a456-a45845bec7b2">P3Y</gild:EquitySecuritiesFVNIRestrictionPeriod>
    <gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
      contextRef="i3878c6df63be4399a67430941e5732c7_D20200527-20200527"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDM5ODA0NjUyMTg5Mw_80297e8e-7d7a-4e8f-b24a-f846527c02db"
      unitRef="number">0.35</gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased>
    <gild:EquitySecuritiesFVNISharesAcquired
      contextRef="i7e4ffaa955f9435b9bf6dff41e50e726_D20200529-20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDEyOA_84b4779c-8141-4139-be1b-df8cfe9ca399"
      unitRef="shares">8200000</gild:EquitySecuritiesFVNISharesAcquired>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i7e4ffaa955f9435b9bf6dff41e50e726_D20200529-20200529"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDE3OA_900f9c6f-62cb-4fb1-9267-94cf15c27750"
      unitRef="usd">261000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <gild:EquitySecuritiesFVNISharesAcquired
      contextRef="i18ae4cc7725f4c96842b14bc9e4daf0e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDI5OQ_4ba40085-e890-45f2-a978-7c3f59f2aef7"
      unitRef="shares">5700000</gild:EquitySecuritiesFVNISharesAcquired>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i18ae4cc7725f4c96842b14bc9e4daf0e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDM0Ng_288aa44e-82d5-4e2c-b55a-b3c902547ade"
      unitRef="usd">220000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <gild:EquitySecuritiesFVNIShares
      contextRef="i48dadb586c444781b30fb3c1b0888939_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDM5MQ_fb8559bb-cd8c-4c3f-b095-f9bacff69edf"
      unitRef="shares">13800000</gild:EquitySecuritiesFVNIShares>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i819ce30a96d84a66915bb6c431c7a737_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNDQ0Mw_577a4625-f93d-4ba2-b576-4617f149add6"
      unitRef="number">0.195</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="iaeaa95ca088c4fe285e88b406cff5320_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_230e2a29-572b-4f33-983f-485ee1565b9f"
      unitRef="usd">0</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements
      contextRef="ibcaa35425c334e66adfe9c0143a54cc5_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_4864fd96-6cf2-4609-a984-cb113106e18a"
      unitRef="usd">0</gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements>
    <gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements
      contextRef="i36771d101b1945cd9d9de5fa0410171b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_4afdc8f0-68c2-4bda-b2e4-b79146dd9150"
      unitRef="usd">0</gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="i2084f6bcb60540018e9a4b1e4715c369_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_4dd2910b-9d1e-4c46-a0cd-c76486c9e9bd"
      unitRef="usd">0</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="ibcaa35425c334e66adfe9c0143a54cc5_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_5ae15d95-62a0-4380-b29f-3ddae755dff1"
      unitRef="usd">0</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="i36771d101b1945cd9d9de5fa0410171b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_723762d9-9781-4133-87df-a8c274ad643f"
      unitRef="usd">0</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements
      contextRef="iaeaa95ca088c4fe285e88b406cff5320_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_aed5f23f-9d19-43a6-8e88-c803a28206bc"
      unitRef="usd">0</gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements>
    <gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements
      contextRef="i2084f6bcb60540018e9a4b1e4715c369_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV81OC9mcmFnOjMyNDIzNWIwNjUzYTQwOTJiYzQ3NzE1YjMyMzZlNTkzL3RleHRyZWdpb246MzI0MjM1YjA2NTNhNDA5MmJjNDc3MTViMzIzNmU1OTNfNTQ5NzU1ODE1MDgxOQ_de793d99-d8a9-4285-bb54-1b0169f5f8f0"
      unitRef="usd">0</gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfOTgy_4d0a2862-0163-4fab-8342-2cf4ab1c9f0e">DEBT AND CREDIT FACILITIES&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of our borrowings under various financing arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.52%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;variable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior unsecured notes and term loan facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt and other obligations, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2021, we repaid $3.75 billion of debt. We repaid $1.0 billion of senior unsecured notes due April 2021 in the first quarter of 2021 and $1.25 billion of senior unsecured notes due December 2021 in the third quarter of 2021. Additionally, we repaid $1.0 billion principal amount outstanding under our three-year $1.0 billion senior unsecured term loan facility due October 2023 and $500 million of our senior unsecured floating rate notes due September 2021 upon maturity. In October 2021, we exercised our option to call $500 million of our floating rate senior unsecured notes and $500 million of our 0.75% senior unsecured notes, both having a final maturity of September 2023. The notes will be repaid in November 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No new debt was issued during the three and nine months ended September 30, 2021. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of September&#160;30, 2021, we were in compliance with all covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and December&#160;31, 2020, there were no amounts outstanding under our $2.5 billion revolving credit facility maturing in June 2025, and we were in compliance with all covenants.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfOTg5_5d00ecbd-bc9b-42b5-bb63-c14f26a1a2c0">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of our borrowings under various financing arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.52%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;variable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior unsecured notes and term loan facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt and other obligations, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i075533c7d37d491793ebc09f561f12c8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMi02LTEtMS0w_e3918455-da77-48ba-a933-83d228cf51ca"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i075533c7d37d491793ebc09f561f12c8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMi04LTEtMS0w_ad1cea55-439a-4cc0-8adb-ee7c0c48ff01"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1beee1ec406146d38e3211fa2933708d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMi0xMC0xLTEtMA_b9b1502b-a5e6-463d-819d-4a2b719c73cb"
      unitRef="usd">1000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i43c2519105dc4bfdb185e7ebc59a5a2a_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMy02LTEtMS0wL3RleHRyZWdpb246YmY3YmNjZTNjNmZkNDQ3YmFmMDU2YTQyMTJiZjM2MDhfMjA_26bb615f-31f1-4036-a1e9-5ed6c7628c5a"
      unitRef="number">0.0015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i7b6417210f0c45cab95af5ede847f506_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMy04LTEtMS0w_a37e2541-280f-4168-98cc-0879d9e86925"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic250ebc316ec45b1bbe84636770ce814_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMy0xMC0xLTEtMA_e1f1ea24-7717-4b16-87a8-c921f765fe46"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5a816c3a555a4fa08e58b54a04015ffb_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNC02LTEtMS0w_08e4c8f2-b66f-4503-88b8-26405e0e3138"
      unitRef="number">0.0440</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i5a816c3a555a4fa08e58b54a04015ffb_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNC04LTEtMS0w_8587bdbc-482c-4bb8-8ee0-07ea1aa35632"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie2fd7afacc2446fdb2b73b021c7ec4c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNC0xMC0xLTEtMA_6e1deb4c-6d6a-41cd-86f5-d2883262328a"
      unitRef="usd">1249000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4c2641db1ef947ebb5c2e598d80af8b7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNS02LTEtMS0w_cda0f8e4-c7c3-4751-a2a9-89a361589aaa"
      unitRef="number">0.0195</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i4c2641db1ef947ebb5c2e598d80af8b7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNS04LTEtMS0w_bae7f328-57c5-4135-a289-a413975fee3c"
      unitRef="usd">500000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i047f7d6efaab4949ba75985dec2bd448_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNS0xMC0xLTEtMA_0717004b-c700-41bd-b07b-6cb708bc9f04"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0b207ad1f4604e47bf243a142f719c3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNi02LTEtMS0w_fa45a78b-5932-46bf-b4df-648b45c75da5"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i0b207ad1f4604e47bf243a142f719c3d_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNi04LTEtMS0w_70778c1d-9c2d-42e6-b201-515d0fe648a3"
      unitRef="usd">999000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ide3713760e2f406f87de6a771c56330c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNi0xMC0xLTEtMA_ec19a8f7-fbe1-45d9-8f47-0255beaf62a3"
      unitRef="usd">998000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i378aa93017824e3e9bd151f32b47c054_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNy02LTEtMS0w_5650ad9d-fff8-4ac6-86b7-b648d05c4f67"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i378aa93017824e3e9bd151f32b47c054_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNy04LTEtMS0w_b42d6dcb-b4dd-44db-911c-186b99f1bb8f"
      unitRef="usd">748000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4ebf78ad2ccb4d43a991df3fd307bba9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfNy0xMC0xLTEtMA_c8c9f3af-f828-40b4-b758-3ce5f73dfa35"
      unitRef="usd">748000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iafda4276088e42e3a214977fd3664e77_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfOC02LTEtMS0wL3RleHRyZWdpb246NTE3MjRhNDhkYTY5NDZhN2I5YjdmYWJiYjk3YjU4N2JfMjA_11c3cd05-aa5a-4c84-99f4-3ddc5bf5b4b4"
      unitRef="number">0.0052</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="ie2c0f1bb661849bbafaaac95aa413df7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfOC04LTEtMS0w_b59c7e54-9744-4340-a3d7-6c3efb710256"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i718060d949f64ee2b8c966d8822e9de3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfOC0xMC0xLTEtMA_4195f8d2-ec90-40c0-a31b-5da10847dd9b"
      unitRef="usd">498000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icd18b3372b0d4339ba7e932b3bcfb631_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfOS02LTEtMS0w_a19f5428-c8d3-4365-b5f6-1b350883b415"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icd18b3372b0d4339ba7e932b3bcfb631_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfOS02LTEtMS0w_cfde161c-af6b-4d9e-b9f7-cdf45873ab25"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="icd18b3372b0d4339ba7e932b3bcfb631_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfOS04LTEtMS0w_e134bb60-6cf6-4183-9509-b48b388790c7"
      unitRef="usd">1994000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3a673086504e43c08aba24aa7d8a2fb6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfOS0xMC0xLTEtMA_f7c78b88-a943-4367-a590-177394acb4b5"
      unitRef="usd">1992000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie39bf03ca3dd4c7eaf82c5f3247707e0_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTAtOC0xLTEtMA_2b85d003-8d3a-43e2-9bd6-8b7415a2fe5c"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i96e9697694914c628eb31495e561618f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTAtMTAtMS0xLTA_732d35b4-a941-4ccb-92b4-2b843f103843"
      unitRef="usd">998000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if73fdd4a8341456487fd2dedf6c2e9d7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTEtNi0xLTEtMA_020ecc61-0402-4246-9335-6f0838dbfbc2"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if73fdd4a8341456487fd2dedf6c2e9d7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTEtOC0xLTEtMA_3016ef49-9b85-4e1d-b844-d05b49417c75"
      unitRef="usd">1747000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i81c97bf760b64de9bbdde1c94a7b8ae2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTEtMTAtMS0xLTA_698a293f-9e8a-4651-a6c9-56174957cb28"
      unitRef="usd">1746000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id4ac5b7017d1476fb5bcd16b536f43e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTItNi0xLTEtMA_2041fab4-7d80-4816-89e6-45253b8350ec"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="id4ac5b7017d1476fb5bcd16b536f43e8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTItOC0xLTEtMA_262e2e94-e9a6-4268-93ca-c479416ff58d"
      unitRef="usd">1747000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ifb213534bbcd45118c1bb26b41e1e907_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTItMTAtMS0xLTA_10458695-92c1-4789-88ad-361159ec75da"
      unitRef="usd">1746000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia58159b24bd345179d097a8c8fa338da_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTMtNi0xLTEtMA_c2d1397c-3b06-4367-bf7c-a5daa9c74fbd"
      unitRef="number">0.0365</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ia58159b24bd345179d097a8c8fa338da_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTMtOC0xLTEtMA_5dff9b8e-617a-4b98-8c7a-beade7426bb0"
      unitRef="usd">2738000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6a046019e56c4f54b51b48b7aa1d9d88_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTMtMTAtMS0xLTA_e41173d6-937e-4d62-94d6-febdafb8a861"
      unitRef="usd">2737000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3836e4ff9f5545ad88927b7ccfe6ce9a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTQtNi0xLTEtMA_9968fd62-8a04-4fec-81b4-a2b01526495a"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i3836e4ff9f5545ad88927b7ccfe6ce9a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTQtOC0xLTEtMA_6f811084-c9eb-45a3-805c-37fed9ce4c0a"
      unitRef="usd">1246000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic4cd61c4d420435f8f8a47a822a2fb94_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTQtMTAtMS0xLTA_30779990-bec5-457c-a2db-3788306638f1"
      unitRef="usd">1246000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia75a4a1f883644e593643caeeb64e8c8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTUtNi0xLTEtMA_67cf099b-7794-4393-b848-bde3d82f7bfa"
      unitRef="number">0.0120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia75a4a1f883644e593643caeeb64e8c8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTUtNi0xLTEtMA_680adc62-f37b-45b4-8fe3-22800b24e12a"
      unitRef="number">0.0120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ia75a4a1f883644e593643caeeb64e8c8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTUtOC0xLTEtMA_0a5f424a-29bb-46e0-b370-065687292c5d"
      unitRef="usd">746000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i831cf307aaac48e3a4f36b76c1ae6821_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTUtMTAtMS0xLTA_d5bfbdbe-f3ae-40a2-84e3-0e2a0c85123a"
      unitRef="usd">745000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia606b7a94a2a4a27be3bac90bae27db7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTYtNi0xLTEtMA_784b6b86-615f-4745-97ba-eeb492e9ed28"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia606b7a94a2a4a27be3bac90bae27db7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTYtNi0xLTEtMA_aee01b7e-865a-4fcc-a6df-89db2317250a"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ia606b7a94a2a4a27be3bac90bae27db7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTYtOC0xLTEtMA_0056b7fc-30c3-44cd-ad6a-fe986d2d08b2"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i033466f65d06435daaf05ce68cdea42a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTYtMTAtMS0xLTA_581289e5-2554-4b62-b782-5a3976dd9512"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i26def8fc057343cea1511af0a42bbd82_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTctNi0xLTEtMA_450ef8a8-220c-438f-ab31-6c8ad15b2086"
      unitRef="number">0.0460</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i26def8fc057343cea1511af0a42bbd82_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTctOC0xLTEtMA_7ce38a0b-1c2f-4592-aa0a-14fe367b9f60"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i793861fc864b4d84a4d7675fd3879f56_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTctMTAtMS0xLTA_0a712125-574f-4083-95fe-a4ebb97e3dda"
      unitRef="usd">991000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i334415af3e3b4544a67d9d7fca63abc9_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTgtNi0xLTEtMA_2619a274-767e-4afd-a1c4-fcf5e1703f5f"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i334415af3e3b4544a67d9d7fca63abc9_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTgtOC0xLTEtMA_3b490209-e224-4bb6-a88a-b2c049520c3a"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iab18c39cd70d4664b5614e5d608d97f5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTgtMTAtMS0xLTA_f020a9a0-b20e-4361-a980-5b1dc96e24a7"
      unitRef="usd">741000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib3a50f56b0a243339131abb7a4e8302f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTktNi0xLTEtMA_44337804-1373-450a-ad1d-dcfc36d4191e"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib3a50f56b0a243339131abb7a4e8302f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTktNi0xLTEtMA_c125b541-5f91-4729-a8e0-3564caf008cb"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ib3a50f56b0a243339131abb7a4e8302f_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTktOC0xLTEtMA_456a5f01-5d93-4472-8d2e-39890a462859"
      unitRef="usd">987000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3aab6acda6824604a29d697a10699b89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMTktMTAtMS0xLTA_a50df14b-a3f9-4be6-9a53-f4e4abe81eef"
      unitRef="usd">986000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i56cf1e78acd541bf8bda7634c9734818_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjAtNi0xLTEtMA_db73d87d-75a2-44f6-80ad-96223cfe2381"
      unitRef="number">0.0565</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i56cf1e78acd541bf8bda7634c9734818_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjAtOC0xLTEtMA_0f957e67-0a5c-4249-8514-819cc9bc5dc0"
      unitRef="usd">996000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i2d8992e066ac492e96f9427867db1b37_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjAtMTAtMS0xLTA_ce21cfc5-e893-4250-bc51-0afd18671861"
      unitRef="usd">996000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id18ba93f1f954ea7825f560783159641_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjEtNi0xLTEtMA_f9907386-d43a-4452-9ead-154b726abb4c"
      unitRef="number">0.0480</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="id18ba93f1f954ea7825f560783159641_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjEtOC0xLTEtMA_37c2476d-eab8-4bf2-a28d-55de88e999fa"
      unitRef="usd">1736000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i47bdb44a5bf54303b2b1c5d712c9b5f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjEtMTAtMS0xLTA_031cc743-64b2-48b3-a389-8eafbda9cbe3"
      unitRef="usd">1735000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i69e5c28f892a4699b116990ce04af8d5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjItNi0xLTEtMA_c78fd149-3827-4680-9925-0baf7542ce86"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i69e5c28f892a4699b116990ce04af8d5_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjItOC0xLTEtMA_879e6d2b-6a04-4efa-bd4e-6e52b5837a3a"
      unitRef="usd">1733000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ida4a76b2bb9c486ab32b0ed960911667_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjItMTAtMS0xLTA_fab89540-0655-418b-bd58-8ca5b3217ae2"
      unitRef="usd">1732000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2c9e673628f24f989a48a76bc085f8ad_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjMtNi0xLTEtMA_7dc6a714-f6f5-4d9c-900c-8400614874b1"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i2c9e673628f24f989a48a76bc085f8ad_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjMtOC0xLTEtMA_c46e3517-3d99-4df6-85d7-c58052f0b63b"
      unitRef="usd">2220000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib475552eda99433d86c1a416ace1cc9a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjMtMTAtMS0xLTA_88a7212e-1964-4d3b-be0f-020db5700f1a"
      unitRef="usd">2219000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i063be5049ee1464b8b050a5513490bf2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjQtNi0xLTEtMA_8bb62e97-e120-44db-ad48-6fa9f37988a1"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i063be5049ee1464b8b050a5513490bf2_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjQtOC0xLTEtMA_5a159373-c121-49ea-a6fa-dcbed92c52cd"
      unitRef="usd">1727000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3282c94d1c174c6ea5efa7ab36b47b19_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjQtMTAtMS0xLTA_c5e51df7-055c-4d90-b165-118a52522fe4"
      unitRef="usd">1726000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if1bfce21e9994d52bbeedde558474519_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjUtNi0xLTEtMA_23e2a05a-2475-40c6-8939-f7d55e284767"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if1bfce21e9994d52bbeedde558474519_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjUtNi0xLTEtMA_ad9f6a4a-5636-4882-8e2e-3dd785d41ecb"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if1bfce21e9994d52bbeedde558474519_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjUtOC0xLTEtMA_e1f7d169-4b8f-45c2-95e7-0706cd16546d"
      unitRef="usd">1476000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i729835fd97c847689dae526ba4c3f80f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjUtMTAtMS0xLTA_459f8908-2dcd-4cf0-bb58-66552f061dc6"
      unitRef="usd">1476000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i09bfaa553aa8422b9801e9811d4f84ff_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjYtOC0xLTEtMA_a242eeeb-f53f-4335-8b48-a2d915a09107"
      unitRef="usd">26565000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i31b25ed89c604903b3ab2cb0f953dae9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjYtMTAtMS0xLTA_0753e2e5-60b6-49d8-91cc-ecebe119d5b6"
      unitRef="usd">30295000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iacd82538440946f2b5a64f02e99bd78e_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjctOC0xLTEtMA_f633dad5-20eb-4549-9508-d4cb095e6daf"
      unitRef="usd">1121000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4ecfcc11f2b44bee8fc31ff744993188_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjctMTAtMS0xLTA_29ddbd4e-0439-40e2-a31f-0f9fb177378c"
      unitRef="usd">1107000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjgtOC0xLTEtMA_00e9427c-f662-4359-9864-fc0c05e556ff"
      unitRef="usd">27686000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjgtMTAtMS0xLTA_2f562d56-a1ed-4c68-8018-b33bb023ae2e"
      unitRef="usd">31402000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjktOC0xLTEtMA_d12f571b-c515-4581-ada9-c7ac0cd3f9b1"
      unitRef="usd">2511000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMjktMTAtMS0xLTA_494961c8-9702-49ef-aa22-cb2333a457f6"
      unitRef="usd">2757000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMzAtOC0xLTEtMA_2d908b1d-3126-4078-8c59-8a933f2614dc"
      unitRef="usd">25175000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0300f6dad76745ceafff278866806c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RhYmxlOjU5ZThiZTU4MmIyNzQxMTJhYzMzMGY1ZDFkOWJiZTJmL3RhYmxlcmFuZ2U6NTllOGJlNTgyYjI3NDExMmFjMzMwZjVkMWQ5YmJlMmZfMzAtMTAtMS0xLTA_b3b358f7-6e4b-4461-8875-e50bd5733c8d"
      unitRef="usd">28645000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0NjQ5Nw_f00fd7df-6a44-469d-95f1-808f59388d87"
      unitRef="usd">3750000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="i20624e63c9d342039f2acd0aa0e221dc_D20210101-20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0Njc4MA_53d8742c-0ba0-4458-80cf-fbbcc7a5922a"
      unitRef="usd">1000000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ia5e1397cca1b4612bda3fec5029c7caa_D20210701-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0NjUyOA_5b588ef0-e45d-43e9-bb75-fdff1d81488e"
      unitRef="usd">1250000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="i4a838956d382494aa01dce9ce9a74af3_D20210101-20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0Njc5NQ_cd0a7b9b-0779-4a75-91a3-093f4dfa9a4e"
      unitRef="usd">1000000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:DebtInstrumentTerm
      contextRef="i4a838956d382494aa01dce9ce9a74af3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfNTQ5NzU1ODE0NTYwMA_3bceaa41-f914-425f-b4bb-46848f2886ff">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i4f517572134b4e7bb737cffba5c07c94_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0NjU4Nw_0fde0df5-4c8c-4e92-b194-148900596bcf"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="i50cd74cb77d0435b838bbc259636ca23_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0NjYyMA_ef02ffd5-7d54-4485-8f85-1f9739a76b35"
      unitRef="usd">500000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i755d8293c829458682df87bc82180dd0_D20211001-20211031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0NjczNg_7f196d14-c0ba-408f-b0b0-26cbaf8906fe"
      unitRef="usd">500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iaf9f1c5fb1234d22a178a74091f99dd1_D20211001-20211031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0Njc1MQ_40df2e5e-651a-4966-a873-10f2cceadda6"
      unitRef="usd">500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icd18b3372b0d4339ba7e932b3bcfb631_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0Njc1OQ_a19f5428-c8d3-4365-b5f6-1b350883b415"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icd18b3372b0d4339ba7e932b3bcfb631_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfMTY0OTI2NzQ0Njc1OQ_cfde161c-af6b-4d9e-b9f7-cdf45873ab25"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfNTQ5NzU1ODE0NTYwNw_9e14aebe-9f40-43fa-8b57-0c84097c8978"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfNTQ5NzU1ODE0NTYwNw_cec7e564-b51b-473f-ad64-8d6fccda7d5b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:LineOfCredit
      contextRef="i6198bb2c3e1b4f7a86b03b31b9a31291_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfODQw_744258b5-d32f-4ece-8c1e-90f7762a740e"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ife22d5290cb340d48c49cda6ebce356c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfODQw_d62de857-72a3-41ca-affa-f75554b4aaad"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia55d69200ead47739810b75c12b1c289_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82MS9mcmFnOjg5ODBjMjc5YTQyNDRkY2ViZmVmYmFmYzhlMDk5OTgwL3RleHRyZWdpb246ODk4MGMyNzlhNDI0NGRjZWJmZWZiYWZjOGUwOTk5ODBfODcz_c421aac7-331c-409a-af7c-0e9bc0a866bd"
      unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMjU2NTE_c5d30b7e-7926-4cf5-80aa-6341e5e8cbbb">COMMITMENTS AND CONTINGENCIES &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, it is not possible to determine the outcome of these matters or the outcome (including in excess of any accrual) is not expected to be material, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss. In the third quarter of 2021, we reversed a $175 million previously recorded litigation accrual following a favorable court decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not have any material accruals for the matters described below on our Condensed Consolidated Balance Sheets as of September&#160;30, 2021 and December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Related to Sofosbuvir&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of the HCV. In 2013, we received approval from FDA for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation with the University of Minnesota&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The University of Minnesota (the &#x201c;University&#x201d;) has obtained U.S. Patent No. 8,815,830 (the &#x201c;&#x2019;830 patent&#x201d;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#x2019;830 patent. We believe the &#x2019;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concludes the inter partes review that it has initiated. In May 2021, the PTAB issued a written decision finding the asserted claims of the University&#x2019;s patent invalid. In July 2021, the University appealed this decision. The litigation in the U.S. District Court will remain stayed through the appeal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation with NuCana plc. (&#x201c;NuCana&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NuCana has obtained European Patent No. 2,955,190 (the &#x201c;EP &#x2019;190 patent&#x201d;) that allegedly covers sofosbuvir. In Opposition proceedings before the European Patent Office (&#x201c;EPO&#x201d;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#x2019;190 patent in amended form. We believe that the amended EP &#x2019;190 patent claims are invalid. Subsequently, we initiated proceedings to invalidate the UK counterpart of the EP &#x2019;190 patent in the High Court of England &amp;amp; Wales. In March 2021, NuCana filed a counterclaim against us in the High Court of England &amp;amp; Wales alleging patent infringement of the UK counterpart and seeking damages and other relief. In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#xfc;sseldorf alleging patent infringement of the German counterpart of the EP &#x2019;190 patent and seeking damages and other relief. The hearing date for the German NuCana case has been scheduled for May 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Related to Axicabtagene Ciloleucel&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#x201c;Juno&#x201d;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes on U.S. Patent No. 7,446,190 (the &#x201c;&#x2019;190 patent&#x201d;). A jury trial was held on the &#x2019;190 patent, and in December 2019, the jury found that the asserted claims of the &#x2019;190 patent were valid, and that we willfully infringed the asserted claims of the &#x2019;190 patent. The jury also awarded Juno damages in amounts of $585 million in an up-front payment and a 27.6% running royalty from October 2017 through the date of the jury&#x2019;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#x2019;s verdict, enhanced the past damages by 50% and maintained the royalties on future Yescarta sales at 27.6%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge, and in July 2021, the appeals court heard oral arguments. In August 2021, the Court of Appeals for the Federal Circuit (the &#x201c;CAFC&#x201d;) reversed the jury verdict finding the asserted claims of Juno&#x2019;s patent invalid. In October 2021, Juno filed a petition for rehearing with the CAFC. We believe that the likelihood of a material adverse outcome in this matter is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Related to Bictegravir&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, ViiV Healthcare Company (&#x201c;ViiV&#x201d;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes ViiV&#x2019;s U.S. Patent No. 8,129,385 (the &#x201c;&#x2019;385 patent&#x201d;) covering ViiV&#x2019;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the &#x2019;385 patent. The court has set a trial date of January 2022 for this lawsuit. ViiV is seeking billions of dollars for alleged damages comprised of ViiV&#x2019;s lost profits and a royalty on sales of bictegravir from launch through the trial. ViiV calculates these damages based on the cumulative U.S. revenues from Biktarvy since launch, which have totaled $16.4 billion through September&#160;30, 2021. In addition, should a court find that we are liable for infringement, we expect ViiV will seek a royalty on sales after the trial. Although we cannot predict with certainty the ultimate outcome of this litigation, an adverse judgment could result in substantial monetary damages, including ViiV&#x2019;s lost profits and royalties through trial, and a going-forward royalty stream on future sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, ViiV also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound have infringed ViiV&#x2019;s Canadian Patent No. 2,606,282 (the &#x201c;&#x2019;282 patent&#x201d;), which was issued to Shionogi &amp;amp; Co. Ltd. and ViiV. The &#x2019;282 patent is the compound patent covering ViiV&#x2019;s dolutegravir. We believe that bictegravir does not infringe the claims of the &#x2019;282 patent. In January 2020, the court held a summary trial to assess ViiV&#x2019;s infringement allegations. In April 2020, the court determined that bictegravir does not infringe the claims of the &#x2019;282 patent and dismissed the case. ViiV appealed this decision, and in June 2021, the Canadian Federal Court of Appeal upheld the Federal Court of Canada&#x2019;s decision. ViiV has sought leave to appeal to the Canadian Supreme Court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November and December 2019, ViiV filed lawsuits in France, Germany, Ireland and the UK asserting the relevant national designations of European Patent No. 3 045 206 (&#x201c;EP &#x2019;206&#x201d;); in Australia asserting Australian Patent No. 2006239177; in Japan asserting Japanese Patent No. 4295353; and in Korea asserting Korean Patent Nos. 1848819 (&#x201c;KR &#x2019;819&#x201d;) and 1363875. These patents all relate to molecules that ViiV claims would act as integrase inhibitors. We believe that bictegravir does not infringe the claims of any of ViiV&#x2019;s patents. In 2019, we filed an opposition in the EPO requesting revocation of EP &#x2019;206. The EPO hearing took place in January 2021, and the patent claims, which do not cover bictegravir, were maintained in amended form. Both parties have appealed this decision. Additionally, in 2020, we filed a petition in the Korean Intellectual Property Office requesting invalidation of KR &#x2019;819. Following a trial, a tribunal of the Korean Intellectual Property Trial and Appeal Board found KR &#x2019;819 to be invalid. In March 2021, ViiV appealed this decision. In April 2021, the court in Germany held a hearing on the issue of infringement, and in September 2021, determined that Gilead does not infringe ViiV&#x2019;s EP &#x2019;206 patent both in its original form and as amended by the EPO. ViiV has appealed this decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In all jurisdictions, to the extent that the claims of ViiV&#x2019;s patents are interpreted to cover bictegravir, we believe that those claims are invalid. We cannot predict the ultimate outcome of intellectual property claims related to bictegravir. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Relating to Pre-Exposure Prophylaxis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#x201c;HHS Patents&#x201d;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of emtricitabine and tenofovir or TDF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#x201c;PrEP&#x201d;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the Court of Federal Claims, alleging violations of four material transfer agreements (&#x201c;MTAs&#x201d;) related to the research underlying the HHS Patents and a clinical trial agreement (&#x201c;CTA&#x201d;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#x2019;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the Court of Federal Claims has been set for June 2022, and a trial date for the lawsuit in the District Court of Delaware has been set for May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation with Generic Manufacturers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#x201c;NCE&#x201d;) exclusivity period during which other manufacturers&#x2019; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#x201c;ANDA&#x201d;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#x2019;s approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Starting in December 2019, we received letters from Lupin Ltd., Apotex Inc., Shilpa Medicare Ltd., Sunshine Lake Pharma Co. Ltd., Laurus Labs, Natco Pharma Ltd., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. (collectively, &#x201c;generic manufacturers&#x201d;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of certain of our tenofovir alafenamide (&#x201c;TAF&#x201d;)-containing products. Between them, these generic manufacturers seek to market generic versions of Odefsey, Descovy and Vemlidy. Some generic manufacturers have challenged the validity of four patents listed on the Orange Book and associated with TAF, while others have challenged the validity of two of our Orange Book-listed patents associated with TAF. We filed lawsuits against the generic manufacturers, and we intend to enforce and defend our intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, we received a letter from Lupin Ltd. indicating that it has submitted an ANDA to the FDA requesting permission to market and manufacture a generic version of Symtuza. We are evaluating the letter and intend to enforce and defend our intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;European Patent Claims&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. An appeal hearing originally scheduled for July 2021 has been canceled and a new date has not yet been set by the EPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. Two of the original opposing parties have appealed, requesting full revocation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2026. In 2017, the EPO upheld the validity of the claims of our TAF patent. Three parties have appealed this decision. The appeal hearing was held in March 2021, and the validity of all claims were upheld.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. Three parties have appealed this decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, three parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2027. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. Two parties have appealed this decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF, TAF hemifumarate and cobicistat in the European Union could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust and Consumer Protection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We (along with Japan Tobacco, Inc. (&#x201c;Japan Tobacco&#x201d;), Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;) and Johnson &amp;amp; Johnson, Inc.) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Japan Tobacco was dismissed from the lawsuit after a favorable court ruling on the defendants&#x2019; motion to dismiss. Plaintiffs allege that we (and the other remaining defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of two nationwide classes - one of direct purchasers consisting largely of wholesalers, and another of end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In September 2021, we, along with BMS and generic manufacturer Teva Pharmaceuticals USA (&#x201c;Teva&#x201d;), were named as defendants in similar lawsuits filed by CVS, Rite Aid, Walgreens, Safeway, Kroger, Albertsons and HEB (the &#x201c;Retailers&#x201d;) in the U.S. District Court for the Northern District of California. The Retailers are opting out of the proposed direct purchaser class and, based on assignments by their wholesalers, seek to bring claims substantially the same as the putative class.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we, along with generic manufacturers Cipla Ltd. and Cipla USA Inc. (together, &#x201c;Cipla&#x201d;), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#x201c;Jacksonville Trust&#x201d;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and Cipla, which settled a patent dispute relating to patents covering our Emtriva, Truvada, and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. The Plaintiff seeks damages, permanent injunctive relief and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, we along with BMS and Teva were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named as a defendant in one class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Missouri and New Jersey, involve more than 24,000 plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we received a subpoena from the U.S. Attorney&#x2019;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#x2019;s decision not to intervene in the suit, the relator served us with a Second Amended Complaint in January 2021. The lawsuit alleges that Gilead&#x2019;s HCV patient access programs, clinical educator programs, speaker programs, and other sales and marketing programs violated the federal False Claims Act and various state false claims acts. In July 2021, the relator filed a Third Amended Complaint, removing allegations against us regarding our patient access programs, clinical educator programs and relationships with specialty pharmacies. The relator seeks all available relief under these statutes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Two former employees filed a qui tam lawsuit against Gilead in April 2020 in California state court. These same former employees had previously filed a qui tam lawsuit in federal court in California, and the U.S. Department of Justice declined intervention and moved to dismiss relators&#x2019; federal False Claims Act claims. Relators subsequently voluntarily dismissed their federal lawsuit and refiled their lawsuit in California state court. Following the California Attorney General&#x2019;s Office&#x2019;s decision not to intervene, relators served Gilead with their complaint in August 2020. The complaint alleges violations of the California False Claims Act (&#x201c;CFCA&#x201d;) and employment law claims. Relators seek all available relief under the CFCA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health Choice Advocates, LLC (&#x201c;Health Choice&#x201d;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#x2019;s Office&#x2019;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court&#x2019;s dismissal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#x2019;s Office&#x2019;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#x201c;TMFPA&#x201d;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA. In September 2021, the Texas Court of Appeals for the Sixth Court Appeals District granted our request to stay the Texas litigation. The case is stayed pending final judgment in the Eastern District of Pennsylvania lawsuit filed in March 2017, as discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019, which were consolidated in September 2019. Plaintiffs filed a consolidated complaint in November 2019 and an amended complaint in July 2021. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#x2019; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the U.S. District Court for the District of New Jersey. While we believe this case is without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMjQxODkyNTU5MDAyNjU_b2afa065-56c0-4d48-a037-9ffd2975bc18"
      unitRef="usd">-175000000</us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i294c3dd1a0044d64b2a2c206819a4787_D20191201-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfNTA4Nw_91ecd9dd-7383-4c45-bccf-246dc2393bf6"
      unitRef="usd">585000000</us-gaap:LossContingencyDamagesAwardedValue>
    <gild:JudgmentRoyaltyRateFromOctober2017
      contextRef="i294c3dd1a0044d64b2a2c206819a4787_D20191201-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfNTExOQ_14efcc23-0095-40f9-94eb-9d7dfb5ccd80"
      unitRef="number">0.276</gild:JudgmentRoyaltyRateFromOctober2017>
    <gild:JudgmentEnhancedDamagesOnPastSales
      contextRef="i08188eab1c8f48659c9fb097dbfa6ad9_I20200430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfNTM5MQ_8bfe8800-2bb7-4839-bc80-aecc5e996f28"
      unitRef="number">0.50</gild:JudgmentEnhancedDamagesOnPastSales>
    <gild:JudgmentRoyaltyRateOnFutureSales
      contextRef="i08188eab1c8f48659c9fb097dbfa6ad9_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfNTQ1MQ_11353d2a-187a-40ce-90ba-88635dde7a7b"
      unitRef="number">0.276</gild:JudgmentRoyaltyRateOnFutureSales>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i1e74f009f33c41a1b3024e5689146bb1_D20210101-20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfNzg4OQ_2e2b40f6-b1ed-422b-b018-64c92d933f9f"
      unitRef="usd">16400000000</us-gaap:LossContingencyDamagesSoughtValue>
    <gild:LossContingencyMaterialTransferAgreementsNumber
      contextRef="i40650c0325e24e0db701d2ab8acfe659_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTE1ODk_aae5497a-17dd-4ce4-b9b9-f94ee4480c78"
      unitRef="agreement">4</gild:LossContingencyMaterialTransferAgreementsNumber>
    <gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioOne
      contextRef="ie57e22e42a844c1c934bc94bfc2e2e72_D20191201-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTQwNzY_29f93f42-43fc-4917-a96a-b4eb71596a8d"
      unitRef="patent">4</gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioOne>
    <gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo
      contextRef="ie57e22e42a844c1c934bc94bfc2e2e72_D20191201-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTQxODM_6a40ba83-73a3-4f34-a381-ac127b470397"
      unitRef="patent">2</gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="ic6c268206d494d42a3e01744ecb78d28_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTUxNDY_9434634c-1adb-4606-9044-b29052bdfcff"
      unitRef="opposingparty">2</gild:LossContingencyPartiesAppealedNumber>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="i842ab5644f88423ea3fb5a3f08f81d21_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTU0Mzg_f25278fa-e493-4ccd-93f5-ac6bf4de0b89"
      unitRef="opposingparty">3</gild:LossContingencyPartiesAppealedNumber>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="ie5c2c8d7ed2c407cb3c28ad661f37190_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTU4MDY_eed2e7c3-4313-4709-9d67-50f06f856557"
      unitRef="opposingparty">3</gild:LossContingencyPartiesAppealedNumber>
    <gild:LossContingencyPartiesFilingOppositionNumber
      contextRef="ib144fc19e2424cdea1de575c395ea438_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTU4NTY_24070d07-e50b-40b1-bbe9-68e1ac840fbd"
      unitRef="party">3</gild:LossContingencyPartiesFilingOppositionNumber>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="i32e0f49607724a678979d40a5566567c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMTYwNjg_88c05758-5314-4362-b53a-f166c329d572"
      unitRef="opposingparty">2</gild:LossContingencyPartiesAppealedNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i50d725ee8e5d42e8b1d6a84547e3f2dc_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfNTQ5NzU1ODIyNDI4OA_9b359531-3b8b-4169-aba4-2a1dc9817e4d"
      unitRef="lawsuit">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i50d725ee8e5d42e8b1d6a84547e3f2dc_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfNTQ5NzU1ODIyNDI5Nw_1a1ad6d9-c505-4b11-874d-6c6ed4b03b7a"
      unitRef="plaintiff">24000</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="if347b8e9f0f441978924331eb15b50e0_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82NC9mcmFnOjU2MjgyYzNiZmZiMDQ5YWNiOGI3MDU1ZGIyMWJmZmVmL3RleHRyZWdpb246NTYyODJjM2JmZmIwNDlhY2I4YjcwNTVkYjIxYmZmZWZfMjIzNTQ_ce15150b-5669-4e7f-8a21-61dc5688c57f"
      unitRef="plaintiff">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTYwOA_49506f63-1ebf-42ba-a68f-5acdf9195b22">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Repurchase Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2016, our Board of Directors authorized a $12.0 billion stock repurchase program (&#x201c;2016 Program&#x201d;) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, our Board of Directors authorized a new $5.0 billion&#160;stock repurchase program (&#x201c;2020 Program&#x201d;), which will commence upon the completion of the&#160;2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2021, we repurchased and retired 2.1 million and 7.5 million shares of our common stock for $145 million and $497 million, respectively, through open market transactions under the 2016 Program. During the three and nine months ended September 30, 2020, we repurchased and retired 3.0 million and 22.4 million shares of our common stock for $201 million and $1.6 billion, respectively, through open market transactions under the 2016 Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the remaining authorized repurchase amount under both programs was $6.3 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in AOCI by component, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income (loss) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts reclassified to net income (loss) for gains and losses on cash flow hedges are recorded as part of Product sales on our Condensed Consolidated Statements of Operations. See Note 5. Derivative Financial Instruments for additional information. The amounts reclassified to net income (loss) for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net on our Condensed Consolidated Statements of Operations. Gross realized gains and losses on available-for-sale debt securities were not material for the nine months ended September 30, 2021 and 2020. The income tax impact allocated to each component of other comprehensive income (loss) was not material for the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i86e5d209900446c0b30dc2880295f243_I20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTA0_28917f6c-e98a-44e9-aa2b-cec71563c4a7"
      unitRef="usd">12000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="id644c4f270bd409c8d4eb7dbc0893a59_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMzU3_e47b9f49-05e8-492b-a0ae-25c6646be5c2"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTUzOTMxNjI3OTA1NDI_0e27f5f4-93cd-4777-917b-568104f1a825"
      unitRef="shares">2100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTUzOTMxNjI3OTA1OTg_d9d5d635-f3a9-4c97-9706-2d6fb11cc33a"
      unitRef="shares">7500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTUzOTMxNjI3OTA1NzE_d15f9bd3-dfbd-4774-b35d-ea27a9dbb614"
      unitRef="usd">145000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTUzOTMxNjI3OTA2MzA_877dd657-0e7d-4760-aae3-a17f5d8b21c8"
      unitRef="usd">497000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTU5NDI5MTg2MDQ2MzE_31eb2a74-87fc-4109-a110-9db2fd4a8f6d"
      unitRef="shares">3000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTU5NDI5MTg2MDQ2Mzg_66381c9e-11b6-4000-b498-fc323f582ae0"
      unitRef="shares">22400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTU5NDI5MTg2MDQ2NTM_0e12dcad-4b6d-407d-a4df-0d1d5416231c"
      unitRef="usd">201000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTU5NDI5MTg2MDQ2NzA_953cbbbb-7f1b-481b-bfac-01f543deb7bb"
      unitRef="usd">1600000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTUzOTMxNjI3OTA2NjE_4eb1c112-a71c-4799-8761-53b3a47e717c"
      unitRef="usd">6300000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RleHRyZWdpb246MWE5ZmYzOTNiOGEwNDIxZThhNTA2YjE0YTlmNDEwZGFfMTYxMg_c076a63a-d7f4-483e-b42d-810467e72533">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in AOCI by component, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income (loss) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a5998ee4b384480a72487be18641c7e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMS0yLTEtMS0w_3a254c4c-14ae-4144-8f9e-2cb1d332a758"
      unitRef="usd">51000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7c3d265770c244a0a765e499a4ee7cb9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMS00LTEtMS0w_e2270ee6-6f34-40a5-b0ac-7c1831013ce6"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c0ff94d0a674ceabb8a179fc4e48905_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMS02LTEtMS0w_dc67e61a-8a3b-4c53-b908-805e8537bc37"
      unitRef="usd">-113000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i68c8176bb4194abc96d3c13de341cd01_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMS04LTEtMS0w_c4b28401-0e18-4397-9f11-0a6c3067b149"
      unitRef="usd">-60000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i45325645469947adb3cc8720858aa852_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMi0yLTEtMS0w_6b368d4d-85b3-4c8b-a5dd-56c6c159a0cf"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2b5cc9befb344284aed69e9c8209aba9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMi00LTEtMS0w_ab2aff5d-eeac-4449-9386-621129e61bca"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if101dcd8b89a438ab7ac5691e108990a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMi02LTEtMS0w_9e810dd4-c544-49fd-a79b-261bb8df0a63"
      unitRef="usd">92000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ibdca6d608af14f87aeafba62f5b528f1_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMi04LTEtMS0w_7c105c09-bc46-4b5c-a1ed-1100b2faee97"
      unitRef="usd">74000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i45325645469947adb3cc8720858aa852_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMy0yLTEtMS0w_5e9c1019-38dd-4f65-ac78-d40e461d721c"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2b5cc9befb344284aed69e9c8209aba9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMy00LTEtMS0w_2aa227af-6a7d-4645-8d9f-c62482cf7c2d"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if101dcd8b89a438ab7ac5691e108990a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMy02LTEtMS0w_71c64ca7-5c3d-45c0-abbb-b3e97840f861"
      unitRef="usd">-60000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ibdca6d608af14f87aeafba62f5b528f1_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfMy04LTEtMS0w_1356fba5-6ca3-499d-8f3f-62ea87fc9128"
      unitRef="usd">-60000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i45325645469947adb3cc8720858aa852_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNC0yLTEtMS0w_ae1c3d29-f4e5-4287-b55d-9c6616bdf5d0"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2b5cc9befb344284aed69e9c8209aba9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNC00LTEtMS0w_54013248-3b68-462b-8d6b-a79fed6815a2"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if101dcd8b89a438ab7ac5691e108990a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNC02LTEtMS0w_68261b09-75ab-44db-a87e-01a1bcc34a27"
      unitRef="usd">152000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibdca6d608af14f87aeafba62f5b528f1_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNC04LTEtMS0w_591915a5-70bc-4156-97e6-9e115b3c7657"
      unitRef="usd">134000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia8bee7f2d6524b07b87afe756d78590e_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNS0yLTEtMS0w_cbb47e00-3b3a-42f0-bce9-c40e9b48e607"
      unitRef="usd">36000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4990ffc169374b34bdd3f918810fc418_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNS00LTEtMS0w_5e14e655-d1b3-48f8-bd43-851ca9b20960"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79d0985dca0949ec872d8eb72624d97f_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNS02LTEtMS0w_9c195daa-938d-4cbf-b975-b62920c22f80"
      unitRef="usd">39000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic607fe5efeb4462ba677a36d66cea69e_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOjM0YjRjZDMyMDhmZjQ3ZTE4ZTY1OWFhNmVkYTM3M2NmL3RhYmxlcmFuZ2U6MzRiNGNkMzIwOGZmNDdlMThlNjU5YWE2ZWRhMzczY2ZfNS04LTEtMS0w_475f3cd7-77d0-4779-833b-65adc94e9391"
      unitRef="usd">74000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i414821821100441394f7829f268ffe4e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMS0yLTEtMS0w_9dc96859-43b5-4771-9e76-58f55f315eca"
      unitRef="usd">53000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0cf07b371d2f4766b8d9469daa886de3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMS00LTEtMS0w_0969b318-ebf7-4cab-a5fc-0f3239fd2f23"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e4e4f7365f94609beeaed0a72a5533b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMS02LTEtMS0w_f9ce5fa9-6584-4cfa-8e6c-a14f6635de6a"
      unitRef="usd">31000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i188cf2bc805343608e1a7c9417d2404d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMS04LTEtMS0w_6502473d-7d86-4fd4-b5f0-34f8ba13c7e6"
      unitRef="usd">85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i967254dd024046df825693124da51c02_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMi0yLTEtMS0w_91a90771-517a-4474-be3c-495a8e401e5f"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="id89abf1e3aba470fbcbb850fec50b11b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMi00LTEtMS0w_9f07105a-0271-4912-ab57-abc253b2c59d"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i216f4d250c4d49e19ca6cf3b0d5a5818_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMi02LTEtMS0w_3c4adc70-1bd8-488f-a53f-aa765edc3033"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i57db840e2919481eb28184ec2cbb0a50_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMi04LTEtMS0w_367cd7a5-e56e-486d-b552-bbc9fe29f1a0"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i967254dd024046df825693124da51c02_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMy0yLTEtMS0w_e0d05b08-ddcf-45d5-a240-7294d2fce624"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="id89abf1e3aba470fbcbb850fec50b11b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMy00LTEtMS0w_0430790a-7129-4713-83d8-e3b08decad99"
      unitRef="usd">17000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i216f4d250c4d49e19ca6cf3b0d5a5818_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMy02LTEtMS0w_39b05ad3-0eb8-4896-b1b5-6eba753e079d"
      unitRef="usd">50000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i57db840e2919481eb28184ec2cbb0a50_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfMy04LTEtMS0w_35c079c6-632f-40b3-86fa-33175aa0d0ae"
      unitRef="usd">67000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i967254dd024046df825693124da51c02_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNC0yLTEtMS0w_d869a47c-ace5-44be-a58f-7c3f93bdb623"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id89abf1e3aba470fbcbb850fec50b11b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNC00LTEtMS0w_d186201b-e550-4782-8c02-8fc399214f2d"
      unitRef="usd">25000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i216f4d250c4d49e19ca6cf3b0d5a5818_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNC02LTEtMS0w_910c645b-c77d-4df2-8d9e-6055227b6ef6"
      unitRef="usd">-75000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i57db840e2919481eb28184ec2cbb0a50_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNC04LTEtMS0w_f63682a2-15ff-4fa6-8a71-b89ff89684ed"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i54fe2a88a4c14a76a2d768cacc3e0995_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNS0yLTEtMS0w_690c93ae-15a7-4200-a85d-5c1bf2049157"
      unitRef="usd">41000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i20b67d0bcd224fc9a3adb44b3d27fd5b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNS00LTEtMS0w_7c93d1d4-cced-462a-9c08-e54f5df79860"
      unitRef="usd">26000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5cf587a459224feaac6e5a4412d46585_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNS02LTEtMS0w_c2bc5911-9c19-4425-924e-add4350b0d93"
      unitRef="usd">-44000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1eb53663397049a380603edf12d76c3a_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV82Ny9mcmFnOjFhOWZmMzkzYjhhMDQyMWU4YTUwNmIxNGE5ZjQxMGRhL3RhYmxlOmYwMzg5ZmQ4NTM2MTQ2ZjM4MWU0ODdkYzFjMmEzMDIyL3RhYmxlcmFuZ2U6ZjAzODlmZDg1MzYxNDZmMzgxZTQ4N2RjMWMyYTMwMjJfNS04LTEtMS0w_d8a42ccf-5b91-4b27-8d9a-7f20c38eeea6"
      unitRef="usd">23000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RleHRyZWdpb246MGVhMWM5YzRlMzExNGQ2ZjliMmY1ZWNjNmJlOGE4OWFfMTAzNA_dea10c16-a393-4c9c-a5b9-564dd5efac00">NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share attributable to Gilead common stockholders is calculated based on the weighted average number of shares of our common stock outstanding during the period. Diluted net income (loss) per share attributable to Gilead common stockholders is calculated based on the weighted average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock metho&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential shares of common stock excluded from the computation of diluted net income (loss) per share attributable to Gilead common stockholders because their effect would have been antidilutive were 14 million and 15 million for the three and nine months ended September 30, 2021, respectively, and 13 million and 38 million for the three and nine months ended September 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the calculation of basic and diluted net income (loss) per share attributable to Gilead common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to Gilead common stockholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to Gilead common stockholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RleHRyZWdpb246MGVhMWM5YzRlMzExNGQ2ZjliMmY1ZWNjNmJlOGE4OWFfODA1_5dd44657-0ef4-42a8-af54-1903b9148d83"
      unitRef="shares">14000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RleHRyZWdpb246MGVhMWM5YzRlMzExNGQ2ZjliMmY1ZWNjNmJlOGE4OWFfODEy_88494450-17e8-4ba1-934d-231033d66f2f"
      unitRef="shares">15000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RleHRyZWdpb246MGVhMWM5YzRlMzExNGQ2ZjliMmY1ZWNjNmJlOGE4OWFfODQ1_90bd147e-489e-4abe-b2f6-a3fbe803dcc1"
      unitRef="shares">13000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RleHRyZWdpb246MGVhMWM5YzRlMzExNGQ2ZjliMmY1ZWNjNmJlOGE4OWFfODUy_cb0600fe-be42-4c68-b7ae-a8cd3a9313dd"
      unitRef="shares">38000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RleHRyZWdpb246MGVhMWM5YzRlMzExNGQ2ZjliMmY1ZWNjNmJlOGE4OWFfMTAzNQ_ad51bf35-61b7-42e3-8665-3ad106723c1f">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the calculation of basic and diluted net income (loss) per share attributable to Gilead common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to Gilead common stockholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to Gilead common stockholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfMy0yLTEtMS0w_2ae7cead-ef05-4ba5-88dc-033def53f9fa"
      unitRef="usd">2592000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfMy00LTEtMS0w_619513d8-4af8-4e7a-accd-ae0fb4fe598f"
      unitRef="usd">360000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfMy02LTEtMS0w_cfb36777-8a2f-4112-b343-fff0f7a7549f"
      unitRef="usd">5843000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfMy04LTEtMS0w_510fc3b6-f7e7-4062-bf87-9dde725bac5e"
      unitRef="usd">-1428000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNC0yLTEtMS0w_103ec50a-b78b-4fed-ac5f-2030c87c7d6e"
      unitRef="shares">1256000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNC00LTEtMS0w_fd2d1425-2084-4df7-aab7-f66b7706a933"
      unitRef="shares">1255000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNC02LTEtMS0w_aee8a1b2-95fd-44aa-9800-427a3d3a6366"
      unitRef="shares">1256000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNC04LTEtMS0w_c9231cae-e69f-4312-825e-3cde090aead9"
      unitRef="shares">1257000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNS0yLTEtMS0w_eb53ef0c-3a86-47fa-9cb5-611922e6aa78"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNS00LTEtMS0w_5ce0e860-6f66-4004-8894-4b97bab0ac1a"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNS02LTEtMS0w_18fc4ae5-1a4a-4f00-8a5c-d48518ede98b"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNS04LTEtMS0w_fbbc1564-98ab-4cf5-ad3e-2ab4bcf4cb3f"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNi0yLTEtMS0w_b7cf0d64-6c19-40e9-9acf-01fc846458a8"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNi00LTEtMS0w_5184d87a-f9fd-42a3-864d-e732c4e00ceb"
      unitRef="shares">1261000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNi02LTEtMS0w_17c9bdf3-0924-4728-b891-8ecb1d1d65c6"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfNi04LTEtMS0w_c4a4f6ab-bbe0-4f6a-bb7f-41e6331dba43"
      unitRef="shares">1257000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOC0yLTEtMS0w_57cb18e4-86cd-42b9-b9c6-e8ae752c1e01"
      unitRef="usdPerShare">2.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOC00LTEtMS0w_4a639e4d-44dd-45e5-8d17-24cb56f74acb"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOC02LTEtMS0w_510e00ca-66e9-40a6-8ccf-6fdecc9c22ea"
      unitRef="usdPerShare">4.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOC04LTEtMS0w_1e58b78f-9d8b-44d1-b26f-eda768b91943"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOS0yLTEtMS0w_277950c8-cf9a-45af-ace0-d655273d9efa"
      unitRef="usdPerShare">2.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOS00LTEtMS0w_ed69da37-78d1-4c11-94b5-68260ef74e68"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOS02LTEtMS0w_2429d6fa-2dec-4550-a254-6fd6573da824"
      unitRef="usdPerShare">4.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83MC9mcmFnOjBlYTFjOWM0ZTMxMTRkNmY5YjJmNWVjYzZiZThhODlhL3RhYmxlOjE1MWIzMmQ5YTcyZDQzYjJiM2EyODBmYTUzNGMzNmU1L3RhYmxlcmFuZ2U6MTUxYjMyZDlhNzJkNDNiMmIzYTI4MGZhNTM0YzM2ZTVfOS04LTEtMS0w_50288d8f-aed1-4ad1-9a6f-f3d78414a826"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RleHRyZWdpb246NmE1MjMyZDcwNDE0NDJhNjg4NzA2N2E5NDM1OGI5ZjdfMTY0Mw_b9e67c8f-2333-40a9-ae6c-2447244edca7">INCOME TAXES &lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our income tax expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions, except percentages)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our effective income tax rate of 24.8% for the three months ended September 30, 2021 is higher than the U.S. federal statutory rate of 21% primarily due to remeasurement of certain deferred tax liabilities related to acquired intangible assets, partially offset by provision to return adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our effective income tax rate of 22.5% for the nine months ended September 30, 2021 is higher than the U.S. federal statutory rate of 21% primarily due to remeasurement of certain deferred tax liabilities related to acquired intangible assets and unfavorable changes in the fair value of our equity investment in Galapagos that are non-deductible for income tax purposes, partially offset by provision to return adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our effective income tax rate of 57.2% for the three months ended September 30, 2020 differed from the U.S. federal statutory rate of 21% primarily due to certain acquired IPR&amp;amp;D charges and unfavorable changes in the fair value of our equity investment in Galapagos that are non-deductible for income tax purposes, partially offset by a net discrete tax benefit related to a settlement with a taxing authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our effective income tax rate of (903.4)% for the nine months ended September 30, 2020 differed from the U.S. federal statutory rate of 21% primarily due to a non-deductible $4.5&#160;billion IPR&amp;amp;D charge recorded in connection with our second quarter 2020 acquisition of Forty Seven, in addition to the above mentioned amounts for the three months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently under examination by the U.S. Internal Revenue Service for the tax years from 2016 to 2018 and by various state and foreign jurisdictions. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We regularly evaluate our exposures associated with our tax filing positions to determine our assessment of unrecognized tax benefits in accordance with the income tax guidance which clarifies the accounting for uncertainty in income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RleHRyZWdpb246NmE1MjMyZDcwNDE0NDJhNjg4NzA2N2E5NDM1OGI5ZjdfMTY0NA_02572c17-fb2a-4c12-add8-0958df003f29">&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our income tax expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions, except percentages)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfMy0yLTEtMS0w_c0f1cedd-4c62-4504-894e-7eefdca5190a"
      unitRef="usd">3438000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfMy00LTEtMS0w_a56b9641-1ce3-494e-a175-8cf605cf57a0"
      unitRef="usd">825000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfMy02LTEtMS0w_1c722f21-6020-46f6-b702-e020c6c8c9c0"
      unitRef="usd">7519000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfMy04LTEtMS0w_da3022a1-b718-4531-8fa2-a345a27b5be3"
      unitRef="usd">-145000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNC0yLTEtMS0w_a739ce53-4f96-4153-8951-72935364c9eb"
      unitRef="usd">852000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNC00LTEtMS0w_b5d7c797-e715-40a7-935f-481f179b605f"
      unitRef="usd">472000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNC02LTEtMS0w_09d911e5-2d90-4d5f-a4af-4f421ca32902"
      unitRef="usd">1694000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNC04LTEtMS0w_15ad47df-33bb-49cb-8941-eed6fec54dd9"
      unitRef="usd">1310000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNS0yLTEtMS0w_bf4a9491-15b3-42ff-818e-5eb09d5aaae9"
      unitRef="number">0.248</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNS00LTEtMS0w_c025ce5d-e795-49e3-a0c0-2afca3f67b5d"
      unitRef="number">0.572</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNS02LTEtMS0w_9a705fee-e122-4210-bea8-b2c3ed1b73f7"
      unitRef="number">0.225</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RhYmxlOjg4ZDU0ZTY2MDNmMjRkMzY5ZjIwZjZiZGE1ZjgxN2ZmL3RhYmxlcmFuZ2U6ODhkNTRlNjYwM2YyNGQzNjlmMjBmNmJkYTVmODE3ZmZfNS04LTEtMS0w_11ee4293-7f5d-47ed-a485-335d9461845d"
      unitRef="number">-9.034</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RleHRyZWdpb246NmE1MjMyZDcwNDE0NDJhNjg4NzA2N2E5NDM1OGI5ZjdfMTAy_bf4a9491-15b3-42ff-818e-5eb09d5aaae9"
      unitRef="number">0.248</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RleHRyZWdpb246NmE1MjMyZDcwNDE0NDJhNjg4NzA2N2E5NDM1OGI5ZjdfNTMw_9a705fee-e122-4210-bea8-b2c3ed1b73f7"
      unitRef="number">0.225</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6780596b267f474480b87b8ce4471b81_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RleHRyZWdpb246NmE1MjMyZDcwNDE0NDJhNjg4NzA2N2E5NDM1OGI5ZjdfNzcw_c025ce5d-e795-49e3-a0c0-2afca3f67b5d"
      unitRef="number">0.572</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ieb3951ce6d6543ccb289aeb87195fc13_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RleHRyZWdpb246NmE1MjMyZDcwNDE0NDJhNjg4NzA2N2E5NDM1OGI5ZjdfNzc3_11ee4293-7f5d-47ed-a485-335d9461845d"
      unitRef="number">-9.034</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i3ce0a2da343c4d92b5c1b28c7b50805f_D20200401-20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJjMWI0ZDEwMmQ5OTQzNGI5NTZiM2I4NjE2ZDA4MzZhL3NlYzoyYzFiNGQxMDJkOTk0MzRiOTU2YjNiODYxNmQwODM2YV83My9mcmFnOjZhNTIzMmQ3MDQxNDQyYTY4ODcwNjdhOTQzNThiOWY3L3RleHRyZWdpb246NmE1MjMyZDcwNDE0NDJhNjg4NzA2N2E5NDM1OGI5ZjdfODky_ae9960fb-b3a8-4f6f-b977-63462fc13111"
      unitRef="usd">4500000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753356873896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 29, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GILEAD SCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3047598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Lakeside Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">574-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value, $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">GILD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254,383,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753352934168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,362<span></span>
</td>
<td class="nump">$ 5,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">4,566<span></span>
</td>
<td class="nump">4,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,676<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,011<span></span>
</td>
<td class="nump">2,013<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">13,991<span></span>
</td>
<td class="nump">15,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">5,037<span></span>
</td>
<td class="nump">4,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">33,900<span></span>
</td>
<td class="nump">33,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,332<span></span>
</td>
<td class="nump">8,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">4,739<span></span>
</td>
<td class="nump">5,708<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">67,098<span></span>
</td>
<td class="nump">68,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">585<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AccruedGovernmentAndOtherRebates', window );">Accrued government and other rebates</a></td>
<td class="nump">3,368<span></span>
</td>
<td class="nump">3,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">3,781<span></span>
</td>
<td class="nump">4,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of long-term debt and other obligations, net</a></td>
<td class="nump">2,511<span></span>
</td>
<td class="nump">2,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,245<span></span>
</td>
<td class="nump">11,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">25,175<span></span>
</td>
<td class="nump">28,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable</a></td>
<td class="nump">4,642<span></span>
</td>
<td class="nump">5,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">4,603<span></span>
</td>
<td class="nump">3,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">962<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 per share; 5,600 shares authorized; 1,255 and 1,254 shares issued and outstanding, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">4,492<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">74<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">16,903<span></span>
</td>
<td class="nump">14,381<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Gilead stockholders&#8217; equity</a></td>
<td class="nump">21,470<span></span>
</td>
<td class="nump">18,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">21,471<span></span>
</td>
<td class="nump">18,221<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 67,098<span></span>
</td>
<td class="nump">$ 68,407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccruedGovernmentAndOtherRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Government And Other Rebates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccruedGovernmentAndOtherRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753356826072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753356728568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 7,421<span></span>
</td>
<td class="nump">$ 6,577<span></span>
</td>
<td class="nump">$ 20,061<span></span>
</td>
<td class="nump">$ 17,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">1,223<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
<td class="nump">3,974<span></span>
</td>
<td class="nump">3,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">1,147<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">3,336<span></span>
</td>
<td class="nump">3,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">5,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">1,190<span></span>
</td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">3,596<span></span>
</td>
<td class="nump">3,421<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">3,579<span></span>
</td>
<td class="nump">4,576<span></span>
</td>
<td class="nump">11,083<span></span>
</td>
<td class="nump">15,848<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">3,842<span></span>
</td>
<td class="nump">2,001<span></span>
</td>
<td class="nump">8,978<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="num">(763)<span></span>
</td>
<td class="num">(717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(154)<span></span>
</td>
<td class="num">(940)<span></span>
</td>
<td class="num">(696)<span></span>
</td>
<td class="num">(848)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">3,438<span></span>
</td>
<td class="nump">825<span></span>
</td>
<td class="nump">7,519<span></span>
</td>
<td class="num">(145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(852)<span></span>
</td>
<td class="num">(472)<span></span>
</td>
<td class="num">(1,694)<span></span>
</td>
<td class="num">(1,310)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">2,586<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">5,825<span></span>
</td>
<td class="num">(1,455)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Gilead</a></td>
<td class="nump">$ 2,592<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
<td class="nump">$ 5,843<span></span>
</td>
<td class="num">$ (1,428)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to Gilead common stockholders - basic (in dollars per share)</a></td>
<td class="nump">$ 2.06<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in per share calculation - basic (in shares)</a></td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share attributable to Gilead common stockholders - diluted (in dollars per share)</a></td>
<td class="nump">$ 2.05<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 4.63<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in per share calculation - diluted (in shares)</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 7,356<span></span>
</td>
<td class="nump">$ 6,493<span></span>
</td>
<td class="nump">$ 19,848<span></span>
</td>
<td class="nump">$ 17,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753357308504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 2,586<span></span>
</td>
<td class="nump">$ 353<span></span>
</td>
<td class="nump">$ 5,825<span></span>
</td>
<td class="num">$ (1,455)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation gain (loss), net of tax</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Net unrealized gain (loss), net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to net income (loss), net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Net unrealized gain (loss), net of tax</a></td>
<td class="nump">37<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassifications to net income (loss), net of tax</a></td>
<td class="nump">18<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">35<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss)</a></td>
<td class="nump">2,621<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="nump">5,959<span></span>
</td>
<td class="num">(1,517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interest</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Gilead</a></td>
<td class="nump">$ 2,627<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 5,977<span></span>
</td>
<td class="num">$ (1,490)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753345940024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative effect from the adoption of new accounting standard</div></th>
<th class="th"><div>Common Stock&#160;</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th">
<div>Retained Earnings </div>
<div>Cumulative effect from the adoption of new accounting standard</div>
</th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 22,650<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 3,051<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 19,388<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Change in noncontrolling interest</a></td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(1,714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">(2,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">17,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,712<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">13,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2020</a></td>
<td class="nump">18,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,511<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">14,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Change in noncontrolling interest</a></td>
<td class="num">(82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(229)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">(866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 17,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,712<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">13,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 18,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="nump">14,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">5,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">$ (2,714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 21,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,492<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">16,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="nump">19,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,271<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">15,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">2,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(183)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">$ (905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 21,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 4,492<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 16,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753343670216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared (in dollars per share)</a></td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="nump">$ 2.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753357231096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 5,825<span></span>
</td>
<td class="num">$ (1,455)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expense</a></td>
<td class="nump">1,276<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">5,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">243<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Net loss from equity securities</a></td>
<td class="nump">667<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">601<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">272<span></span>
</td>
<td class="num">(334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(242)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(463)<span></span>
</td>
<td class="num">(428)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(851)<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">8,179<span></span>
</td>
<td class="nump">6,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable debt securities</a></td>
<td class="num">(2,891)<span></span>
</td>
<td class="num">(19,809)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable debt securities</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">12,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable debt securities</a></td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">8,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, including in-process research and development, net of cash acquired</a></td>
<td class="num">(1,401)<span></span>
</td>
<td class="num">(5,804)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchases of equity securities</a></td>
<td class="num">(332)<span></span>
</td>
<td class="num">(388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(423)<span></span>
</td>
<td class="num">(469)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,853)<span></span>
</td>
<td class="num">(5,638)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt financing, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuances of common stock</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(497)<span></span>
</td>
<td class="num">(1,583)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt and other obligations</a></td>
<td class="num">(3,750)<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payments of dividends</a></td>
<td class="num">(2,711)<span></span>
</td>
<td class="num">(2,591)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(134)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(6,935)<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(26)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(1,635)<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">5,997<span></span>
</td>
<td class="nump">11,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 4,362<span></span>
</td>
<td class="nump">$ 12,886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753342471656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and a variable interest entity (&#8220;VIE&#8221;) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We did not have any material VIEs as of September&#160;30, 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one operating segment, which focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of the company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies, Estimates and Judgments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these Condensed Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the coronavirus disease 2019 (&#8220;COVID-19&#8221;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. </span></div>We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States and Europe. There were no material write-offs charged against the allowance for the three and nine months ended September 30, 2021 and 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753342437048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.660%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,189&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,722&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,547&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis B virus (&#8220;HBV&#8221;) / Hepatitis Delta virus (&#8220;HDV&#8221;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,923&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,509&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,577&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.660%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,132&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,777&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,213&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,720&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,681&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">HCV</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">HBV / HDV</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,208&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ranexa</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,002&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,559&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,061&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,890&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,698&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues from Major Customers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:</span></div><div style="margin-bottom:4pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:60.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues Recognized from Performance Obligations Satisfied in Prior Periods </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $190 million and $625 million for the three and nine months ended September 30, 2021, respectively, and $206 million and $618 million for the three and nine months ended September 30, 2020, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates for variable consideration related to sales made in prior years resulted in a $188 million and $661 million increase in revenues for the three and nine months ended September 30, 2021, respectively, and $13 million and $94 million increase in revenues for the three and nine months ended September 30, 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $167 million and $198 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were $85&#160;million and $97&#160;million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. During the three and nine months ended September 30, 2021 and 2020, revenue recognized that was included in the contract liability balance as of the beginning of the respective years was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753343913448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.661%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,134&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,279&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,008&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:4.5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes our equity investment in Arcus Biosciences, Inc. (&#8220;Arcus&#8221;) of $482 million as of September&#160;30, 2021 recorded in Prepaid and other current assets and $212 million as of December&#160;31, 2020 recorded in Other long-term assets on our Condensed Consolidated Balance Sheets. See Note 9. Collaborations and Other Arrangements for further information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis on our Condensed Consolidated Balance Sheets:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:4.5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;See the table under the Equity Investment in Galapagos NV (&#8220;Galapagos&#8221;) for more information.</span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of equity securities resulted in net unrealized loss of $142&#160;million and $667&#160;million for the three and nine months ended September 30, 2021, respectively, and $964&#160;million and $1.0 billion for the three and nine months ended September 30, 2020, respectively, which were included in Other income (expense), net on our Condensed Consolidated Statements of Operations.</span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale debt securities are classified as cash equivalents, short-term marketable securities and long-term marketable securities in our Condensed Consolidated Balance Sheets. See Note 4. Available-For-Sale Debt Securities for additional information. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investment in Galapagos</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity investment in Galapagos in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected and applied the fair value option to account for our equity investment in Galapagos whereby the investment is marked to market through earnings each reporting period based on the market price of Galapagos shares. We believe the fair value option best reflects the underlying economics of the investment. The portion of the investment subject to long-term contractual lock-up provisions is classified within Other long-term assets and the remainder is classified as Prepaid and other current assets on our Condensed Consolidated Balance Sheets. In April 2021, we amended the Galapagos subscription agreement to extend the initial lock-up provision for certain Galapagos shares from August 2021 to August 2024. As of September&#160;30, 2021, all of our equity investment in Galapagos was classified as Other long-term assets on our Condensed Consolidated Balance Sheets.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Equity Securities</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments not measured at fair value and excluded from the above tables were limited partnerships and other equity method investments of $96 million and $58 million at September&#160;30, 2021 and December&#160;31, 2020, respectively, and other equity investments without readily determinable fair values of $211 million and $204 million at September&#160;30, 2021 and December&#160;31, 2020, respectively. These amounts were included in Other long-term assets on our Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Transaction</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, Gilead donated certain equity securities at fair value to the Gilead Foundation, a California nonprofit organization (the &#8220;Foundation&#8221;). The Foundation is a related party as certain officers of the Company also serve as directors of the Foundation. The donation expense of $212&#160;million was recorded within Selling, general and administrative expenses on our Condensed Consolidated Statements of Operations during the nine months ended September 30, 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair values of Level 2 financial instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates (&#8220;LIBOR&#8221;) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair values of our aggregate short-term and long-term debt, determined using Level 2 inputs based on their quoted market values, were approximately $29.6 billion and $34.6 billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and the carrying values were $26.6&#160;billion and $30.3 billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3 Inputs </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We measured assets acquired and liabilities assumed at fair value as of the acquisition on a nonrecurring basis, in connection with our first quarter 2021 acquisition of MYR. The liability for contingent consideration of $341 million as of the acquisition date is remeasured on a recurring basis. The estimated fair value of this contingent liability was $328&#160;million as of September&#160;30, 2021. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of Hepcludex. See Note 6. Acquisitions for additional information. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measured assets acquired and liabilities assumed at fair value as of the acquisition on a nonrecurring basis, in connection with our fourth quarter 2020 acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;). The liability related to future royalties assumed is recorded at amortized cost, which approximated fair value as of September&#160;30, 2021 and December&#160;31, 2020. See Note 6. Acquisitions and Note 10. Debt and Credit Facilities for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753343934632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">AVAILABLE-FOR-SALE DEBT SECURITIES</a></td>
<td class="text">AVAILABLE-FOR-SALE DEBT SECURITIES<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-bottom:11pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held a total of 214 and 208 positions which were in unrealized loss positions as of September&#160;30, 2021 and 2020, respectively. The unrealized losses were largely due to changes in interest rates. Aggregated gross unrealized losses on available-for-sale debt securities were not material for the three and nine months ended September 30, 2021 and 2020. No impairment was recognized for the three and nine months ended September 30, 2021 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753357041560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE FINANCIAL INSTRUMENTS</a></td>
<td class="text">DERIVATIVE FINANCIAL INSTRUMENTS<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we may hedge a portion of our foreign currency exposure related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward or option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for certain monetary assets and liabilities that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are not designated as hedges and, as a result, changes in their fair value are recorded in Other income (expense), net on our Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of 18 months or less. Upon executing a hedging contract and quarterly thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses in Accumulated other comprehensive income (&#8220;AOCI&#8221;) are reclassified into product sales when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of September&#160;30, 2021 are expected to be reclassified to product sales within 12 months.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts for the nine months ended September 30, 2021 and 2020 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had notional amounts on foreign currency exchange contracts outstanding of $3.0 billion and $2.4 billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. The following table summarizes the classification and fair values of derivative instruments on our Condensed Consolidated Balance Sheets:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.315%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: </span></div><div style="margin-bottom:11pt;margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) reclassified from AOCI into product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Condensed Consolidated Statements of Operations. There were no discontinuances of cash flow hedges for the three and nine months ended September 30, 2021 and 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, we only held foreign currency exchange contracts. The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts Not Offset <br/>on our Condensed <br/>Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts<br/>&#160;of Recognized <br/>Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts<br/>&#160;Offset on our <br/>Condensed <br/>Consolidated <br/>Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amounts of Assets/Liabilities Presented<br/>&#160;on our Condensed Consolidated<br/>Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Derivative <br/>Financial <br/>Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cash Collateral <br/>Received/<br/>Pledged</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Amount<br/>&#160;(Legal Offset)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753342655016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text">ACQUISITIONS<div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Condensed Consolidated Balance Sheets. Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. Transaction costs associated with business combinations are expensed as they are incurred. The first quarter 2021 acquisition of MYR and the fourth quarter 2020 acquisition of Immunomedics were accounted for as business combinations. </span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets. For an asset acquisition, no goodwill is recorded and contingent consideration, such as payments upon achievement of various development, regulatory and commercial milestones, generally is not recognized as of the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are expensed unless there is an alternative future use. The second quarter 2020 acquisition of Forty Seven, Inc. (&#8220;Forty Seven&#8221;) was accounted for as an asset acquisition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYR</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provided Gilead with Hepcludex, which was conditionally approved by the European Medicines Agency (&#8220;EMA&#8221;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. Upon closing, MYR became a wholly-owned subsidiary of Gilead. The financial results of MYR were included in our Condensed Consolidated Financial Statements from the date of the acquisition. Acquisition-related expenses were not material for the three and nine months ended September 30, 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate consideration for this acquisition of &#8364;1.3 billion (or $1.6 billion) primarily consists of &#8364;1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to &#8364;300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability-weighted scenarios for FDA approval, was $341 million as of the acquisition date and was initially recorded in Other long-term obligations on our Condensed Consolidated Balance Sheets. In the second quarter of 2021, the balance was reclassified to Accrued and other current liabilities on our Condensed Consolidated Balance Sheets. The estimated fair value of the contingent liability was $328&#160;million as of September&#160;30, 2021. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value estimates for the assets acquired and liabilities assumed were based upon valuations using information known and knowable as of the date of this filing. Changes to these assumptions and estimates could cause an impact to the valuation of assets acquired, including intangible assets, goodwill and the related tax impacts of the acquisition, as well as legal and other contingencies. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finite-lived intangible asset of $845 million represents the estimated fair value of Hepcludex for HDV in Europe as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Hepcludex for HDV in Europe and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 10 years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangible assets related to IPR&amp;D consist of Hepcludex for HDV in all other regions without regulatory approval, including the United States. The estimated aggregate fair value of $1.2 billion as of the acquisition date was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to this asset and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the more significant assumptions inherent in the development of intangible asset fair values include: estimates of projected future cash flows including revenues and operating profits; probability of success; the discount rate selected; the life of the potential commercialized products and the risks related to the viability of and potential alternative treatments in any future target markets, among other factors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived assets until the completion or abandonment of the associated R&amp;D efforts. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The inputs used for valuing these identifiable intangibles are unobservable and considered Level 3 under the fair value measurement and disclosure guidance. See Note 3. Fair Value Measurements for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability was based upon the difference between the estimated book basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of MYR.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $226 million was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for MYR is not expected to be deductible for income tax purposes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the three and nine months ended September 30, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunomedics</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we completed the acquisition of Immunomedics, a company focused on the development of antibody-drug conjugate technology, for cash consideration of $20.6 billion. Upon closing, Immunomedics became a wholly-owned subsidiary of Gilead. The acquisition was financed with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $1.0 billion borrowing under a new senior unsecured term loan facility and cash on hand. During the nine months ended September 30, 2021, we repaid the borrowing under the senior unsecured term loan facility. See Note 10. Debt and Credit Facilities for further information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlicense contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the three and nine months ended September 30, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forty Seven</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, we completed the acquisition of Forty Seven, a clinical-stage immuno-oncology company focused on developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for total consideration of $4.7 billion, net of acquired cash. Upon closing, Forty Seven became a wholly-owned subsidiary of Gilead. During the nine months ended September 30, 2020, we recorded a $4.5 billion charge representing an acquired IPR&amp;D asset with no alternative future use in Acquired in-process research and development expenses, and stock-based compensation expense of $144 million primarily in Research and development expenses on our Condensed Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753460087000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND INTANGIBLE ASSETS</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from the acquisition of MYR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,332&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="margin-top:1.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,477)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,715&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,936)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,780&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,897&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)(2)(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,936)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes $910&#160;million reclassified from indefinite-lived assets - IPR&amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes Trodelvy for metastatic triple-negative breast cancer which was granted approval by FDA in April 2021 and Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer (&#8220;UC&#8221;) which was granted accelerated approval by FDA in April 2021. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&amp;D.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes $1.2&#160;billion recognized from the first quarter 2021 acquisition of MYR. See Note 6. Acquisitions for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200&#160;million will be reclassified to finite-lived assets in the fourth quarter of 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to finite-lived intangible assets was $441 million and $1.3 billion for the three and nine months ended September 30, 2021 and $281 million and $844 million for the three and nine months ended September 30, 2020, respectively, and was primarily included in Cost of goods sold on our Condensed Consolidated Statements of Operations.</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of September&#160;30, 2021:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753342524440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">OTHER FINANCIAL INFORMATION</a></td>
<td class="text">OTHER FINANCIAL INFORMATION<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net:</span></div><div style="margin-bottom:1pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,284&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,560&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,566&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,892&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,797&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,797&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued and other current liabilities </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Accrued and other current liabilities:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753342619240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATIONS AND OTHER ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborativeandOtherArrangementsAbstract', window );"><strong>Collaborative and Other Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborativeAndOtherArrangementsTextBlock', window );">COLLABORATIONS AND OTHER ARRANGEMENTS</a></td>
<td class="text">COLLABORATIONS AND OTHER ARRANGEMENTS<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to pursue licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements and cost-sharing arrangements. We also continue to pursue equity investments in third parties focused on the development and commercialization of products and product candidates. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merck Sharp &amp; Dohme Corp. (&#8220;Merck&#8221;) </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2021, we entered into a license and collaboration agreement with Merck, a subsidiary of Merck &amp; Co., Inc. to jointly develop and commercialize long-acting investigational treatments in HIV that combine Gilead&#8217;s investigational capsid inhibitor, lenacapavir, and Merck&#8217;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The collaboration will initially focus on long-acting oral and injectable formulations. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Gilead and Merck will share global development and commercialization costs at 60% and 40%, respectively, across the oral and injectable formulation programs. For long-acting oral products, Gilead will lead commercialization in the United States, and Merck will lead commercialization in the European Union (&#8220;EU&#8221;) and rest of the world. For long-acting injectable products, Merck will lead commercialization in the United States and Gilead will lead commercialization in the EU and rest of the world. Gilead and Merck will jointly promote the combination products in the United States and certain other major markets. We will share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $2.0 billion in net product sales for the oral combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Upon passing $3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Reimbursements of research and development costs to or from Merck are recorded within Research and development expenses on our Condensed Consolidated Statements of Operations. Expenses recognized under the agreement were not material for the three and nine months ended September 30, 2021. No revenues have been recognized under the agreement for the three and nine months ended September 30, 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also have the option to license certain of Merck&#8217;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#8217;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for such investigational oral integrase inhibitor of the other company within the first five years after execution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt-out, in which case the non-exercising company will be paid a royalty.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arcus</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On&#160;May 27, 2020, we entered into a transaction with Arcus, which included entry into an option, license and collaboration agreement (the &#8220;Collaboration Agreement&#8221;) and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended the &#8220;Stock Purchase Agreements&#8221;). Under the Stock Purchase Agreements, we have the right to purchase additional shares of Arcus from Arcus over the five-year period beginning on the closing of the Stock Purchase Agreements, up to a maximum of 35% of the outstanding voting stock. We are subject to a three-year standstill, which period began on the date the parties entered into the Stock Purchase Agreements, restricting our ability to acquire voting stock of Arcus exceeding more than 35% of the then issued and outstanding voting stock of Arcus, subject to certain exceptions. Additionally, we agreed not to dispose of any equity securities of Arcus prior to the second anniversary of the closing of the Stock Purchase Agreements without the prior consent of Arcus, subject to certain exceptions. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Collaboration Agreement and Stock Purchase Agreements which closed on July 13, 2020, and a separate secondary equity offering which closed on May 29, 2020, we acquired approximately 8.2&#160;million shares of Arcus common stock for approximately $261 million. In the first quarter of 2021, we amended and restated the common stock purchase agreement and acquired approximately 5.7&#160;million additional shares of Arcus common stock for $220 million. As a result, we currently own a total of 13.8&#160;million shares of Arcus, which represented approximately 19.5% of the issued and outstanding voting stock of Arcus immediately following the closing of the first quarter 2021 transaction. The amendment and restatement of the common stock purchase agreement in the first quarter of 2021 did not modify any of the terms above. We elected and applied the fair value option to account for our equity investment in Arcus whereby the investment is marked to market each reporting period based on the market price of Arcus shares. We believe the fair value option best reflects the underlying economics of the investment. Changes in fair value of the investment are recognized in Other income (expense), net on our Condensed Consolidated Statements of Operations. We initially recorded our equity investments in Arcus in Other long-term assets on our Condensed Consolidated Balance Sheets as the investments are subject to contractual lock-up provisions, subject to certain conditions. In the third quarter of 2021, we reclassified our equity investments in Arcus to Prepaid and other current assets on our Condensed Consolidated Balance Sheets as the contractual lock-up provisions will expire in July 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Arrangements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2021 and 2020, we entered into several collaborations, equity investments and licensing arrangements as well as other similar arrangements that we do not consider to be individually material. We recorded upfront collaboration expenses related to these arrangements within Acquired in-process research and development expenses on our Condensed Consolidated Statements of Operations. Upfront collaboration expenses and cash payments made related to our equity investments were not material for the three and nine months ended September 30, 2021 and 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the financial terms of these arrangements, we may be required to make payments upon achievement of developmental, regulatory and commercial milestones, which could be significant. Future milestone payments, if any, will be reflected in our Condensed Consolidated Statements of Operations when the corresponding events become probable. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeAndOtherArrangementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and Other Arrangements [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeAndOtherArrangementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeandOtherArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and Other Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeandOtherArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753342492328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT AND CREDIT FACILITIES</a></td>
<td class="text">DEBT AND CREDIT FACILITIES<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.382%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.15%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.52%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes and term loan facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,565&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,295&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,686&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,402&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,511&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,757&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, we repaid $3.75 billion of debt. We repaid $1.0 billion of senior unsecured notes due April 2021 in the first quarter of 2021 and $1.25 billion of senior unsecured notes due December 2021 in the third quarter of 2021. Additionally, we repaid $1.0 billion principal amount outstanding under our three-year $1.0 billion senior unsecured term loan facility due October 2023 and $500 million of our senior unsecured floating rate notes due September 2021 upon maturity. In October 2021, we exercised our option to call $500 million of our floating rate senior unsecured notes and $500 million of our 0.75% senior unsecured notes, both having a final maturity of September 2023. The notes will be repaid in November 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No new debt was issued during the three and nine months ended September 30, 2021. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of September&#160;30, 2021, we were in compliance with all covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, there were no amounts outstanding under our $2.5 billion revolving credit facility maturing in June 2025, and we were in compliance with all covenants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753343935192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, it is not possible to determine the outcome of these matters or the outcome (including in excess of any accrual) is not expected to be material, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss. In the third quarter of 2021, we reversed a $175 million previously recorded litigation accrual following a favorable court decision.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any material accruals for the matters described below on our Condensed Consolidated Balance Sheets as of September&#160;30, 2021 and December&#160;31, 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Sofosbuvir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of the HCV. In 2013, we received approval from FDA for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with the University of Minnesota</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The University of Minnesota (the &#8220;University&#8221;) has obtained U.S. Patent No. 8,815,830 (the &#8220;&#8217;830 patent&#8221;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#8217;830 patent. We believe the &#8217;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#8220;PTAB&#8221;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concludes the inter partes review that it has initiated. In May 2021, the PTAB issued a written decision finding the asserted claims of the University&#8217;s patent invalid. In July 2021, the University appealed this decision. The litigation in the U.S. District Court will remain stayed through the appeal proceedings.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with NuCana plc. (&#8220;NuCana&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NuCana has obtained European Patent No. 2,955,190 (the &#8220;EP &#8217;190 patent&#8221;) that allegedly covers sofosbuvir. In Opposition proceedings before the European Patent Office (&#8220;EPO&#8221;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#8217;190 patent in amended form. We believe that the amended EP &#8217;190 patent claims are invalid. Subsequently, we initiated proceedings to invalidate the UK counterpart of the EP &#8217;190 patent in the High Court of England &amp; Wales. In March 2021, NuCana filed a counterclaim against us in the High Court of England &amp; Wales alleging patent infringement of the UK counterpart and seeking damages and other relief. In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#252;sseldorf alleging patent infringement of the German counterpart of the EP &#8217;190 patent and seeking damages and other relief. The hearing date for the German NuCana case has been scheduled for May 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Axicabtagene Ciloleucel</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes on U.S. Patent No. 7,446,190 (the &#8220;&#8217;190 patent&#8221;). A jury trial was held on the &#8217;190 patent, and in December 2019, the jury found that the asserted claims of the &#8217;190 patent were valid, and that we willfully infringed the asserted claims of the &#8217;190 patent. The jury also awarded Juno damages in amounts of $585 million in an up-front payment and a 27.6% running royalty from October 2017 through the date of the jury&#8217;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#8217;s verdict, enhanced the past damages by 50% and maintained the royalties on future Yescarta sales at 27.6%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge, and in July 2021, the appeals court heard oral arguments. In August 2021, the Court of Appeals for the Federal Circuit (the &#8220;CAFC&#8221;) reversed the jury verdict finding the asserted claims of Juno&#8217;s patent invalid. In October 2021, Juno filed a petition for rehearing with the CAFC. We believe that the likelihood of a material adverse outcome in this matter is remote.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Bictegravir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV Healthcare Company (&#8220;ViiV&#8221;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes ViiV&#8217;s U.S. Patent No. 8,129,385 (the &#8220;&#8217;385 patent&#8221;) covering ViiV&#8217;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the &#8217;385 patent. The court has set a trial date of January 2022 for this lawsuit. ViiV is seeking billions of dollars for alleged damages comprised of ViiV&#8217;s lost profits and a royalty on sales of bictegravir from launch through the trial. ViiV calculates these damages based on the cumulative U.S. revenues from Biktarvy since launch, which have totaled $16.4 billion through September&#160;30, 2021. In addition, should a court find that we are liable for infringement, we expect ViiV will seek a royalty on sales after the trial. Although we cannot predict with certainty the ultimate outcome of this litigation, an adverse judgment could result in substantial monetary damages, including ViiV&#8217;s lost profits and royalties through trial, and a going-forward royalty stream on future sales. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound have infringed ViiV&#8217;s Canadian Patent No. 2,606,282 (the &#8220;&#8217;282 patent&#8221;), which was issued to Shionogi &amp; Co. Ltd. and ViiV. The &#8217;282 patent is the compound patent covering ViiV&#8217;s dolutegravir. We believe that bictegravir does not infringe the claims of the &#8217;282 patent. In January 2020, the court held a summary trial to assess ViiV&#8217;s infringement allegations. In April 2020, the court determined that bictegravir does not infringe the claims of the &#8217;282 patent and dismissed the case. ViiV appealed this decision, and in June 2021, the Canadian Federal Court of Appeal upheld the Federal Court of Canada&#8217;s decision. ViiV has sought leave to appeal to the Canadian Supreme Court. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019, ViiV filed lawsuits in France, Germany, Ireland and the UK asserting the relevant national designations of European Patent No. 3 045 206 (&#8220;EP &#8217;206&#8221;); in Australia asserting Australian Patent No. 2006239177; in Japan asserting Japanese Patent No. 4295353; and in Korea asserting Korean Patent Nos. 1848819 (&#8220;KR &#8217;819&#8221;) and 1363875. These patents all relate to molecules that ViiV claims would act as integrase inhibitors. We believe that bictegravir does not infringe the claims of any of ViiV&#8217;s patents. In 2019, we filed an opposition in the EPO requesting revocation of EP &#8217;206. The EPO hearing took place in January 2021, and the patent claims, which do not cover bictegravir, were maintained in amended form. Both parties have appealed this decision. Additionally, in 2020, we filed a petition in the Korean Intellectual Property Office requesting invalidation of KR &#8217;819. Following a trial, a tribunal of the Korean Intellectual Property Trial and Appeal Board found KR &#8217;819 to be invalid. In March 2021, ViiV appealed this decision. In April 2021, the court in Germany held a hearing on the issue of infringement, and in September 2021, determined that Gilead does not infringe ViiV&#8217;s EP &#8217;206 patent both in its original form and as amended by the EPO. ViiV has appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In all jurisdictions, to the extent that the claims of ViiV&#8217;s patents are interpreted to cover bictegravir, we believe that those claims are invalid. We cannot predict the ultimate outcome of intellectual property claims related to bictegravir. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Relating to Pre-Exposure Prophylaxis</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#8220;HHS Patents&#8221;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of emtricitabine and tenofovir or TDF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#8220;PrEP&#8221;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the Court of Federal Claims, alleging violations of four material transfer agreements (&#8220;MTAs&#8221;) related to the research underlying the HHS Patents and a clinical trial agreement (&#8220;CTA&#8221;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#8217;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the Court of Federal Claims has been set for June 2022, and a trial date for the lawsuit in the District Court of Delaware has been set for May 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Generic Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#8220;NCE&#8221;) exclusivity period during which other manufacturers&#8217; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#8220;ANDA&#8221;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#8217;s approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in December 2019, we received letters from Lupin Ltd., Apotex Inc., Shilpa Medicare Ltd., Sunshine Lake Pharma Co. Ltd., Laurus Labs, Natco Pharma Ltd., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. (collectively, &#8220;generic manufacturers&#8221;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of certain of our tenofovir alafenamide (&#8220;TAF&#8221;)-containing products. Between them, these generic manufacturers seek to market generic versions of Odefsey, Descovy and Vemlidy. Some generic manufacturers have challenged the validity of four patents listed on the Orange Book and associated with TAF, while others have challenged the validity of two of our Orange Book-listed patents associated with TAF. We filed lawsuits against the generic manufacturers, and we intend to enforce and defend our intellectual property.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we received a letter from Lupin Ltd. indicating that it has submitted an ANDA to the FDA requesting permission to market and manufacture a generic version of Symtuza. We are evaluating the letter and intend to enforce and defend our intellectual property.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Claims</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. An appeal hearing originally scheduled for July 2021 has been canceled and a new date has not yet been set by the EPO.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. Two of the original opposing parties have appealed, requesting full revocation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2026. In 2017, the EPO upheld the validity of the claims of our TAF patent. Three parties have appealed this decision. The appeal hearing was held in March 2021, and the validity of all claims were upheld.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. Three parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, three parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2027. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. Two parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF, TAF hemifumarate and cobicistat in the European Union could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust and Consumer Protection</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We (along with Japan Tobacco, Inc. (&#8220;Japan Tobacco&#8221;), Bristol-Myers Squibb Company (&#8220;BMS&#8221;) and Johnson &amp; Johnson, Inc.) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Japan Tobacco was dismissed from the lawsuit after a favorable court ruling on the defendants&#8217; motion to dismiss. Plaintiffs allege that we (and the other remaining defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of two nationwide classes - one of direct purchasers consisting largely of wholesalers, and another of end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In September 2021, we, along with BMS and generic manufacturer Teva Pharmaceuticals USA (&#8220;Teva&#8221;), were named as defendants in similar lawsuits filed by CVS, Rite Aid, Walgreens, Safeway, Kroger, Albertsons and HEB (the &#8220;Retailers&#8221;) in the U.S. District Court for the Northern District of California. The Retailers are opting out of the proposed direct purchaser class and, based on assignments by their wholesalers, seek to bring claims substantially the same as the putative class.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we, along with generic manufacturers Cipla Ltd. and Cipla USA Inc. (together, &#8220;Cipla&#8221;), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#8220;Jacksonville Trust&#8221;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and Cipla, which settled a patent dispute relating to patents covering our Emtriva, Truvada, and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. The Plaintiff seeks damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we along with BMS and Teva were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in one class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Missouri and New Jersey, involve more than 24,000 plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#8217;s decision not to intervene in the suit, the relator served us with a Second Amended Complaint in January 2021. The lawsuit alleges that Gilead&#8217;s HCV patient access programs, clinical educator programs, speaker programs, and other sales and marketing programs violated the federal False Claims Act and various state false claims acts. In July 2021, the relator filed a Third Amended Complaint, removing allegations against us regarding our patient access programs, clinical educator programs and relationships with specialty pharmacies. The relator seeks all available relief under these statutes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two former employees filed a qui tam lawsuit against Gilead in April 2020 in California state court. These same former employees had previously filed a qui tam lawsuit in federal court in California, and the U.S. Department of Justice declined intervention and moved to dismiss relators&#8217; federal False Claims Act claims. Relators subsequently voluntarily dismissed their federal lawsuit and refiled their lawsuit in California state court. Following the California Attorney General&#8217;s Office&#8217;s decision not to intervene, relators served Gilead with their complaint in August 2020. The complaint alleges violations of the California False Claims Act (&#8220;CFCA&#8221;) and employment law claims. Relators seek all available relief under the CFCA.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice Advocates, LLC (&#8220;Health Choice&#8221;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court&#8217;s dismissal.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#8220;TMFPA&#8221;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA. In September 2021, the Texas Court of Appeals for the Sixth Court Appeals District granted our request to stay the Texas litigation. The case is stayed pending final judgment in the Eastern District of Pennsylvania lawsuit filed in March 2017, as discussed above.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019, which were consolidated in September 2019. Plaintiffs filed a consolidated complaint in November 2019 and an amended complaint in July 2021. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#8217; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the U.S. District Court for the District of New Jersey. While we believe this case is without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753343893816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Programs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2016, our Board of Directors authorized a $12.0 billion stock repurchase program (&#8220;2016 Program&#8221;) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a new $5.0 billion&#160;stock repurchase program (&#8220;2020 Program&#8221;), which will commence upon the completion of the&#160;2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2021, we repurchased and retired 2.1 million and 7.5 million shares of our common stock for $145 million and $497 million, respectively, through open market transactions under the 2016 Program. During the three and nine months ended September 30, 2020, we repurchased and retired 3.0 million and 22.4 million shares of our common stock for $201 million and $1.6 billion, respectively, through open market transactions under the 2016 Program.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the remaining authorized repurchase amount under both programs was $6.3 billion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in AOCI by component, net of tax:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income (loss) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts reclassified to net income (loss) for gains and losses on cash flow hedges are recorded as part of Product sales on our Condensed Consolidated Statements of Operations. See Note 5. Derivative Financial Instruments for additional information. The amounts reclassified to net income (loss) for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net on our Condensed Consolidated Statements of Operations. Gross realized gains and losses on available-for-sale debt securities were not material for the nine months ended September 30, 2021 and 2020. The income tax impact allocated to each component of other comprehensive income (loss) was not material for the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753342473928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</a></td>
<td class="text">NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share attributable to Gilead common stockholders is calculated based on the weighted average number of shares of our common stock outstanding during the period. Diluted net income (loss) per share attributable to Gilead common stockholders is calculated based on the weighted average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock metho</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential shares of common stock excluded from the computation of diluted net income (loss) per share attributable to Gilead common stockholders because their effect would have been antidilutive were 14 million and 15 million for the three and nine months ended September 30, 2021, respectively, and 13 million and 38 million for the three and nine months ended September 30, 2020, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the calculation of basic and diluted net income (loss) per share attributable to Gilead common stockholders:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.822%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,843&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,428)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753514233800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES <div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our income tax expense:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.822%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,438&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,519&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of 24.8% for the three months ended September 30, 2021 is higher than the U.S. federal statutory rate of 21% primarily due to remeasurement of certain deferred tax liabilities related to acquired intangible assets, partially offset by provision to return adjustments.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of 22.5% for the nine months ended September 30, 2021 is higher than the U.S. federal statutory rate of 21% primarily due to remeasurement of certain deferred tax liabilities related to acquired intangible assets and unfavorable changes in the fair value of our equity investment in Galapagos that are non-deductible for income tax purposes, partially offset by provision to return adjustments.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of 57.2% for the three months ended September 30, 2020 differed from the U.S. federal statutory rate of 21% primarily due to certain acquired IPR&amp;D charges and unfavorable changes in the fair value of our equity investment in Galapagos that are non-deductible for income tax purposes, partially offset by a net discrete tax benefit related to a settlement with a taxing authority.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of (903.4)% for the nine months ended September 30, 2020 differed from the U.S. federal statutory rate of 21% primarily due to a non-deductible $4.5&#160;billion IPR&amp;D charge recorded in connection with our second quarter 2020 acquisition of Forty Seven, in addition to the above mentioned amounts for the three months ended September 30, 2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently under examination by the U.S. Internal Revenue Service for the tax years from 2016 to 2018 and by various state and foreign jurisdictions. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We regularly evaluate our exposures associated with our tax filing positions to determine our assessment of unrecognized tax benefits in accordance with the income tax guidance which clarifies the accounting for uncertainty in income taxes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753344017480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and a variable interest entity (&#8220;VIE&#8221;) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We did not have any material VIEs as of September&#160;30, 2021.</span></div>The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">We have one operating segment, which focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of the company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Significant Accounting Policies, Estimates and Judgments</a></td>
<td class="text">The preparation of these Condensed Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the coronavirus disease 2019 (&#8220;COVID-19&#8221;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States and Europe. There were no material write-offs charged against the allowance for the three and nine months ended September 30, 2021 and 2020.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. </span></div>Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair values of Level 2 financial instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates (&#8220;LIBOR&#8221;) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753357310824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenues</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.660%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,302&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,189&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,722&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,547&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis B virus (&#8220;HBV&#8221;) / Hepatitis Delta virus (&#8220;HDV&#8221;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,923&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,509&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,577&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.660%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,132&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,777&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,213&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,720&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,681&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">HCV</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">HBV / HDV</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,208&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ranexa</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,002&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,559&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,061&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,890&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,698&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Revenues from Major Customers</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:</span></div><div style="margin-bottom:4pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:60.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753357538536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.661%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,134&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,279&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,008&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:4.5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes our equity investment in Arcus Biosciences, Inc. (&#8220;Arcus&#8221;) of $482 million as of September&#160;30, 2021 recorded in Prepaid and other current assets and $212 million as of December&#160;31, 2020 recorded in Other long-term assets on our Condensed Consolidated Balance Sheets. See Note 9. Collaborations and Other Arrangements for further information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of Classification of Equity Securities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis on our Condensed Consolidated Balance Sheets:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:4.5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;See the table under the Equity Investment in Galapagos NV (&#8220;Galapagos&#8221;) for more information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity investment in Galapagos in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753346230424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Reconciliation of Available-for-Sale Debt Securities from Cost Basis to Fair Value</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Classification of Available-for-Sale Debt Securities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-bottom:11pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Available-for-Sale Debt Securities by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753352759736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of Classification and Fair Value of Derivative Instruments</a></td>
<td class="text">The following table summarizes the classification and fair values of derivative instruments on our Condensed Consolidated Balance Sheets:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.315%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Effect of Foreign Currency Exchange Contracts</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: </span></div><div style="margin-bottom:11pt;margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) reclassified from AOCI into product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Summary of Potential Effect of Offsetting Derivatives</a></td>
<td class="text">The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts Not Offset <br/>on our Condensed <br/>Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts<br/>&#160;of Recognized <br/>Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts<br/>&#160;Offset on our <br/>Condensed <br/>Consolidated <br/>Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amounts of Assets/Liabilities Presented<br/>&#160;on our Condensed Consolidated<br/>Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Derivative <br/>Financial <br/>Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cash Collateral <br/>Received/<br/>Pledged</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Amount<br/>&#160;(Legal Offset)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753342583048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlicense contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753342279624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from the acquisition of MYR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,332&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="margin-top:1.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,477)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,715&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,936)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,780&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,897&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)(2)(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,936)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes $910&#160;million reclassified from indefinite-lived assets - IPR&amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes Trodelvy for metastatic triple-negative breast cancer which was granted approval by FDA in April 2021 and Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer (&#8220;UC&#8221;) which was granted accelerated approval by FDA in April 2021. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&amp;D.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes $1.2&#160;billion recognized from the first quarter 2021 acquisition of MYR. See Note 6. Acquisitions for additional information.</span></div>(4) &#160;&#160;&#160;&#160;In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200&#160;million will be reclassified to finite-lived assets in the fourth quarter of 2021.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="margin-top:1.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,477)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,715&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,936)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,780&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,897&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)(2)(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,936)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes $910&#160;million reclassified from indefinite-lived assets - IPR&amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes Trodelvy for metastatic triple-negative breast cancer which was granted approval by FDA in April 2021 and Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer (&#8220;UC&#8221;) which was granted accelerated approval by FDA in April 2021. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&amp;D.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of September&#160;30, 2021 includes $1.2&#160;billion recognized from the first quarter 2021 acquisition of MYR. See Note 6. Acquisitions for additional information.</span></div>(4) &#160;&#160;&#160;&#160;In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200&#160;million will be reclassified to finite-lived assets in the fourth quarter of 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of September&#160;30, 2021:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753441733016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net:</span></div><div style="margin-bottom:1pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,284&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,560&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,566&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,892&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,797&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,797&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Accrued and other current liabilities:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753342486344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Debt Carrying Amount</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.382%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.15%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.52%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes and term loan facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,565&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,295&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,686&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,402&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,511&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,757&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753344354920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of Changes in Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in AOCI by component, net of tax:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income (loss) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753343821352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of the Calculation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the calculation of basic and diluted net income (loss) per share attributable to Gilead common stockholders:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.822%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,843&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,428)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753342478568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of the Provision for Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our income tax expense:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.822%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,438&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,519&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753353017176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs charged against allowance | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753337576200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Disaggregation of Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 7,421<span></span>
</td>
<td class="nump">$ 6,577<span></span>
</td>
<td class="nump">$ 20,061<span></span>
</td>
<td class="nump">$ 17,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5,509<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">14,002<span></span>
</td>
<td class="nump">12,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,031<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="nump">3,559<span></span>
</td>
<td class="nump">2,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=gild_OtherInternationalMember', window );">Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">881<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">1,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7,356<span></span>
</td>
<td class="nump">6,493<span></span>
</td>
<td class="nump">19,848<span></span>
</td>
<td class="nump">17,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5,479<span></span>
</td>
<td class="nump">5,076<span></span>
</td>
<td class="nump">13,932<span></span>
</td>
<td class="nump">12,835<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">997<span></span>
</td>
<td class="nump">877<span></span>
</td>
<td class="nump">3,419<span></span>
</td>
<td class="nump">2,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">880<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
<td class="nump">1,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,189<span></span>
</td>
<td class="nump">4,547<span></span>
</td>
<td class="nump">11,777<span></span>
</td>
<td class="nump">12,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,302<span></span>
</td>
<td class="nump">3,722<span></span>
</td>
<td class="nump">9,132<span></span>
</td>
<td class="nump">10,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">569<span></span>
</td>
<td class="nump">1,776<span></span>
</td>
<td class="nump">1,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">869<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">Atripla</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">Atripla | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">Atripla | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">Atripla | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,276<span></span>
</td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">6,094<span></span>
</td>
<td class="nump">5,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,875<span></span>
</td>
<td class="nump">1,584<span></span>
</td>
<td class="nump">4,926<span></span>
</td>
<td class="nump">4,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">707<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">461<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="nump">1,227<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="nump">994<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">846<span></span>
</td>
<td class="nump">2,123<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">669<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">437<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
<td class="nump">1,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">773<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="nump">1,488<span></span>
</td>
<td class="nump">1,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">809<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="nump">466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">1,155<span></span>
</td>
<td class="nump">1,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="nump">704<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">589<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,923<span></span>
</td>
<td class="nump">873<span></span>
</td>
<td class="nump">4,208<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">785<span></span>
</td>
<td class="nump">2,763<span></span>
</td>
<td class="nump">785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">684<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">632<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">513<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Zydelig</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Zydelig | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Zydelig | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Zydelig | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=gild_OtherInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=gild_OtherInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsStribildMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_VekluryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_VekluryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_TrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_TrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753357513128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Revenues from Major Customers (Details) - Revenue from Contract with Customer Benchmark - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember', window );">AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gild_CardinalHealthIncMember', window );">Cardinal Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gild_MckessonCorpMember', window );">McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_MckessonCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_MckessonCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753353250424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Change in estimate of variable consideration</a></td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 661<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Contract with customer, performance obligation satisfied in previous period</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
<td class="nump">$ 618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753350245928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 4,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">7,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">2,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Equity investment in Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Other publicly traded equity securities | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">2,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Equity investment in Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">2,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Equity investment in Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Equity investment in Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_EquityinvestmentinGalapagosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_EquityinvestmentinGalapagosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_ForeignCurrencyDerivativeContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_ForeignCurrencyDerivativeContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753358080504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Classification of Equity Securities (Details) - Equity Securities - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 4,774<span></span>
</td>
<td class="nump">$ 6,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">2,768<span></span>
</td>
<td class="nump">4,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">871<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">$ 1,135<span></span>
</td>
<td class="nump">$ 1,756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753352926104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Net loss from equity securities</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 964<span></span>
</td>
<td class="nump">$ 667<span></span>
</td>
<td class="nump">$ 1,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity investments not measured at fair value</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable fair values</a></td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | MYR GmbH | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | MYR GmbH | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Market value | MYR GmbH | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Market value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Short-term and long-term debt</a></td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Short-term and long-term debt, carrying values</a></td>
<td class="nump">$ 26,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=gild_EquitySecuritiesDonationMember', window );">Equity Securities Donation | Gilead Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Donation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=gild_EquitySecuritiesDonationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=gild_EquitySecuritiesDonationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gild_GileadFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gild_GileadFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753343773800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Equity Investment In Galapagos (Details) - Galapagos NV - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investment</a></td>
<td class="nump">$ 881<span></span>
</td>
<td class="nump">$ 1,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosNVMember', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosNVMember', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investment</a></td>
<td class="nump">$ 881<span></span>
</td>
<td class="nump">$ 1,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753353074344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 2,489<span></span>
</td>
<td class="nump">$ 2,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">2,489<span></span>
</td>
<td class="nump">2,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember', window );">Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">$ 447<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753357162744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 2,489<span></span>
</td>
<td class="nump">$ 2,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember', window );">Short-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember', window );">Long-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 1,099<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753353214920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized&#160;Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Within one year</a></td>
<td class="nump">$ 1,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">After one year through five years</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost', window );">After five years</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">2,489<span></span>
</td>
<td class="nump">$ 2,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within one year</a></td>
<td class="nump">1,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After one year through five years</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">After five years</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 2,489<span></span>
</td>
<td class="nump">$ 2,026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753353190680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of positions held in an unrealized loss position | position</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Impairment recognized | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753353182616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet', window );">Discontinuances of cash flow hedges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Maturities of derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1', window );">Time estimate for gains (losses) to be reclassified from AOCI to product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period for the anticipated transfer of gain (loss), net, from accumulated other comprehensive income into earnings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net gain (loss) reclassified into earnings when foreign currency cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753356792680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Other&#160;long-term&#160;obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753352913288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Gains (losses) recognized in AOCI</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="num">$ (52)<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="num">$ (28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Gains (losses) reclassified from AOCI into product sales</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Gains (losses) recognized in Other income (expense), net</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753353225704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Derivative assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Gross Amounts of Recognized Assets/Liabilities</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Gross Amounts Offset on our Condensed Consolidated Balance Sheets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction', window );">Derivative Financial Instruments</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash Collateral Received/ Pledged</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net Amount (Legal Offset)</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Gross Amounts of Recognized Assets/Liabilities</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossAsset', window );">Gross Amounts Offset on our Condensed Consolidated Balance Sheets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Derivative Financial Instruments</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Cash Collateral Received/ Pledged</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net Amount (Legal Offset)</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (109)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753351331720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Narrative (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 23, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,171,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,000,000<span></span>
</td>
<td class="nump">$ 5,792,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gild_FortySevenIncMember', window );">Forty Seven, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PaymentsToAcquireAssetsNetOfCashAcquired', window );">Consideration, net of acquired cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Acquired share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D | Forty Seven, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition consideration transferred</a></td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="nump">&#8364; 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition</a></td>
<td class="nump">1,200,000,000<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Fair value of contingent liability</a></td>
<td class="nump">341,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="nump">845,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">226,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Expected tax deductible goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH | Level 3 | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 328,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 328,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 341,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH | Hepcludex For HDV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="nump">$ 845,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH | Hepcludex For HDV | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IntangibleAssetMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH | Acquired IPR&amp;D | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IntangibleAssetMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,991,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics | Three-Year Senior Term Loan Facility | Medium-term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowing from senior unsecured term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsToAcquireAssetsNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Assets, Net Of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsToAcquireAssetsNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=gild_FortySevenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=gild_FortySevenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexForHDVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexForHDVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753352278104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITIONS - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 04, 2021</div></th>
<th class="th"><div>Oct. 23, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(513)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet', window );">Other assets (and liabilities), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH | Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired IPR&amp;D</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 1,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,565)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability', window );">Liability related to future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet', window );">Other assets (and liabilities), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,991<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics | Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics | Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics | Outlicense contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyForMTNBCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyForMTNBCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753353096888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 8,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill resulting from the acquisition of MYR</a></td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Measurement period adjustments</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 8,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753346019048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,660)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,660)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified amounts</a></td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="num">$ (910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D | Forecast | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember', window );">Intangible asset - sofosbuvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,952)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,952)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember', window );">Intangible asset - axicabtagene ciloleucel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember', window );">Intangible asset - Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified amounts</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexForHDVMember', window );">Intangible asset - Hepcludex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (540)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | Forecast | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetsGrossReclassified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Gross, Reclassified</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetsGrossReclassified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexForHDVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexForHDVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_CellTherapyProductsTecartusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_CellTherapyProductsTecartusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753352759736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Aggregate amortization expense related to finite-lived intangible assets</a></td>
<td class="nump">$ 441<span></span>
</td>
<td class="nump">$ 281<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753445173384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2021 (remaining three months)</a></td>
<td class="nump">$ 441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">1,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">10,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 17,780<span></span>
</td>
<td class="nump">$ 16,236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753352271000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 5,284<span></span>
</td>
<td class="nump">$ 5,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AccountsReceivableChargebacksCurrent', window );">Less: chargebacks</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AccountsReceivableCashDiscountsAndOtherCurrent', window );">Less: cash discounts and other</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowances for credit losses</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 4,566<span></span>
</td>
<td class="nump">$ 4,892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccountsReceivableCashDiscountsAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Cash Discounts and Other, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccountsReceivableCashDiscountsAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccountsReceivableChargebacksCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Chargebacks, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccountsReceivableChargebacksCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753356784696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,067<span></span>
</td>
<td class="nump">$ 1,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">727<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_InventoryNetAndInventoryNoncurrent', window );">Total</a></td>
<td class="nump">2,797<span></span>
</td>
<td class="nump">3,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,676<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">$ 1,121<span></span>
</td>
<td class="nump">$ 1,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_InventoryNetAndInventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory Net And Inventory Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_InventoryNetAndInventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753343943336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and employee benefits</a></td>
<td class="nump">$ 691<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Allowance for sales returns</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 3,781<span></span>
</td>
<td class="nump">$ 4,336<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=123410239&amp;loc=SL49130611-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753344609192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATIONS AND OTHER ARRANGEMENTS (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 13, 2021</div></th>
<th class="th"><div>May 29, 2020</div></th>
<th class="th"><div>May 27, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts', window );">Percent of global development and commercialization costs</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod', window );">Option period to license</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp agreement | Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts', window );">Percent of global development and commercialization costs</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp agreement | Oral Formulation Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementNetProductSalesThreshold', window );">Net product sales threshold</a></td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementPercentOfGlobalProductRevenues', window );">Percent of global product revenues</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp agreement | Injectable Formulation Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementNetProductSalesThreshold', window );">Net product sales threshold</a></td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementPercentOfGlobalProductRevenues', window );">Percent of global product revenues</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember', window );">Arcus stock purchase agreement | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember', window );">Other collaboration arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CashPaymentsMadeRelatedToEquityInvestments', window );">Cash payments made related to equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements', window );">Upfront collaboration expenses related to other collaborative arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | Arcus stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIPurchasePeriod', window );">Purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIRestrictionPeriod', window );">Restriction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNISharesAcquired', window );">Equity securities acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Payments to acquire equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIShares', window );">Equity securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | The &#8220;Stock Purchase Agreements&#8221;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased', window );">Maximum percentage of outstanding stock allowed to be purchased (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CashPaymentsMadeRelatedToEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Payments Made Related to Equity Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CashPaymentsMadeRelatedToEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementNetProductSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Net Product Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementNetProductSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Percent Of Global Development And Commercialization Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementPercentOfGlobalProductRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Percent Of Global Product Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementPercentOfGlobalProductRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Restriction Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNISharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNISharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Collaboration Expenses Related To Other Collaborative Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gild_MerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gild_MerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OralFormulationProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OralFormulationProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_InjectableFormulationProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_InjectableFormulationProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753345215304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 27,686<span></span>
</td>
<td class="nump">$ 31,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of long-term debt and other obligations, net</a></td>
<td class="nump">2,511<span></span>
</td>
<td class="nump">2,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, net</a></td>
<td class="nump">25,175<span></span>
</td>
<td class="nump">28,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember', window );">Senior Notes and Medium-Term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 26,565<span></span>
</td>
<td class="nump">30,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Unsecured Notes Due April 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.15% LIBOR Senior Unsecured Notes Due September 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.15% LIBOR Senior Unsecured Notes Due September 2021 | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest Rate, variable rate</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.40% Senior Unsecured Notes Due December 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.95% Senior Unsecured Notes Due March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.25% Senior Unsecured Notes Due September 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 999<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.50% Senior Unsecured Notes Due September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.52% LIBOR Senior Unsecured Notes Due September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.52% LIBOR Senior Unsecured Notes Due September 2023 | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest Rate, variable rate</a></td>
<td class="nump">0.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.75% Senior Unsecured Notes Due September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,994<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.70% Senior Unsecured Notes Due April 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,747<span></span>
</td>
<td class="nump">1,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.50% Senior Unsecured Notes Due February 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,747<span></span>
</td>
<td class="nump">1,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.65% Senior Unsecured Notes Due March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 2,738<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.95% Senior Unsecured Notes Due March 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,246<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.20% Senior Unsecured Notes Due October 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 746<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.65% Senior Unsecured Notes Due October 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.60% Senior Unsecured Notes Due September 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.00% Senior Unsecured Notes Due September 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 742<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.60% Senior Unsecured Notes Due October 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 987<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.65% Senior Unsecured Notes Due December 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 996<span></span>
</td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.80% Senior Unsecured Notes Due April 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Unsecured Notes Due February 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,733<span></span>
</td>
<td class="nump">1,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Unsecured Notes Due March 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 2,220<span></span>
</td>
<td class="nump">2,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.15% Senior Unsecured Notes Due March 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,727<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.80% Senior Unsecured Notes Due October 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate, stated percentage</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,476<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Medium-term Notes | Variable Term Loan Note Due October 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Liability related to future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,121<span></span>
</td>
<td class="nump">$ 1,107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A450SeniorUnsecuredNotesDueApril2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A450SeniorUnsecuredNotesDueApril2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A440SeniorUnsecuredNotesDueDecember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A440SeniorUnsecuredNotesDueDecember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A195SeniorUnsecuredNotesDueMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A195SeniorUnsecuredNotesDueMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A325SeniorUnsecuredNotesDueSeptember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A325SeniorUnsecuredNotesDueSeptember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A250SeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A250SeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A370SeniorUnsecuredNotesDueApril2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A370SeniorUnsecuredNotesDueApril2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A350SeniorUnsecuredNotesDueFebruary2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A350SeniorUnsecuredNotesDueFebruary2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A365SeniorUnsecuredNotesDueMarch2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A365SeniorUnsecuredNotesDueMarch2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A295SeniorUnsecuredNotesDueMarch2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A295SeniorUnsecuredNotesDueMarch2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A460SeniorUnsecuredNotesDueSeptember2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A460SeniorUnsecuredNotesDueSeptember2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A400SeniorUnsecuredNotesDueSeptember2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A400SeniorUnsecuredNotesDueSeptember2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A565SeniorUnsecuredNotesDueDecember2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A565SeniorUnsecuredNotesDueDecember2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A480SeniorUnsecuredNotesDueApril2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A480SeniorUnsecuredNotesDueApril2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A450SeniorUnsecuredNotesDueFebruary2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A450SeniorUnsecuredNotesDueFebruary2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A475SeniorUnsecuredNotesDueMarch2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A475SeniorUnsecuredNotesDueMarch2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A415SeniorUnsecuredNotesDueMarch2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A415SeniorUnsecuredNotesDueMarch2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_VariableTermLoanNoteDueOctober2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_VariableTermLoanNoteDueOctober2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753337521576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Debt issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amounts outstanding under revolving credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | The "2020 Revolving Credit Facility"</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Unsecured Notes Due April 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of senior unsecured notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.40% Senior Unsecured Notes Due December 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.15% LIBOR Senior Unsecured Notes Due September 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of senior unsecured notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.52% LIBOR Senior Unsecured Notes Due September 2023 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.75% Senior Unsecured Notes Due September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.75% Senior Unsecured Notes Due September 2023 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Medium-term Notes | Three-Year Senior Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of senior unsecured notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A450SeniorUnsecuredNotesDueApril2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A450SeniorUnsecuredNotesDueApril2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A440SeniorUnsecuredNotesDueDecember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A440SeniorUnsecuredNotesDueDecember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753352498760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>agreement </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>opposingParty </div>
<div>patent</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>plaintiff </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>party</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease', window );">Litigation accrual reversed | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne', window );">Number of patents challenged, scenario one | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo', window );">Number of patents challenged, scenario two | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember', window );">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_JudgmentRoyaltyRateFromOctober2017', window );">Running royalty rate from October 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_JudgmentEnhancedDamagesOnPastSales', window );">Enhancement rate on past damages</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_JudgmentRoyaltyRateOnFutureSales', window );">Running royalty rate on future sales</a></td>
<td class="nump">27.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember', window );">ViiV Healthcare Company | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember', window );">Pre-Exposure Prophylaxis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyMaterialTransferAgreementsNumber', window );">Number of material transfer agreements | agreement</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2024ExpirationMember', window );">European Patent Claims 2024 Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesAppealedNumber', window );">Number of parties appealed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2026ExpirationMember', window );">European Patent Claims 2026 Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesAppealedNumber', window );">Number of parties appealed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember', window );">European Patent Claims 2032 Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesAppealedNumber', window );">Number of parties appealed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2027ExpirationMember', window );">European Patent Claims 2027 Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesAppealedNumber', window );">Number of parties appealed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesFilingOppositionNumber', window );">Number of parties filing opposition | party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_ProductLiabilityMember', window );">Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of class action lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs involved | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_QuiTamMember', window );">Qui Tam</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs involved | plaintiff</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentEnhancedDamagesOnPastSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment: Enhanced Damages On Past Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentEnhancedDamagesOnPastSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentRoyaltyRateFromOctober2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment: Royalty Rate from October 2017</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentRoyaltyRateFromOctober2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentRoyaltyRateOnFutureSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment: Royalty Rate on Future Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentRoyaltyRateOnFutureSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyMaterialTransferAgreementsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Material Transfer Agreements, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyMaterialTransferAgreementsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPartiesAppealedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Parties Appealed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPartiesAppealedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPartiesFilingOppositionNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Parties Filing Opposition, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPartiesFilingOppositionNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Patents Allegedly Infringed, Number, Scenario One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2024ExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_EuropeanPatentClaims2024ExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2026ExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_EuropeanPatentClaims2026ExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2027ExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_EuropeanPatentClaims2027ExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_ProductLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_ProductLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_QuiTamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_QuiTamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753344373432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Additional Information (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased and retired (in shares)</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Value of shares repurchased and retired</a></td>
<td class="nump">$ 145,000,000<span></span>
</td>
<td class="nump">$ 201,000,000<span></span>
</td>
<td class="nump">$ 497,000,000<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount under stock repurchase programs</a></td>
<td class="nump">$ 6,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember', window );">2016 Stock Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount under stock repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember', window );">2020 Stock Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount under stock repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753345537112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 19,710<span></span>
</td>
<td class="nump">$ 18,142<span></span>
</td>
<td class="nump">$ 18,221<span></span>
</td>
<td class="nump">$ 22,650<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">35<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">21,471<span></span>
</td>
<td class="nump">17,471<span></span>
</td>
<td class="nump">21,471<span></span>
</td>
<td class="nump">17,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">35<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="num">$ (44)<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="num">$ (44)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753352226344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from earnings per share computation (in shares)</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753357259784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Gilead</a></td>
<td class="nump">$ 2,592<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
<td class="nump">$ 5,843<span></span>
</td>
<td class="num">$ (1,428)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in per share calculation - basic (in shares)</a></td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of stock options and equivalents (in shares)</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in per share calculation - diluted (in shares)</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to Gilead common stockholders - basic (in dollars per share)</a></td>
<td class="nump">$ 2.06<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share attributable to Gilead common stockholders - diluted (in dollars per share)</a></td>
<td class="nump">$ 2.05<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 4.63<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139753356911720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">$ 3,438<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,519<span></span>
</td>
<td class="num">$ (145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">$ (852)<span></span>
</td>
<td class="num">$ (472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,694)<span></span>
</td>
<td class="num">$ (1,310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">24.80%<span></span>
</td>
<td class="nump">57.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.50%<span></span>
</td>
<td class="num">(903.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Non-deductible IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4HDB=JOB*)TY;.5$+*69\RHS1SPP&4R1DXZ&6E@IF<-NG=-8[<#D# .R%;!
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MH-H4E292MR:^T/M3J*=L\_YTJZGL5KEG>'\*]%4![P_!](0Q10OP_@#*\/X
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M_$/UET%OXH/]9=TI=Z':W)6(^2_I0L-\@;]L!IPR --/)  !G#* ,IPR]##
M*3LYK5>PO_7ED.K[2Q^C7!K. B7B3H[QW@9R!_+U5X+6;\IL67]?Y$M6EMFB
M?CD7D2RR%4#^_UV6E4]OJJ^@;+Z8=?I_4$L#!!0    ( +J#8U/;H4N!LP(
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M!S&IMQQ@RE?$!!KL=$62>=S8BZ;'O>PGCN(-<;:/K QKN9HCT;$M&YZLT!V
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M<K0!ZX5%&T\/I*#_$G[V'U!+ P04    " "Z@V-3W[G)4(<,  "!'@  &0
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M^/0F$DE'(R0^M6R&$A"+ E P4^NMN-8S96N$37G>F8;Z>*_3)N)OF#,(JG:
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MP$=1X=C0[:WO3.^C+TY^[9AY]^Y8.?3[&MV,V51+-G37R$E[>N73Z>[J% $
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M!\*V/WBV-W6UYA\9IU6-XQE?KC0 TI( OE]45=W?D('A5^<W_P%02P,$%
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M"&A\"W?N-"#I8/Q<W_Z6:0<M4^G4A<E^UVFY>+%SO"-2-9-55EZ9VU]4H.>
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MCO^HK]J6BGT/O7_)&3WJ8E;BYL%PFYOQ^>'HY*AQ,+2R&[+#WY7@28GR@%"
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MVNN ;5K 9N/-*K1="^.IB0O+DKIFM,Q YTMC_/V&+VC[\)/_ %!+ P04
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M&:3^MZDVU*W-9L]C$S&B@9@'!#SD\;@8YZSU'8 3DK,>B>*I:Z5-'T@Q<3P
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MQS_!BG\$N^2?/4UL"';!'^<(!.5H ;Z?6E2>] <=T/X.[L7_ %!+ P04
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M,X:R@Z',&\K^G[">!7-].3(M*W$24.,9U"\8G+, L[)4&VD-=4V)_(4M!?9
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M41/A[%J:L!X_P3+DRK2VLPL=]GTE'>_AV&K1Y?SVMU,*"FF\W189"I8([%I
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M>.4=/K#S5G8[N?34#O7)[HDSU=PC]@#IY<B%$H.;9@6-I Z1]@X"?*N >SY
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M\Q_CX5\:LZ0_@#,U$):4].,"_+VJ<0!\/S.F\;_@ N$O(OWT;U!+ P04
M" "Z@V-34EV4%= %   J$   &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6S=6&M3VT84_2MW7*;%,\2VY!>$QPP8DC!- L6DG4ZG'];2VMJ)I%5V5QCZ
MZWON2A9V"I30?.I,HL=Z[[GWGOO2<K#4YK--I'1TFZ6Y/6PESA6ONUT;)3(3
MMJ,+F>.7N3:9<'@UBZXMC!2Q%\K2;MCKC;J94'GKZ,"O79JC UVZ5.7RTI M
MLTR8NQ.9ZN5A*VBM%J[4(G&\T#TZ*,1"3J7[5%P:O'4;E%AE,K=*YV3D_+!U
M'+P^&?!^O^%7)9=V[9G8DYG6G_GE/#YL]=@@F<K(,8+ [49.9)HR$,SX4F.V
M&I4LN/Z\0G_C?8<O,V'E1*>_J=@EAZW=%L5R+LK47>GE.UG[,V2\2*?67VE9
M[0VA,2JMTUDMC/=,Y=5=W-8\K GL]AX1"&N!T-M=*?)6G@HGC@Z,7I+AW4#C
M!^^JEX9Q*N>@3)W!KPIR[FAZ?3'Y^=W%^].SJ^E/=/;+I_/KWP^Z#LC\>S>J
M44XJE/ 1E#WZH'.76#K+8QEORG=A46-6N#+K)'P2<"J+#O5[.Q3VPN )O'[C
M9M_C]1_!._M2*G='?QS/K#/(A#^?P!PTF ./.?B/U#T?Y<<?=L-@O%]CT=3I
MZ#-=R:(T48+,HTNC%T9DELYS<HFDN3+6T9=2&"<-Z3G8"D8[I$M#)UJ8F)=.
ME4$!:&-)E"[11OTE8Q*T%82='LU4FG)M6*_)W&LJ*DVTS2:%O7T&7JGW2\%^
MFTH$V] R45&R)FN1GG<TD[C%DE1E*3<1+)C/:#/:\&IAU(UP,KVC7"ZT4WB.
M";')K?#U:COTFX1A[%N\ 5^I9=1UJQCS&*"I7^T\05'8>QY%.5K*UO#;6 I[
M7[.T4Q.T! A%.D-#BR25A:[LPTJ12M^@8,G73G7H\D&W[]5\-[)/2Z/RA9=W
MB9&21!Y3CF2EK"IMR:5-*$PGLQDL654G')1KI,1>T, E@^>P$Z!K5?3Q^K@S
M;-YM(@S\@ML<#::FX1C#!ADZ&&[(;@WVQJN%'6BPA?0M/;W;89-UN4@V7%_W
M[Y&D>;G;O2?=[B-KUDT/P\[@V7[#P$V_@\YHE8/?S>]C;\!#T>2]1O(\9V+6
M*F(M\46FR]S5X#/MDE4I6%H*2UNC3G]E,51%49F5J<^Y"Z ;FB#IC4QXM-](
M5"HXD'3-U:I3?"7X@(A9*NM/!6BW5;$D(E_@F4O]8G).LSM?/SJ7N=M!:CM?
M0^+V-6UC2\VA;1/F-Z9S3I/2&)3?'5TS1;#(,_JQDKL6M_0IQX=-ZKU]"P*L
MY_^]MEQ_B,;QC5 I&_8*@7HU%;#P5,X<:(R01DY)^RUH$V$3>@-_Z9V,%U_)
M7FLG4CH1J>!V(1P4176D@BH!:8N& 2XA_F\'0;_-]U&O[5'*>]4+J*;M%&K;
MV#?$!5OW0AH/,%JB5%BKYBH25;HX[6E454AJ*3^6POWF/NKQ/U83>4(=%=(H
MC5[JHQMM1'<3JC$@&(84] ?K'OXS&>%1?^3=8^?Z>[C ZO]]; -V=-C'Q3/
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M$,V.R@UZ"K:49F<E]<"X,V>;3:X0=W4%43HR#4-YH7(ND^UQ@&U1Z8I!AH.
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MXBH5\$[IINB=#_5-2RK0G,@^\^#L.\=3DJ';X36:U,X>N>%J%)^,($8/(X?
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M.^# <(Z7?P"5H6$=E;$3'.G\HP I-]QD1+@(AT$M$1(I!VQBW \Q\O\,=(^
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MM@]GQ]JBQ-8H(+0#O72"'@HY:0_,[D"\'YW! .#'!OO.38W,0DG5ZZIN:Q/
M<<3-^XB;^%$[G>AZGO$)^-*@9ZX\#OB(._D1'VB/^ QUU$X_S_YBK*T>L1Q>
MXWC7CI[*B?&]*\N"%6-(Y4J!6]O;RV%UN/L]:Z\\]^3MQ?%G72^STE)N%MCJ
MCV+D0]U>QK:3IEJ["]!IU2"@;KC"0<;43(#WBZIJ^@D+&&[$W_T'4$L#!!0
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M .[/!5;18F$8E/_I./\'4$L#!!0    ( +J#8U/<GG7S200  )8+   9
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MHXDA#=64*'1+5<"$VDJ"?IVLX3@0ZK<&%/T21=^BZ!_S*BL')"(T95@I&M$
M9XP%('>82O2,V9:8 X<1'TI-L\U50E D&%2D<5*;#.=E27\'5S5L!^^Q1 ;+
MB\&B#)AP#X96P@>'Q5:BJ8"L<T5",U*"T1!KF-Q@AGE T-(P5ETAR*DFZ9K(
M,K%5)R=*P:GJRF>*UY1E&>E0#B7!&.!3W;?!JP3N^,Y>L0)W%(VY!8D52H
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MAX^TS)ZIV42+C7T:KH6&AZ8=)O"R)](<@/U( +?SB3%0_J]@_ =02P,$%
M  @ NH-C4\YRP6![ P  'P@  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&ULS59=;RHW$/TKHU54@42S'^Q"H( $I/<6J;=)0V[[4/7![,Z"=;TVU_:&
MI+^^8^]"N%&2MF]]8?TQ<^:<&=O#Y*#T%[-#M/!8"6FFP<[:_3@,3;[#BIE+
MM4=).Z72%;,TU=O0[#6RPCM5(DRB:!!6C,M@-O%KMWHV4;457.*M!E-7%=-/
M"Q3J, WBX+APQ[<[ZQ;"V63/MKA&^WE_JVD6GE *7J$T7$G06$Z#>3Q>I,[>
M&_S&\6#.QN"4;)3ZXB:K8AI$CA *S*U#8/1YP"4*X8"(QM<6,SB%=([GXR/Z
M!Z^=M&R8P:42O_/"[J;!50 %EJP6]DX=?L)63^;P<B6,_X5#8SM, \AK8U75
M.A.#BLOFRQ[;/)PY7$5O."2M0^)Y-X$\RVMFV6RBU0&TLR8T-_!2O3>1X](5
M96TU[7+RL[/Y\M?/J_7J?G7SRQHZ]VPCT'0GH25H9Q#F+<RB@4G>@!G!)R7M
MSL"/LL#B6_^0*)UX)4=>B^1=P#7N+Z$?]2")DO@=O/Y)9]_C]=_ 6]2&5HR!
MI:HV7++F2,@"YL;0T9_G7VMNN%_]8[XQ5M-Q^?.=N.DI;NKCIF_IH%M4U )!
ME7"'N=I*_A<6L"I06EYR; F8AH&FN2/U,V<;+H@.&K=?5R]SVJ3PW=#N.H_-
MGN4X#>B^&M0/&,SN=PBE$G07N=R"=?5N+R3Q,H#&<CKJ1*-D7,,#$S6M$G?6
ML&3G+,492]:PI*^SMA2%G:6T(,@Q=+BD(RP$K9@NS"M52PLK:9G<<L>CB3&&
M#UQRB]\+NJX%\!?[< %7:?:<KM7MW7>LVO]P#7$O'D5PC25J[1US52%)?$33
M TF>G2SN=^&&R.FCGLX+'=W6,KX:=N%>62: MZ7RJ7*;K6O<Z_<S^*A4<2!-
MD"2#UB$G>>2DFS-V08;9((;_7>*7S.P\6NX&2#X4E*0:HCPD,2OY0#.E79!1
M.OCOA4I[@RAZM5!9;SB(X,:UB)S>=W0I\S<.XF'V7$$JW3=2.REE,NN>;L<3
M=07A<V85E+6M-8)63TPTUG0>HNC?U7N0_E.Q!R1F\%SM?F\TBE^M-^F0IA5P
M0:]7+QL-X;6')#Q[M"O46]^:#*%1<9KW^[1ZZG[SYM%_-F]:YR>FMUP:$%B2
M:W0YS +033MJ)E;M?0O8*$L-Q0]WU,%1.P/:+Y6RQXD+</I/,/L;4$L#!!0
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MDZ@#LGX&KC^T*.W3ZT1H+7*[G%.246D(\'PJ,$^;#Z.@?8L_^!M02P,$%
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M;1OC4=T//AVONVJ,X[(0&CA;(-1^33U0=:=:+XQ<N^YP)@WVFFZZPN:>*7L
MWR\DAJ596 'MWX7A_U!+ P04    " "Z@V-3&/+Z18@#  "*"   &0   'AL
M+W=O<FMS:&5E=',O<VAE970S,BYX;6S=5FUOVS80_BL'K=AL((W>+#O); ..
MDS;!VB6+G0W#L ^T=+:(4J1+4G&R7]\CI:C.T!CH/@ZP*9*Z>^XYWAU/XYW2
MGTR):.&Q$M),@M+:[5D8FKS$BIECM45);]9*5\S24F]"L]7("J]4B3")HF%8
M,2Z#Z=COW>KI6-56<(FW&DQ=54P_G:-0NTD0!\\;=WQ36K<13L=;ML$%VOOM
MK:95V*$4O$)IN)*@<3T)9O'9^<#)>X'?.>[,WAR<)RNE/KG%=3$)(D<(!>;6
M(3!Z/. <A7! 1.-SBQET)IWB_OP9_9WWG7Q9,8-S)?[@A2TGP4D !:Y9+>R=
MVEUAZT_F\'(EC!]AU\@.23BOC555JTP,*BZ;)WMLSV%/X21Z12%I%1+/NS'D
M65XPRZ9CK7:@G32AN8EWU6L3.2Y=4!96TUM.>G:Z6-[,?[FZ^7!Q>;?X"2Y_
MN[]>_@F])5L)-/UQ:,F$$PSS%NZ\@4M>@3N%CTK:TL"E++!XJ1\2M8Y?\LSO
M/#D(N,#M,:31$211$A_ 2SM_4X^7OH)W^;GF]@G^FJV,U902?Q_ ''28 X\Y
M>(UCD]"@UC OF=R@ 2YAEN=U50MFL8 ;6Z*&N:JH<$J7T0\(US)7%4+O@S+?
M/NF#1EVQGIDMRW$2$*A!_8#!=%DBK)6@2N-R ]9%L2TW_@^Q(A:0[S&\F5_#
MZ@F(QU9)E/8()%T#Y(9ECV?0(Y&*"T'%8_I -4 9+F%>:XTR?X*E9M*0>_3Z
M"'YM]);L$>XE70Z"[!7PGBX% TP6X)PDHU2&LP?&A2/VEFZ4MPM&#"]P96&!
M>:VYY6B^!VW.3 GOR%^XPF+S+]VELDS .1-,Y@C,DJ$<JQ5%(HU]0D7P!K*8
MAH3^O3A.^^XYC/H>I?YJ>D.FH2=<I$@NHX%$3Q,8#> .<\&,X6N>^[.@4U;^
M&'D;WT;KQQ].DCCYN7L.(_=S9G)_H!:VJ+DJ0/E4R5^DRDNHCD"<)1"G@WT/
MJ5QLZV);,^11.O3N.>?24QJ(]?\^MK%S-$MI\"?@AI/L<%B3/@P2Z"5TNMGW
MAK47CP@BH\SI#4?]_QI78I!DT!NY^ YI<2BP+G<'/G=]= <#%]XDA6_=9^%>
M?ZA0;WP7-$2FEK9I%=UNUVAG37_Y*MYTZ8],;URH!*Y)-3H>90'HIO,U"ZNV
MOMNLE*7>Y:<E?2R@=@+T?JV4?5XX ]WGQ_0+4$L#!!0    ( +J#8U-M^<'H
M3P,  *@'   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;*U5;8_B-A#^
M*Z/T5(%$20@OM[L%)&#I[:J[@(!K/U3]8)*!6.O$.=LYMOWU'3LA"]K;U>E4
M1;+'SLPSS\S8X^%1JB>=(!IX3D6F1UYB3'[C^SI*,&6Z+7/,Z,]>JI096JJ#
MKW.%+'9&J?##(!CX*>.9-QZZO94:#V5A!,]PI4 7:<K4/U,4\CCR.MYI8\T/
MB;$;_GB8LP-NT'S.5XI6?HT2\Q0SS64&"O<C;]*YF?:LOE/X@^-1G\E@(]E)
M^607]_'("RPA%!@9B\!H^HHS%,("$8TO%:97N[2&Y_()_3<7.\6R8QIG4OS)
M8Y.,O"L/8MRS0IBU/-YA%4_?XD52:#?"L=(-/(@*;61:&1.#E&?ES)ZK/'R/
M05@9A(YWZ<BQO&6&C8=*'D%9;4*S@@O561,YGMFB;(RBOYSLS'@QW\+]8K9\
MG$/C8;G9-&$U7\/F;K*>PV2[7=]//V\GTX<Y;)?PZ?YA/KD%4GY<+F"S7<Y^
MOUL^W,[7&VALV4Z@;@Y]0Z0LM!]5!*8E@? - M?P*#.3:)AG,<:7]CX%4T<4
MGB*:AN\";C!O0S=H01B$G7?PNG6&N@ZO^P;>G*F,9P<-*U2P29A"^&NRTT;1
M@?K['?Q>C=]S^+VW^-(]BPN!(/=@$H09$U$AF#NSM#5EFD? LAANN2@,QO":
MT+>R_K[3+3G:2T%7DI# V.)5]Y+_B]KQB"YY[&H><<4CHY;!LTBF" TAM6Y"
M3H2TRQ S1O%=40(;"9^XH(X!I)P2')WJZ"F1(D:E;V";*,2+4P +HGNY0U4U
MF.[(@2WMY:K!,[H:0A!3W0)\CNCO.9=4%IDA>O9 V"$XDQ:O@GB#^@<(6_WK
MD.;N(*"QW[KJ=6EN=%J]\*I9%D)#H8DL\7EQ?Y['7ZHT=EIA?^#&_IG\L2PQ
M=2G _9[:ELV[RQ7(W-IKEW_\4O"O3"#%! /W_?S35=@)?_U>#J<"DL]!Z,;.
MBTPL7N?D1PI;!TN9:P<#FH)V>$U3KSWHN\2U.[WF_^?L%)5SU[]PUZW=?>N^
M^F?=,T5U<&^$)B]T:LI&6N_6S]"D[+XOZN4;]LC4@5.9!.[)-&A_['N@RG>A
M7!B9NUZ\DX8ZNQ,3"@F55:#_>RG-:6$=U(_S^#]02P,$%     @ NH-C4\":
M?M&N @  M04  !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL?51M;^(P
M#/XK5G630$*T]&7 !$BP<;I]V X-[D4ZW8=27!HM;7I)&-S]^G/2TH$T^!+;
MB9_'=A)[M!?R566(&@XY+]38R;0N[UQ7)1GFL>J*$@LZ287,8TVFW+JJE!AO
M+"CGKN]YMVX>L\*9C.S>0DY&8J<Y*W A0>WR/)9_9\C%?NSTG./&"]MFVFRX
MDU$9;W&)^ENYD&2Y#<N&Y5@H)@J0F(Z=:>]N%AI_Z_"=X5Z=Z& J60OQ:HS'
MS=CQ3$+(,=&&(2;QAO?(N2&B-/[4G$X3T@!/]2/[9UL[U;*.%=X+_H-M=#9V
M!@YL,(UW7+^(_1>LZXD,7R*XLBOL*]_0=R#9*2WR&DP9Y*RH9'RH[^$$,/ N
M /P:X-N\JT VRX=8QY.1%'N0QIO8C&)+M6A*CA7F499:TBDCG)X\/M]_?9K#
M:OISOH36*EYS5.V1JXG:.+A)33.K:/P+-$-X$H7.%,R+#6[.\2ZEU.3E'_.:
M^5<)EUAV(? ZX'M^[PI?T-096+[@4IU%(G*$57R !Z82+M1.(OR:KI66]#-^
M7PD1-B%"&R*\E'+UKT&DH#.$A11OS/Y=:AUXCX_JH^N]3KTBOE1PZB!6;$&;
M5ZK;B/U#!6(G@54!-!6(!VI9A7>PRB3BV<O ,S&?[]!-:\S7*.UUGULM5M"G
MXYRJ4!WB3>@42I0)%II:5K7M\YC%.]'J6EMTR>2Q1JH?3_*CA#]!T F# <F!
M']':[T2](<E6+XS:1_Q)*>9H$/EM(\-^)7N=VV%8:T'/:\,\3='VN$7*6"/X
M87< -Q#UNSX)W^]&)%I#+^@2\N:C-W=/6BE'N;4#0T$B=H6NNJK9;6;2M&K%
M=_=JH#W%<LL*!1Q3@GK=?N2 K(9$96A1VL9<"TUM;M6,YBI*XT#GJ1#Z:)@
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M#8#D5F %0+TD=P2@KHXL.BA$?DI'_N^/^\W-=IVZ92&P4F%UHP[AMIZK;M1
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MQ1- 1=^[,<ND,SR33SQE9#AF4G1#\:8JO*O*_+8J0/W0$1)))(HN<.2'DE$
M*%KF[RO>4B6="SA;=B<5YE;T5>E>*LS%Z*O9W50J5/<A^((@^5(;@>0+A!&!
M8C5WGCDHO>&@Y'2=V4.%61=]55A$\<S0Z*NY(LKC"*EWW @CW[XAC.J" S"Q
MPA_/G)0^RTGYP^NW%S^LDHU4F&'15Z5;J3#GHJ]F-U.ID,RA.A8AE)),$*I3
MA\ A5!M[.>"9<])G.2<?V++SF&=>1>\*JR/>\7Y6<]61QQ&>)Q:I4&*4>KX
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ME"F"K!!&/4OH6C$AD5DHO6&A?*+)3EC,J^BIM,3!/(O>Z!J80Y3MC$$8E;
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M(9"7V[T1H:*5P)[9(WV6/5(P=V:R8QY%WY561IA7T1L=#7-H3*D5CRS:9X9
MC)(< 2@F%3.3I+=,DM.[]?[XZ9"\:2P&=Z7%$&9#]$8WPPR&>E!KH58C *2*
M!0#&.:6&(%1L(<DLD-ZR0#Z0E)'/F-W0]Z6E#V8_]$93PQRN@*U$I3, 4C$1
M8'0R2PXDILEBOV5\#$S9"8PY#'U?6@9A5D-OM#/,X0KUFE5< 7E#<953UP%
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M:F-QJJ+!*29&KMT/>2$-;H(;9M@3@K( _+Z2TKQ.K(&JRQS\ 5!+ P04
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MJWDS*XW)^%@<27Q@0.,S%9,9N78DT0%7.?9&&AMP#]%RWLQ*@D':M!:,J'9
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M][LT+9HGU0]4['["Y/3_4$L#!!0    ( +N#8U,F=6D= @,  (\)   9
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M'W1WCNAT)02+YG!#))/PYX/6!_>*AO*O"F_<S!LW]L8]X,T7S0T!EQ)F@H=
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M(KDE2R:*+^-+F@E7BH?Q<*%K2X41T,]GG*OWB3&0W55V_@902P,$%     @
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MV8IJQU07Q0L[1!=<Z9%LCYE>RR",@_Z^Y%QM+R9 L^C'_P!02P,$%     @
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M#HDP ?KY@G/U<F,^<.0?M 9_ 5!+ P04    " "[@V-3G".'WCD#   0"0
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M O@^DG@OS2;V4IQ_!(V^ E!+ P04    " "[@V-36?C[>U$&  !Z'@  &0
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ME%[.*(%LU@+P^X1#7+(;_?UJ\[FY^Q]02P,$%     @ NX-C4Z;G %^A!
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MS$$9S-):3Y_F9MVG2NB[5-NIT>7XCX?)='(_N?E]"D[!5.^KM& $\#FXQE2
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M$Y[);V[S(@V%?%O<=<M)P<-Q[90F7>1YK)N&<=8Y.J@_^U0<'>13D<09_U2
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MX9@7E8'\_C;/Q<\WU07FYY>/_@=02P,$%     @ NX-C4V2*E=2W @  ]08
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M_^W&<^"HFP [!]T6Q4FRA]@0='FU[Z>_<X#9G\>#:3;*%3!<&%EPT3$ERO)
M+B=:K-R9-A?:G)!NF)M_&$H;8-XOA-#O$WM,UG_%_C]02P,$%     @ NX-C
M4P=B+&"\ @  ? <  !D   !X;"]W;W)K<VAE971S+W-H965T-3@N>&ULC97;
M;N(P$(9?Q8IZT4K;Y@1)6@$2A45%VM(*VNW%:B],,H!5Q\[:!KIOO[9#HQ1"
MM#>)#_//?#,^]?9<O,L-@$(?.66R[VR4*NY<5Z8;R+&\X04P/;/B(L=*=\7:
ME84 G%E13MW \R(WQX0Y@YX=>Q:#'M\J2A@\"R2W>8[%WWN@?-]W?.=S8$[6
M&V4&W$&OP&M8@'HMGH7NN967C.3 ).$,"5CUG:%_-TJ,O37X26 O:VUD,EER
M_FXZTZSO> 8(**3*>,#ZMX,14&H<:8P_!Y].%=((Z^U/[Q.;N\YEB26,.'TC
MF=KTG<1!&:SPEJHYWS_ (9^N\9=R*NT7[4O;.')0NI6*YP>Q)L@)*__XXU"'
MFL#OG!$$!T'POX+P( AMHB6936N,%1[T!-\C8:RU-].PM;%JG0UA9A472NA9
MHG5J\/3R\'V.)M/9<#::#G^@Z6SR-'\<ODR?9N@:3=D.F.*"@$278U"84'FE
MQU\78W1Y<84N$&'HD5"J5T3V7*6!C%LW/02_+X,'9X(OH+A!H?<-!5[@-\A'
M[?(QI%KN6[GW5>[J,E2U"*I:!-9?>*X6:@,"30C#+"68ZNS+4V*VVZ_A4BJA
M-]WOED!A%2BT@3IG LWQ7J^A J&C-):ME$=6;L[A;N![4=QS=_7B-!DE7F7T
MA:Q3D75:R=[TF3-K6@B>@FQD*QUT:V'CX!CMU.8VCIK)NA59MY5,+PO1VSQ#
M:\ZS1K#N25#?\\(CLE.CVV[23!959%$KV0M7F#8!12>Q@OCVN%2G1J'G=YJ)
MXHHH;B6J'=LFKOBT4%%M>4JN)J,D;.9**JZDE:L\8)2S];7>_#G"4H)J1$Q.
M][9OKH@OB U&8>@?(;JUN]&\2X]8K F3B,)*R[R;6*<HRKN^["A>V.MRR96^
M?&USHY]'$,9 SZ\X5Y\=<P-7#^[@'U!+ P04    " "[@V-3:9DL5,8"   E
M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6R-E=]OVC 0Q_\5*]I#
M*VW-3Q):020*0T5JH8)V>YCVX(0#K#IV9IO2_O>SG32C$-!>$CNY[]WGSF>[
MM^/B16X %'HK*)-]9Z-4>>.Z,M] @>45+X'I/RLN"JST5*Q=60K 2RLJJ!MX
M7NP6F# G[=EOCR+M\:VBA,&C0');%%B\WP+EN[[C.Q\?YF2]4>:#F_9*O(8%
MJ.?R4>B9VWA9D@*8))PA :N^,_!OAHFQMP8_".SDWAB93#+.7\QDLNP[G@$"
M"KDR'K!^O<(0*#6.-,:?VJ?3A#3"_?&']['-7>>280E#3G^2I=KTG:Z#EK#"
M6ZKF?'<'=3X=XR_G5-HGVM6VGH/RK52\J,6:H""L>N.WN@Y[ C\Z(0AJ0?"_
M@K 6A#;1BLRF-<(*ISW!=T@8:^W-#&QMK%IG0YA9Q842^B_1.I7.GNZ^S]%X
M,AU,AY/!/9I,Q[/YP^!I,INB;VB0YV(+2X39$LW4!@0:;H4 IM ]P1FA1!&0
MZ&($"A,J+[7B>3%"%U\NT1=$&'H@E.JUDCU7:503T,UKK-L**SB!M8#R"H7>
M5Q1X@=\B'YZ7CR#7<M_*O<]R5Q>HJ5+05"FP_L)35;*YCPG#+">8H@FK]H]I
MQ%^#3"JAV_'WF4!A$RBT@:(3@8:\T/M35IY-U:$H*7\'0!DP6!'56LO*9VQ]
MFFW[FL;7NFJO^P4[MNG&46/S"39J8*.SL!.6\P*0PF^Z"4K\CC,*;7B5E\Y>
MZ"A*#O".;3K7W7:\3H/7.8LWH/J(T@L&2"\6DIAJ2@%J*]H;LG-,$'H'E"TV
MW:2=,FXHX[.456OA>J/1?]NJC3$^BA_X?G@ V6(4G*),&LKD+.435YBV$25'
M;14FW</>.S:*PC ^('+W#C%S@3Q@L29,(@HK+?.N$IV1J [E:J)X:<^UC"M]
M2MKA1M]C((R!_K_B7'U,S%'9W(SI7U!+ P04    " "[@V-3^G0-ZH0%  !X
M&   &0   'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6R]66USVC@0_BL:[J[3
MSMP!LGEM$V9(2!-FFI"!].ZS, +K*ENN)(>D<S_^5K:Q#34R[27'AV ;[;.K
MU:-GU\K95L@ORJ=4HZ> A^J\X6L=O6^UE.?3@*BFB&@(OZR%#(B&6[EIJ4A2
MLDJ, MYRVNU>*R L;(S.DF?W<G0F8LU92.\E4G$0$/E\0;G8GC=P8_=@SC:^
M-@]:H[.(;.B"ZL_1O82[5HZR8@$-%1,ADG1]WACC]U.W8PR2$7\RNE6E:V2F
MLA3BB[F9KLX;;1,1Y=33!H+ UR.]I)P;)(CC:P;:R'T:P_+U#OUC,GF8S)(H
M>BGX7VRE_?/&H(%6=$UBKN=B>T.S"74-GB>X2OZB;3JVWV\@+U9:!)DQ1!"P
M,/TF3UDB2@: 4VW@9 ;.H4'GB(&;&;B'!NX1@TYFT#G50S<SZ)YJT,L,>J<:
M]#.#_JD&@\Q@<*K!,#,8)G1(UR]9_ G19'0FQ19),QK0S$7"H,0:UIR%ANP+
M+>%7!G9Z=#G[]&E\,9N/'Z:SNP4:WTW0[.'F:H[&\_GX[OKJ]NKN88'>3J@F
MC*MWZ _T>3%!;W]]AY1/)%6(A>B6<0[$56<M#1$9W):7>;](O3M'O-\2V438
M_1TY;0=7F%_6F3\C9YA8MRNL)R=8]X]:7]FM%S1J(K=]-/2/)\S<Q4?-KT_W
M7A7\S7\+?OK3WEO OYR$3DY")\'K'$L&E=X7M !"1>@-":(/:"+\@*)+ 0_(
M1E(*\JHMCMS<D9LX<H^Q77!.ED(2H[!H+"4)-PFVLH!W<O".=1;W, N 0F*-
M-EPL"0?1?81J$AD'B(0KY(D@@$&,</:-)%KO"77H.]TW=E>]=K/=_LT2<S>/
MN6L%FD.$84RA;'EB$[)O=%6U$U*,7H)AJN?C"%;]L4PWVXB]P'IY8#UK8+,H
MR4]$)1,KI 7B#)*K:%6N[$A=]$R)M"UP/X^I_P(T1?^@9*#%X2!W.'AYN@YS
M\.'_1U>[JTX=77&[*%?MEUF#F809F7XHYFGL]U*L8L^F(KA4-/'++PPNY!#;
M]? .FMPH#1<IPJ'*:A]JK2]XU?:\R-#*NP]ZW>Q3O0UQH9C8_4&:["*3J794
MEWT[:*];1XA"=+%="D\FQ#3\&QILLN3T1VE1B"GNO@(M"DG$=B7[45KTOJ.%
MVZVA12&%V*Z%/TD+.V@]+0KEQ ,KU%A"\XR@?09R1+'T?'@AVJ-#,L#FJM!1
M/'SY57<*Q7/LBC?;AE0JGT6F&)J<PSLH6CZC4(2>"+4$[RS<()$,JVI$:_#Q
ML-FU)MTI9-'!]E"U3R44B3P?YFWVQ'R4>D7G%=)=Z)UCEZ9+HGP4D><$$=ZT
M5J8Y JV@21="O\9,/\-+SR-5NL)IVB]E+KK'&Z;K;(BMIZI'F5I1]A-0"*IC
M%]3/T5H"KPZ6D3Y%IOU2Y62(P^6&]3B^W%EJ.G7SOJX?<E,_9&H=LI^:0M\=
M>[><BDJF'4?%Q4;#0NN=WBNPO)!OIT:^=U&G#7;5RW,-0GU;[11B[=C%>@Z;
M23*OU/%7!F0'<>L#*B3=L3>L5^DV5]2+)=,,:$\\>"2!]V]9F!U]O*LZL,B
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M+52^UG>#0G_>Z@;H1LEE\9?%/-N;9\8\ZS#_D*DHT6G\J-ZA5*JV^&\,^,9
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M?'R1T4+F90/]^U.F[Y7M07F"_1[LB_\#4$L#!!0    ( +N#8U/)[EQ ]@0
M /87   9    >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;+586V_B.!C]*U:T
M(\U(VR:V";V((G'5(K4S5:&[6JWVP00#T20Q8SO02OOCUTY"#"48,B/Z0'/Q
M.=_5QXY;&\:_BR6E$KS%42(>G*64JWO7%<&2QD1<LQ5-U)LYXS&1ZI8O7+'B
ME,PR4!RYR/.:;DS"Q&FWLF?/O-UBJ8S"A#YS(-(X)OR]2R.V>7"@LWWP$BZ6
M4C]PVZT56= QE:^K9Z[NW))E%L8T$2%+ *?S!Z<#[X>XJ0'9B#]#NA$[UT"'
M,F7LN[X9S1X<3WM$(QI(34'4OS7MT2C23,J/'P6I4]K4P-WK+?LP"UX%,R6"
M]ECT5SB3RP?GU@$S.B=I)%_8Y@]:!.1KOH!%(OL%FV*LYX @%9+%!5AY$(=)
M_I^\%8G8 2B>:@ J .A< "X ^%Q HP TS@7X!<#_"&@< 30+0%9,-T]6END^
MD:3=XFP#N!ZMV/1%5JX,K1(<)KJSQI*KMZ'"R79_T)V SM<^Z+T,^J,)&'9Z
MH\?19#08@RO0F<U"77\2@5&2=['NAL]]*DD8B2]JR.NX#S[_]J7E2N6,IG2#
MPG W-XR.&(;@B25R*< @F=%9!;YGQ^-3^($=?V?!NRJ)92;1-I-=9"7\%LAK
M@.'O 'D(5L5CAX_I2L&]H_"^'?Y$N-7ZX->L#^WP/@U*ZYXEE[CL2ISQX:-\
M4ZE:3DB>*A63X)]'-0",)(W%OQ;Z1DG?R.@;1^A?Z(J\:V(!V!Q$+%E<2<IC
MI4A3696[G*V9L6FI7K?QC>_E?RUW7>&)7WKB6SW) @V%2*NG@']@V-C+7<M'
M^)4C]CQJEAXU3^1FS:)UF"Q CU,U_<&0!&$4RG=+WF]*[IM+E/6VI+^UNMZ)
M69K5-)5"DF2F@TC5[.9J"=P&%>1!S?.@0BJJTGYK26J>]I,CAK>6TNU%=U=&
M=_=SA0'_@<F2 D?//7!TE&-),/3,:N%=HH)P9SF"UBB?R%L8IS&8,JZP6<7(
M2H7PL?^*)0(>9!EM)^;'DITW=M]M9-Q&5K?'- D9!U^9I$+5HW'M>Y] \? U
M$31(536*U_V4@LZ*AU&%V.Z;-W()+Z*7T @FK*.8(@\L+0-+=&!5BQ8\E$[H
MG4BZT4YH%\^Q)%(97U$>*,_4/KBR1>P<6:4J=P^U<?M1&+V%=L$]:)V&O774
M6DOCJ1*U4]UC5!E>1):AT65H%^::ZVT/'HHG1/8%%QH9A78=/:]K[!Q9D2J[
MIC9N?Z]IA!AY=;K&NX;^)_ XZGY[L?6.VN;)LYH'&<%&\!+-@XRT(KNT_J3T
M# K:W28Z(??(Z"W"];+OH[K9QPHW3J>"_DAUV@9K]6O+EY%JU+A(08SL(KOT
MU9S-772XBSU5"".>J)9X>M<WOE4\]TM@2X=13W01]41&/9%=/<\2K!,<66(J
M9TEMW'X41G;1"=G]I4K5FRS8R"B^R'X6&WG$]OULW<F"#W>I)R8+-DJ*[4KZ
MI#X(TCBWOZW#9,DIO?J;$KXMQD2_?F0D.>?+#^]\T5]DBXJ-[N&+;%$'N/X6
M%1NMQ':M[+%$<A+(E$1 Y[W2 3L%!N^J.L*6(R.7V"Z7];ZN"K(3F2F".&ML
M[K:[<UP94[[(#I8%"/37>W[>5CXM#Z\[V9'MA^<]>-_/CZ -37XB_D3X(DP$
MB.A<46JQ<0#/#YGS&\E6V:'HE$G)XNQR2<F,<CU O9\SU2_%C390'O6W_P=0
M2P,$%     @ NX-C4VKYH,9U!0  81<  !D   !X;"]W;W)K<VAE971S+W-H
M965T-C,N>&ULM5A=;]LV%/TKA-$!+=#%$NG/PC&0R,Z:K4F].NT>ACTP$FT3
ME425I.($Z(_?I:2(7BPQ-C"_))*L>^[AT>7A)2=;(;^K#6,:/29QJLX[&ZVS
M#]VN"C<LH>I,9"R%7U9")E3#K5QW5289C8J@).YBSQMT$\K3SG12/%O(Z43D
M.N8I6TBD\B2A\NF2Q6)[WO$[SP^^\/5&FP?=Z22C:[9D^FNVD'#7K5$BGK!4
M<9$BR5;GG0O_PQ49F8#BC6^<;=7.-3)#N1?BN[FYCLX[GF'$8A9J T'AWP,+
M6!P;).#QHP+MU#E-X.[U,_I5,7@8S#U5+!#Q7SS2F_/.J(,BMJ)YK+^([4=6
M#:AO\$(1J^(OVI;O]N'E,%=:)%4P,$AX6OZGCY40.P$$MP3@*@"_".AY+0&D
M"B O K#?$M"K GHO*0U; OI50/]%@#]N"1A4 8-"^U*L0ND9U70ZD6*+I'D;
MT,Q%\;F*:!"8IZ:REEK"KQSB]#3X?'-S?7<SO[U;HHO;&0H^W]Y=W_XVOPVN
MYTOT=L8TY;%ZA]X@GJ(;'L=0#FK2U9#: '3#*LUEF0:WI/'1C4CU1J%Y&K&H
M(7[FCB>OQ<_=\>/7XJ]>X8\= %W0O!8>/PM_B9V(%YD\0\1[C["'/;J6C,%\
MU5D,9J#Y:M5 ,7 #SE@(@+X!],=?ES/T]LT[D65"\72]H%(_951#AB;MW<!+
MEM5,_0JXZ0L<CU*/-J9;E?,F;E>'#WJ0F5$Z/@VIYP0I0$D+Z">A% K@<X-R
M+ TY4^CO3_ .NM8L4?\X,O3J#+TB0Z\M ]=\32MK#65.8W#I!R85B]!/]*;I
M&Y6 @P+0+!</4W_8GW0?&ECT:Q9])XO;/+EG$HD5*DM#H7!#XYC!J*/W2(4L
MI9(+)&#D/U%K]01EDOX.LUXSKT'-:_!_\-);X>0UV..%FWD-:UY#)Z_?\U2@
MNPV3-&.YYJ%ZCZY3J#^:1F@9"YJB/YC63$+9H("F(8PA &Y,.BIF5.<>G:@F
MQW6&L7-T,YI *Z$0W5(9M=9A,-ZKP_ZHI0Y]SRY"GC/WESQ-C6I2/-%8/R$)
M'Q6MI$C0YU +4PPPOX=-=%X!QL.S@?>+0QU_9Z'TG5#S=&.^J7'IDA],WHPJ
MC:)2N,9%T0W9]\X\-SMLV>'C%02&JUSGDB%%XQ:&;MC7];.FZA,GU#?.OZ&/
M#-AM0@J4 I%D-'V".ENP-#+<K2NZ$EJ/]7LGFC*^=5#?;:'UI$E$#G71/&?F
M%<A_S'O0\[R6:6-]TG<;Y4*R7^>/L,2;3[R0(ML\Q?21*]?0K-GYPU/)9TW-
M'QWH]+!' ..$=5!+FJH5/*Q[(@6RUC>--3PZ= 7RK1GZ;C><YR G TM?%.L+
M"J!5291I7GH().?RM3K%UORP=R*AL34O['::W255:I."9C"\N+$7#BJP Y9.
M; T*NYVD7=#!@8):I\&GZM^P-1?L[N".%+2W)RAI$=1:#W9;3ZN@!!\HJ/49
M/#B5H-9NL+NY.E+0X<&"6C/";C-JK]#A@8):=\'C$PE*K*T0=^MSG* 5V %3
MGEC3(<>:SHK'9J$OMZ7%]N<G:MBUE3L_LN]"+=^86!<B;A>"13+*0PVM!KT'
M+N[MXLY^\52&0ZSAD$,-)XPII*/ER5RU<S9K9/LF>D[V_<=OD=+Z#SEX]_B\
MC5>(IP\B?BAV#ZZCC#G9WS1B:(A:.B)BG8JX.Z(_<X[N:.)2W#H2.54#1*SG
MD$,;H.-%O"3[?<_+.=O=.1E,F%P79[BPGS;=:GE653^MSXDOBM/1%\\O_0]!
M>=IK8<K#YQLJUSQ5*&8K@/3.AL!'EN>YY8T667'^>"^T%DEQN6$T8M*\ +^O
MA-#/-R9!?:H^_1=02P,$%     @ NX-C4[\AD0!V P  30P  !D   !X;"]W
M;W)K<VAE971S+W-H965T-C0N>&ULM5=K;]HP%/TK5C1IK;21=R@5(+5 ']JJ
M=;!NFJ9]<(DA5ITXLYW2[=?/CS0$"!E:53Z '_<<WWM\;5_Z*\H>>(*0 $\I
MR?C 2H3(3VV;SQ.40MZA.<KDS(*R% K994N;YPS!6(-28GN.$]DIQ)DU[.NQ
M6S;LTT(0G*%;!GB1II#]/D>$K@:6:ST/3/$R$6K 'O9SN$0S).[R6R9[=L42
MXQ1E'-,,,+086&?NZ:7K*8"V^(K1BM?:0(5R3^F#ZES' \M1'B&"YD)10/GS
MB$:($,4D_?A5DEK5F@I8;S^S7^C@93#WD*,1)=]P+)*!=6*!&"U@0<24KJY0
M&5"H^.:4</T-5J6M8X%YP05-2[#T(,69^85/I1 U@.1I!G@EP-L&!'L ?@GP
M#UTA* '!H8"P!(2' J(2$&T#HCV ;@GHZLTRZNJM&4,!AWU&5X I:\FF&GI_
M-5KN",Y4*LX$D[-8XL1P]N73Z,/5IX_CR73V%DP^WUU_^0[>@[,XQBI5( '7
MF4EXE3A'8R0@)OQ8FMS-QN#HS3'@"62( YR!&TR(M.)]6TC/%+\]+[TX-UYX
M>[SPP0W-1,+!)(M1W( ?M^-[+7A;*E+)XCW+<NZU$LY0W@&^\PYXCN<V^#,Z
M'.XTA?.RU2<O6_VB'7X#F82[>^&7!\/=J&4K_"I#?<WG[^$;$<@YH LP$W3^
M 'Y\E//@6J"4_VQA#RKV0+,'^[0RV<M07K!Y(N^T&, LEGV!F6P?R;0V"7[<
ME-6&VS6'2]WZCT.O(W?LL9XJQBBLV?B;%N,&FFXGW#2:-*WE=8+*:B/\L H_
M; W_*R0%4N+R5AV:8C?$4<T=-P@=_=D28-=2ID:3Y7C7,NAUFRPG#:M'CK-E
MNB%)5$D2M4HR1>H%Q]D2P$(DE.$_**[I F!*BTR 0MXT\DG7.5F;S1E=,I@V
MWH'1CL^1O^.S$>(@TXWPNE5XW=;PU*DLC])T[?:M<;OE0)U4_">O<%Q[%7NO
MU?NS]98<M ]-UU=O-W4\IUU<UUD_I\X_Y/6<_Y'7K3W8[BL(['IK?N^U);XH
MEZAK'.Z3V*X5+REB2UV7<C!72YM7HAJM:M\S7?%MC9^[IR.W87SLGDY,9;NF
M-X6V?*J6... H(5<RNETY:W"3.UJ.H+FNG2ZIT(68KJ9R'H?,64@YQ>4BN>.
M6J#Z!S'\"U!+ P04    " "[@V-3\SN^(*<%  #A&P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970V-2YX;6S-66UOVS80_BN$46 M4-4F*;\%B8'$<M=@;9/%
MR89AV =:HFVADNA1=-SNUX^4%-$6*=I--R!?$DE^[GAW/#Z/*)[O&/^2KRD5
MX&N:9/E%9RW$YJS;S<,U34G^CFUH)G]9,IX2(6_YJIMO."51890F7=3K#;HI
MB;/.Y+QX=LLGYVPKDCBCMQSDVS0E_-L53=CNH@,[3P_NXM5:J ?=R?F&K.B<
MBH?-+9=WW=I+%*<TRV.6 4Z7%YU+>#;#OC(H$+_%=)?O70.5RH*Q+^KF.KKH
M]%1$-*&A4"Z(_/=(IS1)E"<9Q]^5TTX]IC+<OW[R_KY(7B:S(#F=LN3W.!+K
MB\ZH R*Z)-M$W+'=!UHEU%?^0I;DQ5^PJ["]#@BWN6!I92PC2..L_$^^5H78
M,Y!^[ :H,D!- [_% %<&^-01_,K /W6$?F50I-XM<R\*%Q!!)N><[0!7:.E-
M7135+ZQEO>),-<I<</EK+.W$9'Y_,_WEP\W'8'8W_PG,?GVXOO\#>&!>]@U@
M2S!=DVQ%<Q!GX#(,M^DV(8)&X$:L*0=3ELK^7*O&>:3@.@M92L'KCRS/WX#7
M 14D3N25!Q[F 7C]Z@UXI=Q\BI-$-DE^WA4R Q5'-ZRBO2JC12W18O")96*=
M@UD6T<AB'[CMQP[[KJQ<73[T5+XKY'0XIYMW /?> M1#T!+/]'3SGBV='QM]
M]NS1#XJ!ZU["A3_<XN_R9GJM>B#91G&V K>,%UQP*02/%UM!%@D%@H'/3+9)
M)CB372!AUYF@G.;B+?@L>5$VW#WY"OZ\D[\"204[PJ._'+'Y=6Q^$9O?$ML5
M7<59IL9;D(1D(;4U7^EB4+A0#/LX@>,AE*5YW)]2"VH$?72("FPHI&9I'S4S
M40@-^GK$@US[=:Y]9Z[ET@P/EF9<+<U$+4U;[J7+_EXDN-](W(1X_K"1MHF!
MV&\D;?$S0/:4!W7* V?*<CT?F=N!,2B"_K Q'U,3!8<&*CC)U^R8KX-$AW6B
M0V>B]TR0Q+$>1K6?T8M;J^,ZMO&/K]6QV:_CQF2:D&%C+0<FQ!LT,#,3,^K;
M)Q'VM.KVG"FJ\FTS^6:7Q/](,5W)-[KVM1E4S@XR:2XJ"Z8MRKUW ^B,\HZ&
M"<GS>!F'1+5'KEHBDZ$?8Y.@<KP?C5%7"\8;#%MB1CIF]-^37^73R7X6C$E_
M%I#)?S9/;00(M?A"_(,46#EPM='4@D&XF>1Q/S.WG\,4M89#MXA+CI$O_AF8
M;CFG6?@-W'.2Y4G1F_N4Y. @J$44]E\<0T*M=] M>*=P9 !-">HW5<J&:9LH
M+5+0K5+?26]#<SW ?C-.&ZAMT6@5A*/_B^%&1CP&P;D@AP%K:81N;7P.O070
M(G-F@6V@E@(C+73(+73'60F9PH4'#5:R8/SF2]D)?F9N/X<I:I5$;I5\T(W^
MLVST') L FH++#?-BC >Y298L86W9-R;$TD; 5T(,*?AEL<BIOF)U(6T!B+T
MXJ@+::%";J$ZB;J013^:DVE"VN92*PQR*\SW$5?E[&#)X&:4)L9O6U5:FY![
MA_=\VD+FYJM)6Q:(!UO>RY 6+.06K&<1%S+%R2RP93?6\N:+M( AMX"=0%LV
M/6K2EHE!@R9M'?<S<_LY3%%+'W)+WQ':FI)\#=XGTNL'&JU.)RFM9&C\XD@*
M:]W";MTZB:2P*2<>A,T&M:!P"U%A+3K8+3K?1U38W&J-FW1JP7AM"PEK*<+N
M[=CSF0J;NR1C"VG!>&U?S_#>9TRW0#V+JK!%C?I&C4V0-VRKL18M[!:MXV2%
MS>^,QM<2"\;S&]NZX 1'LR..RB2[>T<6*>6KXJPHET7?9J+\XEP_K<^C+HM3
MF,;S*W@VA9;G 3R;E:=-VGUY^/6)\)7BNX0NY5"]=T,Y';P\3RIO!-L4!R8+
M)@1+B\LU)1'E"B!_7S(FGF[4 /6IWN1?4$L#!!0    ( +N#8U/$.26QPP(
M  T'   9    >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;*55T6[:,!3]E:L\
MK=+6A"3=N@J0 F0K&A1$Z/8P[<$DAEAU[,QV2O?WLYV0T2Z@:GLAMG/.N>=>
M7V[Z>RX>9(ZQ@J>",CEP<J7*&]>5:8X+)"]YB9E^L^6B0$IOQ<Z5I< HLZ2"
MNK[GO7<+1)@S[-NSI1CV>:4H87@I0%9%@<2O$:9\/W!ZSN%@17:Y,@?NL%^B
M'4ZPNB^70N_<5B4C!6:2< 8";P=.U+N)0X.W@*\$[^71&DPF&\X?S&::#1S/
M&,(4I\HH(/UXQ&-,J1'2-GXVFDX;TA"/UP?U3S9WG<L&23SF]!O)5#YPKAW(
M\!955*WX_A8W^5P9O913:7]AWV ]!])**EXT9.V@(*Q^HJ>F#D<$K=--\!N"
M_Y(0GB $#2%X;82P(82OC7#5$&SJ;IV[+=P$*33L"[X'8=!:S2QL]2U;UXLP
MTR>)$OHMT3PUO(O7,+T;+^8QO)DMDN0"EO$*DMMH%4.T7J^FH_MU-)K%L%[
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MRZ";9J/9KA:OGXG7_W_$R^?;9?+UJ^0K!#TI@RKD*X-0OF*++H.JY+-R4UI
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M]I9$49+X$<#\"J((0^!MQ!%, 6C D"BJ]L&]_2A<[U/AYO>OX6]02P,$%
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M&^IM!'K;:+.;0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O1[V=0&]'O9U
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M<F]P<R]A<' N>&UL4$L! A0#%     @ NH-C4S$)I>#N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ NH-C
M4YE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " "Z@V-3#-MM;44%  !Z%0  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ NH-C
M4T2F>0QP!@  )QH  !@              ("!B T  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( +J#8U-<%1R=PP(  ,H(   8
M      " @2X4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" "Z@V-3/2UX+4$&  !K&P  &               @($G%P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ NH-C4^KB(B.L!   K!(  !@
M             ("!GAT  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( +J#8U._#B; )PD  *0U   8              " @8 B  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "Z@V-3VZ%+@;,"  #B
M!@  &               @('=*P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ NH-C4RCZSO[^!@  HAT  !@              ("!QBX
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( +J#8U/6J0C:
MKPD  !47   8              " @?HU  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " "Z@V-3W[G)4(<,  "!'@  &0
M@('?/P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( +J#
M8U,?_O&J$ \  *4O   9              " @9U,  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ NH-C4R:JZ,^+!   DPL  !D
M         ("!Y%L  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " "Z@V-3_S([AKH(  #[&P  &0              @(&F8   >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( +J#8U-F-R/W*PT  !,G
M   9              " @9=I  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ NH-C4ZHUMQ2Z!@  [Q   !D              ("!^78
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "Z@V-3TPP5
M1+T#  "S"   &0              @('J?0  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( +J#8U,UG5&P^0L  (PC   9
M  " @=Z!  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MNH-C4RS)/#@Q!@  $Q$  !D              ("!#HX  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " "Z@V-3*GA&T%D@   =:0  &0
M            @(%VE   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( +J#8U-27905T 4  "H0   9              " @0:U  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ NH-C4X-V1?\^!
MQ@L  !D              ("!#;L  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " "Z@V-36%/BAV(%   0#@  &0              @(&"
MOP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( +J#8U/J
M6/[T$0X  )HE   9              " @1O%  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ NH-C4V5O_GX)"@  '1<  !D
M     ("!8],  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +J#8U/]ZR9:208  )<7   9              "
M@?GP  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ NH-C
M4U8A)VCP P  DPD  !D              ("!>?<  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " "Z@V-3=D,. :T$   Z#   &0
M        @(&@^P  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( +J#8U,8\OI%B ,  (H(   9              " @80  0!X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ NH-C4VWYP>A/ P  J <
M !D              ("!0P0! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " "Z@V-3P)I^T:X"  "U!0  &0              @(')!P$
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( +J#8U-S+J 9
MJ@(  #\'   9              " @:X* 0!X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ NH-C4R^[ VY?&@  S>(  !D
M ("!CPT! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "Z
M@V-3X,5XY D#  "!"P  &0              @($E* $ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( +J#8U.Q\,=[.P,  '$*   9
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M970T,BYX;6Q02P$"% ,4    " "[@V-36>!#LP4%   8&P  &0
M    @(%+1@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M +N#8U.&K6S]T (  ,<(   9              " @8=+ 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ NX-C4P5N0*;9 @  ?0@  !D
M             ("!CDX! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " "[@V-3J@7[.<L"  #T!P  &0              @(&>40$ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( +N#8U/11B!<+P,
M /\)   9              " @:!4 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ NX-C4]_Z.&_B P  W!(  !D              ("!
M!E@! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "[@V-3
MG".'WCD#   0"0  &0              @($?7 $ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( +N#8U/A7#*SBP,  ! -   9
M      " @8]? 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ NX-C4UGX^WM1!@  >AX  !D              ("!46,! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "[@V-3IN< 7Z$$   _$@
M&0              @('9:0$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( +N#8U,P)9$2B0(  /,%   9              " @;%N 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ NX-C4V',ZLUY
M!P  RRP  !D              ("!<7$! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " "[@V-39(J5U+<"  #U!@  &0
M@($A>0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( +N#
M8U,IB\,$R0(  &$'   9              " @0]\ 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ NX-C4WB2A@VQ @  (0<  !D
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M=#8Q+GAM;%!+ 0(4 Q0    ( +N#8U/)[EQ ]@0  /87   9
M  " @=J6 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
MNX-C4VKYH,9U!0  81<  !D              ("!!YP! 'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    " "[@V-3OR&1 '8#  !-#   &0
M            @(&SH0$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( +N#8U/S.[X@IP4  .$;   9              " @6"E 0!X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ NX-C4\0Y);'# @
M#0<  !D              ("!/JL! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    " "[@V-3B/CU5>@#  #3#   &0              @($X
MK@$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( +N#8U/M
M34FB$@,  *P)   9              " @5>R 0!X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ NX-C4VM\V5$W P  #!,   T
M     ( !H+4! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "[@V-3EXJ[',
M   3 @  "P              @ $"N0$ 7W)E;',O+G)E;'-02P$"% ,4
M" "[@V-3QA*5D4\%  !#+0  #P              @ 'KN0$ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ NX-C4Q;=:Q0F @  8R@  !H
M ( !9[\! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
MNX-C4^'L7A'T 0  HB<  !,              ( !Q<$! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     $P 3 #+%   ZL,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>906</ContextCount>
  <ElementCount>396</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>154</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUES</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127106 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ACQUISITIONS</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2131107 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137108 - Disclosure - OTHER FINANCIAL INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATION</Role>
      <ShortName>OTHER FINANCIAL INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2142109 - Disclosure - COLLABORATIONS AND OTHER ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS</Role>
      <ShortName>COLLABORATIONS AND OTHER ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2144110 - Disclosure - DEBT AND CREDIT FACILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIES</Role>
      <ShortName>DEBT AND CREDIT FACILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2148111 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2150112 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2154113 - Disclosure - NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS</Role>
      <ShortName>NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2158114 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/REVENUES</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ACQUISITIONSTables</Role>
      <ShortName>ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/ACQUISITIONS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2338307 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables</Role>
      <ShortName>OTHER FINANCIAL INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OTHERFINANCIALINFORMATION</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2345308 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables</Role>
      <ShortName>DEBT AND CREDIT FACILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/DEBTANDCREDITFACILITIES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2351309 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2355310 - Disclosure - NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables</Role>
      <ShortName>NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2359311 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/INCOMETAXES</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - REVENUES - Disaggregation of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails</Role>
      <ShortName>REVENUES - Disaggregation of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - REVENUES - Revenues from Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails</Role>
      <ShortName>REVENUES - Revenues from Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - REVENUES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESAdditionalInformationDetails</Role>
      <ShortName>REVENUES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Classification of Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Classification of Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - FAIR VALUE MEASUREMENTS - Equity Investment In Galapagos (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Equity Investment In Galapagos (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2425415 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2426416 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2429417 - Disclosure - ACQUISITIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ACQUISITIONSNarrativeDetails</Role>
      <ShortName>ACQUISITIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2430418 - Disclosure - ACQUISITIONS - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>ACQUISITIONS - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2435421 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2436422 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2439423 - Disclosure - OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2440424 - Disclosure - OTHER FINANCIAL INFORMATION - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2441425 - Disclosure - OTHER FINANCIAL INFORMATION - Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - COLLABORATIONS AND OTHER ARRANGEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails</Role>
      <ShortName>COLLABORATIONS AND OTHER ARRANGEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails</Role>
      <ShortName>DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - DEBT AND CREDIT FACILITIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails</Role>
      <ShortName>DEBT AND CREDIT FACILITIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2449429 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2452430 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2453431 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails</Role>
      <ShortName>NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails</Role>
      <ShortName>NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="gild-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2460434 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/INCOMETAXESTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="gild-20210930.htm">gild-20210930.htm</File>
    <File>gild-20210930.xsd</File>
    <File>gild-20210930_cal.xml</File>
    <File>gild-20210930_def.xml</File>
    <File>gild-20210930_lab.xml</File>
    <File>gild-20210930_pre.xml</File>
    <File>gildq32021ex311ceocertific.htm</File>
    <File>gildq32021ex312cfocertific.htm</File>
    <File>gildq32021ex32section906ce.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>84
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gild-20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 35,
   "contextCount": 906,
   "dts": {
    "calculationLink": {
     "local": [
      "gild-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gild-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "gild-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gild-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gild-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gild-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 620,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 34,
   "keyStandard": 362,
   "memberCustom": 97,
   "memberStandard": 48,
   "nsprefix": "gild",
   "nsuri": "http://www.gilead.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.gilead.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - REVENUES",
     "role": "http://www.gilead.com/role/REVENUES",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127106 - Disclosure - ACQUISITIONS",
     "role": "http://www.gilead.com/role/ACQUISITIONS",
     "shortName": "ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131107 - Disclosure - GOODWILL AND INTANGIBLE ASSETS",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137108 - Disclosure - OTHER FINANCIAL INFORMATION",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATION",
     "shortName": "OTHER FINANCIAL INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborativeAndOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142109 - Disclosure - COLLABORATIONS AND OTHER ARRANGEMENTS",
     "role": "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS",
     "shortName": "COLLABORATIONS AND OTHER ARRANGEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborativeAndOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144110 - Disclosure - DEBT AND CREDIT FACILITIES",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIES",
     "shortName": "DEBT AND CREDIT FACILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148111 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150112 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.gilead.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154113 - Disclosure - NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS",
     "role": "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS",
     "shortName": "NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158114 - Disclosure - INCOME TAXES",
     "role": "http://www.gilead.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - REVENUES (Tables)",
     "role": "http://www.gilead.com/role/REVENUESTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES (Tables)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - ACQUISITIONS (Tables)",
     "role": "http://www.gilead.com/role/ACQUISITIONSTables",
     "shortName": "ACQUISITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338307 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables",
     "shortName": "OTHER FINANCIAL INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345308 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables",
     "shortName": "DEBT AND CREDIT FACILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2351309 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "role": "http://www.gilead.com/role/STOCKHOLDERSEQUITYTables",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2355310 - Disclosure - NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)",
     "role": "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables",
     "shortName": "NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2359311 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.gilead.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - REVENUES - Disaggregation of Revenues (Details)",
     "role": "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails",
     "shortName": "REVENUES - Disaggregation of Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "ibea8c08b19a845a7bc3ab84d8743dac6_D20210701-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "ie89b30127587468d9e71733bf07d5081_D20210701-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - REVENUES - Revenues from Major Customers (Details)",
     "role": "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails",
     "shortName": "REVENUES - Revenues from Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "ie89b30127587468d9e71733bf07d5081_D20210701-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - REVENUES - Additional Information (Details)",
     "role": "http://www.gilead.com/role/REVENUESAdditionalInformationDetails",
     "shortName": "REVENUES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "ia1be5d0f90b94ff6beab639c85963cc9_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "ie8a9ceaf8e034398898fc7c7ed8656c9_I20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "ia1be5d0f90b94ff6beab639c85963cc9_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Classification of Equity Securities (Details)",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Classification of Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "ib6ef3db73cbc4509905d24a522ce5757_I20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i78a2c5f5c07343a095efd1f37fda91fd_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - FAIR VALUE MEASUREMENTS - Equity Investment In Galapagos (Details)",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Equity Investment In Galapagos (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i78a2c5f5c07343a095efd1f37fda91fd_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i4fcdeab4094c40bc957aa0ac494ab157_I20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unitRef": "position",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Additional Information (Details)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0300f6dad76745ceafff278866806c16_I20201231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425415 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426416 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details)",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429417 - Disclosure - ACQUISITIONS - Narrative (Details)",
     "role": "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
     "shortName": "ACQUISITIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i90be553f64364971a7f334cad33d512f_D20200401-20200630",
      "decimals": "-8",
      "lang": "en-US",
      "name": "gild:PaymentsToAcquireAssetsNetOfCashAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i59fefc5ad8ec413db93d451131df6e85_I20210304",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430418 - Disclosure - ACQUISITIONS - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "ACQUISITIONS - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i59fefc5ad8ec413db93d451131df6e85_I20210304",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0300f6dad76745ceafff278866806c16_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435421 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details)",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436422 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details)",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439423 - Disclosure - OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details)",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440424 - Disclosure - OTHER FINANCIAL INFORMATION - Inventories (Details)",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441425 - Disclosure - OTHER FINANCIAL INFORMATION - Accrued and Other Current Liabilities (Details)",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Accrued and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i19f0cbf8e15f44e3a8bf106f16ddf237_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i19f0cbf8e15f44e3a8bf106f16ddf237_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i199d5ca3470540be922bc9d2707767c8_D20210313-20210313",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - COLLABORATIONS AND OTHER ARRANGEMENTS (Details)",
     "role": "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails",
     "shortName": "COLLABORATIONS AND OTHER ARRANGEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i199d5ca3470540be922bc9d2707767c8_D20210313-20210313",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails",
     "shortName": "DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i1c6ca75c669d44f793cf15f1cc2fffe8_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - DEBT AND CREDIT FACILITIES - Additional Information (Details)",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
     "shortName": "DEBT AND CREDIT FACILITIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449429 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452430 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)",
     "role": "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i93cee50aef154d89907a30e4b6fe3dad_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453431 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "ibdca6d608af14f87aeafba62f5b528f1_D20210101-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details)",
     "role": "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails",
     "shortName": "NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details)",
     "role": "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails",
     "shortName": "NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460434 - Disclosure - INCOME TAXES (Details)",
     "role": "http://www.gilead.com/role/INCOMETAXESDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i0c6c4b6c9c514c3e9825d30a96f14d6c_D20210701-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210930.htm",
      "contextRef": "i47316bd9c40a46c9bddae051abd406b2_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 154,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.15% LIBOR Senior Unsecured Notes Due September 2021",
        "label": "0.15% LIBOR Senior Unsecured Notes Due September 2021 [Member]",
        "terseLabel": "0.15% LIBOR Senior Unsecured Notes Due September 2021"
       }
      }
     },
     "localname": "A015LIBORSeniorUnsecuredNotesDueSeptember2021Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.52% LIBOR Senior Unsecured Notes Due September 2023",
        "label": "0.52% LIBOR Senior Unsecured Notes Due September 2023 [Member]",
        "terseLabel": "0.52% LIBOR Senior Unsecured Notes Due September 2023"
       }
      }
     },
     "localname": "A052LIBORSeniorUnsecuredNotesDueSeptember2023Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A075SeniorUnsecuredNotesDueSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.75% Senior Unsecured Notes Due in September 2023 [Member]",
        "label": "0.75% Senior Unsecured Notes Due September 2023 [Member]",
        "terseLabel": "0.75% Senior Unsecured Notes Due September 2023"
       }
      }
     },
     "localname": "A075SeniorUnsecuredNotesDueSeptember2023Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A120SeniorUnsecuredNotesDueOctober2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.20% Senior Unsecured Notes Due October 2027",
        "label": "1.20% Senior Unsecured Notes Due October 2027 [Member]",
        "terseLabel": "1.20% Senior Unsecured Notes Due October 2027"
       }
      }
     },
     "localname": "A120SeniorUnsecuredNotesDueOctober2027Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A165SeniorUnsecuredNotesDueOctober2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.65% Senior Unsecured Notes Due October 2030",
        "label": "1.65% Senior Unsecured Notes Due October 2030 [Member]",
        "terseLabel": "1.65% Senior Unsecured Notes Due October 2030"
       }
      }
     },
     "localname": "A165SeniorUnsecuredNotesDueOctober2030Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A195SeniorUnsecuredNotesDueMarch2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.95% Senior Unsecured Notes Due March 2022 [Member]",
        "label": "1.95% Senior Unsecured Notes Due March 2022 [Member]",
        "terseLabel": "1.95% Senior Unsecured Notes Due March 2022"
       }
      }
     },
     "localname": "A195SeniorUnsecuredNotesDueMarch2022Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A2016StockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Stock Repurchase Program [Member]",
        "label": "2016 Stock Repurchase Program [Member]",
        "terseLabel": "2016 Stock Repurchase Program"
       }
      }
     },
     "localname": "A2016StockRepurchaseProgramMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A2020StockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Repurchase Program [Member]",
        "label": "2020 Stock Repurchase Program [Member]",
        "terseLabel": "2020 Stock Repurchase Program"
       }
      }
     },
     "localname": "A2020StockRepurchaseProgramMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A250SeniorUnsecuredNotesDueSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.50% Senior Unsecured Notes Due September 2023",
        "label": "2.50% Senior Unsecured Notes Due September 2023 [Member]",
        "terseLabel": "2.50% Senior Unsecured Notes Due September 2023"
       }
      }
     },
     "localname": "A250SeniorUnsecuredNotesDueSeptember2023Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A260SeniorUnsecuredNotesDueOctober2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.60% Senior Unsecured Notes Due October 2040",
        "label": "2.60% Senior Unsecured Notes Due October 2040 [Member]",
        "terseLabel": "2.60% Senior Unsecured Notes Due October 2040"
       }
      }
     },
     "localname": "A260SeniorUnsecuredNotesDueOctober2040Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A280SeniorUnsecuredNotesDueOctober2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.80% Senior Unsecured Notes Due October 2050",
        "label": "2.80% Senior Unsecured Notes Due October 2050 [Member]",
        "terseLabel": "2.80% Senior Unsecured Notes Due October 2050"
       }
      }
     },
     "localname": "A280SeniorUnsecuredNotesDueOctober2050Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A295SeniorUnsecuredNotesDueMarch2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.95% Senior Unsecured Notes Due March 2027 [Member]",
        "label": "2.95% Senior Unsecured Notes Due March 2027 [Member]",
        "terseLabel": "2.95% Senior Unsecured Notes Due March 2027"
       }
      }
     },
     "localname": "A295SeniorUnsecuredNotesDueMarch2027Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A325SeniorUnsecuredNotesDueSeptember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.25% Senior Unsecured Notes Due September 2022",
        "label": "3.25% Senior Unsecured Notes Due September 2022 [Member]",
        "terseLabel": "3.25% Senior Unsecured Notes Due September 2022"
       }
      }
     },
     "localname": "A325SeniorUnsecuredNotesDueSeptember2022Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A350SeniorUnsecuredNotesDueFebruary2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.50% Senior Unsecured Notes Due February 2025 [Member]",
        "label": "3.50% Senior Unsecured Notes Due February 2025 [Member]",
        "terseLabel": "3.50% Senior Unsecured Notes Due February 2025"
       }
      }
     },
     "localname": "A350SeniorUnsecuredNotesDueFebruary2025Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A365SeniorUnsecuredNotesDueMarch2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.65% Senior Unsecured Notes Due March 2026",
        "label": "3.65% Senior Unsecured Notes Due March 2026 [Member]",
        "terseLabel": "3.65% Senior Unsecured Notes Due March 2026"
       }
      }
     },
     "localname": "A365SeniorUnsecuredNotesDueMarch2026Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A370SeniorUnsecuredNotesDueApril2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Senior Unsecured Notes Due April 2024 [Member]",
        "label": "3.70% Senior Unsecured Notes Due April 2024 [Member]",
        "terseLabel": "3.70% Senior Unsecured Notes Due April 2024"
       }
      }
     },
     "localname": "A370SeniorUnsecuredNotesDueApril2024Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A400SeniorUnsecuredNotesDueSeptember2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.00% Senior Unsecured Notes Due September 2036",
        "label": "4.00% Senior Unsecured Notes Due September 2036 [Member]",
        "terseLabel": "4.00% Senior Unsecured Notes Due September 2036"
       }
      }
     },
     "localname": "A400SeniorUnsecuredNotesDueSeptember2036Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A415SeniorUnsecuredNotesDueMarch2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.15% Senior Unsecured Notes Due March 2047 [Member]",
        "label": "4.15% Senior Unsecured Notes Due March 2047 [Member]",
        "terseLabel": "4.15% Senior Unsecured Notes Due March 2047"
       }
      }
     },
     "localname": "A415SeniorUnsecuredNotesDueMarch2047Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A440SeniorUnsecuredNotesDueDecember2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.40% Senior Unsecured Notes Due December 2021",
        "label": "4.40% Senior Unsecured Notes Due December 2021 [Member]",
        "terseLabel": "4.40% Senior Unsecured Notes Due December 2021"
       }
      }
     },
     "localname": "A440SeniorUnsecuredNotesDueDecember2021Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A450SeniorUnsecuredNotesDueApril2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Senior Unsecured Notes Due April 2021 [Member]",
        "label": "4.50% Senior Unsecured Notes Due April 2021 [Member]",
        "terseLabel": "4.50% Senior Unsecured Notes Due April 2021"
       }
      }
     },
     "localname": "A450SeniorUnsecuredNotesDueApril2021Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A450SeniorUnsecuredNotesDueFebruary2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Senior Unsecured Notes Due February 2045 [Member]",
        "label": "4.50% Senior Unsecured Notes Due February 2045 [Member]",
        "terseLabel": "4.50% Senior Unsecured Notes Due February 2045"
       }
      }
     },
     "localname": "A450SeniorUnsecuredNotesDueFebruary2045Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A460SeniorUnsecuredNotesDueSeptember2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.60% Senior Unsecured Notes Due September 2035",
        "label": "4.60% Senior Unsecured Notes Due September 2035 [Member]",
        "terseLabel": "4.60% Senior Unsecured Notes Due September 2035"
       }
      }
     },
     "localname": "A460SeniorUnsecuredNotesDueSeptember2035Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A475SeniorUnsecuredNotesDueMarch2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.75% Senior Unsecured Notes Due March 2046 [Member]",
        "label": "4.75% Senior Unsecured Notes Due March 2046 [Member]",
        "terseLabel": "4.75% Senior Unsecured Notes Due March 2046"
       }
      }
     },
     "localname": "A475SeniorUnsecuredNotesDueMarch2046Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A480SeniorUnsecuredNotesDueApril2044Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.80% Senior Unsecured Notes Due April 2044 [Member]",
        "label": "4.80% Senior Unsecured Notes Due April 2044 [Member]",
        "terseLabel": "4.80% Senior Unsecured Notes Due April 2044"
       }
      }
     },
     "localname": "A480SeniorUnsecuredNotesDueApril2044Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A565SeniorUnsecuredNotesDueDecember2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.65% Senior Unsecured Notes Due December 2041 [Member]",
        "label": "5.65% Senior Unsecured Notes Due December 2041 [Member]",
        "terseLabel": "5.65% Senior Unsecured Notes Due December 2041"
       }
      }
     },
     "localname": "A565SeniorUnsecuredNotesDueDecember2041Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AccountsReceivableCashDiscountsAndOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Cash Discounts and Other, Current",
        "label": "Accounts Receivable, Cash Discounts and Other, Current",
        "terseLabel": "Less: cash discounts and other"
       }
      }
     },
     "localname": "AccountsReceivableCashDiscountsAndOtherCurrent",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AccountsReceivableChargebacksCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Chargebacks, Current",
        "label": "Accounts Receivable, Chargebacks, Current",
        "terseLabel": "Less: chargebacks"
       }
      }
     },
     "localname": "AccountsReceivableChargebacksCurrent",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AccruedGovernmentAndOtherRebates": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Government And Other Rebates",
        "label": "Accrued Government And Other Rebates",
        "terseLabel": "Accrued government and other rebates"
       }
      }
     },
     "localname": "AccruedGovernmentAndOtherRebates",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AmerisourcebergenCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmerisourceBergen Corp [Member]",
        "label": "AmerisourceBergen Corp [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourcebergenCorpMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Biosciences, Inc.",
        "label": "Arcus Biosciences, Inc. [Member]",
        "terseLabel": "Arcus"
       }
      }
     },
     "localname": "ArcusBiosciencesIncMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Stock Purchase Agreement",
        "label": "Arcus Stock Purchase Agreement [Member]",
        "terseLabel": "Arcus stock purchase agreement"
       }
      }
     },
     "localname": "ArcusStockPurchaseAgreementMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AxicabtageneciloleucelDLBCLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "axicabtagene ciloleucel (DLBCL) [Member]",
        "label": "axicabtagene ciloleucel (DLBCL) [Member]",
        "terseLabel": "Intangible asset - axicabtagene ciloleucel"
       }
      }
     },
     "localname": "AxicabtageneciloleucelDLBCLMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability",
        "negatedTerseLabel": "Liability related to future royalties"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net",
        "terseLabel": "Other assets (and liabilities), net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health Inc [Member]",
        "label": "Cardinal Health Inc [Member]",
        "terseLabel": "Cardinal Health, Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CashPaymentsMadeRelatedToEquityInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Payments Made Related to Equity Investments",
        "label": "Cash Payments Made Related to Equity Investments",
        "terseLabel": "Cash payments made related to equity investments"
       }
      }
     },
     "localname": "CashPaymentsMadeRelatedToEquityInvestments",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_CellTherapyProductsTecartusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Tecartus",
        "label": "Cell Therapy Products, Tecartus [Member]",
        "terseLabel": "Tecartus"
       }
      }
     },
     "localname": "CellTherapyProductsTecartusMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CellTherapyProductsTotalCellTherapyProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Total Cell Therapy Product Sales",
        "label": "Cell Therapy Products, Total Cell Therapy Product Sales [Member]",
        "terseLabel": "Total Cell Therapy"
       }
      }
     },
     "localname": "CellTherapyProductsTotalCellTherapyProductSalesMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CellTherapyProductsYescartaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Yescarta [Member]",
        "label": "Cell Therapy Products, Yescarta [Member]",
        "terseLabel": "Yescarta"
       }
      }
     },
     "localname": "CellTherapyProductsYescartaMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period",
        "label": "Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period",
        "terseLabel": "Option period to license"
       }
      }
     },
     "localname": "CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_CollaborationArrangementNetProductSalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Net Product Sales Threshold",
        "label": "Collaboration Arrangement, Net Product Sales Threshold",
        "terseLabel": "Net product sales threshold"
       }
      }
     },
     "localname": "CollaborationArrangementNetProductSalesThreshold",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Percent Of Global Development And Commercialization Costs",
        "label": "Collaboration Arrangement, Percent Of Global Development And Commercialization Costs",
        "terseLabel": "Percent of global development and commercialization costs"
       }
      }
     },
     "localname": "CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_CollaborationArrangementPercentOfGlobalProductRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Percent Of Global Product Revenues",
        "label": "Collaboration Arrangement, Percent Of Global Product Revenues",
        "terseLabel": "Percent of global product revenues"
       }
      }
     },
     "localname": "CollaborationArrangementPercentOfGlobalProductRevenues",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_CollaborativeAndOtherArrangementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative and Other Arrangements [Text Block]",
        "label": "Collaborative And Other Arrangements [Text Block]",
        "terseLabel": "COLLABORATIONS AND OTHER ARRANGEMENTS"
       }
      }
     },
     "localname": "CollaborativeAndOtherArrangementsTextBlock",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gild_CollaborativeandOtherArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative and Other Arrangements [Abstract]",
        "label": "Collaborative and Other Arrangements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeandOtherArrangementsAbstract",
     "nsuri": "http://www.gilead.com/20210930",
     "xbrltype": "stringItemType"
    },
    "gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Purchase Agreement and Investor Rights Agreement",
        "label": "Common Stock Purchase Agreement and Investor Rights Agreement [Member]",
        "terseLabel": "The \u201cStock Purchase Agreements\u201d"
       }
      }
     },
     "localname": "CommonStockPurchaseAgreementAndInvestorRightsAgreementMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CreditFacilityDueJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility Due June 2025",
        "label": "Credit Facility Due June 2025 [Member]",
        "terseLabel": "The \"2020 Revolving Credit Facility\""
       }
      }
     },
     "localname": "CreditFacilityDueJune2025Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DeferredCompensationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Compensation Plan [Member]",
        "label": "Deferred Compensation Plan [Member]",
        "terseLabel": "Deferred compensation plan"
       }
      }
     },
     "localname": "DeferredCompensationPlanMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EquitySecuritiesDonationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Donation",
        "label": "Equity Securities Donation [Member]",
        "terseLabel": "Equity Securities Donation"
       }
      }
     },
     "localname": "EquitySecuritiesDonationMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased",
        "label": "Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased",
        "terseLabel": "Maximum percentage of outstanding stock allowed to be purchased (up to)"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_EquitySecuritiesFVNIPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Purchase Period",
        "label": "Equity Securities, FV-NI, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIPurchasePeriod",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_EquitySecuritiesFVNIRestrictionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Restriction Period",
        "label": "Equity Securities, FV-NI, Restriction Period",
        "terseLabel": "Restriction period"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIRestrictionPeriod",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_EquitySecuritiesFVNIShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Shares",
        "label": "Equity Securities, FV-NI, Shares",
        "terseLabel": "Equity securities (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIShares",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gild_EquitySecuritiesFVNISharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Shares Acquired",
        "label": "Equity Securities, FV-NI, Shares Acquired",
        "terseLabel": "Equity securities acquired (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesFVNISharesAcquired",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gild_EquityinvestmentinGalapagosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity investment in Galapagos [Member]",
        "label": "Equity investment in Galapagos [Member]",
        "terseLabel": "Equity investment in Galapagos"
       }
      }
     },
     "localname": "EquityinvestmentinGalapagosMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EuropeanPatentClaims2024ExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Patent Claims 2024 Expiration",
        "label": "European Patent Claims 2024 Expiration [Member]",
        "terseLabel": "European Patent Claims 2024 Expiration"
       }
      }
     },
     "localname": "EuropeanPatentClaims2024ExpirationMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EuropeanPatentClaims2026ExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Patent Claims 2026 Expiration",
        "label": "European Patent Claims 2026 Expiration [Member]",
        "terseLabel": "European Patent Claims 2026 Expiration"
       }
      }
     },
     "localname": "EuropeanPatentClaims2026ExpirationMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EuropeanPatentClaims2027ExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Patent Claims 2027 Expiration",
        "label": "European Patent Claims 2027 Expiration [Member]",
        "terseLabel": "European Patent Claims 2027 Expiration"
       }
      }
     },
     "localname": "EuropeanPatentClaims2027ExpirationMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EuropeanPatentClaims2032ExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Patent Claims 2032 Expiration",
        "label": "European Patent Claims 2032 Expiration [Member]",
        "terseLabel": "European Patent Claims 2032 Expiration"
       }
      }
     },
     "localname": "EuropeanPatentClaims2032ExpirationMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "totalLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetsGrossReclassified": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Gross, Reclassified",
        "label": "Finite-Lived Intangible Assets, Gross, Reclassified",
        "terseLabel": "Reclassified amounts"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGrossReclassified",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_ForeignCurrencyDerivativeContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Derivative Contracts [Member]",
        "label": "Foreign Currency Derivative Contracts [Member]",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeContractsMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FortySevenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forty Seven, Inc.",
        "label": "Forty Seven, Inc. [Member]",
        "terseLabel": "Forty Seven, Inc."
       }
      }
     },
     "localname": "FortySevenIncMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GalapagosNVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Galapagos NV",
        "label": "Galapagos NV [Member]",
        "terseLabel": "Galapagos NV"
       }
      }
     },
     "localname": "GalapagosNVMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GileadFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead Foundation",
        "label": "Gilead Foundation [Member]",
        "terseLabel": "Gilead Foundation"
       }
      }
     },
     "localname": "GileadFoundationMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Product Sales",
        "label": "HCV Product Sales [Member]",
        "terseLabel": "Total HCV"
       }
      }
     },
     "localname": "HCVProductSalesMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductsLedipasvirSofosbuvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Products, Ledipasvir/Sofosbuvir",
        "label": "HCV Products, Ledipasvir/Sofosbuvir [Member]",
        "terseLabel": "Ledipasvir/Sofosbuvir"
       }
      }
     },
     "localname": "HCVProductsLedipasvirSofosbuvirMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductsSofosbuvirVelpatasvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Products, Sofosbuvir/Velpatasvir",
        "label": "HCV Products, Sofosbuvir/Velpatasvir [Member]",
        "terseLabel": "Sofosbuvir/Velpatasvir"
       }
      }
     },
     "localname": "HCVProductsSofosbuvirVelpatasvirMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Product Sales",
        "label": "HIV Product Sales [Member]",
        "terseLabel": "Total HIV"
       }
      }
     },
     "localname": "HIVProductSalesMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsAtriplaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Atripla [Member]",
        "label": "HIV Products, Atripla [Member]",
        "terseLabel": "Atripla"
       }
      }
     },
     "localname": "HIVProductsAtriplaMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsBiktarvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Biktarvy [Member]",
        "label": "HIV Products, Biktarvy [Member]",
        "terseLabel": "Biktarvy"
       }
      }
     },
     "localname": "HIVProductsBiktarvyMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsCompleraEvipleraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Complera/Eviplera [Member]",
        "label": "HIV Products, Complera/Eviplera [Member]",
        "terseLabel": "Complera/Eviplera"
       }
      }
     },
     "localname": "HIVProductsCompleraEvipleraMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsDescovyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Descovy [Member]",
        "label": "HIV Products, Descovy [Member]",
        "terseLabel": "Descovy"
       }
      }
     },
     "localname": "HIVProductsDescovyMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsGenvoyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Genvoya [Member]",
        "label": "HIV Products, Genvoya [Member]",
        "terseLabel": "Genvoya"
       }
      }
     },
     "localname": "HIVProductsGenvoyaMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsOdefseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Odefsey [Member]",
        "label": "HIV Products, Odefsey [Member]",
        "terseLabel": "Odefsey"
       }
      }
     },
     "localname": "HIVProductsOdefseyMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsStribildMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Stribild [Member]",
        "label": "HIV Products, Stribild [Member]",
        "terseLabel": "Stribild"
       }
      }
     },
     "localname": "HIVProductsStribildMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsTruvadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Truvada [Member]",
        "label": "HIV Products, Truvada [Member]",
        "terseLabel": "Truvada"
       }
      }
     },
     "localname": "HIVProductsTruvadaMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product [Member]",
        "terseLabel": "Total HBV/HDV"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Other",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Other [Member]",
        "terseLabel": "Other HBV/HBD"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductOtherMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]",
        "terseLabel": "Vemlidy"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]",
        "terseLabel": "Viread"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductVireadMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepcludexForHDVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepcludex For HDV",
        "label": "Hepcludex For HDV [Member]",
        "terseLabel": "Hepcludex For HDV",
        "verboseLabel": "Intangible asset - Hepcludex"
       }
      }
     },
     "localname": "HepcludexForHDVMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ImmunomedicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunomedics, Inc. (\u201cImmunomedics\u201d), a leading company in antibody-drug conjugate (\u201cADC\u201d) technology",
        "label": "Immunomedics, Inc. [Member]",
        "terseLabel": "Immunomedics"
       }
      }
     },
     "localname": "ImmunomedicsIncMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_InjectableFormulationProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Injectable Formulation Product",
        "label": "Injectable Formulation Product [Member]",
        "terseLabel": "Injectable Formulation Product"
       }
      }
     },
     "localname": "InjectableFormulationProductMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_IntangibleAssetMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Asset, Measurement Input",
        "label": "Intangible Asset, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "IntangibleAssetMeasurementInput",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "gild_IntangibleAssetSofosbuvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sofosbuvir [Member]",
        "label": "Intangible Asset - Sofosbuvir [Member]",
        "terseLabel": "Intangible asset - sofosbuvir"
       }
      }
     },
     "localname": "IntangibleAssetSofosbuvirMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_InventoryNetAndInventoryNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Net And Inventory Noncurrent",
        "label": "Inventory Net And Inventory Noncurrent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNetAndInventoryNoncurrent",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_JudgmentEnhancedDamagesOnPastSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Enhanced Damages On Past Sales",
        "label": "Judgment: Enhanced Damages On Past Sales",
        "terseLabel": "Enhancement rate on past damages"
       }
      }
     },
     "localname": "JudgmentEnhancedDamagesOnPastSales",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JudgmentRoyaltyRateFromOctober2017": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Royalty Rate from October 2017",
        "label": "Judgment: Royalty Rate from October 2017",
        "terseLabel": "Running royalty rate from October 2017"
       }
      }
     },
     "localname": "JudgmentRoyaltyRateFromOctober2017",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JudgmentRoyaltyRateOnFutureSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Royalty Rate on Future Sales",
        "label": "Judgment: Royalty Rate on Future Sales",
        "terseLabel": "Running royalty rate on future sales"
       }
      }
     },
     "localname": "JudgmentRoyaltyRateOnFutureSales",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, \u201cJuno\u201d)",
        "label": "Juno Therapeutics, Inc. and Sloan Kettering Cancer Center [Member]",
        "terseLabel": "Juno Therapeutics, Inc. and Sloan Kettering Cancer Center"
       }
      }
     },
     "localname": "JunoTherapeuticsIncAndSloanKetteringCancerCenterMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_LossContingencyMaterialTransferAgreementsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Material Transfer Agreements, Number",
        "label": "Loss Contingency, Material Transfer Agreements, Number",
        "terseLabel": "Number of material transfer agreements"
       }
      }
     },
     "localname": "LossContingencyMaterialTransferAgreementsNumber",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPartiesAppealedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Parties Appealed, Number",
        "label": "Loss Contingency, Parties Appealed, Number",
        "terseLabel": "Number of parties appealed"
       }
      }
     },
     "localname": "LossContingencyPartiesAppealedNumber",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPartiesFilingOppositionNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Parties Filing Opposition, Number",
        "label": "Loss Contingency, Parties Filing Opposition, Number",
        "terseLabel": "Number of parties filing opposition"
       }
      }
     },
     "localname": "LossContingencyPartiesFilingOppositionNumber",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario One",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario One",
        "terseLabel": "Number of patents challenged, scenario one"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumberScenarioOne",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two",
        "terseLabel": "Number of patents challenged, scenario two"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_MYRGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MYR GmbH",
        "label": "MYR GmbH [Member]",
        "terseLabel": "MYR GmbH"
       }
      }
     },
     "localname": "MYRGmbHMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MarketableSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Current [Member]",
        "label": "Marketable Securities, Current [Member]",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MarketableSecuritiesNoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Noncurrent [Member]",
        "label": "Marketable Securities, Noncurrent [Member]",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrentMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MckessonCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corp [Member]",
        "label": "McKesson Corp [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "MckessonCorpMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MerckMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck",
        "label": "Merck [Member]",
        "terseLabel": "Merck"
       }
      }
     },
     "localname": "MerckMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck Sharp &amp; Dohme Corp License And Collaboration Agreement",
        "label": "Merck Sharp &amp; Dohme Corp License And Collaboration Agreement [Member]",
        "terseLabel": "Merck Sharp &amp; Dohme Corp agreement"
       }
      }
     },
     "localname": "MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OralFormulationProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oral Formulation Product",
        "label": "Oral Formulation Product [Member]",
        "terseLabel": "Oral Formulation Product"
       }
      }
     },
     "localname": "OralFormulationProductMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherCollaborationArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Collaboration Arrangements [Member]",
        "label": "Other Collaboration Arrangements [Member]",
        "terseLabel": "Other collaboration arrangements"
       }
      }
     },
     "localname": "OtherCollaborationArrangementsMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]",
        "terseLabel": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.gilead.com/20210930",
     "xbrltype": "stringItemType"
    },
    "gild_OtherHepatitisCVirusProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Hepatitis C Virus Products",
        "label": "Other Hepatitis C Virus Products [Member]",
        "terseLabel": "Other HCV"
       }
      }
     },
     "localname": "OtherHepatitisCVirusProductsMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other International [Member]",
        "label": "Other International [Member]",
        "terseLabel": "Other International"
       }
      }
     },
     "localname": "OtherInternationalMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsAmBisomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, AmBisome [Member]",
        "label": "Other Products, AmBisome [Member]",
        "terseLabel": "AmBisome"
       }
      }
     },
     "localname": "OtherProductsAmBisomeMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsLetairisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Letairis [Member]",
        "label": "Other Products, Letairis [Member]",
        "terseLabel": "Letairis"
       }
      }
     },
     "localname": "OtherProductsLetairisMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Other [Member]",
        "label": "Other Products, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductsOtherMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsRanexaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Ranexa [Member]",
        "label": "Other Products, Ranexa [Member]",
        "terseLabel": "Ranexa"
       }
      }
     },
     "localname": "OtherProductsRanexaMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsTotalOtherProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Total Other product sales",
        "label": "Other Products, Total Other product sales [Member]",
        "terseLabel": "Total Other"
       }
      }
     },
     "localname": "OtherProductsTotalOtherProductSalesMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsZydeligMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Zydelig [Member]",
        "label": "Other Products, Zydelig [Member]",
        "terseLabel": "Zydelig"
       }
      }
     },
     "localname": "OtherProductsZydeligMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PaymentsToAcquireAssetsNetOfCashAcquired": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Assets, Net Of Cash Acquired",
        "label": "Payments To Acquire Assets, Net Of Cash Acquired",
        "terseLabel": "Consideration, net of acquired cash"
       }
      }
     },
     "localname": "PaymentsToAcquireAssetsNetOfCashAcquired",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PreExposureProphylaxisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Exposure Prophylaxis",
        "label": "Pre-Exposure Prophylaxis [Member]",
        "terseLabel": "Pre-Exposure Prophylaxis"
       }
      }
     },
     "localname": "PreExposureProphylaxisMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability",
        "label": "Product Liability [Member]",
        "terseLabel": "Product Liability"
       }
      }
     },
     "localname": "ProductLiabilityMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductsOtherHIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products, Other HIV [Member]",
        "label": "Products, Other HIV [Member]",
        "terseLabel": "Other HIV"
       }
      }
     },
     "localname": "ProductsOtherHIVMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductsRevenueShareSymtuzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products, Revenue Share-Symtuza [Member]",
        "label": "Products, Revenue Share-Symtuza [Member]",
        "terseLabel": "Revenue share - Symtuza"
       }
      }
     },
     "localname": "ProductsRevenueShareSymtuzaMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_QuiTamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qui Tam",
        "label": "Qui Tam [Member]",
        "terseLabel": "Qui Tam"
       }
      }
     },
     "localname": "QuiTamMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ResidentialMortgageAndAssetBackedSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Residential Mortgage And Asset-Backed Securities [Member]",
        "label": "Residential Mortgage And Asset-Backed Securities [Member]",
        "terseLabel": "Residential mortgage and asset-backed securities",
        "verboseLabel": "Residential mortgage and asset-backed securities"
       }
      }
     },
     "localname": "ResidentialMortgageAndAssetBackedSecuritiesMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_RoyaltyContractAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Contract, And Other [Member]",
        "label": "Royalty, Contract, And Other [Member]",
        "terseLabel": "Royalty, contract and other revenues"
       }
      }
     },
     "localname": "RoyaltyContractAndOtherMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorNotesAndMediumTermNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes And Medium-Term Notes",
        "label": "Senior Notes And Medium-Term Notes [Member]",
        "terseLabel": "Senior Notes and Medium-Term Notes"
       }
      }
     },
     "localname": "SeniorNotesAndMediumTermNotesMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Year Senior Unsecured Term Loan Facility",
        "label": "Three Year Senior Unsecured Term Loan Facility [Member]",
        "terseLabel": "Three-Year Senior Term Loan Facility"
       }
      }
     },
     "localname": "ThreeYearSeniorUnsecuredTermLoanFacilityMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.",
        "label": "Total Indefinite Lived Intangible Assets Excluding Goodwill",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_TrodelvyForMTNBCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trodelvy for mTNBC [Member]",
        "label": "Trodelvy for mTNBC [Member]",
        "terseLabel": "Finite-lived intangible asset"
       }
      }
     },
     "localname": "TrodelvyForMTNBCMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TrodelvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trodelvy",
        "label": "Trodelvy [Member]",
        "terseLabel": "Trodelvy",
        "verboseLabel": "Intangible asset - Trodelvy"
       }
      }
     },
     "localname": "TrodelvyMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Collaboration Expenses Related To Other Collaborative Arrangements",
        "label": "Upfront Collaboration Expenses Related To Other Collaborative Arrangements",
        "terseLabel": "Upfront collaboration expenses related to other collaborative arrangements"
       }
      }
     },
     "localname": "UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_VariableTermLoanNoteDueOctober2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Term Loan Note Due October 2023",
        "label": "Variable Term Loan Note Due October 2023 [Member]",
        "terseLabel": "Variable Term Loan Note Due October 2023"
       }
      }
     },
     "localname": "VariableTermLoanNoteDueOctober2023Member",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_VekluryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Veklury",
        "label": "Veklury [Member]",
        "terseLabel": "Veklury"
       }
      }
     },
     "localname": "VekluryMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ViiVHealthcareCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV Healthcare Company (\u201cViiV\u201d)",
        "label": "ViiV Healthcare Company [Member]",
        "terseLabel": "ViiV Healthcare Company"
       }
      }
     },
     "localname": "ViiVHealthcareCompanyMember",
     "nsuri": "http://www.gilead.com/20210930",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r0",
      "r140",
      "r145",
      "r151",
      "r239",
      "r415",
      "r416",
      "r417",
      "r431",
      "r432",
      "r505",
      "r506",
      "r507",
      "r508",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative effect from the adoption of new accounting standard"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r0",
      "r140",
      "r145",
      "r151",
      "r239",
      "r415",
      "r416",
      "r417",
      "r431",
      "r432",
      "r505",
      "r506",
      "r507",
      "r508",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period Of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r0",
      "r140",
      "r145",
      "r151",
      "r239",
      "r415",
      "r416",
      "r417",
      "r431",
      "r432",
      "r505",
      "r506",
      "r507",
      "r508",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period Of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r206",
      "r383",
      "r390",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r309",
      "r346",
      "r407",
      "r410",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r584",
      "r652",
      "r656",
      "r681",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r206",
      "r383",
      "r390",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r203",
      "r383",
      "r388",
      "r585",
      "r651",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r203",
      "r383",
      "r388",
      "r585",
      "r651",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r309",
      "r346",
      "r396",
      "r407",
      "r410",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r584",
      "r652",
      "r656",
      "r681",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r309",
      "r346",
      "r396",
      "r407",
      "r410",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r584",
      "r652",
      "r656",
      "r681",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r146",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r146",
      "r151",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r204",
      "r205",
      "r383",
      "r389",
      "r654",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r204",
      "r205",
      "r383",
      "r389",
      "r654",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r146",
      "r151",
      "r283",
      "r408",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40",
      "r550"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r207",
      "r208"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r207",
      "r208"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r17",
      "r605",
      "r635"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r19",
      "r605",
      "r635"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r78",
      "r87",
      "r88",
      "r89",
      "r90",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r78",
      "r87",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r76",
      "r77",
      "r78",
      "r637",
      "r661",
      "r662"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r75",
      "r78",
      "r87",
      "r88",
      "r89",
      "r137",
      "r138",
      "r139",
      "r473",
      "r657",
      "r658",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r70",
      "r78",
      "r87",
      "r88",
      "r89",
      "r473",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "OTHER FINANCIAL INFORMATION"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r23",
      "r418",
      "r550"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r415",
      "r416",
      "r417",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r121",
      "r271"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r411",
      "r412",
      "r419",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r29",
      "r209",
      "r240"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Less: allowances for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Write-offs charged against allowance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r121",
      "r263",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Aggregate amortization expense related to finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from earnings per share computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r130",
      "r187",
      "r196",
      "r201",
      "r237",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r467",
      "r474",
      "r529",
      "r548",
      "r550",
      "r603",
      "r634"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r56",
      "r130",
      "r237",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r467",
      "r474",
      "r529",
      "r548",
      "r550"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r511"
     ],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r217",
      "r220",
      "r624"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "After five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r217",
      "r221",
      "r625"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "After five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "terseLabel": "Amortized\u00a0Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r219"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r217",
      "r219",
      "r623"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r211",
      "r214",
      "r247",
      "r609"
     ],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "netLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r485",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r406",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r406",
      "r409",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r458"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Expected tax deductible goodwill"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r452",
      "r453",
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Acquisition consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r451",
      "r454",
      "r457"
     ],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Liability for MYR GmbH (\u201cMYR\u201d) contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": {
     "auth_ref": [
      "r447",
      "r448"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability",
        "verboseLabel": "Fair value of contingent liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r447",
      "r448"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Finite-lived intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r447",
      "r448"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "Intangible assets:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r447",
      "r448"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Combination, Separately Recognized Transactions [Line Items]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Line Items]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing the disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Table]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Table]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r118",
      "r123",
      "r124"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r118",
      "r530"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r49",
      "r282",
      "r610",
      "r642"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r291",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends declared (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r137",
      "r138",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r550"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.001 per share; 5,600 shares authorized; 1,255 and 1,254 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r83",
      "r85",
      "r86",
      "r97",
      "r616",
      "r647"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Gilead"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r83",
      "r85",
      "r96",
      "r465",
      "r466",
      "r478",
      "r615",
      "r646"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r83",
      "r85",
      "r95",
      "r464",
      "r478",
      "r614",
      "r645"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r206",
      "r527",
      "r528",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r206",
      "r527",
      "r528",
      "r664",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r206",
      "r527",
      "r528",
      "r664",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r173",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r177",
      "r178",
      "r206",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r206",
      "r527",
      "r528",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r369",
      "r371",
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r369",
      "r370",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Change in estimate of variable consideration"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Contract with customer, performance obligation satisfied in previous period"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.",
        "label": "Contract with Customer, Refund Liability, Current",
        "terseLabel": "Allowance for sales returns"
       }
      }
     },
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r397",
      "r405",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r100",
      "r585"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r176",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Current portion of long-term debt and other obligations, net"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r126",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r323",
      "r330",
      "r331",
      "r333",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT AND CREDIT FACILITIES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r17",
      "r18",
      "r129",
      "r135",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r336",
      "r337",
      "r338",
      "r339",
      "r543",
      "r604",
      "r606",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Interest Rate, variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r18",
      "r334",
      "r606",
      "r632"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Short-term and long-term debt, carrying values"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r46",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest Rate, stated percentage",
        "verboseLabel": "Stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r47",
      "r129",
      "r135",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r336",
      "r337",
      "r338",
      "r339",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r47",
      "r129",
      "r135",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r336",
      "r337",
      "r338",
      "r339",
      "r361",
      "r364",
      "r365",
      "r366",
      "r540",
      "r541",
      "r543",
      "r544",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Contractual term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      },
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Total",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of Classification of Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r225",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of positions held in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r121",
      "r131",
      "r429",
      "r435",
      "r436",
      "r437"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r121",
      "r277"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r57",
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement",
        "terseLabel": "Derivative Assets"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r58",
      "r68",
      "r488"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Fair Value, Gross Liability",
        "negatedTerseLabel": "Gross Amounts Offset on our Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.",
        "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net Amount (Legal Offset)"
       }
      }
     },
     "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r60",
      "r64"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.",
        "label": "Derivative Asset, Not Offset, Policy Election Deduction",
        "negatedTerseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r59",
      "r63",
      "r66",
      "r524"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "totalLabel": "Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Asset [Abstract]",
        "terseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeCollateralObligationToReturnCash": {
     "auth_ref": [
      "r61",
      "r64",
      "r65",
      "r498"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.",
        "label": "Derivative, Collateral, Obligation to Return Cash",
        "negatedTerseLabel": "Cash Collateral Received/ Pledged"
       }
      }
     },
     "localname": "DerivativeCollateralObligationToReturnCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralRightToReclaimCash": {
     "auth_ref": [
      "r61",
      "r64",
      "r65",
      "r498"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.",
        "label": "Derivative, Collateral, Right to Reclaim Cash",
        "terseLabel": "Cash Collateral Received/ Pledged"
       }
      }
     },
     "localname": "DerivativeCollateralRightToReclaimCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r57",
      "r66",
      "r67",
      "r488",
      "r566"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Gross Amounts of Recognized Assets/Liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r57",
      "r66",
      "r67",
      "r488",
      "r566"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "negatedTerseLabel": "Gross Amounts of Recognized Assets/Liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r504",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "DERIVATIVE FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period for the anticipated transfer of gain (loss), net, from accumulated other comprehensive income into earnings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer",
        "terseLabel": "Time estimate for gains (losses) to be reclassified from AOCI to product sales"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r493",
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Gains (losses) recognized in Other income (expense), net"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r59",
      "r63",
      "r66",
      "r524"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "negatedTotalLabel": "Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability [Abstract]",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossAsset": {
     "auth_ref": [
      "r58",
      "r65",
      "r68",
      "r488"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Liability, Fair Value, Gross Asset",
        "terseLabel": "Gross Amounts Offset on our Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r57",
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement",
        "negatedLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.",
        "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "negatedTotalLabel": "Net Amount (Legal Offset)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r60",
      "r64"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.",
        "label": "Derivative Liability, Not Offset, Policy Election Deduction",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r480",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Maturities of derivative instruments"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r490",
      "r494",
      "r497",
      "r499",
      "r502",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r367",
      "r628"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedTerseLabel": "Dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r98",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r152",
      "r154",
      "r159",
      "r160",
      "r161",
      "r165",
      "r166",
      "r508",
      "r509",
      "r617",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income (loss) per share attributable to Gilead common stockholders - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r98",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r154",
      "r159",
      "r160",
      "r161",
      "r165",
      "r166",
      "r508",
      "r509",
      "r617",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income (loss) per share attributable to Gilead common stockholders - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r87",
      "r88",
      "r89",
      "r137",
      "r138",
      "r139",
      "r142",
      "r148",
      "r150",
      "r168",
      "r239",
      "r360",
      "r367",
      "r415",
      "r416",
      "r417",
      "r431",
      "r432",
      "r507",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r657",
      "r658",
      "r659",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Marketable equity securities",
        "verboseLabel": "Equity investment"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r12",
      "r16",
      "r231",
      "r633",
      "r665",
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Other publicly traded equity securities",
        "verboseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r321",
      "r336",
      "r337",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement",
        "verboseLabel": "Market value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r511",
      "r512",
      "r513",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r511",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r511",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Summary of Classification of Equity Securities"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r321",
      "r336",
      "r337",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r512",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r321",
      "r336",
      "r337",
      "r511",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r511",
      "r512",
      "r515",
      "r516",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r321",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r321",
      "r397",
      "r398",
      "r403",
      "r405",
      "r512",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r321",
      "r336",
      "r337",
      "r397",
      "r398",
      "r403",
      "r405",
      "r512",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r321",
      "r336",
      "r337",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r512",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r321",
      "r336",
      "r337",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r518",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r485",
      "r490",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r223",
      "r224",
      "r233",
      "r234",
      "r235",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r332",
      "r358",
      "r504",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2021 (remaining three months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r264",
      "r267",
      "r270",
      "r274",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r270",
      "r587"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r264",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r270",
      "r586"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r397",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Non-U.S. government securities"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet": {
     "auth_ref": [
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net gain (loss) reclassified into earnings when foreign currency cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.",
        "label": "Gain (Loss) on Discontinuation of Foreign Currency Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net",
        "terseLabel": "Discontinuances of cash flow hedges"
       }
      }
     },
     "localname": "GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r254",
      "r255",
      "r550",
      "r602"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill resulting from the acquisition of MYR"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "GOODWILL AND INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r256",
      "r259"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r258",
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Measurement period adjustments"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r483",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r187",
      "r195",
      "r197",
      "r200",
      "r202",
      "r600",
      "r611",
      "r619",
      "r649"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income (loss) before income taxes",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r426",
      "r427",
      "r428",
      "r433",
      "r438",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r149",
      "r150",
      "r186",
      "r424",
      "r434",
      "r439",
      "r650"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount",
        "terseLabel": "Non-deductible IPR&amp;D charges"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r116",
      "r232"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedTerseLabel": "Net loss from equity securities"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r161"
     ],
     "calculation": {
      "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive effect of stock options and equivalents (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r266",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r266",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r262",
      "r268"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Including Goodwill) [Abstract]",
        "terseLabel": "Intangible Assets, Net (Including Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r91",
      "r185",
      "r539",
      "r542",
      "r618"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r30",
      "r253"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1": {
       "order": 3.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r54",
      "r550"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails": {
       "order": 1.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails": {
       "order": 2.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r32",
      "r253"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1": {
       "order": 1.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r31",
      "r253"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1": {
       "order": 2.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Debt Securities by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Equity investments not measured at fair value"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r231",
      "r601",
      "r626",
      "r668",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "AVAILABLE-FOR-SALE DEBT SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r130",
      "r237",
      "r529",
      "r550",
      "r608",
      "r640"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r45",
      "r130",
      "r237",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r468",
      "r474",
      "r475",
      "r529",
      "r548",
      "r549",
      "r550"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r511"
     ],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Outlicense contract"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r18",
      "r606",
      "r632"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Amounts outstanding under revolving credit facilities"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r18",
      "r320",
      "r335",
      "r336",
      "r337",
      "r606",
      "r636"
     ],
     "calculation": {
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total debt, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Less: current portion of long-term debt and other obligations, net"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Short-term and long-term debt"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Total long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r47",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r290",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in loss contingency liability.",
        "label": "Loss Contingency Accrual, Period Increase (Decrease)",
        "negatedLabel": "Litigation accrual reversed"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r282",
      "r285",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r282",
      "r285",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damages amount"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of class action lawsuits"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs involved"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r43"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "verboseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MediumTermNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instruments with maturities ranging from five to ten years.",
        "label": "Medium-term Notes [Member]",
        "terseLabel": "Medium-term Notes"
       }
      }
     },
     "localname": "MediumTermNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r53",
      "r130",
      "r237",
      "r295",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r529",
      "r607",
      "r639"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership percentage by noncontrolling owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "terseLabel": "Change in noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r118",
      "r119",
      "r122"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r81",
      "r84",
      "r89",
      "r93",
      "r122",
      "r130",
      "r141",
      "r143",
      "r144",
      "r145",
      "r146",
      "r149",
      "r150",
      "r158",
      "r187",
      "r195",
      "r197",
      "r200",
      "r202",
      "r237",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r509",
      "r529",
      "r612",
      "r643"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to Gilead",
        "totalLabel": "Net income (loss) attributable to Gilead"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r84",
      "r89",
      "r149",
      "r150",
      "r470",
      "r477"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r367",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Liability related to future royalties"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r187",
      "r195",
      "r197",
      "r200",
      "r202"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r44"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Available-for-sale debt securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r72",
      "r73"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r72",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r78",
      "r87",
      "r88",
      "r90",
      "r531",
      "r533",
      "r537"
     ],
     "calculation": {
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "verboseLabel": "Net unrealized gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r71",
      "r76"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r71",
      "r76"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "verboseLabel": "Net unrealized gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r71",
      "r76",
      "r487",
      "r491",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gains (losses) recognized in AOCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r76",
      "r79"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassifications to net income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r76",
      "r79",
      "r492"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Gains (losses) reclassified from AOCI into product sales"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Net foreign currency translation gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r82",
      "r85",
      "r87",
      "r88",
      "r90",
      "r94",
      "r360",
      "r531",
      "r536",
      "r537",
      "r613",
      "r644"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r76",
      "r79",
      "r80",
      "r230"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedLabel": "Reclassifications to net income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of other liabilities.",
        "label": "Other Liabilities, Fair Value Disclosure",
        "terseLabel": "Deferred compensation plan"
       }
      }
     },
     "localname": "OtherLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other\u00a0long-term\u00a0obligations"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Impairment recognized"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r105",
      "r109"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedTerseLabel": "Payments of dividends"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r103",
      "r106",
      "r212"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r107",
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid for acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisitions, including in-process research and development, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r116",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "terseLabel": "Payments to acquire equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Purchases of equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20",
      "r550"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r36",
      "r37"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from debt financing, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuances of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Debt issued"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Borrowing from senior unsecured term loan facility"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r103",
      "r104",
      "r212"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r112",
      "r115"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r103",
      "r104",
      "r212"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales",
        "verboseLabel": "Total product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r81",
      "r84",
      "r89",
      "r117",
      "r130",
      "r141",
      "r149",
      "r150",
      "r187",
      "r195",
      "r197",
      "r200",
      "r202",
      "r237",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r464",
      "r469",
      "r471",
      "r477",
      "r478",
      "r509",
      "r529",
      "r619"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r278",
      "r550",
      "r627",
      "r641"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r78",
      "r87",
      "r88",
      "r90",
      "r531",
      "r535",
      "r537"
     ],
     "calculation": {
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Reclassifications to net income (loss)"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r404",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r404",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party",
        "terseLabel": "Donation expense"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r404",
      "r545",
      "r547",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayments of debt and other obligations"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfUnsecuredDebt": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.",
        "label": "Repayments of Unsecured Debt",
        "terseLabel": "Repayments of senior unsecured notes"
       }
      }
     },
     "localname": "RepaymentsOfUnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r367",
      "r418",
      "r550",
      "r638",
      "r660",
      "r662"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r137",
      "r138",
      "r139",
      "r142",
      "r148",
      "r150",
      "r239",
      "r415",
      "r416",
      "r417",
      "r431",
      "r432",
      "r507",
      "r657",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r183",
      "r184",
      "r194",
      "r198",
      "r199",
      "r203",
      "r204",
      "r206",
      "r382",
      "r383",
      "r585"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r177",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r381",
      "r386",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r78",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of Changes in Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Available-for-Sale Debt Securities from Cost Basis to Fair Value"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r218",
      "r222",
      "r226",
      "r227",
      "r228",
      "r229",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of the Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of Debt Carrying Amount"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r486",
      "r494",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Effect of Foreign Currency Exchange Contracts"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of Classification and Fair Value of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r490",
      "r494",
      "r497",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Summary of Potential Effect of Offsetting Derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of the Calculation of Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r264",
      "r269",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r264",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r260",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r273",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r33",
      "r34",
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Revenues from Major Customers"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r50",
      "r127",
      "r169",
      "r170",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r353",
      "r358",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Estimated Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.",
        "label": "Share-based Payment Arrangement, Accelerated Cost",
        "terseLabel": "Acquired share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r125",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r51",
      "r87",
      "r88",
      "r89",
      "r137",
      "r138",
      "r139",
      "r142",
      "r148",
      "r150",
      "r168",
      "r239",
      "r360",
      "r367",
      "r415",
      "r416",
      "r417",
      "r431",
      "r432",
      "r507",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r657",
      "r658",
      "r659",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r168",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r20",
      "r21",
      "r360",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Issuances under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r360",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance under equity incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r20",
      "r21",
      "r360",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuances under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r367",
      "r413",
      "r414"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances under equity incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Authorized amount under stock repurchase program"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining authorized repurchase amount under stock repurchase programs"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r20",
      "r21",
      "r360",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Shares repurchased and retired (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r20",
      "r21",
      "r360",
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "terseLabel": "Value of shares repurchased and retired"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r20",
      "r21",
      "r360",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchases of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r20",
      "r21",
      "r360",
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r26",
      "r27",
      "r130",
      "r210",
      "r237",
      "r529",
      "r550"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Gilead stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r88",
      "r130",
      "r137",
      "r138",
      "r139",
      "r142",
      "r148",
      "r237",
      "r239",
      "r367",
      "r415",
      "r416",
      "r417",
      "r431",
      "r432",
      "r462",
      "r463",
      "r476",
      "r507",
      "r529",
      "r531",
      "r532",
      "r537",
      "r658",
      "r659",
      "r698"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r128",
      "r345",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r538",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r538",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r538",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r223",
      "r224",
      "r233",
      "r234",
      "r235",
      "r332",
      "r358",
      "r504",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r134",
      "r397",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agencies securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r134",
      "r397",
      "r405",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r171",
      "r172",
      "r174",
      "r175",
      "r179",
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Significant Accounting Policies, Estimates and Judgments"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r153",
      "r161"
     ],
     "calculation": {
      "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used in per share calculation - diluted (in shares)",
        "totalLabel": "Shares used in per share calculation - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r152",
      "r161"
     ],
     "calculation": {
      "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in per share calculation - basic (in shares)",
        "verboseLabel": "Shares used in per share calculation - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.gilead.com/role/NETINCOMELOSSPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130611-203046-203046"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(i)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r683": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r684": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r685": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r686": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r687": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r688": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r689": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r690": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r691": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r692": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r693": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r694": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r695": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r696": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>85
<FILENAME>0000882095-21-000029-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000882095-21-000029-xbrl.zip
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M]S>H;EMP/;C"2-/A9K7@WC#:H#S][8*K\JV%Q?L;=YBUGG,:6"8_:IKX!*U
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M#<O(6,6@43O+Y1B0L4\%0-$)J,D<I&!C(BV-K'LQCZUV[.2T<T@KSIL\>RM
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MVA@JE0E7J#G[U[1T2*O65$=*9IU#L4S6U.EF:%BK8*GK6OF21<EDG^V_W-J
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M=4]&'86PT/0C53H%#<U1H1^E#\CN^EB[HF5X*JB2MU-'*-D5&AI)R+1BQ;)
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M1YF-?,<T<T*YC1:C9A/V&=U@3UMPC(/4.S0QA:,,17[- CJD*:6EB1G9A>O
M6KM,>G1EP1F],JZPQ;XH;>Q3T UY1J4X"EG!Z2DX&P"E"LUFO)%7RVVL1AO[
MY,,8N>M4BDM&G82J!0AK<FVU>>6S9HY#&_L,)#4J8XMRF!).=6B6K,"8$Q@8
M+W#<;0_:V.FL2,U-A5J>7J2'<:1"$S<@]Y*A+C"[XQ53?O',X_+BR^/#QDYG
MXEM'5<H@@#-8U9&B6Y+Y/9O!ZVI;\+<CEK4S&S"V 0[<,M8\/<:@*B/WQKUT
MEQ3G]>4XJ+&/?E(+W[IPA_!DU2 ,:)T(1@)(N%K1QH_3SR$MF;8N3V)(H(+"
MJE4]D8N-Z!"T6LW&,J2Q3[NYU&L9KCUH8.<AK;?,)(B&B66!<^HKD\8NDIF>
MH7D;P#,813'2/+#*C$I]6$VT6E"Z,FGLHY\6H:-ONJD8M1./5$?S^5<I,]@Y
M2?T<TI*<J("AAD%!*\[3@VP%&S-N52=>;0?^YHOC<\9.X>EV$@4E;XZB],P;
MD\I< %I5Z+K M(1;E\K:^8R4G$K;-FB)L$_ 8$V6*GI+6F:P>A;,01AC%_5,
M&*7D0*-A09+&-8_1&K96J4==H*/*/ZR>0]H1<RHX^9";"^8A,@.-FKKIEMU4
M6:U&8Q'"V&DJ9,H4==[P,:52E2JI1>[%57&]L&(IPMA%,&E [1T5ME9];3 A
M!X*F[C(#&5\MC[$N8>QS[&1(YHZMJ E.("6NY* VL15ZM-7.+=T&8>R3C4H
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M4'>PHXQ>.2D/M(]0.KA5*D+5D9"Y->#1MD,/$#, /KY0%O= NZ@&LN?(O=D
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M"NDH;6WOI&;6SDEH2RF\E$3>4$@96Q!Q U"RD1?(;.ZGG!/*4VB!T7IK/=5
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M[99!'1YA;4JI/DLL:DS :J,NQ;%,ZQT"C:ZGQU8KKEAG0X^T76_H&_ELA":
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M:>+MYF.-[#+6A*J!$P@X0E-,[UF/X+PB;U0!WJ2*QP/A%1Z<1M+ 3L";4A7
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MBWL"T" 8"&K7]C&Y;!N@,Q0C!T>^)MMZ0^7A,M#U*JOAX7<PE,,J'*P18X'
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M"V.TY)MR!68/%D)OQ=[8L7"+M0O1*4[YI'QN^K/22Q@)7V1;2Z*6HJ$(+!K
M,HO^##!11G'#YXL)%M? %DH4-5 R-K&%%%MOYLXV4O"Q@9<1U.__&RM]-*WZ
MM=#R%)>O];.%F_$E5X?G4 BCD;,^>" %! 1K<[5$O5>X%2O%I.$3QH2,:TKP
MAVQ#(0?$7I&1"IN2,-?<T/M1C%L:DBN)?U9C$D="&!$-1&.+1B 56@ *EB!3
MZG,D^[SXX1/&!(OK*"+(/O9N1:6%  $5",4E2K4VB57*Q!:?M%/\IQ5I:21L
M4:%RM!48G $?6FX90;V(<SWE6:8S$6."Q0JU10H(:%O.?;2MA*)_^8HB&K5*
MGLX3?UK]JON8S/T]ES86OLC>UN9-ZIOND,4C-!\IQ6I18G8C&" ^ >-Z&",:
MQ0$60*?,H=)"/&$MAE!<XC$<A/@W=OJH"GQC)V\V*TQ=X5$([R'&%@,;]2&!
M$9L)5<FBLB X'#YC3,"XIJ'L+*HWJPG)J[@0M,%:!8>"@HBS&SYC#,B5:,C_
MY]OM_L]R:4/AC%1\CK;5'(&@-Q $3C&%QCZGWM1F^)PQ0>.Z\A@>P 9L7O4%
M! ",B0NG5C%ZI#K@EJ1#A(:Y"C3&DOE$LKGZ4CD95LD!%*+5V)6CR5Q2FTYI
MCPT:JV,-\AB,.@XRZ,![7ZRW2!JO@&1O7)M8XU/27!]U*&]4+_R9ZAT*9WA$
MBE@98W;]4"ZZPK$DM":60GDZ0#4N8*RP&4RLS4K*BHT EEHFQA0]U*+12K93
M!O13@!$^&B?_WO(#QM(,QG$NQ8F)RAN@-TIL!5S**D3)DA]!1<:$C&NJXK*9
ML/AF6PD@F+(+JCE,RMZ&$F$Z6_)) C3_27$?C*7F$Q(Q::0:J 7PQI,C6P,G
MZVJAT*8]DS'!8G5L$8N$ZG++Q2%TM6FM_FFJJ IMF</$%I\"BRN4$L)8TI^,
MH%I3:8)*A1R1O",C7*(IBI$X*8R1(6.%>R:U2$P^*FTX:"47A-RA4DT.+>/4
M0.J3D/'1(XH7Y3HPELPGZ4<)P0EC*> ]YUZ/ 58#%+&UEA'LL4ZPN(YV<WU$
M:C!01"Q$H$PF& S!>BB&VK3#^DFPL'\&B['4<'F7U8\ VVH3U"@8I&%2E1&5
M1\A..<\QP6*%)U8MM2K.2E$GPD'5IPBSA) A0;#3SNHGI<(_&J:^286'L>R1
M)%>R#XU+J@J%F NC!!<)H?J6S0C.N$_ N!Y]4:BAZ@F/F,$Y*MDH>V1K&5J&
M-MI=U3-+O86*6W,>9W<*;\D%X5QJ5!5H/'DD5\FT$KPNXM%Z^C4;:(55TY6S
M"SX#F *Q.0H8H1FG/I@X91GK"KI\],P6W^'KWD?D;"K?Q>VQ+""0VFJU5BT#
MH'HHM^IM:PF@%&_'?YAR/?9983[,1 <2?2WLP1E?FM,E91"-.&>YOM_D=(#S
MI@>H4=8RZ6[]T^XU#K9>16Y%2Q"M(T;?I ;C2DT5<42#JH<$IC6->UG_?.S>
M_"F7T.=N.BB@I*2,)*6?MDZ S6],!^9/TUY_'U/[SY<B3P27[P'KLE/9UUAG
M!_KU#8JD5@6J%FP*R5D/!)*(DD^U-<)03:IE],, M@=+UR)8@ZF<H%)*W,_S
MDS(0476A1!\KNLWAG"T:=KA^TDDA:)Q:?-4_(.28';><2._:;)C-.:JLN4"5
MZNQ)9K]YR5,ZEG^=ZE7>?:5_?. ]WWW"#:!Y2",$K+DRFO6IJ]'YK31;0R.-
MVX&=0YNR*C)3;"N%V4YH_DNH6DG#YW4MJU$".=JBWMU5+QJPMH0Y4L_Q6BKH
MK2LCJ#>^K3"9G5QJK'<-^$A>+0Y>S>;/WGW22(18$^<XN&(J>3 ,N4+IQXR$
MJO@01S#/;6BV667GQ,"Q.&,$&5+R)5M#*53;"[-='L%.]^IM\_<]P+MOI[S_
MS].Y7*&!YU!6K$K;ZM7]HS$ '($<NNI,S+8@I'PV,,L6Z\YD0;\QO*5[O#SY
MXO[L9/8,3_3^;3Q^>[],S;'8?RY+/)+3DUD]OC>OM^;\^$"#W/\K)ZHB.F1P
M7F5Y6_I\J^OUF+;TY7PECWG^U)5X3)-MSH*ZS'.#'$.II9$IB:EA1+[8$-7(
M>7 K?^"F?8>G#:QF15I)T(PIS?L*%BUYXT!"S,5")+)C2F:\,=WC$SPY/7Z7
MLK]32*N)?G_2WR7K?XN6'V>S'[\5/#AY7G$IMQ>'1SC?E%SIZ7QV#AY\MA3I
MU_H&$8>"QQJ6G'\';QZ^?)W+1R_O]Q?Z< +6Q&"J\2Z(@M%P[]K.#BEC;Z4:
MQDHAWRWE[J]'B_X=?+=<'#U_?8#ZX'")XHVACQ0<'[/R^6.?;&()2=6[@,,,
M4&TM'J@6H%:=.$EN#4I@J-[UC1D61PH>Y; C?:/7'[;&Y5.^ZT_Y9*/46%W4
M[R<RE-ZN%KT8FP"D4LKLSDHQ1JC*[I[J:A.<?W<&U=L'.#L\[H,K=#'.EE?Q
M!7]K#;YO_+_3&51-0B$"M*PWO:!O%/0/DUM6@K2;99\X.OOTPZ8U<Q)V%4RJ
MY#7418[1-I]L,1ME'^_&8)^W?-A'2?/H+Y$E65V'U1:5* YZHTW+ZM1"]24(
M@L]G'BQ>*&<;-\3J+EVGU=_QK_'*>E:?NJKHU3LQ#4HT*;G>^"Z75!CZB:X8
M0TQUHY;P]1ISY4OX '\Y/IU]1(=>//C)RS@83AIG2):@BD<R68ZJ20,D\<W]
ML;QQ@ 'PGP0="SZM)_=G2)M4L/,[KRN6^S?7/L+MEP]_,C":AT192E,^ %N4
M"7I;.RMD P4CYQOR&H2> V-\T>CWI[-]/+QF.)S%GU>#PWNAZM_@\!QU+>MW
M6'J6.59#WK *L6Q<"4V->,;A<<B%RH^?XU(>R='ILCY7J^D:?K;$PW?...DG
M>'RRJ"__\*QK)?+X;B7PWVG H6%,A>:2(?6O164S""7N;1:*QS<YGI$;R9F;
M-U)?22LRDE-#E"P"U,_/9(,JBG(BL3F"K4F&O\/:4\%G2<B[_U)U\+IG8A=S
MO?M>=OA6K:>'IP?Z7-Y?XOSXX(PQ;_&+T^.3PVLI;;B67==4/;L84C+5 :#:
M*P:!4A!$-!P=P6&T3[?7 SGY8;X4/)C])GQO_DK.+?:-^OW[B^.QG+(IU;16
M@(W&'% %B3+:5%H%@5S,"!HK?[KE+DVD%E1M\OSK@\4OWPH_D^^45T>SY"!X
M%Z+&"[$42,CD:\W)F1PR8@YN!/'#X+ER_=6YCD*MA:21!W 94#@64=6B-D#"
MLM%6OG&&7;^]F^T'B3A3;__E,U+"&F*Q8E6>%H,;;>^;YN7UFQLSJ4!JCF-P
M0$;C_H1-4HB<<BAF!&?$!\O=UW-F7-=@:]7&XI/&)D#,OA6;LS6JF,;0.7P$
M+'Q-8X?8E!RXHBE0I$LESAKXN^B@3Q#91,NM4>>N<,E9Z$>1S@YM %A?H*7L
M2G,QMR8@P]T8&1%%KG OVM2F?LPGRZY!BI$R%XU16(.2'%G\)MIKC12Y0LMY
M74VZN'P,32UF-.H0#3=Z[JWW@?*TB99;'T6NT' E)A> V3@P$+EEIR&#M^K8
M,-AJW,6.D;W<,=HH)[>.5("Y>JQ@5A8KL(:$U*QXC?LAF4:5* =SUL6$K*6-
MMO)Z4P%KL;>SL0&[8"JP*E9;*L;:/!D.&/J4HDVV]UI3 6LQ=X F3C420K5]
M1  Z3C%7K-6+*>4B$;]95E['EM?*CI09BHD-578.6BWHL4^"(<\N-0ZTB?9:
M[Y;7ROJHU!9R0@BE6TX0:Y2 &ELZAACR1JZTM6YYK:SE:16CM(A]I#APZ7LC
MEERNB8+))K3W*Z/B]5OP+[B63ZA+BG_!M?SW[-<OEG*\.%U6.3Z_^UR0SRZ6
M9Z^^_!_]XW+@B"5@:QSWR1) )43RE*.-;+*/^'./\W[_G>.3UP?Z/1W.YKO/
M9?;L^<D7WG^>PM')/WZ9\<GS+ZPQ_\]G[SRU7]"NDL6S^1?+_@OZZ/$1SK_\
M'UK^M[[R^>WS-WCS-E_^STEO4GGY$K18ZJ7OUL7! 1X=RQ>7-_[!L^.C WRM
M<#J8S67W[)?^<8C+9WIYM#@Y61Q^T2_ME2Q/9A4/+B[C[(K.'[ZXZE(^S\'W
M"S_1;^B$+]_XXC-]?O:9_ON$__A8R9\7\_&'S>?VS6/_??;:R\LG7'Y]1_T;
MT=_3#]6_B__W,__9>Y_[XI/H,W=X<=J_E_]ESO[YQQ%R/U;XA=FQ9R_S^_O\
M]]EW\0'+O66.*OVHZ(4]+A_7RU@LO[A\@Z: VFUX.#MX_<7_V5<..MYY(+_L
M/%H<XOS__->Q.N[=8X5@.W_BL7J$+YS1;_SL[B_GGS#IZYR9Y^(36]>_KQ\>
MW-N_>V?G\?ZM_;N/WX7! *_V\=W;/SRZMW_O[N.=6P_N[-S]_VY_>^O!-W=W
M;C_<V[OW^/&]AP_6]Q&LN])'^.G6XV_O/?AF_^&#_]JY\_GMSW><"5#6=]GE
MO:N&#U[U__Y?-II_?-)5WBQU>/LY>#=PZE!VV#E>',QX$YCCZX>/]G;^1SW:
M?#%_<'JH+U)W+AS?(VEGXQB]C<2E@D&(M1 SB@D6>ZUGI \6Q>S,L?M_EMD7
M=Q;UK/-%[SCTV476Q?_XFNXL7MUWCUX]\7NG_.+NJZ??E!</7_SSQ=Y/]\S3
M.W=_V3O\/CS<__ZW!]_<"P_VG\[VW#UX\.*N>WKG%NS]]O3Y??_@X,EOB]=/
M?OMZ]N";[W_=N_//EP_W7YJ]WQ[-'N[_X)Z\>#![>.?)KP\.O__EX9T]]^3'
M_.M]]_3UDY]J?/KBWFM]_=_V[NSI\P\.'MQY>O#PI[N_/+CSH[[_D_#T\)[;
M^^8'>+*_]XJ_^1'XVW\>/'4'K^C%T>&>_N[3.WN_[/WV_6\/?_K!/#C\(3S9
MOV4>_+3WZ],7!X=/7CSYY>G^\^=[-L/#6S]S:C9ZPMWL:]@%+'4WQU9W,02]
M;<A%RY]]:<WN]V>JXG<;?+DSK=(!K-)WOQQ]\W]\;-U^2($-RFBJ)3\WY]_]
MAZSV]E?__F/N\^C@2D;[%"QX_46[^I>-\'F.[E,@]C$\7>+%'?W:$?.VZ0^D
M_?$K7QQ=G<-O+6=XL//#?%87+#M[CZ^J1O[@U\\MNFK^;HOE(9[H;^LGUM#M
M"UHL#@@/#A8GM/CU0_3^_:E&7;(\>/U(CA;+DU$R_=<S^N:'^.#.WF][O[W\
M9>^G[\/>3S]8?<_?]GZZ^_K)BZ]>/MT_>+ZW_U2]P"U]C9<7O_.COE>8/]U?
MF/Z;#_=O_?KTSLM?G^[_H)]O[]<G^_^<[7WSJ+^O7N.3UWMW;IF'/^9?[N_?
M.ME[;'[5OW^FI#$C".X&J'$73%4W49+?)>@-%E-J'%M7;R5!_,?[GN(-YUS
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MA68K.NRZU8H?20>MDA__WT$S>?'1>3=^](%XYY$C/[P4D91M,#PQ,_+I2Z&
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M>N&'7W-3O^$X?HLOZ+P1O[1VT"D.&]>+)*]'>/]G5)_9]CDL-I+9-K/M<P4
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M*L 5C; V$=N**PBBDJ;6"*.\*[*S(Y5G6*\OK!<;>LBP?A)8ER(0$E&*)#6
M8\X %2JUYB(2,$F@]!P+C5B1L3!["<?J92Q4-^HPK%]K[]51678BPK,N-+7X
MZ@WI<-F(Y'*<=3*6V[^5M4!\P-9+P 6"@,(BZ*"B!1-M%PQ1,$S+PG@1\TI<
MR'7FU@[^BZ_YD.$_ _Q+(0G(="3N5.;!)=_%I=QKB#!@E ?- G?41]^%1OC/
MJ\-[AO_:P7_QE2(R_&>!?RETH:WPCAC@@TB-[H@ *NK\Z.A$&I>4($/5QC9"
MFU#.JVA3QO_:X7_Q!28R_F? ?RG&H2UCGF,- K7I$%:J$&-]) $B*',8*6]\
MQ#^;8_OQ7$5V=FSNMVWGW-="MW->ZUSX%/+KM)>>8_&L.7"Q$9##X:2WOPQ7
MPMM.3C:;D 8/RD$0IG%*N4@-?K$"5'@&9%RM("C+A: H1*)+01!)9TXVFQPK
M*[3!\ZP98+%!D,P LS- *0Y"$?/,(P8T20Q ) 72>0D@L2P@8K5(Q67P9K1B
M,P-D!JA"'"0SP!P8H)1SB4-4]AP!+JT&U# $=+3@ &78!F0#XSJZ0G)3B7D5
MG<D,L'8,L-A(2&: V1F@' RAU$ O U ZT@!-U2ET-.( )CY @Z,=@$)*SZ1X
M7EG758R%K%H^R'Z$7]?WKBM2+#L/9 4)[L4R*U)<S5_.6)N&P-Z7PQC88$NH
MMX!;'0 -B@$E560Q$JQ702 74M- =I^^?LN'7]<!G',(061PSA.<I0@#@\*J
MP%)%B91.2C4'AF -L-60*A&=1AFM"_Q H;L,SK4 Y]QK261PS@C.&\W)"6,6
M6PRH3.$_Y@TP3K-4\\4$K%702&YL"WX_"2*#<RW .0?'/8-SGN L^^4,F?@?
M!$P0DB)S&!BF'> A.B$!$LTDC.!$]PN[+ 6<:Y]]<-@_]=U:<YB#\&+D=O^V
M66O[_K)3$-:<I>;@?/?B \=7=^FJT6EW;D<3,W%-0UP?R_ZXA")@[S1P3CE
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M/A>%SJ7&$0HPQJ'&7"$K=9'Z0Y]?SE]FNN?#="N0Z)0Y;Q;.*X4AB6."*26
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M+K)^C%G50$P^HSL5_[TO!UA(M(D(=1A80F0JY^&!C/^ 2'TZ1&)4(OE.9.8
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M'!W'/P[JC>.CVN'K^+?#W?_WK\.W>_4/1__[/Q(C\:I6?_]Q__AD><^GQL+
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M!FC'+&#6*^R(M-C@C6W"YK0KF1&;>37/4IZEE9JEQ08RLO9[:NU7CF(X)7R
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M!DGK O0K.#KN]$XA5ROO^2_5\4G?']H!5,<=VRU!.0];L48E&-- C)%"<:K
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M@'W. 9Y# [MR:M-H;EFDU!18?:QPH!LPM;##NT!J:P*I#*R$2 P*1*C$#E5
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M_.*)_/X%UZZAS$2J,7).&L1#8O/:XH!48$$K$:,4L+*N[M%$K"AT@=TBI?O
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M^>;FH[FV?YDD-"8C+UHB.#?>&Z454*M8M)IBR6=VT]3)UEG"$+9.^CG%N@Y
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M14%9B(%1S6RRH?C]N49Q<#183>?.-8J:SD--)T1#2I&]&@H)S37BR01 +BA
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M8]B>2\.S=<6=XB%I/$>9 ?(F4M^+I;;JS !WH7:R4-;HX"V*)L$:UX(A+:-
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M[^ PM@Z\V/WV,1I%<(R HI(.<4UMLD&]1IX$98PW5DL]HL?M[@F$C4QN:9*
M)49X"(Q3YUR:=&DB,.6QLM*M5)#HZ7%6POX)I/WR[]W=C;?OJ[U7U?[.Z];.
MJYW-C=9!M;&YN?=WZV"G];IZDW0\8=7^&=\:KX1+<)NNC0=25Z$<:\\O!W-Q
M\#JHD)9/4CE@W-OT/V8C,Y$R0Z7WY,;MU"Q,<?ZP@W9=\^I-'P9)C^NWOS(U
M#ZA ]0#VXB7E.1W]^8P5B.]M?.32.JE4HOP>5#(G!$;62X:"TC2Q?^DT,Y?7
M((EIL5K+0Q21!\VT80[2FA64,1<YN:Q -ZQ(OG:I.,KGD\&P'4\O8/YX'UC0
M[G=P>(DJG^^&U68O#W P^JFV=VS^]3@OS7:J_;30853O[=!^A<H!=*OC/AS;
M_J@3=WYP/]0M"+^UAX?5WVO[:]4GZ$+?=CJG^3(<YT?:\W6;;F^GAQ]WTALF
M6ST])!&#]M%9EG3ZTG9W9,,G#5NK\N@GEP:3\;3K@*/T:IU.94.>]M'ODYB3
MI@S'L17=_*1.U0=_TN_7*=A3'QT>VF'Z ZHTQXG"YE_F>UZW.V!#M9^VIMR:
M*#&WKE^K?LO]X"A^.;JZ6O^+O*S&O_T&EW_3.^F?_2:]Y?B7)X/Q[_Z=IK+3
MAJ]I$M)45EU(7S2P_=-Z2FP5;;N?Y_D<:O*X\DA'1RB#LVL0ZAD:P#73F#YQ
MTAF.G]\;GG]'6F'ITR'MQ=GPR0\^^R1\/X;LZ:@'D;\MGJ3)C>WLZ*A.P?;S
MF]0#[)Y6@Q,W@/][DN?L[+M'@[N9Y"ZYWLRB+6>K<SA^R,FX9.)X]51I=53?
M#GM)1U#O6S<])4]G.[23>/*2Z":-J;ZF?V1?P6A^89#/T8;MX>GY4OQG9_M\
M.66Q?#ML^\/J&]0BKU=+DDI>5"XI9")?Z>FG:]5&IS-ZXOC5JF$_S=+(N3*M
MYFE])I/-UFOL57JZGW[I>B1YJ-\.T]#R=Z;7R,LC?W5:1[T\3<->E;2\UK-N
ME:V\LU4,Z5F]H[9/NI7N3,J9,*1N:9JFK7<$U6^=WF#P[\H.A_VV.ZD=)OEA
M:7O-(-Y/TY;E<38M>;;K";U!0%-B2=^_EU;IJ()V/J5,4DL/'FM6-E(2#EP>
M97ZM+*3^X+!]/!%&'X:VW1W!X. D3?SYG+C3^O[TJ:Q/6<DNC3S!9_[@6O5$
M5.5=6G*#019U6@YUH?*?+\(\P[9*R[<: W"2>]HGIG#.]OLYB+2&Y%H;TN*W
M:8[3UM/KU^">99O!+]&RT7?7GTW_<C:O@-YH21SWOJ71)!&'=C\GF8[T\2S;
M^NS;\DCJS>"HEP0[F-@J&2J3DHQO'.L;42\'D\61UDV]7>4ML"[4?C)=ICU_
M=788]5V5UW3^RA&TUGZ-?#4-"]JUSN7I&8X;XUT858*/3DBO,LPKK-Y7'4R/
M\FP)IQO6JB2+T XUXM>ZG#4\;:9)L&FMIT_DZ<KOO9\WYB,'_9']Q_!JE;GG
M)?2^; PL[1*]WG+Y)0N\WRZ0UT/M84P?:&4'99;4+ \8'-:B=QE,;(TTZ1T^
MGW1'YR<UXZI7](3/W6)$(VP:C:H[&E4&\32TLWV_WNNAFRO9;*7E.;5*2+U*
MTEH9;W#A#'LWNMT,IF]K_<S:E[:,HP3ZZ/\D M%)GSL?;$T1]S,A&^E@'M)9
MT'B5>WRT!X-,_>JU-RVR]5O!Y>)LQ'WX5&/0SH2_/A6 ?VCOT&CFWIZ!>[%M
MLVW[Z7OKVT?.L;>><R0-MHC3Z)!F.4U;B4BUBDRI*[9JV@)JZ+_QO'4PFN_Y
M9KGMM%Y=.'U-:\WG$]AOB=PE6^5*3923#"M[<<S'NI_&BV!RL(J?F<1W#SZ=
M[OWU,0G:2R\E G :<>&3Q#5U*%*04FLO(C8KZ[TN7#D9_7_LO6MO9,>1+?I7
M&KS P1Q J<E'9&:$!!#P6)IK'QQ)5V/9AOS%B,B,E"AW-QLD6Y;TZV]DD>RJ
MUI/JIKHW2VF/>TC6KEV[=NZUXK4RXM'Y[;U\=+/"[]S$!..\/;^\;J4Q*;A;
M2'?^M5Y\^XZMW]?Z^/S9"T=KCL$S3]C,QMEW+R+/LZ=/S[^^#A>?J$6.Q@\[
MIYOGUI]YP/.G3\Q[W[UF1N"ISICAD^F1?WFFP]C=V'[W[D^&>2QZ\<[T0>:%
MM-WK^\N>3],D?_>$_V5^VVV@\T=;DMM(YYV;:/TF2GILU,#3AIFW;7:H7=O8
M>>[SO:-_X^;=!CSVI8Q"KX,I]^\S"]-D9M?>??31//,N2[ _]?QU?^Z?>*O]
M908IE]=AB%WMSN^[=HEWU_+U+B%BX9#=[9N0^^:,_#6?/=Y%./-#OSS_]WRK
MS "CZ[/'Y[M0XE(/W] NS).TV/SI3<AV[65<FLUNUQ+,PS6]O87_\[_XR;/W
M/W@1+SZ[./_*'.(#=_F':SA/MENJ%^F)=Z8?<G/+#R_IR?E,MSR_R>8\G8[
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M_?D#%^B%D;].'.UB@9M\V$\\2@=/SQ_:U?.#ZL$3_M8^S(!P\;V\V&V:ZO(
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MJ[S)QH1KI7^KE::8(-267:]S"E@#=)Q\=C6;BVO ,V8WG_;I^0^JQ*_PA[V
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M@^/P)Z>Q+L7C\2(X4VHM% -M$FACB)8&6:I0#J*X"O@;1/"^@(^V;)XJN5Q
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MU87A5;LP[.Y1A.W/4CB_XL>'*H:WI2:3\XNN%VZJ%_R[=M,>79X_/NN/;F_
M<9-R@Y*ZSQ8A"?C6A12ACNY'#E[T+AN@#RL33Y\_<?W\RMT<L1C[33/VIX<-
M#LHHL:)ZYWV:G>NX6.PDQ25-.'BTCKF?G*9WDK\O/>FO@-(#DIO^G@DBU)!+
M'J-AG=-8 @L#>1\A98K9KPX)6^2 PU$.(_G:4%T:,1D'5'7(E5P+/HT6FK92
M3T[+8H#% #^UM;,G[MB]MT<%S#N0.@BK1.%(RFL>TS898.\%^(!M]!+<P#G
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MZ.Q]77-Q#1) [A!]GPWL5]_<XX6P$$8N4CGK $\B(=64!AJ@6416O[0M0OA
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MNKK]YGL+PZ^\A8)S3D5C:B5"8* 1H%AX8$$]9 L9%H8WB.$#H8*/4M.HP>4
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M:&55-V=$OCC4)^0!.0I61]S)@?;BB$ LJBL]%JTTA)9F]:@AG#,8=N?^$1F
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M,+&1,0R7@41*[37'V6?&/_C)6(L!?K/A>,&G47L7%8B)18"+_>-#EVHW9S'
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M86T3^WL1%GDL ]F[D8?Y_9G5425R(S:%$ #\D)D06-A?V/^^!%M*,\.?A(9
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M21$TE(H8A@_!P^H/L$4<'V@#%$<50#/."F%N:?*.5;+K+2FG6@M"/3D-JSW
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M*0<UD9#9^BC=O"E=7=?=.V(+P ^<"KL)^4TTJZ+5P5S6LG[RT7+*8Y\,/Z(
M?*MW1(8:M8P "C,#R!Z#9HG!C6(:L?4B:U+D+@&V OQ ;PAL8[X-8Y)=D4M5
MB&WHR /7L+JV%>"8"G!R4ZCJ#/1%0_$\<P")'B3:"%/5>]-HJ>6I '6O FX%
M^*'I.E6<8\.4!*-$%ICI(TP- )[UP&TF<YSOXH['_^T6_N;/GFYE>!?*<+)H
M"%*+%2C0B#T@0 TBC&$4R\U:+=W[U90!@@0?;GG8\O #/>;7,/+DK9NL'O/S
M9[4>D]8V_\W*'KYU3!DX^3@FZ(2D'GPDFB6"]<"]Q)"UM5S6[N\HE]!C^@(\
M'C_6-P(>R%"0.SD[_H[S[N]]W<M[[^LWX8,\WSI[^H4^\9N[[\XJ?K3W^__[
MJ?ZJ^WM[+B6XJ0OU2)I8"(LT[5F4T*A-G91^FQ'MV\%XH,CWT;D_IC4H5CH'
MZEX#JDE0Z"F,7BPZS=JXKOGM[Y5X7]TW[@VP=^QPWCJ[=?9^NQRINL\R%&.;
MZJKSEY111VN1.D&-6V<?FLZ>VY":RR"S0*79.L]5@\8Q"XP*:T!D@Y;TZCJ]
M%_.=G0A;9[?.;IW]$4=G+9R<;:KLZBE7!"6/4N/@5,NP/1#PD%)Z2EE]"F:C
M9//J8 S8:PQ<F<,H$=VY6H&^VM1L(=U"NH7T30IIKQVU=NXE8<_.-&O)'(7K
M2#CKQIVP/C25/;?-"3F8UE"LU8 I4M"9PX9,43MVZ*(WO8(0MLYNG=TZ^P9U
MMM>,*55*XAGS3'%RDN0C#DGS[[0;-CTXG3UW)^;5?LNMA8[4 P[00# \<*)8
M?3F74UXKL/.VV4*[A78+[1MLN!-3T^'0NS0LJS5>;XUBZ9Z]4NG;QG%(+3WY
M/*N(]IXX5.IK5#BG0);6O, :1_;68BM7UYSOJVO65M*MI%M)O^_0'*U._HR8
MI2,O^W49-?99.YK&/F[3]6@KZ=M7TI,OED:OK0J'T:*M>:NZ)BGU$*D-@F0
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M=^ZCNQ7B0A6B8@5/,RDH>> L/"5V+W5@3ZT-];Z[\#XTA3AW5]C,%"J.&)I
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MA9$_GCL<4H7"5EL09 @XD\:@E3B0#"@ZHN5N5]=\7]WHM^WU> A+5O688#@
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MSI;&..8EE5DFI/MJX[(EX-(D8&B%V*VZC#AOGTXC09KX%QS4:M]9P#$EX.3
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M*2'G0)ISZ)J2%M%&:^$8[EXR;M?^81D>;4CF! J8,()1MUIB3MER;S'19OB
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MK9FT@)HLL&N?==9(:>;75)=CO.T9EEL ?L ER#RS[4BTFL>5K S<LZ4T9AX
M5& +P!$%X)0"U S)B6NH4B;VU7.@VBT4=/#8B=WXZCJ7O!5@*\#W*D"M6:V6
MUAH0YC'+@5D!S$I 6J5:;#<R.Z("G%D8/.,8N>;0"U/ &?F7RQ""<)S)7)F5
MP.K]VN*=VT9N!;A0!:#.4=*::V:*F9VQ,<<<#40(D^^EV0,JP+D#(J5>U^&R
M,+@N!\3J99CBLB2"QE'6K)R\YA+>UY&S+0&7)@$:N90&>6;_%5D&Q6IC5!VU
M(LU,<DO (27@K/T#SVN6Z[),((29_&M@=0VIY#6J7BVNA8![ZZ2V%>#2%*
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M<X-6)__JSLD\SY)N50/; ;?9_Q^C>Z0TX8X90= 2L*&6DBS6>1_-U& /#7A
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M@Q,OFAPK3L%[[DW"_.5EZ Z 3Q;@!J(EE(40"XMEYM0;.533(L>$H9VGML
M^'0 OLD;T%E7 I]434G<Z-Y!GH)NXDM#3HT2VL@#X#<?X*U+.*A%E@%#P(A:
M5Y\SMV1R;J-XR$2!O,D;$$^IN62;JDQ10<QBJ6T!U2G:VQ1SP&LAPF] UL#U
MKCKP\U%EN8E1=.!CLBW:AN(<6U\<))N2:.IBQ/H*VVHHHX7 ]-CVU^VT 6T
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M\MT!A-6 ?-&#5TOQZ@O_G1>_\N[LP=YB?V^Q"N)]C%J"YRH ^^Y!/CO.5UT
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MXUBMRI:"*IYB3*:?#+F\\UH#S-,%LPLVZF92*#E"UIR@0-6UIIA2!?,6)3U
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MLC[\53K\WON+F0@74_OB<\,1V-@>)H[$/38^#OB'J!6$M7 E80R?_LUJ";0
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M5N,K*K%>ZPVRJO=JI_8\:SG@S6DGW_RH":I?Z3W<_!_;;78&O6DX6(<;' [
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MAC'++>^[@U&@ME,-JCH1F%*O9IQW2%EU)QIY78GC3!V>6P.9B-$3*:6EDKO
M8.DRLR S#FR6<*F!O^C^4?:;Q9T,;]?%[O86;AQ_^0%C8.#<,"V8XC*B)&0
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MDDE8C)5<NF.=G?8H13S^E7?Z"2XN64^1E0#'Z89JB3@NG?-(,)X0CRXAS6U
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M&"H2+*0/7@WI0HJ1_7)5F H&EIFDS+#$O>6.<,>9Y,%R&J0F)<=@"95X.L=
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MB]+5B<7!B<5,>X< ;PF"-;?(<@6ZJHTFAC'"L "+0SRXE=,*URM.I5]<Z>5
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MEB_+RM@['HS<&GE^6:AE^0KB;-J[TF,UG.52_M40@#%!>,NXPH)C%PW-[I!
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MAH"9%L?1Y\2$4* A$._O5SVC]GP7GT\FY1>C[(C)3EKXK>0RV#E>G8_HL H
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M1GG!1J"#SF9@'F7R6SRQ7#6L!3P(\"J[9^F5H^.8Q7D5)[&3DHH0_S.+)28
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MP>OK1US2?NSD9-$'Y]261ACSB5PA+4K1P2W,2!NSJ\M;L ,\3Y%J$;5V'$M
MIH)1?/\T\BK7$N;2V)#[,)/ZJ..C464V["UF,$>!^%L#@:L1Z=_>4H8CM=0@
MH6CV>S&&C ;S@<,N12*D<";=JFC >6N9X%1XQGB4TH;L=,6$,RNX]Z+V;=:[
MC>^ZVS5Q+T47FJJ9^<X7:;S<6*_%E1T9+,B :\E3,!(!4U*P!K!!-K?8\XX0
M1K",1-M;D0&32I% ,''$<.&#@?]&D2SF\)DBKB8#TI'!1I&!3<'KA)'4'LC
M!8L<C;P<-LIE"&"OXUN1 <6:)^F\DSFY'A,=C>6.1*X(" AI[E\KULG^N^]V
M"-00[) ))"+NN406^X"\DB /O(G&A4V4_=UNWV6W12[?"T8@22U&G&D,O&T2
M8KE1K1(BI$0V4<1WNWV7W5:4*4F#04;I$@5G2*N0D 7!GCOH2LYNA^L>"<5W
M"OU!R<#&(!(%/ \BW@#36XDT[!OR&C-+-<6@FS=1H7=D\*!D$*(R+!B#@K9
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M*!_B!L#>96 /M.<)3Q2VT%*/5RGH'F?'/"D"S@BIE4)4V@E.9J<P!7A(G6<
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M36LUBJ/WDB#,,46<<HD,8P+)A#73P27G:6X:H[J*PD>&DG?CI,Z?_'ALU#(
M&28R)F[ [-,"\4@" H#)4< B=Y DRJOB3U9<;9 _N>/9!^993;Q1+BF)G>0A
M&N="B/ 9M\II&VD7 WIJGFW;AM)H2PU+R$1M$9>Y)[;T!H&MKL!F5]Y173&M
MW""F_1:"0%U)XMW7[F#T8=YTYFZFSC>Z<#]&-Y[9\46V$3>Y(>L7;R,"J/7"
M*4Q4(%S)Y(3S@4@GF$R<1=W9B$^N*/?:-B+%G"3K.%)!8\1U/GG71(FXH((Y
MS028D-E&?+"N,UVXX:9=#._$21W>?#PV:@<))8U@N7,4C07FH?ED>>8M\ER!
MA2A3$CH\D(W8A0@WEV>3HX2)G#+J Q>$:$^<H])Q$DDT6'4VXE/S;-M&))@+
M+8U AGJ"N-(&:6T#8I(086+IJOU -F(70>PBB$_1F?1NMLXWNG+SLP4WN9_K
M%V\A6J%!NCK*76"@(Y4)V"BKO4Z6,1UL9R$^N9K<;UN(GH9\/)I'S&%9I=.[
M!']:T([6>,63"]E"E-WI@H^,-N_&21W:?#PV:EF((J1DG(Y($F41=T8C[>$W
M%VV("BQ&Y_"SYW1+L4WJD=CQ[ /SK+282TQ,%-+S)+@3)-<2*FM),$%?<_Q@
MQ[./P[-M"S%R0A0+.6]&1<2#I,C 3Y2B"S8Y;;4D%=-N4NB_BR)N5$QG ]?N
MWF=7?*,K-[<0U0:OVA=O(3+-9.0 EY(07%C0BH8JI[Q/4?IH.@OQZ=7D;VT+
MT1BI4]:-&L -XBEZI$DNRZ .$T$E-\+FDRL>[/SY+AYQT[X%=^*D#FT^'ANU
M+$29-,DM#9$WT2'8+H8T%AXQE6(P/G*/2SB";E0XHN/9A^X.Q'V0Q// *>9,
M))VTY<IJ2G.K$<,["_&I>;9M(3*LE#$&(Q>] *;-CE$:'#"MU@Q+R70BF\>T
M70QQHV(Z&[AV78/2>W<=N9N-V$41;Q9%5,)R2Q)(6<EY% ;^8=[&Z"2/VG=Y
MID^O*%^W;42I?,+&. 3J,O?6-RP746GD0F1!TZ1<LAT-?.4TH+$-7E*4F,H&
MCN-(I\@0I1IC1WDD-!LXV_1RKG$76G[DT/*=6*OK=?*@K-/R#6 K$J?<(FH<
ML(Z,8' PA1&60FI%#?4BY//U-JF8K6/*AZY 9<0G,#CS&4%<1V9Y8M(IZ8F-
M4E/2-2!Z!*9L&_]!N.2"BZ#0;$0<6XHT!X6&([78:P%;83-77O9[=\'AC3?]
MO]$09W?JY?U-?[;)Z_;EF_X2@]:SAEL*&)4J%QFL@\'.1JJ"Z]H0/;V:?-,V
M^Y3F3CHMD20B(0[J$!GE+ )C@AL:30RY%4-' U\S#8#EB(E3$6F9#R)-WB,K
M0T+:! =X55%18IOKDLB[G(%'-OWOQ%J=E?&@K-,V_;& _4@>,>P9XMP'9(.T
M*$6C9: !:T=SE]-['V;0)05L+E-BQKB428J )6>Y\B9AX<'J]R%:3FUG^C\"
M4[9-?Z$)U28*1(7@"  .14YIBH1E1LD0#!C_F\:57=1_HV*P&[AV7>7P_5>.
M;?+*??'&/Y4A)IT\%HIQYJ,E@A!0AJ $G0N:=H;?DRM*WS;\N,"P7U8C2K%'
MG.F$K&,$2:]M(,)1K.6SYWQ;=CV('QE2WHV3.DCYH)S2LO.4CTQ;[!#Q-"$N
M#$768HL(3Y%)Y4R2^$$091?BW5RF5(9I29+7DCL>-+<\**E$"DPKD\0U!TUV
M3/E@3-FV\[!5A!(JD% <N!*7 V!31)9'YXR*+.0>4<:0#>+*+L2[40&W#5R[
MKO[W >R\35ZY+][.8XSGT_42B\QQP;F5*IB@DK>26>=-9^<]N:(\7NHC+(FQ
M5'$$<"4B;E- EGB.DD\B$H59$BG;>;CK(_S8-<!WXJ0.4CXHI[2/DW'< (8W
M*%*:(P=.(JNU18YZS(V@V%=)@YL4.>B8\J&#[(YHSXP/"@<NP=@3DO H@L0Z
M&)5$9^<] E.V[;P$RVV-Q<"&..8NAP19HS$2C@1O9*3<JLR5][;SNGA>%\_[
M<E)YO]&56Z3R\DU>MR_>RG/,"IR$=-A2SA@SA!'KG+(\:H9IZJR\)U>3[Y>B
M>;!)2F.."%,,<8$MLH$$%'SR3 9.#(D=#7S=-. )%4YP@D0R^=0$:L!^B1@Q
M(;FW"6/M7>[VM2:BVX5X']?*N!MK=5;&@[).R_3G0EJ1,+!.,#F55U&D XV(
M&6VPY9)J89X]-WJ3FLEV3/G0_CAKG;0^6*DIEYA;:H(TRA(LC7':=*;_(S!E
MV_0'&1D2X0Y9E@SB+DIDK& H\<BMBYJ P9ZY<I-JZ[L0[T:%VS9N[7:CGT=X
M2;=P=UHXOLD+]\6;_D+Z1*+2H G!F'!)NV"59-P;Q;@F7?.F)U>3[W;:9E]P
MB@6M E+"4L"N2:+<S@D922GS*5*FR;/GXN&. >IB23<$E'?CI Y0/BBGM LV
MDQ$J2H6P%1YQR@W2@G"DB?'>."^"+XF\F]00MF/*A\ZN#]H8&K$$4Z]T.9#)
M<*JT5,$1QZXY";9CR@=CRK:5YR,E/GF!HLZ^%RHP E8DP*0I$-@64H[RV2RN
M[ *\&Q5NV[BU:XZC(;Q;M9NOVL[9N#_(]MTFK]H7;]^!4'76L$0 #?%HE:8B
M"8F59D08R4EGWSVY@GS9MN^2,5@Q+5'@S()])R@R$>P[(KA35%KGN,\)O+HK
MU'QD*'DW3NH.!'D\-FIG]RI/N9(!1>LTXBY19*D.2(@0M8[&F%0.\5%LD\()
M'<\^,,]RY8+CW J7!&>8.>H(&/Z*4&^<2->TZNUX]G%X=JG(DQ'O%6=(<D<1
MUXXAR[1!.MKD@C7>158Q;=?)]PNT#K_14-;!Z,,\!G@W4^<;7;@?HQO/[/@B
MVXAW:^;3Q0!O9"-*$X6G.FE#+<_9+X3 3^PCYC;I(#H;\<D5Y=Y2ZJ?2*1!N
M$--4(2XU1L90@;"S20E.?:R:^8BNR/.1\>;=.*G#FX_'1BT;42L39: .R7)>
M<DP6N< CDE%0)S13EM4V(MN@8$3'LP_MU['<*@F6H3.>:VD=HP['8"0VP+WR
MFA!AQ[./P[-+!:+6:2-X.7))($ZT Z85&FD/1CZC1-E(*Z;=I,+M+H*X45&=
M#5R[KN7K_6*O_&YM@+HHXLW:O7J 2HI)@+:4)Z.-Y3HK38^U2-J&SD)\<C6Y
MOW362_#2*L)1D@FT9# >&8P]TD ,DG"MN"/90E0/E27:121NFI!V)T[JT.;C
ML5'+0O1<1B:(0BP8 VR4DZU%4,@+C05-V$F6:VRWZ)JC<KLHXE?#LXXK(02-
MP1K#&0LZ'_7)B;0^$N_--:=^=#S[.#S;MA UR%-*:$3$2 Y,R\!"C#@AV*+@
MA,(X$5N8EI@-8MHNBKA1,9T-7+NN6>P]+42UP:OVQ5N(&*!0%)B;& F7W&F'
M!;9"$,8-=JD[$.3IU>1O;0M1.R=I- I%0C'B/#AD ]=()FL24P:T:+$025='
M^-AGS-V)DSJT^7ALU+(0A27"Y"9<GE""8,\LLL!"*'@7@Z%>4!]*.(+>NYE,
M%T/<7)YE5%-O>"">*.YEM"(FJZQC$FQ'1ZYI)M/Q[./P[%(-HHB"A*00%KDR
M.!B,')$"$:*MH(+2%'G%M%T5XA=H(7ZCD;"NS>S]V\R*35ZW+]Y&3,2E7/^=
MRV]X$-2Y&$.(0FBNN"#=82)/KRA?+QTFPB*U6%A$N1*(8R^1-LR@I((0D<*N
M2=71P-=- S:8)"VW2$@F$=>:(AUSK\P0E!:!DUBUF5U3C]J%EA_7"+D;:W5&
MR./Q5<MQ$ E(42)SHTN=CQGU%!D1P2116'KX0G!9' <@8S<H2M7Q[$,?-$J-
M9B(%HWQ6I]H$&P65SG+/DL:I<QP\-<^V'0=<F*0-UH@&'Q#W"2/GA$92BIP.
M(DGP<O.8=JWC@));QZLJYF,;;LP=C:9VT)M4CH19XTCH#4=3>(<=AAX Q=/>
M8 0C2];W!_WIQ5/',]QH'.(834=GW^%M 0L]&0WZH9?7ZBL7?]BX9*T0S%K-
M*75&8X OFI# D^;IFL[XG?A[#/'WI@U9+.4TQNA0$@P@"V,":<<ULC08(BPV
M!(,Y2.666--\]&Y^TYMRQA<4"/EVF9T11T4,VGB)N<',,>NH=[E/)P/8TP5)
MGIS9EYIQ*,' T!=(8@>&OPD:&>(]BCZZ2(@)P@'687B+FB^%VV\/A+Y 9_8O
M?>L*JNF-XR [PGK342_-IH"">N/1A1U,^W'2.6(^IZ"S/F@JF.8<&RX3=<)*
MGC"-QKB@=.Q0S=,*.M]&-4DRT#Y!((H!VG#!#3("3+S 0349$66P*=MTA-[[
MS-'.$;.Y/,NC3]X3 MS*N8M1)\](2HIS8QC1N@,G3\VS;7!"30BE5P/FS"".
M(T46M@L!EDR.*,64]H5I\2:=X?4M.F("D/I6;QBGG9/EJ40;\=););R4)G">
ME&$^$9$ S%.@['C-P12=:'L,T7:\=&H%COF  H^2E!1Q)@".:,E1\MAC$860
M"> (55OR_@>A=4Z6KX_9,<,X 68-2BHN?+3 XE1I+:7&TA/9X9BG9O8E').$
MI$%(9$G, 26ID<9$(\>8<Y@R&VE\]IR1+8X?JIU-YV1Y""=+G$R^Z_G9>!R'
MT][9:%S8<I1Z ^ ,5"),&?B4>--H>A+'O9&#4=M\V>3N<.@!K;EO5T(^.AQZ
M49%))RAO)2B73FP.!"2E(@YY003B0A-D@S7(*PNX*+!D<C\3NB7(0SEI-@44
M=2S_)8*BCN7OQO)+R3:&&TF\1D9AFDOK$K*64N0=98Q9+E22F>>5>"@?S^9!
MH^O\/V;#,5+E_UD&1)_-$W1#U%LMR'<,UC",9FX0>\TZ7+/W-Y*/&[?\_WU'
MP^!AENBK41V/CA8/1D/?:8_;:X^/2X>_TF"P=B0@1JA$'*O<(588I*UA+%%)
M>/"@/,066=,"[UZ&]8/PSQ.[VCIIVDG3KP.(=]+TSM*TC<4=<TSHI)",W"'.
M)4%:*X&BP"X(Q9C7 <2IWI+\:Q*G!;#_[]3":^'?T/\PKVD[F)T"L_CG_P<?
M-E,YM>/C_K ,: 6;OYM-IOUT\=GY4ZWR)\W\F?E@OOIE$NL'S?,JKAEV]5%_
M&("+OJ.Y:6Q1%H\L:JJIS,:PI[WI2>P-X<O>*=QQ,NE%&%OH+0K@&=[*1?!D
MJW<>>^-X9H$N_OM6Q\8Q(ETPGF/+I3<N!!NQ(-8%CJ6C;W<+Z(/_HK7H3]U*
M7OT. [S(1:R3P[0VLF*^3(DUB/_Z_>*O/\.9HUP>[K[G^S_M@\0:G!SL[N&#
MGWY_]]>?/Y_^]>=?_3=__O7N\*?7YS"._/RT?_0&'Q[M49!N^.#=;^+@_&T"
MO1%42$A:SA$',(X,H'"DL4[",*V#5L^>LW4-C7NN/QC4[OEL@V[W_KP345 L
M*8^2>1,8IYB91*T/V%H<*27!KQ(%6U%B^LY$,6^'T5'%G"H\S]V7&&P[ISZ?
M?)2;F.5S(+!/*#GGO;+"4)I/<-F^7)O<)HHK:H7"+/::,ZHIZ?6'1>RD_G@R
M[?UG9L?3'-5)U9<YSG,;6K(B$F:4]Y8X4*;4!<M2] )3XY6WMJ8EU0F81R"E
MUQ>'0$I.:!T31I&+@#B+!CD'"">%E$C0A,.WF93H]0+F&EK:C7[>GF5.3M.3
M_CBLDM-V;P>P2WZV'0PN[JS$K&;:"!F8IMQPD%,@I**!_UG%;6*?4F*=O'I0
M>24.?GN;U85RQB&LE$'< GT98AF"M4\\)&LLCY^05R"0AKY_9@<]>PJH>=H;
MS::3*<B?C(L 16<JFHU[_[<$4Q^ ,%JD .#-?Q=FXW, X$#OUS?FR++F&]OX
M@R. +!]?D\/=E_C@Z,UY/H[:@:UK.4')$( O5"3DN'/Y[#ZN$P4#.&=U34_&
M,:*+:,>K9L;M&#\)HH2BA'''HP(QQI1/R5GAL?*&7^&RO!V__P+P^S"] ";O
M3W^LZVCW[=_]T]GI#Z/Q>'0.]/C"GL$WTXM.!%1ZA@.0!1@;<<B'<GCM$8^&
M(D<,1Z!@#,;"2.?3)T3 )1USN:*Y*)Q%6RO*;HU0!/9!<>^4"I@SX4!D *BB
M,$ FO:6?U!ZW<]E\6GM\H5Z;!R*=-Q>Y94C"-*4@D H"A C7 ND$/T@RBIE\
MB @3SYX+O(9T3A<()6N'2Q24@'JF68.,[32V,,M23SG2FYW!,V!/P0J?7FSW
M]H9M&JNL[?AW'/O^!)Z97S0Z*W0V'?5@%P>W(D E1-#4, \_ -A+34/2RL&?
M1.,0<$6 !-<$"/;6?7R&GX3(WS;]^8\'QV]5(D8&T%\>S"W$P?)&#CN,J/3.
MYKX8,L6;T=\RN5W3J^%6-E4RB7B1'*&,![#\B-( :+ !_C AD(Y@'I-@R/YO
M;SDH.AI%1%(0(!@C);):,41PHAX 40A6WHQ@;M=CS@>B'6.*.APX8\99%0VC
M#E!8<I*1KL?<9]SWP]_>6F*2X%0CKP,#6UH*Y$22B(""PEHSQXFX;=_ ;D^?
M=D\]X%8BB4<V29=[)D?D3%+(AP3:6>56#K"G>)T#]G(?P"M$_E;/C:8GO1/[
M(>L&VTO](=BY#=[(LF )C[#MWM%)@U;.06#TW-Q1TA_V#D8?%M!E^RL)@#Q>
M$*.P3ELAIO[?,:"/<3Q:9:E?QR,?8YC\.!Z=[DTF,SOT8!LN:4/\C7'0J@\
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M]B[VLU  @;(J0, BO3C<A7'2_/W>^<'NX.0-C.W-.W]^</3'^S?O]OY^ ]^
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M]M+*6T>NQ#N!O$%'Y!''(;"%CT4AUC.IX""\+4/)BM(R*V7 GK(W+&9W0L6
M&?<V\X<1K@Z@(IW1;!"J!)5%$/8,YMHV?$Y'PSBUXXM>L*?V.%:<<T.BZP,@
MA%7RTZSJX=5G,5M><XZ:R^3+R]-PY^0,9E"CX'[QWE66<[XK?P>0O3W8<9S
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M@)Q/.3^Q@U2D\/FH[CARGK,'"S4"1Z(F!AV /N E9[.Q/P&-,)Y4IY)6B'\
MXJ$H!Q#Y)Z-!S$G#30Z+'58[E4L2AP&=V0N8P>(Q;?H\J>HM^\-)E1-8)4J
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M,*K18^VI(H%E4>B1V'?BXW_=Y\(]85B4<AQZ/LA.)[]KW3!U:# LQ:T2H ?
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MSI%1'U(F!T4EDVQTZO,6=ESLC=PU>>HPH=4_+!;W!VM0R<%RTZL6IV7?J8$
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M$KFF)R/FNXX$GA=@RDSWO=!LO1-LO7:'A&;KS;'UB(?"Y<"YW#,]QP9UW(I
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MEHM4VC)CXT2;K]\;%P@*:G,Y":Z=M <J+8/M[<E"SZ]F)C/E7T!5M]Q=, E
MD #2P12'JFU2+AZHV/UVM]2_*RF#IDS" 4*1OV"NJ.\W#'3>P3[W@?@JN81F
M26'W(.6 C%4@7[IG4AQW__H:R$N*TD*[?W%0^ZZ,#1!FN=J\(4,5KRSY/<%W
MRE9Z6\J[,2PWWH."W2D_J.9>.HA'IK]OW*7]0E2!$558V;BN..46@_6#]_91
M!+<2M9RP<_>!RP,BL9A%X3)0$C K- ?\?IL)?#VL'!MPC4 ["FU+9?BT%#\A
MG=^B#9@#T:@5:*"LQHX0#%]8.L>+]1AXQ89R?6" X@>R?DM.F:/5UT>4 ;QC
MH! <I>UVHBA_W[B%0:9JQ=0'>^Q'07+EX+@B!2$YZE *;5/@X!)F8(W[75&8
MUG?E1\>I'#DO+;D>%Z;327'WBJ$/Q3L^#GB9Y)4!B3_<IYF@K5 L,.!ZED3]
MRB$SLBDPMZ94H#)BF.,]'= JDT[AP%-K,,:K^Z.'#J-\!7,9[)V20J6AK.3!
M"&(6%%D(3B#*3,9]7$.0Q'E2J70%,0N9<QA\14YR6I\:98>2(CZ TFJ<GNX;
M:!H8Y' PZREU=H8_J@#9D<D/"'F>,ER8&*@1-T!IJW:YG,!0.T0:5VXTG/0(
MB"AP$B M<XG_I?SQ$ZLU0@?I0,TKG#4#Q9!7BN&.^,*^#"D$$+)@Y6'7O?:T
M^BS&U6<VHCXK0V-ZI4I0F+6VA;_S.W#BN,.3 4 CR(,:KFJ,*1DZU,XO1QAP
M1*8#=A0>F$RB'E<A)# ='J95(_PW>]XU+O9:H(M7S1H=PW+/:&9X -#L];JO
M7[VZO;UM ,LUKM.;5X<9;X*TR5]) 7K2*Y@[>Q4$MA6ZKW"<Q5_M8M#>R$^F
M;9G%CXJP?C::O?;>P6&GTU>NRTF[\K__?L4.!BY,=%^6;M]CR977M^ WAY2'
M)94EV>^,;([ HX)%MFFIB)&A$B8&W61SX_=1P2W'+LW HQ(M#O>-)^ZZNZ2]
M7^JFFVQ// KE-5P<LM'%^6-:LUI$(*$NNPP_%"J^!)T2U&% I^)SDTYG=?QP
M+3O*Q+O#R\@L8M3!7#I#*MT+U3\T)M!+JUZI7B'0J,MFA0TMZ#$-'^CV'6[,
M+3ET.1H7GT\^?CX]^6<W!//[I(7R^)(G$N@!M)/3#F\,;-OBZJ0WY';*NP*(
M7?T""%S^V,\')G&""FF4I-TF SV,R[X*C@>A#"9XYZZPX)HH0/M9WD?*0QH#
M^00:*IA+Z"[O-;.T?]U4LKR-EATB/,)]&[L.E2%_>+8($A#L$IC(X#P%W5<J
MD@\=C<K!4-KC":#Y;9JUU"D9'B6!'9H"C2OKN' &@MW0J^)=Q TRF#HHZZ0W
MZC!D,)2\-#E1HRYL%?R8T4IB:>*X@",[^&CI01BS#_\\_;QOW"1H]32!24$3
M3O+29X*&GQI-H<Q(-?O!A!W74 R:H<&C)G(+"G<Y<YBB*$]RU:*]2W.T(8Z2
MWMV^<034"'/N)*QA[ 8=(S(B:H)2F:2XVS#Z'U*Y8+(4CPP'MFQN'+;?)GG:
MED\B +RI#HDSM;7I<S5<9]-IS.CHC#X:? %*+N+3C0JN?>,0Z*W;8GKQ5EF\
MM\F/'LMN[O3JK;)Z1^PN[Z4=O7@K+1X(VQ9($;UZRZ_>JY.;1"_>RJ1W+'.>
M:M![U.(I'?5#=O)!K^(JJWC2!K7E1O/O:HO7!<TYUXNWTN*]EYV;]$XOWDJ+
M]R<HRVDGT8NWTN+)KK)X?V[K\CVU4_W>]?L]ZK?D30(#%/(/M9BY5@!7I,3_
MW,%H)->KM]+J_25[+,F2ISE%V?G5NQ RSJ4V/E9:O(^L(W]JMEUI[2[3&]82
M6G=9;?$PRBEI";UZJZS>%<C:K-?7$F.UU<M2(5O:7[7JZO5OF- RXS&+IYU]
MCUO%NRC->WKM5EF[S_)'JY]I[%MQ\=JM1.C%6VWQ$@P-UFNWTMJEN;S1IL9*
M:_=%YJ@M:XUEA=53<6I?[T!=3J[U^BV_?D4"%NMB);ZJ%I#*7ACX[M4*5_Y3
M3#.[&PWUPXMS;JT2[HJ7#W-N/G546+V*$BX2 5DK3PUXJJ5>,,@PDE65#BQ<
MH<*#$VY@9DN5<E4>"Q:#* YJ9G[$*(,WRR(S7:9"&?-^E"<B@0GM&X>YO.XS
M596$=55T:+YO_/77T43RZZV<.<RJSMH@TF_T>SS-NJGZ(&9G=.0@KV@D!?4&
MIGJ=2;EXU</9Q9 W%)S\MDI=_1-^;.&%+33\?R=_/"H4M3:E%BXZ^.WKN\4G
M,U:@@_H->X%@6W.CT;8JL-O;('*.KQE1B0$ %1>\ET9%Z2JBX$*5D2D*LF()
M-<SJ5)'GO:S('9O,0L_[W2ZF0%1H4,12G\F,_S!4,2WC*&U,!,FKJX-0=_C.
MH* 0(J'$G&3&52)AY5@J$M+:454&:OB10?X;9G6;'XY-HA+-6!= \K_RKI?U
M!2MJ6AAQDN4]4Z6IJF!S-5ST&V (N<K^4*_%^D@JJT.%K\-28,R\[#$4-8#G
M*IA7FAUY7> @!MOGO3+T?##%J_.W1]4,EXD8UY3]-)2MTFW>I6F1*7&<]:^-
M0]$&VE:% 9"DJIU[=WPX+$Q0:0*5>WA86FQ 0)B<+#!O>)R*$,J[>4$]F8PS
ME=9U9[PU.<KC;H:)USDF47 4R*V[=K>91BV@)""QENS_D.V$#<9T^-=?0V(:
MC"4IJEHILBYR\S"U_.CPHW%EJ*^4C#"<ALK:$"K?4PT2WKM$NJRFS771YC"W
MLJ#._X+N9WQ0J3[C2(D7JIT'%#/*Y*.C(@UH'U7",M^&%4BL,!B ^FV"(A6T
M0N,O529$&H=P->&#M'P@<T4.E2VG8/AG5]62 /*HZE; -HX\5":$S.& ^RF_
MI2HJEO1?T#O,=IC6GG9$@<U8)!>6;#YAZH)K!XXSO^!:C6JG:9!8(TC\693$
M.6(=/.\8BJ9*15I8-&%]1:PCH>IGHZ)BW#;3(O,5Q)),\*V]V]08Y@JB&"E*
MY_1 .*&ZDW9D6>BA7205#A6D,F.O48WT>XHUT@[[*&E;"2AC[U6FW]LL01MT
MW[B$0?V26:NH6B!F6,-%=4K\?9B]5V9 WL@Y*]'/995^7A3>,BZR*,$I&->M
M-!K79=7,;Q+83'C5=<:*.6%WA&'-H\)&*;/D5%+D$%!AB#Q+\Z*>05%;J*B$
M5(Y6"]D-\,]A_QK6:E3"JK)RW2XH5B >2YMDTMZ94V9KQ-]1M'XHJC 7CI6B
M#K,!O,!@(]-$(AOD6'Q%"3L@0L53(SH94K!(@-N*5%FL8E,^KJ0V4&=;;3?F
MSZ+/:2?L_,\J8_>X3.C5++%IFPA5P %X,E7TJ)7>FB)5)8=!./0,^#OH$*J4
M.<)]E8Q96,U2)*R'+LZA>,$1*&RLY 2AQH]KY!A5V4HE8=LN_H0B!QVN-TE6
MT7SK3NFP6'*MT!YQ1*K44P]8I8>M5Y" 2JM&8^JF,16=Q6<#<7A8NKX+Y!RU
M-I!86K+#..MB64#TP8]7(V2M?: \^!A692_R^TV"!1#S!(&YF40)F!#[QBT#
M UR5RKIA514/9;#D1F=0'ZZJN55YB5!M..EG:5?"9\\&U0<.KV6'+T9$SB0)
MD6 !^L&;UDT]_D+$\^V!?[9KSF[#?H0/W6X$#_C0GX3'@@6Y?':Y9CQA*NO@
MB>KH!FM[#>I.%C7U<F7_Y_)__5(K4;70\[Q?E#$LJFK=7\*XLADF&AE@2PW%
MXF">Q_VL*/F$,?4M0YT:(9;#.BLY;K ;^%W9$F7-RUL9Y4K=ZAE8/^M:^2P:
M/&TW8 Q,X($2(K\Z1 ,FA$= QHA"K5)*.!86*>I,+?JID?X)V$^A."14#3TZ
M:L9%-4%L*J+6M'P,=+!4YNK,#VOO]9*>.L,;5"4;8$M/%8<OC\54B<O!RPK%
M\=YZ1&JI%STDV]")V'#LP[)(TX=C4V.?Y0\I[,J!RR6##3>56MW-Y>OJ+V^P
MXT&+W;U..FHPZJ$WY5*4?IH9IU_J>\7EH9.B816."NS3.FQ(6UYNJ$L3S6J+
M:Y0T@L">>]EJD!6O.0%=Z<G[!NLW/'_5\3S_6 ,2Z+%NS5A=9_XWZS;6)UI7
MVUWTK3.:R5=8I@I([NR=J@]VB;$S'JGZ?%O8Y?O^MS]X:SAU:]D]?-H!_SR-
MPR?UN2DA:A4]([">VEFJJFB>8!7-R6;I3[QNN[_$YWA"5(L5U@RZ?=0S5M-6
M\^9.KN[6\N6,/4;/2YUV^'>LIEDT2\SW#5FT).C*#&F15=UYN]BDHZDL_**7
MX1_KI872I$1[V4(7K:%*^AK5Y+>*9=#+LL#J+#CEE[=XUM/ S%9,_T@UH="\
MI7E+\];&>*M^VL8&-)B(\1_7&<AZ89;[P[F4<?QF=8YX/LWGX>/0PK9/>ZH?
MEFK9EB^"*_,691[/K'$Q+6,;EO2WR55<YPJ,SCS#C]9JZOX^M4EQV/>$BP $
M8"RY&)J@-4&O,G5OW_7]72?HP3OL1XF^ARE[(_NKWKA0-)_:<>*L?;L?N]?U
M6)A_:>5 8^ECIFY;^Y:GM0--T3M#T<3?M[U@URE:JP>C6^YI]6!E]:!^'J!:
M>)5B]<]6N8W.91$[VI;&[ZTTS_\P6*^HPJ*B)'MIF=*[DLXXL1X+2]@9Z[AK
M(G36%#>.%/=K??MN:"^)F;,9XDEEH*:Y':(YQ[.VGN+6)#FV074X/]-BXJ6S
MK+L?T&4];_5C6DUSVT1SOY-]:@=385Q;1&]:2-3=&*R%@3GAX-D&W#E.L'Z1
M,"3+L%]Z7IF9@RC,39Q&[#)\SYKBQC'B?LNR8;FK.>-JY%S5)+=-)&<U['#K
M26Y-(F-GE ;-LSO-L[3AK1C242.>U22W323W.VD0NKA=63]RTR*B[C;@D]F5
MK]0)WL&]-5&>J +?$Y>!JLL$SL\,TSA/>\:99&C;QOW68^H@CI6JVFAUM_%<
M CP?QAKR16$AXOP+3X5_\QO4B(I4RV%E5U5?H)VJ['>)V>_&6,YM6;2)8W7H
MK*BH])O7\*;>D[.V1 =!DJH>)YCKLV]TLP06$29KB+XLBSV7P\I92ZK^)66K
MLZ+TV[OC0W-0/G"\H'XSS;L*6+ 1RGCQV:**:Y9VL!1</Z^JQ<(@2#@H>WUT
M\?GTV"3AH.CY;NS[2## ["@ 5>'N-WNX9?M8!O$W-.!AH28</0,/S_ZC",3Q
MK"JGM_@:VF[WD4I97$ME2*D!3U%.*[V56-G^?_VD**UJ I7PHI+7=-U41375
MSI]^^*BZ1AP/:O##A[)KK'56\HL!PO6V5[R!P3L*(L7!85WCDN;0!P;[%F=I
M6]&JA*'T[LJJ@ZIIS<BHX='WK,6Z[#J%K?X\&,O@QV'M_0MXUV"(6"\=2\/F
M2ZV_9<#B2.,WTK 'C(ES477KBCTINO",%*(M$JN+DFBC<RB*^&<<^.AMDN8\
MP8ID^42W#75]6$3^ [SO#F;1;O<[:6^L?]#88\5]P^>N8+_3L89#PV87>&G8
M- &&>I7\ @Z?:$\T]OKBCK6N+"E6%LNUM6$IL6&)+B)_#QPY='X1>1Q](O[?
M7F)S$E%!+%N$(75H%+I>Y$2!1SQA!8['O@7VWD$M*L_7HH[>QY/+3W]=71H7
M[XR+#R<?#Z].+\XOZUF]^=YY%"K*Q\ETQZT6ORBV8H#5]!:+S)9E"OMME *_
M9-%+I9!T)J@TF5E*O4+0H9:F<+G2VE[O;$U$W_&VIVZ;KH>W1>NJQ[I58[47
M>ZLN.W:/,-5U 7>W+J F_(=VI1X5X?3J/BN][T =.UVQ3E?5TE6U=,4ZS5M;
MM7B:M\86X*'PY]TISO8A2T6?]XJ#RM<; 9CUJJQU^^@+F6:-UG9-N0M%B)M3
M<_[]\_2SCC]]Z<& =)\$VQ\TKFENNVC.I2N6+:P1S0W>L4#AH9TH+O3[$LFH
MZ]FN>LQ[(Z4%-6+5:6Z$[/NK5EJM$61IHMLJHK/WO6#%BI0U(KJ7)R=]+2=7
M,*4?66=NT8[:]B8BX0I[^^CS1##E,ERV:*V-^[ALT3HO]<-"NG1F<XW+H>SH
M%GE4;]'&M^@);;KU;%<]YKV:3;?SU'._/KI/@V7+26L6?_9-\NBR-H/>I(WC
MT>^AQN&7=OSV]O.K/X^?Y AN^TWN^TMKZ=.#VF\1T8ZKS6_1DF!,-L-6]9C\
MDYSR;#\)W=]0T5K6Y-=<_LQ;Y*W:$D9OT0:!>#-L58_)/\DQPG:8!&6E'^V;
M6L'M$=K;7Z!_QS<I\'=HBW1->TWC,V,;;4L[R6N^21J(MAF(7I27^$BV6F5%
MM]7TPIVWK>[W0]K+=O?3YN]SJ^[:FU^#+5H2DMW-N/?K,7GM*E[!#^EH(*[Y
M%E&JO?F;WZ(EL8ANAJWJ,?D7["J^RE(A6S?:5[R"PFGI +F:;Q%6*"?VF]W9
MIA?GI-%TOI![PEM6?->8QG=SBS04;7Z#M+]X87*]4.U*M(-BA:#B[6_7N^M;
MM"&OH]ZBQV2VV#H;7E//@O'$.U!C9>>W2/OQ-[]%R\83:Q_Q$_B(;;?FMD#1
M3JP[6J9WTSZ:12JRUHO5[D?#?<==-K]BR96HB]O@Y6VNMT_#%>,$=W!SZ[F!
MRPK"S<1]UF/R&Z]YLF/X0,+]@*X8Z[V# +%KN^OO6_:RYNCN[FX]=W!9^%]Q
M/W<0_M=T*/*0_0,LL"'^_9C>L5;O;A]FU^EE# R@83?W;++#LG8N+*P4ZU.2
MFN]0H*,X-[]#2Q^2./J41)//HK65EK5B-8<_>S"!/JG>_!8M"\)$'U6O^8C$
M5>9O?8V$XH3D4>;  S;V@JZ"@B)>.[!N(NU'+3GHC+=$P\A=:]GQ%$NT<=Y\
MX#R)VBLF)ZQSE3;LE](\HWEFF6,Z=^FPH=WCF9?GR]5'>5I5T;"[.1/7VK<\
MK:MHIM%,L]2ALNT]+F1@%YCFY2DK*P8)[J"RHMQ+KWH,*/>@[(,WTKIO9&K?
M^WDOB>_6/0W_(4:U<<S?'OAGO)'?=._!(9>^J<N4SL\,TSA/>\:99!T@JKC?
M>F@6""7A4_9+7)R2U!3>I9G1:TKX?R:ET8;[F[DA.T(*XU)V>[(=R<QPK'W#
MMFP"*-/NL@RN]=*%G[(6W%BJ_)KCR_0,._VPF(%U*L8A)$\SUDO2SFO %9GA
M797#\T,9$GXY%A)^#Q'023=N.;_BIP3>W^F]MFV\:R-3GAGK;B0=GDF6PSY'
M=P9Q_H6$\)O?H$:4M%JP,$:\##WMCQ'4;U[#G7I/SMK2Z,($4@$?5_2T#V-*
M8"5AQH;H2WQT.*QBF&ELE(6_&UCI<4'J9JT\-3(9MR3OY>KK&.B2=/IP.\B2
MVUX37_PV^=%CV<V="GX9OZG?[;$?$F^J:LG@F/&>3YVDAQ_ML1X,#Y\<K4)9
M+7(^__:3?I9V9</X!UX?]1ALEAA^!*:7]J^;ZM$X[6<PT/_U6=:#R>&"&8S_
MKY_D"5(N#NZTW>YWTK84"<_WC=,.;QB_8TZ^;;T9O:1^(F_^*):P6N+<N)49
M; F\/F$MV((TCG/90WIHI7#)^//T\SC1[!L,%OUG%U95BAF;-['0L@.[S15E
MR%XQYCAMP;L!8-6]%[R71M746FFNMEO^Y*U^GMPDO;MB_?LW3#"U=(>]+.FV
MV,RU;>PX.,%F[ 8835&5 1,>0E%0(!%MV&M!(KH8$A6< 0/!\1JW0.8SB9L!
M;?.DRY#LJIOA#<4T;M)6OZTP QAW0+>_RS90+0<Q'N'=%7N^NSJJN+* ']E)
MX_0FR0R1Y"FLS\^D9<1]& )\;/#4U?&[ZJD_S$@MV0!P1);<R XNX4;9<.:=
MX_NM8.<WUPZ,=KDS!=X\8I\?VE9%7VI?E6A(X$G$L"'6\2;K=&0+'H1%[*79
MW1B\#986^$7(=L+-3+84%>2]E/_ A817+S @O.T6Y07\N_CP0,P=RYRG-Z,?
M*VY@8,"P:VET )IS>!0_!D/C4JWPQ$O>R\Y->L=&7E)0Y0SZG@'[  :5<, !
M#^3C!+L.WMT$MH:OPXK@4/#_Y2]SQZS$7B%!!H12O!76K*)9_'LUU(HF,O@&
MHE>&LRQD/'PNDG<I?CDWVOU6#TA-5N0.&YW)@:S"-\*VRN)=L*L_9.]!@;$=
M<(K[>G3Q^?38).& / =+J=:UH':%2@B^$;!U1^; JJ<S&%C)^!&<VP=Z'4$3
M>%T.S,F /87,>[ O0+0R&ZA'^($>4%"O#2M3KG2%C.4MO6:2B8%:4V[G&Z,)
ME QOVC<2? Y0#!6P''\"W;6\.Q_0PZ?&96/Z0SW4^GK]K(-_ZV;2'"Q("U[4
MVGTEX6A7E(2CA90$.QR(D$<I"1Z=>L]#YLH !&.)" R\DB AYH"8*(R'.D/%
M?;'ZKVE6':+X?-3<=;*5N'R])#?>&I^3K)\/%)X_WWX>J$FOC.%]Q[+58Y/W
M'@_NW1$F>/M940=,[%[CW2^XP:;^6KC!)F1I;BC(O93^GV6[E8B[<;5XR###
MP9>*P_ ]\.IKF5Z#)=U,4*'I]_)$R%E:)I "Z*="_AS3*8D]&#DJ6*S?X4VP
MF7NHQN(+AW*,\0P5W<(8']&'44C&20:2;<3N)I-V]]F7C\;[=O3G@/;@AX&1
M/9?XRLVE=L-'TNNFQ0M?*UT25N?-;2)ZS=(Q//I@R=[6\!$6Y;"LO?F/C!#Z
MA)^5*T5H0R3MN..K,_IG,ZM&TP44-",@DA\FBV&PKUGKEMWE>Z_&IPCSFUC2
MR=4H)GGP[RB#1V=\>*Y7=QM0<[(AWE9C73F9F98B:81K\04$OK,(L(U[R68[
M TJD:Z9Y%QWT%9(!ON1)WD-%X#;I-4O+A2O%H)]=*Q5XH %P],&!0=1,6G+*
MVZG,%V7+*!N-Q;$L#590T&':UV6V'BC3G6M0V@=OK0S33#D<X85)!Q^%.<-=
MU7B37XJ:"H?D#>,\Z;#R%OSE%A9IS!J+8(#]Z#M:;6@   4E<<+!2D!TAR=;
MZ"7 )P%P989.34PNO!V8>M6D!J8>;$D?+-B1-[4&)L2$WW-@[^63PR_G6)J*
M"]ES6\+:,QL;;35_SW*2SU)F7%(J,[:]%F6&S%"*%E-FQKUH)8,#,7Z1.0?*
M9,-A#:Q0N(KLU\6YI)A)&V-N;0J$WV+(_6]-CLO0NFMWF["DBF/R7H;<7!XX
MP'#FO $V,6WA1U!727@?WCA\T8.'#5.(IMQ@4YZ<*XE3 YUZ3'6;.=$V\BRL
MT-B$'AK'#K'H5(^!K6;/P0'43/EK#0V"!W9X65X==T3'?2"F=\>'!NO".&Y
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M%-HOKE&@-,>;>]EJD!6ON<[\C][WY'V#]1L!"9Y@K$Y ]5CU6%_Z6.W%WOI
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M)\W4#TI\JKL.[.;.!E0W$MHM!],2-1IWUL&D8>'1'<:(K1,K=G5O::!!?[=
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MB7.)\*R726QFX)XP:%T&G0EN9.,,JJM^!Z)^GYYFD)[0[08@I$>HFYP]'<H
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MRH^/#OL;?G8\7/W2AW[YT&)/#\_Z9]]AK<.SD:Q5UKKO:QVL]]1]:,VZ](+
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M>-:(O.V3A?_.#]UP(A:^6%N%PW?2.Q_6'S<@UKW(VV;6_;!!?[*U!7;TQ+6
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MVPZLMBA)*[F P3K<(JB\:!;=^L"3P)UY(1R<J6=>\O7BG7Y!S_HJF-(1"4T
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MLC-@+U]3JR0\!1>$K9+4=>Q<S1XD(SHR<).DH-OGY"U3;CY#[PLI88 .4R=
MY4]Z:$YM-MR<QS^CC:I  BHT=FA1^HCP[C7SQOL3[S;R1T-P[NYU4(/N\;L8
MW5(4JAEW>:-3J"Y "PBF$#_,Q@'V?Z:I,E?H]IK$0"B,36CFL\OUIU7P0DA>
M>=4+?0E.,W6;8<5GCRIE)JK&I7!:V4#R)VK0ISFYI)MUCR@[LFJF8Q0O(KJ:
M\A!"5;QPYS3W)2:@OY*X=T1]7TQO-5H-./0@[LQM+\94)"M(/M[WIEGV?SPP
MN4#"4;R_>OC7+.E9)7V7-[! $!?G B04CJCS&>R[!0B_4=>7%Y^-NO[J3+Q
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MJ$/4Z#"MT;QX3O?#.+LO' F^<S&W38<PT<W>!TB$ ]WY73A<I'455_35CWC
M<S^.@<;*:5@E9" 4'F+V!JI*' DYSJ;7GN70%EPC*E-@J"(@K+X7^2::+3UJ
MEH53%?9GK5*E!])( 1G/;#=N]8K5+<=.^(0Z>_C"M'"@R_J']'F5#IHIO'<C
MFQ/0(G +QSSZ)L#CK'6A(LPD]I$UJ%CI_B?#Y&T61PO/Q50:^&$QN?5W"F4K
M&H,"P0(=JK5X4">"VLK48S'9HHO>2%KGGFLPL_AU#(^MP:K)*31?XM9=ET95
M)9@!?#@BH2?^Q F'-JCJ,"^_*)>#YM=R7N^ E6RA%^0EES9O6&' S9[&7FA
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M7/?J373'GMQCMWP1C[52/W!E'.;<2JE2%@>\2!#(,S'8%7I 2=ZXI4V4190
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ML,-/%'*<B?1H\V6<<5P)[F7T0E2JTILRU)U-#+)FU>=*I%7V% $V@GMSL.S
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M:S56N0ZP/L;JWFI&D]-DA7SMHJ,RQQ]BMQWV-&%9RA8X-/W=[)Q+?N_P<"'
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MA,A&$<(;HO+][RC6UCG'F@_E0_.,YBO[E$8D05:>WB(=\\#FQ,ZOV*)T:F!
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M>V1ZSAZ5IV:6/'B,&AJAM+1QH;H)[GI^ +0Z#<_WIKCGD=;;&_R0^0K4VE>
M8EYY%D\)!-S(H!+_4=G:%ZLRY9H-^9OL+HI_)*K.E9SN<)^.@V2DJ(K":"9<
M\/DI1NA-#6[S9Q2>+28OTZ7@B^38IE!$S(9CF6=%83'J2"S<K1DDJ)!@+H$Z
M41G4F ^C]</P!B-!6<\F%-C0>NU1D!]F)KRZ \@_81C8D-DZJ1JOF&@V1>R_
MR >J4"/*:(-J&DC O[3$ ='$N)@J(+*0=(\R+;RJ[E=Y:2+^F.>M? B9=H3
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M#52]K<A=PS20_\A$CF-EPD#@4:8R\^%C"7\PF00W<;8!8(DD#[K VM)T9\*
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MD.WN+,AV#<CN)\BV.TZSY[:/?+?5ZSF.[GL-[I^,LBZ%K=JOC[*-!91U.XO
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M$@3NNLF\UT5\QF0N,YD;=L+X,GFK@/ :/P$.QQ6X]\6;6ZVW-I(-Z)FLP =
MKV&J\+8:]#:2%=A=!7<G43R%D3#K..0&[?AQ;D)I_#H& ZN'@>YNV[X-4VBW
MAQCH.':SW>HY7;O#7^H>>4[WL.DT7/LWA]WW>KZ@W;X8<@O7^LQ2?BRM/DOO
M& NM*W83)"F$BQ'E3KTP8&/KXH]_Z+I.Y\.I-Z]9/L+>U^B63?K\FPT;+=ZN
M ;XJ =^.._T:IHAN#X'O :>?J#"^+F^T GDRBW#W8(*-@3T#>]LQ.8 ]4PEG
M8*\(>\+FO7R0FVL) F(&8<:6+4N #3(:9*P0,IJ2%H.,163LK0,9\WR&!AT-
M.E80'?>Z7,6@8QDZ-@J<,X\N25D&E@8:#316$!KWNMS$0&.IXMA^? 3EEVCD
MA:%G?6'Q(&"Q#)] UHR+(6.G9_"N2GBWX[F"#5,OLK]XMR17L-D81;,D" GU
M!-X=*X7OZ<C7-$5U.XV1NYY::$I*]AXCBZF%35E20FPXR?(@<P$7C6%L0+"2
M(+C7124&!$M!T"$0O'J*KW !#^%%/29ST?\W&P (JO#*(3+8&+PT>%D=O&R:
M>A2#ET6\='-*XY-"+$:--+"X"[!H2E0,+!9AL?'X^ J'/]_SK4LO3I@J3KEF
MTY2J4]R>B;$8S-NFR0'FF>H4@WE%S&L^UG^80SRC]AD(K"0$FDH5 X%%"&P]
MWQHVH+@/H.CN=NO/YK84J6Q$ #+1^)P?V4D(1S5+,<'-R($@"--HF248I(DB
MT$_P%7;/!C,\ZM%P& Q8G.3$:PZY.>0;..3;4FNQT4.N6(8OXV@:!RP%"J7S
M$&-^9//P\WL>WL)5S?_U-"3@)SWUN K ?P= 01Y^?.\'5P]DOPT#!U6 @QTW
MA$Q]P1X:0H[3:SANR^[836[^-(Y\K+C*%UQM!T1:!S&[#1+=J?['/SAM^P.W
MJ=JFZ=K3H#2-IIN"&EJT/Q^XK]JZ<H,3!"SM;!1*-SCY8V"FQ,.O8$#&PBZX
M/90=VE:-KV.O42O!A9J5CA@'E"0-TED*-I-U$=]X83"P3D9L I^:(S[\'$0#
M]<+!^<7)S^_P=?XHS[KF$AFE7&K6;?T_];NZ=7!U]NGX'7]X=,/X#\3679".
M\*>&T7@<W<%'!: G[_'USQR*PH0M3N64#30 <F@N3OE<8%@T*O[SU@$\%SZ\
M^/!W'U;_:$Y^XC?=1_^F^#9^J?2WX>-/F?03?U]^>]D C 9<$=CN[C!L=[<
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M'03A8#S#,A0(9J%WWN)P5-(B8B&Q9,VS[3PJ6^/ >4=^\L7_PE1Q'GQ0(M
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MV%WXF^K!7MSM6S,X!U]^^#]02P,$%     @ NX-C4_CQ>J1C+   M<X! !4
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M7Y9XF3@)(FIIF(/,.WA1S-+C7%<'S[_E.-_]YN/A>C>[2.Z89UX317'6I71
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M+407N!<U^C,1& %5O!FM W$^ 8%(I4LJ,)7:Q"&+H*OB83_SC+<IC\:X&L(
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M<K4??%L6B8*0RLR-T_;TQLD93^!3SHG$[#&HC2819Z4A^#?GJ*,YTSK9^EN
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MG@WK;=FT[5=]MFH (D*[CH]_[XTNQPO,"U4&214W:EY7WM%<KA:6-@42C*?
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M8[OW4UJV^; 5@[5XQ%[:/IW&+Y N^_ ASR*K7V'R99A.KJ/U^]\%>.\O9FW
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MRQR..^!>MK/1-GLUKP"N KBH#=L 8N>;=TL@][YEUP[!#;93VF"GHUVZ9:C
M?'89P_< BN,J:Q/QH /! #Z%;&W6J4Z=\+T):*NLC6[ULPDI7>WN7L_+\U78
M)ZDSPT$;64)[94J3)VN)M-:B":C)HO)YU0/H#F._92=:F^SB[L+)WAJSSNX
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MZ"C0 %?5;/)UR/:32]X&>X\*8@?3=RF-I!*H"!%E;UPID>*)RQJ(H5%[E21
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M!_*T[KUE(JO (_J4P8=2>;1D2^NDB/6)61?*7>$Z^4\;@'Q1_EHM\BJDNC\
M=>6+UP1N53]M0\#[\=&J":"YT%ICKT9YZPUA&^]=Y,!(]%S@;*\SL2 "$=$J
M04%HE^L<$!^$V![QR0Y5:YN0UO8VY"_PM51[A[_>#D>_O/Y]OJ0'[ZEWHFSJ
M.!P]"%6*:7@2<#'GN)[3R)KM9:W\^.X=IZJ,#%LU9Y5V#V%R4QYT*N\L;!#,
M,:*C*)=IM"<.O"/.2NVB2#Y"G7GB/I87Y>_L2$6+]YI6([KU#C3!5=5_68=L
M/X[*KLP]*(0=S5ZET/,:?%;EF+BDR%H*I1&V(<ZY1)C2061I#.>UFJ!W*8='
M7(FNU+")M=MV#3XC??"?&/>?PJ W'/TV&$.\'.&,6')RAW[PUL?I'>3%(@<R
MY3)TRA,GDOM 7(A\NH,E8U)10S.?8;/G[J-'3QMD#;NQ= 5WHN1E3Q!9L4,I
M1CQ5?Z+E?IL+))<1EZ606*TB$=9[ <9Y;>HD3ZU"\Z)<BIWIJ'!!=AG3HM!Y
M U1578K5N/;C4.S.VR-"V,'H%1R*->A0Z\QH*XD47)6VJ[K<Z<YE:HM"8G D
M<ITM_BZE\(@ST942-K%U!07\"JEW>5'6M/?#R7511NY]TBD88JTQI1F8(T'*
M0&)6*L8(G.DZ E@)IWMOH@VNAFT;NH+7L%S#X5KHC.=D1#*$4HXKG@.+0O><
M6)Z8]^@UBUSG3&8=HA?E/;1"2X5*!JMPS5^-)LBJ>A'KL>W'DVB'PP;"V(&
M*NO)6H3>&96BBQA_T=+,70$)G@F2O 7-K0-<7)^%-![Q++I6QB9V[T 1KWOC
M6"Z??\(I=-$;R6HNG):$B5*TDDF-6)DFT5O&T2K4JCKUV1_'UKWOT1:3CPAD
M1QI:=$;&H\G9IW+G<M:@#Y@.-)5ZX"D2F1,EUNA @ JN><PVL$;UG?%3;^D
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M7@'IN&12"A%(8+EX7V5*MY"!&,$S\](G,'4:-[X*LG582MTGU[916O<7SX\
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M-MJ#HCNNF-B$:]E@H &RSNNEGL>TAZ*IWG0[JJJ8?JEC''K*65NB<\DR*-/
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M:/&1,R<!76-FDT1/J%GAR#.+O'65=R6_KC> K^/TX:_;T60V3E_'H]NKNVO
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M>SRGBS1]RY&(']KS;!<(/FXZ[WO^YP58=4YC#:C- 9^[.L?<.^V!U7Y]UW,
MC>O9]D#=GM_;QS,MO>*#)42^";5TK8[U+!>/>:$6$-;72"]]F2W<&0T$BI@G
MH!LIH74<! GW/8AC(I@7"8QH8.0,6T.9FL*N, .R BUG\*O:.*2"#9:9["=0
M5I5S-O[Z7!MN.),_HR,U7>)1NF=H3_A(F2*UPMOVV=J2S0MK6WIT@L^FLU_?
MUQ[.N"[OV;3M>;KG/]'V"$]['.\JGZO5O8+,;^D\?:C6/^[S;V*Q+#*5MF\6
MNISC0/@0Q1&'*,($DI@)Z 6Q)P(A4! (BRTZ?003W6JKDG>NL:MM&J%&SY_!
MU[G@#X*;'M?1[A$]S>R9X+&.ZK2@+S:XO0!KX&H5NH9>I4_M\Y2.*5\]G]'1
M;G[D$SJFM.R?SS%^@N6L/5ND/)TO55/K T$?OJNTHM+!K8K\/CTO%\T:[P=2
M*)%5V4BK%#ZULLXBPA+7)S[D6$[:$>(NQ(*XT/4%QC3Q<>1KQ3GVBFIJ7N:F
M4:!<605$8U9=&5LTMJBD%:!4UE19V!I;P0]I5G]:_F@X]^^EHS47 <;NOJ%7
M S9[;FT0^+#5<QLVJ87;UBJ5G[I.RW;1NU/:*]']+A#T@FS<E8(^R=Q;,NCU
MX>?NJ*FR6YG\:KW61^ 7.R>;$0F22' !F1,SB$02P=CS"*1>X'HD#D,?&1W+
MU&UX:HJ]N0_3(C<^4Z[-NNE.5W]<CKB=M0)]T:3>6 QZC-R4K8'VITXT_D:;
M4'J4'-]ITKS?\MAXDY3C[^GBL=VZ6N7G:':VUN%2,]\)D.>JH%B'JETD)F?<
M 95N:) X0>@)F@BC8"2SYJ<F7.VF<;%":'BNW(Q\/>4:CM*!]:L%#OZ4R%?[
M[UMY@EK"OYTFW/Q(NA5O_9Y2-X,P[L%U*WKVSK+;/<7B>'N52KU)JUY>/KU+
M2]E6D[.!NL1EKN=([9)2ACS9&80&'/HTB&(:.%3X6BIVJJ&IZ56+SN#$<Q>-
MW7K4)SD#*T]=OZ*%J>:/-5";DA9=A!D< N^)N)&.>=L3:':(6X.5SF/:7?>/
M=Q!;PXJMH]8ZUULH9%T@.ET5C$ZS3V1.GLE#7C;?5\?# A$1018A3^HD0Y#$
M&$.'$N8@J92!WKEJO>:FII8U8+!&K-)'KS ;2,)IHC64M%?Z!M;3;N9L5/4T
MA0;:VBN5(RGLN92:Z:PV0YUJ>_HIXVFNMD5;RJM_5V_'6"\S7H4V5<%/956.
MX9*6E=-L?RZQXZ$3DHU#9PRKHX,5=K !'OS>PN]Q$<N.MZ%/_75!>.L3?!KT
M:)S&TWG*>:_7YI._I^4,!Q%R&%;T$Y7 #/MJ%<N'* Q8$(0X\+E1&/21=J;F
MT*S>K^TW22(U/'!RC%<S?3J#K;&$R( H:[DY0L,@NK+;UIL(R!&#CRG%L<LM
M9CQ?1,'^:/Q%$O.(N9X/0Z(VWUP:P9C)"4X2"ODQCWWF:6G [H.G]M)7T P\
M[4V.-*8EEI8/_ )7J&SF&9O6&\PH+%D8:>[0_14PFQD<L+1S#K!Y_7C>_@&4
M6W[]H;_;N1A?BYP)P4L56O"%+)J @Z^%>*ZK I;2N[DB\WEYF^RF?U[')\P<
MC,/(<0GTB B50Q)!(D0,0Y[0V$EP0*/$Q"'I!=74E*PUJ@X#>EJ9I?:[GTCQ
MAUA4&]Q<I50O+3/3]].=>G[0Z)TTL.AN]\_:H@NP85,UGZNLJA-,GTQ_WY_#
MU2O?O;IG_2 ;U9GKE<Q=UZ_?AY][#.$ZDY/1:IPN;_+%>U&F#YF*Y+\L?Q'\
M(<T>-B[X1-),94:]$8M9Y/H.)J& (G#E+%-*.23,BR#&7/Z,_"#PJ%EYD3,1
M34W0%;02_#"7Z$3YXT84A5K;K+>4FEQA/S3Y7GZTR!=V?D?JR?FHW3.PE*]M
M 1M8@;0&K,T!I 2-09M770!E$_A!627[ZZ:CO\XX"'$FQP.=C[!%]4;')LXD
M\?AIBG,??'[@+1?)\5/#.Q&AKA\0[O, ,APZ$ 480^R$'O01C:.$,Q:&GFT<
MK@&.J<GS=CQI:PC\?/B,OGVTKDE7Z4GQ"!TPL ";<3]:;*\%F8.%^II@>;/(
M7PO"N@*!;1YGJ:7J.,3>\=\F6[1+8DQ$(*"O4GTA'%-(11# P)>?NG'L"<,4
M!QV-34X5J[-B^T?E;5-R=_&LJ78]L3>TI%D39RY9&HSTJTM=#8XK/AJF[RF,
MSCV6QPL*P=/%1\*J -_F:\T8%50X,221'TCY2")(5+D.#Z/0Q<(C7F(D'X<:
MF9ILU!A!"])2+0[2J:<2YY(TL#H8\V,>W]]!0+]1_(<:&C=6O\/4O8C\KFLM
M]EA_N?ZM"555RW%M=!X.8XH%11 G00R1'WF0>GX$ QP2APOA.@'3WFT]V,34
M7OC[?$'F0$(UV'T\S)W&+NS9C S\=DM\;70XJ!#:[,T>9L=@E_9LED;:K]UC
MJZ>]VT[[.W=Q#]\YWGYN)_*MG=WN*RV3=]2)X=LHS( RC_+(@0)3 1'G"8S]
MP(&<<L]+&(WCT*@4T?;CIZ9C-JL[.X3I.2CV- PL7NT:RP AIX=M[C=#Q'83
MXZ9Z.&C>7LZ&PU>=NP9\?&=0'3#,E+]39_G97F%DQ&4H=AT8(]>7;[?K0OFU
MP)!%GOR/SR/B8;O%8#M 4].#;:QJ?7)[SUY9MKNOWR9N*1?@'2G34B7*^DC2
M OQ&YDO#Y+IG=[#I$O+PW3;B6O)^?,5F-^WT[3BKRN?Q.]#RLB6H-UIG/H_"
MXPO.9S[78O9XZ8?!G<C2O/@UJV*X!+_)%Z)\OQ1?Y),>9<>%C>,?(19$E"/H
MXCA1&2 %)*[\-8A(X"0HBA.]9&B&[4Y-C_V?PN!?08T=K,"#"CV0\$&%'R@#
M#.9:!OV@,3T=AMV!9=. 6)O9K '#!E/<89@>:=[;QU?9;$9L3E?G--G@<>/-
MG<UMW)I06]S>8\#=9<:;B)%+)O]4C3WOTY+-\U(BV?3:@\CAA$ '<0P10\I_
MYP3Z! N2J$S R#T[UDX3S-1&B/<?OEW_=GE__=L'\/'ZYO+FZOKR,[B^N;O_
M]NN7#S?W=SV$T^EVDY[O/1;Y P\@1X+H5 !T&S:W-@6L;9%^]Q >=Q^L#A\V
MIPOH[2/F#*G3"I8S?::=TEZOSK.75W-2EFF2"O[NM<W-M"3S)NCZ]3U9B)WI
MLQ,@Q@@*(/<<!)$;41B'U(%!3&G 0R*=<:.C*N> F9K2WBV?GDCQJKDH0E_!
MAI7M@8E7,SD^JR_UY'BL'AI8CC?, &L[CO4"4+8,N@+2!ZV]ZO%9@$;5XSZH
MV]7C7IYIL^*!'.>(?WTGJ:@\:\_QV[F@$Q+*O(3#V/>$='1==:C$=R'!D2^(
MY^(HTLH9;-'VU-06_>0XG=/%E0U &6$R-S?K$YT5D,&8'E@U#4FV6@DQ8]MD
M-60PUD=:$>GK*VZX*F)%6_?*B-DC1UP=L;)U>X7$[A%VOOLW40JU[")G"N_%
MBYCGS^IK^*$^'E?GN:]F#W7EO.NL.DJITNV4BUG@H" ,HP3R6$00T22$,<$N
MI"%+B(-CAP5&KOL96*8VEK2F5+-SOC:F+31O& !Q3B_I.>4C<3_PZ+)%^X8=
MH#$$_+ R!:QJA:89:*RIMI2/%V@Q=LE[(+57C_P</*,ZY#T0M^N/]_%(.XG]
ME.?\SW0^ERWO'K$YM*;I.!@1)W&@A[A4U<CS(*$X@1[&V(V9CQ@S6GHV:WYJ
M0OKI]O;]WZ\_?P:7-^_!]<W]Y<VGZW>?/X#+N[L/IDO-AAVA)YS#T3NP5K;
M*ZW</P(X^/JQ'7&]ZJ$AA%$ET(Z>7=6S?(IU[0\FU/*&FL1\2\L_OHI"?4 >
MA#N+,,%)2#%$,1(08<^!E' "$RX\CX3(9:%1CL2NQJ8F8FMH:BFWJ,L2&+J
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M\T_!K_)R,?-]YH6N\*4WP1%$E$A'(G$#2$*1A(&'!69&*M8KNJFI704:Y)D
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M-GN:=@7OC">9UXQ[WSCDU<&<M"YBIPI0S9S$Q4% $Q@X200127P8N]);2H+
M9<SU<1@2W7IQQQJ9FI:U.,$::%,!3;],W%%"NR6K+YH&%B4+AHPJPYVBP*HJ
MW-&'CE81[I19F]7@3EYKY^S4)Y#OR?<#6X4T"CWA$@81QG)2Y#D44A>I4.N0
MQ%Z$&1+<Q*OI:&MJKWR3 D!B-=Q+-"99SV7IB;J!9<":-6/O0X./7MV,KO9&
M]2<T#-]U''1NL4DRAL)CZ3KOI"'53,QS_*!9%<!>1!TDQ<1UJ:O2C#F0.EQ
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M(G(2)W& ,!UZYW\F=6ZDTGUUBKS>^9_#W\\NHX$Z,L^8X>GQSO\<V.%W_H,
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M']:KN_J+WAR ;[6^X($\:R_0^AR\&V3C0V\OT(V_3=)J'K4.KVI2,N_[(0-
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M89Y'"<SR*&;Z-"S.I7D/N&OBYD9%K78V[<>N0MK/,_Z!&IE?M*Z@41:TVMZ
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MN(6K14#$)*%9$K* "F/6OR)L;E3_[;L _TNI%^B+D_7R25^-U": UH;_9<%
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M!6>0Q22!>48X+>*4,R7]:W /TG#;=I$^S:8/4$_Z!/;*%B_.6@S6$-LQR87
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M)'%A&@(IA5F:QL2A!:S]O$,S'='/67LHM93?!%)CE[BU_3K8G YT@F['U.H
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MRHL,\BC6C,,QAXPR33LRI7F:YT(0JWO^SC,/C7B2GW'TGZ"2'JS%!Z7\0"L
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M9A3Y:K&.:-,4<6C40+P:\)XY6;0T@K<)_]H?#,T\\SZ!OI,J#QP)11)8KCM
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MXO03<?B5+YL"Q;LJ@?62Y,H+Q2GUD1FG_TGE&!K3IA'/MA2.F^!HALXF"NH
M>$__?CJM]S;K#XO\?/X9SU(R5WP*:YB5+'E@JCX]5-6G"#I"9))KE1B6FX/I
MAZJ-_ 9EXV8JF@%M4(5\1T[>V]./'\/RRZ*<&?UPI]$/ZZ]RW[]<;=#U6[F1
M@\CC&'ZG-#H(YRQP'R*=M '!:U& B12-J(_259L+]:.$O%NZ(/0#+Q?SY6V/
M9.*2-"(7#=%66V",!E^[GEM6[T0YG0B-+NX&8Z%C?W,7[-U[HA]5Q1T<^5=<
MF7,VZPGS;(E_/\5Y^K(I&LH\!%O[\C/AR8<.AE?/N4#41@3Z3Z!O4\NY!7&=
MX/&XL+G?'1U$ASW!\BZ&SDN4?.!,TMD)CG-RIW*JC^82H^UOBP@^>A)=6UC>
M3UPGL!P*$/<!;B#M= JXU>6^O>BYPXMTCGSW0M%;/6'(VXY)0&%6Y^B<%-@F
M9;0-=9U ;BA(; &Y@_33$^8>?;G\\J]37!)1'[Z\P,]X-@[#HW,9I034B7:J
MK@(TK("3R&*(DG/1V,X]2%\G.9Y>3N"A--D3/J_NN=O\7?3J3QB5<0*4S[;6
M>&*]+0_ F,<0562RM'F<O1.9G5C) 7&RC:$<1&D](?+Y_--IG61*$N,7P\2R
MT%EI!%T2G2Z)!8B<SH)@$ZJDZ #0C9/AMXGJ!&W#0^$^T!VHETXA)BY8B4E&
MH2,D$S3)210(*M)7UHEH:-.*UMFMVT1U<OR. K%]]-(IQ.0Y*\(JG@VYQS97
M+\1R$I%)$40D)S8E)D1J7#-TFZA.+E=&@=@^>ND)8M<R !MO]ZQG7S194H $
M)3('*BK:,8G5-UI:1>F9LZQQ)'LW89U K9=@XF#=]03%KSG[6F-[\K&.ZKMX
M;BB90E,[::0J*H6.).=D 6&D<C:KP%6;"1K;4->)%S<$'+Y=07B8;CK V^O:
M<HA4\_4V] XNSZVZ(MGPJ UPA;%67W)PPG@0FM'&95YZW^;5Q0Y$=H*^P1"R
M.(ZZ.D#BUZ=+6_"6O(J.10Z<7%E0,BF(V5LHVO 0O1+6M$F?[$+EN%AL!I6;
M53>M]-8!)J^<)ALGY_$LK,[.$6&4-SDXP#HT5QE51YEP#5EJ)X*V$67S-/-U
MDL9](]2=,WB OGH"WIDX[ZO<_66^B"M<?JZ"VX1A]->+>2*Q;Q1_50KGAX\S
M7$B/"4S*M5V24!2990[&D7RLC<+KQGGG@3GJY, _#' /U]>,H_T.=L$O;]\M
M-[Q_>5L9/[<EFX-$:RZ%9!**R@C*2X08181LD47EZ+,:=4R[GZ9.D#@J9A9-
M%-@%%']:?,;EO$:3)^^1)(:K)QC7M_ABBG,D-P>DK'QAK*TN"R=7RLI@)2N,
MM7E+M"V%G:3 ^X)I ^5V -IGBR5.W\^_,G<W4TEGZ6T$EFH'1:DUN)H$5BJ+
MR"T/F-LTG]^*O*YRG'W =7BU=H#5QTCA:IG2C^'J57F"GQ:KZ?KB.H$7D=)F
MG]6YW\PX"!0H0I2&.6,"QYLC\(9JRG _45V%6WW@<B@5]H#&Q?+38DF,W+FU
M0F%)%J7!.AGK]%(%(04+1D;FLRF"VT9X?(BLK1"I_[D0.9@:QQX*^097TTQJ
MF(;9SXOE^GUXCR?SO!'6HY!^PWR+.X_*&>4BV%(\!:#%U8X&=0XBYPR]8%[?
MN+2\9V;DSDMO!43S3P'$(^BN VOY\V*.7WX.R]]P_>QTGB^X4*($SD2"8FP&
MI2W9_"0U")NUBIY[K=J\W[J;GJU@:?\I8#F@XL8VC&>/?J>7SWVG\Y_"+'P*
M[Q=?'6'E$SG#8(PA;FQ.X(.HY:(!7=%1\RBW,H3?7&HKA+E_"H0UT$T'ANZ,
MH=N.1& NH@I01&V;X86'R!3]8J7&&&L;WS8S>>^F9RL8^G\*& ZHN+$-W9/S
M-1\O/G["^6HCI=>S,+^8<TW1?DS* =;:=\5+!&=E@A0SCT+&(F78RLH]O,YV
M26[V3P&NH=4R-L+.\TJ/29";=VBXG'X^ZSM[WJ/Q,G<?R $5*8*QNG;\K#N&
M60O6A^2E3C*4[4[4;5?<#G7_''<K[535P0'[Z'0UG>-J=9+(8*\VDZK.;E.=
M#RP9!;D6ZRG%#,0D25!2%&:X%"JTR5'?0U!7N9:1BBV&T%6GD*M?+O%B+"BF
M8@+%1)#)7:5PB':3DSS51K=:>\^9R6T>LGR3M'&OG <!P!:@VE\;8Y^H/__G
MFY\^QK]>3$IGGD?:<:1I7BGW&7SU!6SA$84J*1BSU;%Y[6/[P\ !^EH,(KR1
MIVQ=F?IZ9T>RV]]%?!D^GLV<TC$Z);D&4RQMGMI&.S)AP,>L/#*K11EN;-LA
ME':5Y3WR$7A4+8^,YOOX.-_>QD:36<YG?=E5C!$BF7DHV3C/!3J^G6>V%5X?
MIF6\R6#'P\*BB6+&/B=)/Z>K1]/%*DTIG,'5\WFZN#>. :4NF6B/'I2-!3P3
M 8(3(G#NT!FQU9EY[Q+CH69(!2X&EV8'KOD01O[%Y92*:(4./ CR2%&"HK"8
M/(B@0(C$HN8IRM:O.(=@HZM;K+'+_(^.BPXVQ1G/=SRQN6SMZ&62/I*E\"G7
M,>Z>0\@9Z1?GZE^A9FW>Z7V3M*Y*I(\)FT5+'?8 RL]A.JO[^MEB^3;,\.M-
MR_7*FXD0AL7@"#U&I]H9($ T05)P&+.+1J2LVI1.;4OAN! =&!@W8=="2[NC
MSY^A;X[K)I>RSSZ_G$ZD%RX4%\%M.E!D[L!)\GDR"<D9[9EJU'SF+FK&+;EO
MBZF#I=^!];IQFW)QA[(1W!URFTB=4E(L0BJ^]DY.'%P4#M#ZH*-SPJ8V1FQ'
M0L>MG6^+NY8ZZP"2]PIO8I55R>4 .B@#"HND\"W6;@(J9T&18;9M7A[?2]*X
MI?"-C\Q!]+ _H!;K,!L$4%=<W0=EI611G%D(WE>O5C @5C@=_QDQIV@PM'D?
MO!U]73U>&S& :*#-#HS>Q672X\7'.)UOU%KM.HF.E$-?U3+JY?F,D(L)H=H&
MSDA8$!TC5U4$!.>0 8N\3NZ+,=LV,Q3W(';<V*(%9NZYO6VEP XP^FK]X>N
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MPWW5*^V*FQB2,5IG**NW8N0> -96:4F1^V!L87BW\>\CMZG/+M5MP[!MD-)
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M;NW\Z^SD?W,Z3+6>N)SD='6G5)<E&!,9MUV-Y?+BC$[5JK&;K<)C5DXS H[
M6KCF%:PFUBC%0U YB:C;6+:1&7E1)G 3K#X^#7O_ .C?5GY$<EVK)[S#\X(G
M/V]D^_DTO=-84A>]DBI*B$XI4$P7")$.:&LCER93/*+<;V!)'UCM2Z;M3J''
MZ<^;O75KY,SRLBF,1958"0*2J;,8M?.T8[P#%3GG(IB(N4T!]K84ORC;N GZ
M!KB'XZNT@[30FL_;\JL]3+U"6:+P!!Q=VR='!\YK#MPG%"8*(TW;G7N'H.Z
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M,BS*)#3MPK:MSU_8A/F- +#QA/E-M#%U#/OKD'1KG4-+T9*HL[!5K-W.@DY
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M<VL2ID5:4US,]ZZB+KRS+^?S^->?%XOX#8F[.]PDJY)3OH"3IL[H(F,5)";
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M$%_9R<3)0*(TX)BI%0N>MI64"<CM9T4E*:5NTZ5Y$'G] &H;#-SOHS6R0CI
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M!+?>8OWE\I;-:Q-J$+;!<V28:>6)Y"4\L$X2C$\#DS$$%^J\,]R:Q'YK"O;
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M[0T+G8^,()_'?G'[\V3VYZ^0;N"B4<<#>]Q$+A@+)'K?O)MCB0-@A,>4K%3
M3&*UP=F&T'[OH@^.S<YU-RQHOA6F/5VI6HY!F<,-Y[*2I2/0X\$ AAA&;=3(
M7P+?E]OX Z6#-YS=A+]5%3@ @%Y"+%?[XSR.C?+*+,86/!^OYD5-Z^P1;MCS
M?.W_^G;-E0/WO#0S.^\\D<8G8A/C1&L,$D-BCMLZ 74-;@;OM>Z!O]G P#"
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MQSB]#';#RN8&OG9IS(ZU+P?B89M-GOBCYGA;@UC3/"6"3A*%1^^I.\:-])C
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M-G950OP+J,QQ!G92?H;U(HTB1>-"P3ZOY WB!R1CB<3P+S5%RZ"7OU4*YOL
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M4$L! A0#%     @ NX-C4Y>E#1"YX0, IW4W !$              ( !
M &=I;&0M,C R,3 Y,S N:'1M4$L! A0#%     @ NX-C4^RJ_V_ %P  UP<!
M !$              ( !Z.$# &=I;&0M,C R,3 Y,S N>'-D4$L! A0#%
M  @ NX-C4_CQ>J1C+   M<X! !4              ( !U_D# &=I;&0M,C R
M,3 Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( +N#8U/AI*]B0W8  .89!0 5
M          "  6TF! !G:6QD+3(P,C$P.3,P7V1E9BYX;6Q02P$"% ,4
M" "[@V-3;']%[D,E 0!/% P %0              @ 'CG 0 9VEL9"TR,#(Q
M,#DS,%]L86(N>&UL4$L! A0#%     @ NX-C4WM;TTYBL0  X_P' !4
M         ( !6<(% &=I;&0M,C R,3 Y,S!?<')E+GAM;%!+ 0(4 Q0    (
M +N#8U.!AV*?O@<  ,4?   >              "  >YS!@!G:6QD<3,R,#(Q
M97@S,3%C96]C97)T:69I8RYH=&U02P$"% ,4    " "[@V-3YFD:?* '  #N
M'0  '@              @ 'H>P8 9VEL9'$S,C R,65X,S$R8V9O8V5R=&EF
M:6,N:'1M4$L! A0#%     @ NX-C4XF+K32=!0  /A8  !X
M ( !Q(,& &=I;&1Q,S(P,C%E>#,R<V5C=&EO;CDP-F-E+FAT;5!+!08
.."0 ) &X"  "=B08    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
